PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Alberman, E; Noble, JM				Alberman, E; Noble, JM			Commentary: Food should be fortified with folic acid	BRITISH MEDICAL JOURNAL			English	Editorial Material							NEURAL-TUBE DEFECTS; PREVENTION		St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Alberman, E (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.							DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Mathews F, 1998, BRIT J OBSTET GYNAEC, V105, P954, DOI 10.1111/j.1471-0528.1998.tb10257.x; Murphy M, 1996, ARCH DIS CHILD-FETAL, V75, pF133, DOI 10.1136/fn.75.2.F133; Wald NJ, 1998, LANCET, V351, P834, DOI 10.1016/S0140-6736(05)78966-2; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Wild J, 1997, LANCET, V350, P30, DOI 10.1016/S0140-6736(05)66239-3	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					93	93						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398634				2022-12-28	WOS:000081438200032
J	Fluckiger, J; Dallenbach, A; Blunier, T; Stauffer, B; Stocker, TF; Raynaud, D; Barnola, JM				Fluckiger, J; Dallenbach, A; Blunier, T; Stauffer, B; Stocker, TF; Raynaud, D; Barnola, JM			Variations in atmospheric N2O concentration during abrupt climatic changes	SCIENCE			English	Article							ICE-CORE; GREENLAND ICE; NITROUS-OXIDE; AIR; HOLOCENE; SUMMIT; CH4	Nitrous oxide (N2O) is an important greenhouse gas that is presently increasing at a rate of 0.25 percent per year. Records measured along two ice cores from Summit in Central Greenland provide information about variations in atmospheric N2O concentration in the past. The record covering the past millennium reduces the uncertainty regarding the preindustrial concentration. Records covering the last glacial-interglacial transition and a fast climatic change during the last ice age show that the N2O concentration changed in parallel with fast temperature variations in the Northern Hemisphere. This provides important information about the response of the environment to global climatic changes.	Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France	University of Bern; Centre National de la Recherche Scientifique (CNRS)	Stauffer, B (corresponding author), Univ Bern, Inst Phys, Sidlerstr 5, CH-3012 Bern, Switzerland.		Blunier, Thomas/M-4609-2014; Fluckiger, Jacqueline/G-3457-2011; Raynaud, Dominique/H-9626-2016; Stocker, Thomas/B-1273-2013; raynaud, dominique/ABG-4718-2020	Blunier, Thomas/0000-0002-6065-7747; 				ANKLIN M, 1995, TELLUS B, V47, P461, DOI 10.1034/j.1600-0889.47.issue4.6.x; Battle M, 1996, NATURE, V383, P231, DOI 10.1038/383231a0; BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; BOUWMAN AF, 1993, GLOBAL BIOGEOCHEM CY, V7, P557, DOI 10.1029/93GB01186; Chappellaz J, 1997, J GEOPHYS RES-ATMOS, V102, P15987, DOI 10.1029/97JD01017; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Dore JE, 1998, NATURE, V396, P63, DOI 10.1038/23921; ENTING IG, 1987, J GEOPHYS RES-ATMOS, V92, P10977, DOI 10.1029/JD092iD09p10977; Etheridge D., 1988, ANN GLACIOL, V10, P28, DOI DOI 10.1017/S0260305500004110; FUHRER K, 1993, ATMOS ENVIRON A-GEN, V27, P1873, DOI 10.1016/0960-1686(93)90292-7; HAAN D, 1998, J GEOPHYS RES B, V50, P253; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Khalil M.A.K., 1988, ANN GLACIOL, V10, P73; Kroeze C, 1999, GLOBAL BIOGEOCHEM CY, V13, P1, DOI 10.1029/1998GB900020; LEUENBERGER M, 1992, NATURE, V360, P449, DOI 10.1038/360449a0; MACHIDA T, 1995, GEOPHYS RES LETT, V22, P2921, DOI 10.1029/95GL02822; Prather M, 1995, CLIMATE CHANGE 1994, P73; PRINN RG, 1994, TRENDS 93 COMPENDIUM, P396; Schwander J, 1997, J GEOPHYS RES-ATMOS, V102, P19483, DOI 10.1029/97JD01309; Smith HJ, 1997, J GEOPHYS RES-OCEANS, V102, P26577, DOI 10.1029/97JC00163; ZARDINI D, 1989, J ATMOS CHEM, V8, P189, DOI 10.1007/BF00053723	23	206	220	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					227	230		10.1126/science.285.5425.227	http://dx.doi.org/10.1126/science.285.5425.227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398593				2022-12-28	WOS:000081346000033
J	Soll, R				Soll, R			Consensus and controversy over resuscitation of the newborn infant	LANCET			English	Editorial Material							NEONATAL RESUSCITATION		Univ Vermont, Coll Med, Dept Paediat, Burlington, VT 05405 USA	University of Vermont	Soll, R (corresponding author), Univ Vermont, Coll Med, Dept Paediat, Burlington, VT 05405 USA.							Edwards AD, 1998, ARCH DIS CHILD-FETAL, V78, pF85, DOI 10.1136/fn.78.2.F85; Ginsberg HG, 1998, CLIN PERINATOL, V25, P1; Guyer B, 1998, PEDIATRICS, V102, P1333, DOI 10.1542/peds.102.6.1333; HEIN HA, 1993, PEDIATRICS, V91, P496; Kamenir SA, 1997, J TROP PEDIATRICS, V43, P170, DOI 10.1093/tropej/43.3.170; Kattwinkel J, 1999, CIRCULATION, V99, P1927, DOI 10.1161/01.CIR.99.14.1927; Nadkarni V, 1997, CIRCULATION, V95, P2185, DOI 10.1161/01.CIR.95.8.2185; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; SAUGSTAD OD, 1996, PRENAT NEONAT MED, V1, P26; TYSON JE, 1995, SEMIN PERINATOL, V19, P98, DOI 10.1016/S0146-0005(05)80030-8; *WHO, 1997, WORLD HLTH REP 1995, P21; Wiswell Thomas, 1998, Pediatric Research, V43, p203A; Zhu X. Y., 1997, SMJ, V38, P485	13	8	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					4	5		10.1016/S0140-6736(99)00149-X	http://dx.doi.org/10.1016/S0140-6736(99)00149-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406355				2022-12-28	WOS:000081243200004
J	Westphal, RS; Tavalin, SJ; Lin, JW; Alto, NM; Fraser, IDC; Langeberg, LK; Sheng, M; Scott, JD				Westphal, RS; Tavalin, SJ; Lin, JW; Alto, NM; Fraser, IDC; Langeberg, LK; Sheng, M; Scott, JD			Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; D-ASPARTATE RECEPTORS; POSTSYNAPTIC DENSITY; ANCHORING PROTEIN; SUBUNIT NR1; PDZ-DOMAIN; BINDING; SCAFFOLD; CHANNEL; IDENTIFICATION	Regulation of N-methyl-D-aspartate (NMDA) receptor activity by kinases and phosphatases contributes to the modulation of synaptic transmission. Targeting of these enzymes near the substrate is proposed to enhance phosphorylation-dependent modulation. Yotiao, an NMDA receptor-associated protein, bound the type I protein phosphatase (PP1) and the adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA) holoenzyme. Anchored PP1 was active, limiting channel activity, whereas PKA activation overcame constitutive PP1 activity and conferred rapid enhancement of NMDA receptor currents. Hence, yotiao is a scaffold protein that physically attaches PP1 and PKA to NMDA receptors to regulate channel activity.	Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA; Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Howard Hughes Medical Institute; Oregon Health & Science University; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Scott, JD (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, 3181 SW Sam Jackson Rd, Portland, OR 97201 USA.		Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	NIGMS NIH HHS [GM 48231] Funding Source: Medline; NINDS NIH HHS [NS10202, F32 NS010202, NS10543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010543, F32NS010202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BLANK T, 1997, P NATL ACAD SCI USA, V94, P14853; Brenman JE, 1998, J NEUROSCI, V18, P8805; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CARR DW, 1992, J BIOL CHEM, V267, P13376; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI KY, 1994, CELL, V78, P499; Corbin J D, 1974, Methods Enzymol, V38, P287; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ehlers MD, 1998, J NEUROSCI, V18, P720; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUSKEN ZE, 1996, PROTEIN TARGETING PR; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krupp JJ, 1996, MOL PHARMACOL, V50, P1680; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lin JW, 1998, J NEUROSCI, V18, P2017; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; REINHART PH, 1995, J NEUROSCI, V15, P4572; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Snyder GL, 1998, J NEUROSCI, V18, P10297; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilson GF, 1998, P NATL ACAD SCI USA, V95, P10938, DOI 10.1073/pnas.95.18.10938; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	50	411	428	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					93	96		10.1126/science.285.5424.93	http://dx.doi.org/10.1126/science.285.5424.93			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390370				2022-12-28	WOS:000081199800037
J	Wolf, SG; Frenkiel, D; Arad, T; Finkel, SE; Kolter, R; Minsky, A				Wolf, SG; Frenkiel, D; Arad, T; Finkel, SE; Kolter, R; Minsky, A			DNA protection by stress-induced biocrystallization	NATURE			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; HELICOBACTER-PYLORI; STATIONARY-PHASE; OXIDATIVE-STRESS; BINDING PROTEIN; NONHEME IRON; DPS; FERRITIN; COMPLEXES	The crystalline state is considered to be incompatible with life. However, in living systems exposed to severe environmental assaults, the sequestration of vital macromolecules in intracellular crystalline assemblies may provide an efficient means for protection. Here we report a generic defence strategy found in Escherichia coli, involving co-crystallization of its DNA with the stress-induced protein Dps(1,2). We show that when purified Dps and DNA interact, extremely stable crystals form almost instantaneously, within which DNA is sequestered and effectively protected against varied assaults. Crystalline structures with similar lattice spacings are formed in E. coli in which Dps is slightly over expressed, as well as in starved wild-type bacteria. Hence, DNA-Dps co-crystallization is proposed to represent a binding mode that provides wide-range protection of DNA by sequestration. The rapid induction and large-scale production of Dps in response to stress, as well as the presence of Dps homologues in many distantly related bacteria, indicate that DNA protection by biocrystallization may be crucial and widespread in prokaryotes.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Weizmann Institute of Science; Weizmann Institute of Science; Harvard University; Harvard Medical School	Minsky, A (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; BERNARDIN WD, 1986, J MOL BIOL, V189, P503; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FLARDH K, 1992, J BACTERIOL, V174, P6780, DOI 10.1128/JB.174.21.6780-6788.1992; FRAZIER BA, 1993, J BACTERIOL, V175, P966, DOI 10.1128/JB.175.4.966-972.1993; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; HOBOT JA, 1985, J BACTERIOL, V162, P960, DOI 10.1128/JB.162.3.960-971.1985; KOLTER R, 1993, ANNU REV MICROBIOL, V47, P855, DOI 10.1146/annurev.micro.47.1.855; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; PENA MMO, 1995, ARCH MICROBIOL, V163, P337, DOI 10.1007/BF00404206; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; PINSINCE JM, 1992, J MOL BIOL, V228, P409, DOI 10.1016/0022-2836(92)90830-D; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; ROBINOW C, 1994, MICROBIOL REV, V58, P211, DOI 10.1128/MMBR.58.2.211-232.1994; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Wai SN, 1997, MICROBIOL IMMUNOL, V41, P461, DOI 10.1111/j.1348-0421.1997.tb01879.x	22	284	297	0	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					83	85		10.1038/21918	http://dx.doi.org/10.1038/21918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403254				2022-12-28	WOS:000081255700056
J	Sever, P				Sever, P			Personal view - Abandoning diastole	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1773	1773		10.1136/bmj.318.7200.1773	http://dx.doi.org/10.1136/bmj.318.7200.1773			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381743	Green Published			2022-12-28	WOS:000081216900082
J	Feighner, SD; Tan, CP; McKee, KK; Palyha, OC; Hreniuk, DL; Pong, SS; Austin, CP; Figueroa, D; MacNeil, D; Cascieri, MA; Nargund, R; Bakshi, R; Abramovitz, M; Stocco, R; Kargman, S; O'Neill, G; Van der Ploeg, LHT; Evans, J; Patchett, AA; Smith, RG; Howard, AD				Feighner, SD; Tan, CP; McKee, KK; Palyha, OC; Hreniuk, DL; Pong, SS; Austin, CP; Figueroa, D; MacNeil, D; Cascieri, MA; Nargund, R; Bakshi, R; Abramovitz, M; Stocco, R; Kargman, S; O'Neill, G; Van der Ploeg, LHT; Evans, J; Patchett, AA; Smith, RG; Howard, AD			Receptor for motilin identified in the human gastrointestinal system	SCIENCE			English	Article							GROWTH-HORMONE SECRETAGOGUE; BINDING-SITES; SMOOTH-MUSCLE; SEQUENCE; RABBIT; EXPRESSION; LOCALIZATION; ERYTHROMYCIN; PRECURSOR; PITUITARY	Motilin is a 22-amino acid peptide hormone expressed throughout the gastrointestinal (GI) tract of humans and other species. It affects gastric motility by stimulating interdigestive antrum and duodenal contractions. A heterotrimeric guanosine triphosphate-binding protein (G protein)-coupled receptor for motilin was isolated from human stomach, and its amino acid sequence was found to be 52 percent identical to the human receptor for growth hormone secretagogues. The macrolide antibiotic erythromycin also interacted with the cloned motilin receptor, providing a molecular basis for its effects on the human GI tract. The motilin receptor is expressed in enteric neurons of the human duodenum and colon. Development of motilin receptor agonists and antagonists may be useful in the treatment of multiple disorders of GI motility.	Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Human Genet, West Point, PA 19486 USA; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H3H 3L1, Canada; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Baylor College of Medicine; Baylor College of Medicine	Howard, AD (corresponding author), Merck Res Labs, Dept Metab Disorders, Bldg RY-80Y-265,126 E Lincoln Ave, Rahway, NJ 07065 USA.	howarda@merck.com		MacNeil, Doug/0000-0001-7089-0668				Benson DA, 1998, NUCLEIC ACIDS RES, V26, P1, DOI 10.1093/nar/26.1.1; BOND CT, 1988, MOL ENDOCRINOL, V2, P175, DOI 10.1210/mend-2-2-175; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BROWN JC, 1973, CAN J BIOCHEM CELL B, V51, P533, DOI 10.1139/o73-066; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; DAIKH DI, 1989, DNA-J MOLEC CELL BIO, V8, P615, DOI 10.1089/dna.1989.8.615; Depoortere I, 1997, AM J PHYSIOL-GASTR L, V272, pG994, DOI 10.1152/ajpgi.1997.272.5.G994; DEPOORTERE I, 1993, PEPTIDES, V14, P1153, DOI 10.1016/0196-9781(93)90169-H; DEPOORTERE I, 1995, REGUL PEPTIDES, V55, P227, DOI 10.1016/0167-0115(94)00111-A; Depoortere I, 1997, BRAIN RES, V777, P103; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; ITOH Z, 1984, AM J PHYSIOL, V247, pG688, DOI 10.1152/ajpgi.1984.247.6.G688; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; Kenakin T, 1996, PHARMACOL REV, V48, P413; MACIELAG MJ, 1992, PEPTIDES, V13, P565, DOI 10.1016/0196-9781(92)90090-P; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MILLER P, 1995, PEPTIDES, V16, P11, DOI 10.1016/0196-9781(94)00148-Y; PEETERS T, 1989, AM J PHYSIOL, V257, pG470, DOI 10.1152/ajpgi.1989.257.3.G470; PEETERS TL, 1988, REGUL PEPTIDES, V23, P171, DOI 10.1016/0167-0115(88)90025-0; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Poitras P, 1996, PEPTIDES, V17, P701, DOI 10.1016/0196-9781(96)00053-8; Poitras P, 1994, GUT PEPTIDES BIOCH P, P261; Porter AJ, 1997, GASTROENTEROLOGY, V113, P1916, DOI 10.1016/S0016-5085(97)70011-8; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAKAI T, 1994, REGUL PEPTIDES, V53, P249, DOI 10.1016/0167-0115(94)90173-2; Scarpignato C, 1997, DIGEST DIS, V15, P112, DOI 10.1159/000171626; SEINO Y, 1987, FEBS LETT, V223, P74, DOI 10.1016/0014-5793(87)80512-4; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621; Tonini M, 1996, PHARMACOL RES, V33, P217, DOI 10.1006/phrs.1996.0030; WEBER FH, 1993, AM J GASTROENTEROL, V88, P485; YANO H, 1989, FEBS LETT, V249, P248, DOI 10.1016/0014-5793(89)80633-7	33	305	372	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2184	2188		10.1126/science.284.5423.2184	http://dx.doi.org/10.1126/science.284.5423.2184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381885				2022-12-28	WOS:000081099300054
J	Haber, JE				Haber, JE			Sir-Ku-itous routes to make ends meet	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; STRAND BREAKS; YEAST KU; RECOMBINATION; MAINTENANCE		Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Haber, JE (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.			Haber, James/0000-0002-1878-0610				Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Garcia SN, 1999, CELL, V97, P825, DOI 10.1016/S0092-8674(00)80794-1; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HEUDE M, 1993, GENETICS, V133, P489; Jackson SP, 1997, NATURE, V388, P829, DOI 10.1038/42136; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; LEE SE, 1999, IN PRESS CURR BIOL; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288	19	56	58	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					829	832		10.1016/S0092-8674(00)80795-3	http://dx.doi.org/10.1016/S0092-8674(00)80795-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399911	Bronze			2022-12-28	WOS:000081162800004
J	Cervero, F; Laird, JMA				Cervero, F; Laird, JMA			Visceral pain	LANCET			English	Article							IRRITABLE-BOWEL-SYNDROME; THORACIC SPINAL-CORD; AFFERENT-FIBERS; NEURONS; STIMULATION; PATHWAY; NOCICEPTORS; PERCEPTION; MECHANISMS; THALAMUS	Visceral pain is the most common form of pain produced by disease and one of the most frequent reasons why patients seek medical attention. Yet much of what we know about the mechanisms ef pain derives from experimental studies of somatic not visceral nociception. The conventional view is that visceral pain is simply a variant of somatic pain, a view based on the belief that a single neurological mechanism is responsible for all pain. However, the more we learn about the mechanisms of somatic and visceral pain, the more we realise that although these two processes have much in common, they also have important differences. Although visceral pain Is an important part of the normal sensory repertoire of all human beings and a prominent symptom of many clinical conditions, not much clinical research has been done in tills field and there are few clinical scientists with expertise In the management of visceral pain. Instead, visceral pain is usually treated by a range of specialists who take quite different approaches to the management of this type of pain. Thus, the management of visceral pain is frequently unsatisfactory. In this review, we consider visceral pain as a separate form of pain and examine its distinct sensory properties from a clinical perspective. We describe recent research findings that may change the way we think about visceral pain and, more importantly, may help develop new procedures for its management.	Univ Alcala de Henares, Dept Fisiol, E-28871 Madrid, Spain	Universidad de Alcala	Cervero, F (corresponding author), Univ Alcala de Henares, Dept Fisiol, E-28871 Madrid, Spain.	ffcervero@fisfar.alcala.es	Drewes, Asbjørn/AAR-7479-2021	Drewes, Asbjørn/0000-0001-7465-964X; Laird, Jennifer/0000-0001-6570-3995				ACCARINO AM, 1995, GASTROENTEROLOGY, V108, P636, DOI 10.1016/0016-5085(95)90434-4; Al-Chaer ED, 1998, J NEUROPHYSIOL, V79, P3143, DOI 10.1152/jn.1998.79.6.3143; AlChaer ED, 1997, J NEUROPHYSIOL, V78, P521, DOI 10.1152/jn.1997.78.1.521; AlChaer ED, 1996, J NEUROPHYSIOL, V76, P2661, DOI 10.1152/jn.1996.76.4.2661; [Anonymous], [No title captured]; [Anonymous], [No title captured]; BERNARD JF, 1994, J NEUROPHYSIOL, V71, P1646, DOI 10.1152/jn.1994.71.5.1646; CERVERO F, 1984, J COMP NEUROL, V230, P88, DOI 10.1002/cne.902300108; CERVERO F, 1992, TRENDS NEUROSCI, V15, P374, DOI 10.1016/0166-2236(92)90182-8; CERVERO F, 1994, PHYSIOL REV, V74, P95, DOI 10.1152/physrev.1994.74.1.95; Cervero F, 1988, PAIN RES CLIN MANAGE, P216; DAVIS KD, 1995, NEUROREPORT, V6, P369, DOI 10.1097/00001756-199501000-00035; JANIG W, 1990, J AUTONOM NERV SYST, V30, pS89, DOI 10.1016/0165-1838(90)90108-U; JANIG W, 1992, AUTONOMIC NERVOUS SY, V2, P523; Jasmin L, 1997, J NEUROSCI, V17, P3751; Katter JT, 1996, J NEUROPHYSIOL, V75, P2606, DOI 10.1152/jn.1996.75.6.2606; Laird JMA, 1997, AM J PHYSIOL-REG I, V272, pR1409, DOI 10.1152/ajpregu.1997.272.5.R1409; Laird JMA, 1995, J PHYSIOL-LONDON, V489, P545, DOI 10.1113/jphysiol.1995.sp021071; LEMANN M, 1991, DIGEST DIS SCI, V36, P1249, DOI 10.1007/BF01307517; LEMBO T, 1994, GASTROENTEROLOGY, V107, P1686, DOI 10.1016/0016-5085(94)90809-5; LENZ FA, 1994, PAIN, V59, P119, DOI 10.1016/0304-3959(94)90055-8; MAYER EA, 1990, GASTROENTEROLOGY, V99, P1688, DOI 10.1016/0016-5085(90)90475-G; Naliboff BD, 1997, GUT, V41, P505, DOI 10.1136/gut.41.4.505; Nauta HJW, 1997, J NEUROSURG, V86, P538, DOI 10.3171/jns.1997.86.3.0538; Perry MJ, 1998, NEUROSCIENCE, V85, P293, DOI 10.1016/S0306-4522(97)00629-5; PIGAREV IN, 1994, NEUROSCIENCE, V62, P1237, DOI 10.1016/0306-4522(94)90355-7; Roza C, 1998, J NEUROPHYSIOL, V79, P1603, DOI 10.1152/jn.1998.79.4.1603; SEMENENKO FM, 1992, NEUROSCIENCE, V47, P197, DOI 10.1016/0306-4522(92)90132-L; Silverman DHS, 1997, GASTROENTEROLOGY, V112, P64, DOI 10.1016/S0016-5085(97)70220-8; Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896-6273(00)81003-X; TATTERSALL JEH, 1986, J NEUROPHYSIOL, V56, P1411, DOI 10.1152/jn.1986.56.5.1411	31	338	375	3	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2145	2148		10.1016/S0140-6736(99)01306-9	http://dx.doi.org/10.1016/S0140-6736(99)01306-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382712				2022-12-28	WOS:000080969300040
J	Marsh, M; McMahon, HT				Marsh, M; McMahon, HT			Cell biology - The structural era of endocytosis	SCIENCE			English	Review							PLECKSTRIN HOMOLOGY DOMAIN; CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; TYROSINE KINASE SUBSTRATE; DEEP-ETCH VISUALIZATION; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; ADAPTER COMPLEX; COATED VESICLES; EPS15 HOMOLOGY		UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of London; University College London; University of London; University College London; MRC Laboratory Molecular Biology	Marsh, M (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	m.marsh@ucl.ac.uk; hmm@mrc-lmb.cam.ac.uk	Marsh, Mark/B-4105-2009	Marsh, Mark/0000-0002-0213-3259				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; HEUSER JE, 1987, J CELL BIOL, V105, P1999, DOI 10.1083/jcb.105.5.1999; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; McMahon HT, 1999, CURR BIOL, V9, pR332, DOI 10.1016/S0960-9822(99)80206-1; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; Ungewickell E, 1999, CURR BIOL, V9, pR32, DOI 10.1016/S0960-9822(99)80040-2; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537	87	464	479	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					215	220		10.1126/science.285.5425.215	http://dx.doi.org/10.1126/science.285.5425.215			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398591				2022-12-28	WOS:000081346000031
J	Cooper, C; Coggon, D				Cooper, C; Coggon, D			Physical activity and knee osteoarthritis	LANCET			English	Editorial Material							RISK		Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England	University of Southampton	Cooper, C (corresponding author), Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.							COOPER C, 1995, J RHEUMATOL S43, V22, P1012; Lane NE, 1996, ANN RHEUM DIS, V55, P682, DOI 10.1136/ard.55.9.682; Maetzel A, 1997, J RHEUMATOL, V24, P1599; McAlindon TE, 1999, AM J MED, V106, P151, DOI 10.1016/S0002-9343(98)00413-6; NEGRET P, 1994, BR J RHEUMATOL, V33, P267; ROOS H, 1994, AM J SPORT MED, V22, P219, DOI 10.1177/036354659402200211; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA	8	18	22	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2177	2178		10.1016/S0140-6736(99)90094-6	http://dx.doi.org/10.1016/S0140-6736(99)90094-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392979				2022-12-28	WOS:000081091300007
J	Peshkin, BN; Lerman, C				Peshkin, BN; Lerman, C			Genetic counselling for hereditary breast cancer	LANCET			English	Editorial Material							OVARIAN CANCER; BRCA1; FAMILIES; PREDISPOSITION; SUSCEPTIBILITY		Georgetown Univ, Med Ctr, Washington, DC 20007 USA	Georgetown University	Peshkin, BN (corresponding author), Georgetown Univ, Med Ctr, Washington, DC 20007 USA.		Lerman, Caryn/AHC-5180-2022					Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; Cull A, 1998, BRIT J CANCER, V77, P830, DOI 10.1038/bjc.1998.135; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LERMAN C, 1994, J CLIN ONCOL, V12, P843, DOI 10.1200/JCO.1994.12.4.843; Lerman C, 1998, J CLIN ONCOL, V16, P1650, DOI 10.1200/JCO.1998.16.5.1650; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Patenaude AF, 1996, PSYCHO-ONCOLOGY, V5, P241; Watson M, 1999, BRIT J CANCER, V79, P868, DOI 10.1038/sj.bjc.6690139; Watson M, 1996, PSYCHO-ONCOL, V5, P233	10	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2176	2177		10.1016/S0140-6736(99)90078-8	http://dx.doi.org/10.1016/S0140-6736(99)90078-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392978	hybrid			2022-12-28	WOS:000081091300006
J	van Gijn, J				van Gijn, J			Low doses of aspirin in stroke prevention	LANCET			English	Editorial Material									Univ Utrecht, Med Ctr, Dept Neurol, NL-3508 GA Utrecht, Netherlands	Utrecht University	van Gijn, J (corresponding author), Univ Utrecht, Med Ctr, Dept Neurol, NL-3508 GA Utrecht, Netherlands.		van Gijn, Jan/A-9444-2008					Algra A, 1996, J NEUROL NEUROSUR PS, V60, P197, DOI 10.1136/jnnp.60.2.197; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; Barnett HJM, 1996, STROKE, V27, P588, DOI 10.1161/01.STR.27.4.588; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; DYKEN ML, 1992, STROKE, V23, P1395, DOI 10.1161/01.STR.23.10.1395; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; OBRIEN JR, 1968, LANCET, V1, P779; Vandenbroucke JP, 1998, LANCET, V352, P2001, DOI 10.1016/S0140-6736(98)10208-8; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801	10	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2172	2173		10.1016/S0140-6736(99)00199-3	http://dx.doi.org/10.1016/S0140-6736(99)00199-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392974				2022-12-28	WOS:000081091300002
J	Lu, PJ; Wulf, G; Zhou, XZ; Davies, P; Lu, KP				Lu, PJ; Wulf, G; Zhou, XZ; Davies, P; Lu, KP			The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein	NATURE			English	Article							PAIRED HELICAL FILAMENTS; SUBSTRATE RECOGNITION; DISEASE; DEMENTIA; MITOSIS; CHROMOSOME-17; EXPRESSION; MUTATIONS; ISOFORMS; DISTINCT	One of the neuropathological hallmarks of Alzheimer's disease is the neurofibrillary tangle, which contains paired helical filaments (PHFs) composed of the microtubule-associated protein tau(1,2). Tau is hyperphosphorylated in PHFs(3-5), and phosphorylation of tau abolishes its ability to bind microtubules and promote microtubule assembly(6,7). Restoring the function of phosphorylated tau might prevent or reverse PHF formation in Alzheimer's disease. Phosphorylation on a serine or threonine that precedes proline (pS/T-P) alters the rate of prolyl isomerization and creates a binding site for the WW domain of the prolyl isomerase Pin1 (refs 8-14), Pin1 specifically isomerizes pS/T-P bonds and regulates the function of mitotic phosphoproteins(8-10,12). Here we show that Pin1 binds to only one pT-P motif in tau and copurifies with PHFs, resulting in depletion of soluble Pin1 in the brains of Alzheimers disease patients. Pin1 can restore the ability of phosphorylated tau to bind microtubules and promote microtubule assembly in vitro, As depletion of Pin1 induces mitotic arrest and apoptotic cell death(8), sequestration of Pin1 into PHFs may contribute to neuronal death. These findings provide a new insight into the pathogenesis of Alzheimer's disease.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.		Wulf, Gerburg/AAS-6713-2021					ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kondratick CM, 1996, J NEUROCHEM, V67, P2405; Kosik KS, 1996, ANN NY ACAD SCI, V777, P114, DOI 10.1111/j.1749-6632.1996.tb34409.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lu KP, 1996, NATURE, V380, P544; LU KP, IN PRESS PROG CELL C; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Nagy Z, 1997, ACTA NEUROPATHOL, V93, P294, DOI 10.1007/s004010050617; Preuss U, 1998, EUR J CELL BIOL, V76, P176, DOI 10.1016/S0171-9335(98)80032-0; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	30	602	630	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					784	788						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391244				2022-12-28	WOS:000081101600054
J	Pauwels, RA; Lofdahl, CG; Laitinen, LA; Schouten, JP; Postma, DS; Pride, NB; Ohlsson, SV				Pauwels, RA; Lofdahl, CG; Laitinen, LA; Schouten, JP; Postma, DS; Pride, NB; Ohlsson, SV		European Resp Soc Study Chronic Obstruct Pulm D	Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIR-FLOW OBSTRUCTION; CHRONIC-BRONCHITIS; CORTICOSTEROID-THERAPY; BRONCHODILATOR THERAPY; FLUTICASONE PROPIONATE; COPD; SMOKERS; ASTHMA; RESPONSIVENESS; BECLOMETHASONE	Background and Methods Although patients with chronic obstructive pulmonary disease (COPD) should stop smoking, some do not. In a double-blind, pla cebo-controlled study, we evaluated the effect of the inhaled glucocorticoid budesonide in subjects with mild COPD who continued smoking. After a six-month run-in period, we randomly assigned 1277 subjects (mean age, 52 years; mean forced expiratory volume in one second [FEV1], 77 percent of the predicted value; 73 percent men) to twice-daily treatment with 400 mu g of budesonide or placebo, inhaled from a dry-powder inhaler, for three years. Results Of the 1277 subjects, 912 (71 percent) completed the study. Among these subjects, the median decline in the FEV1 after the use of a bronchodilator over the th ree-year period was 140 ml in the budesonide group and 180 mi in the placebo group (P=0.05), or 4.3 percent and 5.3 percent of the predicted value, respectively. During the first six months of the study, the FEV1 improved at the rate of 17 mi per year in the budesonide group, as compared with a decline of 81 mi per year in the placebo group (P<0.001). From nine months to the end of treatment, the FEV1 declined at similar rates in the two groups (P=0.39). Ten percent of the subjects in the budesonide group and 4 percent of those in the placebo group had skin bruising (P<0.001). Newly diagnosed hypertension, bone fractures, postcapsular cataracts, myopathy, and diabetes occurred in less than 5 percent of the subjects, and the diagnoses were equally distributed between the groups. Conclusions In persons with mild COPD who continue smoking, the use of inhaled budesonide is associated with a small one-time improvement in lung function but does not appreciably affect the long-term progressive decline. (N Engl J Med 1999;340:1948-53.) (C) 1999, Massachusetts Medical Society.	Ghent Univ Hosp, Dept Resp Dis, B-9000 Ghent, Belgium; Univ Lund Hosp, Dept Resp Med, Lund, Sweden; Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland; Univ Groningen, Dept Epidemiol & Stat, Groningen, Netherlands; Univ Groningen Hosp, Div Resp Dis, Groningen, Netherlands; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Div Resp, London, England; Astro Draco AB, Clin Res & Dev, Lund, Sweden	Ghent University; Ghent University Hospital; Lund University; Skane University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Groningen; University of Groningen; Imperial College London	Pauwels, RA (corresponding author), Ghent Univ Hosp, Dept Resp Dis, Pintelaan 185, B-9000 Ghent, Belgium.	romain.pauweis@ac.be						AKAIKE H, 1970, ANN I STAT MATH, V22, P203, DOI 10.1007/BF02506337; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; AUFFARTH B, 1991, THORAX, V46, P372, DOI 10.1136/thx.46.5.372; Burrows B., 1991, EUR RESPIR REV, V1, P340; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; Confalonieri M, 1998, THORAX, V53, P583, DOI 10.1136/thx.53.7.583; Davidian M, 1995, NONLINEAR MODELS REP; DOMPELING E, 1992, EUR RESPIR J, V5, P945; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; ELIASSON O, 1986, CHEST, V89, P484, DOI 10.1378/chest.89.4.484; ENGEL T, 1989, EUR RESPIR J, V2, P935; Jeffery PK, 1998, THORAX, V53, P129, DOI 10.1136/thx.53.2.129; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LlewellynJones CG, 1996, AM J RESP CRIT CARE, V153, P616, DOI 10.1164/ajrccm.153.2.8564107; MAK VHF, 1992, EUR RESPIR J, V5, P1068; *NAT HEART LUNG BL, 1995, NIH PUBL; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Paggiaro PL, 1998, LANCET, V351, P1968; PAUWELS RA, 1992, EUR RESPIR J, V5, P1254; Pinheiro J.C., 1995, LME NLME MIXED EFFEC; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P56; POSTMA DS, 1988, EUR RESPIR J, V1, P22; Pride NB, 1995, CHRONIC OBSTRUCTIVE, P69; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Renkema TEJ, 1996, CHEST, V109, P1156, DOI 10.1378/chest.109.5.1156; SAETTA M, 1994, EUR RESPIR J, V7, P1505, DOI 10.1183/09031936.94.07081505; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; THOMPSON AB, 1992, AM REV RESPIR DIS, V146, P389, DOI 10.1164/ajrccm/146.2.389; WATSON A, 1992, CHEST, V101, P350, DOI 10.1378/chest.101.2.350; WEIR DC, 1993, THORAX, V48, P309, DOI 10.1136/thx.48.4.309	35	706	736	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1948	1953		10.1056/NEJM199906243402503	http://dx.doi.org/10.1056/NEJM199906243402503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379018				2022-12-28	WOS:000081088500003
J	Matray, TJ; Kool, ET				Matray, TJ; Kool, ET			A specific partner for abasic damage in DNA	NATURE			English	Article							APURINIC APYRIMIDINIC SITES; DEOXYRIBONUCLEIC-ACID; REPLICATION FIDELITY; OLIGODEOXYNUCLEOTIDES; FLUORESCENCE; SELECTIVITY; POLYMERASES; MECHANISM; INSERTION; CRYSTAL	In most-models of DNA replication, Watson-Crick hydrogen bonding drives the incorporation of nucleotides into the new strand of DNA and maintains the complementarity of bases with the template strand. Studies with nonpolar analogues of thymine and adenine, however, have shown that replication is still efficient in the absence of hydrogen bonds(1-4). The replication of base pairs might also be influenced by steric exclusion, whereby inserted nucleotides need to be the correct size and shape to fit the active site against a template base(5,6). A simple steric-exclusion model map not require Watson-Crick hydrogen bonding to explain the fidelity of replication, nor should canonical purine and pyrimidine shapes be necessary for enzymatic synthesis of a base pair if each can fit into the DNA double helix without steric strain(6). Here we test this idea by using a pyrene nucleoside triphosphate (dPTP) in which the fluorescent 'base' is nearly as large as an entire Watson-Crick base pair. We show that the non-hydrogen-bonding dPTP is efficiently and specifically inserted by DNA polymerases opposite sites that lack DNA bases. The efficiency of this process approaches that of a natural base pair and the specificity is 10(2)-10(4)-fold. We use these properties to sequence abasic lesions in DNA, which are a common form of DNA damage in vivo(7). In addition to their application in identifying such genetic lesions, our results show that neither hydrogen bonds nor purine and pyrimidine structures are required to form a base pair with high efficiency and selectivity. These findings confirm that steric complementarity is an important factor in the fidelity of DNA synthesis.	Univ Rochester, Dept Chem, Rochester, NY 14627 USA	University of Rochester	Kool, ET (corresponding author), Univ Rochester, Dept Chem, Rochester, NY 14627 USA.							Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Diederichsen U, 1998, ANGEW CHEM INT EDIT, V37, P1655, DOI 10.1002/(SICI)1521-3773(19980703)37:12<1655::AID-ANIE1655>3.0.CO;2-2; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IDE H, 1993, BIOCHEMISTRY-US, V32, P8276, DOI 10.1021/bi00083a031; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Matray TJ, 1998, J AM CHEM SOC, V120, P6191, DOI 10.1021/ja9803310; Maulik G, 1999, NUCLEIC ACIDS RES, V27, P1316, DOI 10.1093/nar/27.5.1316; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MISHRA MC, 1991, J CHEM SOC CHEM COMM, P1276; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Paris PL, 1998, NUCLEIC ACIDS RES, V26, P3789, DOI 10.1093/nar/26.16.3789; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; Shibutani S, 1997, J BIOL CHEM, V272, P13916, DOI 10.1074/jbc.272.21.13916; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WEISS B, 1972, ADV ENZYMOL REL AREA, V60, P1	30	216	233	2	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					704	708		10.1038/21453	http://dx.doi.org/10.1038/21453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385125				2022-12-28	WOS:000080932800065
J	Colvin, M				Colvin, M			Gertrude Belle Elion - (1918-1999) - Retrospective	SCIENCE			English	Biographical-Item									Duke Comprehens Canc Ctr, Durham, NC 27710 USA	Duke University	Colvin, M (corresponding author), Duke Comprehens Canc Ctr, Durham, NC 27710 USA.								0	2	2	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1480	1480		10.1126/science.284.5419.1480	http://dx.doi.org/10.1126/science.284.5419.1480			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10383327				2022-12-28	WOS:000080548100026
J	Young, DB; Robertson, BD				Young, DB; Robertson, BD			Microbiology - TB vaccines: Global solutions for global problems	SCIENCE			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; BCG		Imperial Coll Sch Med, Dept Infect Dis & Microbiol, London W2 1PG, England	Imperial College London	Young, DB (corresponding author), Imperial Coll Sch Med, Dept Infect Dis & Microbiol, Norfolk Pl, London W2 1PG, England.			Robertson, Brian D./0000-0001-5785-5307				Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Behr MA, 1997, NATURE, V389, P133, DOI 10.1038/38151; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; de Saizieu A, 1998, NAT BIOTECHNOL, V16, P45, DOI 10.1038/nbt0198-45; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869	9	12	13	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1479	1480		10.1126/science.284.5419.1479	http://dx.doi.org/10.1126/science.284.5419.1479			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10383326				2022-12-28	WOS:000080548100025
J	Beecham, L; Ferriman, A				Beecham, L; Ferriman, A			The BMA's annual representative meeting	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					193	198						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406778				2022-12-28	WOS:000081619300057
J	Monto, AS; Robinson, DP; Herlocher, ML; Hinson, JM; Elliott, MJ; Crisp, A				Monto, AS; Robinson, DP; Herlocher, ML; Hinson, JM; Elliott, MJ; Crisp, A			Zanamivir in the prevention of influenza among healthy adults - a randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	38th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 24-28, 1998	SAN DIEGO, CA				A VIRUS; B VIRUS; AMANTADINE; INHIBITOR; NEURAMINIDASE; RIMANTADINE; SIALIDASE; RESISTANT; EFFICACY; INFECTION	Context The neuraminidase inhibitor zanamivir, a sialic add analog administered directly to the respiratory tract, has been demonstrated in clinical studies to be effective in treatment of type A acid B influenza. It has also been shown to prevent influenza infection and disease in an experimental model. Objective To examine the efficacy of zanamivir, administered once daily, in the prevention of influenza infection and disease. Design Double-blind, randomized, placebo-controlled trial. Setting Two midwestern university communities. Participants A total of 1107 healthy adults (mean age [range], 29 [18-69] years) were recruited in November 1997, before the influenza season. Intervention At the start of the influenza outbreak, 554 subjects were randomized to receive placebo and 553 to receive zanamivir, The drug, 10 mg once per day, or identical placebo was administered by oral inhalation for a 4-week period. Main Outcome Measures Illness occurrence was recorded by participants daily and records were evaluated weekly. Specimens were collected for viral isolation when symptoms were reported within 3 days of illness onset. Infection was also identified by testing paired serum samples for rise in antibody titer against the circulating influenza viruses. Results Zanamivir was 67% efficacious (95% confidence interval [CI], 39%-83%; P<.001) in preventing laboratory-confirmed clinical influenza meeting the case definition and 84% efficacious (95% CI, 55%-94%; P = .001) in preventing laboratory-confirmed illnesses with fever. All influenza infections occurring during the season, with or without symptoms, were prevented with an efficacy of 31% (95% CI, 4%-50%; P = .03). The nature and incidence of adverse events in the zanamivir group did not differ from placebo. Compliance with the once-daily dosage was high. Conclusions Zanamivir administered once daily is efficacious and well tolerated in the prevention of influenza for a 4-week period in healthy adults.	Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Univ Missouri, Columbia, MO USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Greenford, Middx, England	University of Michigan System; University of Michigan; University of Missouri System; University of Missouri Columbia; GlaxoSmithKline; GlaxoSmithKline	Monto, AS (corresponding author), Univ Michigan, Sch Publ Hlth, 109 Observ St, Ann Arbor, MI 48109 USA.	asmonto@umich.edu						[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P72; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P196; COX DR, 1966, BIOMETRIKA, V53, P215, DOI 10.2307/2334067; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.1093/biomet/57.3.471; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; Hart GJ, 1995, BIOCHEM MOL BIOL INT, V36, P695; HAYDEN FG, 1991, ANTIMICROB AGENTS CH, V35, P1741, DOI 10.1128/AAC.35.9.1741; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; KOCH GG, 1998, BIOPHARMACEUTICAL ST, P403; MONTO AS, 1992, CLIN INFECT DIS, V15, P362, DOI 10.1093/clinids/15.2.362; MONTO AS, 1979, JAMA-J AM MED ASSOC, V241, P1003, DOI 10.1001/jama.241.10.1003; MONTO AS, 1973, AM J EPIDEMIOL, V97, P338, DOI 10.1093/oxfordjournals.aje.a121514; Monto AS, 1996, INT CONGR SER, V1123, P45; OXFORD JS, 1970, NATURE, V226, P82, DOI 10.1038/226082a0; POSTMA JU, 1975, J AM GERIATR SOC, V23, P212, DOI 10.1111/j.1532-5415.1975.tb00187.x; SABIN AB, 1967, J AMER MED ASSOC, V200, P943, DOI 10.1001/jama.200.11.943; Schilling M, 1998, VACCINE, V16, P1771, DOI 10.1016/S0264-410X(98)00141-8; THOMAS RG, 1992, CONTROL CLIN TRIALS, V13, P134, DOI 10.1016/0197-2456(92)90019-V; vonItzstein M, 1996, J MED CHEM, V39, P388, DOI 10.1021/jm950294c; WOODS JM, 1993, ANTIMICROB AGENTS CH, V37, P1473, DOI 10.1128/AAC.37.7.1473	24	226	238	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					31	35		10.1001/jama.282.1.31	http://dx.doi.org/10.1001/jama.282.1.31			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	212BE	10404908	Bronze			2022-12-28	WOS:000081195800025
J	Ranieri, VM; Suter, PM; Tortorella, C; De Tullio, R; Dayer, JM; Brienza, A; Bruno, F; Slutsky, AS				Ranieri, VM; Suter, PM; Tortorella, C; De Tullio, R; Dayer, JM; Brienza, A; Bruno, F; Slutsky, AS			Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-EXPIRATORY PRESSURE; TUMOR-NECROSIS-FACTOR; TIDAL VOLUME; PROTECTIVE-VENTILATION; PERSISTENT ELEVATION; ALVEOLAR MACROPHAGES; PULMONARY-EDEMA; LUNG INJURY; ARDS; CYTOKINES	Context Studies have shown that an inflammatory response may be elicited by mechanical ventilation used for recruitment or derecruitment of collapsed lung units or to overdistend alveolar regions, and that a lung-protective strategy may reduce this response. Objective To test the hypothesis that mechanical ventilation induces a pulmonary and systemic cytokine response that can be minimized by limiting recruitment or derecruitment and overdistention. Design and Setting Randomized controlled trial in the intensive care units of 2 European hospitals from November 1995 to February 1998, with a 28-day follow-up. Patients Forty-four patients (mean [SD] age, 50 [18] years) with acute respiratory distress syndrome were enrolled, 7 of whom were withdrawn due to adverse events. Interventions After admission, volume-pressure curves were measured and bronchoalveolar lavage and blood samples were obtained. Patients were randomized to either the control group (n = 19). tidal volume to obtain normal values of arterial carbon dioxide tension (35-40 mm Hg) and positive end-expiratory pressure (PEEP) producing the greatest improvement in arterial oxygen saturation without worsening hemodynamics; or the lung-protective strategy group (n = 18), tidal volume and PEEP based on the volume-pressure curve. Measurements were repeated 24 to 30 and 36 to 40 hours after randomization. Main Outcome Measures Pulmonary and systemic concentrations of inflammatory mediators approximately 36 hours after randomization. Results Physiological characteristics and cytokine concentrations were similar in both groups at randomization. There were significant differences (mean [SD]) between the control and lung-protective strategy groups in tidal volume (11.1 [1.3] vs 7.6 [1.1] mL/kg), end-inspiratory plateau pressures (31.0 [4.5] vs 24.6 [2.4] cm H2O), and PEEP (6.5 [1.7] vs 14.8 [2.7] cm H2O) (P<.001), Patients in the control group had an in crease in bronchoalveolar lavage concentrations of interleukin (IL) 1 beta, IL-6, and IL-1 receptor agonist and in both bronchoalveolar lavage and plasma concentrations of tumor necrosis factor (TNF) alpha, IL-6, and TNF-alpha receptors over 36 hours (P<.05 for all). Patients in the lung-protective strategy group had a reduction in bronchoalveolar lavage concentrations of polymorphonuclear cells, TNF-alpha, IL-1 beta, soluble TNF-alpha receptor 55, and IL-8, and in plasma and bronchoalveolar lavage concentrations of IL-6, soluble TNF-alpha receptor 75, and IL-1 receptor antagonist (P<.05). The concentration of the inflammatory mediators 36 hours after randomization was significantly lower in the lung-protective strategy group than in the control group (P<.05). Conclusions Mechanical ventilation can induce a cytokine response that may be attenuated by a strategy to minimize overdistention and recruitment/derecruitment of the lung, Whether these physiological improvements are associated with improvements in clinical end points should be determined in future studies.	Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Bari, Osped Policlin, Ist Anestesiol & Rianimaz, Bari, Italy; Univ Bari, Osped Policlin, Serv Pneumol, Bari, Italy; Univ Bari, Osped Policlin, Dipartimento Med Interna, Bari, Italy; Univ Geneva, Hop Cantonal Univ Geneva, Div Surg Intens Care, Geneva, Switzerland; Univ Geneva, Hop Cantonal Univ Geneva, Div Immunol & Allergy, Geneva, Switzerland	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Geneva; University of Geneva	Ranieri, VM (corresponding author), Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Room 656A,600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Slutsky, Arthur S/A-6013-2008; Slutsky, Arthur/M-3325-2019; Ranieri, Marco/AFX-8152-2022	Slutsky, Arthur S/0000-0002-6063-3876; Tortorella, Cosimo/0000-0002-4504-9313				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; CHIUMELLO D, 1998, AM J RESP CRIT CARE, V157, pA45; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Douzinas EE, 1997, AM J RESP CRIT CARE, V155, P53, DOI 10.1164/ajrccm.155.1.9001289; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593; HAMILTON PP, 1983, J APPL PHYSIOL, V55, P131, DOI 10.1152/jappl.1983.55.1.131; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; Hudson LD, 1998, NEW ENGL J MED, V338, P385, DOI 10.1056/NEJM199802053380609; KAWANO T, 1987, J APPL PHYSIOL, V62, P27, DOI 10.1152/jappl.1987.62.1.27; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Meduri GU, 1998, AM J RESP CRIT CARE, V158, P1432; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303; Meduri GU, 1997, CHEST, V112, P1154, DOI 10.1378/chest.112.5.1154; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; MICHIE HR, 1990, ARCH SURG-CHICAGO, V125, P531; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Nahum A, 1997, CRIT CARE MED, V25, P1733, DOI 10.1097/00003246-199710000-00026; Pugin J, 1998, AM J PHYSIOL-LUNG C, V275, pL1040, DOI 10.1152/ajplung.1998.275.6.L1040; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; Schwartz MD, 1996, CRIT CARE MED, V24, P1285, DOI 10.1097/00003246-199608000-00004; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; VANOTTEREN GM, 1995, AM J RESP CELL MOL, V13, P399, DOI 10.1165/ajrcmb.13.4.7546769; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U	42	1268	1340	1	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					54	61		10.1001/jama.282.1.54	http://dx.doi.org/10.1001/jama.282.1.54			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404912	Bronze			2022-12-28	WOS:000081195800029
J	McGuffin, P; Martin, N				McGuffin, P; Martin, N			Science, medicine and the future - Behaviour and genes	BRITISH MEDICAL JOURNAL			English	Review							TWIN POPULATION; DEPRESSION; SYMPTOMS		Univ London Kings Coll, Inst Psychiat, Social Genet & Dev Psychiat Res Ctr, London SE5 8AF, England; Univ Wales Coll Med, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales	University of London; King's College London; Cardiff University	McGuffin, P (corresponding author), Univ London Kings Coll, Inst Psychiat, Social Genet & Dev Psychiat Res Ctr, London SE5 8AF, England.		McGuffin, Peter/A-1565-2012	McGuffin, Peter/0000-0002-9888-2907				ASHERSON P, 1998, CNS, V1, P18; BERTELSEN A, 1977, BRIT J PSYCHIAT, V130, P330, DOI 10.1192/bjp.130.4.330; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Daniels J, 1998, AM J HUM GENET, V62, P1189, DOI 10.1086/301816; EDWARDS J. H., 1960, ACTA GENET ET STATIST MED, V10, P63; Farmer A, 1999, PSYCHOL MED, V29, P279, DOI 10.1017/S0033291798008095; Fisher PJ, 1999, HUM MOL GENET, V8, P915, DOI 10.1093/hmg/8.5.915; FOLSTEIN S, 1977, J CHILD PSYCHOL PSYC, V18, P297, DOI 10.1111/j.1469-7610.1977.tb00443.x; GOTTESMAN II, 1999, SCHIZOPHRENIA GENETI; Grigorenko EL, 1997, AM J HUM GENET, V60, P27; HESTON LL, 1966, BRIT J PSYCHIAT, V112, P819, DOI 10.1192/bjp.112.489.819; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KETY SS, 1994, ARCH GEN PSYCHIAT, V51, P442; MCGUFFIN P, 1990, AM J HUM GENET, V46, P994; McGuffin P, 1996, ARCH GEN PSYCHIAT, V53, P129; MCGUFFIN P, 1994, SEMINARS PSYCHIAT GE; Moldin SO, 1997, NAT GENET, V17, P127, DOI 10.1038/ng1097-127; Neale MC, 1992, METHODOLOGY GENETIC; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; Plomin R., 1997, BEHAV GENET; Risch N, 1996, NAT GENET, V12, P351, DOI 10.1038/ng0496-351; RUTHERFORD J, 1993, PSYCHOL MED, V23, P425, DOI 10.1017/S003329170002852X; SAIKH S, 1997, CNS DRUGS, V8, P1; Thapar A, 1999, BRIT J PSYCHIAT, V174, P105, DOI 10.1192/bjp.174.2.105; Thapar A, 1998, J CHILD PSYCHOL PSYC, V39, P1153, DOI 10.1017/S0021963098003229; Woodman R, 1999, BRIT MED J, V318, P1093, DOI 10.1136/bmj.318.7191.1093	26	16	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					37	40		10.1136/bmj.319.7201.37	http://dx.doi.org/10.1136/bmj.319.7201.37			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214KE	10390460	Green Published			2022-12-28	WOS:000081326500034
J	Rowland-Jones, S				Rowland-Jones, S			HIV infection: where have all the T cells gone?	LANCET			English	Editorial Material							CD4(+); REPERTOIRE; TURNOVER; THERAPY; AIDS		John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England	University of Oxford	Rowland-Jones, S (corresponding author), John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Haynes BF, 1999, J CLIN INVEST, V103, P921, DOI 10.1172/JCI5201E1; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wilson JDK, 1998, J EXP MED, V188, P785, DOI 10.1084/jem.188.4.785; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543	17	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					5	7		10.1016/S0140-6736(99)90017-X	http://dx.doi.org/10.1016/S0140-6736(99)90017-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406356				2022-12-28	WOS:000081243200005
J	Woodman, R				Woodman, R			Royal college demands 2000 more NHS consultant physicians	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					12	12		10.1136/bmj.319.7201.12	http://dx.doi.org/10.1136/bmj.319.7201.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390448	Green Published			2022-12-28	WOS:000081326500019
J	Crowcroft, NS; Infuso, A; Ilef, D; Le Guenno, B; Desenclos, JC; Van Loock, F; Clement, J				Crowcroft, NS; Infuso, A; Ilef, D; Le Guenno, B; Desenclos, JC; Van Loock, F; Clement, J			Risk factors for human hantavirus infection: Franco-Belgian collaborative case-control study during 1995-6 epidemic	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Sci Inst Publ Hlth Louis Pasteur, Dept Epidemiol, Infect Dis Unit, Brussels, Belgium; Reseau Natl Sante Publ, St Maurice, France; Direct Rag Affaires Sanit & Sociales Nord, Lille, France; Inst Pasteur, Ctr Natl Reference Fievres Hemorrag & Arbovirus, Paris, France; Queen Astrid Mil Hosp, Natl Reference Ctr Hantavirus Infect, Belgian Zoonosis Workgrp, B-1120 Brussels, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Queen Astrid Military Hospital	Crowcroft, NS (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England.	mcrowcro@ogks.co.uk						Clement J, 1997, EMERG INFECT DIS, V3, P205, DOI 10.3201/eid0302.970218; CLEMENT J, 1994, LANCET, V343, P114, DOI 10.1016/S0140-6736(94)90841-9; LEGUENNO B, 1994, MED MALADIES INFECT, V24, P512, DOI 10.1016/S0399-077X(05)81257-0; LeGuenno B, 1997, MED MALADIES INFECT, V27, P703, DOI 10.1016/S0399-077X(97)80179-5; VANLOOCK F, IN PRESS CLIN INFECT	5	41	44	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1737	1738		10.1136/bmj.318.7200.1737	http://dx.doi.org/10.1136/bmj.318.7200.1737			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381709	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000081216900031
J	McQuay, H				McQuay, H			Opioids in pain management	LANCET			English	Article							INDUCED RESPIRATORY DEPRESSION; CANCER PAIN; MORPHINE; RAT; METABOLITES; ANALGESIA; CIRRHOSIS	Opioids are our most powerful analgesics, but politics, prejudice, and our continuing ignorance still impede optimum prescribing. Just over 100 years ago, opium poppies were still gown on the Cambridgeshire fens in the UK to provide oblivion for the working man and his family, but the brewing lobby argued on thin evidence that their potions were less dangerous. The restriction of opioid availability to protect society and the individual continues in many countries. In this review I focus on chronic and cancer pain, but many of the principles apply in acute pain. The justification for this focus is that patients with chronic pain may suffer longer and unnecessarily if we prescribe and legislate badly.	Univ Oxford, Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 7LJ, England	University of Oxford	McQuay, H (corresponding author), Univ Oxford, Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 7LJ, England.							ANDERSEN R, 1976, CAN ANAESTH SOC J, V23, P366, DOI 10.1007/BF03005916; BANNING A, 1991, PAIN, V47, P129, DOI 10.1016/0304-3959(91)90195-4; Borgbjerg FM, 1996, PAIN, V64, P123, DOI 10.1016/0304-3959(95)00088-7; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; EISENACH JC, 1995, PAIN, V61, P391, DOI 10.1016/0304-3959(94)00209-W; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; FRASER HM, 1992, PAIN, V49, P33, DOI 10.1016/0304-3959(92)90185-E; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; HANKS GW, 1981, ANAESTHESIA, V36, P37, DOI 10.1111/j.1365-2044.1981.tb08596.x; HASSELSTROM J, 1990, BRIT J CLIN PHARMACO, V29, P289, DOI 10.1111/j.1365-2125.1990.tb03638.x; Houde R. W., 1965, ANALGESICS, P75; HOUDE RW, 1985, NIDA RES MONOGR, V55, P4; HOUDE RW, 1986, ADV PAIN RES THER, V8, P261; HOUDE RW, 1966, INT ENCY PHARM THERA, P59; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Kalso E, 1996, PAIN, V67, P443, DOI 10.1016/0304-3959(96)03161-2; LAIDLAW J, 1961, GASTROENTEROLOGY, V40, P389; MAVES TJ, 1992, ANESTHESIOLOGY, V76, P91, DOI 10.1097/00000542-199201000-00014; MCQUAY HJ, 1988, BRIT J ANAESTH, V61, P121, DOI 10.1093/bja/61.1.121; MCQUAY HJ, IN PRESS TXB PAIN; McQuay HJ, 1998, EVIDENCE BASED RESOU; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; PATWARDHAN RV, 1981, GASTROENTEROLOGY, V81, P1006; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; PORTER J, 1980, NEW ENGL J MED, V302, P123; Rossi GC, 1996, NEUROSCI LETT, V216, P1; SULLIVAN AF, 1989, BRAIN RES, V482, P219, DOI 10.1016/0006-8993(89)91184-0; SZETO HH, 1977, ANN INTERN MED, V86, P738, DOI 10.7326/0003-4819-86-6-738	29	225	243	1	36	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2229	2232		10.1016/S0140-6736(99)03528-X	http://dx.doi.org/10.1016/S0140-6736(99)03528-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10393001				2022-12-28	WOS:000081091300043
J	Durr, HA; Dudzik, E; Dhesi, SS; Goedkoop, JB; van der Laan, G; Belakhovsky, M; Mocuta, C; Marty, A; Samson, Y				Durr, HA; Dudzik, E; Dhesi, SS; Goedkoop, JB; van der Laan, G; Belakhovsky, M; Mocuta, C; Marty, A; Samson, Y			Chiral magnetic domain structures in ultrathin FePd films	SCIENCE			English	Article							RESONANCE EXCHANGE SCATTERING; X-RAY-SCATTERING; POLARIZATION; EDGES; IRON	The magnetization profile of magnetically ordered patterns in ultrathin films was determined by circular dichroism in x-ray resonant magnetic scattering (CDXRMS), When this technique was applied to single crystalline iran palladium alloy layers, magnetic flux closure domains were found whose thickness can constitute a large fraction (similar to 25 percent) of the total film.	SERC, Daresbury Lab, Magnet Spect Grp, Warrington WA4 4AD, Cheshire, England; Univ York, York YO1 5DD, N Yorkshire, England; Univ Amsterdam, NL-1081 XE Amsterdam, Netherlands; CEA Grenoble, Serv Phys Mat & Microstruct, F-38054 Grenoble 9, France	STFC Daresbury Laboratory; University of York - UK; University of Amsterdam; CEA	van der Laan, G (corresponding author), SERC, Daresbury Lab, Magnet Spect Grp, Warrington WA4 4AD, Cheshire, England.		marty, alain/H-7941-2014; van der Laan, Gerrit/Q-1662-2015; Durr, Hermann A/F-6205-2012; MOCUTA, Cristian/AAZ-9342-2020	marty, alain/0000-0001-5709-6945; van der Laan, Gerrit/0000-0001-6852-2495; Durr, Hermann/0000-0001-9680-8730				BLUME M, 1985, J APPL PHYS, V57, P3615, DOI 10.1063/1.335023; CARRA P, 1994, REV MOD PHYS, V66, P1509, DOI 10.1103/RevModPhys.66.1509; Gehanno V, 1997, PHYS REV B, V55, P12552, DOI 10.1103/PhysRevB.55.12552; GIBBS D, 1988, PHYS REV LETT, V61, P1241, DOI 10.1103/PhysRevLett.61.1241; HANNON JP, 1988, PHYS REV LETT, V61, P1245, DOI 10.1103/PhysRevLett.61.1245; Hill JP, 1996, ACTA CRYSTALLOGR A, V52, P236, DOI 10.1107/S0108767395012670; KAO C, 1990, PHYS REV LETT, V65, P373, DOI 10.1103/PhysRevLett.65.373; KITTEL C, 1946, PHYS REV, V70, P965, DOI 10.1103/PhysRev.70.965; KORTRIGHT JB, 1995, PHYS REV B, V51, P10240, DOI 10.1103/PhysRevB.51.10240; LUO J, 1993, PHYS REV LETT, V71, P287, DOI 10.1103/PhysRevLett.71.287; Sacchi M, 1998, PHYS REV LETT, V81, P1521, DOI 10.1103/PhysRevLett.81.1521; Stamm C, 1998, SCIENCE, V282, P449, DOI 10.1126/science.282.5388.449; TONNERRE JM, 1995, PHYS REV LETT, V75, P740, DOI 10.1103/PhysRevLett.75.740; van der Laan G, 1999, PHYS REV LETT, V82, P640, DOI 10.1103/PhysRevLett.82.640	14	163	163	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2166	2168		10.1126/science.284.5423.2166	http://dx.doi.org/10.1126/science.284.5423.2166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381879				2022-12-28	WOS:000081099300048
J	Eschenmoser, A				Eschenmoser, A			Chemical etiology of nucleic acid structure	SCIENCE			English	Review							RNA P-RNA; TEMPLATE-DIRECTED SYNTHESIS; PYRANOSYL-RNA; HOMO-DNA; HYBRIDIZATION PROPERTIES; SELF-REPLICATION; HAIRPIN OLIGONUCLEOTIDES; CATALYZED SYNTHESIS; PAIRING PROPERTIES; AQUEOUS-SOLUTION	Systematic chemical studies indicate that the capability of Watson-Crick base-pairing is widespread among potentially natural nucleic acid alternatives taken from RNA's close structural neighborhood. A comparison of RNA and such alternatives with regard to chemical properties that are fundamental to the biological function of RNA provides chemical facts that may contain clues to RNA's origin.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland	Scripps Research Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich	Eschenmoser, A (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Krishnamurthy, Ramanarayanan/AAO-6030-2020	Krishnamurthy, Ramanarayanan/0000-0001-5238-610X				BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Beier M, 1999, SCIENCE, V283, P699, DOI 10.1126/science.283.5402.699; BENNUASKALMOWSKI B, 1995, TETRAHEDRON LETT, V36, P7845, DOI 10.1016/0040-4039(95)01667-7; Bhat B, 1996, J AM CHEM SOC, V118, P3065, DOI 10.1021/ja954178a; BOHRINGER M, 1992, HELV CHIM ACTA, V75, P1416, DOI 10.1002/hlca.19920750503; Bolli M, 1997, CHEM BIOL, V4, P309, DOI 10.1016/S1074-5521(97)90074-0; Bolli M, 1997, HELV CHIM ACTA, V80, P1901, DOI 10.1002/hlca.19970800613; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DHINGRA MM, 1978, NATURE, V272, P798, DOI 10.1038/272798a0; Diederichsen U, 1996, ANGEW CHEM INT EDIT, V35, P445, DOI 10.1002/anie.199604451; DIEDERICHSEN U, 1993, THESIS ETH ZURICH; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; DOUGHERTY JP, 1992, J AM CHEM SOC, V114, P6254, DOI 10.1021/ja00041a058; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; Eigen M., 1987, STUFEN LEBEN; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; Ertem G, 1996, NATURE, V379, P238, DOI 10.1038/379238a0; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; ESCHENMOSER A, 1992, HELV CHIM ACTA, V75, P218, DOI 10.1002/hlca.19920750120; Eschenmoser A, 1996, NATO ADV SCI INST SE, V320, P293; ESCHENMOSER A, 1990, VERH GES DTSCH NATUR, V116, P135; FERRIS JP, 1966, J AM CHEM SOC, V88, P1074, DOI 10.1021/ja00957a050; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; FERRIS JP, 1984, TETRAHEDRON, V40, P1093, DOI 10.1016/S0040-4020(01)99315-9; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; FISCHER RW, 1992, THESIS ETH ZURICH; Fujii M, 1998, CHEM COMMUN, P717, DOI 10.1039/a708674a; Groebke K, 1998, HELV CHIM ACTA, V81, P375, DOI 10.1002/hlca.19980810302; GROEBKE K, 1993, THESIS ETH ZURICH; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMMER R, 1992, THESIS ETH ZURICH; HASHIMOTO H, 1992, J AM CHEM SOC, V114, P6255, DOI 10.1021/ja00041a059; HELG AG, 1994, THESIS ETH ZURICH; Herdewijn P, 1996, LIEBIGS ANN, P1337; HUNZIKER J, 1993, HELV CHIM ACTA, V76, P259, DOI 10.1002/hlca.19930760119; HUNZIKER J, 1995, MODERN SYNTHETIC MET, V7, P331; Hyrup B, 1996, BIOORGAN MED CHEM, V4, P5, DOI 10.1016/0968-0896(95)00171-9; James KD, 1997, CHEM BIOL, V4, P595, DOI 10.1016/S1074-5521(97)90245-3; Joyce G. F., 1993, COLD SPRING HARB SYM, V24, P49; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JUNGMANN O, UNPUB; Kauffman S. A., 1993, ORIGINS ORDER SELFOR; KIERZEK R, 1992, NUCLEIC ACIDS RES, V20, P1685, DOI 10.1093/nar/20.7.1685; Koppitz M, 1998, J AM CHEM SOC, V120, P4563, DOI 10.1021/ja974190y; Koshkin AA, 1998, J AM CHEM SOC, V120, P13252, DOI 10.1021/ja9822862; Krishnamurthy R, 1996, ANGEW CHEM INT EDIT, V35, P1537, DOI 10.1002/anie.199615371; KRISHNAMURTHY R, 1994, THESIS ETH ZURICH; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUHN H, 1981, ANGEW CHEM INT EDIT, V20, P500, DOI 10.1002/anie.198105001; Kurz M, 1997, ANGEW CHEM INT EDIT, V36, P842, DOI 10.1002/anie.199708421; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; Lee DH, 1997, NATURE, V390, P591, DOI 10.1038/37569; LEWIN R, 1986, SCIENCE, V231, P545, DOI 10.1126/science.231.4738.545; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; Lifson S, 1997, J MOL EVOL, V44, P1, DOI 10.1007/PL00006115; Luther A, 1998, NATURE, V396, P245, DOI 10.1038/24343; MICULKA C, 1995, THESIS ETH ZURICH; Micura R, 1997, ANGEW CHEM INT EDIT, V36, P870, DOI 10.1002/anie.199708701; Micura R, 1999, ANGEW CHEM INT EDIT, V38, P680, DOI 10.1002/(SICI)1521-3773(19990301)38:5<680::AID-ANIE680>3.0.CO;2-C; MICURA R, UNPUB; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MULLER D, 1990, HELV CHIM ACTA, V73, P1410, DOI 10.1002/hlca.19900730526; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORGEL LE, 1974, ACCOUNTS CHEM RES, V7, P368, DOI 10.1021/ar50083a002; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; ORGEL LE, 1995, ACCOUNTS CHEM RES, V28, P109, DOI 10.1021/ar00051a004; ORO J, 1961, NATURE, V191, P1193, DOI 10.1038/1911193a0; OTTING G, 1993, HELV CHIM ACTA, V76, P2701, DOI 10.1002/hlca.19930760802; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; PITSCH S, 1995, HELV CHIM ACTA, V78, P1621, DOI 10.1002/hlca.19950780702; PITSCH S, 1993, HELV CHIM ACTA, V76, P2161, DOI 10.1002/hlca.19930760602; Prakash TP, 1997, ANGEW CHEM INT EDIT, V36, P1522, DOI 10.1002/anie.199715221; Prakash TP, 1996, CHEM COMMUN, P1793, DOI 10.1039/cc9960001793; RECK F, UNPUB; RENZ M, 1971, BIOCHIM BIOPHYS ACTA, V240, P463, DOI 10.1016/0005-2787(71)90703-9; Roberts C, 1997, J AM CHEM SOC, V119, P4640, DOI 10.1021/ja970123s; Sawai H, 1996, J BIOMOL STRUCT DYN, V13, P1043, DOI 10.1080/07391102.1996.10508919; Schlonvogt I, 1996, HELV CHIM ACTA, V79, P2316, DOI 10.1002/hlca.19960790820; SCHONING KU, UNPUB; Seela F, 1999, EUR J ORG CHEM, V1999, P485, DOI 10.1002/(SICI)1099-0690(199902)1999:2<485::AID-EJOC485>3.0.CO;2-J; SEQUIN U, 1973, EXPERIENTIA, V29, P1059; Sheppard TL, 1996, J AM CHEM SOC, V118, P9810, DOI 10.1021/ja962184g; Sievers D, 1998, CHEM-EUR J, V4, P629, DOI 10.1002/(SICI)1521-3765(19980416)4:4<629::AID-CHEM629>3.0.CO;2-0; Singh SK, 1998, CHEM COMMUN, P1247, DOI 10.1039/a801571f; SOAI K, 1995, NATURE, V378, P767, DOI 10.1038/378767a0; SPINNER C, UNPUB; SWITZER CY, 1993, BIOCHEMISTRY-US, V32, P10489, DOI 10.1021/bi00090a027; TARKOY M, 1993, HELV CHIM ACTA, V76, P481, DOI 10.1002/hlca.19930760132; TJIRIKUA T, 1990, J AM CHEM SOC, V112, P1249; Turner DH., 1993, RNA WORLD, P447; USHER DA, 1972, NATURE-NEW BIOL, V235, P207, DOI 10.1038/newbio235207a0; USHER DA, 1977, SCIENCE, V196, P311, DOI 10.1126/science.583625; USHER DA, 1976, P NATL ACAD SCI USA, V73, P1149, DOI 10.1073/pnas.73.4.1149; VANAERSCHOT A, 1995, ANGEW CHEM INT EDIT, V34, P1338; VIVLEMORE T, UNPUB; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; Wengel J, 1997, BIOORG MED CHEM LETT, V7, P1999, DOI 10.1016/S0960-894X(97)00352-1; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; WINTNER EA, 1994, J AM CHEM SOC, V116, P8877, DOI 10.1021/ja00099a003; Woese C, 1967, GENETIC CODE, P179; WOOLLEY P, 1992, STEPS LIFE; WU T, 1992, J AM CHEM SOC, V114, P7963, DOI 10.1021/ja00047a001; WU TF, 1992, J AM CHEM SOC, V114, P5496, DOI 10.1021/ja00040a002; WU TF, 1992, J AM CHEM SOC, V114, P317, DOI 10.1021/ja00027a040; Yao S, 1998, NATURE, V396, P447, DOI 10.1038/24814; Zou RM, 1996, TETRAHEDRON LETT, V37, P941, DOI 10.1016/0040-4039(95)02396-8; Zubay G, 1998, ORIGINS LIFE EVOL B, V28, P13, DOI 10.1023/A:1006551410542; [No title captured]	110	445	466	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2118	2124		10.1126/science.284.5423.2118	http://dx.doi.org/10.1126/science.284.5423.2118			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381870	Green Published			2022-12-28	WOS:000081099300039
J	Graves, LE; Segal, S; Goodwin, EB				Graves, LE; Segal, S; Goodwin, EB			TRA-1 regulates the cellular distribution of the tra-2 mRNA in C. elegans	NATURE			English	Article							SEX-DETERMINING GENE; NEMATODE CAENORHABDITIS-ELEGANS; ZINC FINGER PROTEINS; MOLECULAR ANALYSIS; TRANSFORMATION; HEDGEHOG; MEMBER; FAMILY	The GLI protein family is involved in several key developmental processes in both vertebrates and invertebrates, The Drosophila GLI protein, Cubitus interuptus (Ci), regulates segment polarity and wing and leg development. In vertebrates, the GLI proteins control neural, lung, bone and gut development(1), In the nematode Caenorhabditis elegans, the GLI family member TRA-1 is necessary for normal sexual development(2,3). GLI, Ci and TRA-1 each contain five zinc-finger domains and bind the identical DNA sequence. Previous analyses are consistent with these proteins being transcription factors(4,5). Here we show that TRA-1 can act post-transcriptionally to govern gene activity. Our results indicate that the binding of TRA-1 to the 3' untranslated region of tra-2 regulates the export of tra-2 messenger RNA from the nucleus. The fact that TRA-1 is part of a conserved family of proteins raises the possibility that GLI family members are both transcriptional and post-transcriptional regulators of gene expression.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Goodwin, EB (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.	ebg778@nwu.edu						Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BRENNER S, 1974, GENETICS, V77, P71; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; Goodwin EB, 1997, DEVELOPMENT, V124, P749; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HODGKIN J, 1993, GENETICS, V133, P543; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1986, GENETICS, V114, P15; HODGKIN JA, 1977, GENETICS, V86, P275; Jan E, 1997, EMBO J, V16, P6301, DOI 10.1093/emboj/16.20.6301; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; Kuwabara PE, 1998, DEV BIOL, V204, P251, DOI 10.1006/dbio.1998.9062; KUWAMURA S, 1992, P ESO C HIGH RESOLUT, V2, P461; Mello C, 1995, METHOD CELL BIOL, V48, P451; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Weed M, 1997, MATRIX BIOL, V16, P53, DOI 10.1016/S0945-053X(97)90072-X; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	22	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					802	805						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391248				2022-12-28	WOS:000081101600058
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Test tube kidneys	SCIENCE			English	Article									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Sikorski, R (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Humes HD, 1999, NAT BIOTECHNOL, V17, P451, DOI 10.1038/8626	1	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1952	1952						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10400538				2022-12-28	WOS:000080932700034
J	Ohndorf, UM; Rould, MA; He, Q; Pabo, CO; Lippard, SJ				Ohndorf, UM; Rould, MA; He, Q; Pabo, CO; Lippard, SJ			Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins	NATURE			English	Article							ANTICANCER DRUG CISPLATIN; INTRASTRAND CROSS-LINK; HMG-DOMAIN; DUPLEX; BOX; ADDUCT; CRYSTAL; SRY	The anticancer activity of cis-diamminedichloroplatinum(II) (cisplatin) arises from its ability to damage DNA, with the major adducts formed being intrastrand d(GpG) and d(ApG) crosslinks(1). These-crosslinks bend and unwind the duplex, and the altered structure attracts high-mobility-group domain (HMG) and other proteins(2). This binding of HMG-domain proteins to cisplatin-modified DNA-has been postulated to mediate the antitumour properties of the drug(3,4). Many HMG-domain proteins recognize altered DNA structures such as four-way junctions and cisplatin-modified DNA(5), but until now:the molecular basis for this recognition was unknown. Here we describe mutagenesis, hydroxyl-radical footprinting and X-ray studies that elucidate the structure of a 1:1. cisplatin-modified DNA/HMG-domain complex Domain A of the structure-specific HMG-domain protein HMG1 binds to the widened minor groove of a 16-base-pair DNA duplex containing a site-specific cis-[Pt(NH3)(2){d(GpG)-N7(1),-N7(2)}] adduct, The DNA is strongly kinked at a hydrophobic notch created at the platinum-DNA crosslink and protein binding extends exclusively to the 3' side of the platinated strand. A phenylalanine residue at position 37 intercalates into a hydrophobic notch created at the platinum crosslinked d(GpG) site and binding of the domain is dramatically reduced in a mutant in which alanine is substituted for phenylalanine at this position.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balaeff A, 1998, PROTEINS, V30, P113, DOI 10.1002/(SICI)1097-0134(19980201)30:2<113::AID-PROT2>3.0.CO;2-O; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; BernersPrice SJ, 1997, EUR J BIOCHEM, V243, P782, DOI 10.1111/j.1432-1033.1997.00782.x; Broadhurst RW, 1995, BIOCHEMISTRY-US, V34, P16608, DOI 10.1021/bi00051a008; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; Dunham SU, 1998, J AM CHEM SOC, V120, P5395, DOI 10.1021/ja9742592; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; HARDING JJ, 1994, REDOX REP, V1, P34, DOI 10.1080/13510002.1994.11746953; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEPRE CA, 1990, NUCLEIC ACIDS MOL BI, P9, DOI DOI 10.1007/978-3-642-84150-7_2; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read C., 1995, NUCL ACIDS MOL BIOL, P222; Rould MA, 1997, METHOD ENZYMOL, V276, P461, DOI 10.1016/S0076-6879(97)76072-5; SHERMAN SE, 1988, J AM CHEM SOC, V110, P7368, DOI 10.1021/ja00230a017; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Weiss MA, 1997, J BIOMOL STRUCT DYN, V15, P177, DOI 10.1080/07391102.1997.10508185; WEMER MH, 1995, CELL, V81, P705; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; Yoshioka K, 1999, BIOCHEMISTRY-US, V38, P589, DOI 10.1021/bi981834l; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	30	505	515	1	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					708	712		10.1038/21460	http://dx.doi.org/10.1038/21460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385126				2022-12-28	WOS:000080932800066
J	Apostolou, S; De Rienzo, A; Murthy, SS; Jhanwar, SC; Testa, JR				Apostolou, S; De Rienzo, A; Murthy, SS; Jhanwar, SC; Testa, JR			Absence of BCL10 mutations in human malignant mesothelioma	CELL			English	Article									Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.							Lee WC, 1996, CANCER RES, V56, P4297; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5	2	34	35	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					684	686		10.1016/S0092-8674(02)09765-9	http://dx.doi.org/10.1016/S0092-8674(02)09765-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380921	Bronze			2022-12-28	WOS:000080886300006
J	Otto, CM; Lind, BK; Kitzman, DW; Gersh, BJ; Siscovick, DS				Otto, CM; Lind, BK; Kitzman, DW; Gersh, BJ; Siscovick, DS		Cardiovascular Hlth Study	Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL CORONARY-ARTERIES; DOPPLER-ECHOCARDIOGRAPHY; NATURAL-HISTORY; ANGINA-PECTORIS; EARLY LESION; STENOSIS; PROGRESSION; ADULTS; DISEASE; EXPRESSION	Background Although aortic-valve stenosis is clearly associated with adverse cardiovascular outcomes, it is unclear whether valve sclerosis increases the risk of cardiovascular events. Methods We assessed echocardiograms obtained at base line from 5621 men and women 65 years of age or older who were enrolled in a population-based prospective study, On echocardiography, the aortic valve was normal in 70 percent (3919 subjects), sclerotic without outflow obstruction in 29 percent (1610), and stenotic in 2 percent (92), The subjects were followed for a mean of 5.0 years to assess the risk of death from any cause and of death from cardiovascular causes. Cardiovascular morbidity was defined as new episodes of myocardial infarction, angina pectoris, congestive heart failure, or stroke. Results There was a stepwise increase in deaths from any cause (P for trend, <0.001) and deaths from cardiovascular causes (P for trend, <0.001) with increasing aortic-valve abnormality; the respective rates were 14.9 and 6.1 percent in the group with normal aortic valves, 21.9 and 10.1 percent in the group with aortic sclerosis, and 41.3 and 19.6 percent in the group with aortic stenosis, The relative risk of death from cardiovascular causes among subjects without coronary heart disease at base line was 1.66 (95 percent confidence interval, 1.23 to 2.23) for those with sclerotic valves as compared with those with normal valves, after adjustment for age and sex. The relative risk remained elevated after further adjustment for clinical factors associated with sclerosis (relative risk, 1.52; 95 percent confidence interval, 1.12 to 2.05), The relative risk of myocardial infarction was 1.40 (95 percent confidence interval, 1.07 to 1.83) among subjects with aortic sclerosis, as compared with those with normal aortic valves. Conclusions Aortic sclerosis is common in the elderly and is associated with an increase of approximately 50 percent in the risk of death from cardiovascular causes and the risk of myocardial infarction, even in the absence of hemodynamically significant obstruction of left ventricular outflow. (N Engl J Med 1999;341:142-7) (C) 1999, Massachusetts Medical Society.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; Wake Forest Univ, Sch Med, Div Cardiol, Winston Salem, NC USA; Mayo Clin, Div Cardiol, Rochester, MN USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Mayo Clinic	Otto, CM (corresponding author), Univ Washington, Div Cardiol, Box 356422, Seattle, WA 98195 USA.			Otto, Catherine/0000-0002-0527-9392	NHLBI NIH HHS [N01-HC85081, N01-HC85079, N01-HC85080] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085079, N01HC085081, N01HC085080] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARONOW WS, 1987, AM J CARDIOL, V59, P998, DOI 10.1016/0002-9149(87)91144-1; Boon A, 1997, HEART, V78, P472, DOI 10.1136/hrt.78.5.472; BRENER SJ, 1995, J AM COLL CARDIOL, V25, P305, DOI 10.1016/0735-1097(94)00406-G; CHIZNER MA, 1980, AM HEART J, V99, P419, DOI 10.1016/0002-8703(80)90375-0; DEUTSCHER S, 1984, J CHRON DIS, V37, P407, DOI 10.1016/0021-9681(84)90108-5; FAGGIANO P, 1992, AM J CARDIOL, V70, P229, DOI 10.1016/0002-9149(92)91280-H; FRANK S, 1973, BRIT HEART J, V35, P41; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; GARDIN JM, 1992, J AM SOC ECHOCARDIOG, V5, P550; GEORGESON S, 1990, J AM COLL CARDIOL, V15, P751, DOI 10.1016/0735-1097(90)90271-P; GOTOH T, 1995, AM J CARDIOL, V76, P928, DOI 10.1016/S0002-9149(99)80263-X; HOAGLAND PM, 1985, AM J CARDIOL, V55, P744, DOI 10.1016/0002-9149(85)90149-3; HORSTKOTTE D, 1988, EUR HEART J, V9, P57, DOI 10.1093/eurheartj/9.suppl_E.57; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Julius BK, 1997, CIRCULATION, V95, P892; Kaufmann P, 1996, J AM COLL CARDIOL, V28, P745, DOI 10.1016/0735-1097(96)00194-5; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; MARCUS ML, 1982, NEW ENGL J MED, V307, P1362, DOI 10.1056/NEJM198211253072202; MOHLER ER, 1991, CLIN CARDIOL, V14, P995, DOI 10.1002/clc.4960141210; NADELL R, 1983, J AM COLL CARDIOL, V2, P258, DOI 10.1016/S0735-1097(83)80161-2; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523; OKEEFE JH, 1987, MAYO CLIN PROC, V62, P986, DOI 10.1016/S0025-6196(12)65068-X; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; OLSSON M, 1994, J AM COLL CARDIOL, V24, P1664, DOI 10.1016/0735-1097(94)90172-4; Omran H, 1996, HEART, V75, P377, DOI 10.1136/hrt.75.4.377; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Otto CM, 1997, CIRCULATION, V95, P2262, DOI 10.1161/01.CIR.95.9.2262; OTTO CM, 1989, J AM COLL CARDIOL, V13, P545, DOI 10.1016/0735-1097(89)90590-1; PETER M, 1993, CHEST, V103, P1715, DOI 10.1378/chest.103.6.1715; PETROPOULAKIS PN, 1995, CIRCULATION, V92, P1437, DOI 10.1161/01.CIR.92.6.1437; ROGER VL, 1990, AM HEART J, V119, P331, DOI 10.1016/S0002-8703(05)80024-9; Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735-1097(96)00563-3; TEERLINK JR, 1997, CIRCULATION S1, V96, P82; TURINA J, 1987, EUR HEART J, V8, P471, DOI 10.1093/oxfordjournals.eurheartj.a062307	36	917	961	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					142	147		10.1056/NEJM199907153410302	http://dx.doi.org/10.1056/NEJM199907153410302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403851				2022-12-28	WOS:000081413800002
J	Herman, WH				Herman, WH			Clinical evidence - Glycaemic control in diabetes	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTENSIFIED INSULIN-TREATMENT; MICROVASCULAR COMPLICATIONS; MELLITUS		Univ Michigan, Med Ctr, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Herman, WH (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol & Metab, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	wherman@umich.edu						[Anonymous], 1996, DIABETES, V45, P1289; Diabet Control Complications Trial Res Grp, 1996, ANN INTERN MED, V124, P379, DOI 10.7326/0003-4819-124-4-199602150-00001; Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; REICHARD P, 1991, J INTERN MED, V229, P9, DOI 10.1111/j.1365-2796.1991.tb00299.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	10	19	20	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					104	106		10.1136/bmj.319.7202.104	http://dx.doi.org/10.1136/bmj.319.7202.104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398638	Green Published			2022-12-28	WOS:000081438200037
J	Geisler, WS				Geisler, WS			Motion streaks provide a spatial code for motion direction	NATURE			English	Article							VISUAL AREA MT; HUMAN-VISION; ORIENTATION; SELECTIVITY; PATTERNS; NEURONS; MACAQUE; CORTEX; MODEL	Although many neurons in the primary visual cortex (V1) of primates are direction selective(1), they provide ambiguous information about the direction of motion of a stimulus(2,3), There is evidence that one of the ways in which the visual system resolves this ambiguity is by computing, from the responses of V1 neurons, velocity components in two or more spatial orientations and then combining these velocity components(2-9). Here I consider another potential neural mechanism for determining motion direction. When a localized image feature moves fast enough, it should become smeared in space owing to temporal integration in the visual system, creating a spatial signal-a 'motion streak'-oriented in the direction of the motion. The orientation masking and adaptation experiments reported here show that these spatial signals for motion direction exist in the human visual system for feature speeds above about 1 feature width per 100 ms. Computer simulations show that this psychophysical finding is consistent with the known response properties of V1 neurons, and that these spatial signals, when appropriately processed, are sufficient to determine motion direction in natural images.	Univ Texas, Dept Psychol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Geisler, WS (corresponding author), Univ Texas, Dept Psychol, Austin, TX 78712 USA.			Geisler, Wilson/0000-0003-4630-6614				ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ANDERSON CH, 1990, NATURE, V343, P419, DOI 10.1038/343419b0; BURR D, 1980, NATURE, V284, P164, DOI 10.1038/284164a0; Burr DC, 1997, P ROY SOC B-BIOL SCI, V264, P431, DOI 10.1098/rspb.1997.0061; DERRINGTON A, 1991, VISION RES, V31, P139, DOI 10.1016/0042-6989(91)90081-F; DEVALOIS RL, 1982, VISION RES, V22, P531, DOI 10.1016/0042-6989(82)90112-2; Geisler WS, 1997, VISUAL NEUROSCI, V14, P897, DOI 10.1017/S0952523800011627; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MARR D, 1981, PROC R SOC SER B-BIO, V211, P151, DOI 10.1098/rspb.1981.0001; MORGAN MJ, 1989, NATURE, V340, P385, DOI 10.1038/340385a0; RAMACHAN.VS, 1974, PERCEPTION, V3, P97, DOI 10.1068/p030097; Simoncelli EP, 1998, VISION RES, V38, P743, DOI 10.1016/S0042-6989(97)00183-1; Smith A. T., 1994, VISUAL DETECTION MOT; STONE LS, 1990, VISION RES, V30, P1049, DOI 10.1016/0042-6989(90)90114-Z; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322	17	243	245	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					65	69		10.1038/21886	http://dx.doi.org/10.1038/21886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403249				2022-12-28	WOS:000081255700051
J	Weber, TK; Chin, HM; Rodriguez-Bigas, M; Keitz, B; Gilligan, R; O'Malley, L; Urf, E; Diba, N; Pazik, J; Petrelli, NJ				Weber, TK; Chin, HM; Rodriguez-Bigas, M; Keitz, B; Gilligan, R; O'Malley, L; Urf, E; Diba, N; Pazik, J; Petrelli, NJ			Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; MLH1 MUTATIONS; HNPCC FAMILIES; SSCP ANALYSIS; HEREDITARY; GENE; SURVIVAL; HOMOLOG; LOCUS	Context Germline mutations of the DNA mismatch repair(MMR) genes hMLH1 and hMSH2 have been shown to cosegregate with the colorectal cancer phenotype in multiple hereditary non polyposis colorectal cancer (HNPCC) pedigrees. However, the frequency of these mutations among African American patients with colorectal cancer is unknown. Objective To investigate the frequency of germline alterations of the DNA MMR genes hMLH1 and hMSH2 among African Americans affected by HNPCC and early-age onset colorectal cancer. Design, Setting, and Patients Forty unrelated African American HNPCC and early-age onset colorectal cancer patients (8 women, 3 men) were identified from the cancer registry at a National Cancer institute-designated referral center, 11 of whom were available for and agreed to study participation from January 1997 to February 1998. The mean age of the subjects was 44 years. An additional 50 age- and sex-matched African Americans without personal or family history of colorectal, endometrial, ovarian, urinary tract, or upper gastrointestinal tract malignancy were also studied as a polymorphism control population. In all subjects, genomic DNA was amplified by polymerase chain reaction for all hMLH1 and hMSH2 exons and screened using single-strand conformation polymorphism (SSCP) analysis. Samples demonstrating significant SSCP shifts underwent automated nucleotide sequencing analysis. Main Outcome Measure Frequency of hMLH1 and hMSH2 germline alterations in the affected and control subjects. Results Germline hMLH1 and hMSH2 mutations were detected in 3 (27%) of the African American colorectal cancer probands studied. Each mutation was novel. Two hMLH1 (an A-->T transversion at codon 26 and a GG-->AT substitution across codons 177 and 178) mutations and 1 hMSH2 mutation (a C-->T transition at codon 389) were identified in 3 female study subjects. Six other hMLH1 and hMSH2 alterations were detected but were presumed to be polymorphisms. Neither missense mutation (at codons 26 and 389) was detected in the control population. Conclusions The results of our analysis support an association between the 3 mutations reported and predisposition to colorectal cancer. Further studies are needed to define DNA MMR gene-associated colorectal cancer in African Americans, an understudied population at increased risk of fatal colorectal cancer.	Roswell Pk Canc Inst, Div Surg Oncol, Buffalo, NY 14263 USA; Catholic Univ, Coll Med, St Vincents Hosp, Dept Surg, Suwon, South Korea; Univ Manchester, Fac Med, Manchester, Lancs, England	Roswell Park Cancer Institute; Catholic University of Korea; University of Manchester	Weber, TK (corresponding author), Roswell Pk Canc Inst, Div Surg Oncol, Elm & Carlton St, Buffalo, NY 14263 USA.	weber@sc3102.med.buffalo.edu			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck NE, 1997, HUM GENET, V99, P219, DOI 10.1007/s004390050343; BORING CC, 1992, CA-CANCER J CLIN, V42, P7, DOI 10.3322/canjclin.42.1.7; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Cooper GS, 1997, CANCER EPIDEM BIOMAR, V6, P283; FAN E, 1993, MUTAT RES, V288, P85, DOI 10.1016/0027-5107(93)90210-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, EUR J CANCER, V32A, P178, DOI 10.1016/0959-8049(95)00464-5; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; KOLODNER RD, 1995, CANCER RES, V55, P242; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; Lewis CM, 1996, CANCER RES, V56, P1382; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Mauillon JL, 1996, CANCER RES, V56, P5728; MAYBERRY RM, 1995, J NATL CANCER I, V87, P1686, DOI 10.1093/jnci/87.22.1686; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moisio AL, 1996, AM J HUM GENET, V59, P1243; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NAROD SA, 1991, LANCET, V338, P82; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1995, GASTROENTEROLOGY, V109, P2031, DOI 10.1016/0016-5085(95)90774-2; Percesepe A, 1997, INT J CANCER, V71, P373, DOI 10.1002/(SICI)1097-0215(19970502)71:3<373::AID-IJC12>3.0.CO;2-H; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PURTILO DT, 1987, CANCER GENET CYTOGEN, V24, P11, DOI 10.1016/0165-4608(87)90079-3; RodriguezBigas MA, 1996, DIS COLON RECTUM, V39, P649, DOI 10.1007/BF02056944; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TANNERGARD P, 1995, CANCER RES, V55, P6092; Tomlinson IPM, 1997, J MED GENET, V34, P39, DOI 10.1136/jmg.34.1.39; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7; Wahlberg SS, 1997, INT J CANCER, V74, P134, DOI 10.1002/(SICI)1097-0215(19970220)74:1<134::AID-IJC22>3.3.CO;2-1; Warthin AS, 1925, J CANCER RES CLIN, V9, P279; Watson P, 1998, CANCER, V83, P259, DOI 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L; Weber T, 1996, LANCET, V348, P465, DOI 10.1016/S0140-6736(05)64545-X; Weber TK, 1997, CANCER RES, V57, P3798; White RL, 1998, CANCER RES, V58, P4038; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1996, AM J HUM GENET, V58, P300; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Xia L, 1996, CANCER RES, V56, P2289; Yamamoto H, 1998, CANCER RES, V58, P997; 1999, MSH2 MLH1 MUTATION D	61	38	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2316	2320		10.1001/jama.281.24.2316	http://dx.doi.org/10.1001/jama.281.24.2316			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386556	Bronze			2022-12-28	WOS:000080925600031
J	Dunnett, SB; Bjorklund, A				Dunnett, SB; Bjorklund, A			Prospects for new restorative and neuroprotective treatments in Parkinson's disease	NATURE			English	Review							FIBROBLAST GROWTH-FACTOR; ENCAPSULATED PC12 CELLS; ALPHA-SYNUCLEIN; DOPAMINERGIC-NEURONS; TYROSINE-HYDROXYLASE; GENE-THERAPY; FUNCTIONAL RECOVERY; RAT MODEL; IN-VITRO; L-DOPA	The degeneration of forebrain dopamine systems in Parkinson's disease has been an effective target for pharmaceutical research over the past four decades. However, although dopamine replacement may alleviate the symptoms of the disease, it does not half the underlying neuronal degeneration. The past decade has seen major advances in identifying discrete genetic and molecular causes of parkinsonism and mapping the events involved in nigral cell death. This new understanding of the pathogenesis of the disease now offers novel prospects for therapy based on targeted neuroprotection of vulnerable neurons and effective strategies for their replacement.	Univ Cambridge, Ctr Brain Repair, Cambridge CB2 2PY, England; Lund Univ, Wallenberg Neurosci Ctr, S-22362 Lund, Sweden	University of Cambridge; Lund University	Dunnett, SB (corresponding author), Univ Cambridge, Ctr Brain Repair, Forvie Site,Robinson Way, Cambridge CB2 2PY, England.		Björklund, Anders/ABA-1326-2020; Dunnett, Stephen B/A-5869-2010	Dunnett, Stephen B/0000-0003-1826-1578; Bjorklund, Anders/0000-0002-5676-6203				AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053; ANTON R, 1994, EXP NEUROL, V127, P207, DOI 10.1006/exnr.1994.1097; BARKER R, 1994, EXP BRAIN RES, V101, P365; BECKER JB, 1990, BRAIN RES, V508, P60, DOI 10.1016/0006-8993(90)91117-Y; Bencsics C, 1996, J NEUROSCI, V16, P4449; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; BOER GJ, 1994, J NEUROL, V242, P1, DOI 10.1007/BF00920568; BOUVIER MM, 1995, J NEUROSCI, V15, P7141; Brooks DJ, 1998, ANN NEUROL, V44, pS10, DOI 10.1002/ana.410440704; Brundin P, 1994, FUNCTIONAL NEURAL TR, V2, P9; Burke RE, 1998, ANN NEUROL, V44, pS126, DOI 10.1002/ana.410440719; Butler D, 1998, NATURE, V391, P320; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CHASE TN, 1989, NEUROLOGY, V39, P7; Choi-Lundberg DL, 1998, EXP NEUROL, V154, P261, DOI 10.1006/exnr.1998.6887; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; CONSTANTINI LC, 1998, NEUROBIOL DIS, V5, P97; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DUNNETT SB, 1994, FUNCTIONAL NEURAL TR; Ebadi M, 1996, PROG NEUROBIOL, V48, P1, DOI 10.1016/0301-0082(95)00029-1; EMERICH DF, 1993, EXP NEUROL, V122, P37, DOI 10.1006/exnr.1993.1105; Espejo EF, 1998, NEURON, V20, P197, DOI 10.1016/S0896-6273(00)80449-3; Farrer M, 1998, ANN NEUROL, V43, P394, DOI 10.1002/ana.410430320; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; FORNO LS, 1990, PARKINSONS DISEASE, P185; FRIM DM, 1994, P NATL ACAD SCI USA, V91, P5104, DOI 10.1073/pnas.91.11.5104; Gash DM, 1998, ANN NEUROL, V44, pS121, DOI 10.1002/ana.410440718; Gasser T, 1998, ANN NEUROL, V44, pS53, DOI 10.1002/ana.410440708; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; GOEDERT M, 1998, NEUROSCI NEWS, V1, P47; GOETZ CG, 1991, NEUROLOGY, V41, P1719, DOI 10.1212/WNL.41.11.1719; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hagg T, 1998, EXP NEUROL, V149, P183, DOI 10.1006/exnr.1997.6684; ISACSON O, 1995, SCIENCE, V269, P856, DOI 10.1126/science.7638605; Isacson O, 1997, NAT MED, V3, P964, DOI 10.1038/nm0997-964; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; JORDAN J, 1995, MOL PHARMACOL, V47, P1095; Kang UJ, 1998, MOVEMENT DISORD, V13, P59; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koller WC, 1998, ANN NEUROL, V44, pS155, DOI 10.1002/ana.410440723; Kordower JH, 1997, CELL TRANSPLANT, V6, P213, DOI 10.1016/S0963-6897(97)00019-5; Kordower JH, 1997, EXP NEUROL, V144, P41, DOI 10.1006/exnr.1996.6386; Kordower JH, 1998, MOVEMENT DISORD, V13, P88; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Langston JW, 1998, ANN NEUROL, V44, pS45, DOI 10.1002/ana.410440707; Leff SE, 1998, EXP NEUROL, V151, P249, DOI 10.1006/exnr.1998.6803; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; Lindvall O, 1997, NEUROREPORT, V8, pR3, DOI 10.1097/00001756-199709290-00036; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Lundberg C, 1996, EXP NEUROL, V139, P39, DOI 10.1006/exnr.1996.0079; Mandel RJ, 1997, P NATL ACAD SCI USA, V94, P14083, DOI 10.1073/pnas.94.25.14083; MARSDEN CD, 1977, LANCET, V1, P345; Marsden CD, 1997, ADV NEUROL, V74, P143; Marsden CD, 1998, ANN NEUROL, V44, pS189, DOI 10.1002/ana.410440727; MAYER E, 1993, DEV BRAIN RES, V72, P253, DOI 10.1016/0165-3806(93)90190-L; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; MIZUNO Y, 1997, MOVEMENT DISORDERS N, P161; Morrish PK, 1996, BRAIN, V119, P585, DOI 10.1093/brain/119.2.585; Olanow CW, 1997, ADV NEUROL, V74, P249; Olanow CW, 1998, ANN NEUROL, V44, pS167; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; Owen AM, 1998, MEMORY NEURODEGENERA, P157; PAKZABAN P, 1994, NEUROSCIENCE, V62, P989, DOI 10.1016/0306-4522(94)90338-7; Palfi S., 1998, Society for Neuroscience Abstracts, V24, P41; Perl DP, 1998, ANN NEUROL, V44, pS19, DOI 10.1002/ana.410440705; Poewe W., 1997, MOVEMENT DISORDERS N, P201; Pollak P, 1997, ADV NEUROL, V74, P213; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Raymon HK, 1997, EXP NEUROL, V144, P82, DOI 10.1006/exnr.1996.6392; Rodriguez MC, 1998, ANN NEUROL, V44, pS175, DOI 10.1002/ana.410440726; Rosenblad C, 1996, NEUROSCIENCE, V75, P979; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Shoulson I, 1998, ANN NEUROL, V43, P318; Sinclair SR, 1996, NEUROREPORT, V7, P2547, DOI 10.1097/00001756-199611040-00029; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Starr PA, 1998, NEUROSURGERY, V43, P989, DOI 10.1097/00006123-199811000-00001; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Tatton NA, 1998, ANN NEUROL, V44, pS142, DOI 10.1002/ana.410440721; Tseng JL, 1997, J NEUROSCI, V17, P325, DOI 10.1523/JNEUROSCI.17-01-00325.1997; Unsicker K, 1996, CIBA F SYMP, V196, P70; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; WINN SR, 1989, EXP NEUROL, V105, P244, DOI 10.1016/0014-4886(89)90126-X; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Yurek DM, 1998, EXP NEUROL, V153, P195, DOI 10.1006/exnr.1998.6884; Zawada WM, 1998, BRAIN RES, V786, P96, DOI 10.1016/S0006-8993(97)01408-X	98	474	498	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738		S			A32	A39		10.1038/399a032	http://dx.doi.org/10.1038/399a032			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JQ	10392578				2022-12-28	WOS:000081101700006
J	Selkoe, DJ				Selkoe, DJ			Translating cell biology into therapeutic advances in Alzheimer's disease	NATURE			English	Review							AMYLOID PRECURSOR PROTEIN; BETA-PEPTIDE DEPOSITION; NECROSIS-FACTOR-ALPHA; C-TERMINAL FRAGMENTS; APOLIPOPROTEIN-E; CAENORHABDITIS-ELEGANS; SECRETASE CLEAVAGE; TRANSGENIC MICE; IN-VIVO; ENDOPLASMIC-RETICULUM	Studies of the molecular basis of Alzheimer's disease exemplify the increasingly blurred distinction between basic and applied biomedical research. The four genes so far implicated in familial Alzheimer's disease have each been shown to elevate brain levels of the self-aggregating amyloid-beta protein, leading gradually to profound neuronal and glial alteration, synaptic loss and dementia. Progress in understanding this cascade has helped to identify specific therapeutic targets and provides a model for elucidating other neurodegenerative disorders.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Selkoe, DJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.							Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Baumeister R, 1997, Genes Funct, V1, P149; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Biere AL, 1995, NEUROBIOL DIS, V2, P177, DOI 10.1006/nbdi.1995.0019; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; EIKELENBOOM P, 1994, TRENDS PHARMACOL SCI, V15, P447, DOI 10.1016/0165-6147(94)90057-4; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; Goedert M., 1996, MOL GENETIC BASIS NE, P613; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; ITAGAKI S, 1994, BRAIN RES, V645, P78, DOI 10.1016/0006-8993(94)91640-3; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MANN DMA, 1995, ACTA NEUROPATHOL, V90, P472; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MATTSON MP, 1992, J NEUROSCI, V12, P379; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; Perez RG, 1997, J NEUROSCI, V17, P9407; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; REBECK GW, 1993, NEURON, V11, P575; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; WONG P, 1997, NATURE, V397, P288; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yamazaki T, 1996, J CELL SCI, V109, P999; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	100	1458	1570	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738		S			A23	A31		10.1038/399a023	http://dx.doi.org/10.1038/399a023			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JQ	10392577				2022-12-28	WOS:000081101700005
J	Yuan, ZM; Shioya, H; Ishiko, T; Sun, XG; Gu, JJ; Huang, YY; Lu, H; Kharbanda, S; Weichselbaum, R; Kufe, D				Yuan, ZM; Shioya, H; Ishiko, T; Sun, XG; Gu, JJ; Huang, YY; Lu, H; Kharbanda, S; Weichselbaum, R; Kufe, D			P73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage	NATURE			English	Article							PROTEIN; P53; ACTIVATION; RADIATION; AGENTS; GROWTH	The protein p73 is a structural and functional homologue of the p53 tumour-suppressor protein but, unlike p53, it is not induced in response to DNA damage(1,2). The tyrosine kinase c-Abl is activated by certain DNA-damaging agents(3) and contributes to the induction of programmed cell death (apoptosis) by p53-dependent and p53-independent mechanisms(4). Here we show that c-Abl binds to p73 in cells, interacting through its SH3 domain with the carboxy-terminal homo-oligomerization domain of p73, c-Abl phosphorylates p73 on a tyrosine residue at position 99 both in vitro and in cells that have been exposed to ionizing radiation. Our results show that c-Abl stimulates p73-mediated transactivation and apoptosis. This regulation of p73 by c-Abl in response to PNA damage is also demonstrated by a failure of ionizing-radiation-induced apoptosis after disruption of the c-Abl-p73 interaction. These findings show that p73 is regulated by a c-Abl-dependent mechanism and that p73 participates in the apoptotic response to DNA damage.	Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oregon Health & Science University; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Biol, 665 Huntington Ave, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu		Huang, Ying/0000-0003-1145-3606				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo CM, 1996, J BIOL CHEM, V271, P4497; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhu JH, 1998, CANCER RES, V58, P5061	21	519	530	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					814	817		10.1038/21704	http://dx.doi.org/10.1038/21704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391251				2022-12-28	WOS:000081101600061
J	Thomsen, PEB; Huikuri, H; Kober, L; Linde, C; Koistinen, J; Ohm, OJ; Rokkedal, J; Torp-Pedersen, C				Thomsen, PEB; Huikuri, H; Kober, L; Linde, C; Koistinen, J; Ohm, OJ; Rokkedal, J; Torp-Pedersen, C			Lessons from the Nordic ICD pilot study	LANCET			English	Article							SIGNAL-AVERAGED ELECTROCARDIOGRAM; ACUTE MYOCARDIAL-INFARCTION; HEART-RATE-VARIABILITY; TRACE		Kobenhavns Amt, Dept Cardiol, DK-2900 Hellerup, Denmark		Thomsen, PEB (corresponding author), Kobenhavns Amt, Dept Cardiol, DK-2900 Hellerup, Denmark.		Torp-Pedersen, Christian/E-5931-2013	LInde, Cecilia/0000-0002-9039-6023; Kober, Lars/0000-0002-6635-1466				FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; Hartikainen JEK, 1996, J AM COLL CARDIOL, V28, P296, DOI 10.1016/0735-1097(96)00169-6; KOBER L, 1995, AM J CARDIOL, V76, P1, DOI 10.1016/S0002-9149(99)80791-7; KOBER L, 1994, EUR HEART J, V15, P1616; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602	5	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2130	2130		10.1016/S0140-6736(98)04999-X	http://dx.doi.org/10.1016/S0140-6736(98)04999-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382706				2022-12-28	WOS:000080969300022
J	Hederstedt, L				Hederstedt, L			Bioenergetics - Respiration without O-2	SCIENCE			English	Editorial Material							SUCCINATE-QUINONE OXIDOREDUCTASES; MEMBRANE-INTEGRAL DOMAIN; MENAQUINONE; CHAIN		Univ Lund, Dept Microbiol, SE-22362 Lund, Sweden	Lund University	Hederstedt, L (corresponding author), Univ Lund, Dept Microbiol, Solvegatan 12, SE-22362 Lund, Sweden.			Hederstedt, Lars/0000-0002-6650-6296				Gomes CM, 1999, BBA-BIOENERGETICS, V1411, P134, DOI 10.1016/S0005-2728(99)00046-8; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1998, BIOCHEM SOC T, V26, P408, DOI 10.1042/bst0260408; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; LEMMA E, 1990, ARCH MICROBIOL, V155, P62, DOI 10.1007/BF00291276; Muratsubaki H, 1998, ARCH BIOCHEM BIOPHYS, V352, P175, DOI 10.1006/abbi.1998.0583; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schirawski J, 1998, EUR J BIOCHEM, V257, P210, DOI 10.1046/j.1432-1327.1998.2570210.x; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0	12	53	53	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1941	1942		10.1126/science.284.5422.1941	http://dx.doi.org/10.1126/science.284.5422.1941			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10400536				2022-12-28	WOS:000080932700029
J	Miller, HI				Miller, HI			Policy forum: Genetic engineering - A rational approach to labeling biotech-derived foods	SCIENCE			English	Article									Stanford Univ, Hoover Inst, Stanford, CA 94305 USA; Competit Enterprise Inst, Washington, DC 20036 USA	Stanford University	Miller, HI (corresponding author), Stanford Univ, Hoover Inst, Stanford, CA 94305 USA.	miller@hoover.stanford.edu						AYERS T, 1998, SCIENCE, V281, P714; CHRISPEELS M, 1994, PLANTS GENES AGR, P348; *CTR FOOD SAF APPL, 1996, FOODS DER NEW PLANT; *FOOD DRUG LAW I, 1993, COMP FOOD DRUG LAWS, P30; GOODMAN RM, 1987, SCIENCE, V236, P48, DOI 10.1126/science.236.4797.48; *I FOOD TECHN, 1996, APPR OV PLANTS INH T; JAMES C, 1998, ISAAA BRIEFS, V8; MILLER HI, 1993, JAMA-J AM MED ASSOC, V269, P910; MILLER HI, 1997, POLICY CONTROVERSY B, pCH3; National Research Council, 1989, FIELD TEST GEN MOD O; *NIH OFF DIR, 1992, NAT BIOT POL BOARD R, pE27; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; TAKEMOTO K, 1994, GENOBASE 1 1 ESCHERI; WILLIAMS N, 1998, SCIENCE, V281, P769; 1992, FED REG         0529, V57, P22984	15	14	15	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1471	1472		10.1126/science.284.5419.1471	http://dx.doi.org/10.1126/science.284.5419.1471			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10383324				2022-12-28	WOS:000080548100020
J	Hodges, A				Hodges, A			Making a mark	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kagando Hosp, Kasese, Uganda		Hodges, A (corresponding author), Kagando Hosp, Kasese, Uganda.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					201	201		10.1136/bmj.319.7203.201	http://dx.doi.org/10.1136/bmj.319.7203.201			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406784	Green Published			2022-12-28	WOS:000081619300059
J	Hayakawa, K; Asano, M; Shinton, SA; Gui, M; Allman, D; Stewart, CL; Silver, J; Hardy, RR				Hayakawa, K; Asano, M; Shinton, SA; Gui, M; Allman, D; Stewart, CL; Silver, J; Hardy, RR			Positive selection of natural autoreactive B cells	SCIENCE			English	Article							REGION GENE-EXPRESSION; TRANSGENIC MICE; AUTOIMMUNE-DISEASE; CLONAL SELECTION; NORMAL MOUSE; IMMUNOGLOBULIN; ANTIGEN; AUTOANTIBODIES; ANTIBODY; LINEAGE	Lymphocyte development is critically influenced by self-antigens. T cells are subject to both positive and negative selection, depending on their degree of seif-reactivity. Although B cells are subject to negative selection, it has been difficult to test whether self-antigen plays any positive role in B cell development. A murine model system of naturally generated autoreactive B cells with a germ Line gene-encoded specificity for the Thy-1 (CD90) glycoprotein was developed, in which the presence of self-antigen promotes B cell accumulation and serum autoantibody secretion. Thus, B cells can be subject to positive selection, generated, and maintained on the basis of their autoreactivity.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; NCI, Lab Canc & Dev Biol, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Cornell Univ Med Coll, N Shore Univ Hosp, Div Mol Med, Manhasset, NY 11030 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Cornell University; Northwell Health; North Shore University Hospital	Hayakawa, K (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.							ARNOLD LW, 1994, J EXP MED, V179, P1585, DOI 10.1084/jem.179.5.1585; BOYDEN S, 1964, NATURE, V201, P200, DOI 10.1038/201200a0; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; CUNNINGHAM AJ, 1974, NATURE, V252, P749, DOI 10.1038/252749a0; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; DIGHIERO G, 1985, J IMMUNOL, V134, P765; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hannum LG, 1996, J EXP MED, V184, P1269, DOI 10.1084/jem.184.4.1269; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; HARTLEY SB, 1994, INT IMMUNOL, V6, P1417, DOI 10.1093/intimm/6.9.1417; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HAYAKAWA K, 1990, J EXP MED, V172, P869, DOI 10.1084/jem.172.3.869; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Kearney J F, 1992, Curr Top Microbiol Immunol, V182, P81; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lang J, 1996, J EXP MED, V184, P1685, DOI 10.1084/jem.184.5.1685; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MARTIN WJ, 1974, NATURE, V249, P564, DOI 10.1038/249564a0; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Page DM, 1997, J IMMUNOL, V159, P5285; PENNELL CA, 1989, EUR J IMMUNOL, V19, P1289, DOI 10.1002/eji.1830190721; PENNELL CA, 1988, J IMMUNOL, V141, P2788; POTTER M, 1982, MOL IMMUNOL, V19, P1619, DOI 10.1016/0161-5890(82)90273-5; SCHLESINGER M, 1965, NATURE, V207, P429, DOI 10.1038/207429b0	33	462	473	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					113	116		10.1126/science.285.5424.113	http://dx.doi.org/10.1126/science.285.5424.113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390361				2022-12-28	WOS:000081199800043
J	Delbanco, TL; Hartman, EE				Delbanco, TL; Hartman, EE			A 29-year-old man with multiple sclerosis, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Rudick RA, 1998, JAMA-J AM MED ASSOC, V280, P1432, DOI 10.1001/jama.280.16.1432	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2329	2329		10.1001/jama.281.24.2329	http://dx.doi.org/10.1001/jama.281.24.2329			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386558				2022-12-28	WOS:000080925600033
J	Durant, J; Clevenbergh, P; Halfon, P; Delgiudice, P; Porsin, S; Simonet, P; Montagne, N; Boucher, CAB; Schapiro, JM; Dellamonica, P				Durant, J; Clevenbergh, P; Halfon, P; Delgiudice, P; Porsin, S; Simonet, P; Montagne, N; Boucher, CAB; Schapiro, JM; Dellamonica, P			Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial	LANCET			English	Article							SOCIETY USA PANEL; ANTIRETROVIRAL THERAPY; UPDATED RECOMMENDATIONS; TREATMENT FAILURE; INFECTION	Background Growing evidence has linked HIV-1 resistance mutations and drug failure. The use of genotypic-resistance analysis to assist therapeutic decision-making in patients failing therapy has not been investigated. We assessed the virological and immunological impact of genotypic-resistance testing. Methods We did a prospective, open, randomised, controlled study of HIV-1-infected patients in whom combination therapy was not successful. We randomly assigned patients standard care (control, n=43) or treatment according to the resistance mutations in protease and reverse-transcriptase genes (genotypic group, n=65), The major endpoint was the change in HIV-1 PNA viral load. Analysis was by intention to treat. Findings 108 patients were enrolled, All patients were similar for risk factors, age, sex, previous treatment, CD4-cell count (214/mu L [SD14]) and log HIV-1 RNA Viral load at baseline (4.7 copies/mL [0.1]). At month 3, the mean change in HIV-1 RNA was -1.04 log (0.14) in the study group compared with -0.46 log (0.17) in the control group (mean difference 0.58 log [95% CI 0.14-1.02], p=0.01). At month 6, changes were -1.15 (0.15) log copies/mL, and -0.67 (0.19) log copies/mL in the genotypic group and the control group, respectively (mean difference 0.48 log [0.01-0.97], p=0.05). Difference in the drop in viral load combined at 3 months and 6 months was significant (p=0.015), At month 3, HIV-1 RNA was lower than detection level (200 copies/mL) in 29% (19/65) of patients in the genotypic group versus 14% (6/43) in the control group (p=0.017). At month 6, the values were 32% (21/65) and 14% (6/43) (p=0.067) for the genotypic group and the control group, respectively. Therapy was generally well tolerated, with ten patients (six in the genotypic group, four in the control group) requiring toxic-effect-related drug modification. Interpretation We found genotypic-resistance testing to have a significant benefit on the virological response when choosing a therapeutic alternative. Further study of the use of genotypic-resistance testing in assisting clinical decisionmaking is warranted.	Hop Archet, Serv Malad Infect & Trop, Dept Infect Dis, F-06202 Nice 03, France; Alphabio Lab, Dept Virol, Marseille, France; Cannes Hosp, Cannes, France; Univ Hosp, Dept Virol, Utrecht, Netherlands; Natl Haemophilia Ctr, Tel Hashomer, Israel; Bonnet Hosp, Frejus, France	CHU Nice	Durant, J (corresponding author), Hop Archet, Serv Malad Infect & Trop, Dept Infect Dis, Route St Antoine Ginestiere, F-06202 Nice 03, France.							Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; DUCHAUD F, 1997, 6 EUR C CLIN ASP TRE; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; HARRIGAN PR, 1998, 2 INT WORKSH DRUG RE; HAVLIR DV, 1998, 2 INT WORKSH DRUG RE; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; MAYERS D, 1997, INT WORKSH HIV DRUG; PATIK AK, 1998, 2 INT WORKSH DRUG RE; Perrin L, 1998, SCIENCE, V280, P1871, DOI 10.1126/science.280.5371.1871; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; ZOLOPA R, 1998, 2 INT WORKSH DRUG RE	16	589	610	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2195	2199		10.1016/S0140-6736(98)12291-2	http://dx.doi.org/10.1016/S0140-6736(98)12291-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392984				2022-12-28	WOS:000081091300012
J	Sadetzki, S; Modan, B				Sadetzki, S; Modan, B			Epidemiology as a basis for legislation: how far should epidemiology go?	LANCET			English	Editorial Material							RADIATION		Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Stanley Steyer Inst Canc Epidemiol, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University	Modan, B (corresponding author), Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel.							BROWN WMC, 1955, LANCET, V1, P1283; CRAWFORD GM, 1951, NEW ENGL J MED, V245, P726, DOI 10.1056/NEJM195111082451904; DAMESHEK W, 1957, JAMA-J AM MED ASSOC, V163, P838, DOI 10.1001/jama.1957.02970450040010; HARDER D, 1995, DIGNITY DISCOVERY RA; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; *ICRP, 1992, ICRP PUBL, V59; KAPLAN I I, 1957, Can Med Assoc J, V76, P43; LANGE RD, 1954, BLOOD, V9, P574, DOI 10.1182/blood.V9.6.574.574; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; MARCH HC, 1950, AM J MED SCI, V220, P282, DOI 10.1097/00000441-195022030-00007; March HC., 1944, RADIOLOGY, V43, P275, DOI DOI 10.1148/43.3.275; Modan B, 1975, Harefuah, V88, P541; MODAN B, 1974, LANCET, V1, P277; MODAN B, 1987, MED ONCOL TUMOR PHAR, V4, P141; MOLONEY WC, 1995, SCIENCE, V121, P308; RON E, 1984, ISRAEL J MED SCI, V20, P1164; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; RON E, 1982, AM J EPIDEMIOL, V16, P149; *US DHEW, 1964, PHS PUBL; VETTER RJ, 1993, HEALTH PHYS, V64, P115; WERNER A, 1968, PHYS MED BIOL, V13, P247, DOI 10.1088/0031-9155/13/2/310; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P320	22	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2238	2239		10.1016/S0140-6736(98)12327-9	http://dx.doi.org/10.1016/S0140-6736(98)12327-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10393003				2022-12-28	WOS:000081091300045
J	Lynch, KR; O'Neill, GP; Liu, QY; Im, DS; Sawyer, N; Metters, KM; Coulombe, N; Abramovitz, M; Figueroa, DJ; Zeng, ZZ; Connolly, BM; Bai, C; Austin, CP; Chateauneuf, A; Stocco, R; Greig, GM; Kargman, S; Hooks, SB; Hosfield, E; Williams, DL; Ford-Hutchinson, AW; Caskey, CT; Evans, JF				Lynch, KR; O'Neill, GP; Liu, QY; Im, DS; Sawyer, N; Metters, KM; Coulombe, N; Abramovitz, M; Figueroa, DJ; Zeng, ZZ; Connolly, BM; Bai, C; Austin, CP; Chateauneuf, A; Stocco, R; Greig, GM; Kargman, S; Hooks, SB; Hosfield, E; Williams, DL; Ford-Hutchinson, AW; Caskey, CT; Evans, JF			Characterization of the human cysteinyl leukotriene CysLT(1) receptor	NATURE			English	Article							DOUBLE-BLIND TRIAL; GUINEA-PIG LUNG; CHRONIC ASTHMA; ANTAGONIST; MONTELUKAST; POTENT; PHARMACOLOGY; MULTICENTER; EXPRESSION; RESPONSES	The cysteinyl leukotrienes-leukotriene C-4(LTC4), leukotriene D-4(LTD4) and leukotriene E-4(LTE4)-are important mediators of human bronchial asthma(1-3). Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors, designated CysLT(1) and CysLT(2) (refs 4-6). The CysLT(1)-selective antagonists, such as montelukast (Singulair)(7-10), zafirlukast (Accolate)(11) and pranlukast (Onon)(12), are important in the treatment of asthma. Previous biochemical characterization of CysLT(1) antagonists and the CysLT(1) receptor has been in membrane preparations from tissues enriched for this receptor(13). Here we report the molecular and pharmacological characterization of the cloned human CysLT(1) receptor. We describe the functional activation (calcium mobilization) of this receptor by LTD4 and LTC4, and competition for radiolabelled LTD4 binding to this receptor by the cysteinyl leukotrienes and three structurally distinct classes of CysLT(1)-receptor antagonists. We detected CysLT(1)-receptor messenger RNA in spleen, peripheral blood leukocytes and lung. In normal human lung, expression of the CysLT(1)-receptor mRNA was confined to smooth muscle cells and tissue macrophages. Finally, we mapped the human CysLT(1)-receptor gene to the X chromosome.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Merck Frosst Canada & Co, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck & Co Inc, Dept Pharmacol, West Point, PA 19486 USA; Merck & Co Inc, Dept Human Genet, West Point, PA 19486 USA	University of Virginia; Merck & Company; Merck & Company; Merck & Company	Evans, JF (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA.	jilly_evans@merck.com		IM, DONG-SOON/0000-0001-8054-8946				CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; CHARETTE L, 1987, BRIT J PHARMACOL, V91, P179, DOI 10.1111/j.1476-5381.1987.tb08997.x; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; ELLIS C, 1998, Patent No. 0874047; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; Grossman J, 1997, J ASTHMA, V34, P321, DOI 10.3109/02770909709067222; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Kolakowski LF, 1998, J NEUROCHEM, V71, P2239; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Martin V, 1999, J BIOL CHEM, V274, P8597, DOI 10.1074/jbc.274.13.8597; McClintock TS, 1996, J CELL PHYSIOL, V167, P1; METTERS KM, 1993, J BIOL CHEM, V268, P6487; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; UNGRIN MD, IN PRESS ANAL BIOCH; Wright DH, 1998, BRIT J PHARMACOL, V123, P1317; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	28	801	826	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					789	793						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391245				2022-12-28	WOS:000081101600055
J	Witelson, SF; Kigar, DL; Harvey, T				Witelson, SF; Kigar, DL; Harvey, T			The exceptional brain of Albert Einstein	LANCET			English	Article							INTELLIGENCE		McMaster Univ, Fac Hlth Sci, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada	McMaster University	Witelson, SF (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Psychiat & Behav Neurosci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	witelson@mcmaster.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018954] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18954, NS62344] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson B, 1996, NEUROSCI LETT, V210, P161, DOI 10.1016/0304-3940(96)12693-8; BRIAN D, 1996, EINSTEIN LIFE, P437; Cajal SRY, 1989, RECOLLECTIONS MY LIF; CHI JG, 1977, ANN NEUROL, V1, P86, DOI 10.1002/ana.410010109; CLARK RW, 1971, EINSTEIN LIFE TIMES, P630; Connolly CJ, 1950, EXTERNAL MORPHOLOGY; Crammond DJ, 1997, TRENDS NEUROSCI, V20, P54, DOI 10.1016/S0166-2236(96)30019-2; CRITCHLEY M, 1971, PARIETAL LOBES; Deary IJ, 1997, TRENDS NEUROSCI, V20, P365, DOI 10.1016/S0166-2236(97)01070-9; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; DIAMOND MC, 1985, EXP NEUROL, V88, P198, DOI 10.1016/0014-4886(85)90123-2; DONALDSON HENRY HERBERT, 1928, JOUR COMP NEUROL, V46, P1; Einstein A., 1949, ESSAY PSYCHOL INVENT, P142; Fontes V., 1944, MORFOLOGIA CORTEX CE; Gardner H, 1983, FRAMES MIND THEORY M; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GOULD SJ, 1981, MISMEASURE MAN; Highfield R., 1993, PRIVATE LIVES A EINS; Hines T, 1998, EXP NEUROL, V150, P343, DOI 10.1006/exnr.1997.6759; KIGAR DL, 1997, SOC NEUR ABST, V23; Ono M, 1990, ATLAS CEREBRAL SULCI; Pais A., 1994, EINSTEIN LIVED HERE; Spitzka E. A., 1907, T AM PHILOS SOC, V21, P175, DOI DOI 10.2307/1005434; Stevens CF, 1989, NEURAL COMPUT, V1, P473, DOI 10.1162/neco.1989.1.4.473; Tagaris GA, 1996, NEUROREPORT, V7, P773, DOI 10.1097/00001756-199602290-00022; TOMLINSON BE, 1992, GREENFIELDS NEUROPAT; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; WAGNER R, 1860, VORSTUDIEN EINER WIS, V1; WAGNER R, 1862, VORSTUDIEN EINER WIS, V2; WELKER WI, 1963, J COMP NEUROL, V120, P19, DOI 10.1002/cne.901200103; WESCHLER D, 1955, MANUAL WESCHLER ADUL; WICKETT JC, 1994, PERS INDIV DIFFER, V16, P831, DOI 10.1016/0191-8869(94)90227-5; WINOKUR M, 1984, EINSTEIN PORTRAIT; WITELSON SF, 1991, SCHIZOPHRENIA BULL, V17, P583, DOI 10.1093/schbul/17.4.583; WITELSON SF, 1992, J COMP NEUROL, V323, P326, DOI 10.1002/cne.903230303; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; WITELSON SF, 1988, HDB NEUROPSYCHOLOGY, V1; 1951, NY TIMES        0224	38	122	125	2	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2149	2153		10.1016/S0140-6736(98)10327-6	http://dx.doi.org/10.1016/S0140-6736(98)10327-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382713				2022-12-28	WOS:000080969300041
J	Ferriman, A				Ferriman, A			BMA backs junior doctors' fight against government	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					74	74		10.1136/bmj.319.7202.74	http://dx.doi.org/10.1136/bmj.319.7202.74			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398613	Green Published			2022-12-28	WOS:000081438200008
J	[Anonymous]				[Anonymous]			BMA chairman warns of fight ahead	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					128	128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398654				2022-12-28	WOS:000081438200063
J	Hardebeck, JL; Hauksson, E				Hardebeck, JL; Hauksson, E			Role of fluids in faulting inferred from stress field signatures	SCIENCE			English	Article							SAN-ANDREAS FAULT; 1995 KOBE EARTHQUAKE; CAJON PASS; KM DEPTH; RUPTURE NUCLEATION; INTERNAL STRUCTURE; CENTRAL CALIFORNIA; FOCAL MECHANISMS; SEISMIC IMAGE; PRESSURE	The stress orientation signature of weak faults containing high-pressure fluids has been observed for segments of the San Andreas fault system in southern California. The inferred lithostatic fluid pressures extend into the surrounding relatively intact rock in a zone scaling with the width of the interseismic strain accumulation. Repeated strain-related fracturing and crack sealing may have created low-permeability barriers that seal fluids into the network of currently active fractures.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA	California Institute of Technology	Hardebeck, JL (corresponding author), CALTECH, Seismol Lab, MC 252-21, Pasadena, CA 91125 USA.			Hauksson, Egill/0000-0002-6834-5051; Hardebeck, Jeanne/0000-0002-6737-7780				AXEN GJ, 1992, J GEOPHYS RES-SOL EA, V97, P8979, DOI 10.1029/92JB00517; BERRY FAF, 1973, AM ASSOC PETR GEOL B, V57, P1219; BLANPIED ML, 1992, NATURE, V358, P574, DOI 10.1038/358574a0; BRUNE JN, 1969, J GEOPHYS RES, V74, P3821, DOI 10.1029/JB074i015p03821; BYERLEE J, 1990, GEOPHYS RES LETT, V17, P2109, DOI 10.1029/GL017i012p02109; BYERLEE J, 1993, GEOLOGY, V21, P303, DOI 10.1130/0091-7613(1993)021<0303:MFEFOH>2.3.CO;2; BYERLEE J, 1978, PURE APPL GEOPHYS, V116, P615, DOI 10.1007/BF00876528; CASTILLO DA, 1995, J GEOPHYS RES-SOL EA, V100, P6249, DOI 10.1029/94JB02476; CHESTER FM, 1993, J GEOPHYS RES-SOL EA, V98, P771, DOI 10.1029/92JB01866; Fuis G S., 1996, EOS T AM GEOPHYS UN, V77, P173; GEPHART JW, 1984, J GEOPHYS RES, V89, P9305, DOI 10.1029/JB089iB11p09305; HANDA S, 1985, J GEOMAGN GEOELECTR, V37, P93, DOI 10.5636/jgg.37.93; HAUKSSON E, 1994, B SEISMOL SOC AM, V84, P917; HAUKSSON E, UNPUB; HEATON TH, 1990, PHYS EARTH PLANET IN, V64, P1, DOI 10.1016/0031-9201(90)90002-F; HUBBERT MK, 1959, GEOL SOC AM BULL, V70, P115; KANAMORI H, 1975, B SEISMOL SOC AM, V65, P1073; LACHENBRUCH AH, 1992, J GEOPHYS RES-SOL EA, V97, P4995, DOI 10.1029/91JB01506; LACHENBRUCH AH, 1972, EARTH PLANET SC LETT, V15, P116, DOI 10.1016/0012-821X(72)90051-9; LISOWSKI M, 1991, J GEOPHYS RES-SOLID, V96, P8369, DOI 10.1029/91JB00199; Liu Y, 1997, GEOPHYS J INT, V129, P439, DOI 10.1111/j.1365-246X.1997.tb01594.x; Lockner DA, 1995, PURE APPL GEOPHYS, V145, P717, DOI 10.1007/BF00879597; MAGEE ME, 1993, GEOLOGY, V21, P809, DOI 10.1130/0091-7613(1993)021<0809:EFAWIT>2.3.CO;2; Magistrale H, 1996, J GEOPHYS RES-SOL EA, V101, P3031, DOI 10.1029/95JB03447; MICHAEL AJ, 1987, J GEOPHYS RES-SOLID, V92, P357, DOI 10.1029/JB092iB01p00357; Moore DE, 1996, GEOLOGY, V24, P1041, DOI 10.1130/0091-7613(1996)024<1041:SOCSGU>2.3.CO;2; MOORE DE, 1997, EOS T AGU, V78, pF732; Morrow C., 1992, FAULT MECH TRANSPORT, V51, P69, DOI DOI 10.1016/S0074-6142(08)62815-6; MORROW CA, 1992, J GEOPHYS RES-SOL EA, V97, P5145, DOI 10.1029/90JB00423; MOUNT VS, 1992, J GEOPHYS RES-SOL EA, V97, P11995, DOI 10.1029/92JB00130; Rice J., 1992, FAULT MECH TRANSPORT, P475, DOI DOI 10.1016/S0074-6142(08)62835-1; SEEBER L, 1995, J GEOPHYS RES-SOL EA, V100, P8285, DOI 10.1029/94JB02939; SHAMIR G, 1992, J GEOPHYS RES-SOL EA, V97, P5059, DOI 10.1029/91JB02959; SIBSON RH, 1992, TECTONOPHYSICS, V211, P283, DOI 10.1016/0040-1951(92)90065-E; SIEH KE, 1978, B SEISMOL SOC AM, V68, P1731; SLEEP NH, 1992, NATURE, V359, P687, DOI 10.1038/359687a0; SONDER LJ, 1990, TECTONICS, V9, P769; Stern TA, 1998, TECTONOPHYSICS, V286, P63, DOI 10.1016/S0040-1951(97)00255-2; THATCHER W, 1990, SAN ANDREAS FAULT SY, P189; Thurber C, 1997, GEOPHYS RES LETT, V24, P1591, DOI 10.1029/97GL01435; Unsworth MJ, 1997, GEOLOGY, V25, P359, DOI 10.1130/0091-7613(1997)025<0359:ISOTSA>2.3.CO;2; WYSS M, 1995, GEOPHYS RES LETT, V22, P547, DOI 10.1029/95GL00074; YERKES RF, 1990, 1487 US GEOL SURV PR, P235; YUKUTAKE T, 1985, EARTHQUAKE PRED RES, V3, P345; Zhao DP, 1996, SCIENCE, V274, P1891, DOI 10.1126/science.274.5294.1891; Zhao DP, 1998, J GEOPHYS RES-SOL EA, V103, P9967, DOI 10.1029/97JB03670; ZOBACK MD, 1987, SCIENCE, V238, P1105, DOI 10.1126/science.238.4830.1105; ZOBACK MD, 1993, NATURE, V365, P633, DOI 10.1038/365633a0	48	131	134	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					236	239		10.1126/science.285.5425.236	http://dx.doi.org/10.1126/science.285.5425.236			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398596				2022-12-28	WOS:000081346000036
J	Falcini, F; Battini, ML; Ceruso, M; Cimaz, R				Falcini, F; Battini, ML; Ceruso, M; Cimaz, R			A 4-year-old with a rash	LANCET			English	Article							YOUNG-CHILDREN; EARLY-ONSET; SARCOIDOSIS		Univ Florence, Dept Pediat, Florence Azienda Careggi, Italy; Univ Florence, Inst Dermatol, Florence Azienda Careggi, Italy; Univ Florence, Dept Hand Surg & Reconstruct Microscopy, Florence Azienda Careggi, Italy; ICP, Dept Pediat, Milan, Italy	University of Florence; University of Florence; University of Florence	Cimaz, R (corresponding author), Pediat Clin, Via Commenda 9, I-20122 Milan, Italy.		CIMAZ, Rolando/AAA-9058-2019	CIMAZ, Rolando/0000-0002-3260-4226				Fink CW, 1997, J RHEUMATOL, V24, P174; HAFNER R, 1993, CLIN EXP RHEUMATOL, V11, P685; HETHERINGTON S, 1982, AM J DIS CHILD, V136, P13, DOI 10.1001/archpedi.1982.03970370015002; LINDSLEY CB, 1985, PEDIATRICS, V76, P765; RASMUSSEN JE, 1981, J AM ACAD DERMATOL, V5, P566, DOI 10.1016/S0190-9622(81)70118-X	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					40	40		10.1016/S0140-6736(99)03274-2	http://dx.doi.org/10.1016/S0140-6736(99)03274-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406364				2022-12-28	WOS:000081243200013
J	Chapman, CR; Gavrin, J				Chapman, CR; Gavrin, J			Suffering: the contributions of persistent pain	LANCET			English	Article							POSTTRAUMATIC-STRESS-DISORDER; IMMUNE-SYSTEM; ADRENOCORTICAL AXIS; SELF-DISCREPANCIES; PITUITARY; BRAIN; MECHANISMS; DEPRESSION; EFFICACY; PATHWAYS	Pain is a perceived threat or damage to one's biological integrity. Suffering is the perception of serious threat or damage to the self, and it emerges when a discrepancy develops between what one expected of one's self and what one does or is. Some patients who experience sustained unrelieved pain suffer because pain changes who they are. At a physiological level, chronic pain promotes an extended and destructive stress response characterised by neuroendocrine dysregulation, fatigue, dysphoria, myalgia, and impaired mental and physical performance. This constellation of discomforts and functional limitations can foster negative thinking and create a vicious cycle of stress and disability. The idea that one's pain is uncontrollable in itself leads to stress. Patients suffer when this cycle renders them incapable of sustaining productive work, a normal family life, and supportive social interactions. Although patients suffer for many reasons, the physician can contribute substantially to the prevention or relief of suffering by controlling pain. Suffering is a nebulous concept for most physicians, and its relation to pain is unclear. This review offers a medically useful concept of suffering that distinguishes it from pain, accounts for the contributory relation of pain to suffering by describing pain as a stressor, and explores the implications of these ideas for the care of patients.	Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chapman, CR (corresponding author), Univ Washington, Sch Med, Dept Anesthesiol, Box 356540, Seattle, WA 98195 USA.	crc@u.washington.edu			NCI NIH HHS [R01 CA74269, R01 CA74249] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074249, R01CA074269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baltes MM, 1997, PSYCHOL AGING, V12, P433, DOI 10.1037/0882-7974.12.3.433; BLALOCK JE, 1985, CLIN ENDOCRINOL META, V14, P1021; BRENDL CM, 1995, J PERS SOC PSYCHOL, V69, P1028, DOI 10.1037/0022-3514.69.6.1028; Buckelew SP, 1995, ARTHRIT CARE RES, V8, P43, DOI 10.1002/art.1790080110; CARROLL BJ, 1976, PSYCHOL MED, V6, P43, DOI 10.1017/S0033291700007480; Cassel, 1991, NATURE SUFFERING GOA; CHAPMAN CR, 1995, ADV PAIN RES THER, V22, P283; DEQUESNOY B, 1998, REV RHUM ENGL ED, V65, P33; DEVOR M, 1991, BRIT MED BULL, V47, P619, DOI 10.1093/oxfordjournals.bmb.a072496; DWORKIN RH, 1994, SCHIZOPHRENIA BULL, V20, P235, DOI 10.1093/schbul/20.2.235; FELDMAN S, 1995, NEUROSCI BIOBEHAV R, V19, P235, DOI 10.1016/0149-7634(94)00062-6; Heppelmann B, 1991, Curr Opin Neurobiol, V1, P192, DOI 10.1016/0959-4388(91)90077-K; Herman JP, 1997, TRENDS NEUROSCI, V20, P78, DOI 10.1016/S0166-2236(96)10069-2; HIGGINS ET, 1987, PSYCHOL REV, V94, P319, DOI 10.1037/0033-295X.94.3.319; HIGGINS ET, 1986, J PERS SOC PSYCHOL, V51, P5, DOI 10.1037/0022-3514.51.1.5; Holzberg AD, 1996, CLIN J PAIN, V12, P118, DOI 10.1097/00002508-199606000-00006; JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7; Keefe FJ, 1997, ARTHRIT CARE RES, V10, P177, DOI 10.1002/art.1790100305; LILLY MP, 1992, ARCH SURG-CHICAGO, V127, P1463; Maier SF, 1998, PSYCHOL REV, V105, P83, DOI 10.1037/0033-295X.105.1.83; MASON JW, 1988, J NERV MENT DIS, V176, P498, DOI 10.1097/00005053-198808000-00008; MCEWEN B, 1987, ANN NY ACAD SCI, V512, P394; MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E; MERSKEY H, 1979, PAIN, V7, P271, DOI 10.1016/0304-3959(79)90084-8; MossMorris R, 1997, J PSYCHOSOM RES, V43, P293, DOI 10.1016/S0022-3999(97)00020-2; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; PACAK K, 1995, FRONT NEUROENDOCRIN, V16, P89, DOI 10.1006/frne.1995.1004; PRICE LH, 1997, MEDSCAPE MENT HLTH, V2, P1; RESTAK RM, 1989, J CLIN PSYCHIAT, V50, P23; Rowe JW, 1998, AGING-CLIN EXP RES, V10, P142; Sapolsky RM, 1992, STRESS AGING BRAIN M; Stratakis CA, 1995, ANN NY ACAD SCI, V771, P1, DOI 10.1111/j.1749-6632.1995.tb44666.x; STREHLER BL, 1991, SYNAPSE, V7, P44, DOI 10.1002/syn.890070105; Torpy DJ, 1996, BAILLIERE CLIN RHEUM, V10, P181; Wang S, 1996, INTEGR PHYS BEH SCI, V31, P237, DOI 10.1007/BF02691455; WILKE JT, 1981, J MED PHILOS, V6, P323, DOI 10.1093/jmp/6.3.323; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; YEHUDA R, 1991, BIOL PSYCHIAT, V30, P1031, DOI 10.1016/0006-3223(91)90123-4	38	203	211	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2233	2237		10.1016/S0140-6736(99)01308-2	http://dx.doi.org/10.1016/S0140-6736(99)01308-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	210EC	10393002				2022-12-28	WOS:000081091300044
J	Duchamp-Viret, P; Chaput, MA; Duchamp, A				Duchamp-Viret, P; Chaput, MA; Duchamp, A			Odor response properties of rat olfactory receptor neurons	SCIENCE			English	Article							HOMEOTIC TRANSFORMATION; TARGETED DISRUPTION; BRANCHIAL REGION; CHICK HINDBRAIN; CRANIAL NERVES; MOTOR-NEURONS; NEURAL CREST; MUTANT MICE; HOX CODE; SYSTEM	Molecular biology studies of olfaction have identified a multigene family of molecular receptors that are Likely to be involved in odor transduction mechanisms. However, because previous functional data on peripheral coding were mainly collected from inferior vertebrates, it has been difficult to document the degree of specificity of odor interaction mechanisms. As a matter of fact, studies of the functional expression of olfactory receptors have not demonstrated the Low or high specificity of olfactory receptors. In this study, the selectivity of olfactory receptor neurons was investigated in the rat at the cellular Level under physiological conditions by unitary extracellular recordings. Individual olfactory receptor neurons were broadly responsive to qualitatively distinct odor compounds. We conclude that peripheral coding is based on activated arrays of olfactory receptor cells with overlapping tuning profiles.	Univ Lyon 1, CNRS, Lab Neurosci & Syst Sensoriels, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Duchamp-Viret, P (corresponding author), Univ Lyon 1, CNRS, Lab Neurosci & Syst Sensoriels, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	pduchamp@olfac.univ-lyon1.fr	Duchamp-Viret, Patricia/N-9827-2017	Duchamp-Viret, Patricia/0000-0002-7730-266X				Alexandre D, 1996, DEVELOPMENT, V122, P735; Bateson W., 1894, MAT STUDY VARIATION; BELL E, IN PRESS MECH DEV; BUCK L, 1993, CHEM SENSES, V18, P203, DOI 10.1093/chemse/18.2.203; Burke AC, 1996, DEV BIOL, V178, P192, DOI 10.1006/dbio.1996.0210; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; DUCHAMPVIRET P, 1989, J NEUROPHYSIOL, V61, P1085, DOI 10.1152/jn.1989.61.5.1085; DuchampViret P, 1997, PROG NEUROBIOL, V53, P561, DOI 10.1016/S0301-0082(97)00049-X; Gavalas A, 1997, DEVELOPMENT, V124, P3693; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Goddard JM, 1996, DEVELOPMENT, V122, P3217; Goulding M, 1998, NEURON, V21, P943, DOI 10.1016/S0896-6273(00)80612-1; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; PATA I, UNPUB; POURQUIE O, 1990, DEVELOPMENT, V109, P743; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Tiret L, 1998, DEVELOPMENT, V125, P279; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wingate RJT, 1996, DEVELOPMENT, V122, P2143; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	35	220	226	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2171	2174		10.1126/science.284.5423.2171	http://dx.doi.org/10.1126/science.284.5423.2171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381881	Green Submitted			2022-12-28	WOS:000081099300050
J	Seeger, MA; Beattie, CE				Seeger, MA; Beattie, CE			Attraction versus repulsion: Modular receptors make the difference in axon guidance	CELL			English	Review							C-ELEGANS; UNC-5; IMMUNOGLOBULIN; SUBFAMILY; ENCODES; PROTEIN; CNS		Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Seeger, MA (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12Th Ave, Columbus, OH 43210 USA.							Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123	14	30	31	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					821	824		10.1016/S0092-8674(00)80793-X	http://dx.doi.org/10.1016/S0092-8674(00)80793-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399909	Bronze			2022-12-28	WOS:000081162800002
J	Noseworthy, JH				Noseworthy, JH			Progress in determining the causes and treatment of multiple sclerosis	NATURE			English	Review							MAGNETIC-RESONANCE SPECTROSCOPY; PLACEBO-CONTROLLED TRIAL; INTRAVENOUS IMMUNOGLOBULIN THERAPY; POLYMERASE CHAIN-REACTION; CLINICAL-TRIAL; INTERFERON BETA-1B; DOUBLE-BLIND; GENETIC SUSCEPTIBILITY; DISEASE PROGRESSION; NATURAL-HISTORY	The cause of multiple sclerosis remains unknown after more than a century of study. Unconfirmed work has once more indicated that a viral infection may be important In the aetiology of the disease, and there is considerable evidence for an important genetic influence on disease susceptibility. The clinical course is as variable as that of any disease in medicine. Studies using serial magnetic resonance imaging have helped to define the disease course and response to experimental therapies. Although the predominant pathological characteristic is myelin loss with preservation of axons, some studies recall classic descriptions that irreversible axonal destruction may occur, perhaps even in the early stages of the illness. There are now several, partially effective therapies for relapsing forms of multiple sclerosis and here I review progress in determining the timing and course of the Illness and the steps that need to be taken to identify more effective treatments for this disease.	Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Noseworthy, JH (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1St St Sw, Rochester, MN 55905 USA.							Achiron A, 1998, NEUROLOGY, V50, P398, DOI 10.1212/WNL.50.2.398; ARNOLD DL, 1990, MAGNET RESON MED, V14, P154, DOI 10.1002/mrm.1910140115; ARNOLD DL, 1992, ANN NEUROL, V31, P235, DOI 10.1002/ana.410310302; Bell JI, 1996, NAT GENET, V13, P377, DOI 10.1038/ng0896-377; BOSTOCK H, 1978, J PHYSIOL-LONDON, V280, P273, DOI 10.1113/jphysiol.1978.sp012384; Bulman D. E., 1992, Journal of Tropical and Geographical Neurology, V2, P66; BUNGE MB, 1961, J BIOPHYS BIOCHEM CY, V10, P67, DOI 10.1083/jcb.10.1.67; Calabresi PA, 1997, NEUROLOGY, V48, P1446, DOI 10.1212/WNL.48.5.1446; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; Compston A, 1997, MULT SCLER J, V3, P51, DOI 10.1177/135245859700300201; Compston A, 1997, J NEUROL NEUROSUR PS, V62, P553, DOI 10.1136/jnnp.62.6.553; Compston A, 1998, SEMIN NEUROL, V18, P405, DOI 10.1055/s-2008-1040890; COOK S, 1996, ACTA NEUROL SCAND, V161, P34; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; De Stefano N, 1998, BRAIN, V121, P1469, DOI 10.1093/brain/121.8.1469; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Dyment DA, 1997, HUM MOL GENET, V6, P1693, DOI 10.1093/hmg/6.10.1693; Dyment DA, 1997, HUM MOL GENET, V6, P2189; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; Farrall M, 1996, LANCET, V348, P1674, DOI 10.1016/S0140-6736(05)65817-5; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; GASS A, 1994, ANN NEUROL, V36, P62, DOI 10.1002/ana.410360113; Goodkin DE, 1998, NEUROLOGY, V51, P1689, DOI 10.1212/WNL.51.6.1689; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; Haines JL, 1998, HUM MOL GENET, V7, P1229, DOI 10.1093/hmg/7.8.1229; Herndon RM, 1996, ARCH NEUROL-CHICAGO, V53, P123, DOI 10.1001/archneur.1996.00550020027011; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Johnson KP, 1998, NEUROLOGY, V50, P701, DOI 10.1212/WNL.50.3.701; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kidd D, 1998, BRAIN, V121, P1109, DOI 10.1093/brain/121.6.1109; Kidd D, 1996, J NEUROL NEUROSUR PS, V60, P15, DOI 10.1136/jnnp.60.1.15; Kuokkanen S, 1996, NAT GENET, V13, P477, DOI 10.1038/ng0896-477; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; LIEDTKE W, 1995, J NEUROVIROL, V1, P253, DOI 10.3109/13550289509114021; Little C C, 1914, Science, V40, P904, DOI 10.1126/science.40.1042.904; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Losseff NA, 1996, BRAIN, V119, P2009, DOI 10.1093/brain/119.6.2009; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; LUDWIN SK, 1981, ANN NEUROL, V9, P301; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Matthews PM, 1998, SEMIN NEUROL, V18, P327, DOI 10.1055/s-2008-1040884; Mayne M, 1998, ANN NEUROL, V44, P391, DOI 10.1002/ana.410440317; Merelli E, 1997, J NEUROL, V244, P450, DOI 10.1007/s004150050121; Miller DH, 1998, SEMIN NEUROL, V18, P317, DOI 10.1055/s-2008-1040883; Miller DH, 1998, BRAIN, V121, P3, DOI 10.1093/brain/121.1.3; Murray PD, 1998, J NEUROSCI, V18, P7306; NOSEWORTHY J, 1997, PROBLEM ORIENTED APP, P177; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; NOSEWORTHY JH, 1990, NEUROLOGY, V40, P971, DOI 10.1212/WNL.40.6.971; Noseworthy JH, 1998, NEUROLOGY, V51, P1342, DOI 10.1212/WNL.51.5.1342; NOSEWORTHY JH, 1994, J NEUROL NEUROSUR PS, V57, P11, DOI 10.1136/jnnp.57.Suppl.11; Noseworthy JH, 1998, ANN NEUROL, V44, P504; Noseworthy JH, 1998, SEMIN NEUROL, V18, P377, DOI 10.1055/s-2008-1040887; Noseworthy JH, 1997, ANN NEUROL, V42, pM115; NOSEWORTHY JH, 1989, NEUROLOGY, V39, P977, DOI 10.1212/WNL.39.7.977; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Petkau J, 1998, SEMIN NEUROL, V18, P351, DOI 10.1055/s-2008-1040886; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; RISCH N, 1987, AM J HUM GENET, V40, P1; Rivera-Quinones C, 1998, NAT MED, V4, P187, DOI 10.1038/nm0298-187; RODRIGUEZ M, 1990, ANN NEUROL, V27, P12, DOI 10.1002/ana.410270104; RODRIGUEZ M, 1985, MAYO CLIN PROC, V60, P433, DOI 10.1016/S0025-6196(12)60865-9; Rudick RA, 1997, NEUROLOGY, V49, P358, DOI 10.1212/WNL.49.2.358; Sadovnick AD, 1997, EPIDEMIOL REV, V19, P99, DOI 10.1093/oxfordjournals.epirev.a017951; Sadovnick AD, 1996, LANCET, V347, P1728, DOI 10.1016/S0140-6736(96)90807-7; Sanders VJ, 1996, ARCH NEUROL-CHICAGO, V53, P125, DOI 10.1001/archneur.1996.00550020029012; Sanders VJ, 1996, J NEUROVIROL, V2, P249, DOI 10.3109/13550289609146888; Sawcer S, 1997, TRENDS GENET, V13, P234, DOI 10.1016/S0168-9525(97)01140-2; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SCOLDING NJ, 1995, NEUROREPORT, V6, P441, DOI 10.1097/00001756-199502000-00009; SIBLEY WA, 1985, LANCET, V1, P1313; Simon JH, 1998, ANN NEUROL, V43, P79, DOI 10.1002/ana.410430114; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; Sorensen PS, 1998, NEUROLOGY, V50, P1273, DOI 10.1212/WNL.50.5.1273; Steinman L, 1997, NAT MED, V3, P1321, DOI 10.1038/nm1297-1321; Stone LA, 1997, NEUROLOGY, V49, P862, DOI 10.1212/WNL.49.3.862; Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; VANDENNOORT S, 1998, NATL MS SOC NMSS DIS; vanNoort JM, 1996, J MOL MED-JMM, V74, P285, DOI 10.1007/s001090050030; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; VANWALDERVEEN MAA, 1995, NEUROLOGY, V45, P1684, DOI 10.1212/WNL.45.9.1684; WAKSMAN BH, 1995, NATURE, V377, P105, DOI 10.1038/377105a0; Waxman SG, 1998, NEW ENGL J MED, V338, P323, DOI 10.1056/NEJM199801293380510; Waxman Stephen G., 1997, V73, P109; WEINSHENKER B, 1998, FRONTIERS MULTIPLE S; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; WOLINSKY JS, 1990, NEUROLOGY, V40, P1764, DOI 10.1212/WNL.40.11.1764; Zajicek J, 1995, Mult Scler, V1, P61; Zhang HP, 1997, ANN MED, V29, P493, DOI 10.3109/07853899709007473	101	207	224	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738		S			A40	A47		10.1038/399a040	http://dx.doi.org/10.1038/399a040			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JQ	10392579				2022-12-28	WOS:000081101700007
J	Carr, A; Samaras, K; Thorisdottir, A; Kaufmann, GR; Chisholm, DJ; Cooper, DA				Carr, A; Samaras, K; Thorisdottir, A; Kaufmann, GR; Chisholm, DJ; Cooper, DA			Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; X-RAY ABSORPTIOMETRY; MYOCARDIAL-INFARCTION; DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE; INFECTED PATIENTS; BODY-COMPOSITION; HDL-CHOLESTEROL; RISK; TRIGLYCERIDE	Background The prevalence and severity of lipodystrophy syndrome with long-term therapy for HIV-1 infection that includes a protease inhibitor is unknown. We studied the natural course of the syndrome to develop diagnostic criteria and identifying markers that. predict its severity. Methods We assessed 113 patients who were receiving HIV-1 protease inhibitors (mean 21 months) and 45 HIV-1-infected patients (28 with follow-up) never treated with a protease inhibitor. Lipodystrophy was assessed by questionnaire (including patients' rating of severity), physical examination, and dual-energy x-ray absorptiometry. Body composition and lasting lipid and glycaemic variables were compared with data obtained 8 months previously. Oral glucose tolerance was investigated. Findings There was 98% concordance between patients' reports of the presence or absence of lipodystrophy (reported by 83% of protease-inhibitor recipients and 4% of treatment-naive patients; p=0.0001) and physical examination. Patients' ratings of lipodystrophy were significantly associated with declining total body fat (p=0.02). Lower body fat was independently associated with longer duration of protease inhibitor therapy and lower bodyweight before therapy, and more severe lipodystrophy was associated with higher previous (p<0.03) and current (p less than or equal to 0.01) triglyceride and C-peptide concentrations, and less peripheral and greater central fat (p=0.005 and 0.09, respectively). Body fat declined a mean 1.2 kg over 8 months in protease-inhibitor recipients (p=0.05). The prevalence of hyperlipidaemia remained stable over time (74% of treated patients vs 28% of naive patients; p=0.0001). Impaired glucose tolerance occurred in 16% of protease-inhibitor recipients and diabetes mellitus in 7%; in all but three patients these abnormalities were detected on 2 h post-glucose load values. Interpretation Diagnosis and rating severity of lipodystrophy is aided by the combination of physical examination, patient's rating, and measurement of body fat, fasting triglycerides, and C-peptide. Weight before therapy, fasting triglyceride, and C-peptide concentrations early in therapy, and therapy duration seem to predict lipodystrophy severity. Lipodystrophy was common and progressive after almost 2 years of protease inhibitor therapy, but. was not usually severe. Hyperlipidaemia and impaired glucose tolerance were also common.	St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ New S Wales, Garvan Inst Med Res, Div Metab, Sydney, NSW, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute; Garvan Institute of Medical Research; University of New South Wales Sydney	Carr, A (corresponding author), St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au	Chisholm, Donald J/J-9332-2013	Chisholm, Donald J/0000-0002-5349-5735				BURCHFIEL CM, 1995, CIRCULATION, V92, P1430, DOI 10.1161/01.CIR.92.6.1430; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CHIDIAC C, 1995, AIDS, V9, P215, DOI 10.1097/00002030-199502000-00022; Coyle P, 1996, MED J AUSTRALIA, V165, P587, DOI 10.5694/j.1326-5377.1996.tb138654.x; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1999, DIABETES CARE, V22, pS5; Gaziano JM, 1997, CIRCULATION, V96, P2520, DOI 10.1161/01.CIR.96.8.2520; HAARBO J, 1991, CLIN PHYSIOL, V11, P331, DOI 10.1111/j.1475-097X.1991.tb00662.x; Herry I, 1997, CLIN INFECT DIS, V25, P937, DOI 10.1086/597649; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Jeppesen J, 1998, CIRCULATION, V97, P1029, DOI 10.1161/01.CIR.97.11.1029; KERULY JE, 1998, 5 C RETR OPP INF FEB; Lamarche B, 1996, ATHEROSCLEROSIS, V119, P235, DOI 10.1016/0021-9150(95)05653-X; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; LUMPKIN MM, 1997, FDA PUBLIC HLTH 0611; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Miller KK, 1998, CLIN INFECT DIS, V27, P68, DOI 10.1086/514638; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; OSULLIVAN AJ, 1994, J CLIN ENDOCR METAB, V78, P381, DOI 10.1210/jc.78.2.381; ROSENBURG HE, 1998, 5 C RETR OPP INF FEB; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Striker R, 1998, CLIN INFECT DIS, V27, P218, DOI 10.1086/517682; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Viraben R, 1998, AIDS, V12, pF37, DOI 10.1097/00002030-199806000-00001; Welborn TA, 1997, METABOLISM, V46, P35, DOI 10.1016/S0026-0495(97)90315-2	33	1222	1252	3	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2093	2099		10.1016/S0140-6736(98)08468-2	http://dx.doi.org/10.1016/S0140-6736(98)08468-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382692				2022-12-28	WOS:000080969300008
J	Newell-Price, J; Grossman, A				Newell-Price, J; Grossman, A			Diagnosis and management of Cushing's syndrome	LANCET			English	Editorial Material							CORTICOTROPIN-RELEASING HORMONE; DIFFERENTIAL-DIAGNOSIS; SERUM CORTISOL; DISEASE		St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England	University of London; Queen Mary University London	Newell-Price, J (corresponding author), St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England.							CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; Dickstein G, 1996, J CLIN ENDOCR METAB, V81, P2934, DOI 10.1210/jc.81.8.2934; HALL WA, 1994, ANN INTERN MED, V120, P817, DOI 10.7326/0003-4819-120-10-199405150-00001; Invitti C, 1999, J CLIN ENDOCR METAB, V84, P440, DOI 10.1210/jc.84.2.440; KENNEDY L, 1984, BRIT MED J, V289, P1188, DOI 10.1136/bmj.289.6453.1188; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; McCance DR, 1996, CLIN ENDOCRINOL, V44, P1, DOI 10.1046/j.1365-2265.1996.614436.x; MILLER DL, 1992, RADIOLOGY, V185, P143, DOI 10.1148/radiology.185.1.1523298; Newell-Price J, 1998, ENDOCR REV, V19, P647, DOI 10.1210/er.19.5.647; NEWELLPRICE J, 1995, CLIN ENDOCRINOL, V43, P545, DOI 10.1111/j.1365-2265.1995.tb02918.x; NewellPrice J, 1997, J CLIN ENDOCR METAB, V82, P176, DOI 10.1210/jc.82.1.176; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; TRAINER PJ, 1995, J CLIN ENDOCR METAB, V80, P412, DOI 10.1210/jc.80.2.412; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x	15	19	20	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2087	2088		10.1016/S0140-6736(99)99091-8	http://dx.doi.org/10.1016/S0140-6736(99)99091-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382687				2022-12-28	WOS:000080969300003
J	Taylor, B; Miller, E; Farrington, CP; Petropoulos, MC; Favot-Mayaud, I; Li, J; Waight, PA				Taylor, B; Miller, E; Farrington, CP; Petropoulos, MC; Favot-Mayaud, I; Li, J; Waight, PA			Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; ADVERSE EVENTS; CASE SERIES; PERTUSSIS; DISORDERS; CHILDREN	Background. We undertook an epidemiological study to investigate whether measles, mumps, and rubella (MMR) vaccine may be causally associated with autism. Methods. Children with autism born since 1979 were identified from special needs/disability registers and special schools in eight North Thames health districts, UK. Information from clinical records was linked to immunisation data held on the child health computing system. We looked for evidence of a change in trend in incidence or age at diagnosis associated with the introduction of MR IR vaccination to the UK in 1988. Clustering of onsets within defined postvaccination periods was investigated by the case-series method. Findings. We identified 498 cases of autism (261 of core autism, 166 of atypical autism, and 71 of Asperger's syndrome). In 293 cases the diagnosis could be confirmed by the criteria of the International Classification of Diseases, tenth revision (ICD10: 214 [82%] core autism, 52 [31%] atypical autism. 27 [38%] Asperger's syndrome). There was a steady increase in cases by year of birth with no sudden "step-up" or change in the trend line after the introduction of MMR vaccination. There was no difference in age at diagnosis between the cases vaccinated before or after 18 months of age and those never vaccinated. There was no temporal association between onset of autism within 1 or 2 years after vaccination with MMR (relative incidence compared with control period 0.94 [95% Cl 0.60-1.47] and 1.09 [0.79-1.52]). Developmental regression was not clustered in the months after vaccination (relative incidence within 2 months and 4 months after MMR vaccination 0.92 [0.38-2.21] and 1.00 [0.52-1.95]). No significant temporal clustering for age at onset of parental concern was seen far cases of core autism or atypical autism with the exception of a single interval within 6 months of MMR vaccination. This appeared to be an artifact related to the difficulty of defining precisely the onset of symptoms in this disorder. Interpretation. Our analyses do not support a causal association between MMR vaccine and autism. If such an association occurs, it is so rare that it could not be identified in this large regional sample.	UCL, Royal Free & Univ Coll Med Sch, Dept Community Child Hlth, London NW3 2QG, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England; Open Univ, Dept Stat, Milton Keynes, Bucks, England	University of London; University College London; Public Health England; Open University - UK	Taylor, B (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Community Child Hlth, Royal Free Campus, London NW3 2QG, England.			Farrington, Conor Patrick/0000-0002-7148-2612; Petropoulos, Maria-Christina/0000-0003-0618-7016				Bedford H, 1998, LANCET, V351, P907, DOI 10.1016/S0140-6736(05)70320-2; *CDSC, 1998, COMMUN DIS REP CDR W, V8, P345; Chadwick N, 1998, J MED VIROL, V55, P305, DOI 10.1002/(SICI)1096-9071(199808)55:4&lt;305::AID-JMV9&gt;3.0.CO;2-4; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; Farrington CP, 1996, AM J EPIDEMIOL, V143, P1165; FARRINGTON CP, 1995, BIOMETRICS, V51, P228, DOI 10.2307/2533328; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; Fombonne E, 1997, J AM ACAD CHILD PSY, V36, P1561, DOI 10.1016/S0890-8567(09)66566-7; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; GILLBERG C, 1998, AUTISM, V2, P423; Lee JW, 1998, LANCET, V351, P905, DOI 10.1016/S0140-6736(98)26012-0; Morrell JM, 1997, AM J PRIMATOL, V41, P37, DOI 10.1002/(SICI)1098-2345(1997)41:1<37::AID-AJP3>3.0.CO;2-0; NICHOLL A, 1998, BMJ-BRIT MED J, V316, P715; SIEGEL B, 1988, J DEV BEHAV PEDIATR, V9, P199; THOMPSON NP, 1995, EUR J GASTROEN HEPAT, V7, P385; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; Wing L, 1996, BRIT MED J, V312, P327	19	461	473	0	519	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2026	2029		10.1016/S0140-6736(99)01239-8	http://dx.doi.org/10.1016/S0140-6736(99)01239-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376617	Green Accepted			2022-12-28	WOS:000080812200012
J	Haggard, M				Haggard, M			Commentary: Plausible candidates for treatment of glue ear - is one issue really three?	BRITISH MEDICAL JOURNAL			English	Editorial Material									MRC, Inst Hearing Res, Nottingham NG7 2RD, England		Haggard, M (corresponding author), MRC, Inst Hearing Res, Univ Pk, Nottingham NG7 2RD, England.							Buxton M, 1996, J Health Serv Res Policy, V1, P35; Haggard MP, 1991, SCREENING CHILDRENS	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1178	1178						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10383203				2022-12-28	WOS:000080277900030
J	Josefson, D				Josefson, D			Scientists raise possibility of vaccine for Alzheimer's disease	BRITISH MEDICAL JOURNAL			English	News Item																		Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124	1	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					145	145						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406743				2022-12-28	WOS:000081619300014
J	Richards, T; Parboosingh, J				Richards, T; Parboosingh, J			Educator with a vision	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Coll Phys & Surg Canada, Ottawa, ON, Canada										0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					146	146						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406745				2022-12-28	WOS:000081619300016
J	Drolet, BA; Esterly, NB; Frieden, IJ				Drolet, BA; Esterly, NB; Frieden, IJ			Primary care - Hemangiomas in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							KASABACH-MERRITT-SYNDROME; INTRALESIONAL CORTICOSTEROID INJECTION; PULSED DYE-LASER; VASCULAR MALFORMATIONS; KAPOSIFORM HEMANGIOENDOTHELIOMA; CAPILLARY HEMANGIOMA; CUTANEOUS HEMANGIOMAS; SUBGLOTTIC HEMANGIOMA; FACIAL HEMANGIOMAS; INFANCY		Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Drolet, BA (corresponding author), Froedert E,9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	drolet@post.its.mcw.edu		Frieden, Ilona/0000-0001-7305-5940				Achauer BM, 1998, PLAST RECONSTR SURG, V101, P1212, DOI 10.1097/00006534-199804050-00006; Achauer BM, 1997, PLAST RECONSTR SURG, V99, P1301, DOI 10.1097/00006534-199704001-00014; ALBRIGHT AL, 1989, PEDIATRICS, V83, P977; Amir J, 1986, Pediatr Dermatol, V3, P331, DOI 10.1111/j.1525-1470.1986.tb00535.x; APFELBERG DB, 1995, ANN PLAS SURG, V35, P144, DOI 10.1097/00000637-199508000-00004; ASHINOFF R, 1993, PEDIATR DERMATOL, V10, P77, DOI 10.1111/j.1525-1470.1993.tb00021.x; ASSAF A, 1992, ANN OPHTHALMOL, V24, P12; Barlow CF, 1998, J PEDIATR-US, V132, P527, DOI 10.1016/S0022-3476(98)70034-4; Blei F, 1998, ARCH DERMATOL, V134, P718, DOI 10.1001/archderm.134.6.718; Boon LM, 1996, J PEDIATR-US, V128, P329, DOI 10.1016/S0022-3476(96)70276-7; Boon LM, 1996, J PEDIATR-US, V129, P346, DOI 10.1016/S0022-3476(96)70065-3; BURNS AJ, 1991, PEDIATRICS, V88, P1257; Burrows PE, 1998, DERMATOL CLIN, V16, P455, DOI 10.1016/S0733-8635(05)70246-1; Burrows PE, 1998, RADIOLOGY, V207, P601, DOI 10.1148/radiology.207.3.9609880; BURTON BK, 1995, PRENATAL DIAG, V15, P209, DOI 10.1002/pd.1970150302; Chantrenne H, 1997, HIST PHIL LIFE SCI, V19, P7; COHEN RC, 1986, J PEDIATR SURG, V21, P6, DOI 10.1016/S0022-3468(86)80640-6; CREMER HJ, 1995, CHIR PRAX, V49, P295; DEANS RM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1743, DOI 10.1001/archopht.1992.01080240083036; Dubois J, 1998, ACAD RADIOL, V5, P390, DOI 10.1016/S1076-6332(98)80158-X; ELSAS FJ, 1994, J PEDIATR OPHTHALMOL, V31, P153; ENJOLRAS O, 1990, PEDIATRICS, V85, P491; Enjolras O, 1997, PEDIATR DERMATOL, V14, P173, DOI 10.1111/j.1525-1470.1997.tb00232.x; Enjolras O, 1997, Adv Dermatol, V13, P375; ENJOLRAS O, 1993, PEDIATR DERMATOL, V10, P311, DOI 10.1111/j.1525-1470.1993.tb00393.x; Enjolras O, 1997, J PEDIATR-US, V130, P631, DOI 10.1016/S0022-3476(97)70249-X; Esterly N B, 1996, Curr Probl Pediatr, V26, P3, DOI 10.1016/S0045-9380(96)80023-5; ESTERLY NB, 1992, PEDIATR DERMATOL, V9, P353, DOI 10.1111/j.1525-1470.1992.tb00628.x; ESTERLY NB, 1983, J AM ACAD DERMATOL, V8, P504, DOI 10.1016/S0190-9622(83)70056-3; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; FINN MC, 1983, J PEDIATR SURG, V18, P894; Frieden IJ, 1996, ARCH DERMATOL, V132, P307, DOI 10.1001/archderm.132.3.307; Frieden IJ, 1997, ARCH DERMATOL, V133, P1593, DOI 10.1001/archderm.133.12.1593; Frieden IJ, 1997, J AM ACAD DERMATOL, V37, P631, DOI 10.1016/S0190-9622(97)70183-X; Frieden IJ, 1997, PEDIATR DERMATOL, V14, P57; FRIEDEN IJ, 1998, 12 INT WORKSH VASC A; Gangopadhyay AN, 1997, INT SURG, V82, P49; GARDEN JM, 1992, J PEDIATR-US, V120, P555, DOI 10.1016/S0022-3476(05)82481-3; GOLDBERG NS, 1986, ARCH DERMATOL, V122, P684, DOI 10.1001/archderm.122.6.684; GORLIN RJ, 1994, AM J MED GENET, V52, P130, DOI 10.1002/ajmg.1320520203; Greinwald JH, 1999, ARCH OTOLARYNGOL, V125, P21, DOI 10.1001/archotol.125.1.21; HERSH JH, 1985, AM J MED GENET, V21, P177, DOI 10.1002/ajmg.1320210127; Kasabach HH, 1940, AM J DIS CHILD, V59, P1063, DOI 10.1001/archpedi.1940.01990160135009; KISHNANI P, 1995, AM J MED GENET, V59, P44, DOI 10.1002/ajmg.1320590110; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MORELLI JG, 1994, ARCH PEDIAT ADOL MED, V148, P1104; MULLIKEN JB, 1982, PLAST RECONSTR SURG, V69, P412, DOI 10.1097/00006534-198203000-00002; NAKAYAMA H, 1981, J DERMATOL, V2, P277; OPITZ JM, 1982, AM J MED GENET, V12, P443, DOI 10.1002/ajmg.1320120408; Orlow SJ, 1997, J PEDIATR-US, V131, P643, DOI 10.1016/S0022-3476(97)70079-9; OZSOYLU S, 1991, J PEDIATR-US, V119, P676, DOI 10.1016/S0022-3476(05)82432-1; OZSOYLU S, 1992, EUR J PEDIATR, V151, P389, DOI 10.1007/BF02113268; PascualCastroviejo I, 1996, AM J NEURORADIOL, V17, P461; Pitanguy I, 1996, ANN PLAS SURG, V36, P586, DOI 10.1097/00000637-199606000-00005; REESE V, 1993, J PEDIATR-US, V122, P379, DOI 10.1016/S0022-3476(05)83420-1; REYES BA, 1989, J DERMATOL SURG ONC, V15, P828, DOI 10.1111/j.1524-4725.1989.tb01171.x; RICKETTS RR, 1994, ANN SURG, V219, P605, DOI 10.1097/00000658-199406000-00003; RUTTUM MS, 1993, J PEDIATR OPHTHALMOL, V30, P4; Sadan N, 1996, J PEDIATR-US, V128, P141, DOI 10.1016/S0022-3476(96)70446-8; Sarihan H, 1997, EUR J PEDIATR SURG, V7, P158, DOI 10.1055/s-2008-1071080; Sarkar M, 1997, PLAST RECONSTR SURG, V100, P1377, DOI 10.1097/00006534-199711000-00001; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sherrington CA, 1997, ARCH DIS CHILD, V76, P458, DOI 10.1136/adc.76.5.458; SHIM WKT, 1968, AM J SURG, V116, P896, DOI 10.1016/0002-9610(68)90462-5; SIE KCY, 1994, ANN OTO RHINOL LARYN, V103, P167, DOI 10.1177/000348949410300301; Soumekh B, 1996, ANN OTO RHINOL LARYN, V105, P201, DOI 10.1177/000348949610500305; SUTULA FC, 1987, OPHTHALMIC SURG LAS, V18, P103; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Tamayo L, 1997, ARCH DERMATOL, V133, P1567, DOI 10.1001/archderm.133.12.1567; Tanner JL, 1998, PEDIATRICS, V101, P446, DOI 10.1542/peds.101.3.446; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; VinChristian K, 1997, ARCH DERMATOL, V133, P1573, DOI 10.1001/archderm.133.12.1573; ZUKERBERG LR, 1993, AM J SURG PATHOL, V17, P321, DOI 10.1097/00000478-199304000-00001	73	390	417	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					173	181		10.1056/NEJM199907153410307	http://dx.doi.org/10.1056/NEJM199907153410307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403856				2022-12-28	WOS:000081413800007
J	Axelsen, M; Smith, U; Eriksson, JW; Taskinen, MR; Jansson, PA				Axelsen, M; Smith, U; Eriksson, JW; Taskinen, MR; Jansson, PA			Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; LIPID INTOLERANCE; METABOLIC DEFECTS; FOLLOW-UP; MELLITUS; SMOKERS; NIDDM; RISK; MORTALITY; SECRETION	Background: Impaired ability to eliminate lipids in the postprandial state is an atherogenic trait associated with insulin resistance. Objective: To assess insulin sensitivity and postprandial triglyceride metabolism in prediabetic persons. Design: Cross-sectional study. Setting: Sahlgrenska University Hospital, Goteborg, Sweden. Participants: 13 healthy, normotriglyceridemic men with two first-degree relatives with type 2 diabetes and 13 carefully matched controls without known diabetes heredity. Measurements: Oral glucose tolerance test, insulin sensitivity (euglycemic clamp technique), and fasting and postprandial triglyceride levels after a mixed meal. Results: Relatives of persons with type 2 diabetes were insulin resistant but had normal glucose tolerance. They exhibited postprandial hypertriglyceridemia; the 6-hour triglyceride incremental area under the curve was 50% higher than that of the control group (P = 0.037). Conclusions: These healthy male first-degree relatives of patients with type 2 diabetes are insulin resistant and exhibit postprandial lipid intolerance despite having normal fasting triglyceride levels. These characteristics, which occur in the absence of glucose intolerance, are associated with an increased risk for macroangiopathy.	Univ Gothenburg, Dept Internal Med, Lundberg Lab Diabet Res, SS,Sahlgrenska Univ Hosp, S-41345 Gothenburg, Sweden; Norrland Univ Hosp, Dept Med, S-90185 Umea, Sweden; Univ Helsinki, Helsinki, Finland	Sahlgrenska University Hospital; University of Gothenburg; Umea University; University of Helsinki	Axelsen, M (corresponding author), Univ Gothenburg, Dept Internal Med, Lundberg Lab Diabet Res, SS,Sahlgrenska Univ Hosp, S-41345 Gothenburg, Sweden.		Taskinen, Marja-Riitta/AAN-5432-2020; Eriksson, Jan/AAB-5820-2021	Taskinen, Marja-Riitta/0000-0002-6229-3588; 				AXELSEN M, 1995, J INTERN MED, V237, P449, DOI 10.1111/j.1365-2796.1995.tb00869.x; Eliasson B, 1997, ATHEROSCLEROSIS, V129, P79, DOI 10.1016/S0021-9150(96)06028-5; ELIASSON B, 1994, ARTERIOSCLER THROMB, V14, P1946, DOI 10.1161/01.ATV.14.12.1946; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; LAAKSO M, 1989, ARTERIOSCLEROSIS, V9, P665, DOI 10.1161/01.ATV.9.5.665; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; PATSCH JR, 1994, ATHEROSCLEROSIS, V110, pS23, DOI 10.1016/0021-9150(94)05372-P; Perseghin G, 1997, DIABETES, V46, P1001, DOI 10.2337/diabetes.46.6.1001; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; PIMENTA W, 1995, JAMA-J AM MED ASSOC, V273, P1855, DOI 10.1001/jama.273.23.1855; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Syvanne M, 1997, LANCET S1, V350, pS120, DOI DOI 10.1016/S0140-6736(97)90024-6; TUOMILEHTO J, 1997, INT TXB DIABETES MEL, P1559; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; VAAG A, 1995, J CLIN INVEST, V95, P690, DOI 10.1172/JCI117715; *WHO, 1985, TECHN REP SER, V727; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	20	112	122	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					27	31		10.7326/0003-4819-131-1-199907060-00006	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391812				2022-12-28	WOS:000081345200005
J	Loucks, RR; Mavrogenes, JA				Loucks, RR; Mavrogenes, JA			Gold solubility in supercritical hydrothermal brines measured in synthetic fluid inclusions	SCIENCE			English	Article							PARTIAL MOLAL PROPERTIES; HIGH-PRESSURES; THERMODYNAMIC PROPERTIES; THEORETICAL PREDICTION; AQUEOUS-ELECTROLYTES; 5 KB; TEMPERATURES; SYSTEM; COMPLEXES; BEHAVIOR	Dissolved gold contents in chloride brines that were experimentally saturated with gold, magnetite, iron sulfides, orthoclase, and muscovite at 550 degrees to 725 degrees C and 100 to 400 megapascals are reported here. Microsamples of the fluid were isolated at the experimental temperature and pressure as fluid inclusions in quartz. Individual fluid inclusions were opened by Laser ablation and analyzed by inductively coupled plasma mass spectrometry. The results show that gold solubility as sulfide species in supercritical brines is far higher than previously supposed. Dissolved gases such as molecular hydrogen sulfide that are ineffective metal-complexing agents at Low pressures evidently become highly effective at high pressures.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Australian Natl Univ, Dept Geol, Canberra, ACT 0200, Australia	Australian National University; Australian National University	Loucks, RR (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.			Mavrogenes, John/0000-0001-6064-2900				Audetat A, 1998, SCIENCE, V279, P2091, DOI 10.1126/science.279.5359.2091; Benning LG, 1996, GEOCHIM COSMOCHIM AC, V60, P1849, DOI 10.1016/0016-7037(96)00061-0; Bodnar R.J., 1987, HYDROTHERMAL EXPT TE, P423; Bondarenko GV, 1997, GEOCHIM COSMOCHIM AC, V61, P1413, DOI 10.1016/S0016-7037(97)00020-3; DADZE TP, 1993, GEOCHEM INT, V30, P36; GAMMONS CH, 1995, GEOCHIM COSMOCHIM AC, V59, P3453, DOI 10.1016/0016-7037(95)00234-Q; Gammons CH, 1997, ECON GEOL BULL SOC, V92, P45, DOI 10.2113/gsecongeo.92.1.45; Gibert F, 1998, GEOCHIM COSMOCHIM AC, V62, P2931, DOI 10.1016/S0016-7037(98)00209-9; GOLDFARB RJ, 1993, MINERAL MAG, V57, P375, DOI 10.1180/minmag.1993.057.388.03; Greenough J. D., 1990, P OCEAN DRILLING PRO, P71; Greenwood N.N., 1984, CHEM ELEMENTS; HAYASHI K, 1991, GEOCHIM COSMOCHIM AC, V55, P2111, DOI 10.1016/0016-7037(91)90091-I; HELGESON HC, 1974, AM J SCI, V274, P1089, DOI 10.2475/ajs.274.10.1089; HELGESON HC, 1981, AM J SCI, V281, P1249, DOI 10.2475/ajs.281.10.1249; HENLEY RW, 1978, ECON GEOL, V73, P1, DOI 10.2113/gsecongeo.73.1.1; HODGSON CJ, 1993, GIANT ORE DEPOSITS, P157; JOHNSON JW, 1992, COMPUT GEOSCI-UK, V18, P899, DOI 10.1016/0098-3004(92)90029-Q; KISHIMA N, 1989, GEOCHIM COSMOCHIM AC, V53, P2143; Lancashire RK, 1987, COMPREHENSIVE COORDI, V5, P775; LIKHOIDOV GG, 1994, DOKL AKAD NAUK+, V336, P380; LIKHOIDOV GG, 1992, DOKL AKAD NAUK+, V323, P294; LOUCKS RR, 1995, RES SCH EARTH SCI AN, P138; MEYER M, 1985, MINER DEPOSITA, V20, P284; MIKUCKI EJ, 1993, MINER DEPOSITA, V28, P469, DOI 10.1007/BF02431603; Pearce NJG, 1997, GEOSTANDARD NEWSLETT, V21, P115, DOI 10.1111/j.1751-908X.1997.tb00538.x; PHILLIPS RS, 1993, INT J PUBLIC OPIN R, V5, P100, DOI 10.1093/ijpor/5.1.100; Pokrovskii VA, 1997, CHEM GEOL, V137, P221, DOI 10.1016/S0009-2541(96)00167-2; POWELL R, 1991, J METAMORPH GEOL, V9, P141, DOI 10.1111/j.1525-1314.1991.tb00510.x; RENDERS PJ, 1989, GEOCHIM COSMOCHIM AC, V53, P245, DOI 10.1016/0016-7037(89)90377-3; ROBERT F, 1995, J GEOPHYS RES, V100, P12; RYTUBA JJ, 1977, PROBLEMS ORE DEPOSIT, P320; SHELTON KL, 1980, AM MINERAL, V65, P1233; SHOCK EL, 1989, GEOCHIM COSMOCHIM AC, V53, P2157, DOI 10.1016/0016-7037(89)90341-4; Sillitoe RH, 1997, AUST J EARTH SCI, V44, P373, DOI 10.1080/08120099708728318; Stevens G, 1997, S AFR J GEOL, V100, P363; SuttonPratt A, 1996, T I MIN METALL B, V105, pB3; Sverjensky DA, 1997, GEOCHIM COSMOCHIM AC, V61, P1359, DOI 10.1016/S0016-7037(97)00009-4; SVERJENSKY DA, 1991, GEOCHIM COSMOCHIM AC, V55, P989, DOI 10.1016/0016-7037(91)90157-Z; Togashi S, 1997, GEOCHIM COSMOCHIM AC, V61, P543, DOI 10.1016/S0016-7037(96)00369-9; TOULMIN P, 1964, GEOCHIM COSMOCHIM AC, V28, P641, DOI 10.1016/0016-7037(64)90083-3; URIANO GA, 1982, CERTIFICATE ANAL STA; WEBSTER JG, 1986, GEOCHIM COSMOCHIM AC, V50, P1837, DOI 10.1016/0016-7037(86)90242-5; Wilkinson JJ, 1996, GEOLOGY, V24, P395, DOI 10.1130/0091-7613(1996)024<0395:PFPSAG>2.3.CO;2	43	184	233	5	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2159	2163		10.1126/science.284.5423.2159	http://dx.doi.org/10.1126/science.284.5423.2159			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381877				2022-12-28	WOS:000081099300046
J	Franklyn, JA; Maisonneuve, P; Sheppard, M; Betteridge, J; Boyle, P				Franklyn, JA; Maisonneuve, P; Sheppard, M; Betteridge, J; Boyle, P			Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study	LANCET			English	Article							I-131 THERAPY; FOLLOW-UP; RADIOACTIVE IODINE; BREAST-CANCER; THYROTOXICOSIS; RISK	Background Radioiodine is used increasingly as first-line treatment for hyperthyroidism, but concerns remain about subsequent risk of cancer, especially in those treated at a young age, We investigated cancer incidence and mortality in patients treated with radioiodine for hyperthyroidism, Methods We did a population-based study in 7417 patients treated in Birmingham, UK, between 1950 and 1991. We compared details of all cancer diagnoses and deaths in 1971-91 from the UK Office for National Statistics with data on cancer incidence and mortality for England and Wales specific for age, sex, and period. Findings During 72 073 person-years of follow-up, 634 cancer diagnoses were made, compared with an expected number of 761 (standardised incidence ratio [SIR] 0.83 [95% CI 0.77-0.90]), The relative risk of cancer mortality was also decreased (observed cancer deaths 448, expected 499; standardised mortality ratio [SMR] 0.90 [0.82-0.98]). Incidence of cancers of the pancreas, bronchus, trachea, bladder, and lymphatic and haemopoietic systems was lowered. Mortality from cancers at all these sites was also reduced but findings were significant only for bronchus and trachea. There were significant increases in incidence and mortality for cancers of the small bowel (SIR 4.81 [2.16-10.72], SMR 7.03 [3.16-15.66]) and thyroid (SIR 3.25 [1.69-6.25], SMR 2.78 [1.16- 6.77]), although absolute risk of these cancers was small. Interpretation The decrease in overall cancer incidence and mortality in those treated for hyperthyroidism with radioiodine is reassuring. The absolute risk of cancers of the small bower and thyroid remain low, but the increased relative risk shows the need for long-term vigilance in those receiving radioiodine.	Univ Birmingham, Dept Med, Birmingham, W Midlands, England; European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy	University of Birmingham; IRCCS European Institute of Oncology (IEO)	Franklyn, JA (corresponding author), Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England.		Boyle, Peter/A-4380-2014; Maisonneuve, Patrick/U-9789-2018	Boyle, Peter/0000-0001-6251-0610; Maisonneuve, Patrick/0000-0002-5309-4704				BARBER SG, 1977, LANCET, V2, P967; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BAXTER MA, 1993, Q J MED, V86, P495, DOI 10.1093/qjmed/86.8.495; Boyle P, 1997, LUNG CANCER, V17, P1, DOI 10.1016/S0169-5002(97)00648-X; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; FRANKLYN JA, 1991, CLIN ENDOCRINOL, V34, P71, DOI 10.1111/j.1365-2265.1991.tb01738.x; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; FRANKLYN JA, 1994, NEW ENGL J MED, V330, P1731; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; HALL P, 1992, LANCET, V340, P1; HALL P, 1992, INT J CANCER, V50, P886, DOI 10.1002/ijc.2910500611; HOFFMAN DA, 1982, AM J EPIDEMIOL, V115, P243, DOI 10.1093/oxfordjournals.aje.a113296; HOFFMAN DA, 1982, INT J EPIDEMIOL, V11, P218, DOI 10.1093/ije/11.3.218; HOFFMAN DA, 1983, J NATL CANCER I, V70, P63; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; KERBER RA, 1993, JAMA-J AM MED ASSOC, V270, P2076; MUIR CS, 1987, IARC SCI PUBLICATION, V88; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; Ron E, 1998, JAMA-J AM MED ASSOC, V280, P347, DOI 10.1001/jama.280.4.347; SHORE RE, 1985, J NATL CANCER I, V74, P1177; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; Waterhouse J., 1976, IARC SCI PUBLICATION, V15; Waterhouse JA, 1982, IARC SCI PUBLICATION, VIV; *WHO, 1977, INT CLASS DIS MAN IN, V1	26	165	172	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2111	2115		10.1016/S0140-6736(98)12295-X	http://dx.doi.org/10.1016/S0140-6736(98)12295-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382695				2022-12-28	WOS:000080969300011
J	Rothwell, PM; Warlow, CP				Rothwell, PM; Warlow, CP		European Carotid Surg Trialits Collaborative Gr	Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study	LANCET			English	Article							STENOSIS; TRIALS; SURVIVAL; EVENTS; ARTERY; STROKE; DEATH	Background Carotid endarterectomy lowers the risk of carotid territory ipsilateral ischaemic stroke, and is the treatment of choice, in patients with recently symptomatic 70-99% carotid stenosis. However, the 3-year risk of stroke on medical treatment alone is only about 20%. We investigated whether the efficacy of endarterectomy would be improved if patients with a high risk of stroke on medical treatment and a low risk of operative stroke or death could be identified. Methods We developed two prognostic models from data on patients with 0-69% carotid stenosis in the European Carotid Surgery Trial (ECST). The medical model predicted risk of ipsilateral carotid territory major ischaemic stroke (fatal or lasting longer than 7 days) on medical treatment and the surgical model predicted risk of major stroke and death within 30 days of endarterectomy. From these models we developed a prognostic score to identify patients with a high risk of stroke on medical treatment but a low operative risk. We validated the models and tested the scoring system on 990 ECST patients with 70-99% carotid stenosis assigned surgery (594) or medical treatment only (396). Findings When patients with 70-99% stenosis were stratified by the scoring system, which was based on seven independent prl,gnostic factors, endarterectomy was beneficial in only 162 (16%) patients. The 5-year absolute risk of carotid territory ipsilateral major ischaemic stroke, operative major stroke, or death was lowered by 33% in the 16% of patients with a sr:ore of 4 or more (odds ratio 0.12 [95% CI 0.05-0.29], p<0.0001), but not in the other 828 (84%) patients (1.00 [0.45-1.54], p=0.7). Interpretation Many patients with recently symptomatic 70-99% carotid stenosis may not benefit from carotid endarterectomy. Validation of the predictive score is needed on external datasets, but risk-factor modelling could be useful to identify those patients in whom endarterectomy will be beneficial.	Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Radcliffe Infirmary; University of Edinburgh	Rothwell, PM (corresponding author), Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				ALTMAN DG, IN PRESS STAT MED; BARNETT HJM, 1993, STROKE, V24, P1281, DOI 10.1161/01.STR.24.9.1281; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; DUTCH TIA, 1993, STROKE, V24, P527; ELIASSON J, 1994, NORD HYDROL, V25, P301; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HOES AW, 1995, J HYPERTENS, V13, P805; HOWARD G, 1987, STROKE, V18, P522; HOWARD VJ, 1992, STROKE, V23, P583, DOI 10.1161/01.STR.23.4.583; LAMBERT M, 1995, BMJ-BRIT MED J, V310, P317, DOI 10.1136/bmj.310.6975.317; Morgenstern LB, 1997, NEUROLOGY, V48, P911, DOI 10.1212/WNL.48.4.911; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Rothwell P. M., 1996, CEREBROVASC DIS, V6, P1; Rothwell PM, 1997, BMJ-BRIT MED J, V315, P1571, DOI 10.1136/bmj.315.7122.1571; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; ROTHWELL PM, 1997, HORIZONS MED; ROTHWELL PM, 1997, CEREBROVASC DIS, V7, P17; ROTHWELL PM, 1994, CEREBROVASC DIS, V4, P260; Sharp SJ, 1996, BRIT MED J, V313, P735; STEIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	28	329	336	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2105	2110		10.1016/S0140-6736(98)11415-0	http://dx.doi.org/10.1016/S0140-6736(98)11415-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382694				2022-12-28	WOS:000080969300010
J	Kosunen, E; Vikat, A; Rimpela, M; Rimpela, A; Huhtala, H				Kosunen, E; Vikat, A; Rimpela, M; Rimpela, A; Huhtala, H			Questionnaire study of use of emergency contraception among teenagers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							KNOWLEDGE	Easy accessibility and availability of emergency contraception raises contradictory opinions. Education about emergency contraception is resisted because of a fear that it might lead to irresponsible sexual behaviour and repeated use of emergency contraception instead of regular contraception.(1) In Finland, sales of emergency contraception (the Yuzpe method) increased 10-fold from 1987 to the mid-1990s. In 1994 a national survey among 18-44 year old women showed that knowledge and use of the method was concentrated in the youngest respondents.(2) Reports from other countries confirm that young women and even teenagers are well aware of the method.(3) (4) However, only a few reports have been published on use of emergency contraception among adolescents. We studied knowledge of emergency contraception and frequency of use among teenagers.	Tampere Univ, Sch Med, Dept Gen Practice, FIN-33101 Tampere, Finland; Tampere Univ, Sch Publ Hlth, FIN-33101 Tampere, Finland; Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland	Tampere University; Tampere University	Kosunen, E (corresponding author), Tampere Univ, Sch Med, Dept Gen Practice, POB 607, FIN-33101 Tampere, Finland.	meelko@uta.fi	Rimpela, Arja/J-3910-2014					Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; Kosunen E, 1997, CONTRACEPTION, V55, P153, DOI 10.1016/S0010-7824(97)00022-X; RIMPELA M, 1996, INT J HLTH PROMOTION, V3, P28; Smith BH, 1996, BRIT J OBSTET GYNAEC, V103, P1109, DOI 10.1111/j.1471-0528.1996.tb09592.x; Stubblefield P, 1998, NEW ENGL J MED, V339, P41, DOI 10.1056/NEJM199807023390108	5	25	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					91	91		10.1136/bmj.319.7202.91	http://dx.doi.org/10.1136/bmj.319.7202.91			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398631	Bronze, Green Published			2022-12-28	WOS:000081438200030
J	Wright, J				Wright, J			A memorable patient - No silent areas	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					103	103		10.1136/bmj.319.7202.103	http://dx.doi.org/10.1136/bmj.319.7202.103			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398637	Green Published			2022-12-28	WOS:000081438200036
J	Lindeck, J				Lindeck, J			Starting back at the bottom	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					65	65		10.1136/bmj.319.7201.65	http://dx.doi.org/10.1136/bmj.319.7201.65			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390490	Green Published			2022-12-28	WOS:000081326500073
J	Rhodes, T; Stimson, GV; Fitch, C; Ball, A; Renton, A				Rhodes, T; Stimson, GV; Fitch, C; Ball, A; Renton, A			Rapid assessment, injecting drug use, and public health	LANCET			English	Editorial Material							EPIDEMIC		Univ London, Imperial Coll, Sch Med, Dept Social Sci & Med, London SW6 1RQ, England; WHO, Dept Subst Abuse, CH-1211 Geneva, Switzerland	Imperial College London; University of London; World Health Organization	Rhodes, T (corresponding author), Univ London, Imperial Coll, Sch Med, Dept Social Sci & Med, London SW6 1RQ, England.	t.rhodes@ic.ac.uk	Rhodes, Tim/DNJ-9679-2022	Rhodes, Tim/0000-0003-2400-9838				ALMEDON AM, 1997, HYGIENE EVALUATION P; AYEPONG IA, 1995, MALARIA MANUAL; Ball A L, 1998, Public Health Rep, V113 Suppl 1, P170; BIE NO, 1992, SOC SCI MED, V32, P909; Burrows D, 1998, DRUG ALCOHOL REV, V17, P453, DOI 10.1080/09595239800187291; Carey J, 1975, SOCIOLOGY PUBLIC AFF; CHAMBERS R, 1981, PUBLIC ADMIN DEVELOP, V1, P95, DOI 10.1002/pad.4230010202; DEJONG W, 1998, INJECTING DRUG HIV R; FRIEDMAN S R, 1991, AIDS Care, V3, P239, DOI 10.1080/09540129108253069; HERMAN E, 1993, RAPID ANTHR PROCEDUR; Houweling H, 1998, AIDS, V12, P85, DOI 10.1097/00002030-199801000-00010; KELHER M, 1997, IMPACT CULTURE ETHNI; LADNAIA NN, 1998, 12 WORLD AIDS C GEN; LAMBERT EY, 1990, NATL I DRUG ABUSE RE, V98; LARSON A, 1996, CONTEXTUAL ASSESSMEN; MANDERSON L, 1992, SOC SCI MED, V35, P839, DOI 10.1016/0277-9536(92)90098-B; NICHTER M, 1984, SOC SCI MED, V19, P237, DOI 10.1016/0277-9536(84)90215-6; PAVSKY G, 1996, REPORT RAPID SITUATI; PEARSON R, 1992, RAPID ANTHR PROCEDUR; Renton AM, 1998, CURR OPIN INFECT DIS, V11, P53, DOI 10.1097/00001432-199802000-00012; SAVTCHENKO I, 1998, 12 WORLD AIDS C GEN; Scrimshaw S.C., 1987, RAPID ASSESSMENT PRO; SCRIMSHAW SCM, 1991, HEALTH EDUC QUART, V18, P111, DOI 10.1177/109019819101800111; SMITH GS, 1989, INT J EPIDEMIOL, V18, pS2, DOI 10.1093/ije/18.Supplement_2.S2; STIMSON GV, 1998, DRUG INJECTIONG HIV; Strathdee S A, 1998, AIDS, V12 Suppl A, pS71; *UNAIDS, 1998, REP GLOB HIV AIDS EP; Walberg P, 1998, BRIT MED J, V317, P312, DOI 10.1136/bmj.317.7154.312; *WHO, 1998, RAP ASS RESP GUID PS; *WHO, 1998, RAP ASS RESP GUID SU; *WHO, 1998, PROGR SUBST AB RAP A; 1996, B NARCOTICS, V48	32	56	58	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					65	68		10.1016/S0140-6736(98)07612-0	http://dx.doi.org/10.1016/S0140-6736(98)07612-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406380				2022-12-28	WOS:000081243200042
J	Sandvik, H				Sandvik, H			Health information and interaction on the internet: a survey of female urinary incontinence	BRITISH MEDICAL JOURNAL			English	Article							WORLD-WIDE-WEB; MEDICAL INFORMATION; ADVICE; CONTINENCE; REQUESTS; QUALITY; WOMEN	Objective To evaluate the internet as a source of information about urinary incontinence and to explore interactive facilities. Design Limited survey of internet resources. Subjects 75 websites providing information about incontinence and an opportunity for interactivity, 25 web doctors, and two news groups. Main outcome measures Quality scores according to predefined general and specific criteria. Internet popularity indexes according to number of links to websites. Correlation between quality scores and popularity indexes. Results Few sites provided comprehensive information, but the information actually provided was mostly correct Internet popularity indexes did not correlate with quality scores. The most informative site was easily found xith general internet search engines but was not found in any of the medical index sites investigated. Sixty six per cent of sites responded to an email request for advice from a fictitious incontinent woman, half of them within 24 hours. Twelve responders provided vital information that the woman might suffer from drug induced incontinence. Conclusions Excellent information about urinary incontinence was found on the internet, but the number of links to a site did not reflect quality of content. Patients may get valuable advice and comfort from using interactive services.	Univ Bergen, Dept Publ Hlth & Primary Care, N-5009 Bergen, Norway	University of Bergen	Sandvik, H (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Care, Ulriksdal 8C, N-5009 Bergen, Norway.							Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Eysenbach G, 1998, JAMA-J AM MED ASSOC, V280, P1333, DOI 10.1001/jama.280.15.1333; Fonda D, 1997, EUR UROL, V32, P28; Goldstein M, 1992, J Gerontol Nurs, V18, P15; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Lim PHC, 1997, NEUROUROL URODYNAM, V16, P609, DOI 10.1002/(SICI)1520-6777(1997)16:6<609::AID-NAU10>3.0.CO;2-9; Marshall HJ, 1996, BRIT J CLIN PHARMACO, V42, P507, DOI 10.1046/j.1365-2125.1996.45217.x; NEWMAN DK, 1999, ACCT ACCESS CONTINEN; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; Sandvik H, 1995, Fam Med, V27, P388; SANDVIK H, 1999, FEMALE URINARY INCON; Seim A, 1996, BRIT MED J, V312, P1459, DOI 10.1136/bmj.312.7044.1459; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209	15	109	113	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					29	32		10.1136/bmj.319.7201.29	http://dx.doi.org/10.1136/bmj.319.7201.29			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390457	Green Published, Bronze			2022-12-28	WOS:000081326500031
J	Taylor, DR; Shi, ST; Romano, PR; Barber, GN; Lai, MMC				Taylor, DR; Shi, ST; Romano, PR; Barber, GN; Lai, MMC			Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein	SCIENCE			English	Article							HEPATITIS-C VIRUS; NONSTRUCTURAL 5A PROTEIN; RNA-BINDING; HUMAN-CELLS; DAI; LOCALIZATION; ORGANIZATION; ACTIVATION; SITES	Most isolates of hepatitis C virus (HCV) infections are resistant to interferon, the only available therapy, but the mechanism underlying this resistance has not been defined. Here it is shown that the HCV envelope protein E2 contains a sequence identical with phosphorylation sites of the interferon-inducible protein kinase PKR and the translation initiation factor eIF2 alpha, a target of PKR. E2 inhibited the kinase activity of PKR and blocked its inhibitory effect on protein synthesis and cell growth. This interaction of E2 and PKR may be one mechanism by which HCV circumvents the antiviral effect of interferon.	Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90089 USA; Small Mol Therapeut, Monmouth Junction, NJ 08852 USA; Univ Miami, Sch Med, Miami, FL 33136 USA	University of Southern California; Howard Hughes Medical Institute; University of Southern California; University of Miami	Lai, MMC (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA.		Lai, Michael M. C./I-7001-2012; Yang, Chen/G-1379-2010		NIAID NIH HHS [AI 40038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CLEMENS MJ, 1996, TRANSLATIONAL CONTRO, P575; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 1999, NATURE, V398, P90, DOI 10.1038/18057; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; JIMENEZGARCIA LF, 1993, J CELL SCI, V106, P11; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; TAYLOR DSC, UNPUB; Thomas HC, 1999, HEPATOLOGY, V29, P1333, DOI 10.1002/hep.510290453; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	23	588	632	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					107	110		10.1126/science.285.5424.107	http://dx.doi.org/10.1126/science.285.5424.107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390359				2022-12-28	WOS:000081199800041
J	Jimenez, GS; Bryntesson, F; Torres-Arzayus, MI; Priestley, A; Beeche, M; Saito, S; Sakaguchi, K; Appella, E; Jeggo, PA; Taccioli, GE; Wahl, GM; Hubank, M				Jimenez, GS; Bryntesson, F; Torres-Arzayus, MI; Priestley, A; Beeche, M; Saito, S; Sakaguchi, K; Appella, E; Jeggo, PA; Taccioli, GE; Wahl, GM; Hubank, M			DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CELL-CYCLE ARREST; V(D)J RECOMBINATION; P53; GROWTH; MICE; GENE; PK	Damage to DNA in the cell activates the tumour-suppressor protein p53 (ref. 1), and failure of this activation leads to genetic instability and a predisposition to cancer, It is therefore crucial to understand the signal transduction mechanisms that connect DNA damage with p53 activation. The enzyme known as DNA-dependent protein kinase (DNA-PK) has been proposed to be an essential activator of p53 (refs 2, 3), but the evidence for its involvement in this pathway is controversial(3,4). We now show that the p53 response is fully functional in primary mouse embryonic fibroblasts lacking DNA-PK: irradiation-induced DNA damage in these defective fibroblasts induces a normal response of p53 accumulation, phosphorylation of a p53 serine residue at position 15, nuclear localization and binding to DNA of p53. The upregulation of p53-target genes and cell-cycle arrest also occur normally. The DNA-PR-deficient cell line SCGR11 contains a homozygous mutation in the DNA-binding domain of p53, which may explain the defective response by p53 reported in this line(3), Our results indicate that DNA-PK activity is not required for cells to mount a p53-dependent response to DNA damage.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Sussex, Trafford Ctr, Brighton BN1 9RY, E Sussex, England; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Salk Institute; University of Brighton; University of Sussex; Boston University; University of Sussex; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Hubank, Michael JF/C-1837-2008	Hubank, Michael JF/0000-0002-2901-0742; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Huang LC, 1996, CANCER RES, V56, P2940; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jongmans W, 1996, ONCOGENE, V13, P1133; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rathmell WK, 1997, CANCER RES, V57, P68; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	19	113	116	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					81	83		10.1038/21913	http://dx.doi.org/10.1038/21913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403253				2022-12-28	WOS:000081255700055
J	Bohni, R; Riesgo-Escovar, J; Oldham, S; Brogiolo, W; Stocker, H; Andruss, BF; Beckingham, K; Hafen, E				Bohni, R; Riesgo-Escovar, J; Oldham, S; Brogiolo, W; Stocker, H; Andruss, BF; Beckingham, K; Hafen, E			Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4	CELL			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASE; GROWTH-FACTORS; C-ELEGANS; LIFE-SPAN; MICE; GENE; CYCLE; DIVISION	The control of growth is fundamental to the developing metazoan. Here, we show that CHICO, a Drosophila homolog of vertebrate IRS1-4, plays an essential role in the control of cell size and growth. Animals mutant for chico are less than half the size of wild-type flies, owing to fewer and smaller cells. In mosaic animals, chico homozygous cells grow slower than their heterozygous siblings, show an autonomous reduction in cell size, and form organs of reduced size. Although chico flies are smaller, they show an almost P-fold increase in lipid levels. The similarities of the growth defects caused by mutations in chico and the insulin receptor gene in Drosophila and by perturbations of the insulin/IGF1 signaling pathway in vertebrates suggest that this pathway plays a conserved role in the regulation of overall growth by controling cell size, cell number, and metabolism.	Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich	Hafen, E (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hafen@zool.unizh.ch	Stoecker, Horst/F-8382-2012	Stoecker, Horst/0000-0002-3282-3664				Abe H, 1998, J CLIN INVEST, V101, P1784, DOI 10.1172/JCI1594; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BASLER K, 1988, CELL, V54, P299; BERG CA, 1991, GENETICS, V127, P515; Britton JS, 1998, DEVELOPMENT, V125, P2149; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Chou TB, 1996, GENETICS, V144, P1673; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Follette PJ, 1997, CELL, V88, P309, DOI 10.1016/S0092-8674(00)81869-3; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Ilic D, 1998, J CELL BIOL, V143, P547; Kawamura K, 1999, DEVELOPMENT, V126, P211; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MINARI O, 1963, ANAL BIOCHEM, V6, P320, DOI 10.1016/0003-2697(63)90156-8; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nurse P., 1985, P185; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; ROBERTSON FW, 1963, GENET RES, V4, P74, DOI 10.1017/S001667230000344X; SANTAMARIA P, 1983, DEV BIOL, V96, P285, DOI 10.1016/0012-1606(83)90165-3; SCHMIDT A, 1998, EMBO J, V17, P101; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stern DL, 1999, DEVELOPMENT, V126, P1091; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VANHANDEL E, 1988, J AM MOSQUITO CONTR, V4, P549; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 1997, J BIOL CHEM, V272, P14606, DOI 10.1074/jbc.272.23.14606; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XU T, 1993, DEVELOPMENT, V117, P1223; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yenush L, 1996, MOL CELL BIOL, V16, P2509; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	656	669	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					865	875		10.1016/S0092-8674(00)80799-0	http://dx.doi.org/10.1016/S0092-8674(00)80799-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399915	Bronze			2022-12-28	WOS:000081162800008
J	Tai, AW; Chuang, JZ; Bode, C; Wolfrum, U; Sung, CH				Tai, AW; Chuang, JZ; Bode, C; Wolfrum, U; Sung, CH			Rhodopsin's carboxy-terminal cytoplasmic tail acts as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1	CELL			English	Article							DOMINANT RETINITIS-PIGMENTOSA; PHOTORECEPTOR CELLS; ROD PHOTORECEPTORS; VESICLE TRANSPORT; OUTER SEGMENT; RETINAL RODS; IN-VIVO; COMPLEX; LOCALIZATION; GENE	The interaction of cytoplasmic dynein with its cargoes is thought to be indirectly mediated by dynactin, a complex that binds to the dynein intermediate chain. However, the roles of other dynein subunits in cargo binding have been unknown. Here we demonstrate that dynein translocates rhodopsin-bearing vesicles along microtubules. This interaction occurs directly between the C-terminal cytoplasmic tail of rhodopsin and Tctex-1, a dynein light chain. C-terminal rhodopsin mutations responsible for retinitis pigmentosa inhibit this interaction. Our results point to an alternative docking mechanism for cytoplasmic dynein, provide novel insights into the role of motor proteins in the polarized transport of post-Golgi vesicles, and shed light on the molecular basis of retinitis pigmentosa.	Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Ophthalmol, Margaret M Dyson Vis Res Inst, New York, NY 10021 USA; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Cornell University; Cornell University; Johannes Gutenberg University of Mainz	Sung, CH (corresponding author), Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA.	chsung@mail.med.cornell.edu	Tai, Andrew W./M-8380-2017	Tai, Andrew W./0000-0002-6877-450X	NATIONAL EYE INSTITUTE [R01EY011307] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011307, EY11307] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1988, Peptide Research, V1, P42; Bauch A, 1998, EUR J IMMUNOL, V28, P2167, DOI 10.1002/(SICI)1521-4141(199807)28:07<2167::AID-IMMU2167>3.0.CO;2-L; Beech PL, 1996, J CELL SCI, V109, P889; BESHARSE JC, 1995, J NEUROCYTOL, V24, P371, DOI 10.1007/BF01189064; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Campbell KS, 1998, J IMMUNOL, V161, P1728; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; COLLINS CA, 1987, J CELL BIOL, V105, P2847, DOI 10.1083/jcb.105.6.2847; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DEETIC D, 1998, P NATL ACAD SCI USA, V95, P10620; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HARGRAVE PA, 1982, METHOD ENZYMOL, V81, P251; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HYMAN AA, 1991, J CELL SCI, P125; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; KREBS W, 1977, EXP EYE RES, V25, P511, DOI 10.1016/0014-4835(77)90180-4; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; MACKE JP, 1993, AM J HUM GENET, V53, P80; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Mou T, 1998, FEBS LETT, V435, P275, DOI 10.1016/S0014-5793(98)01069-2; Muresan V, 1996, J CELL BIOL, V135, P383, DOI 10.1083/jcb.135.2.383; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; PAPERMASTER DS, 1986, J HISTOCHEM CYTOCHEM, V34, P5, DOI 10.1177/34.1.2934469; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; ROHLICH P, 1975, CELL TISSUE RES, V161, P421; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; SPENCER M, 1988, INVEST OPHTH VIS SCI, V29, P1012; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; TROUTT LL, 1988, J NEUROSCI, V8, P2371; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; Watanabe TK, 1996, CYTOGENET CELL GENET, V73, P153, DOI 10.1159/000134329; WEISS ER, 1995, BIOCHEM BIOPH RES CO, V216, P755, DOI 10.1006/bbrc.1995.2686; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	62	388	398	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					877	887		10.1016/S0092-8674(00)80800-4	http://dx.doi.org/10.1016/S0092-8674(00)80800-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399916	hybrid			2022-12-28	WOS:000081162800009
J	Miyata, T; Asami, N; Uragami, T				Miyata, T; Asami, N; Uragami, T			A reversibly antigen-responsive hydrogel	NATURE			English	Article							PHASE-TRANSITIONS; POLYMER GEL; RELEASE; GLUCOSE; COLLAPSE; PH	Stimuli-responsive hydrogels that undergo abrupt changes in volume in response to external stimuli such as pH, temperature and solvent composition have potential applications in biomedicine and the creation of 'intelligent' materials systems, for example as media for drug delivery, separation processes and protein immobilization. Hydrogels have been reported that respond to pH(1-3), temperature(4-13), electric fields(14-16) and saccharides(17-22). For some biomedical applications it would be very useful to have a material whose swelling response was dictated by a specific protein. Here we report such a material, which swells reversibly in a buffer solution in response to a specific antigen. The hydrogel was prepared by grafting the antigen and corresponding antibody to the polymer network, so that binding between the two introduces crosslinks in the network. Competitive binding of the free antigen triggers a change in gel volume owing to breaking of these non-covalent crosslinks. In addition, we show that the hydrogel displays shape-memory behaviour, and that stepwise changes in antigen concentration can induce pulsatile permeation of a protein through the network.	Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan; Kansai Univ, High Technol Res Ctr, Osaka 5648680, Japan	Kansai University; Kansai University	Miyata, T (corresponding author), Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan.							AOKI T, 1994, MACROMOLECULES, V27, P947, DOI 10.1021/ma00082a010; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; BAE YH, 1988, MAKROMOL CHEM-RAPID, V9, P185; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; FEIL H, 1991, J MEMBRANE SCI, V64, P283, DOI 10.1016/0376-7388(91)80099-R; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; Kataoka K, 1998, J AM CHEM SOC, V120, P12694, DOI 10.1021/ja982975d; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; Lee SJ, 1996, J MOL RECOGNIT, V9, P549, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<549::AID-JMR299>3.0.CO;2-C; Miyata T, 1996, MACROMOL CHEM PHYSIC, V197, P1135, DOI 10.1002/macp.1996.021970330; MIYATA T, 1994, MACROMOL CHEM PHYSIC, V195, P1111, DOI 10.1002/macp.1994.021950401; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; NATSUME T, 1994, J BIOL CHEM, V269, P31224; OBIDAT AA, 1996, PHARMACEUT RES, V13, P989; OBIDAT AA, 1997, BIOMATERIALS, V18, P801; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; SHOEMAKER SG, 1987, APPL BIOCHEM BIOTECH, V15, P11, DOI 10.1007/BF02798503; SIEGEL RA, 1988, MACROMOLECULES, V21, P3254, DOI 10.1021/ma00189a021; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; TANAKA T, 1978, PHYS REV LETT, V40, P820, DOI 10.1103/PhysRevLett.40.820; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TANAKA T, 1980, PHYS REV LETT, V45, P1636, DOI 10.1103/PhysRevLett.45.1636; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	26	934	971	15	676	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					766	769		10.1038/21619	http://dx.doi.org/10.1038/21619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391240				2022-12-28	WOS:000081101600049
J	Ascherio, A; Rimm, EB; Hernan, MA; Giovannucci, E; Kawachi, I; Stampfer, MJ; Willett, WC				Ascherio, A; Rimm, EB; Hernan, MA; Giovannucci, E; Kawachi, I; Stampfer, MJ; Willett, WC			Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; BETA-CAROTENE; LOGISTIC-REGRESSION; VEGETABLES PROTECT; FOLLOW-UP; DIETARY; PLASMA; ANTIOXIDANT; MORTALITY	Background: Antioxidants increase the resistance of low-density lipoprotein to oxidation and may thereby reduce risk for atherosclerosis. Objective: To determine whether intake of vitamin E, vitamin C, or carotenoids predict risk for total or ischemic stroke. Design: Prospective observational study. Setting: The Health Professionals Follow-up Study. Participants: 43 738 men 40 to 75 years of age who did not have cardiovascular disease or diabetes. Measurements: Repeated and validated dietary assessments were done by using a self-administered 131-item food-frequency questionnaire, which included questions on dose and duration of vitamin supplement use. The follow-up period was 8 years. Results: A total of 328 strokes occurred: 210 ischemic, 70 hemorrhagic, and 48 unclassified. After adjustment for age, smoking, hypertension, hypercholesterolemia, body mass index, physical activity, parental history of myocardial infarction, alcohol consumption, and total energy intake, the relative risk for ischemic stroke in the top quintile of vitamin E intake (median, 411 IU/d) compared with the bottom quintile (5.4 IU/d) was 1.18 (95% Cl, 0.77 to 1.82). The relative risk for ischemic stroke in the top quintile of vitamin C intake (1167 mg/d) compared with the bottom quintile (95 mg/d) was 1.03 (Cl, 0.66 to 1.59). Results for total stroke were similar. Associations of vitamin intake with hemorrhagic stroke were also nonsignificant, but the Cls were wide. Neither dose nor duration of vitamin E or vitamin C supplement use was related to risk for total or ischemic stroke. The relative risk for ischemic stroke was 1.16 (Cl, 0.81 to 1.67) in men using 250 IU or more of vitamin E supplementation per day compared with men who used no vitamin E supplements and was 0.93 (Cl, 0.60 to 1.45) in men using 700 mg or more of vitamin C supplementation per day compared with men who used no vitamin C supplements. A significant inverse relation between lutein intake and risk for ischemic stroke was seen but was not independent of other dietary factors. Conclusions: Vitamin E and vitamin C supplements and specific carotenoids did not seem to substantially reduce risk for stroke in this cohort. Modest effects, however, cannot be excluded.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	alberto.ascherio@channing.harvard.edu			NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHESON RM, 1983, LANCET, V1, P1191; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; Azen SP, 1996, CIRCULATION, V94, P2369, DOI 10.1161/01.CIR.94.10.2369; BENDICH A, 1989, J NUTR, V119, P135, DOI 10.1093/jn/119.1.135; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Daviglus ML, 1997, NEUROEPIDEMIOLOGY, V16, P69, DOI 10.1159/000109673; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DONNAN PT, 1993, AM J CLIN NUTR, V57, P917, DOI 10.1093/ajcn/57.6.917; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GEY KF, 1993, AM J CLIN NUTR, V57, P787; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Key TJA, 1996, BMJ-BRIT MED J, V313, P775, DOI 10.1136/bmj.313.7060.775; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Mark SD, 1998, EPIDEMIOLOGY, V9, P9, DOI 10.1097/00001648-199801000-00005; Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Ross RK, 1997, CIRCULATION, V96, P50; Rothman K., 1998, MODERN EPIDEMIOLOGY; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; STAMPFER MJ, 1995, AM J CLIN NUTR, V62, P1365, DOI 10.1093/ajcn/62.6.1365S; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINER M, 1991, J AM COLL NUTR, V10, P466; STEINER M, 1995, AM J CLIN NUTR, V62, P1381, DOI 10.1093/ajcn/62.6.1381S; VOLLSET SE, 1983, LANCET, V2, P742; WALKER AM, 1981, LANCET, V1, P13; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366	42	152	157	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					963	970		10.7326/0003-4819-130-12-199906150-00003	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383366				2022-12-28	WOS:000080894700002
J	Dawson, K				Dawson, K			William Alexander Dawson - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					192	192		10.1136/bmj.319.7203.192	http://dx.doi.org/10.1136/bmj.319.7203.192			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406777	Green Published			2022-12-28	WOS:000081619300052
J	Keller, IA; Greco, RN				Keller, IA; Greco, RN			Cystic lymphoma of the brain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Keller, IA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					163	163		10.1056/NEJM199907153410305	http://dx.doi.org/10.1056/NEJM199907153410305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403854				2022-12-28	WOS:000081413800005
J	Culleton, BF; Larson, MG; Kannel, WB; Levy, D				Culleton, BF; Larson, MG; Kannel, WB; Levy, D			Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study	ANNALS OF INTERNAL MEDICINE			English	Article						uric acid; cardiovascular diseases; outcome assessment (health care); diuretics; risk factors	DIABETES-MELLITUS; FOLLOW-UP; HYPERTENSIVE PATIENTS; GLUCOSE-TOLERANCE; XANTHINE-OXIDASE; FREE-RADICALS; HYPERURICEMIA; WOMEN; POPULATION; INSULIN	Background: Hyperuricemia is associated with risk for cardiovascular disease and death. However, the role of uric acid independent of established risk factors is uncertain. Objective: To examine the relation of serum uric acid level to incident coronary heart disease, death from cardiovascular disease, and death from all causes. Design: Community-based, prospective observational study. Setting: Framingham, Massachusetts. Patients: 6763 Framingham Heart Study participants (mean age, 47 years). Measurements: Serum uric acid level at baseline (1971 to 1976); event rates per 1000 person-years by sex-specific uric acid quintile. Results: During 117 376 person-years of follow-up, 617 coronary heart disease events, 429 cardiovascular disease deaths, and 1460 deaths from all causes occurred. In men, after adjustment for age, elevated serum uric acid level was not associated with increased risk for an adverse outcome. In women, after adjustment for age, uric acid level was predictive of coronary heart disease (P = 0.002), death from cardiovascular disease (P = 0.009), and death from all causes (P = 0.03). After additional adjustment for cardiovascular disease risk factors, uric acid level was no longer associated with coronary heart disease, death from cardiovascular disease, or death from ail causes. in a stepwise Cox model, diuretic use was identified as the covariate responsible for rendering serum uric acid a statistically nonsignificant predictor of outcomes. Conclusions: These findings indicate that uric acid does not have a causal role in the development of coronary heart disease, death from cardiovascular disease, or death from all causes. Any apparent association with these outcomes is probably due to the association of uric acid level with other risk factors.	Boston Univ, Sch Med, Boston, MA 02118 USA; NHLBI, Framingham Heart Study, Framingham, MA 01702 USA	Boston University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levy, D (corresponding author), NHLBI, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.	Dan@fram.nhlbi.nih.gov	Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; Alderman MH, 1998, J HYPERTENS, V16, pS5; ALDERMAN MH, 1998, AM J HYPERTENS, V11, P16; Anker SD, 1997, HEART, V78, P39, DOI 10.1136/hrt.78.1.39; [Anonymous], 1981, LANCET, V2, P539; ASHRAF M, 1993, J SUBMICR CYTOL PATH, V25, P193; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BENGTSSON C, 1988, ACTA MED SCAND, V224, P549; BOLLI R, 1988, J AM COLL CARDIOL, V12, P239, DOI 10.1016/0735-1097(88)90381-6; BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; CAPPUCCIO FP, 1993, JAMA-J AM MED ASSOC, V270, P354, DOI 10.1001/jama.270.3.354; COX DR, 1972, J R STAT SOC B, V34, P187; CROWLEY LV, 1964, CLIN CHEM, V10, P838; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; EMMERSON BT, 1979, AUST NZ J MED, V9, P451, DOI 10.1111/j.1445-5994.1979.tb04180.x; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479; FRIEDL HP, 1990, AM J PATHOL, V136, P491; GALVAN AQ, 1995, AM J PHYSIOL-ENDOC M, V268, pE1, DOI 10.1152/ajpendo.1995.268.1.E1; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; GINSBERG MH, 1977, J CLIN INVEST, V60, P999, DOI 10.1172/JCI108880; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HAYABUCHI Y, 1993, EUR J PEDIATR, V152, P873, DOI 10.1007/BF01957519; HUIZER T, 1989, J MOL CELL CARDIOL, V21, P691, DOI 10.1016/0022-2828(89)90610-X; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KEIL U, 1988, ACTA MED SCAND, P119; KLEIN R, 1973, ARCH INTERN MED, V132, P401, DOI 10.1001/archinte.132.3.401; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Lehto S, 1998, STROKE, V29, P635, DOI 10.1161/01.STR.29.3.635; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; LEWIS PJ, 1976, LANCET, V1, P564; Leyva F, 1997, EUR HEART J, V18, P858; Liese AD, 1998, CIRCULATION, V97, P822; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; MONTOR SG, 1987, EUR J PHARMACOL, V140, P203, DOI 10.1016/0014-2999(87)90806-5; MURPHY MB, 1982, LANCET, V2, P1293; Newland H, 1975, Med Hypotheses, V1, P152, DOI 10.1016/0306-9877(75)90011-0; PERSKY VW, 1979, CIRCULATION, V59, P969, DOI 10.1161/01.CIR.59.5.969; PORTER KB, 1992, OBSTET GYNECOL, V79, P394, DOI 10.1097/00006250-199203000-00014; *PROGR COOP RES GR, 1985, PREV MED, V14, P312; Rathmann W, 1998, ANN EPIDEMIOL, V8, P250, DOI 10.1016/S1047-2797(97)00204-4; REAVEN GM, 1994, J INTERN MED, V236, P13; REUNANEN A, 1982, ACTA MED SCAND, P49; Sahebjami H, 1998, CHEST, V113, P1604, DOI 10.1378/chest.113.6.1604; *SAS STAT SOFTW, 1996, CHANG ENH REL 6 11 C; SAUGSTAD OD, 1975, PEDIATR RES, V9, P158, DOI 10.1203/00006450-197504000-00002; SHURTLEFF D, 1974, FRAMINGHAM STUDY, P17; Sowers JR, 1998, ARCH INTERN MED, V158, P617, DOI 10.1001/archinte.158.6.617; STETTEN D, 1959, SCIENCE, V129, P1737, DOI 10.1126/science.129.3365.1737; VasquezVivar J, 1996, BIOCHEM J, V314, P869, DOI 10.1042/bj3140869; Wannamethee SG, 1997, HEART, V78, P147, DOI 10.1136/hrt.78.2.147; Ward HJ, 1998, LANCET, V352, P670, DOI 10.1016/S0140-6736(05)60816-1; WILSON PWF, 1991, AM HEART J, V121, P586, DOI 10.1016/0002-8703(91)90729-2; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; 1997, ARCH INTERN MED, V157, P2413	57	927	1004	4	59	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					7	+		10.7326/0003-4819-131-1-199907060-00003	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391820				2022-12-28	WOS:000081345200002
J	Hayashi, T; Tsumura, K; Suematsu, C; Okada, K; Fujii, S; Endo, G				Hayashi, T; Tsumura, K; Suematsu, C; Okada, K; Fujii, S; Endo, G			Walking to work and the risk for hypertension in men: The Osaka Health Survey	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; walking; exercise; middle age; cardiovascular disease	CORONARY HEART-DISEASE; TIME PHYSICAL-ACTIVITY; BLOOD-PRESSURE; COLLEGE ALUMNI; OLDER WOMEN; ATTACK RISK; EXERCISE; TREAT; TRIAL; DEATH	Background: It is not known whether physical activity is effective in reducing the risk for hypertension. Objective: To investigate the association of the duration of the walk to work and leisure-time physical activity with the risk for hypertension. Design: Prospective cohort study. Setting: Work site in Osaka, Japan. Participants: 6017 Japanese men 35 to 60 years of age with systolic blood pressure less than 140 mm Hg, diastolic blood pressure less than 90 mm Hg, normal glucose intolerance, and no history of hypertension or diabetes at baseline. Measurements: Data on physical activity were obtained by using questionnaires. Blood pressure was measured by using a standard technique; a value of at least 160/95 mm Hg was used to diagnose hypertension. Results: During 59 784 person-years of follow-up, 626 cases of hypertension were confirmed. The duration of the walk to work was associated with a reduction in the risk for incident hypertension; multivariate-adjusted relative risks were 1.00 for a walk of 10 minutes or less (reference category), 0.88 (95% CI, 0.75 to 1.04) for an 11- to 20-minute walk, and 0.71 (CI, 0.52 to 0.97) for a walk of 21 minutes or more (P for trend = 0.02). For every 26.3 men who walk more than 20 minutes to work, one case of hypertension will be prevented. Conclusions: Walking to work and other types of physical activity decreased the risk for hypertension in Japanese men. Regular exercise can prevent hypertension.	Osaka City Univ, Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, Osaka 5458585, Japan; Osaka Gas Co Ltd, Med Ctr Employees Hlth, Nishi Ku, Osaka 5500023, Japan; Environm & Publ Hlth Bur, Kita Ku, Osaka 5300005, Japan	Osaka Metropolitan University; Osaka Gas Co., Ltd.	Hayashi, T (corresponding author), Osaka City Univ, Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.		Hayashi, Tomoshige/N-8508-2015					Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; ARROLL B, 1992, J CLIN EPIDEMIOL, V45, P439, DOI 10.1016/0895-4356(92)90093-3; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; FAGARD R, 1990, HYPERTENSION PATHOPH, P1985; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; KINGWELL BA, 1993, MED J AUSTRALIA, V158, P234, DOI 10.5694/j.1326-5377.1993.tb121740.x; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; LEON AS, 1985, MED CLIN N AM, V69, P3, DOI 10.1016/S0025-7125(16)31055-0; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; PAFFENBARGER RS, 1991, ANN MED, V23, P319, DOI 10.3109/07853899109148067; PAFFENBARGER RS, 1995, AM J EPIDEMIOL, V142, P889, DOI 10.1093/oxfordjournals.aje.a117736; PAFFENBARGER RS, 1983, AM J EPIDEMIOL, V117, P245, DOI 10.1093/oxfordjournals.aje.a113537; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; REAVEN PD, 1991, CIRCULATION, V83, P559, DOI 10.1161/01.CIR.83.2.559; SEALS DR, 1991, HYPERTENSION, V18, P583, DOI 10.1161/01.HYP.18.5.583; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; WASHBURN RA, 1990, AM J EPIDEMIOL, V132, P107, DOI 10.1093/oxfordjournals.aje.a115622; WASHBURN RA, 1987, PREV MED, V16, P636, DOI 10.1016/0091-7435(87)90047-8; WILLIAMS RR, 1991, HYPERTENSION, V18, P29, DOI 10.1161/01.HYP.18.3_Suppl.I29; World Health Organization, 1978, WHO TECH REP SER, P7; ZANCHETTI A, 1993, HYPERTENSION, V22, P392	28	148	158	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					21	+		10.7326/0003-4819-131-1-199907060-00005	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391811				2022-12-28	WOS:000081345200004
J	Peters, AL				Peters, AL			The greater rock of ages baptist church	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Peters, AL (corresponding author), 200 UCLA Med Plaza,Suite 365, Los Angeles, CA 90095 USA.			Peters, Anne/0000-0003-0520-0776					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					66	67		10.7326/0003-4819-131-1-199907060-00015	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391818				2022-12-28	WOS:000081345200013
J	Niewoehner, DE; Erbland, ML; Deupree, RH; Collins, D; Gross, NJ; Light, RW; Anderson, P; Morgan, MA				Niewoehner, DE; Erbland, ML; Deupree, RH; Collins, D; Gross, NJ; Light, RW; Anderson, P; Morgan, MA		Dept Vet Affairs Cooperat Study Grp	Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	International Congress of the European-Respiratory-Society	SEP 19-23, 1998	GENEVA, SWITZERLAND	European Resp Soc			CORTICOSTEROID-THERAPY; CONTROLLED TRIAL; STEROID-THERAPY; DOUBLE-BLIND; METAANALYSIS; EQUIVALENCE; ASTHMA; COPD; METHYLPREDNISOLONE; PREDNISONE	Background and Methods Although their clinical efficacy is unclear and they may cause serious adverse effects, systemic glucocorticoids are a standard treatment for patients hospitalized with exacerbations of chronic obstructive pulmonary disease (COPD). We conducted a double-blind, randomized trial of systemic glucocorticoids (given for two or eight weeks) or placebo, in addition to other therapies, for exacerbations of COPD. Most other care was standardized over the six-month period of follow-up. The primary end point was treatment failure, defined as death from any cause or the need for intubation and mechanical ventilation, readmission to the hospital for CORD, or intensification of drug therapy. Results Of 1840 potential study participants at 25 Veterans Affairs medical centers, 271 were eligible for participation and were enrolled; 80 received an eight-week course of glucocorticoid therapy, 80 received a two-week course, and 111 received placebo. About half the potential participants were ineligible because they had received systemic glucocorticoids in the previous 30 days. Rates of treatment failure were significantly higher in the placebo group than in the two glucocorticoid groups combined at 30 days (33 percent vs. 23 percent, P=0.04) and at 90 days (48 percent vs. 37 percent, P=0.04). Systemic glucocorticoids tin both groups combined) were associated with a shorter initial hospital stay (8.5 days, vs. 9.7 days for placebo; P=0.03) and with a forced expiratory volume in one second that was about 0.10 liter higher than that in the placebo group by the first day after enrollment. Significant treatment benefits were no longer evident at six months. The eight-week regimen of therapy was not superior to the two-week regimen. The patients who received glucocorticoid therapy were more likely to have hyperglycemia requiring therapy than those who received placebo (15 percent vs. 4 percent, P=0.002). Conclusions Treatment with systemic glucocorticoids results in moderate improvement in clinical outcomes among patients hospitalized for exacerbations of CORD. The maximal benefit is obtained during the first two weeks of therapy. Hyperglycemia of sufficient severity to warrant treatment is the most frequent complication. (N Engl J Med 1999;340:1941-7.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Pulm Sect 111N, Minneapolis, MN 55417 USA; Vet Affairs Med Ctr, Little Rock, AR USA; Vet Affairs Med Ctr, Hines, IL USA; Vet Affairs Med Ctr, Long Beach, CA USA; Cooperat Studies Program Coordinating Ctr, West Haven, CT USA; Vet Affairs Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Niewoehner, DE (corresponding author), Vet Affairs Med Ctr, Pulm Sect 111N, 1 vET dR, Minneapolis, MN 55417 USA.	niewo001@maroon.tc.umn.edu						ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; CONN HO, 1994, J INTERN MED, V236, P619, DOI 10.1111/j.1365-2796.1994.tb00855.x; Connors AF, 1997, AM J RESP CRIT CARE, V155, P386; Cox D. R., 1984, ANAL SURVIVAL DATA; DAVIS GS, 1978, AM REV RESPIR DIS, V118, P7; DURRLEMAN S, 1990, BIOMETRICS, V46, P329, DOI 10.2307/2531438; EMERMAN CL, 1989, CHEST, V95, P563, DOI 10.1378/chest.95.3.563; Erbland ML, 1998, CONTROL CLIN TRIALS, V19, P404, DOI 10.1016/S0197-2456(98)00011-7; Jones B, 1996, BRIT MED J, V313, P550; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003-4819-119-10-199311150-00001; LEDERLE FA, 1987, ARCH INTERN MED, V147, P2201, DOI 10.1001/archinte.147.12.2201; McEvoy CE, 1998, AM J RESP CRIT CARE, V157, P704, DOI 10.1164/ajrccm.157.3.9703080; McEvoy CE, 1997, CHEST, V111, P732, DOI 10.1378/chest.111.3.732; ODRISCOLL BR, 1993, LANCET, V341, P324, DOI 10.1016/0140-6736(93)90134-3; ROWE BH, 1992, AM J EMERG MED, V10, P301, DOI 10.1016/0735-6757(92)90007-K; SMYLLIE HC, 1968, THORAX, V23, P571, DOI 10.1136/thx.23.6.571; Snedecor G.W., 1989, AMES IOWA STATE U PR; STUCK AE, 1989, REV INFECT DIS, V11, P954; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610	23	548	577	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1941	1947		10.1056/NEJM199906243402502	http://dx.doi.org/10.1056/NEJM199906243402502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	210CX	10379017				2022-12-28	WOS:000081088500002
J	Mendelsohn, AR; Brent, R				Mendelsohn, AR; Brent, R			Protein biochemistry - Protein interaction methods - Toward an endgame	SCIENCE			English	Article							SURFACE-PLASMON RESONANCE; GREEN-FLUORESCENT PROTEIN; ANALYSIS MASS-SPECTROMETRY; REVERSE 2-HYBRID SYSTEM; ENERGY-TRANSFER; GENETIC SYSTEM; BIOMOLECULAR INTERACTIONS; ELECTROSPRAY-IONIZATION; RECRUITMENT SYSTEM; SPLIT-UBIQUITIN		Inst Mol Sci, Berkeley, CA 94704 USA	The Molecular Sciences Institute	Mendelsohn, AR (corresponding author), Inst Mol Sci, 2168 Shattuck Ave, Berkeley, CA 94704 USA.	amendelsohn@sequence.molsci.org						Andersen JS, 1996, NAT BIOTECHNOL, V14, P449, DOI 10.1038/nbt0496-449; Aronheim A, 1997, NUCLEIC ACIDS RES, V25, P3373, DOI 10.1093/nar/25.16.3373; BAIN JD, 1992, NATURE, V356, P537, DOI 10.1038/356537a0; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; BENNER SA, 1994, TRENDS BIOTECHNOL, V12, P158, DOI 10.1016/0167-7799(94)90076-0; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; Colas P, 1998, TRENDS BIOTECHNOL, V16, P355, DOI 10.1016/S0167-7799(98)01225-6; DREES BL, 1999, NUCLEIC ACIDS RES, V27, P919; Dunnwald M, 1999, MOL BIOL CELL, V10, P329, DOI 10.1091/mbc.10.2.329; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Garland PB, 1996, Q REV BIOPHYS, V29, P91, DOI 10.1017/S0033583500005758; GEYER R, IN PRESS P NATL ACAD; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; HARPER JW, 1993, CELL, V75, P805; Huang J, 1997, P NATL ACAD SCI USA, V94, P13396, DOI 10.1073/pnas.94.25.13396; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; HUTCHINSON AM, 1995, MOL BIOTECHNOL, V3, P47, DOI 10.1007/BF02821334; Inouye C, 1997, GENETICS, V147, P479; Jensen ON, 1999, METH MOL B, V112, P571; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Leanna CA, 1996, NUCLEIC ACIDS RES, V24, P3341, DOI 10.1093/nar/24.17.3341; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nelson RW, 1997, ANAL CHEM, V69, P4369, DOI 10.1021/ac9705374; Nelson RW, 1997, ANAL CHEM, V69, P4363, DOI 10.1021/ac970538w; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Remy I, 1999, P NATL ACAD SCI USA, V96, P5394, DOI 10.1073/pnas.96.10.5394; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Shevchenko A, 1997, ELECTROPHORESIS, V18, P2591, DOI 10.1002/elps.1150181415; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; Squillante E, 1998, DRUG DEV IND PHARM, V24, P1163, DOI 10.3109/03639049809108575; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Thompson NL, 1997, CURR OPIN BIOTECH, V8, P58, DOI 10.1016/S0958-1669(97)80158-9; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; VIDAL M, 1999, CURR OPIN CHEM BIOL, V3, P64; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473; Xu X, 1998, NUCLEIC ACIDS RES, V26, P2034, DOI 10.1093/nar/26.8.2034; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Yates JR, 1998, J MASS SPECTROM, V33, P1; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zhang J, 1996, ANAL BIOCHEM, V242, P68, DOI 10.1006/abio.1996.0429	64	109	116	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1948	1950		10.1126/science.284.5422.1948	http://dx.doi.org/10.1126/science.284.5422.1948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10400537				2022-12-28	WOS:000080932700032
J	Jordan, BA; Devi, LA				Jordan, BA; Devi, LA			G-protein-coupled receptor heterodimerization modulates receptor function	NATURE			English	Article							DELTA-OPIOID RECEPTOR; SIGNAL-TRANSDUCTION; CROSS-TALK; INTERNALIZATION; DIMERIZATION; COEXPRESSION; PEPTIDES; SUBTYPES; AGONIST; POTENT	The opioid system modulates several physiological processes, including analgesia, the stress response, the immune response and neuroendocrine function(1). Pharmacological and molecular cloning studies have identified three opioid-receptor types, delta, kappa and mu, that mediate these diverse effects(2,3). Little is known about the ability of the receptors to interact to form new functional structures, the simplest of which would be a dimer, Structural and biochemical studies show that other G-protein-coupled receptors (GPCRs) interact to form homodimers(4,5), Moreover, two nonfunctional receptors heterodimerize to form a functional receptor, suggesting that dimerization is crucial for receptor function(6-11). However, heterodimerization between two fully functional receptors has not been documented. Here we provide biochemical and pharmacological evidence for the heterodimerization of two fully functional opioid receptors, kappa and delta. This results in a new receptor that exhibits ligand binding and functional properties that are distinct from those of either receptor. Furthermore, the kappa-delta heterodimer synergistically binds highly selective agonists and potentiates signal transduction. Thus, heterodimerization of these GPCRs represents a novel mechanism that modulates their function.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University	Devi, LA (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Jordan, Bryen/0000-0002-4967-444X	NIDA NIH HHS [R01 DA008863-17, R01 DA008863, K05 DA019521-08, K05 DA019521] Funding Source: Medline; NINDS NIH HHS [R01 NS026880-22, R01 NS026880] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA019521, R01DA008863] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Herz A., 1993, OPIOIDS; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan B, 1998, BRIT J ANAESTH, V81, P12, DOI 10.1093/bja/81.1.12; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MIOTTO K, 1995, PHARM OPIOID PEPTIDE, P57; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Nock B.U., 1995, PHARM OPIOID PEPTIDE, P29; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; ROTH G, 1990, J MED CHEM, V258, P299; SCHILLER PW, 1993, J MED CHEM, V36, P3182, DOI 10.1021/jm00073a020; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	30	918	987	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					697	700		10.1038/21441	http://dx.doi.org/10.1038/21441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385123	Green Accepted			2022-12-28	WOS:000080932800063
J	Oparka, KJ; Roberts, AG; Boevink, P; Santa Cruz, S; Roberts, L; Pradel, KS; Imlau, A; Kotlizky, G; Sauer, N; Epel, B				Oparka, KJ; Roberts, AG; Boevink, P; Santa Cruz, S; Roberts, L; Pradel, KS; Imlau, A; Kotlizky, G; Sauer, N; Epel, B			Simple, but not branched, plasmodesmata allow the nonspecific trafficking of proteins in developing tobacco leaves	CELL			English	Article							CELL-TO-CELL; GREEN FLUORESCENT PROTEIN; VIRUS MOVEMENT PROTEIN; SIZE-EXCLUSION LIMIT; MOSAIC-VIRUS; ENDOPLASMIC-RETICULUM; NICOTIANA-CLEVELANDII; SETCREASEA-PURPUREA; MOLECULAR-CLONING; SIEVE ELEMENTS	Leaves undergo a sink-source transition during which a physiological change occurs from carbon import to export. In sink leaves, biolistic bombardment of plasmids encoding GFP-fusion proteins demonstrated that proteins with an M-r up to 50 kDa could move freely through plasmodesmata. During the sink-source transition, the capacity to traffic proteins decreased substantially and was accompanied by a developmental switch from simple to branched forms of plasmodesmata. inoculation of sink leaves with a movement protein-defective virus showed that virally expressed GFP, but not viral RNA, was capable of trafficking between sink cells during infection. Contrary to dogma that plasmodesmata have a size exclusion limit below 1 kDa, the data demonstrate that nonspecific "macromolecular trafficking" is a general feature of simple plasmodesmata in sink leaves.	Scottish Crop Res Inst, Cell Biol Unit, Dundee DD2 5DA, Scotland; Univ Erlangen Nurnberg, Lehrstuhl Bot 2, D-91058 Erlangen, Germany; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel	James Hutton Institute; University of Erlangen Nuremberg; Tel Aviv University	Oparka, KJ (corresponding author), Scottish Crop Res Inst, Cell Biol Unit, Dundee DD2 5DA, Scotland.	kopark@scri.sari.ac.uk	Boevink, Petra/AAO-6498-2021; Roberts, Alison/G-6305-2012	Boevink, Petra/0000-0002-7021-9097; 				Angell SM, 1996, VIROLOGY, V216, P197, DOI 10.1006/viro.1996.0046; Balachandran S, 1997, P NATL ACAD SCI USA, V94, P14150, DOI 10.1073/pnas.94.25.14150; BECK DL, 1991, VIROLOGY, V183, P695, DOI 10.1016/0042-6822(91)90998-Q; Blackman LM, 1998, PLANT CELL, V10, P525, DOI 10.1105/tpc.10.4.525; Boevink P, 1996, PLANT J, V10, P935, DOI 10.1046/j.1365-313X.1996.10050935.x; BOEVINK PB, 1999, IN PRESS PLANTA; BURNELL JN, 1988, J EXP BOT, V39, P1575, DOI 10.1093/jxb/39.11.1575; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; CLELAND RE, 1994, PROTOPLASMA, V178, P81, DOI 10.1007/BF01404123; Cook ME, 1997, AM J BOT, V84, P1169, DOI 10.2307/2446040; Cruz SS, 1998, PLANT CELL, V10, P495, DOI 10.1105/tpc.10.4.495; Cruz SS, 1996, P NATL ACAD SCI USA, V93, P6286, DOI 10.1073/pnas.93.13.6286; DEOM CM, 1990, P NATL ACAD SCI USA, V87, P3284, DOI 10.1073/pnas.87.9.3284; Ding B, 1996, PLANT J, V10, P157, DOI 10.1046/j.1365-313X.1996.10010157.x; DING B, 1992, PLANT CELL, V4, P915, DOI 10.1105/tpc.4.8.915; Ding B., 1996, MEMBRANES SPECIALIZE, P489; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; Ehlers K, 1996, PLANTA, V199, P126; Epel BL, 1996, GENE, V173, P75, DOI 10.1016/0378-1119(95)00678-8; ERWEE MG, 1985, PLANTA, V163, P9, DOI 10.1007/BF00395891; FENCZIK CA, 1996, PLANT GEN R, P249; FRANCESCHI VR, 1994, PLANTA, V192, P347; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; GalOn A, 1997, J VIROL METHODS, V64, P103, DOI 10.1016/S0166-0934(96)02146-5; GAMALEI YV, 1994, PLANTA, V194, P443, DOI 10.1007/BF00714455; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; GOODWIN PB, 1983, PLANTA, V157, P124, DOI 10.1007/BF00393645; GUNNING BES, 1978, PLANTA, V143, P121, DOI 10.1007/BF00387786; HATTORI T, 1985, PLANT MOL BIOL, V5, P313, DOI 10.1007/BF00020629; HEPLER PK, 1982, PROTOPLASMA, V111, P121, DOI 10.1007/BF01282070; Imlau A, 1999, PLANT CELL, V11, P309, DOI 10.1105/tpc.11.3.309; Ishiwatari Y, 1998, PLANTA, V205, P12, DOI 10.1007/s004250050291; Itaya A, 1998, PLANT PHYSIOL, V118, P373, DOI 10.1104/pp.118.2.373; Itaya A, 1997, PLANT J, V12, P1223, DOI 10.1046/j.1365-313X.1997.12051223.x; Jackson D, 1997, CURR OPIN GENET DEV, V7, P495, DOI 10.1016/S0959-437X(97)80076-7; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KIKUYAMA M, 1992, PLANT CELL PHYSIOL, V33, P413; KOLLMANN R, 1985, PROTOPLASMA, V126, P19, DOI 10.1007/BF01287669; KOLLMANN R, 1985, PROTOPLASMA, V124, P224, DOI 10.1007/BF01290774; Kragler F, 1998, ANN BOT-LONDON, V81, P1, DOI 10.1006/anbo.1997.0522; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; LUCAS WJ, 1995, CURR OPIN CELL BIOL, V7, P673, DOI 10.1016/0955-0674(95)80109-X; Mezitt LA, 1996, PLANT MOL BIOL, V32, P251, DOI 10.1007/BF00039385; MIZUHIRA V, 1972, ACTA HISTOCHEM CYTOC, V1, P233; OPARKA KJ, 1981, PLANTA, V151, P561, DOI 10.1007/BF00387436; Oparka KJ, 1997, PLANT J, V12, P781, DOI 10.1046/j.1365-313X.1997.12040781.x; Oparka KJ, 1996, TRENDS PLANT SCI, V1, P412, DOI 10.1016/S1360-1385(96)10043-1; OVERALL RL, 1982, PROTOPLASMA, V111, P134, DOI 10.1007/BF01282071; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PETTY ITD, 1990, VIROLOGY, V179, P712, DOI 10.1016/0042-6822(90)90138-H; Raven JA, 1997, EUR J PHYCOL, V32, P95; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Roberts AG, 1997, PLANT CELL, V9, P1381, DOI 10.1105/tpc.9.8.1381; Ryabov EV, 1998, VIROLOGY, V242, P303, DOI 10.1006/viro.1997.9025; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULZ A, 1995, PROTOPLASMA, V188, P22, DOI 10.1007/BF01276793; SEAGULL RW, 1983, PLANTA, V159, P497, DOI 10.1007/BF00409138; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; STIEKEMA WJ, 1988, PLANT MOL BIOL, V11, P255, DOI 10.1007/BF00027383; TERRY BR, 1987, PLANTA, V171, P145, DOI 10.1007/BF00391090; TILNEY LG, 1991, J CELL BIOL, V112, P739, DOI 10.1083/jcb.112.4.739; TOMENIUS K, 1987, VIROLOGY, V160, P363, DOI 10.1016/0042-6822(87)90007-9; TUCKER EB, 1993, PROTOPLASMA, V174, P45, DOI 10.1007/BF01404041; TUCKER EB, 1982, PROTOPLASMA, V113, P193, DOI 10.1007/BF01280907; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433; WANG HL, 1995, PLANT CELL ENVIRON, V18, P373, DOI 10.1111/j.1365-3040.1995.tb00373.x; WANG N, 1994, PLANT PHYSIOL, V104, P17, DOI 10.1104/pp.104.1.17; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377; WOLF S, 1991, PLANT CELL, V3, P593, DOI 10.1105/tpc.3.6.593; Wright KM, 1997, J EXP BOT, V48, P1807, DOI 10.1093/jexbot/48.315.1807; Zhu T, 1998, PROTOPLASMA, V203, P35, DOI 10.1007/BF01280585	77	343	357	2	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					743	754		10.1016/S0092-8674(00)80786-2	http://dx.doi.org/10.1016/S0092-8674(00)80786-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380926	Bronze			2022-12-28	WOS:000080886300012
J	Josefson, D				Josefson, D			Childhood thyroid cancers rise 10-fold in the Ukraine	BRITISH MEDICAL JOURNAL			English	News Item																		Tronko MD, 1999, CANCER, V86, P149, DOI 10.1002/(SICI)1097-0142(19990701)86:1<149::AID-CNCR21>3.0.CO;2-A	1	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					145	145						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406743				2022-12-28	WOS:000081619300015
J	Poulsen, P; Vaag, A; Beck-Nielsen, H				Poulsen, P; Vaag, A; Beck-Nielsen, H			Does zygosity influence the metabolic profile of twins? A population based cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; IMPAIRED GLUCOSE-TOLERANCE; LOW-PROTEIN DIET; 7-YEAR-OLD CHILDREN; INSULIN-RESISTANCE; FETAL GROWTH; MEN; MOTHERS; ASSOCIATION; THINNESS	Objective To study the influence of zygosity on the metabolic variables involved in the pathophysiology of type 2 diabetes. Design Population based cross sectional study. Setting Odense University Hospital, Denmark. Participants 125 monozygotic twin pairs and 178 dizygotic twin pairs of the same sex born between 1921 and 1940. Main outcome measures Clinical characteristics of monozygotic and dizygotic twins with or without a family history of type 2 diabetes. Results Absolute prevalences of type 2 diabetes and impaired glucose tolerance according to the World Health Organisation criteria were similar in both the monozygotic and the dizygotic twins as were measurements of height, weight, body mass index, waist to hip ratio, and fasting plasma glucose and insulin concentrations. During the oral glucose tolerance test, monozygotic twins had a higher incremental plasma insulin area under the curve than dizygotic twins (10.05 (SD 0.68) upsilon 9.89 (0.72) pmol/1xminutes, P < 0.01) indicating insulin resistance. In twins with normal glucose tolerance and without first degree relatives or co-twins with type 2 diabetes or impaired glucose tolerance, both the glucose and insulin areas under the curve were higher among monozygotic twins (glucose 214.4 (88.3) upsilon 189.8 (78.4) mmol/1xminutes, P < 0.05; insulin 20 040 (14 865-32 554) upsilon 17 625 (12 330-23 640) pmol/1xminutes, P = 0.08). Conclusion Zygosity influences both plasma glucose and plasma insulin concentrations during an oral glucose tolerance test This supports an intrauterine influence on glucose homeostasis and perhaps on insulin resistance in humans.	Odense Univ Hosp, Dept Endocrinol & Internal Med, DK-5000 Odense C, Denmark; Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark	University of Southern Denmark; Odense University Hospital; University of Copenhagen	Poulsen, P (corresponding author), Odense Univ Hosp, Dept Endocrinol & Internal Med, DK-5000 Odense C, Denmark.			Vaag, Allan Arthur/0000-0002-3690-2191				COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; Crowther NJ, 1998, DIABETOLOGIA, V41, P1163, DOI 10.1007/s001250051046; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; DESAI M, 1995, BIOCHEM SOC T, V23, P331, DOI 10.1042/bst0230331; Desai M, 1996, BRIT J NUTR, V76, P591, DOI 10.1079/BJN19960065; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hauge M, 1981, PROSPECTIVE LONGITUD, P217; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402; Holness MJ, 1996, FEBS LETT, V396, P53, DOI 10.1016/0014-5793(96)01067-8; IglesiasBarreira V, 1996, ENDOCRINOLOGY, V137, P3797, DOI 10.1210/en.137.9.3797; KEEN H, 1992, INT TXB DIABETES MEL, P19; KYVIK KO, 1995, INT J EPIDEMIOL, V24, P589, DOI 10.1093/ije/24.3.589; LANGMAN J, 1981, MED EMBRYOLOGY, P83; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; Leger J, 1997, BRIT MED J, V315, P341; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MAGNUS P, 1983, CLIN GENET, V24, P103; McKeigue PM, 1998, DIABETOLOGIA, V41, P1133, DOI 10.1007/s001250051042; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; Poulsen P, 1999, DIABETOLOGIA, V42, P139, DOI 10.1007/s001250051131; Poulsen P, 1997, DIABETOLOGIA, V40, P439, DOI 10.1007/s001250050698; RAMASARROYO MA, 1988, ACTA GENET MED GEMEL, V37, P229; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; Skjaerven R, 1997, BRIT MED J, V314, P1376, DOI 10.1136/bmj.314.7091.1376; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606	29	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					151	154		10.1136/bmj.319.7203.151	http://dx.doi.org/10.1136/bmj.319.7203.151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406747	Bronze, Green Published			2022-12-28	WOS:000081619300018
J	Kerem, E; Bistritzer, T; Hanukoglu, A; Hofmann, T; Zhou, ZQ; Bennett, W; MacLaughlin, E; Barker, P; Nash, M; Quittell, L; Boucher, R; Knowles, MR				Kerem, E; Bistritzer, T; Hanukoglu, A; Hofmann, T; Zhou, ZQ; Bennett, W; MacLaughlin, E; Barker, P; Nash, M; Quittell, L; Boucher, R; Knowles, MR			Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYSTIC-FIBROSIS; I PSEUDOHYPOALDOSTERONISM; MUCOCILIARY CLEARANCE; ION-TRANSPORT; GENE; DISEASE; METHACHOLINE; MUTATIONS; CHILDREN; INFANTS	Background Active sodium absorption is the dominant mechanism of ion transport in airway epithelium, but its role in pulmonary physiology and airway host defense is unknown. To address this question, we studied the function of airway epithelial cells and determined the frequency of pulmonary symptoms in patients with systemic pseudohypoaldosteronism, a salt-losing disorder caused by loss-of-function mutations in the genes for the epithelial sodium channel. Methods In nine patients 1.5 to 22 years of age who had systemic pseudohypoaldosteronism, we tested for mutations in the genes for the epithelial sodium channel, estimated the rate of sodium transport in the airway, determined the volume and ion composition of airway surface liquid, reviewed clinical features, collected laboratory data pertinent to pulmonary function, and, in three adults, measured mucociliary clearance. Results The patients with systemic pseudohypoaldosteronism had loss-of-function mutations in the genes for the epithelial sodium-channel subunits, no sodium absorption from airway surfaces, and a volume of airway surface liquid that was more than twice the normal value. The mean (+/-SE) mucociliary transport rate was higher in the 3 adult patients than in 12 normal subjects (2.0+/-0.7 vs. 0.5+/-0.3 percent per minute, P=0.009). Young patients (those five years of age or less) all had recurrent episodes of chest congestion, coughing, and wheezing, but no airway infections with Staphylococcus aureus or Pseudomonas aeruginosa. Older patients (those more than five years of age) had less frequent respiratory symptoms. Conclusions Patients with systemic pseudohypoaldosteronism fail to absorb liquid from airway surfaces; the result is an increased volume of liquid in the airways. These results demonstrate that sodium transport has a role in regulating the volume of liquid on airway surfaces. (N Engl J Med 1999;341: 156-62.) (C) 1999, Massachusetts Medical Society.	Univ N Carolina, Cystic Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Sch Med, Pediat Resp Med & Cyst Fibrosis Ctr, Jerusalem, Israel; Assaf Harofeh Med Ctr, Dept Pediat, IL-70300 Zerifin, Israel; Wolfson Med Ctr, Dept Pediat, Holon, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Univ Giessen, Kinderklin, Giessen, Germany; Univ N Carolina, Ctr Environm Med, Chapel Hill, NC 27599 USA; Univ So Calif, Los Angeles, CA USA; Childrens Hosp Los Angeles, Div Pediat Pulm, Los Angeles, CA 90027 USA; Columbia Presbyterian Med Ctr, Pediat Nephrol Div, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Pediat Pulm Div, New York, NY 10032 USA	University of North Carolina; University of North Carolina Chapel Hill; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Justus Liebig University Giessen; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California; Children's Hospital Los Angeles; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Knowles, MR (corresponding author), Univ N Carolina, Cystic Fibrosis Pulm Res & Treatment Ctr, 7011 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	knowles@med.unc.edu	Hanukoglu, Aaron/L-4892-2016; MacLaughlin, Eric J/L-7316-2019	Hanukoglu, Aaron/0000-0003-1486-6641; MacLaughlin, Eric J/0000-0002-1460-445X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [P01 HL34322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVITAL A, 1988, J PEDIATR-US, V112, P591, DOI 10.1016/S0022-3476(88)80177-X; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; GERHARDT T, 1985, PEDIATR RES, V19, P1165, DOI 10.1203/00006450-198511000-00010; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; HANUKOGLU A, 1994, J PEDIATR-US, V125, P752, DOI 10.1016/S0022-3476(94)70071-0; HANUKOGLU A, 1991, J CLIN ENDOCR METAB, V73, P936, DOI 10.1210/jcem-73-5-936; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; Knowles MR, 1998, J CLIN INVEST, V101, P285; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LODRUPCARLSEN KC, 1993, EUR RESPIR J, V6, P1496; Marthinsen L, 1998, ACTA PAEDIATR, V87, P472; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; OBERFIELD SE, 1979, J CLIN ENDOCR METAB, V48, P228, DOI 10.1210/jcem-48-2-228; Olivier KN, 1996, AM J RESP CRIT CARE, V154, P217, DOI 10.1164/ajrccm.154.1.8680683; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; SANCHEZ I, 1993, AM REV RESPIR DIS, V147, P705, DOI 10.1164/ajrccm/147.3.705; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Smith JJ, 1996, CELL, V87, pU25; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; VANDENPLAS Y, 1992, J PEDIATR GASTR NUTR, V14, P467; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; YAGER D, 1989, J APPL PHYSIOL, V66, P2873, DOI 10.1152/jappl.1989.66.6.2873; Zar J. H., 1996, BIOSTATISTICAL ANAL	35	263	278	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					156	162		10.1056/NEJM199907153410304	http://dx.doi.org/10.1056/NEJM199907153410304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403853	Bronze, Green Published			2022-12-28	WOS:000081413800004
J	Hart, R; Bell-Syer, SEM; Crawford, F; Torgerson, DJ; Young, P; Russell, I				Hart, R; Bell-Syer, SEM; Crawford, F; Torgerson, DJ; Young, P; Russell, I			Systematic review of topical treatments for fungal infections of the skin and nails of the feet	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TERBINAFINE 1-PERCENT CREAM; RANDOMIZED CONTROLLED TRIALS; INTERDIGITAL TINEA-PEDIS; NITRATE 2-PERCENT CREAM; DOUBLE-BLIND; COMPARATIVE EFFICACY; MULTICENTER TRIALS; CLINICAL-TRIALS; NAFTIFINE CREAM; AMOROLFINE	Objective To identify and synthesise the evidence for efficacy and cost effectiveness of topical treatments for superficial fungal infections of the skin and nails of the feet. Design Systematic review Interventions Topical treatments for superficial fungal infections. Main outcome measures Cure confirmed by culture and microscopy for skin and by culture for nails in patients with clinically diagnosed fungal infections. Results Of 126 trials identified in 121 papers, 72 (57.1%) met the inclusion criteria Placebo controlled trials yielded pooled relative risks of failure to cure skin infections: allylamines (0.30, 95% confidence interval 0.24 to 0.38); azoles (0.54, 0.42 to 0.68); undecenoic acid (0.28, 0.11 to 0.74); and tolnaftate (0.46, 0.17 to 1.22). Although mete-analysis of 11 trials comparing allylamines and azoles showed a relative risk of failure to cure of 0.88 (0.78 to 0.99) in favour of allylamines, there was evidence of language bias. Seven reports in English favoured allylamines (0.79, 0.69 to 0.91), but four reports in foreign languages showed no difference between the two drugs (1.01, 0.90 to 1.13). Neither trial of nail infections showed significant differences between alternative topical treatments. Conclusions Allylamines, azoles, and undecenoic acid were efficacious in placebo controlled trials. There are sufficient comparative trials to judge relative efficacy only between allylamines and azoles. Allylamines cure slightly more infections than azoles but are much more expensive than azoles. The most cost effective strategy is first to treat with azoles or undecenoic acid and to use allylamines only if that fails.	Univ York, Dept Hlth Sci & Clin Evaluat, York YO10 5DD, N Yorkshire, England; Univ Wales Coll Cardiff, Inst Cardiff, Fac Community Hlth Sci, Cardiff CF5 2SG, S Glam, Wales; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of York - UK; Cardiff University; University of York - UK	Crawford, F (corresponding author), Univ York, Dept Hlth Sci & Clin Evaluat, York YO10 5DD, N Yorkshire, England.	fc5@york.ac.uk	Russell, Ian T/H-1181-2012; Young, Philip/ABI-1480-2020; Torgerson, David/L-4566-2019	Young, Philip/0000-0003-0201-9277; Torgerson, David/0000-0002-1667-4275				Ablon G, 1996, INT J DERMATOL, V35, P591, DOI 10.1111/j.1365-4362.1996.tb03668.x; AKERS WA, 1989, J AM ACAD DERMATOL, V21, P686, DOI 10.1016/S0190-9622(89)70237-1; ALBANESE G, 1992, MYCOSES, V35, P157, DOI 10.1111/j.1439-0507.1992.tb00837.x; ALEXANDER JOD, 1972, CLIN TRIALS J, V9, P9; Altman D.G., 1991, PRACTICAL STAT MED R; ALY R, 1994, CLIN EXP DERMATOL, V19, P43, DOI 10.1111/j.1365-2230.1994.tb01113.x; [Anonymous], 1997, UNIT COSTS HLTH SOCI; ARENAS R, 1991, INT J DERMATOL, V30, P586, DOI 10.1111/j.1365-4362.1991.tb02648.x; ATHOWFROST TAM, 1986, CURR MED RES OPIN, V10, P107, DOI 10.1185/03007998609110427; AVILA JM, 1985, CURR THER RES CLIN E, V38, P328; BAGATELL F K, 1986, Advances in Therapy, V3, P265; BAGATELL FK, 1991, CUTIS, V48, P85; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERGSTRESSER PR, 1993, J AM ACAD DERMATOL, V28, P648, DOI 10.1016/S0190-9622(08)81787-2; BERMAN B, 1992, J AM ACAD DERMATOL, V26, P956, DOI 10.1016/0190-9622(92)70141-2; BJORNBERG A, 1986, CURR THER RES CLIN E, V40, P471; BOJANOVSKY A, 1985, FORTSCHR MED, V103, P677; BUCK DS, 1994, J FAM PRACTICE, V38, P601; CARTER VH, 1972, CURR THER RES CLIN E, V14, P307; CHRETIEN JH, 1980, INT J DERMATOL, V19, P51, DOI 10.1111/j.1365-4362.1980.tb01997.x; CLAYTON YM, 1982, CLIN EXP DERMATOL, V7, P543, DOI 10.1111/j.1365-2230.1982.tb02473.x; COFFEY W J JR, 1986, Advances in Therapy, V3, P301; CUCE LC, 1980, J INT MED RES, V8, P144, DOI 10.1177/030006058000800208; CUCE LC, 1989, CURR THER RES CLIN E, V45, P421; DAILY AD, 1985, CUTIS, V35, P278; del Palacio A, 1991, J DERMATOLOGICAL TRE, V1, P299; DELPALACIO A, 1992, CLIN EXP DERMATOL, V17, P50, DOI 10.1111/j.1365-2230.1992.tb00279.x; DELPALACIO A, 1992, DERMATOLOGY, V184, P25, DOI 10.1159/000247613; DELPALACIOHERNANZ A, 1989, CLIN EXP DERMATOL, V14, P141, DOI 10.1111/j.1365-2230.1989.tb00912.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOBSON RL, 1989, CLIN TRIALS J, V26, P418; Duncan W. C., 1975, Cutis, V16, P647; Effendy I, 1987, MYKOSEN S1, V30, P104; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Elewski BE, 1996, CUTIS, V58, P305; ELLIS CN, 1989, CURR THER RES CLIN E, V46, P269; Evans E., 1991, J DERMATOL TREAT, V2, P95, DOI [10.3109/09546639109092729, DOI 10.3109/09546639109092729]; EVANS EGV, 1994, BRIT J DERMATOL, V130, P83, DOI 10.1111/j.1365-2133.1994.tb06888.x; EVANS EGV, 1993, BRIT J DERMATOL, V129, P437, DOI 10.1111/j.1365-2133.1993.tb03172.x; EVANS EGV, 1993, BRIT MED J, V307, P645, DOI 10.1136/bmj.307.6905.645; EVANS EGV, 1994, BRIT J DERMATOL, V130, P2; FREDRIKSSON T, 1972, BRIT J DERMATOL, V86, P628, DOI 10.1111/j.1365-2133.1972.tb05079.x; FREDRIKSSON T, 1974, POSTGRAD MED J, V50, P62; FREDRIKSSON T, 1983, DERMATOLOGICA, V166, P14, DOI 10.1159/000249910; Fredriksson T., 1977, Opuscula Medica, V22, P80; FREDRIKSSON T, 1982, P INT ANTIFUNGAL S B, P120; FRIEDERICH HC, 1992, Z ALLGEMEIN MED, V68, P325; FriedmanBirnbaum R, 1997, INT J DERMATOL, V36, P67, DOI 10.1046/j.1365-4362.1997.00024.x; FUERST JF, 1980, CUTIS, V25, P544; FULTON JE, 1975, ARCH DERMATOL, V111, P596, DOI 10.1001/archderm.111.5.596; GALIMBERTI RL, 1984, DERMATOLOGICA, V169, P111, DOI 10.1159/000249649; GENTLES JC, 1975, BRIT J DERMATOL, V93, P79, DOI 10.1111/j.1365-2133.1975.tb06480.x; GENTLES JC, 1973, BMJ-BRIT MED J, V3, P260, DOI 10.1136/bmj.3.5874.260; GIP L, 1983, MYKOSEN, V26, P231; GOMEZ EC, 1986, CLIN THER, V8, P694; GREER D, 1987, J AM ACAD DERMATOL, V17, P53, DOI 10.1016/S0190-9622(87)70169-8; GREER DL, 1987, J AM ACAD DERMATOL, V16, P554, DOI 10.1016/S0190-9622(87)70073-5; GRIGORIU D, 1983, DERMATOLOGICA, V166, P8, DOI 10.1159/000249908; GROOTEN A, 1992, HUISARTS WET, V35, P26; HAAS PJ, 1985, MYKOSEN, V28, P33; HOLTI G, 1970, ACTA DERM-VENEREOL, V50, P229; ISON A E, 1990, Advances in Therapy, V7, P119; IZUNO G T, 1986, Advances in Therapy, V3, P308; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KAGAWA S, 1985, MYKOSEN S1, V28, P82; KASHIN P, 1985, J INT MED RES, V13, P88, DOI 10.1177/030006058501300203; KATAYAMA H, 1987, PROSTAG OTH LIPID M, V34, P797, DOI 10.1016/0090-6980(87)90061-X; KATES SG, 1990, J AM ACAD DERMATOL, V22, P583, DOI 10.1016/0190-9622(90)70076-T; KATZ R, 1972, ARCH DERMATOL, V106, P837, DOI 10.1001/archderm.106.6.837; KLASCHKA F, 1984, Z HAUTKRANKHEITEN, V59, P1218; KLIGMAN AM, 1985, CLIN THER, V7, P409; Korting HC, 1997, CLIN DRUG INVEST, V14, P286, DOI 10.2165/00044011-199714040-00006; Kuhlwein A, 1990, THERAPIEWOCHE, V40, P1643; LASSUS A, 1983, BRIT J DERMATOL, V108, P195, DOI 10.1111/j.1365-2133.1983.tb00062.x; LASSUS A, 1988, CLIN THER, V10, P594; LAUHARANTA J, 1992, CLIN EXP DERMATOL, V17, P41, DOI 10.1111/j.1365-2230.1992.tb00277.x; LESTIENNE MC, 1982, MYKOSEN, V25, P335, DOI 10.1111/j.1439-0507.1982.tb02772.x; Lison E M, 1985, Occup Health (Lond), V37, P66; LYNFIELD YL, 1974, CUTIS, V13, P460; MAILBACH HI, 1978, ARCH DERMATOL, V114, P1773, DOI 10.1001/archderm.114.12.1773; MANDY SJ, 1974, JAMA-J AM MED ASSOC, V230, P72, DOI 10.1001/jama.230.1.72; MCVIE DH, 1986, CLIN EXP DERMATOL, V11, P613, DOI 10.1111/j.1365-2230.1986.tb00518.x; Meinicke K, 1987, MYKOSEN S1, V30, P98; MENSING H, 1992, CLIN EXP DERMATOL, V17, P29, DOI 10.1111/j.1365-2230.1992.tb00274.x; MERTENS RLJ, 1976, DERMATOLOGICA, V153, P228, DOI 10.1159/000251061; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; NOLTING S, 1993, BRIT J DERMATOL, V129, P170, DOI 10.1111/j.1365-2133.1993.tb03522.x; NOLTING S, 1992, CLIN EXP DERMATOL, V17, P56, DOI 10.1111/j.1365-2230.1992.tb00280.x; ORTIZ LG, 1978, CLIN THER, V1, P444; OYEKA CA, 1992, MYCOSES, V35, P357, DOI 10.1111/j.1439-0507.1992.tb00894.x; PARISER DM, 1994, CUTIS, V54, P43; PLOTKIN E, 1990, J AM PODIAT MED ASSN, V80, P314; PRIVAT Y, 1982, P INT ANTIFUNGAL S B, P136; QADRIPUR SA, 1984, CURR THER RES CLIN E, V35, P753; QADRIPUR SA, 1979, MYKOSEN, V22, P441; REINEL D, 1992, DERMATOLOGY, V184, P21, DOI 10.1159/000247612; REINEL D, 1992, CLIN EXP DERMATOL, V17, P44, DOI 10.1111/j.1365-2230.1992.tb00278.x; ROBERTS DT, 1985, MYKOSEN, V28, P550; Ruping K W, 1993, Z Arztl Fortbild (Jena), V87, P425; SANCHEZCARAZO JL, 1994, ACTA DERMATOL SIFILI, V85, P388; Savin R, 1997, J AM ACAD DERMATOL, V36, pS15, DOI 10.1016/S0190-9622(97)70317-7; SAVIN R, 1994, J AM ACAD DERMATOL, V30, P663, DOI 10.1016/S0190-9622(09)80122-9; SAVIN RC, 1990, J AM ACAD DERMATOL, V23, P786, DOI 10.1016/0190-9622(90)70289-T; SCHACHNER L A, 1990, Advances in Therapy, V7, P148; SHELLOW WVR, 1982, J INT MED RES, V10, P28, DOI 10.1177/030006058201000105; SMITH E B, 1986, Advances in Therapy, V3, P250; SMITH E B, 1988, Advances in Therapy, V5, P313; SMITH EB, 1992, J AM ACAD DERMATOL, V26, P125, DOI 10.1016/S0190-9622(08)80528-2; SMITH EB, 1990, J AM ACAD DERMATOL, V22, P1116, DOI 10.1016/S0190-9622(08)81020-1; SMITH EB, 1977, INT J DERMATOL, V16, P52, DOI 10.1111/j.1365-4362.1977.tb00741.x; SMITH EB, 1990, J AM ACAD DERMATOL, V23, P790, DOI 10.1016/0190-9622(90)70290-X; SMITH EB, 1977, SOUTHERN MED J, V70, P47, DOI 10.1097/00007611-197701000-00021; SMITH EB, 1974, POSTGRAD MED J, V50, P64; SPIEKERMANN PH, 1976, ARCH DERMATOL, V112, P350, DOI 10.1001/archderm.112.3.350; STETTENDORF S, 1983, ARZNEIMITTEL-FORSCH, V33-1, P750; TANENBAUM L, 1983, INT J DERMATOL, V22, P318, DOI 10.1111/j.1365-4362.1983.tb02148.x; TANENBAUM L, 1982, THER CLIN, V30, P105; TANENBAUM L, 1982, THER CLIN, V30, P115; TANENBAUM L, 1982, THER CLIN, V30, P118; Terragni L., 1993, Giornale Italiano di Dermatologia e Venereologia, V128, pXLI; Thomas DJ, 1986, ADV TOPICAL ANTIFUNG, P68; Thomas DJ, 1976, CURR MED RES OPIN, V3, P630; Tong M M, 1992, Australas J Dermatol, V33, P145, DOI 10.1111/j.1440-0960.1992.tb00103.x; Tschen E, 1997, J AM ACAD DERMATOL, V36, pS9, DOI 10.1016/S0190-9622(97)70316-5; TSCHEN EH, 1979, CUTIS, V23, P696; Tsuboi R, 1996, INT J DERMATOL, V35, P371, DOI 10.1111/j.1365-4362.1996.tb03644.x; Vermeer B J, 1996, Ned Tijdschr Geneeskd, V140, P1605; Weil M, 1996, ADV THER, V13, P355; WOSCOFF A, 1986, CURR THER RES CLIN E, V39, P753; ZAUG M, 1992, CLIN EXP DERMATOL, V17, P61, DOI 10.1111/j.1365-2230.1992.tb00281.x; Zaug M., 1995, J EUR ACAD DERMATOL, V4, pS23	131	49	49	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					79	82F		10.1136/bmj.319.7202.79	http://dx.doi.org/10.1136/bmj.319.7202.79			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398626	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000081438200021
J	Grakoui, A; Bromley, SK; Sumen, C; Davis, MM; Shaw, AS; Allen, PM; Dustin, ML				Grakoui, A; Bromley, SK; Sumen, C; Davis, MM; Shaw, AS; Allen, PM; Dustin, ML			The immunological synapse: A molecular machine controlling T cell activation	SCIENCE			English	Article							II PEPTIDE COMPLEXES; LIPID-LINKED FORM; ANTIGEN-RECEPTOR; PHOTOBLEACHING RECOVERY; SIGNAL-TRANSDUCTION; PLANAR BILAYERS; ADHESION; RECOGNITION; MEMBRANES; AFFINITY	The specialized junction between a T lymphocyte and an antigen-presenting cell, the immunological synapse, consists of a central cluster of T cell receptors surrounded by a ring of adhesion molecules. Immunological synapse formation is now shown to be an active and dynamic mechanism that allows T cells to distinguish potential antigenic Ligands, initially, T cell receptor ligands were engaged in an outermost ring of the nascent synapse. Transport of these complexes into the central cluster was dependent on T cell receptor-ligand interaction kinetics. Finally, formation of a stable central cluster at the heart of the synapse was a determinative event for T cell proliferation.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Stanford University	Dustin, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	dustin@immunology.wustl.edu	Dustin, Michael/AAM-4611-2020	Davis, Mark/0000-0001-6868-657X; Dustin, Michael/0000-0003-4983-6389				Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Baldwin KK, 1999, J EXP MED, V189, P13, DOI 10.1084/jem.189.1.13; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; Dustin ML, 1996, J IMMUNOL, V157, P2014; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; GAY D, 1986, J IMMUNOL, V136, P2026; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1989, COLD SH Q B, V54, P657; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; VAFUTUTTI S, 1995, NATURE, V375, P148; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WADE WF, 1989, J CELL BIOL, V109, P3325, DOI 10.1083/jcb.109.6.3325; WADE WF, 1994, INT IMMUNOL, V6, P1457, DOI 10.1093/intimm/6.10.1457; Wang W, 1997, J IMMUNOL, V158, P5797; WEISS A, 1987, J IMMUNOL, V138, P2169; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	47	2444	2545	3	217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					221	227		10.1126/science.285.5425.221	http://dx.doi.org/10.1126/science.285.5425.221			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398592				2022-12-28	WOS:000081346000032
J	Scheuer, J; Orenstein, M				Scheuer, J; Orenstein, M			Optical vortices crystals: Spontaneous generation in nonlinear semiconductor microcavities	SCIENCE			English	Article							SCREW DISLOCATIONS; PATTERNS	Broad-area, vertical-cavity surface-emitting lasers were shown to switch their emission mode from the regular single or multilobed Light fields to exhibit complex arrays of "dark beams." Examination of these dark spot arrays revealed that they consist of multiple, closely packed optical vortices: optical fields that have phase singularities and show increased complexity as the injection current Level is raised. Contrary to their complex appearance, most of these Light distributions are not the result of a multimode (multiple-frequency) operation but exhibit single-frequency characteristics. The dark beam patterns can be described as emanating from a spontaneous process of transverse mode Locking of nearly degenerate modes, assisted by the Laser nonlinearity. Surprisingly, these patterns show high resemblance to patterns generated in other nonlinear scenarios that are completely different both in scale and in mechanism.	Technion Israel Inst Technol, Dept Elect Engn, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Scheuer, J (corresponding author), Technion Israel Inst Technol, Dept Elect Engn, IL-32000 Haifa, Israel.							Agrawal G.P., 1986, LONG WAVELENGTH SEMI, P287, DOI [10.1007/978-94-011-6994-3_7, DOI 10.1007/978-94-011-6994-3_7]; BASISTIY IV, 1993, OPT COMMUN, V103, P422, DOI 10.1016/0030-4018(93)90168-5; BAZHENOV VY, 1992, J MOD OPTIC, V39, P985, DOI 10.1080/09500349214551011; BRAMBILLA M, 1991, PHYS REV A, V43, P5090, DOI 10.1103/PhysRevA.43.5090; Coldern L. A., 1995, DIODE LASERS PHOTONI; COULLET P, 1989, OPT COMMUN, V73, P403, DOI 10.1016/0030-4018(89)90180-6; DALESSANDRO G, 1992, PHYS REV A, V46, P537, DOI 10.1103/PhysRevA.46.537; FIRTH WJ, 1994, EUROPHYS LETT, V26, P521, DOI 10.1209/0295-5075/26/7/008; FIRTH WJ, 1992, PHYS REV A, V46, pR3609, DOI 10.1103/PhysRevA.46.R3609; Gahagan KT, 1999, J OPT SOC AM B, V16, P533, DOI 10.1364/JOSAB.16.000533; INDEBETOUW G, 1993, J MOD OPTIC, V40, P73, DOI 10.1080/09500349314550101; MICHAELIS D, 1997, QUELS 97, P70; NYE JF, 1974, P ROY SOC LOND A MAT, V336, P165, DOI 10.1098/rspa.1974.0012; ORENSTEIN M, 1990, APPL PHYS LETT, V56, P2384, DOI 10.1063/1.102923; SCHEUER J, COMMUNICATION; Yariv A., 1991, OPTICAL ELECT	16	119	123	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					230	233		10.1126/science.285.5425.230	http://dx.doi.org/10.1126/science.285.5425.230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398594				2022-12-28	WOS:000081346000034
J	Abrahm, JL				Abrahm, JL		ACP ASIM End Life Care Consensus Panel	Management of pain and spinal cord compression in patients with advanced cancer	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSMUCOSAL FENTANYL CITRATE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONTROLLED CLINICAL-TRIAL; QUALITY-OF-LIFE; TRANSDERMAL FENTANYL; EPIDURAL METASTASES; BREAKTHROUGH PAIN; BONE METASTASES; ORAL MORPHINE; BREAST-CANCER	General internists often care for patients with advanced cancer. These patients have substantial morbidity caused by moderate to severe pain and by spinal cord compression. With appropriate multidisciplinary care, pain can be controlled in 90% of patients who have advanced malignant conditions, and 90% of ambulatory patients with spinal cord compression can remain ambulatory. Guidelines have been developed for assessing and managing patients with these problems, but implementing the guidelines can be problematic for physicians who infrequently need to use them. This paper traces the last year of life of Mr. Simmons, a hypothetical patient who is dying of refractory prostate cancer. Mr. Simmons and his family interact with professionals from various disciplines during this year. Advance care planning is completed and activated. Practical suggestions are offered for assessment and treatment of all aspects of his pain, including its physical, psychological, social, and spiritual dimensions. The methods of pain relief used or discussed include nonpharmacologic techniques, nonopioid analgesics, opioids, adjuvant medications, radiation therapy, and radiopharmaceutical agents. Overcoming resistance to taking opioids; initiating, titrating, and changing opioid routes and agents; and preventing or relieving the side effects they induce are also covered. Data on assessment and treatment of spinal cord compression are reviewed. Physicians can use the techniques described to more readily implement existing guidelines and provide comfort and optimize quality of life for patients with advanced cancer.	Hosp Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrahm, JL (corresponding author), Hosp Univ Penn, 514 Maloney,3600 Spruce St, Philadelphia, PA 19104 USA.							Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.3.CO;2-D; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *AM PAIN SOC, 1992, PRINC AN US TREATM A; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; BAINES M, 1988, J PAIN SYMPTOM MANAG, V3, P815; BENSON H, 1974, PSYCHIATRY, V37, P37, DOI 10.1080/00332747.1974.11023785; Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593; BERGER AM, 1998, PRINCIPLES PRACTICE, P191; BILLINGS JA, 1985, OUTPATIENT MANAGEMEN, P69; Breitbart W, 1997, PAIN, V72, P235, DOI 10.1016/S0304-3959(97)00039-0; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; Breitbart W, 1997, OXFORD TXB PALLIATIV, P933; BREITBART W, 1994, TXB PAIN, P825; BROOMHEAD A, 1997, P AN M AM SOC CLIN, V16, pA61; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; BRUERA E, 1994, J PAIN SYMPTOM MANAG, V9, P515, DOI 10.1016/0885-3924(94)90113-9; BRUERA E, 1997, P ASCO, V16, pA62; Bruera E D, 1985, J Palliat Care, V1, P46; *CANC PAIN ASS TRE, 1992, J CLIN ONCOL, V10, P1976; CARACINI A, 1997, OXFORD TXB PALLIATIV, P727; CHERNY NI, 1996, PAIN PALLIATIVE CARE; CHERNYSHEV AV, 1993, ZOOL ZH, V72, P11; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COBB CA, 1977, J NEUROSURG, V47, P653, DOI 10.3171/jns.1977.47.5.0653; Coleman RE, 1997, CANCER, V80, P1686, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.3.CO;2-T; COLEMAN RE, 1998, ASCO ED BOOK, P100; Coyle N, 1995, CANC PAIN MANAGEMENT, P89; Currow DC, 1997, J PAIN SYMPTOM MANAG, V13, P302, DOI 10.1016/S0885-3924(97)00079-1; Dalal S, 1998, J PAIN SYMPTOM MANAG, V16, P245, DOI 10.1016/S0885-3924(98)00084-0; DECONNO F, 1995, J CLIN ONCOL, V13, P1004, DOI 10.1200/JCO.1995.13.4.1004; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DOYLE D, 1997, OXFORD TXB PALLIATIV; EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Ferrante FM, 1996, ANESTHESIOLOGY, V84, P1243; Ferrell BA, 1998, J AM GERIATR SOC, V46, P635, DOI 10.1111/j.1532-5415.1998.tb01084.x; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007; FERRELLTORRY AT, 1993, CANCER NURS, V16, P93; FINDLAY GFG, 1984, J NEUROL NEUROSUR PS, V47, P761, DOI 10.1136/jnnp.47.8.761; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Foley Kathleen M., 1997, P2807; Foley KM, 1998, J CLIN ONCOL, V16, P3213, DOI 10.1200/JCO.1998.16.10.3213; FOLEY KM, 1997, OXFORD TXB PALLIATIV, P310; GLARE P, 1992, J PAIN SYMPTOM MANAG, V7, P369, DOI 10.1016/0885-3924(92)90092-V; Gloth F M 3rd, 1996, Am J Med, V101, p19S; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; HANKS G, 1997, OXFORD TXB PALLIATIV, P351; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; HEIMDAL K, 1992, J NEURO-ONCOL, V12, P141; HOLLAND JC, 1998, PSYCHO ONCOLOGY; Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; HOSKIN PJ, 1997, OXFORD TXB PALLIATIV, P267; INGHAM J, 1997, OXFORD TXB PALLIATIV, P203; JACOX A, 1994, ACHPR PUBLICATION; Janjan NA, 1997, CANCER-AM CANCER SOC, V80, P1628, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1; Kaiko R., 1996, Clinical Pharmacology and Therapeutics, V59, P130, DOI 10.1038/sj.clpt.1996.19; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; Kanner R M, 1981, Ann N Y Acad Sci, V362, P161, DOI 10.1111/j.1749-6632.1981.tb12804.x; Kaplan R, 1998, J CLIN ONCOL, V16, P3230, DOI 10.1200/JCO.1998.16.10.3230; Kreeger L, 1996, J PAIN SYMPTOM MANAG, V11, P1, DOI 10.1016/S0885-3924(96)90004-4; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277-5379(91)90257-E; Lichter I, 1996, HEMATOL ONCOL CLIN N, V10, P207, DOI 10.1016/S0889-8588(05)70335-X; LIPTON A, 1998, ASCO ED BOOK, P94; Loblaw DA, 1998, J CLIN ONCOL, V16, P1613, DOI 10.1200/JCO.1998.16.4.1613; Loscalzo M, 1996, HEMATOL ONCOL CLIN N, V10, P139, DOI 10.1016/S0889-8588(05)70331-2; LYSS AP, 1997, P AN M AM SOC CLIN, V16, pA41; MACDONALD N, 1997, PALLIATIVE MED CASE; Manfredi PL, 1996, J PAIN SYMPTOM MANAG, V11, P131, DOI 10.1016/0885-3924(95)00150-6; MARANZANO E, 1995, INT J RADIAT ONCOL, V32, P959, DOI 10.1016/0360-3016(95)00572-G; McCaffery M, 1992, Hosp J, V8, P121; McEwan AJB, 1997, SEMIN NUCL MED, V27, P165, DOI 10.1016/S0001-2998(97)80046-3; MCGUIRE DB, 1995, CANC PAIN MANAGEMENT, P1; *MED EC, 1998, RED BOOK; Mercadante S, 1998, J CLIN ONCOL, V16, P3656, DOI 10.1200/JCO.1998.16.11.3656; MERCADANTE S, 1998, PRINCIPLES PRACTICE, P191; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PAYNE R, 1998, PRINCIPLES PRACTICE, P61; PINOVER WH, 1998, PRINCIPLES PRACTICE, P603; PORTENOY RK, 1987, NEUROLOGY, V37, P134, DOI 10.1212/WNL.37.1.134; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; PORTENOY RK, 1989, CANCER, V64, P207; PORTER J, 1980, NEW ENGL J MED, V302, P123; POSNER JB, 1995, CONT NEUROLOGY SERIE, V45; Rhiner M, 1993, Cancer Pract, V1, P137; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; RIPAMONTI C, 1998, PRINCIPLES PRACTICE, P207; ROBINSON RG, 1993, SEMIN ONCOL, V20, P44; RODICHOK LD, 1986, ANN NEUROL, V20, P696, DOI 10.1002/ana.410200608; RODICHOK LD, 1981, AM J MED, V70, P1181, DOI 10.1016/0002-9343(81)90825-1; ROTH SH, 1989, RHEUM DIS CLIN N AM, V15, P479; Saunders C, 1983, LIVING DYING MANAGEM; Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574; SIEGAL T, 1989, SPINE, V14, P223, DOI 10.1097/00007632-198902000-00015; SORENSEN PS, 1994, EUR J CANCER, V30A, P22, DOI 10.1016/S0959-8049(05)80011-5; Spross J. A., 1995, CANC PAIN MANAGEMENT, P159; STOREY P, 1997, HOSPICE PALLIATIVE C; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; SYRJALA KL, 1995, PAIN, V63, P189, DOI 10.1016/0304-3959(95)00039-U; SYRJALA KL, 1996, HYPNOSIS SUGGESTON T, P121; VAINIO A, 1995, LANCET, V346, P667, DOI 10.1016/S0140-6736(95)92281-4; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Waller A, 1996, HDB PALLIATIVE CARE; WESTERLING D, 1982, EUR J CLIN PHARMACOL, V23, P59, DOI 10.1007/BF01061378; WILWERDING MB, 1995, SUPPORT CARE CANCER, V3, P135, DOI 10.1007/BF00365854; World Health Organization, 1996, CANC PAIN REL GUID O; WYCROSS RG, 1974, INT J CLIN PHARM, V7, P184; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; YOUNG RF, 1980, J NEUROSURG, V53, P741, DOI 10.3171/jns.1980.53.6.0741; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	115	34	34	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					37	46		10.7326/0003-4819-131-1-199907060-00009	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391814				2022-12-28	WOS:000081345200007
J	Roux, B; MacKinnon, R				Roux, B; MacKinnon, R			The cavity and pore helices the KcsA K+ channel: Electrostatic stabilization of monovalent cations	SCIENCE			English	Article							MOLECULAR-DYNAMICS; POTASSIUM CHANNEL; PROTEINS; DIPOLES; ENERGY	The electrostatic influence of the central cavity and pore alpha helices in the potassium ion channel from Streptomyces lividans (KcsA K+ channel) was analyzed by solving the finite difference Poisson equation. The cavity and helices overcome the destabilizing influence of the membrane and stabilize a cation at the membrane center. The electrostatic effect of the pore helices is large compared to that described for water-soluble proteins because of the low dielectric membrane environment. The combined contributions of the ion self-energy and the helix electrostatic field give rise to selectivity for monovalent cations in the water-filled cavity. Thus, the K+ channel uses simple electrostatic principles to solve the fundamental problem of ion destabilization by the cell membrane lipid bilayer.	Univ Montreal, Dept Phys, GRTM, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Chim, GRTM, Montreal, PQ H3C 3J7, Canada; Rockefeller Univ, Lab Mol Neurobiol & Biophys, Howard Hughes Med Inst, New York, NY 10021 USA	Universite de Montreal; Universite de Montreal; Howard Hughes Medical Institute; Rockefeller University	Roux, B (corresponding author), Univ Montreal, Dept Phys, GRTM, Case Postal 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; *CCP4 PROGR, 1994, ACTA CRYSTALLOGR D, V50, P60; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HE JJ, 1993, PROTEIN SCI, V2, P1643, DOI 10.1002/pro.5560021010; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOL WGJ, 1978, NATURE, V273, P5662; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Nina M, 1997, J PHYS CHEM B, V101, P5239, DOI 10.1021/jp970736r; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; Simonson T, 1996, J AM CHEM SOC, V118, P8452, DOI 10.1021/ja960884f; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WIBBLE BA, 1994, NATURE, V371, P246	17	371	379	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					100	102		10.1126/science.285.5424.100	http://dx.doi.org/10.1126/science.285.5424.100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390357				2022-12-28	WOS:000081199800039
J	Greenwald, JL; West, NEJ; Bird, AG; Marshall, SE				Greenwald, JL; West, NEJ; Bird, AG; Marshall, SE			A swollen swimmer	LANCET			English	Article									John Radcliffe Hosp, Dept Immunol, Oxford OX3 9DU, England; John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Marshall, SE (corresponding author), John Radcliffe Hosp, Dept Immunol, Oxford OX3 9DU, England.			West, Nick/0000-0003-2966-6562				CHURG J, 1951, AM J PATHOL, V27, P277; D'Cruz DP, 1999, BRIT MED J, V318, P475, DOI 10.1136/bmj.318.7182.475; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2208	2208		10.1016/S0140-6736(99)02164-9	http://dx.doi.org/10.1016/S0140-6736(99)02164-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392987				2022-12-28	WOS:000081091300015
J	Scally, G				Scally, G			Tackling teenage pregnancy in the UK	LANCET			English	Editorial Material									Natl Hlth Serv Execut, Bristol BS34 8SR, Avon, England		Scally, G (corresponding author), Natl Hlth Serv Execut, South West Reg, Bristol BS34 8SR, Avon, England.							Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; *DEP HLTH, 1992, HLTH NAT; JONES EF, 1986, TEENAGE PREGNANCY IN; MCKITTRICK D, 1993, BRIT MED J, V306, P229; Scally G, 1993, Midwives Chron, V106, P232; *SOC EXCL UN, 1999, TEEN PREGN; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S; WELLINGS K, 1995, BRIT MED J, V311, P417, DOI 10.1136/bmj.311.7002.417; 1999, DAILY TELEGRAPH 0615, P23	9	3	3	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2178	2178		10.1016/S0140-6736(99)00208-1	http://dx.doi.org/10.1016/S0140-6736(99)00208-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392980				2022-12-28	WOS:000081091300008
J	Knoll, AH; Carroll, SB				Knoll, AH; Carroll, SB			Early animal evolution: Emerging views from comparative biology and geology	SCIENCE			English	Review							METAZOAN FOSSIL RECORD; HOX GENES; CAMBRIAN BOUNDARY; CARBON-ISOTOPE; MOLECULAR SYSTEMATICS; NORTHWESTERN CANADA; EYE DEVELOPMENT; HOMEOBOX GENES; EYELESS GENE; BODY PLANS	The Cambrian appearance of fossils representing diverse phyla has long inspired hypotheses about possible genetic or environmental catalysts of early animal evolution. Only recently, however, have data begun to emerge that can resolve the sequence of genetic and morphological innovations, environmental events, and ecological interactions that collectively shaped Cambrian evolution. Assembly of the modern genetic tool kit for development and the initial divergence of major animal clades occurred during the Proterozoic Eon. Crown group morphologies diversified in the Cambrian through changes in the genetic regulatory networks that organize animal ontogeny. Cambrian radiation may have been triggered by environmental perturbation near the Proterozoic-Cambrian boundary and subsequently amplified by ecological interactions within reorganized ecosystems.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Univ Wisconsin, Mol Biol Lab, Howard Hughes Med Inst, Madison, WI 53706 USA	Harvard University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	Knoll, AH (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, 26 Oxford St, Cambridge, MA 02138 USA.							Adoutte A, 1999, TRENDS GENET, V15, P104, DOI 10.1016/S0168-9525(98)01671-0; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Arenas-Mena C, 1998, P NATL ACAD SCI USA, V95, P13062, DOI 10.1073/pnas.95.22.13062; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; AX P, 1989, Q REV BIOL, V64, P1; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Balavoine G, 1998, SCIENCE, V280, P397, DOI 10.1126/science.280.5362.397; Bartley JK, 1998, GEOL MAG, V135, P473, DOI 10.1017/S0016756898008772; BAUD A, 1989, GEOL RUNDSCH, V78, P649, DOI 10.1007/BF01776196; Bengtson S., 1992, P1017; BENGTSON S., 1994, EARLY LIFE EARTH, V84, P412; Bowring S.A., 1998, GSA TODAY, V8, P1; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; Brasier, 1993, GEOLOGICAL SOC LONDO, V70, P341, DOI DOI 10.1016/J.EPSL.2005.09.021; Brasier MD, 1996, GEOL MAG, V133, P445, DOI 10.1017/S0016756800007603; BRASIER MD, 1994, GEOL MAG, V131, P767, DOI 10.1017/S0016756800012851; Brasier MD, 1998, J GEOL SOC LONDON, V155, P5, DOI 10.1144/gsjgs.155.1.0005; BRIGGS DEG, 1989, SCIENCE, V246, P241, DOI 10.1126/science.246.4927.241; Bromham L, 1998, P NATL ACAD SCI USA, V95, P12386, DOI 10.1073/pnas.95.21.12386; Budd GE, 1996, LETHAIA, V29, P1, DOI 10.1111/j.1502-3931.1996.tb01831.x; BURKE AC, 1995, DEVELOPMENT, V121, P333; Butterfield NJ, 1997, PALEOBIOLOGY, V23, P247, DOI 10.1017/S009483730001681X; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CHEN J, 1994, ACTA PALAEONTOL SIN, V33, P391; Chen Junyuan, 1997, Bulletin of the National Museum of Natural Science (Taichung), V10, P1; CLOUD PE, 1968, SCIENCE, V160, P729, DOI 10.1126/science.160.3829.729; Cohen BL, 1998, P ROY SOC B-BIOL SCI, V265, P475, DOI 10.1098/rspb.1998.0319; COMPSTON W, 1995, J GEOL SOC LONDON, V152, P599, DOI 10.1144/gsjgs.152.4.0599; Compston W., 1992, J GEOLOGICAL SOC LON, V127, P319; Conway Morris S., 1998, CRUCIBLE CREATION BU; Crimes T.P., 1992, ORIGIN EARLY EVOLUTI, P177; DAlessio M, 1996, MECH DEVELOP, V58, P217, DOI 10.1016/S0925-4773(96)00583-7; Damen WGM, 1998, P NATL ACAD SCI USA, V95, P10665, DOI 10.1073/pnas.95.18.10665; Darwin C., 1877, ORIGIN SPECIES; DAVIDSON EH, 1995, SCIENCE, V270, P1319, DOI 10.1126/science.270.5240.1319; DeRobertis EM, 1997, NATURE, V387, P25, DOI 10.1038/387025a0; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DEROSA R, IN RPESS NATURE; DERRY LA, 1992, GEOCHIM COSMOCHIM AC, V56, P1317, DOI 10.1016/0016-7037(92)90064-P; EERNISSE DJ, 1992, SYST BIOL, V41, P305, DOI 10.1093/sysbio/41.3.305; Fedonkin M.A., 1992, P389; Fedonkin MA, 1997, NATURE, V388, P868, DOI 10.1038/42242; Fedonkin MA., 1992, ORIGIN EARLY EVOLUTI, P87, DOI DOI 10.1007/978-1-4899-2427-8_4; Finnerty JR, 1998, CURR TOP DEV BIOL, V40, P211, DOI 10.1016/S0070-2153(08)60368-3; Finnerty JR, 1996, MOL MAR BIOL BIOTECH, V5, P249; FINNERTY JR, IN RPESS EVOL DEV; Fortey RA, 1996, BIOL J LINN SOC, V57, P13, DOI 10.1006/bijl.1995.0002; GEHLING JG, 1987, ALCHERINGA, V11, P337, DOI 10.1080/03115518708619143; GEHLING JG, 1991, MEMOIRS GEOLOGICAL S, V20, P181; GERMS GJB, 1972, AM J SCI, V272, P752, DOI 10.2475/ajs.272.8.752; Glaessner M.F., 1984, DAWN ANIMAL LIFE BIO; GRANT SWF, 1990, AM J SCI, V290A, P261; Grenier JK, 1997, CURR BIOL, V7, P547, DOI 10.1016/S0960-9822(06)00253-3; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; GROTZINGER JP, 1998, GEOLOGICAL SOC AM AB, V30, pA147; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Halder G, 1998, DEVELOPMENT, V125, P2181; HASZPRUNAR G, 1995, ACTA ZOOL-STOCKHOLM, V76, P141, DOI 10.1111/j.1463-6395.1995.tb00988.x; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; HOFMANN HJ, 1990, GEOLOGY, V18, P1199, DOI 10.1130/0091-7613(1990)018<1199:ERFIBI>2.3.CO;2; Holland LZ, 1997, DEVELOPMENT, V124, P1723; Holland PWH, 1998, AM ZOOL, V38, P829; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; IRVINE S, COMMUNICATION; JENKINS RJF, 1992, ORIGIN EARLY EVOLUTI, P131; Jensen S, 1998, NATURE, V393, P567, DOI 10.1038/31215; Kaufman AJ, 1997, P NATL ACAD SCI USA, V94, P6600, DOI 10.1073/pnas.94.13.6600; Kaufman AJ, 1996, GEOL MAG, V133, P509, DOI 10.1017/S0016756800007810; KHOMENTOVSKY VV, 1993, GEOL MAG, V130, P29, DOI 10.1017/S0016756800023700; Kimmel CB, 1996, TRENDS GENET, V12, P329, DOI 10.1016/S0168-9525(96)80001-1; Kimura H, 1997, EARTH PLANET SC LETT, V147, pE1, DOI 10.1016/S0012-821X(97)00014-9; KNOLL AH, 1986, NATURE, V321, P832, DOI 10.1038/321832a0; KNOLL AH, 1994, P NATL ACAD SCI USA, V91, P6743, DOI 10.1073/pnas.91.15.6743; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; Krogh A., 1941, COMP PHYSL RESP MECH; Landing E, 1998, CAN J EARTH SCI, V35, P329, DOI 10.1139/cjes-35-4-329; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LI C, 1998, SCIENCE, V279, P289; Maley LE, 1998, SCIENCE, V279, P505, DOI 10.1126/science.279.5350.505; Martindale MQ, 1998, AM ZOOL, V38, P672; Martinez DE, 1998, NATURE, V393, P748, DOI 10.1038/31616; MCCAFFREY MA, 1994, GEOCHIM COSMOCHIM AC, V58, P529, DOI 10.1016/0016-7037(94)90481-2; McHugh D, 1998, TRENDS ECOL EVOL, V13, P182, DOI 10.1016/S0169-5347(97)01285-8; McIlroy D, 1999, PALAIOS, V14, P58, DOI 10.2307/3515361; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MIKLOS GLG, 1993, MEMOIRS AUSTRALASIAN, V15, P7; Missarjevsky V.V., 1989, Trudy Geologicheskogo Instituta Akademiya Nauk SSSR, V443, P1; Moczydlowska M., 1991, FOSSILS STRATA, V29, P1; Morris SC, 1998, AM ZOOL, V38, P867; Morris SC, 1998, BIOESSAYS, V20, P676, DOI 10.1002/(SICI)1521-1878(199808)20:8<676::AID-BIES11>3.0.CO;2-W; Morris SC, 1998, CURR OPIN GENET DEV, V8, P662, DOI 10.1016/S0959-437X(98)80034-8; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Mouchel-Vielh E, 1998, MOL PHYLOGENET EVOL, V9, P382, DOI 10.1006/mpev.1998.0498; Muller M, 1996, DEVELOPMENT, V122, P2071; NARBONNE GM, 1994, GEOL SOC AM BULL, V106, P1281, DOI 10.1130/0016-7606(1994)106<1281:ICABOT>2.3.CO;2; Nielsen C, 2012, ANIMAL EVOLUTION: INTERRELATIONSHIPS OF THE LIVING PHYLA, 3RD EDITION, P1; Nielsen C, 1998, BIOL REV, V73, P125, DOI 10.1017/S0006323197005136; NURSALL JR, 1959, NATURE, V183, P1170, DOI 10.1038/1831170b0; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; Panganiban G, 1997, P NATL ACAD SCI USA, V94, P5162, DOI 10.1073/pnas.94.10.5162; Peterson KJ, 1999, DEVELOPMENT, V126, P85; Philippe H, 1998, CURR OPIN GENET DEV, V8, P616, DOI 10.1016/S0959-437X(98)80028-2; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RAFF RA, 1970, NATURE, V228, P1003, DOI 10.1038/2281003a0; Ruiz-Trillo I, 1999, SCIENCE, V283, P1919, DOI 10.1126/science.283.5409.1919; RUNNEGAR B, 1982, ALCHERINGA, V6, P223, DOI 10.1080/03115518208565415; Runnegar Bruce, 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V195, P303; Schierwater B, 1998, MOL PHYLOGENET EVOL, V9, P375, DOI 10.1006/mpev.1998.0489; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; Seilacher A, 1998, SCIENCE, V282, P80, DOI 10.1126/science.282.5386.80; SEILACHER A, 1989, LETHAIA, V22, P229, DOI 10.1111/j.1502-3931.1989.tb01332.x; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SIGNOR PW, 1992, ORIGIN EARLY EVOLUTI, P1; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Sogin ML, 1998, INT J PARASITOL, V28, P11, DOI 10.1016/S0020-7519(97)00181-1; STEIN JG, 1994, POLIT PSYCHOL, V15, P1, DOI 10.2307/3791436; STRATHMANN RR, 1993, ANNU REV ECOL SYST, V24, P89, DOI 10.1146/annurev.es.24.110193.000513; Sun HM, 1997, P NATL ACAD SCI USA, V94, P5156, DOI 10.1073/pnas.94.10.5156; Telford MJ, 1998, P NATL ACAD SCI USA, V95, P10671, DOI 10.1073/pnas.95.18.10671; TOWE KM, 1970, P NATL ACAD SCI USA, V65, P781, DOI 10.1073/pnas.65.4.781; Valentine JW, 1999, DEVELOPMENT, V126, P851; Valentine JW, 1997, P NATL ACAD SCI USA, V94, P8001, DOI 10.1073/pnas.94.15.8001; Vermeij GJ, 1996, SCIENCE, V274, P525, DOI 10.1126/science.274.5287.525; VIDAL G, 1982, NATURE, V297, P57, DOI 10.1038/297057a0; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; Weatherbee SD, 1999, CELL, V97, P283, DOI 10.1016/S0092-8674(00)80737-0; Weatherbee SD, 1999, CURR BIOL, V9, P109, DOI 10.1016/S0960-9822(99)80064-5; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318; Xiao SH, 1998, J PALEONTOL, V72, P1072, DOI 10.1017/S0022336000027414; Xu PX, 1997, DEVELOPMENT, V124, P219; ZHANG Y, 1998, PALEONTOL SOC MEM, V50, P1	138	353	398	5	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2129	2137		10.1126/science.284.5423.2129	http://dx.doi.org/10.1126/science.284.5423.2129			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381872				2022-12-28	WOS:000081099300041
J	Kahana, MJ; Sekuler, R; Caplan, JB; Kirschen, M; Madsen, JR				Kahana, MJ; Sekuler, R; Caplan, JB; Kirschen, M; Madsen, JR			Human theta oscillations exhibit task dependence during virtual maze navigation	NATURE			English	Article							HUMAN HIPPOCAMPAL-FORMATION; RHYTHM; MODULATION; RAT	Theta oscillations (electroencephalographic activity with a frequency of 4-8 Hz) have long been implicated in spatial navigation in rodents(1-3); however, the role of theta oscillators in human spatial navigation has not been explored. Here we describe subdural recordings from epileptic patients learning to navigate computer-generated mazes. Visual inspection of the raw intracranial signal revealed striking episodes of high-amplitude slow-wave oscillations at a number of areas of the cortex, including temporal cortex. Spectral analysis showed that these oscillations were in the theta band. These episodes of theta activity, which typically last several cycles, are dependent on task characteristics. Theta oscillations occur more frequently in more complex mazes; they are also more frequent during recall trials than during learning trials.	Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Brandeis University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Kahana, MJ (corresponding author), Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA.							Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; [Anonymous], 1983, CANADIAN PSYCHOL; ARNOLDS DEAT, 1980, ELECTROEN CLIN NEURO, V50, P324, DOI 10.1016/0013-4694(80)90160-1; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BORST JGG, 1987, BRAIN RES, V407, P81, DOI 10.1016/0006-8993(87)91221-2; Buzsaki G, 1996, CEREB CORTEX, V6, P81, DOI 10.1093/cercor/6.2.81; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; GROSSMANN A, 1985, MATH PLUS PHYSICS, V1; HALGREN E, 1978, ELECTROEN CLIN NEURO, V44, P778, DOI 10.1016/0013-4694(78)90212-2; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; Jensen O, 1998, J NEUROSCI, V18, P10688; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1997, J NEUROSCI, V17, P7103; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; ROUTTENBERG A, 1973, BEHAV BIOL, V8, P801, DOI 10.1016/S0091-6773(73)80122-1; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; SLAWINSKA U, 1995, BRAIN RES, V678, P117, DOI 10.1016/0006-8993(95)00174-O; Sohal VS, 1998, HIPPOCAMPUS, V8, P171, DOI 10.1002/(SICI)1098-1063(1998)8:2<171::AID-HIPO9>3.0.CO;2-O; Sperling MR, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb04541.x; STEWART M, 1991, BRAIN RES, V538, P59, DOI 10.1016/0006-8993(91)90376-7; Talairach J., 1988, COPLANAR STEREOTAXIC; Tesche CD, 1997, BRAIN RES, V749, P53, DOI 10.1016/S0006-8993(96)01286-3; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646	27	454	460	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					781	784		10.1038/21645	http://dx.doi.org/10.1038/21645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391243				2022-12-28	WOS:000081101600053
J	Whiten, A; Goodall, J; McGrew, WC; Nishida, T; Reynolds, V; Sugiyama, Y; Tutin, CEG; Wrangham, RW; Boesch, C				Whiten, A; Goodall, J; McGrew, WC; Nishida, T; Reynolds, V; Sugiyama, Y; Tutin, CEG; Wrangham, RW; Boesch, C			Cultures in chimpanzees	NATURE			English	Article							CHILDREN HOMO-SAPIENS; PAN-TROGLODYTES; WILD CHIMPANZEES; EVOLUTION; IMITATION	As an increasing number of field studies of chimpanzees (Pan troglodytes) have achieved long-term status across Africa, differences in the behavioural repertoires described have become apparent that suggest there is significant cultural variation(1-7). Here we present a systematic synthesis of this information from the seven most long-term studies, which together have accumulated 151 years of chimpanzee observation. This comprehensive analysis reveals patterns of variation that are far more extensive than have previously been documented for any animal species except humans(8-11). We find that 39 different behaviour patterns, including tool usage, grooming and courtship behaviours, are customary or habitual in some communities but are absent in others where ecological explanations have been discounted. Among mammalian and avian species, cultural variation has previously been identified only for single behaviour patterns, such as the local dialects of song-birds(12,13). The extensive, multiple variations now documented for chimpanzees are thus without parallel. Moreover, the combined repertoire of these behaviour patterns in each chimpanzee community is itself highly distinctive, a phenomenon characteristic of human cultures(14) but previously unrecognised in non-human species.	Univ St Andrews, Scottish Primate Res Grp, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland; Gombe Stream Res Ctr, Kigoma, Tanzania; Miami Univ, Dept Zool, Oxford, OH 45056 USA; Miami Univ, Dept Sociol Gerontol & Anthropol, Oxford, OH 45056 USA; Kyoto Univ, Human Evolut Studies Lab, Kyoto 60601, Japan; Univ Oxford, Inst Biol Anthropol, Oxford OX2 6QS, England; Kyoto Univ, Primate Res Inst, Inuyama, Aichi 4848506, Japan; Ctr Int Rech Med Franceville, Franceville, Gabon; Univ Stirling, Dept Biol Sci, Stirling FK9 4LA, Scotland; Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; Max Planck Inst Evolutionary Anthropol, D-04301 Leipzig, Germany	University of St Andrews; University System of Ohio; Miami University; University System of Ohio; Miami University; Kyoto University; University of Oxford; Kyoto University; University of Stirling; Harvard University; Max Planck Society	Whiten, A (corresponding author), Univ St Andrews, Scottish Primate Res Grp, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland.							BLOCH M, 1991, MAN, V26, P183, DOI 10.2307/2803828; BOESCH C, 1994, J HUM EVOL, V26, P325, DOI 10.1006/jhev.1994.1020; Boesch Christophe, 1996, Proceedings of the British Academy, V88, P251; BONNER JT, 1980, EVOLUTION CULTURE AN; Galef B G, 1992, Hum Nat, V3, P157, DOI 10.1007/BF02692251; Goodall J., 1986, CHIMPANZEES GOMBE PA; Huffman Michael A., 1996, P267, DOI 10.1016/B978-012273965-1/50014-5; Imanishi K., 1957, Primates, V1, P1, DOI 10.1007/BF01667196; Kroeber A.L., 1963, CULTURE; Lefebvre L., 1988, P141; MARLER P, 1964, SCIENCE, V146, P1483, DOI 10.1126/science.146.3650.1483; McGrew W.C., 1992, CHIMPANZEE MAT CULTU; McGrew WC, 1998, ANNU REV ANTHROPOL, V27, P301, DOI 10.1146/annurev.anthro.27.1.301; MCGREW WC, 1978, MAN, V13, P234, DOI 10.2307/2800247; MUNDINGER PC, 1980, ETHOL SOCIOBIOL, V1, P183, DOI 10.1016/0162-3095(80)90008-4; Murdock G.P., 1967, ETHNOGRAPHIC ATLAS; NAGELL K, 1993, J COMP PSYCHOL, V107, P174, DOI 10.1037/0735-7036.107.2.174; Nishida T., 1987, P462; Nishida T., 1990, CHIMPANZEES MAHALE M; Paquette D., 1992, Human Evolution, V7, P17, DOI 10.1007/BF02436257; Slater T.L.B., 1995, BIRD SONG THEMES VAR; Spence KW, 1937, PSYCHOL BULL, V34, P806, DOI 10.1037/h0061498; Sugiyama Yukimaru, 1993, P175; SUMITA K, 1985, Primates, V26, P168, DOI 10.1007/BF02382016; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; Tomasello M., 1987, HUM EVOL, V2, P175, DOI DOI 10.1007/BF02436405; WHITEN A, 1992, ADV STUD BEHAV, V21, P239, DOI 10.1016/S0065-3454(08)60146-1; Whiten A, 1998, J COMP PSYCHOL, V112, P270, DOI 10.1037/0735-7036.112.3.270; Whiten A, 1996, J COMP PSYCHOL, V110, P3, DOI 10.1037/0735-7036.110.1.3; Wrangham R. W., 1994, CHIMPANZEE CULTURES	30	1412	1462	6	429	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					682	685		10.1038/21415	http://dx.doi.org/10.1038/21415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	207JB	10385119				2022-12-28	WOS:000080932800058
J	Cooper, JA; Howell, BW				Cooper, JA; Howell, BW			Lipoprotein receptors: Signaling functions in the brain?	CELL			English	Review							LAMINAR ORGANIZATION; CORTICAL-NEURONS; REELER; MICE; DISABLED-1; SCRAMBLER; PROTEINS; DEFECTS		Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.			Howell, Brian/0000-0002-0204-0773				Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; Goldowitz D, 1997, J NEUROSCI, V17, P8767; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; HOFFARTH RM, 1995, J NEUROSCI, V15, P4838; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Lambert de Rouvroit C, 1998, Adv Anat Embryol Cell Biol, V150, P1; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; Rice DS, 1998, DEVELOPMENT, V125, P3719; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412	20	72	75	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					671	674		10.1016/S0092-8674(00)80778-3	http://dx.doi.org/10.1016/S0092-8674(00)80778-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380917	Bronze			2022-12-28	WOS:000080886300002
J	Bammer, G; Dobler-Mikola, A; Fleming, PM; Strang, J; Uchtenhagen, A				Bammer, G; Dobler-Mikola, A; Fleming, PM; Strang, J; Uchtenhagen, A			Drug abuse - The heroin prescribing debate: Integrating science and politics	SCIENCE			English	Editorial Material							PRESCRIPTION; MAINTENANCE; PROGRAM; ENGLAND; TRIAL; WALES		Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; Res Inst Addict, CH-8005 Zurich, Switzerland; Portsmouth City Drugs & Alcohol Serv, Portsmouth PO5 1LR, Hants, England; Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England	Australian National University; University of London; King's College London	Bammer, G (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Bammer, Gabriele/0000-0001-9098-0951				Bammer G, 1996, MED J AUSTRALIA, V164, P690, DOI 10.5694/j.1326-5377.1996.tb122243.x; Bammer G, 1999, CNS DRUGS, V11, P253, DOI 10.2165/00023210-199911040-00002; BAMMER G, 1994, 9 AUSTR NAT U AUSTR; BAMMER G, 1995, REPORT RECOMMENDATIO; *CENTR COMM TREATM, 1997, INV MED PRESCR HER R; DOBLERMIKOLA A, IN PRESS HEROIN METH; FLEMING PM, 1997, FEASIBILITY RES CONT, P1; HARTNOLL RL, 1980, ARCH GEN PSYCHIAT, V37, P877; *INT COMMD RUG ADD, 1965, DRUG ADD 2 REP; Metrebian N, 1998, MED J AUSTRALIA, V168, P596, DOI 10.5694/j.1326-5377.1998.tb141444.x; Minist. Health, 1926, ROLL REP DEP COMM MO; Perneger TV, 1998, BMJ-BRIT MED J, V317, P13, DOI 10.1136/bmj.317.7150.13; Sell L, 1997, DRUG ALCOHOL REV, V16, P221, DOI 10.1080/09595239800187401; SPEAR HB, 1994, HEROIN ADDICTION DRU, P3; Strang J, 1997, DRUG ALCOHOL REV, V16, P7, DOI 10.1080/09595239700186281; THORLEY A, 1981, DRUG PROBLEMS BRITAI, P117; Uchtenhagen A, 1997, EUR ADDICT RES, V3, P160, DOI 10.1159/000259173; UCHTENHAGEN A, IN PRESS PRESCRIPTIO; United Nations International Drug Control Programme, 1997, WORLD DRUG REP; Ward J., 1998, METHADONE MAINTENANC; 1977, SINGL CONV NARC DRUG, P19	21	57	57	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1277	1278		10.1126/science.284.5418.1277	http://dx.doi.org/10.1126/science.284.5418.1277			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	198NN	10383306				2022-12-28	WOS:000080430600024
J	Owen, G				Owen, G			George Sydney Anderson - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					127	127		10.1136/bmj.319.7202.127	http://dx.doi.org/10.1136/bmj.319.7202.127			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398653	Green Published			2022-12-28	WOS:000081438200059
J	Moore, PA; Belvedere, O; Orr, A; Pieri, K; LaFleur, DW; Feng, P; Soppet, D; Charters, M; Gentz, R; Parmelee, D; Li, YL; Galperina, O; Giri, J; Roschke, V; Nardelli, B; Carrell, J; Sosnovtseva, S; Greenfield, W; Ruben, SM; Olsen, HS; Fikes, J; Hilbert, DM				Moore, PA; Belvedere, O; Orr, A; Pieri, K; LaFleur, DW; Feng, P; Soppet, D; Charters, M; Gentz, R; Parmelee, D; Li, YL; Galperina, O; Giri, J; Roschke, V; Nardelli, B; Carrell, J; Sosnovtseva, S; Greenfield, W; Ruben, SM; Olsen, HS; Fikes, J; Hilbert, DM			BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator	SCIENCE			English	Article							MOLECULAR-CLONING; CD40 LIGAND; CELL GROWTH; EXPRESSION; DIFFERENTIATION; IMMUNOGLOBULIN; INTERLEUKIN-5; LYMPHOTOXIN; BSF-2; CDNA	The tumor necrosis factor (INF) superfamily of cytokines includes both soluble and membrane-bound proteins that regulate immune responses. A member of the human TNF family, BLyS (B Lymphocyte stimulator), was identified that induced B cell proliferation and immunoglobulin secretion. BLyS expression on human monocytes could be up-regulated by interferon-gamma. Soluble BLyS functioned as a potent B cell growth factor in costimulation assays. Administration of soluble recombinant BLyS to mice disrupted splenic B and T cell zones and resulted in elevated serum immunoglobulin concentrations. The B cell tropism of BLyS is consistent with its receptor expression on B-Lineage cells. The biological profile of BLyS suggests it is involved in monocyte-driven B cell activation.	Human Genome Sci, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc	Hilbert, DM (corresponding author), Human Genome Sci, 9410 Key W Ave, Rockville, MD 20850 USA.		Carrell, Jeffrey/AAV-7361-2020	Carrell, Jeffrey/0000-0001-7484-4407				AKERSTROM B, 1985, J IMMUNOL, V135, P2589; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1991, ADV EXP MED BIOL, V292, P121; BERTOLINI JN, 1993, EUR J IMMUNOL, V23, P398, DOI 10.1002/eji.1830230215; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRABSTEIN KH, 1993, J IMMUNOL, V150, P3141; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HILBERT DM, 1995, P NATL ACAD SCI USA, V92, P649, DOI 10.1073/pnas.92.3.649; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HILBERT DM, 1993, EUR J IMMUNOL, V23, P2412, DOI 10.1002/eji.1830231006; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Lens SMA, 1998, SEMIN IMMUNOL, V10, P491, DOI 10.1006/smim.1998.0154; Metzger DW, 1995, RES IMMUNOL, V146, P499, DOI 10.1016/0923-2494(96)83023-9; MOORE PS, UNPUB; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; Oshima H, 1998, INT IMMUNOL, V10, P517, DOI 10.1093/intimm/10.4.517; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; POUPART P, 1987, EMBO J, V6, P1219, DOI 10.1002/j.1460-2075.1987.tb02357.x; PUNNONEN J, 1994, ALLERGY, V49, P576, DOI 10.1111/j.1398-9995.1994.tb00122.x; RINGDEN O, 1977, SCAND J IMMUNOL, V6, P1159; SIECKMANN DG, 1978, J EXP MED, V147, P814, DOI 10.1084/jem.147.3.814; TAKATSU K, 1987, P NATL ACAD SCI USA, V84, P4234, DOI 10.1073/pnas.84.12.4234; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; vanKooten C, 1997, INT ARCH ALLERGY IMM, V113, P393, DOI 10.1159/000237614; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	29	934	1117	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					260	263		10.1126/science.285.5425.260	http://dx.doi.org/10.1126/science.285.5425.260			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398604				2022-12-28	WOS:000081346000044
J	Colls, BM				Colls, BM			A salutary lesson - Three very unwise men	BRITISH MEDICAL JOURNAL			English	Article									Christchurch Hosp, Christchurch, New Zealand	Christchurch Hospital New Zealand	Colls, BM (corresponding author), Christchurch Hosp, Christchurch, New Zealand.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1729	1729		10.1136/bmj.318.7200.1729	http://dx.doi.org/10.1136/bmj.318.7200.1729			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381707	Green Published			2022-12-28	WOS:000081216900029
J	Hindie, E; Urena, P; Jeanguillaume, C; Melliere, D; Berthelot, JM; Menoyo-Calonge, V; Chiappini-Briffa, D; Janin, A; Galle, P				Hindie, E; Urena, P; Jeanguillaume, C; Melliere, D; Berthelot, JM; Menoyo-Calonge, V; Chiappini-Briffa, D; Janin, A; Galle, P			Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism	LANCET			English	Article							CHRONIC-RENAL-FAILURE; TECHNETIUM 99M SESTAMIBI; SURGICAL-TREATMENT; SUBTOTAL PARATHYROIDECTOMY; TC-99M SESTAMIBI; DOUBLE-PHASE; LOCALIZATION; TECHNETIUM-99M-SESTAMIBI; SURGERY; PATHOGENESIS	Background Parathyroidectomy is unsuccessful in 10-30% of uraemic patients operated on for secondary hyperparathyroidism, We investigated the usefulness of preoperative radionuclide imaging, with simultaneous recording of the distribution images of iodine-123 and technetium-99m-labelled sestamibi. Methods 11 patients with secondary hyperparathyroidism underwent prospective imaging and parathyroidectomy. Plasma concentrations of intact parathyroid hormone (PTH) were measured in all patients before and 6 months after subtotal parathyroidectomy. Findings Preoperative scanning showed 42 hot-spots suggesting enlarged parathyroid glands, 45 glands were discovered at surgery, and the parathyroidectomy was deemed successful in ten patients. Among the latter, one patient had a supernumerary parathyroid gland detected by scanning and resected from the left thymus. Another patient showed ectopic uptake corresponding to a large parathyroid gland in the upper mediastinum, and another had a parathyroid gland well above the thyroid. No false-positive scan findings were documented. In the patient for whom parathyroidectomy failed, preoperative scanning suggested five enlarged parathyroid glands, though the surgeon found only four glands, in their normal positions. Hyperparathyroidism persisted (intact PTH 527 ng/L, 6 months after surgery). A second scan confirmed the preoperative scan, showing a fifth parathyroid gland in the middle of the right thyroid lobe. Interpretation Simultaneous recording of Tc-99m-sestamibi and I-123 improved the imaging of parathyroid glands in secondary hyperparathyroidism. The technique can identify ectopic and supernumerary parathyroid glands.	Hop Henri Mondor, Dept Nucl Med & Biophys, F-94010 Creteil, France; Hop Henri Mondor, Dept Endocrine Surg, F-94010 Creteil, France; Clin LOrangerie, Nephrol Unit, Aubervilliers, France; Ctr Henri Kuntziger, Haemodyalysis Unit, Paris, France; Hop St Louis, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Hindie, E (corresponding author), Univ Paris 12, Fac Med, Biophys Lab, 8 Rue Gen Sarrail, F-94000 Creteil, France.	hindie@univ-paris12.fr	Galle, Peter R/T-5292-2018; JEANGUILLAUME, Christian/A-1070-2008	Galle, Peter R/0000-0001-8294-0992; Jeanguillaume, Christian/0000-0002-8335-4255				AKERSTROM G, 1984, SURGERY, V95, P14; AKERSTROM G, 1992, WORLD J SURG, V16, P562, DOI 10.1007/BF02067321; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; BLAKE DP, 1983, SURG GYNECOL OBSTET, V157, P325; Borley NR, 1996, BRIT J SURG, V83, P989, DOI 10.1002/bjs.1800830734; Chesser AMS, 1997, NEPHROL DIAL TRANSPL, V12, P97, DOI 10.1093/ndt/12.1.97; COAKLEY AJ, 1989, NUCL MED COMMUN, V10, P791, DOI 10.1097/00006231-198911000-00003; DRUEKE TB, 1995, KIDNEY INT, V48, P259, DOI 10.1038/ki.1995.292; FRAKER DL, 1990, WORLD J SURG, V14, P342, DOI 10.1007/BF01658522; Fukagawa M, 1997, SEMIN SURG ONCOL, V13, P73, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<73::AID-SSU2>3.0.CO;2-Z; GAGNE ER, 1992, J AM SOC NEPHROL, V3, P1008; GAZ RD, 1987, SURGERY, V102, P949; GIANGRANDE A, 1992, NEPHROL DIAL TRANSPL, V7, P412; Hindie E, 1998, J NUCL MED, V39, P1100; HINDIE E, 1995, J CLIN ENDOCR METAB, V80, P302, DOI 10.1210/jc.80.1.302; Hindie E, 1997, RADIOLOGY, V204, P221, DOI 10.1148/radiology.204.1.9205251; Hines OJ, 1998, J CLIN ENDOCR METAB, V83, P2384, DOI 10.1210/jc.83.7.2384; Jeanguillaume C, 1998, RADIOLOGY, V207, P207, DOI 10.1148/radiology.207.1.9580138; Johnston LB, 1996, J CLIN ENDOCR METAB, V81, P346, DOI 10.1210/jc.81.1.346; KESSLER M, 1991, NEPHROL DIAL TRANSPL, V6, P176, DOI 10.1093/ndt/6.3.176; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; ODOHERTY MJ, 1992, J NUCL MED, V33, P313; Parfitt AM, 1997, KIDNEY INT, V52, P3, DOI 10.1038/ki.1997.297; Piga M, 1996, J NUCL MED, V37, P565; Pons F, 1997, EUR J NUCL MED, V24, P1494, DOI 10.1007/s002590050179; PUNCH JD, 1995, ARCH SURG-CHICAGO, V130, P538; ROTHMUND M, 1988, ANN SURG, V207, P310, DOI 10.1097/00000658-198803000-00014; ROTHMUND M, 1990, WORLD J SURG, V14, P393, DOI 10.1007/BF01658536; RUDBERG C, 1986, SURGERY, V99, P643; RUSSELL CF, 1981, ANN SURG, V193, P805, DOI 10.1097/00000658-198106000-00016; SLATOPOLSKY E, 1994, AM J KIDNEY DIS, V23, P229, DOI 10.1016/S0272-6386(12)80977-2; TAILLEFER R, 1992, J NUCL MED, V33, P1801; TAKAGI H, 1986, WORLD J SURG, V10, P605, DOI 10.1007/BF01655536; Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P78, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z; Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P87, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<87::AID-SSU4>3.0.CO;2-Y; WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272-6386(95)90453-0; WEBER CJ, 1993, SURGERY, V114, P1011; WEI JP, 1992, SURGERY, V112, P1111	38	55	56	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2200	2204		10.1016/S0140-6736(98)09089-8	http://dx.doi.org/10.1016/S0140-6736(98)09089-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392985				2022-12-28	WOS:000081091300013
J	Alonso, JM; Hirayama, T; Roman, G; Nourizadeh, S; Ecker, JR				Alonso, JM; Hirayama, T; Roman, G; Nourizadeh, S; Ecker, JR			EIN2, a bifunctional transducer of ethylene and stress responses in Arabidopsis	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; GENETIC-ANALYSIS; PROTEIN-KINASES; ROOT-GROWTH; THALIANA; YEAST; PATHWAY; TRANSPORTER	Ethylene regulates plant growth, development, and responsiveness to a variety of stresses. Cloning of the Arabidopsis EIN2 gene identifies a central component: of the ethylene signaling pathway. The amino-terminal integral membrane domain of EIN2 shows similarity to the disease-related Nramp family of metal-ion transporters. Expression of the EIN2 CEND is sufficient to constitutively activate ethylene responses and restores responsiveness to jasmonic acid and paraquat-induced oxygen radicals to mutant plants. EIN2 is thus recognized as a molecular link between previously distinct hormone response pathways. plants may use a combinatorial mechanism for assessing various stresses by enlisting a common set of signaling molecules.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Ecker, JR (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.		Bruening, Stefan/B-8505-2011; Alonso, Jose M/K-6826-2014; HIRAYAMA, Takashi/B-2496-2011; Ecker, Joseph R/B-9144-2008; Roman, Gregg/W-1586-2019	Alonso, Jose M/0000-0001-7087-1571; HIRAYAMA, Takashi/0000-0002-3868-2380; Ecker, Joseph R/0000-0001-5799-5895; Roman, Gregg/0000-0003-1519-4699				BALCOMBE D, 1986, NATURE, V321, P446; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Coons DM, 1997, YEAST, V13, P9, DOI 10.1002/(SICI)1097-0061(199701)13:1<9::AID-YEA51>3.0.CO;2-U; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; Fleet JC, 1998, NUTR REV, V56, P88, DOI 10.1111/j.1753-4887.1998.tb01701.x; Fujita H, 1996, PLANT CELL PHYSIOL, V37, P1094, DOI 10.1093/oxfordjournals.pcp.a029059; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Matallana E., 1992, Methods in Arabidopsis research., P144; NOURIZADEH S, UNPUB; Oh SA, 1997, PLANT J, V12, P527, DOI 10.1046/j.1365-313X.1997.00527.x; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Penninckx IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/tpc.10.12.2103; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; ROMAN G, 1995, GENETICS, V139, P1393; ROTHENBERG M, UNPUB SCIENCE; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Sambrook J., 2002, MOL CLONING LAB MANU; Smalle J, 1997, P NATL ACAD SCI USA, V94, P2756, DOI 10.1073/pnas.94.6.2756; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; SU WP, 1992, PLANT PHYSIOL, V99, P1569, DOI 10.1104/pp.99.4.1569; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEST AH, 1992, J BIOL CHEM, V267, P24625	43	929	998	17	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2148	2152		10.1126/science.284.5423.2148	http://dx.doi.org/10.1126/science.284.5423.2148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381874				2022-12-28	WOS:000081099300043
J	Jablonski, D				Jablonski, D			The future of the fossil record	SCIENCE			English	Editorial Material							MASS EXTINCTION; EVOLUTION; DIVERSITY; REORGANIZATION; LIMBS	The fossil record provides a powerful basis for analyzing the controlling factors and impact of biological evolution over a wide range of temporal and spacial scales and in the context of an evolving Earth. An increasingly interdisciplinary paleontology has begun to formulate the next generation of questions, drawing on a wealth of new data, and on methodological advances ranging from high-resolution geochronology to simulation of morphological evolution. Key issues related to evolutionary biology include the biotic and physical factors that govern biodiversity dynamics, the developmental and ecological basis for the nonrandom introduction of evolutionary innovations in time and space, rules of biotic response to environmental perturbations, and the dynamic feedbacks between life and the Earth's surface processes. The sensitivity of evolutionary processes to rates, magnitudes, and spatial scales of change in the physical and biotic environment will be important in all these areas.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Jablonski, D (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	djablons@midway.uchicago.edu						Benton Michael J., 1996, P185; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; Coates MI, 1998, BIOESSAYS, V20, P371, DOI 10.1002/(SICI)1521-1878(199805)20:5<371::AID-BIES4>3.0.CO;2-R; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Droser ML, 1997, GEOLOGY, V25, P167, DOI 10.1130/0091-7613(1997)025<0167:ETEAOM>2.3.CO;2; FLESSE KW, 1999, GEOBIOLOGY EARTH SCI; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Gould SJ, 1998, PHILOS T R SOC B, V353, P307, DOI 10.1098/rstb.1998.0211; Holland SM, 1999, GEOLOGY, V27, P491, DOI 10.1130/0091-7613(1999)027<0491:MFSTFR>2.3.CO;2; Jablonski D, 1998, SCIENCE, V279, P1327, DOI 10.1126/science.279.5355.1327; Jackson JBC, 1999, TRENDS ECOL EVOL, V14, P72, DOI 10.1016/S0169-5347(98)01504-3; Kidwell Susan M., 1996, P290; Kirschvink JL, 1997, SCIENCE, V277, P541, DOI 10.1126/science.277.5325.541; LANE HR, 1997, PALEONTOLOGY 21 CENT, V25, P1; LOGAN GA, 1995, NATURE, V376, P53, DOI 10.1038/376053a0; Lupia R, 1999, PALEOBIOLOGY, V25, P1, DOI 10.1666/0094-8373(1999)25[1:MDITER]2.0.CO;2; MALEY C, 1997, GEOL SOC AM ABSTR, V29, pA31; Marshall CR, 1996, SCIENCE, V274, P1360, DOI 10.1126/science.274.5291.1360; McGhee GR, 1999, PERS PALEOB; McKinney ML, 1997, ANNU REV ECOL SYST, V28, P495, DOI 10.1146/annurev.ecolsys.28.1.495; Miller AI, 1998, SCIENCE, V281, P1157, DOI 10.1126/science.281.5380.1157; Morris SC, 1998, PHILOS T R SOC B, V353, P327, DOI 10.1098/rstb.1998.0213; Roy K, 1996, PALEOBIOLOGY, V22, P436, DOI 10.1017/S0094837300016389; Sepkoski J. John Jr, 1996, P211; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P168, DOI 10.1017/S0094837300015852; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Stanley SM, 1998, PALAEOGEOGR PALAEOCL, V144, P3, DOI 10.1016/S0031-0182(98)00109-6; STANLEY SM, 1997, GEOBIOLOGY CRITICAL; Valentine JW, 1999, DEVELOPMENT, V126, P851; VANVALEN L, 1973, SCIENCE, V180, P516	32	36	38	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2114	2116		10.1126/science.284.5423.2114	http://dx.doi.org/10.1126/science.284.5423.2114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381868				2022-12-28	WOS:000081099300037
J	Agami, R; Blandino, G; Oren, M; Shaul, Y				Agami, R; Blandino, G; Oren, M; Shaul, Y			Interaction of c-Abl and p73 alpha and their collaboration to induce apoptosis	NATURE			English	Article							FUNCTIONAL DOMAIN; DNA-DAMAGE; P53; PROTEIN; GENE; IDENTIFICATION; LIBRARIES; LIGANDS; REGION; P73	c-Abl, a non-receptor tyrosine kinase, is activated by agents that damage DNA. This activation results in either arrest of the cell cycle in phase G1 or apoptotic cell death, both of which are dependent on the kinase activity of c-Abl(1). p73, a member of the p53 family of tumour-suppressor proteins(2,3), can also induce apoptosis(3), Here we show that the apoptotic activity of p73 alpha requires the presence of functional, kinase-competent c-Abl. Furthermore, p73 and c-Abl can associate with each other, and this binding is mediated by a PxxP motif in p73 and the SH3 domain of c-Abl. We find that p73 is a substrate of the c-Abl kinase and that the ability of c-Abl to phosphorylate p73 is markedly increased by gamma-irradiation. Moreover, p73 is phosphorylated in vivo in response to ionizing radiation. These findings define a pro-apoptotic signalling pathway involving p73 and c-Abl.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	Ivshaul@weizmann.weizmann.ac.il	Blandino, Giovanni/B-1137-2013; agami, reuven/GOG-8289-2022	Blandino, Giovanni/0000-0002-6970-2241; Agami, Reuven/0000-0002-2848-2473; Oren, Moshe/0000-0003-4311-7172	Telethon [596] Funding Source: Medline	Telethon(Fondazione Telethon)		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Zhu JH, 1998, CANCER RES, V58, P5061	23	489	499	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					809	813						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391250				2022-12-28	WOS:000081101600060
J	Price, DL				Price, DL			New order from neurological disorders	NATURE			English	Editorial Material							TRANSGENIC MICE; NEURODEGENERATIVE DISEASES; MUTATION; GENE; TAU; DEMENTIA; INCLUSIONS; FTDP-17; REPEAT; SYSTEM		Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Neuropathol Lab, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Price, DL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.							Andrews PI, 1996, CURR OPIN NEUROBIOL, V6, P673; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dichgans M, 1998, ANN NEUROL, V44, P731, DOI 10.1002/ana.410440506; Fend F, 1999, AM J PATHOL, V154, P61, DOI 10.1016/S0002-9440(10)65251-0; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Markesbery W, 1998, NEUROPATHOLOGY DEMEN, P293; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Shoulson I, 1998, SCIENCE, V282, P1072, DOI 10.1126/science.282.5391.1072; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Wong PC, 1998, CURR OPIN NEUROBIOL, V8, P791, DOI 10.1016/S0959-4388(98)80123-2	26	63	64	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738		S			A3	A5		10.1038/399a003	http://dx.doi.org/10.1038/399a003			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JQ	10392574	Bronze			2022-12-28	WOS:000081101700002
J	Smith, O				Smith, O			Biomedicine - Pain-killer genes	SCIENCE			English	Editorial Material																		FINEGOLD AA, IN PRESS HUM GENE TH; Wilson SP, 1999, P NATL ACAD SCI USA, V96, P3211, DOI 10.1073/pnas.96.6.3211	2	2	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1634	1634		10.1126/science.284.5420.1634	http://dx.doi.org/10.1126/science.284.5420.1634			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383343				2022-12-28	WOS:000080668300033
J	McLafferty, FW; Fridriksson, EK; Horn, DM; Lewis, MA; Zubarev, RA				McLafferty, FW; Fridriksson, EK; Horn, DM; Lewis, MA; Zubarev, RA			Biochemistry - Biomolecule mass spectrometry	SCIENCE			English	Article							PROTEIN CHARACTERIZATION; ELECTROPHORESIS; IDENTIFICATION; PEPTIDE		Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	McLafferty, FW (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.		Zubarev, Roman A/W-7891-2018	Zubarev, Roman A/0000-0001-9839-2089; Lewis Ph.D., Mark/0000-0002-2273-3729				BIEMANN K, 1995, PROTEIN SCI, V4, P1920, DOI 10.1002/pro.5560040926; CHAIT BT, UNPUB; CHENG XH, 1995, J AM CHEM SOC, V117, P8859, DOI 10.1021/ja00139a023; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; FORET F, 1995, J CHROMATOGR A, V716, P157, DOI 10.1016/0021-9673(95)00621-S; HORN D, UNPUB; Jensen ON, 1997, ANAL CHEM, V69, P1706, DOI 10.1021/ac961189t; Jensen ON, 1998, PROTEINS, P74; Jorgensen TJD, 1998, ANAL CHEM, V70, P4427, DOI 10.1021/ac980563h; Kelleher NL, 1998, PROTEIN SCI, V7, P1796, DOI 10.1002/pro.5560070815; Kelleher NL, 1999, J AM CHEM SOC, V121, P806, DOI 10.1021/ja973655h; Kelleher NL, 1997, J BIOL CHEM, V272, P32215, DOI 10.1074/jbc.272.51.32215; KELLEHER NL, UNPUB; Little DP, 1996, J AM CHEM SOC, V118, P9352, DOI 10.1021/ja9533611; McLafferty FW, 1998, J AM CHEM SOC, V120, P4732, DOI 10.1021/ja9728076; McLafferty FW, 1997, INT J MASS SPECTROM, V165, P457, DOI 10.1016/S0168-1176(97)00171-7; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; Schnier PD, 1998, J AM CHEM SOC, V120, P9605, DOI 10.1021/ja973534h; Schuhmacher M, 1996, ELECTROPHORESIS, V17, P848, DOI 10.1002/elps.1150170506; Senko MW, 1997, J AM SOC MASS SPECTR, V8, P970, DOI 10.1016/S1044-0305(97)00126-8; SHABANOWITZ J, 1999, MASS SPECTROMETRY BI; Valaskovic GA, 1996, SCIENCE, V273, P1199, DOI 10.1126/science.273.5279.1199; Yang LY, 1998, ANAL CHEM, V70, P3235, DOI 10.1021/ac980224o; Zubarev RA, 1999, J AM CHEM SOC, V121, P2857, DOI 10.1021/ja981948k	24	168	184	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1289	1290		10.1126/science.284.5418.1289	http://dx.doi.org/10.1126/science.284.5418.1289			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383309				2022-12-28	WOS:000080430600031
J	Papadopoulos, MC; Chakraborty, A; Waldron, G; Bell, BA				Papadopoulos, MC; Chakraborty, A; Waldron, G; Bell, BA			Lesson of the week - Exacerbating cervical spine injury by applying a hard collar	BRITISH MEDICAL JOURNAL			English	Article							IMMOBILIZATION; PATIENT		Atkinson Morleys Hosp, Dept Neurosurg, London SW20 0NE, England		Bell, BA (corresponding author), Atkinson Morleys Hosp, Dept Neurosurg, London SW20 0NE, England.			Papadopoulos, Marios/0000-0001-9174-4176				ALTHOFF B, 1980, ANN RHEUM DIS, V39, P485, DOI 10.1136/ard.39.5.485; *AM COLL SURG COMM, 1997, ADV TRAUM SUPP DOCT; CURRAN C, 1995, J TRAUMA, V39, P729, DOI 10.1097/00005373-199510000-00022; DODD FM, 1995, ANAESTHESIA, V50, P961, DOI 10.1111/j.1365-2044.1995.tb05928.x; HEWITT S, 1994, INJURY, V25, P323, DOI 10.1016/0020-1383(94)90245-3; Houghton DJ, 1996, BRIT J NEUROSURG, V10, P501, DOI 10.1080/02688699647168; PODOLSKY SM, 1983, ANN EMERG MED, V12, P578, DOI 10.1016/S0196-0644(83)80305-9; RAPHAEL JH, 1994, ANAESTHESIA, V49, P437; Solomon L, 1995, APLEYS SYSTEM ORTHOP, P54; SURIN VV, 1980, ACTA ORTHOP SCAND, V51, P79, DOI 10.3109/17453678008990772; YOUNG JS, 1977, PARAPLEGIA, V15, P133, DOI 10.1038/sc.1977.19	11	41	41	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					171	172		10.1136/bmj.319.7203.171	http://dx.doi.org/10.1136/bmj.319.7203.171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406758	Green Published			2022-12-28	WOS:000081619300028
J	Buller, RS; Arens, M; Hmiel, SP; Paddock, CD; Sumner, JW; Rikihisa, Y; Unver, A; Gaudreault-Keener, R; Manian, FA; Liddell, AM; Schmulewitz, N; Storch, GA				Buller, RS; Arens, M; Hmiel, SP; Paddock, CD; Sumner, JW; Rikihisa, Y; Unver, A; Gaudreault-Keener, R; Manian, FA; Liddell, AM; Schmulewitz, N; Storch, GA			Ehrlichia ewingii, A newly recognized agent of human ehrlichiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN GRANULOCYTIC EHRLICHIOSIS; POLYMERASE CHAIN-REACTION; ETIOLOGIC AGENT; AMBLYOMMA-AMERICANUM; POTENTIAL VECTOR; CANIS; DOGS; CHAFFEENSIS; IDENTIFICATION; DIAGNOSIS	Background Human ehrlichiosis is a recently recognized tick-borne infection. Four species infect humans: Ehrlichia chaffeensis, E. sennetsu, E. canis, and the agent of human granulocytic ehrlichiosis. Methods We tested peripheral-blood leukocytes from 413 patients with possible ehrlichiosis by broad-range and species-specific polymerase-chain-reaction (PCR) assays for ehrlichia. The species present were identified by species-specific PCR assays and nucleotide sequencing of the gene encoding ehrlichia 16S ribosomal RNA. Western blot analysis was used to study serologic responses. Results In four patients, ehrlichia DNA was detected in leukocytes by a broad-range PCR assay, but not by assays specific for E. chaffeensis or the agent of human granulocytic ehrlichiosis. The nucleotide sequences of these PCR products matched that of E. ewingii, an agent previously reported as a cause of granulocytic ehrlichiosis in dogs. These four patients, all from Missouri, presented between May and August 1996, 1997, or 1998 with fever, headache, and thrombocytopenia, with or without leukopenia. All had been exposed to ticks, and three were receiving immunosuppressive therapy. Serum samples obtained from three of these patients during convalescence contained antibodies that reacted with E, chaffeensis and E. canis antigens in a pattern different from that of humans with E. chaffeensis infection but similar to that of a dog experimentally infected with E. ewingii. Morulae were identified in neutrophils from two patients. All four patients were successfully treated with doxycycline. Conclusions These findings provide evidence of E. ewingii infection in humans. The associated disease may be clinically indistinguishable from infection caused by E. chaffeensis or the agent of human granulocytic ehrlichiosis. (N Engl J Med 1999;341: 148-55.) (C) 1999, Massachusetts Medical Society.	St Louis Childrens Hosp, Dept Pediat, Div Infect Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA; St Johns Mercy Med Ctr, St Louis, MO 63141 USA	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Centers for Disease Control & Prevention - USA; University System of Ohio; Ohio State University; Saint Johns Mercy Medical Center	Storch, GA (corresponding author), St Louis Childrens Hosp, Dept Pediat, Div Infect Dis, 1 Childrens Pl, St Louis, MO 63110 USA.				NIAID NIH HHS [R01 AI409343] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1993, AM J TROP MED HYG, V49, P239, DOI 10.4269/ajtmh.1993.49.239; ANDERSON BE, 1992, INT J SYST BACTERIOL, V42, P299, DOI 10.1099/00207713-42-2-299; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; ANZIANI OS, 1990, AM J VET RES, V51, P929; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; Breitschwerdt EB, 1998, J CLIN MICROBIOL, V36, P2645, DOI 10.1128/JCM.36.9.2645-2651.1998; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; DAWSON JE, 1991, J INFECT DIS, V163, P564, DOI 10.1093/infdis/163.3.564; Dawson JE, 1996, AM J VET RES, V57, P1175; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; EWING SA, 1971, J AM VET MED ASSOC, V159, P1771; Greig B, 1996, J CLIN MICROBIOL, V34, P44, DOI 10.1128/JCM.34.1.44-48.1996; Hardin LE, 1998, MO EPIDEMIOL, V20, P6; JOHANSSON KE, 1995, RES VET SCI, V58, P109, DOI 10.1016/0034-5288(95)90061-6; Lockhart JM, 1997, J CLIN MICROBIOL, V35, P1681, DOI 10.1128/JCM.35.7.1681-1686.1997; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MCQUISTON JH, IN PRESS EMERG INFEC; Misao T., 1954, TOKYO IJI SHINSHI, V71, P683; Ohashi N, 1998, J CLIN MICROBIOL, V36, P2671, DOI 10.1128/JCM.36.9.2671-2680.1998; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; Perez M, 1996, J CLIN MICROBIOL, V34, P2133, DOI 10.1128/JCM.34.9.2133-2139.1996; Ratnasamy N, 1996, CLIN INFECT DIS, V23, P314, DOI 10.1093/clinids/23.2.314; Reddy GR, 1998, BIOCHEM BIOPH RES CO, V247, P636, DOI 10.1006/bbrc.1998.8844; RIKIHISA Y, 1992, J CLIN MICROBIOL, V30, P143, DOI 10.1128/JCM.30.1.143-148.1992; Roberts TC, 1997, J CLIN MICROBIOL, V35, P2224, DOI 10.1128/JCM.35.9.2224-2228.1997; STANDAERT SM, 1995, NEW ENGL J MED, V333, P420, DOI 10.1056/NEJM199508173330704; STOCKHAM SL, 1992, AM J VET RES, V53, P63; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; Warner Cynthia K., 1996, P100	31	299	321	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					148	155		10.1056/NEJM199907153410303	http://dx.doi.org/10.1056/NEJM199907153410303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403852				2022-12-28	WOS:000081413800003
J	Kadir, RA; Sabin, C; Whitlow, B; Brockbank, E; Economides, D				Kadir, RA; Sabin, C; Whitlow, B; Brockbank, E; Economides, D			Neural tube defects and periconceptional folic acid in England and Wales: retrospective study	BRITISH MEDICAL JOURNAL			English	Article								The risks of a first occurrence and a recurrence of neural tube defects have been shown to be reduced by periconceptional folic acid supplementation-that is by taking folic acid from 3 months before conception to 3 months after conception.(1 2) The Expert Advisory Group in the United Kingdom recommended in 1992 that women who were trying to conceive should take 0.4 mg folic acid per day.(3) We assessed whether there had been any change in the incidence of neural tube defects since this recommendation was made.	UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, London NW3 2QG, England; UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Populat Sci, London, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Economides, D (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, London NW3 2QG, England.		Abdulkadir, Rezan/C-5589-2008; Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760				CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; *DEP HLTH SCOTT OF, 1992, REP EXP ADV GROUP FO; McGovern E, 1997, BRIT J GEN PRACT, V47, P635; WALD N, 1991, LANCET, V338, P131	4	40	40	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					92	93		10.1136/bmj.319.7202.92	http://dx.doi.org/10.1136/bmj.319.7202.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398632	Bronze, Green Published			2022-12-28	WOS:000081438200031
J	Nightingale, SL				Nightingale, SL			Trovafloxacin public health advisory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					19	19		10.1001/jama.282.1.19	http://dx.doi.org/10.1001/jama.282.1.19			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404896				2022-12-28	WOS:000081195800007
J	Dyer, C				Dyer, C			Doctors as gods	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					64	64		10.1136/bmj.319.7201.64	http://dx.doi.org/10.1136/bmj.319.7201.64			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390489	Green Published			2022-12-28	WOS:000081326500072
J	McConnell, J; Horton, R				McConnell, J; Horton, R			Lancet electronic research archive in international health and eprint server	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), The Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568				Bachrach S, 1998, SCIENCE, V281, P1459, DOI 10.1126/science.281.5382.1459; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Canhos V, 1999, NATURE, V397, P201, DOI 10.1038/16562; Delamothe T, 1999, BRIT MED J, V318, P1637, DOI 10.1136/bmj.318.7199.1637; GIBBS W., 1995, SCI AM           AUG, P76; Haddad H, 1999, CAN MED ASSOC J, V160, P63; Kassirer JP, 1999, NEW ENGL J MED, V340, P803, DOI 10.1056/NEJM199903113401012; McConnell J, 1998, BRIT MED J, V316, P1907; RELMAN AS, 1999, NEW ENGL J MED, V340, P1793; VARMUS H, E BIOMED PROPOSAL EL; 1999, LANCET, V353, P1985	11	14	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					2	3		10.1016/S0140-6736(99)00226-3	http://dx.doi.org/10.1016/S0140-6736(99)00226-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406353				2022-12-28	WOS:000081243200002
J	Peto, R				Peto, R			Failure of randomisation by "sealed" envelope	LANCET			English	Letter											Peto, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.							Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0	1	24	24	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					73	73		10.1016/S0140-6736(05)75340-X	http://dx.doi.org/10.1016/S0140-6736(05)75340-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406390				2022-12-28	WOS:000081243200052
J	Cacace, F; de Petris, G; Pepi, F; Troiani, A				Cacace, F; de Petris, G; Pepi, F; Troiani, A			Experimental detection of hydrogen trioxide	SCIENCE			English	Article							POTENTIAL-ENERGY SURFACE; VIBRATIONALLY EXCITED OH; PROTONATED OZONE; AB-INITIO; HO3; REACTIVITY; MECHANISM; STABILITY; RADICALS; SINGLET	Hydrogen trioxide (HO3) has long been postulated as a key intermediate in important atmospheric processes but has proved difficult to detect. The molecule was unequivocally detected in experiments based on neutralization-reionization and neutralization-reionization/collisionally activated dissociation mass spectrometry, using protonated ozone (HO3+) as the charged precursor. Hydrogen trioxide is a relatively stable species and has a H-O-O-O connectivity and a lifetime exceeding 10(-6) seconds at ambient temperature.	Univ Roma La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biologi, I-00185 Rome, Italy	Sapienza University Rome	de Petris, G (corresponding author), Univ Roma La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biologi, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	depetris@axrma.uniroma1.it	de Petris, Giulia/I-1581-2012	pepi, federico/0000-0001-6617-8192; Troiani, Anna/0000-0002-6412-9407; DE PETRIS, GIULIA/0000-0002-3175-1347				BATES DR, 1950, J GEOPHYS RES, V55, P301, DOI 10.1029/JZ055i003p00301; BLINT RJ, 1973, J CHEM PHYS, V59, P6220, DOI 10.1063/1.1680001; CACACE F, 1994, SCIENCE, V265, P208, DOI 10.1126/science.265.5169.208; CHEN MML, 1981, J CHEM PHYS, V74, P2938, DOI 10.1063/1.441416; DUPUIS M, 1986, J CHEM PHYS, V84, P269; GONZALEZ C, 1991, J PHYS CHEM-US, V95, P6784, DOI 10.1021/j100171a010; GRIGOREVA VM, 1994, KHIM FIZ, V13, P10; HERZBERG G, 1951, J ROY ASTRON SOC CAN, V45, P100; Hunter EPL, 1998, J PHYS CHEM REF DATA, V27, P413, DOI 10.1063/1.556018; ISAKSEN ISA, 1973, GEOPHYS NORV, V30, P2; JACKELS CF, 1986, J CHEM PHYS, V84, P5013, DOI 10.1063/1.450650; Jungkamp TPW, 1996, CHEM PHYS LETT, V257, P15, DOI 10.1016/0009-2614(96)00520-9; Koller J, 1996, J AM CHEM SOC, V118, P2470, DOI 10.1021/ja9503387; Lay TH, 1997, J PHYS CHEM A, V101, P9505, DOI 10.1021/jp972103i; MATHISEN KB, 1983, ACTA CHEM SCAND A, V37, P817, DOI 10.3891/acta.chem.scand.37a-0817; MATHISEN KB, 1984, CHEM PHYS, V90, P225, DOI 10.1016/0301-0104(84)85321-5; MCDADE IC, 1987, J GEOPHYS RES, V92, P7643, DOI 10.1029/JA092iA07p07643; MEINEL AB, 1950, ASTROPHYS J, V112, P120, DOI 10.1086/145321; MEREDITH C, 1991, J AM CHEM SOC, V113, P1186, DOI 10.1021/ja00004a019; RADOM L, 1971, J AM CHEM SOC, V93, P289, DOI 10.1021/ja00750a005; Schalley CA, 1998, CHEM SOC REV, V27, P91; SHALASHILIN DV, 1995, J PHYS CHEM-US, V99, P11627, DOI 10.1021/j100030a001; Speranza M, 1996, INORG CHEM, V35, P6140, DOI 10.1021/ic960549s; SPERARTZA M, 1998, INORG CHEM, V2, P7535; Szichman H, 1997, J PHYS CHEM A, V101, P8817, DOI 10.1021/jp9717608; Varandas AJC, 1997, MOL PHYS, V91, P301, DOI 10.1080/00268979709482720; VINCENT MA, 1995, J PHYS CHEM-US, V99, P3109, DOI 10.1021/j100010a021; WESDEMIOTIS C, 1987, CHEM REV, V87, P485, DOI 10.1021/cr00079a001; ZHAO M, 1993, J PHYS CHEM-US, V97, P4023, DOI 10.1021/j100118a017	29	104	106	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					81	82		10.1126/science.285.5424.81	http://dx.doi.org/10.1126/science.285.5424.81			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390365				2022-12-28	WOS:000081199800032
J	Hudson, EW; Pan, SH; Gupta, AK; Ng, KW; Davis, JC				Hudson, EW; Pan, SH; Gupta, AK; Ng, KW; Davis, JC			Atomic-scale quasi-particle scattering resonances in Bi2Sr2CaCu2O8+delta	SCIENCE			English	Article							D-WAVE SUPERCONDUCTOR; SCANNING-TUNNELING-MICROSCOPY; SINGLE-CRYSTALS; IMPURITY STATES; CONDUCTIVITY; LOCALIZATION; DEFECTS; GAP	Low-temperature scanning tunneling spectroscopy of the high transition temperature (high-T-c) cuprate Bi2Sr2CaCu2O8+delta reveals the existence of large numbers of identical regions with diameters of about 3 nanometers that have a relatively high density of low-energy quasi-particle states. Their spatial and spectroscopic characteristics are consistent with theories of strong quasi-particle scattering from atomic-scale impurities in a d-wave superconductor. These characteristics include breaking of local particle-hole symmetry, a diameter near twice the superconducting coherence length, and an inverse square dependence of their local density-of-states on distance from the scattering center. In addition to the validation of d-wave quasi-particle scattering theories, these observations identify a source for the anomalously high levels of low-energy quasi-particles in Bi2Sr2CaCu2O8+delta at low temperatures.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Kentucky, Dept Phys & Astron, Lexington, KY 40506 USA	University of California System; University of California Berkeley; University of Kentucky	Davis, JC (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		Hudson, Eric/C-4170-2017; Hudson, Eric/C-2746-2008; Gupta, Anjan/E-3805-2010	Hudson, Eric/0000-0001-7064-0351; Hudson, Eric/0000-0001-7064-0351; Gupta, Anjan/0000-0001-9430-300X				ABRIKOSOV AA, 1961, SOV PHYS JETP-USSR, V12, P1243; ABRIKOSOV AA, 1960, ZH EKSP TEOR FIZ, V39, P1781; BALATSKY AV, 1994, PHYS REV LETT, V73, P720, DOI 10.1103/PhysRevLett.73.720; Balatsky AV, 1996, PHYS REV LETT, V76, P2386, DOI 10.1103/PhysRevLett.76.2386; BYERS JM, 1993, PHYS REV LETT, V71, P3363, DOI 10.1103/PhysRevLett.71.3363; Chen C. J., 1993, INTRO SCANNING TUNNE; EDWARDS HL, 1995, PHYS REV LETT, V75, P1387, DOI 10.1103/PhysRevLett.75.1387; Flatte ME, 1997, PHYS REV B, V56, P11213, DOI 10.1103/PhysRevB.56.11213; Flatte ME, 1998, PHYS REV LETT, V80, P4546, DOI 10.1103/PhysRevLett.80.4546; Franz M, 1996, PHYS REV B, V54, pR6897, DOI 10.1103/PhysRevB.54.R6897; GAO Y, 1988, SCIENCE, V241, P954, DOI 10.1126/science.241.4868.954; Hancotte H, 1997, PHYS REV B, V55, pR3410, DOI 10.1103/PhysRevB.55.R3410; Joynt R, 1997, J LOW TEMP PHYS, V109, P811, DOI 10.1007/BF02435491; Kampf AP, 1997, PHYS REV B, V56, P2360, DOI 10.1103/PhysRevB.56.2360; KIRK MD, 1988, SCIENCE, V242, P1673, DOI 10.1126/science.242.4886.1673; LEE PA, 1993, PHYS REV LETT, V71, P1887, DOI 10.1103/PhysRevLett.71.1887; Lee SF, 1996, PHYS REV LETT, V77, P735, DOI 10.1103/PhysRevLett.77.735; Mallozzi R, 1998, J PHYS CHEM SOLIDS, V59, P2095, DOI 10.1016/S0022-3697(98)00181-4; MITZI DB, 1990, PHYS REV B, V41, P6564, DOI 10.1103/PhysRevB.41.6564; Movshovich R, 1998, PHYS REV LETT, V80, P1968, DOI 10.1103/PhysRevLett.80.1968; Noetzel R, 1998, PHYS REV B, V58, P15108, DOI 10.1103/PhysRevB.58.15108; Pan SH, 1998, APPL PHYS LETT, V73, P58, DOI 10.1063/1.121722; Pan SH, 1999, REV SCI INSTRUM, V70, P1459, DOI 10.1063/1.1149605; Pomar A, 1996, PHYS REV B, V54, P7470, DOI 10.1103/PhysRevB.54.7470; Salkola MI, 1996, PHYS REV LETT, V77, P1841, DOI 10.1103/PhysRevLett.77.1841; SALKOLA MI, 1998, PHYS REV B, V58, P5952; WOOLF MA, 1965, PHYS REV, V137, pA557, DOI 10.1103/PhysRev.137.A557; Yazdani A, 1997, SCIENCE, V275, P1767, DOI 10.1126/science.275.5307.1767; YAZDANI A, IN PRESS PHYS REV LE; Ziegler K, 1996, PHYS REV LETT, V77, P3013, DOI 10.1103/PhysRevLett.77.3013	30	198	198	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					88	91		10.1126/science.285.5424.88	http://dx.doi.org/10.1126/science.285.5424.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390368				2022-12-28	WOS:000081199800035
J	Glaser, R; Rabin, B; Chesney, M; Cohen, S				Glaser, R; Rabin, B; Chesney, M; Cohen, S			Stress-induced immunomodulation - Implications for infectious diseases?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR IMMUNE-RESPONSES; HEPATITIS-B VACCINE; PSYCHOLOGICAL STRESS; COMMON COLD; ADRENERGIC-BLOCKADE; DEPRESSIVE SYMPTOMS; MENTAL STRESS; GAY MEN; SUSCEPTIBILITY		Ohio State Univ, Med Ctr, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Clin Immunopathol CLSI, Pittsburgh, PA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, E Orange, NJ USA	University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; Carnegie Mellon University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Glaser, R (corresponding author), Ohio State Univ, Med Ctr, Dept Med Microbiol & Immunol, 2175 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	glaser.1@postbox.acs.ohio-state.edu	Glaser, Ronald/E-3124-2011	Cohen, Sheldon/0000-0003-2248-4600	NIMH NIH HHS [MH00721] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACHEN EA, 1995, PSYCHOSOM MED, V57, P366, DOI 10.1097/00006842-199507000-00008; BENSCHOP RJ, 1994, CIRCULATION, V89, P762, DOI 10.1161/01.CIR.89.2.762; BURACK JH, 1993, JAMA-J AM MED ASSOC, V270, P2568, DOI 10.1001/jama.270.21.2568; Cohen S, 1997, JAMA-J AM MED ASSOC, V277, P1940; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214; Cole SW, 1996, PSYCHOSOM MED, V58, P219, DOI 10.1097/00006842-199605000-00005; Glaser R, 1998, ANN NY ACAD SCI, V840, P649, DOI 10.1111/j.1749-6632.1998.tb09603.x; GLASER R, 1992, PSYCHOSOM MED, V54, P22, DOI 10.1097/00006842-199201000-00005; Glaser R., 1994, HUMAN HERPESVIRUS IN, P245; GRAVENSTEIN S, 1994, J AM GERIATR SOC, V42, P245, DOI 10.1111/j.1532-5415.1994.tb01746.x; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004; Ironson G, 1994, Int J Behav Med, V1, P90, DOI 10.1207/s15327558ijbm0101_6; JABAAIJ L, 1993, J PSYCHOSOM RES, V37, P361, DOI 10.1016/0022-3999(93)90138-6; Kiecolt-Glaser JK, 1998, AM PSYCHOL, V53, P1209, DOI 10.1037/0003-066X.53.11.1209; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; LYKETSOS CG, 1993, JAMA-J AM MED ASSOC, V270, P2563, DOI 10.1001/jama.270.21.2563; Mayne TJ, 1996, ARCH INTERN MED, V156, P2233, DOI 10.1001/archinte.156.19.2233; Padgett DA, 1998, P NATL ACAD SCI USA, V95, P7231, DOI 10.1073/pnas.95.12.7231; Rabin B.S., 1999, STRESS IMMUNE FUNCTI; RASSNICK S, 1994, J NEUROSCI, V14, P6033; SOLOMON GF, 1991, PSYCHONEUROIMMUNOLOG, P1081; TOBACH E, 1956, AM J PHYSIOL, V187, P399, DOI 10.1152/ajplegacy.1956.187.2.399; Vedhara K, 1999, LANCET, V353, P627, DOI 10.1016/S0140-6736(98)06098-X; WETMORE L, 1991, EXP NEUROL, V113, P226, DOI 10.1016/0014-4886(91)90179-G	26	122	124	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2268	2270		10.1001/jama.281.24.2268	http://dx.doi.org/10.1001/jama.281.24.2268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207FN	10386538				2022-12-28	WOS:000080925600001
J	Hinds, CJ; Watson, D				Hinds, CJ; Watson, D			ABC of intensive care - Circulatory support	BRITISH MEDICAL JOURNAL			English	Article									Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med, London E1 4NS, England	University of London; Queen Mary University London	Hinds, CJ (corresponding author), Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med, Mile End Rd, London E1 4NS, England.								0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1749	1752		10.1136/bmj.318.7200.1749	http://dx.doi.org/10.1136/bmj.318.7200.1749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381715	Green Published			2022-12-28	WOS:000081216900037
J	Rzany, B; Correia, O; Kelly, JP; Naldi, L; Auquier, A; Stern, R				Rzany, B; Correia, O; Kelly, JP; Naldi, L; Auquier, A; Stern, R		Study Grp Int Case-Control Study Sever	Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study	LANCET			English	Article							ERYTHEMA MULTIFORME; LAMOTRIGINE; APOPTOSIS; RADIATION; GERMANY; DEATH	Background There is still controversy about whether all antiepileptic drugs are associated with the severe cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We have studied the role of antiepileptic drugs in SJS and TEN, taking into account potential cofactors that might confound or modify the risk. Methods The case-control study in France, Italy, Germany, and Portugal identified cases of SJS/TEN that developed when the patient was not in hospital and were validated by an expert committee. Controls were patients admitted to the same hospital as the case for an acute illness or an elective procedure. Findings 73 (21%) of the 352 SJS/TEN cases and 28 (2%) of the 1579 controls reported intake of antiepileptic drugs. Among the 73 exposed SJS and TEN patients, 36 reported intake of phenobarbital, 14 of phenytoin, 21 of carbamazepine, 13 of valproic acid, and three of lamotrigine. Risk was highest in the first 8 weeks after onset of treatment. For individual antiepileptic drugs the univariate relative risk of SJS/TEN for 8 weeks or less of use was 57 (95% CI 16-360; multivariate risk 59 [12-302]) for phenobarbital; 91(26-infinity) for phenytoin; 120 (34-infinity) for carbamazepine; 25 (5.6-infinity) for lamotrigine, and 24 (5.9-infinity) for valproic acid. The result for valproic acid was based on four case users, all of whom reported concurrent use of other associate drugs. The univariate relative risk for more than 8 weeks of use was 6.2 (2.4-17.0; multivariate risk 2.1 [0.5-9.3]) for phenobarbital, 1.2 (0-5.4) for phenytoin, 0.4 (0.02-2.1) for carbamazepine, and 7.0 (2.4-21.0; multivariate risk 2.0 [0.3-15.0]) for valproic acid. Interpretation SJS and TEN are associated with short-term therapy with phenytoin, phenobarbital, and carbamazepine. The association with valproic acid seems to be confounded by concomitant short-term therapy with other causal drugs. Lamotrigine also has the potential for severe skin reactions. The period of increased risk is largely confined to the first 8 weeks of treatment.	Univ Heidelberg, Fak Klin Med Mannheim, Dept Dermatol, D-6800 Mannheim, Germany; Fac Med, Inst Portugues Oncol & Immunol, Dept Dermatol & Immunol, Porto, Portugal; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Milan, Osped Riuniti, Dept Dermatol, Bergamo, Italy; Inst Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France; Harvard Univ, Sch Med, Beth Israel Deaconess Med CTr, Dept Dermatol, Boston, MA USA	Ruprecht Karls University Heidelberg; Universidade do Porto; Boston University; Ospedali Riuniti di Bergamo; University of Milan; UNICANCER; Gustave Roussy; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rzany, B (corresponding author), Univ Heidelberg, Klinikum Mannheim gGmbH, Fak Klin Med Mannheim, Hautklin, Theodor Kutzer Ufer, D-68135 Mannheim, Germany.		Naldi, Luigi/AFM-8982-2022; Naldi, Luigi/K-6343-2016	Naldi, Luigi/0000-0002-3160-2835; Naldi, Luigi/0000-0002-3160-2835				ASMARK H, 1990, ACTA NEUROL SCAND, V81, P131; BASTUJI S, 1993, ARCH DERMATOL, V125, P92; Borg M F, 1995, Australas Radiol, V39, P42, DOI 10.1111/j.1440-1673.1995.tb00230.x; Chaffin JJ, 1997, ANN PHARMACOTHER, V31, P720, DOI 10.1177/106002809703100609; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; CHEN M, 1995, CANCER RES, V55, P991; DELATTRE JY, 1988, NEUROLOGY, V38, P194, DOI 10.1212/WNL.38.2.194; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DUVAL X, 1995, LANCET, V345, P1301; Fogh K, 1997, SEIZURE, V6, P63, DOI 10.1016/S1059-1311(97)80055-6; GOODMAN LS, 1985, PHARMACOL BASIS THER, P446; Inachi S, 1997, ARCH DERMATOL, V133, P845, DOI 10.1001/archderm.133.7.845; KELLY JP, 1995, J CLIN EPIDEMIOL, V48, P1099, DOI 10.1016/0895-4356(95)00004-N; LEENUTAPHONG V, 1993, INT J DERMATOL, V32, P428, DOI 10.1111/j.1365-4362.1993.tb02814.x; MAICHE A, 1985, LANCET, V2, P45; MIETTINEN OS, 1976, AM J EPIDEMIOL, V109, P226; NAWALKHA PL, 1972, BRIT J RADIOL, V45, P768, DOI 10.1259/0007-1285-45-538-768; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; RUIZMALDONADO R, 1985, J AM ACAD DERMATOL, V13, P623, DOI 10.1016/S0190-9622(85)70207-1; Rzany B, 1996, J CLIN EPIDEMIOL, V49, P769, DOI 10.1016/0895-4356(96)00035-2; Sachs B, 1996, LANCET, V348, P1597, DOI 10.1016/S0140-6736(05)66227-7; SCHOPF E, 1991, ARCH DERMATOL, V127, P839, DOI 10.1001/archderm.127.6.839; STERKER M, 1995, INT J CLIN PHARM TH, V33, P595; STERN RS, 1989, J AM ACAD DERMATOL, V21, P317, DOI 10.1016/S0190-9622(89)70176-6; Sullivan J R, 1996, Australas J Dermatol, V37, P208, DOI 10.1111/j.1440-0960.1996.tb01057.x; Tennis P, 1997, NEUROLOGY, V49, P542, DOI 10.1212/WNL.49.2.542; Wadelius M, 1996, LANCET, V348, P1041, DOI 10.1016/S0140-6736(05)64979-3	29	222	226	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2190	2194		10.1016/S0140-6736(98)05418-X	http://dx.doi.org/10.1016/S0140-6736(98)05418-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392983				2022-12-28	WOS:000081091300011
J	Hong, KS; Hinck, L; Nishiyama, M; Poo, MM; Tessier-Lavigne, M; Stein, E				Hong, KS; Hinck, L; Nishiyama, M; Poo, MM; Tessier-Lavigne, M; Stein, E			A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion	CELL			English	Article							C-ELEGANS; COLORECTAL-CANCER; AXON GUIDANCE; ENCODES; PROTEIN; GENES; IMMUNOGLOBULIN; EXPRESSION; MIGRATIONS; RESPONSES	Netrins are bifunctional: they attract some axons and repel others. Netrin receptors of the Deleted in Colorectal Cancer (DCC) family are implicated in attraction and those of the UNC5 family in repulsion, but genetic evidence also suggests involvement of the DCC protein UNC-40 in some cases of repulsion. To test whether these proteins form a receptor complex for repulsion, we studied the attractive responses of Xenopus spinal axons to netrin-1, which are mediated by DCC. Vie show that attraction is converted to repulsion by expression of UNC5 proteins in these cells, that this repulsion requires DCC function, that the UNC5 cytoplasmic domain is sufficient to effect the conversion, and that repulsion can be initiated by netrin-1 binding to either UNC5 or DCC. The isolated cytoplasmic domains of DCC and UNC5 proteins interact directly, but this interaction is repressed in the context of the full-length proteins. We provide evidence that netrin-1 triggers the formation of a receptor complex of DCC: and UNC5 proteins and simultaneously derepresses the interaction between their cytoplasmic domains, thereby converting DCC-mediated attraction to UNC5/DCC-mediated repulsion.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tessier-Lavigne, M (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Stein, Elke/E-8107-2013	Stein, Elke/0000-0001-8965-5692; Hinck, Lindsay/0000-0002-4009-3913	NINDS NIH HHS [NS22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Gong QZ, 1999, DEVELOPMENT, V126, P1451; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Przyborski SA, 1998, DEVELOPMENT, V125, P41; Rose M, 1990, LAB COURSE MANUAL ME; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tabti N., 1991, CULTURING NERVE CELL, P137; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Van Vactor D, 1999, NEURON, V22, P649, DOI 10.1016/S0896-6273(00)80723-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wadsworth WG, 1996, BIOESSAYS, V18, P355, DOI 10.1002/bies.950180505; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; ZHANG JQ, 1994, NATURE, V368, P140	37	546	568	4	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					927	941		10.1016/S0092-8674(00)80804-1	http://dx.doi.org/10.1016/S0092-8674(00)80804-1			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399920	Bronze			2022-12-28	WOS:000081162800013
J	Izraeli, S; Lowe, LA; Bertness, VL; Good, DJ; Dorward, DW; Kirsch, IR; Kuehn, MR				Izraeli, S; Lowe, LA; Bertness, VL; Good, DJ; Dorward, DW; Kirsch, IR; Kuehn, MR			The SIL gene is required for mouse embryonic axial development and left-right specification	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; SONIC HEDGEHOG; TRANSCRIPTION FACTOR; NODAL EXPRESSION; NOTOCHORD; ZEBRAFISH; INDUCTION; PATTERN; PITX2	The establishment of the main body axis and the determination of left-right asymmetry are fundamental aspects of vertebrate embryonic development. A link between these processes has been revealed by the frequent finding of midline defects in humans with left-right anomalies(1). This association is also seen in a number of mutations in mouse(2-4) and zebrafish(1,5), and in experimentally manipulated Xenopus embryos(5). However, the severity of laterality defects accompanying abnormal midline development varies(6), and the molecular basis for this variation is unknown. Here we show that mouse embryos lacking the early-response gene SIL have axial midline defects, a block in midline Sonic hedgehog (Shh) signalling and randomized cardiac looping. Comparison with Shh mutant embryos(7), which have axial defects but normal cardiac looping, indicates that the consequences of abnormal midline development for left-right patterning depend on the time of onset, duration and severity of disruption of the normal asymmetric patterns of expression of nodal, lefty-2 and Pitx2.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, Med Branch, NIH, Bethesda, MD 20889 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Massachusetts System; University of Massachusetts Amherst; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kuehn, MR (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	kirshi@exchange.nih.gov; mkuehn@box-m.nih.gov	Kuehn, Michael R/A-4573-2014	Kuehn, Michael R/0000-0002-7703-9160	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC009297, ZIABC009297] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 1997, BIOCHEM BIOPH RES CO, V235, P142, DOI 10.1006/bbrc.1997.6750; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Campione M, 1999, DEVELOPMENT, V126, P1225; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CollazoGarcia N, 1995, GENOMICS, V30, P506, DOI 10.1006/geno.1995.1271; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Goldstein AM, 1998, DEV GENET, V22, P278, DOI 10.1002/(SICI)1520-6408(1998)22:3<278::AID-DVG9>3.0.CO;2-3; Good DJ, 1997, NAT GENET, V15, P397, DOI 10.1038/ng0497-397; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Izraeli S, 1997, CELL GROWTH DIFFER, V8, P1171; King T, 1998, MECH DEVELOP, V79, P29, DOI 10.1016/S0925-4773(98)00166-X; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	30	169	172	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					691	694		10.1038/21429	http://dx.doi.org/10.1038/21429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385121				2022-12-28	WOS:000080932800061
J	Hjalmarson, A; Goldstein, S; Fagerberg, B; Wedel, H; Waagstein, F; Kjekshus, J; Wikstrand, J; Westergren, G; Hassle, A; Thimell, M; El Allaf, D; Vitovec, J; Aldershvile, J; Halinen, M; Dietz, R; Neuhaus, KL; Janosi, A; Thorgeirsson, G; Dunselman, P; Gullestad, L; Kuch, J; Herlitz, J; Rickenbacher, P; Ball, S; Gottlieb, S; Deedwania, P; Vandenhoven, G; Novakova, I; Danker, S; Lundstrom, M; Meyer-Sabellek, W; Balla, I; Sveinsdottir, M; Dorhout, B; Hildebrandt, A; Szczurko, I; Larsson, C; Bucher, E; Scott, E; Dwyer, D; Julian, DG; DeMets, DL; Chatterjee, K; Feyzi, J; Lehto, S; Karpati, P; Motz, W; Samuelsson, O; Viersma, JW; Andersson, B; Berthe, C; Boutefeu, JM; Boxho, G; Decroly, P; Derbaudrenghien, JP; El Allaf, D; Pirlet, J; Henry, P; Heyndrickx, G; Missault, L; Nannan, M; Timmermans, P; Vachiery, JL; Van Mieghem, W; Vandenbossche, JL; Dvorak, K; Herold, M; Hradec, J; Kana, A; Petr, P; Rybka, J; Smid, J; Svitil, P; Toman, J; Vitovec, J; Agner, E; Aldershvile, J; Amtorp, O; Egstrup, K; Eliasen, P; Gotzsche, CO; Hildebrandt, P; Johannesen, A; Kaiser-Nielsen, P; Nielsen, H; Nielsen, PE; Pedersen, F; Nielsen, JR; Skagen, K; Halinen, M; Honkanen, T; Hussi, E; Juvonen, J; Jaaskelainen, H; Rinne, J; Salonen, T; Andresen, D; Berwing, H; Dietz, R; Forster, A; Hauf, GF; Krosse, B; Luderitz, B; von Olshausen, KE; Schmailzl, KJG; Schwimmbeck, PL; Sigmund, M; Voller, H; Czuriga, I; Hetey, M; Janosi, A; Katona, A; Lengyel, M; Nyaradi, A; Rednik, A; Sandori, K; Szabo, P; Tarjan, J; Tenczer, J; Timar, S; Valyi, P; Veress, G; Zamolyi, K; Oze, B; Thorgeirsson, G; Thorgeirsson, G; Bernink, PJLM; Bredero, AC; Breedveld, RW; Breuls, PNWM; Bucx, JJJ; Cornel, JH; De Milliano, PAR; Dunselman, PHJM; Hamer, BJB; Holwerda, NL; Hoogsteen, J; Hoorntje, JCA; Kragten, JA; Liem, AH; Linssen, GCM; Michels, HR; Misier, ARR; Schaafsma, HJ; Sijbring, P; Taverne, RJT; Van Kempen, LHJ; Van Stralen, R; Van Veldhuisen, DJ; Veerhoek, MJ; Werter, CJPJ; Wesdorp, JCL; Willems, AR; Withagen, AJAM; Zwart, PAG; Bjornerheim, R; Dahle, M; Dickstein, K; Froland, GS; Gullestad, L; Gundersen, T; Hofsoy, K; Hole, TL; Johansen, T; Mannsverk, J; Nesje, P; Omland, TM; Sjodin, C; Smith, P; Tjonndal, HA; Vikesdal, O; Waage, K; Jaworska, K; Kolodziej, P; Kornacewicz-Jach, Z; Krzeminska-Pakula, M; Kuch, J; Piotrowski, JW; Piwowarska, W; Stogowski, A; Wodniecki, J; Wrabec, K; Ahlstrom, P; Ekdahl, S; Hemmingson, LO; Herlitz, J; Holmberg, L; Lernfelt, B; Nilsson, H; Widgren, B; Angman, K; Erne, P; Mohacsi, P; Polikar, R; Rickenbacher, P; Schlapfer, H; Batin, P; Berkin, KE; Callaghan, TS; Forfar, J; Frenneaux, M; Greenbaum, RA; Maltz, M; Murdoch, D; Reynolds, G; Stephens, J; Struthers, A; Swan, J; Tildesley, G; Abbasi, A; Alagona, P; Alderman, J; Alipour, M; Anderson, JL; Ansari, Z; Ashraf, M; Beanblossom, BT; Bennett, S; Benvenuti, D; Berk, MR; Bhalla, R; Bilazarian, SD; Browne, KF; Buchter, CM; Carlson, R; Carlson, CJ; Danisa, K; Dauber, I; DeWood, MA; Deedwania, P; Dennish, G; Denny, DM; DiBianco, R; Diller, PM; Dunlap, M; Dowd, K; Edmiston, A; El Shahawy, M; Elkayam, U; Farnham, J; Fenster, P; Friedman, S; Heywood, T; Galichia, JP; Geller, M; Ghali, JK; Gheorghiade, M; Giles, T; Gillespe, R; Goldberg, G; Goldberg, MC; Goldscher, DA; Gooden, GP; Goodman, M; Goodman, L; Gorwit, J; Gottlieb, SS; Gradman, A; Grech, D; Hack, T; Hall, JH; Hattenhauer, MT; Higginbotham, MB; Hutchins, S; Imburgia, M; Iteld, BJ; Jackson, B; Jafri, S; Jauch, W; Jennison, S; Kahn, BH; Kao, W; Kaplan, K; Karlsberg, R; Kennedy, HL; Kennedy, JJ; Kirkegaard, L; Kraus, DH; LaBresh, K; Lalonde, L; Lesser, MF; Levites, R; Levy, M; Lewis, RK; Loh, IK; Madyoon, H; Maislos, F; Mann, D; Maurice, GL; Nisar, A; Old, W; Pappas, JD; Phadke, K; Promisloff, S; Rashkow, AM; Reeves, B; Rosen, JH; Rotman, M; Saleem, T; Savran, SV; Shah, R; Shalev, Y; Shanes, JG; O'Shaughnessy, M; Silverman, B; Steingart, RM; Swenson, L; Syed, K; Thadani, U; Thorsen, RD; Tonkon, MJ; Touchon, R; Uhl, G; Vaska, KJ; Wagner, SG; Weaver, CJ; Weiss, RJ; Wickemeyer, WJ; Willens, HJ; Wilson, JR; Wright, R; Yellen, L				Hjalmarson, A; Goldstein, S; Fagerberg, B; Wedel, H; Waagstein, F; Kjekshus, J; Wikstrand, J; Westergren, G; Hassle, A; Thimell, M; El Allaf, D; Vitovec, J; Aldershvile, J; Halinen, M; Dietz, R; Neuhaus, KL; Janosi, A; Thorgeirsson, G; Dunselman, P; Gullestad, L; Kuch, J; Herlitz, J; Rickenbacher, P; Ball, S; Gottlieb, S; Deedwania, P; Vandenhoven, G; Novakova, I; Danker, S; Lundstrom, M; Meyer-Sabellek, W; Balla, I; Sveinsdottir, M; Dorhout, B; Hildebrandt, A; Szczurko, I; Larsson, C; Bucher, E; Scott, E; Dwyer, D; Julian, DG; DeMets, DL; Chatterjee, K; Feyzi, J; Lehto, S; Karpati, P; Motz, W; Samuelsson, O; Viersma, JW; Andersson, B; Berthe, C; Boutefeu, JM; Boxho, G; Decroly, P; Derbaudrenghien, JP; El Allaf, D; Pirlet, J; Henry, P; Heyndrickx, G; Missault, L; Nannan, M; Timmermans, P; Vachiery, JL; Van Mieghem, W; Vandenbossche, JL; Dvorak, K; Herold, M; Hradec, J; Kana, A; Petr, P; Rybka, J; Smid, J; Svitil, P; Toman, J; Vitovec, J; Agner, E; Aldershvile, J; Amtorp, O; Egstrup, K; Eliasen, P; Gotzsche, CO; Hildebrandt, P; Johannesen, A; Kaiser-Nielsen, P; Nielsen, H; Nielsen, PE; Pedersen, F; Nielsen, JR; Skagen, K; Halinen, M; Honkanen, T; Hussi, E; Juvonen, J; Jaaskelainen, H; Rinne, J; Salonen, T; Andresen, D; Berwing, H; Dietz, R; Forster, A; Hauf, GF; Krosse, B; Luderitz, B; von Olshausen, KE; Schmailzl, KJG; Schwimmbeck, PL; Sigmund, M; Voller, H; Czuriga, I; Hetey, M; Janosi, A; Katona, A; Lengyel, M; Nyaradi, A; Rednik, A; Sandori, K; Szabo, P; Tarjan, J; Tenczer, J; Timar, S; Valyi, P; Veress, G; Zamolyi, K; Oze, B; Thorgeirsson, G; Thorgeirsson, G; Bernink, PJLM; Bredero, AC; Breedveld, RW; Breuls, PNWM; Bucx, JJJ; Cornel, JH; De Milliano, PAR; Dunselman, PHJM; Hamer, BJB; Holwerda, NL; Hoogsteen, J; Hoorntje, JCA; Kragten, JA; Liem, AH; Linssen, GCM; Michels, HR; Misier, ARR; Schaafsma, HJ; Sijbring, P; Taverne, RJT; Van Kempen, LHJ; Van Stralen, R; Van Veldhuisen, DJ; Veerhoek, MJ; Werter, CJPJ; Wesdorp, JCL; Willems, AR; Withagen, AJAM; Zwart, PAG; Bjornerheim, R; Dahle, M; Dickstein, K; Froland, GS; Gullestad, L; Gundersen, T; Hofsoy, K; Hole, TL; Johansen, T; Mannsverk, J; Nesje, P; Omland, TM; Sjodin, C; Smith, P; Tjonndal, HA; Vikesdal, O; Waage, K; Jaworska, K; Kolodziej, P; Kornacewicz-Jach, Z; Krzeminska-Pakula, M; Kuch, J; Piotrowski, JW; Piwowarska, W; Stogowski, A; Wodniecki, J; Wrabec, K; Ahlstrom, P; Ekdahl, S; Hemmingson, LO; Herlitz, J; Holmberg, L; Lernfelt, B; Nilsson, H; Widgren, B; Angman, K; Erne, P; Mohacsi, P; Polikar, R; Rickenbacher, P; Schlapfer, H; Batin, P; Berkin, KE; Callaghan, TS; Forfar, J; Frenneaux, M; Greenbaum, RA; Maltz, M; Murdoch, D; Reynolds, G; Stephens, J; Struthers, A; Swan, J; Tildesley, G; Abbasi, A; Alagona, P; Alderman, J; Alipour, M; Anderson, JL; Ansari, Z; Ashraf, M; Beanblossom, BT; Bennett, S; Benvenuti, D; Berk, MR; Bhalla, R; Bilazarian, SD; Browne, KF; Buchter, CM; Carlson, R; Carlson, CJ; Danisa, K; Dauber, I; DeWood, MA; Deedwania, P; Dennish, G; Denny, DM; DiBianco, R; Diller, PM; Dunlap, M; Dowd, K; Edmiston, A; El Shahawy, M; Elkayam, U; Farnham, J; Fenster, P; Friedman, S; Heywood, T; Galichia, JP; Geller, M; Ghali, JK; Gheorghiade, M; Giles, T; Gillespe, R; Goldberg, G; Goldberg, MC; Goldscher, DA; Gooden, GP; Goodman, M; Goodman, L; Gorwit, J; Gottlieb, SS; Gradman, A; Grech, D; Hack, T; Hall, JH; Hattenhauer, MT; Higginbotham, MB; Hutchins, S; Imburgia, M; Iteld, BJ; Jackson, B; Jafri, S; Jauch, W; Jennison, S; Kahn, BH; Kao, W; Kaplan, K; Karlsberg, R; Kennedy, HL; Kennedy, JJ; Kirkegaard, L; Kraus, DH; LaBresh, K; Lalonde, L; Lesser, MF; Levites, R; Levy, M; Lewis, RK; Loh, IK; Madyoon, H; Maislos, F; Mann, D; Maurice, GL; Nisar, A; Old, W; Pappas, JD; Phadke, K; Promisloff, S; Rashkow, AM; Reeves, B; Rosen, JH; Rotman, M; Saleem, T; Savran, SV; Shah, R; Shalev, Y; Shanes, JG; O'Shaughnessy, M; Silverman, B; Steingart, RM; Swenson, L; Syed, K; Thadani, U; Thorsen, RD; Tonkon, MJ; Touchon, R; Uhl, G; Vaska, KJ; Wagner, SG; Weaver, CJ; Weiss, RJ; Wickemeyer, WJ; Willens, HJ; Wilson, JR; Wright, R; Yellen, L		MERIT-HF Study Grp	Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; BETA-RECEPTOR BLOCKADE; MORTALITY; CARDIOMYOPATHY; MORBIDITY; DEATH; SURVIVAL	Background. Metoprolol can improve haemodynamics in chronic heart failure, but survival benefit has, not been proven. We investigated whether metoprolol controlled release/extended release (CR/XL) once daily, in addition to standard therapy, would lower mortality in patients with decreased ejection fraction and symptoms of heart failure. Methods. We enrolled 3991 patients with chronic heart failure in New York Heart Association (NYHA) functional class II-IV and with ejection fraction of 0.40 or less, stabilised with optimum standard therapy, in a double-blind randomised controlled study. Randomisation was preceded by a 2-week single-blind placebo run-in period. 1990 patients were randomly assigned metoprolol CR/XL 12.5 mg (NYHA III-IV) or 25.0 mg once daily (NYHA II) and 2001 were assigned placebo. The target dose was 200 mg once daily and doses were up-titrated over 8 weeks. Our primary endpoint was all-cause mortality, analysed by intention to treat. Findings. The study was stopped early on the recommendation of the independent safety committee. Mean follow-up time was 1 year. All-cause mortality was lower in the metoprolol CR/XL group than in the placebo group (145 [7.2%, per patient-year of follow-up]) vs 217 deaths [11.0%], relative risk 0.66 [95% Cl 0.53-0.81]; p = 0.00009 or adjusted for interim analyses p = 0.0062). There were fewer sudden deaths in the metoprolol CR/XL group than in the placebo group (79 vs 132, 0.59 [0.45-0.78]; p = 0.0002) and deaths from worsening heart failure (30 vs 58, 0.51 [0.33-0.79]; p = 0.0023). Interpretation. Metoprolol CR/XL once daily in addition to optimum standard therapy improved survival. The drug was well tolerated.	Univ Gothenburg, Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-41345 Gothenburg, Sweden; Astra Hassle AB, Molndal, Sweden	Sahlgrenska University Hospital; University of Gothenburg	Fagerberg, B (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-41345 Gothenburg, Sweden.	bjorn.fagerberg@mailer.mednet.gu.se	Vachiery, Jean-Luc/ABC-6631-2021; Hradec, Jaromir/S-2388-2016; LaBresh, Kenneth A/A-6995-2017; Jafri, Wasim/AAE-5085-2020; cornel, jan hein/Y-7065-2019; Mann, Douglas Lowell/AAQ-3524-2021; van Veldhuisen, Dirk Jan/E-8967-2014; Petr, Petr/I-9423-2014	Hradec, Jaromir/0000-0001-7597-8239; LaBresh, Kenneth A/0000-0001-9040-1956; cornel, jan hein/0000-0002-1006-2112; Mann, Douglas/0000-0002-2516-0145; Struthers, Allan/0000-0002-2926-2528				Andersson Bert, 1999, Journal of the American College of Cardiology, V33, p183A; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; Cleland JGF, 1996, EUR HEART J, V17, P1629; Doughty RN, 1997, EUR HEART J, V18, P560; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GOLDSTEIN S, 1999, IN PRESS AM HEART J; GUNDERSEN T, 1983, BRIT HEART J, V50, P135; Herlitz J, 1997, AM J CARDIOL, V80, pJ40, DOI 10.1016/S0002-9149(97)00838-2; HERLITZ J, 1999, IN PRESS CARDIOVASC; HEYDENRICH PA, 1997, J AM COLL CARDIOL, V30, P27; *INT STEER COMM, 1997, AM J CARDIOL, V80, P54; Lauriola P, 1998, LANCET, V351, P1180, DOI 10.1016/S0140-6736(05)79124-8; Lechat P, 1999, LANCET, V353, P9; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; MacMahon S, 1997, LANCET, V349, P375; Narang R, 1996, EUR HEART J, V17, P1390; OLSSON G, 1992, EUR HEART J, V13, P28, DOI 10.1093/oxfordjournals.eurheartj.a060043; OLSSON G, 1991, AM J HYPERTENS, V4, P151, DOI 10.1093/ajh/4.2.151; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RANKIN AC, 1996, HEART FAILURE CLIN P, P189; SANDBERG A, 1988, EUR J CLIN PHARMACOL, V33, pS3, DOI 10.1007/BF00578405; *STEER COMM MEMB A, 1999, AM J CARDIOL, V83, pA2; SWEDBERG K, 1979, LANCET, V1, P1374; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Waagstein F., 1998, European Heart Journal, V19, P307; WIKSTRAND J, 1992, EUR HEART J, V13, P111; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	29	3541	3696	1	107	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2001	2007						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376614				2022-12-28	WOS:000080812200009
J	Fakruddin, JM; Chaganti, RSK; Murty, VVVS				Fakruddin, JM; Chaganti, RSK; Murty, VVVS			Lack of BCL10 mutations in germ cell tumors and B cell lymphomas	CELL			English	Article							DELETIONS		Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, Canc Genet Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Murty, VVVS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.							Baylin SB, 1998, ADV CANCER RES, V72, P141; Forget BG, 1998, ANN NY ACAD SCI, V850, P38, DOI 10.1111/j.1749-6632.1998.tb10460.x; Lee WC, 1996, CANCER RES, V56, P4297; MATHEW S, 1994, CANCER RES, V54, P6265; MURTY VVVS, 1994, ONCOGENE, V9, P2245; OFFIT K, 1993, BLOOD, V82, P2157; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5	8	46	48	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					683	684		10.1016/S0092-8674(00)80781-3	http://dx.doi.org/10.1016/S0092-8674(00)80781-3			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380920	Green Published, hybrid			2022-12-28	WOS:000080886300005
J	Geng, Y; Whoriskey, W; Park, MY; Bronson, RT; Medema, RH; Li, TS; Weinberg, RA; Sicinski, P				Geng, Y; Whoriskey, W; Park, MY; Bronson, RT; Medema, RH; Li, TS; Weinberg, RA; Sicinski, P			Rescue of cyclin D1 deficiency by knockin cyclin E	CELL			English	Article							RETINOBLASTOMA PROTEIN; CELL-PROLIFERATION; S-PHASE; DEPENDENT KINASES; ESTROGEN-RECEPTOR; MAMMARY-GLAND; G1 CYCLIN; E GENE; TRANSCRIPTION; EXPRESSION	D-type cyclins and cyclin E represent two very distinct classes of mammalian G1 cyclins. We have generated a mouse strain in which the coding sequences of the cyclin D1 gene (Ccnd1) have been deleted and replaced by those of human cyclin E (CCNE). In the tissues and cells of these mice, the expression pattern of human cyclin E faithfully reproduces that normally associated with mouse cyclin D1. The replacement of cyclin D1 with cyclin E rescues all phenotypic manifestations of cyclin D1 deficiency and restores normal development in cyclin D1-dependent tissues. Thus, cyclin E can functionally replace cyclin D1. Our analyses suggest that cyclin E is the major downstream target of cyclin D1.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Tufts Univ, Sch Med & Vet Med, Boston, MA 02111 USA; Univ Utrecht, Med Ctr, Jordan Lab, Dept Hematol, NL-3584 CX Utrecht, Netherlands; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Tufts University; Utrecht University; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.		Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381	NCI NIH HHS [535CA39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Botz J, 1996, MOL CELL BIOL, V16, P3401; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Geng Y, 1996, ONCOGENE, V12, P1173; Gudas JM, 1999, MOL CELL BIOL, V19, P612; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Steinberg RH., 1991, PROGR RETINAL RES, V10, P121, DOI 10.1016/0278-4327(91)90011-P; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	25	279	282	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					767	777		10.1016/S0092-8674(00)80788-6	http://dx.doi.org/10.1016/S0092-8674(00)80788-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380928	Bronze			2022-12-28	WOS:000080886300014
J	Rocheleau, CE; Yasuda, J; Shin, TH; Lin, RL; Sawa, H; Okano, H; Priess, JR; Davis, RJ; Mello, CC				Rocheleau, CE; Yasuda, J; Shin, TH; Lin, RL; Sawa, H; Okano, H; Priess, JR; Davis, RJ; Mello, CC			WRM-1 activates the LIT-1 protein kinase to transduce anterior posterior polarity signals in C-elegans	CELL			English	Article							ASYMMETRIC CELL DIVISIONS; CAENORHABDITIS-ELEGANS; BETA-CATENIN; DROSOPHILA EYE; GENE LIN-44; ENCODES; ADHESION; EMBRYOS; IDENTIFICATION; SPECIFICATION	During C. elegans development, Wnt/WG signaling is required for differences in cell fate between sister cells born from anterior/posterior divisions. A beta-catenin-related gene, wrm-1, and the lit-1 gene are effecters of this signaling pathway and appear to downregulate the activity of POP-1, a TCF/LEF-related protein, in posterior daughter cells. We show here that lit-1 encodes a serine/threonine protein kinase homolog related to the Drosophila tissue polarity protein Nemo. We demonstrate that the WRM-1 protein binds to LIT-1 in vivo and that WRM-1 can activate the LIT-1 protein kinase when coexpressed in vertebrate tissue culture cells. This activation leads to phosphorylation of POP-1 and to apparent changes in its subcellular-localization. Our findings provide evidence for novel regulatory avenues for an evolutionarily conserved Wnt/WG signaling pathway.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Japan Soc & Technol Corp, Dept Neuroanat, Ctr Biomed Res, Suita, Osaka 5650871, Japan; Japan Soc & Technol Corp, PRESTO, Suita, Osaka 5650871, Japan; Japan Soc & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Mello, CC (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.		Okano, Hideyuki/I-7584-2019	Yasuda, Jun/0000-0002-3887-6871; Sawa, Hitoshi/0000-0001-9774-7976; Rocheleau, Christian/0000-0001-6738-5636				Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; BRENNER S, 1974, GENETICS, V77, P71; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Han M, 1997, CELL, V90, P581, DOI 10.1016/S0092-8674(00)80517-6; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; Kuhl M, 1997, BIOESSAYS, V19, P101, DOI 10.1002/bies.950190204; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Papavassiliou Athanasios G., 1992, Methods in Molecular and Cellular Biology, V3, P149; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schnabel R., 1997, C ELEGANS, P361; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tournier C, 1999, MOL CELL BIOL, V19, P1569; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; ZHENG L, 1995, DEVELOPMENT, V121, P3045	42	216	228	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					717	726		10.1016/S0092-8674(00)80784-9	http://dx.doi.org/10.1016/S0092-8674(00)80784-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380924	Bronze			2022-12-28	WOS:000080886300010
J	Purnell, BA; Marx, J				Purnell, BA; Marx, J			Microbe management	SCIENCE			English	Editorial Material																			0	3	3	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1301	1301		10.1126/science.284.5418.1301	http://dx.doi.org/10.1126/science.284.5418.1301			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383311				2022-12-28	WOS:000080430600036
J	Gaffney, D; Pollock, AM; Price, D; Shaoul, J				Gaffney, D; Pollock, AM; Price, D; Shaoul, J			The private finance initiative - PFI in the NHS - is there an economic case?	BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England; Northumbria Univ, Social Welf Res Unit, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England; Univ Manchester, Dept Accounting, Manchester M13 9PL, Lancs, England	University of London; University College London; Northumbria University; University of Manchester	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				COOK AN, 1996, APPRAISAL FINANCING, P3; FITZPATRICK M, 1999, GLASGOW HERALD  0601; GAFFNEY D, 1998, DOWNSIZING 21 CENTUR; *HM TREAS, 1992, GREEN BVOOK APPR EV; *N DURH AC HOSP NH, SUMM CONTR DOC, P40; *NAT AUD OFF, 1998, COST OV FUND PROBL D; *NHS MAN EX, 1994, CAP INV MAN; Shaoul J, 1999, PUBLIC FINANCE  0129, V14-6; VELLACOTT DFK, 1999, EC REPORT	9	72	73	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					116	119		10.1136/bmj.319.7202.116	http://dx.doi.org/10.1136/bmj.319.7202.116			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398642	Green Published			2022-12-28	WOS:000081438200041
J	Tanner, RES				Tanner, RES			Personal view - Concern, cooperation, and coexistence in healing	BRITISH MEDICAL JOURNAL			English	Editorial Material									E African Inst Social Res, Kampala, Uganda		Tanner, RES (corresponding author), E African Inst Social Res, Kampala, Uganda.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					133	133		10.1136/bmj.319.7202.133	http://dx.doi.org/10.1136/bmj.319.7202.133			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398661	Green Published			2022-12-28	WOS:000081438200069
J	Dawson, DW; Volpert, OV; Gillis, P; Crawford, SE; Xu, HJ; Benedict, W; Bouck, NP				Dawson, DW; Volpert, OV; Gillis, P; Crawford, SE; Xu, HJ; Benedict, W; Bouck, NP			Pigment epithelium-derived factor: A potent inhibitor of angiogenesis	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC ACTIVITY; DIABETIC-RETINOPATHY; FACTOR VEGF; NEOVASCULARIZATION; EXPRESSION; OXYGEN; GENE; BETA; IDENTIFICATION	In the absence of disease, the vasculature of the mammalian eye is quiescent, in part because of the action of angiogenic inhibitors that prevent vessels from invading the cornea and vitreous. Here, an inhibitor responsible for the avascularity of these ocular compartments is identified as pigment epithelium-derived factor (PEDF), a protein previously shown to have neurotrophic activity. The amount of inhibitory PEDF produced by retinal cells was positively correlated with oxygen concentrations, suggesting that its loss plays a permissive role in ischemia-driven retinal neovascularization. These results suggest that PEDF may be of therapeutic use, especially in retinopathies where pathological neovascularization compromises vision and leads to blindness.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bouck, NP (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	n-bouck@nwu.edu	Dawson, David/I-5917-2014	Volpert, Olga/0000-0003-1381-5543				ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; DAWSON D, UNPUB; DIPAOLO BR, 1995, EXP CELL RES, V220, P178, DOI 10.1006/excr.1995.1304; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, MOL BASIS CANC, P206; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gulledge CJ, 1996, ANTICANCER RES, V16, P741; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hayasaka K, 1998, LIFE SCI, V63, P1089, DOI 10.1016/S0024-3205(98)00205-7; HENKIND P, 1978, AM J OPHTHALMOL, V85, P287, DOI 10.1016/S0002-9394(14)77719-0; KAMINSKA GM, 1993, INVEST OPHTH VIS SCI, V34, P222; KLINTWORTH GK, 1991, CORNEAL ANGIOGENESIS; Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; PREIS I, 1977, AM J OPHTHALMOL, V84, P323; Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365; SCHACHAT A, 1994, RETINA; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; TANAWAKI T, 1995, J NEUROCHEM, V64, P2509; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Vinores SA, 1998, J NEUROIMMUNOL, V89, P43, DOI 10.1016/S0165-5728(98)00075-7; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; XU HJ, 1991, CANCER RES, V51, P4481	36	1261	1385	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					245	248		10.1126/science.285.5425.245	http://dx.doi.org/10.1126/science.285.5425.245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398599				2022-12-28	WOS:000081346000039
J	Stramski, D; Reynolds, RA; Kahru, M; Mitchell, BG				Stramski, D; Reynolds, RA; Kahru, M; Mitchell, BG			Estimation of particulate organic carbon in the ocean from satellite remote sensing	SCIENCE			English	Article							OPTICAL-PROPERTIES; LIGHT-SCATTERING; WATERS; PHYTOPLANKTON; INHERENT; NITROGEN; VOLUME; COLOR	Measurements from the Southern Ocean show that particulate organic carbon (POC) concentration is welt correlated with the optical backscattering by particles suspended in seawater. This relation, in conjunction with retrieval of the backscattering coefficient from remote-sensing reflectance, provides an algorithm for estimating surface POC from Satellite data of ocean color. Satellite imagery from SeaWiFS reveals the seasonal progression of POC, with a zonal band of elevated POC concentrations in December coinciding with the Antarctic Polar Front Zone. At that time, the POC pool within the top 100 meters of the entire Southern Ocean south of 40 degrees S exceeded 0.8 gigatons.	Univ Calif San Diego, Scripps Inst Oceanog, Marine Phys Lab, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Res, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California San Diego; Scripps Institution of Oceanography	Stramski, D (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Marine Phys Lab, La Jolla, CA 92093 USA.		Reynolds, Rick A/C-7470-2014	Reynolds, Rick A/0000-0002-1579-3600; Mitchell, B. Greg/0000-0002-8550-4333				Bohren C., 2008, ABSORPTION SCATTERIN; Carder KL, 1999, J GEOPHYS RES-OCEANS, V104, P5403, DOI 10.1029/1998JC900082; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; GARDNER WD, 1993, DEEP-SEA RES PT II, V40, P171, DOI 10.1016/0967-0645(93)90012-C; Garver SA, 1997, J GEOPHYS RES-OCEANS, V102, P18607, DOI 10.1029/96JC03243; GORDON HR, 1975, APPL OPTICS, V14, P417, DOI 10.1364/AO.14.000417; GORDON HR, 1982, J MAR RES, V40, P491; GORDON HR, 1983, APPL OPTICS, V22, P20, DOI 10.1364/AO.22.000020; HOOKER SB, 1992, 104566 NASA, V1; Loisel H, 1998, LIMNOL OCEANOGR, V43, P847, DOI 10.4319/lo.1998.43.5.0847; LONGHURST AR, 1989, PROG OCEANOGR, V22, P47, DOI 10.1016/0079-6611(89)90010-4; Maffione RA, 1997, APPL OPTICS, V36, P6057, DOI 10.1364/AO.36.006057; MARRA J, 1995, J GEOPHYS RES-OCEANS, V100, P6633, DOI 10.1029/94JC01127; Mitchell BG, 1998, CAL COOP OCEAN FISH, V39, P133; Mobley C., 1994, LIGHT WATER RAD TRAN, P60; MONTAGNES DJS, 1994, LIMNOL OCEANOGR, V39, P1044, DOI 10.4319/lo.1994.39.5.1044; MOORE K, 1998, AESOPS DATA SCI WORK, V1, P247; MOREL A, 1977, LIMNOL OCEANOGR, V22, P709, DOI 10.4319/lo.1977.22.4.0709; MOREL A, 1991, J MAR RES, V49, P177, DOI 10.1357/002224091784968639; PREISENDORFER RW, 1961, UNION GEOD GEOPHYS I, V10, P11; STRAMSKI D, 1991, PROG OCEANOGR, V28, P343, DOI 10.1016/0079-6611(91)90032-H; Stramski D, 1999, DEEP-SEA RES PT I, V46, P335, DOI 10.1016/S0967-0637(98)00065-X; STRAMSKI D, 1990, DEEP-SEA RES, V37, P245, DOI 10.1016/0198-0149(90)90126-G; STRAMSKI D, 1993, LIMNOL OCEANOGR, V38, P1347, DOI 10.4319/lo.1993.38.7.1347; Tomczak M., 1994, REGIONAL OCEANOGRAPH, P67, DOI [10.1016/B978-0-08-041021-0.50010-2, DOI 10.1016/B978-0-08-041021-0.50010-2]; VERITY PG, 1992, LIMNOL OCEANOGR, V37, P1434, DOI 10.4319/lo.1992.37.7.1434; Volk T., 1985, GEOPHYS MONOGR SER, V32, P99, DOI DOI 10.1029/GM032P0099	27	206	221	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					239	242		10.1126/science.285.5425.239	http://dx.doi.org/10.1126/science.285.5425.239			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398597				2022-12-28	WOS:000081346000037
J	Haan, MN; Shemanski, L; Jagust, WJ; Manolio, TA; Kuller, L				Haan, MN; Shemanski, L; Jagust, WJ; Manolio, TA; Kuller, L			The role of APOE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E EPSILON-4; DEPENDENT DIABETIC-PATIENTS; ALZHEIMERS-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR HEALTH; E GENOTYPE; POPULATION; DEMENTIA; OLDER; ASSOCIATION	Context Cognitive decline in elderly persons is often an early predictor of dementia. Subclinical cardiovascular disease (CVD) and diabetes mellitus may contribute to substantial decline in cognitive function in the elderly. These risks may be modified by gene-environment interactions between apolipoprotein E (APOE) genotype and CVD risk factors or subclinical CVD. Objectives To examine the association between subclinical CVD and decline in cognitive functioning in the elderly and to examine effect modification by the APOE genotype of the association between subclinical disease and cognitive decline. Design The Cardiovascular Health Study, a population-based, prospective cohort study. Setting and Population A total of 5888 randomly selected Medicare-eligible participants from Sacramento County, California; Forsyth County, North Carolina; Washington County, Maryland; and Pittsburgh, Pa, aged 65 years or older, who were recruited in 1989-1990 (n = 5201) and in 1992-1993 (n = 687) and who were followed up for 7 and 5 years, respectively. Main Outcome Measures Change over time in scores on the Modified Mini-Mental State Examination and the Digit Symbol Substitution Test as a function of APOE genotype, subclinical CVD, and diabetes mellitus. Results Seventy percent of participants had no significant decline on the Modified Mini-Mental State Examination. Systolic blood pressure, the ankle-arm brachial index, atherosclerosis of the internal carotid artery, diabetes mellitus, and several diagnoses of prevalent CVD were significantly associated with declines in scores on the Modified Mini-Mental State Examination and the Digit Symbol Substitution Test. The rate of cognitive decline associated with peripheral vascular disease, atherosclerosis of the common and internal carotid arteries, or diabetes mellitus was increased by the presence of any APOE epsilon 4 allele. Conclusions Most healthy elderly people did not experience cognitive decline. Measures of subclinical CVD were modest predictors of cognitive decline. Those with any APOE epsilon 4 allele in combination with atherosclerosis, peripheral vascular disease, or diabetes mellitus were at substantially higher risk of cognitive decline than those without the APOE epsilon 4 allele or subclinical CVD. High levels of atherosclerosis increased cognitive decline independently of APOE genotype.	Univ Calif Davis, Sch Med, Dept Epidemiol & Prevent Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; NHLBI, Dept Epidemiol, Bethesda, MD 20892 USA; NHLBI, Dept Biometry, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Haan, MN (corresponding author), Univ Calif Davis, Sch Med, Dept Epidemiol & Prevent Med, 1 Shields Ave, Davis, CA 95616 USA.	mnhaan@ucdavis.edu	Jagust, William/ABE-6426-2020; Haan, Mary N/Y-9354-2018	Haan, Mary N/0000-0001-9312-4501	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG033751] Funding Source: NIH RePORTER; NIA NIH HHS [R03 AG033751] Funding Source: Medline; NIDDK NIH HHS [R01 DK060753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen JB, 1996, NEUROPSYCHOLOGIA, V34, P459, DOI 10.1016/0028-3932(95)00115-8; APPLEGATE WB, 1994, ARCH INTERN MED, V154, P2154, DOI 10.1001/archinte.154.19.2154; BERES CA, 1981, J GERONTOL, V36, P591, DOI 10.1093/geronj/36.5.591; Berr C, 1996, NEUROSCI LETT, V218, P9, DOI 10.1016/S0304-3940(96)13059-7; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; Cattin L, 1997, ARTERIOSCL THROM VAS, V17, P91, DOI 10.1161/01.ATV.17.1.91; Chandra V, 1998, NEUROEPIDEMIOLOGY, V17, P225, DOI 10.1159/000026175; Crawford JG, 1998, MED HYPOTHESES, V50, P25, DOI 10.1016/S0306-9877(98)90173-6; Curb JD, 1999, NEUROLOGY, V52, P971, DOI 10.1212/WNL.52.5.971; Dey J, 1997, DIABETES CARE, V20, P32, DOI 10.2337/diacare.20.1.32; Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Finch CE, 1997, EXP NEUROL, V143, P82, DOI 10.1006/exnr.1996.6339; Fujishima M, 1995, Hypertens Res, V18, P111, DOI 10.1291/hypres.18.111; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; Glynn RJ, 1999, JAMA-J AM MED ASSOC, V281, P438, DOI 10.1001/jama.281.5.438; Guo ZC, 1997, AM J PUBLIC HEALTH, V87, P623, DOI 10.2105/AJPH.87.4.623; Heckbert SR, 1997, J AM GERIATR SOC, V45, P1423, DOI 10.1111/j.1532-5415.1997.tb03191.x; Helkala EL, 1996, NEUROSCI LETT, V204, P177, DOI 10.1016/0304-3940(96)12348-X; Hyman BT, 1996, ANN NEUROL, V40, P55, DOI 10.1002/ana.410400111; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/BF00402181; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; KURITA A, 1995, ACTA NEUROL SCAND, V92, P319; Kurita A, 1996, DIABETES CARE, V19, P361, DOI 10.2337/diacare.19.4.361; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Messier C, 1996, BEHAV BRAIN RES, V75, P1, DOI 10.1016/0166-4328(95)00153-0; MOORADIAN AD, 1988, ARCH INTERN MED, V148, P2369, DOI 10.1001/archinte.148.11.2369; MORTEL KF, 1994, ANGIOLOGY, V45, P171, DOI 10.1177/000331979404500301; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; Naor M, 1997, J DIABETES COMPLICAT, V11, P40, DOI 10.1016/1056-8727(95)00106-9; O'Hara R, 1998, J AM GERIATR SOC, V46, P1493, DOI 10.1111/j.1532-5415.1998.tb01532.x; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PEREZMUNOZ M, 1995, ACTAS LUSO ESPANOLES, V24, P332; Perlmuter L C, 1988, J Diabet Complications, V2, P210, DOI 10.1016/S0891-6632(88)80011-4; Phillips NA, 1997, STROKE, V28, P777, DOI 10.1161/01.STR.28.4.777; Price T R, 1993, Ann Epidemiol, V3, P504; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; REAVEN GM, 1990, DIABETES CARE, V13, P16, DOI 10.2337/diacare.13.1.16; ROSES AD, 1977, INT PSYCHOLOGERIA S1, V9, P277; RYAN CM, 1993, J CLIN EXP NEUROPSYC, V15, P685, DOI 10.1080/01688639308402589; *SAS I INC, 1999, SAS STAT COMP PROGR; Skoog I, 1998, J NEUROL NEUROSUR PS, V64, P37, DOI 10.1136/jnnp.64.1.37; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Slooter AJC, 1998, ARCH NEUROL-CHICAGO, V55, P964, DOI 10.1001/archneur.55.7.964; Small BJ, 1998, PSYCHOL AGING, V13, P80, DOI 10.1037/0882-7974.13.1.80; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tun P A, 1990, Clin Geriatr Med, V6, P731; UREN RC, 1990, J AM GERIATR SOC, V38, P505, DOI 10.1111/j.1532-5415.1990.tb02398.x; WORRALL G, 1993, J FAM PRACTICE, V36, P639; Worrall GJ, 1996, J DIABETES COMPLICAT, V10, P320, DOI 10.1016/1056-8727(94)00078-6	59	365	371	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					40	46		10.1001/jama.282.1.40	http://dx.doi.org/10.1001/jama.282.1.40			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	212BE	10404910				2022-12-28	WOS:000081195800027
J	Hollenberg, SM; Kavinsky, CJ; Parrillo, JE				Hollenberg, SM; Kavinsky, CJ; Parrillo, JE			Cardiogenic shock	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; RIGHT-VENTRICULAR INFARCTION; INTRAAORTIC BALLOON COUNTERPULSATION; CONGESTIVE-HEART-FAILURE; TISSUE-PLASMINOGEN-ACTIVATOR; RANDOMIZED PROSPECTIVE TRIAL; BYPASS GRAFT-SURGERY; LONG-TERM SURVIVAL; GUSTO-I TRIAL	Purpose: To review the cause, epidemiology, pathophysiology, and treatment of cardiogenic shock. Data Sources: A MEDLINE search of the English-language reports published between 1976 and 1998 and a manual search of bibliographies of relevant papers. Study Selection: Experimental, clinical, and basic research studies related to cardiogenic shock. Data Extraction: Data in selected articles were reviewed, and relevant clinical information was extracted. Data Synthesis: Cardiogenic shock is a state of inadequate tissue perfusion due to cardiac dysfunction, most commonly caused by acute myocardial infarction. Mortality rates for patients with cardiogenic shock remain frustratingly high, ranging from 50% to 80%. The pathophysiology of cardiogenic shock involves a downward spiral: Ischemia causes myocardial dysfunction, which, in turn, worsens ischemia. Areas of nonfunctional but viable (stunned or hibernating) myocardium can also contribute to the development of cardiogenic shock. The key to achieving a good outcome is an organized approach that includes rapid diagnosis and prompt initiation of therapy to maintain blood pressure and cardiac output. Expeditious coronary revascularization is crucial. When available, emergency cardiac catheterization and angioplasty seem to improve survival. More recent developments, such as placement of coronary stents and use of glycoprotein IIb/IIIa antagonists, are promising but have not yet been well studied in patients with cardiogenic shock, in hospitals without direct angioplasty capability, stabilization with intra-aortic balloon counterpulsation and thrombolysis followed by transfer to a tertiary care facility may be the best option. Conclusions: Improved understanding of the pathophysiology of shock and myocardial infarction has led to improved treatment. If cardiogenic shock is managed with rapid evaluation and prompt initiation of supportive measures and definitive therapy, outcomes can be improved.	Rush Presbyterian St Lukes Med Ctr, Cardiol Sect, Chicago, IL 60612 USA	Rush University	Hollenberg, SM (corresponding author), Rush Presbyterian St Lukes Med Ctr, Cardiol Sect, 1725 W Harrison St,Suite 1159, Chicago, IL 60612 USA.		Hollenberg, Steven/AAR-4522-2020	Hollenberg, Steven/0000-0003-1293-8496				Anderson RD, 1997, J AM COLL CARDIOL, V30, P708, DOI 10.1016/S0735-1097(97)00227-1; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; ANSELL J, 1984, ARCH INTERN MED, V144, P949, DOI 10.1001/archinte.144.5.949; Antoniucci D, 1998, J AM COLL CARDIOL, V31, P294, DOI 10.1016/S0735-1097(97)00496-8; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ARNOLD JMO, 1985, J AM COLL CARDIOL, V6, P1026, DOI 10.1016/S0735-1097(85)80305-3; ATAR D, 1995, J MOL CELL CARDIOL, V27, P783, DOI 10.1016/0022-2828(95)90085-3; BALLANTYNE CM, 1987, J AM COLL CARDIOL, V10, P710, DOI 10.1016/S0735-1097(87)80216-4; BARRY WH, 1994, CIRCULATION, V89, P2421, DOI 10.1161/01.CIR.89.5.2421; Bartling B, 1998, BASIC RES CARDIOL, V93, P71, DOI 10.1007/s003950050065; Bates ER, 1998, INT J CARDIOL, V65, pS37, DOI 10.1016/S0167-5273(98)00049-7; BATES ER, 1998, CARDIAC INTENSIVE CA, P215; BECKER RC, 1993, AM HEART J, V125, P919, DOI 10.1016/0002-8703(93)90199-J; BENGTSON JR, 1992, J AM COLL CARDIOL, V20, P1482, DOI 10.1016/0735-1097(92)90440-X; BENOTTI JR, 1980, CIRCULATION, V62, P28, DOI 10.1161/01.CIR.62.1.28; BENOTTI JR, 1978, NEW ENGL J MED, V299, P1373, DOI 10.1056/NEJM197812212992501; Berger PB, 1997, CIRCULATION, V96, P122; Berger PB, 1999, CIRCULATION, V99, P873, DOI 10.1161/01.CIR.99.7.873; BOLLI R, 1992, CIRCULATION, V86, P1671, DOI 10.1161/01.CIR.86.6.1671; Bolli R, 1998, PROG CARDIOVASC DIS, V40, P477, DOI 10.1016/S0033-0620(98)80001-7; BOLOOKI H, 1989, CIRCULATION, V79, P137; BONOW RO, 1995, AM J CARDIOL, V75, pA17, DOI 10.1016/S0002-9149(99)80379-8; Bowers TR, 1998, NEW ENGL J MED, V338, P933, DOI 10.1056/NEJM199804023381401; Brar Rupinder, 1996, Journal of the American College of Cardiology, V27, p386A; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODIE BR, 1991, AM J CARDIOL, V67, P7, DOI 10.1016/0002-9149(91)90090-8; CALIFF RM, 1994, NEW ENGL J MED, V330, P1724, DOI 10.1056/NEJM199406163302406; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHAMBERLAIN DA, 1988, LANCET, V1, P545; Chaux A, 1998, Semin Thorac Cardiovasc Surg, V10, P93; COHN JN, 1979, ANN INTERN MED, V91, P752, DOI 10.7326/0003-4819-91-5-752; COL NF, 1994, AM J CARDIOL, V73, P149, DOI 10.1016/0002-9149(94)90206-2; DELLITALIA LJ, 1985, CIRCULATION, V72, P1327, DOI 10.1161/01.CIR.72.6.1327; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; DISLER L, 1987, HEART LUNG, V16, P649; ELTCHANINOFF H, 1995, AM HEART J, V130, P459, DOI 10.1016/0002-8703(95)90352-6; Fauci AS, 1998, HARRISONS PRINCIPLES, P214; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FLAHERTY JT, 1983, CIRCULATION, V68, P576, DOI 10.1161/01.CIR.68.3.576; FLAHERTY JT, 1985, J AM COLL CARDIOL, V6, P434, DOI 10.1016/S0735-1097(85)80183-2; FORRESTER JS, 1976, NEW ENGL J MED, V295, P1404, DOI 10.1056/NEJM197612162952505; GACIOCH GM, 1992, J AM COLL CARDIOL, V19, P647, DOI 10.1016/S0735-1097(10)80286-4; GAGE J, 1986, CIRCULATION, V74, P367, DOI 10.1161/01.CIR.74.2.367; GARBER PJ, 1995, CAN J CARDIOL, V11, P30; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GILLESPIE TA, 1977, AM J CARDIOL, V39, P588, DOI 10.1016/S0002-9149(77)80170-7; GOLDBERG LI, 1977, PROG CARDIOVASC DIS, V19, P327, DOI 10.1016/0033-0620(77)90007-X; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GREENBERG MA, 1989, J AM COLL CARDIOL, V13, P1071, DOI 10.1016/0735-1097(89)90262-3; Grines CL, 1996, AM J CARDIOL, V78, P29, DOI 10.1016/S0002-9149(96)00491-2; GRINES CL, 1989, CIRCULATION, V80, P245, DOI 10.1161/01.CIR.80.2.245; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Gunnar R M, 1990, Circulation, V82, P664; HANDS ME, 1989, J AM COLL CARDIOL, V14, P40, DOI 10.1016/0735-1097(89)90051-X; HANSEN RM, 1986, ANESTHESIOLOGY, V64, P764, DOI 10.1097/00000542-198606000-00015; HARIZI RC, 1988, ARCH INTERN MED, V148, P99, DOI 10.1001/archinte.148.1.99; HEUSER RR, 1986, J AM COLL CARDIOL, V7, pA219; HIBBARD MD, 1992, J AM COLL CARDIOL, V19, P639, DOI 10.1016/S0735-1097(10)80285-2; HOCHMAN J, 1998, CARDIOGENIC SHOCK AN; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; HOCHMAN JS, 1999, SHOULD WE EMERGENTLY; Hollenberg S M, 1997, New Horiz, V5, P207; Hollenberg SM, 1997, J HEART LUNG TRANSPL, V16, pS7; HOLLENBERG SM, 1993, SURG INTENSIVE CARE, P417; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; HOLZER J, 1973, AM J CARDIOL, V32, P79, DOI 10.1016/S0002-9149(73)80088-8; HUNT D, 1992, LANCET, V339, P753; Hunt SA, 1998, CIRCULATION, V97, P2079, DOI 10.1161/01.CIR.97.20.2079; ISHIHARA M, 1991, AM HEART J, V122, P385, DOI 10.1016/0002-8703(91)90990-Y; JASKI BE, 1985, J CLIN INVEST, V75, P643, DOI 10.1172/JCI111742; JEROUDI MO, 1994, AM J CARDIOL, V73, pB2, DOI 10.1016/0002-9149(94)90257-7; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KAPLAN AJ, 1990, J AM COLL CARDIOL, V15, P155; KENNEDY JW, 1985, AM J CARDIOL, V55, P871, DOI 10.1016/0002-9149(85)90709-X; KERN MJ, 1993, CIRCULATION, V87, P500, DOI 10.1161/01.CIR.87.2.500; KEUNG ECH, 1981, JAMA-J AM MED ASSOC, V245, P144, DOI 10.1001/jama.245.2.144; KHAN S S, 1991, Cardiology Clinics, V9, P689; Killen DA, 1997, ANN THORAC SURG, V63, P138; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KINCH JW, 1994, NEW ENGL J MED, V330, P1211, DOI 10.1056/NEJM199404283301707; KLONER RA, 1991, ANNU REV MED, V42, P1; Kovack PJ, 1997, J AM COLL CARDIOL, V29, P1454, DOI 10.1016/S0735-1097(97)82537-5; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; LAKS H, 1986, CIRCULATION 2, V74; Landerholm E, 1988, LIFELONG LEARNING, V11, P11; Laney Phillip L., 1993, Journal of the American College of Cardiology, V21, p77A; LANGE LG, 1994, NEW ENGL J MED, V330, P1129; LARAMEE LA, 1988, CIRCULATION S2, V78, P634; LEE L, 1991, J AM COLL CARDIOL, V17, P599, DOI 10.1016/S0735-1097(10)80171-8; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEOR J, 1993, AM J MED, V94, P265, DOI 10.1016/0002-9343(93)90058-W; MARBAN E, 1991, CIRCULATION, V83, P681, DOI 10.1161/01.CIR.83.2.681; Matsuwaka R, 1996, HEART VESSELS, V11, P27, DOI 10.1007/BF01744596; MCGHIE AL, 1992, CHEST S2, V102, P6265; MEYER P, 1990, ARCH MAL COEUR VAISS, V83, P329; MILLARD RW, 1980, J MOL CELL CARDIOL, V12, P647, DOI 10.1016/0022-2828(80)90022-X; MOOSVI AR, 1992, J AM COLL CARDIOL, V19, P907, DOI 10.1016/0735-1097(92)90269-S; MORRISON D, 1995, AM J CARDIOL, V76, P313, DOI 10.1016/S0002-9149(99)80090-3; MOYER JH, 1953, AM J MED, V15, P330, DOI 10.1016/0002-9343(53)90087-4; MUELLER H, 1972, CIRCULATION, V45, P335, DOI 10.1161/01.CIR.45.2.335; NISHIMURA RA, 1984, J AM COLL CARDIOL, V4, P1080, DOI 10.1016/S0735-1097(84)80125-4; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; ONEILL W, 1985, CIRCULATION, V72, P309; OROURKE MF, 1981, AM J CARDIOL, V47, P815, DOI 10.1016/0002-9149(81)90179-X; PAGE DL, 1971, NEW ENGL J MED, V285, P133, DOI 10.1056/NEJM197107152850301; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PREWITT RM, 1992, J AM COLL CARDIOL, V20, P1626, DOI 10.1016/0735-1097(92)90459-Z; Reardon MJ, 1997, ANN THORAC SURG, V64, P1509, DOI 10.1016/S0003-4975(97)00776-5; RICHARD C, 1983, CIRCULATION, V67, P620, DOI 10.1161/01.CIR.67.3.620; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SCHEIDT S, 1970, AM J CARDIOL, V26, P556, DOI 10.1016/0002-9149(70)90407-8; Schomig A, 1997, J AM COLL CARDIOL, V29, P28, DOI 10.1016/S0735-1097(96)00450-0; Schultz RD, 1996, CATHETER CARDIO DIAG, V39, P143, DOI 10.1002/(SICI)1097-0304(199610)39:2<143::AID-CCD7>3.0.CO;2-F; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SEYDOUX C, 1992, AM J CARDIOL, V69, P968, DOI 10.1016/0002-9149(92)90804-8; SHANI J, 1986, J AM COLL CARDIOL, V7, pA149; Stauffer JC, 1997, CIRCULATION S1, V96, P1; STOMEL RJ, 1994, CHEST, V105, P997, DOI 10.1378/chest.105.4.997; Stone GW, 1998, J AM COLL CARDIOL, V31, P23, DOI 10.1016/S0735-1097(97)00439-7; SUBRAMANIAN VA, 1980, NEW YORK STATE J MED, V80, P947; Tcheng JE, 1996, AM J CARDIOL, V78, P35, DOI 10.1016/S0002-9149(96)00490-0; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1984, J AM COLL CARDIOL, V4, P1123, DOI 10.1016/S0735-1097(84)80131-X; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; TUTTLE RR, 1975, CIRC RES, V36, P185, DOI 10.1161/01.RES.36.1.185; VANDEWERF F, 1990, LANCET, V336, P71; VERNA E, 1989, EUR HEART J, V10, P958, DOI 10.1093/oxfordjournals.eurheartj.a059420; VOCI P, 1995, CIRCULATION, V91, P1714, DOI 10.1161/01.CIR.91.6.1714; Vogt A, 1998, EUR HEART J, V19, P917, DOI 10.1053/euhj.1997.0835; WAKSMAN R, 1993, EUR HEART J, V14, P71, DOI 10.1093/eurheartj/14.1.71; Webb JG, 1998, CAN J CARDIOL, V14, P233; Webb JG, 1997, AM J CARDIOL, V79, P81, DOI 10.1016/S0002-9149(96)00683-2; WEISMAN HF, 1987, PROG CARDIOVASC DIS, V30, P73, DOI 10.1016/0033-0620(87)90004-1; WIDIMSKY P, 1988, COR VASA, V30, P27; Wijns W, 1998, NEW ENGL J MED, V339, P173, DOI 10.1056/NEJM199807163390307; WILCOX RG, 1988, LANCET, V2, P525; WILLERSON JT, 1975, AM J MED, V58, P183, DOI 10.1016/0002-9343(75)90568-9; YAMAMOTO H, 1992, JPN CIRC J, V56, P815, DOI 10.1253/jcj.56.815; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	143	172	187	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					47	59		10.7326/0003-4819-131-1-199907060-00010	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391815				2022-12-28	WOS:000081345200008
J	Heaney, LG; McAllister, D; MacMahon, J				Heaney, LG; McAllister, D; MacMahon, J			Cost minimisation analysis of provision of oxygen at home: Are the Drug Tariff guidelines cost effective?	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the level of oxygen cylinder use at which it becomes more cost effective to provide oxygen by concentrator at home in Northern Ireland, and to examine potential cost savings if cylinder use above this level had been replaced by concentrator in 1996. Design Cost minimisation analysis. Setting Area health boards in Northern Ireland. Main outcome measures Cost effective cut off point for switch to provision of oxygen from cylinder to concentrator. Potential maximum and minimum savings in Northern Ireland (sensitivity analysis) owing to switch to more cost effective strategy on the basis of provision of cylinders in 1996. Results In Northern Ireland it is currently cost effective to provide oxygen by concentrator when the patient is using three or more cylinders per month independent of the duration of the prescription. More widespread use of concentrators at this level of provision is likely to lead to a cost saving. Conclusions The Drug Tariff prescribing guidelines, advocating that provision of oxygen by concentrator becomes cheaper when 21 cylinders are being used per month-are currently inaccurate in Northern Ireland, Regional health authorities should review their current arrangements for provision of oxygen at home and perform a cost analysis to determine at what level it becomes more cost effective to provide oxygen by concentrator.	Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland; Univ Ulster, Sch Publ Policy & Law, Jordanstown, North Ireland	Belfast City Hospital; Ulster University	Heaney, LG (corresponding author), Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland.	LiamHeaney@ukgateway.net						[Anonymous], 1980, ANN INTERN MED, V93, P391; *DEP HLTH, 1996, DRUG TAR 10; Drummond MF, 2015, METHODS EC EVALUATIO; FLENLEY DC, 1981, LANCET, V1, P681; Rees P. J., 1998, BMJ, V317, P935	5	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					19	23		10.1136/bmj.319.7201.19	http://dx.doi.org/10.1136/bmj.319.7201.19			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390453	Bronze, Green Published			2022-12-28	WOS:000081326500024
J	Short, A; Cumming, A				Short, A; Cumming, A			ABC of intensive care - Renal support	BRITISH MEDICAL JOURNAL			English	Article																			0	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					41	44		10.1136/bmj.319.7201.41	http://dx.doi.org/10.1136/bmj.319.7201.41			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390462	Green Published			2022-12-28	WOS:000081326500035
J	Allan, RB; Balch, WE				Allan, RB; Balch, WE			Cell biology - Protein sorting by directed maturation of Golgi compartments	SCIENCE			English	Review							RETINAL-PIGMENT EPITHELIUM; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; BREFELDIN-A; INTRACELLULAR-TRANSPORT; GUANINE-NUCLEOTIDE; SECRETORY PATHWAY; MEMBRANE-FUSION; PLASMA-MEMBRANE; MAMMALIAN-CELLS	How does the Golgi stack mediate transport of cargo from the endoplasmic reticulum (ER) to the cell surface? A possibility is that cargo-containing vesicles derived from the ER form early Golgi compartments that then mature by retrieval of processing enzymes from later Golgi compartments. Maturation continues at terminal Golgi compartments by retrieval of transport components from the endocytic pathway to promote sorting of cargo to multiple cellular destinations; Hence, retrograde movement may integrate exocytic and endocytic pathways in eukaryotic cells and coordinate membrane flow and cargo transport through the Golgi stack.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM 33301, GM 42336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033301, R01GM042336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; DASCHER C, 1994, J BIOL CHEM, V269, P1437; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Gaynor EC, 1998, BBA-MOL CELL RES, V1404, P33, DOI 10.1016/S0167-4889(98)00045-7; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; GRASSE MP, 1957, CR HEBD ACAD SCI, V245, P1278; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARRIS SL, 1996, J CELL BIOL, V132, P982; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOE MH, 1995, J BIOL CHEM, V270, P25057, DOI 10.1074/jbc.270.42.25057; Holthuis JCM, 1998, MOL BIOL CELL, V9, P3383, DOI 10.1091/mbc.9.12.3383; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Keller P, 1997, J CELL SCI, V110, P3001; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Klumperman J, 1998, J CELL SCI, V111, P3411; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; LeBorgne R, 1997, J CELL BIOL, V137, P335; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Lord JM, 1998, J CELL BIOL, V140, P733; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Marmorstein AD, 1998, J CELL BIOL, V142, P697, DOI 10.1083/jcb.142.3.697; Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x; MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Mironov AA, 1997, J CELL BIOL, V138, P481, DOI 10.1083/jcb.138.3.481; MORRE D J, 1974, P107; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; NILSSON T, COMMUNICATION; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; Pelham HRB, 1998, TRENDS CELL BIOL, V8, P45, DOI 10.1016/S0962-8924(97)01185-9; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	83	104	104	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					63	66		10.1126/science.285.5424.63	http://dx.doi.org/10.1126/science.285.5424.63			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390362				2022-12-28	WOS:000081199800029
J	Cacciola, I; Pollicino, T; Squadrito, G; Cerenzia, G; Orlando, ME; Raimondo, G				Cacciola, I; Pollicino, T; Squadrito, G; Cerenzia, G; Orlando, ME; Raimondo, G			Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; POSITIVE PATIENTS; CHRONIC CARRIERS; DNA; REACTIVATION; REPLICATION; HBSAG; GENE; TRANSPLANTATION	Background Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known. Methods With the polymerase chain reaction, we searched for HBV DNA in liver and serum samples from 200 HBsAg-negative patients with hepatitis C virus (HCV)-related liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). One hundred of the patients had detectable antibodies to the HBV core antigen (anti-HBc); 100 were negative for all HBV markers. Eighty-three were treated with interferon alfa. We also studied 50 patients with liver disease who were negative both for HBsAg and for HCV markers. In six patients found to have occult HBV infection, we evaluated possible genomic rearrangements through cloning or direct sequencing procedures. Results Sixty-six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C (14 percent, P = 0.01). Among the 66 patients, 46 were anti-HBc-positive and 20 were negative for all HBV markers (P<0.001). Twenty-two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent, P = 0.04). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective (P = 0.06). None of the sequenced HBV genomes had changes known to interfere with viral activity and gene expression. Conclusions Occult hepatitis B infection occurs frequently in patients with chronic hepatitis C liver disease and may have clinical significance. (N Engl J Med 1999;341:22-6.) (C)1999, Massachusetts Medical Society.	Univ Messina, Policlin Univ, Dipartimento Med Interna, I-98100 Messina, Italy	AOU Policlinico Gaetano Martino; University of Messina	Raimondo, G (corresponding author), Univ Messina, Policlin Univ, Dipartimento Med Interna, I-98100 Messina, Italy.		Pollicino, Teresa/K-5790-2016; Cacciola, Irene/K-1174-2019; Pollicino, Teresa/HDN-3708-2022	Pollicino, Teresa/0000-0001-6602-3035; Cacciola, Irene/0000-0001-7721-6799; 				ALBERTI A, 1995, J HEPATOL, V22, P38; Armitage P., 2001, STAT METHODS MED RES; BLUM HE, 1991, J VIROL, V65, P1836, DOI 10.1128/JVI.65.4.1836-1842.1991; BRECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P3906, DOI 10.1073/pnas.78.6.3906; Brunetto MR, 1998, LANCET, V351, P1535; Carman WF, 1997, HEPATOLOGY, V26, P1658, DOI 10.1002/hep.510260640; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; CRESPO J, 1994, AM J GASTROENTEROL, V89, P1147; FATTOVICH G, 1991, J INFECT DIS, V163, P400, DOI 10.1093/infdis/163.2.400; FERAY C, 1992, J CLIN INVEST, V89, P1361, DOI 10.1172/JCI115723; GROTZINGER T, 1992, VIROLOGY, V187, P383, DOI 10.1016/0042-6822(92)90332-J; GRUMAYER ER, 1989, J HEPATOL, V8, P232, DOI 10.1016/0168-8278(89)90012-3; HOOFNAGLE JH, 1982, ANN INTERN MED, V96, P447, DOI 10.7326/0003-4819-96-4-447; Huo TI, 1998, HEPATOLOGY, V28, P231, DOI 10.1002/hep.510280130; Koike K, 1998, J MED VIROL, V54, P249, DOI 10.1002/(SICI)1096-9071(199804)54:4&lt;249::AID-JMV3&gt;3.0.CO;2-4; KORBA BE, 1989, HEPATOLOGY, V9, P461, DOI 10.1002/hep.1840090321; LIANG TJ, 1991, HEPATOLOGY, V13, P1044, DOI 10.1002/hep.1840130607; LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; MARCELLIN P, 1991, GASTROENTEROLOGY, V100, P1432; MARION PL, 1991, MOL BIOL HEPATITIS B, P39; MICHALAK TI, 1994, J CLIN INVEST, V93, P230, DOI 10.1172/JCI116950; MICHALAK TI, 1994, J CLIN INVEST, V94, pA905; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; PATERLINI P, 1990, NEW ENGL J MED, V323, P80, DOI 10.1056/NEJM199007123230202; Penna A, 1996, J CLIN INVEST, V98, P1185, DOI 10.1172/JCI118902; Pollicino T, 1997, HEPATOLOGY, V26, P495, DOI 10.1002/hep.510260235; Pollicino T, 1996, J GEN VIROL, V77, P1833, DOI 10.1099/0022-1317-77-8-1833; POLLICINO T, 1995, VIROLOGY, V208, P672, DOI 10.1006/viro.1995.1198; SATO S, 1994, J HEPATOL, V21, P159, DOI 10.1016/S0168-8278(05)80389-7; Schepis F, 1997, J HEPATOL, V26, P765, DOI 10.1016/S0168-8278(97)80240-1; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; SHEEN IS, 1992, J INFECT DIS, V165, P831, DOI 10.1093/infdis/165.5.831; SHEU JC, 1992, GASTROENTEROLOGY, V103, P1322, DOI 10.1016/0016-5085(92)91523-7; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Siegel S., 1998, NONPARAMETRIC STAT B; THIERS V, 1988, LANCET, V2, P1273; VILLA E, 1993, LANCET, V341, P1413, DOI 10.1016/0140-6736(93)90980-U; VILLARI D, 1989, J CLIN PATHOL, V42, P689, DOI 10.1136/jcp.42.7.689; WAITE J, 1988, AIDS, V2, P443, DOI 10.1097/00002030-198812000-00006; YAMAMOTO K, 1994, J VIROL, V68, P2671, DOI 10.1128/JVI.68.4.2671-2676.1994; Yotsuyanagi H, 1998, HEPATOLOGY, V27, P1377, DOI 10.1002/hep.510270526; Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0; ZHANG YY, 1993, HEPATOLOGY, V17, P538, DOI 10.1002/hep.1840170403; Zignego AL, 1997, J MED VIROL, V51, P313, DOI 10.1002/(SICI)1096-9071(199704)51:4&lt;313::AID-JMV9&gt;3.0.CO;2-8	46	517	544	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					22	26		10.1056/NEJM199907013410104	http://dx.doi.org/10.1056/NEJM199907013410104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387938				2022-12-28	WOS:000081195600004
J	Gilon, D; Buonanno, FS; Joffe, MM; Leavitt, M; Marshall, JE; Kistler, JP; Levine, RA				Gilon, D; Buonanno, FS; Joffe, MM; Leavitt, M; Marshall, JE; Kistler, JP; Levine, RA			Lack of evidence of an association between mitral-valve prolapse and stroke in young patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL ISCHEMIC EVENTS; LEAFLET PROLAPSE; EMBOLIC STROKE; RISK-FACTORS; PREVALENCE; DIAGNOSIS; CLASSIFICATION; REGURGITATION; POPULATION	Background Previous studies have reported a high prevalence of mitral-valve prolapse among patients with embolic stroke (28 to 40 percent), especially among young patients (those less than or equal to 45 years old); this finding has practical implications for prophylaxis. However, diagnostic criteria for prolapse have changed and are now based on three-dimensional analysis of the shape of the valve; use of the current criteria reduces markedly the frequency of such a diagnosis and increases its specificity. Previously described complications must therefore be reconsidered. Methods In a case-control study, we reviewed data on 213 consecutive patients 45 years of age or younger with documented ischemic stroke or transient ischemic attack between 1985 and 1995; they underwent complete neurologic and echocardiographic evaluations. The prevalence of prolapse in these patients was compared with that in 263 control subjects without known heart disease, who were referred to our institution for assessment of ventricular function before receiving chemotherapy. Results Mitral-valve prolapse was present in 4 of the 213 young patients with stroke (1.9 percent), as compared with 7 of the 263 controls (2.7 percent); prolapse was present in 2 of 71 patients (2.8 percent) with otherwise unexplained stroke. The crude odds ratio for mitral-valve prolapse among the patients who had strokes, as compared with those who did not have strokes, was 0.70 (95 percent confidence interval, 0.15 to 2.80; P = 0.80); after adjustment for age and sex, the odds ratio was 0.59 (95 percent confidence interval, 0.12 to 2.50; P = 0.62). Conclusions Mitral-valve prolapse is considerably less common than previously reported among young patients with stroke or transient ischemic attack, including unexplained stroke, and no more common than among controls. Using more specific and currently accepted echocardiographic criteria, therefore, we could not demonstrate an association between the presence of mitral-valve prolapse and acute ischemic neurologic events in young people. (N Engl J Med 1999;341:8-13.) (C)1999, Massachusetts Medical Society.	Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Stroke Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Levine, RA (corresponding author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, VBK-508,32 Fruit St, Boston, MA 02114 USA.				NHLBI NIH HHS [HL53702, HL38176] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053702, R29HL038176, R01HL038176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARLETTA G A, 1984, Journal of Cardiovascular Ultrasonography, V3, P147; BARNETT HJM, 1980, NEW ENGL J MED, V302, P139, DOI 10.1056/NEJM198001173020303; BOUGHNER DR, 1985, STROKE, V16, P175, DOI 10.1161/01.STR.16.2.175; BRAUNWALD E, 1992, HEART DIS TXB CARDIO, V2, P1029; BUSCH EH, 1986, CHEST, V90, P454, DOI 10.1378/chest.90.3.454; DEBONO DP, 1981, LANCET, V1, P343; DEVEREUX RB, 1987, AM HEART J, V113, P1265, DOI 10.1016/0002-8703(87)90955-0; EGEBLAD H, 1984, ACTA MED SCAND, V216, P385; EGEBLAD H, 1987, AM HEART J, V114, P648, DOI 10.1016/0002-8703(87)90765-4; Freed LA, 1999, NEW ENGL J MED, V341, P1, DOI 10.1056/NEJM199907013410101; Gross C M, 1989, J Am Soc Echocardiogr, V2, P94; HECK AF, 1989, ANGIOLOGY, V40, P743, DOI 10.1177/000331978904000810; JONES HR, 1982, STROKE, V13, P451, DOI 10.1161/01.STR.13.4.451; KELLEY RE, 1988, STROKE, V19, P443, DOI 10.1161/01.STR.19.4.443; KISTLER JP, 1994, NEW ENGL J MED, V331, P1517, DOI 10.1056/NEJM199412013312211; KISTLER JP, 1994, HARRISONS PRINCIPLES, P2233; KOUVARAS G, 1985, Q J MED, V56, P387; KRIWISKY M, 1987, AM J CARDIOL, V59, P1149, DOI 10.1016/0002-9149(87)90864-2; LEVINE RA, 1989, CIRCULATION, V80, P589, DOI 10.1161/01.CIR.80.3.589; LEVINE RA, 1988, J AM COLL CARDIOL, V11, P1010, DOI 10.1016/S0735-1097(98)90059-6; LEVY D, 1987, AM HEART J, V113, P1281, DOI 10.1016/0002-8703(87)90956-2; MARKIEWICZ W, 1978, AM HEART J, V96, P555, DOI 10.1016/0002-8703(78)90172-2; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; NIDORF SM, 1993, J AM SOC ECHOCARDIOG, V6, pS8; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P1305, DOI 10.1056/NEJM198511213132101; PERLOFF JK, 1982, NEW ENGL J MED, V307, P369, DOI 10.1056/NEJM198208053070609; PERLOFF JK, 1989, CIRCULATION, V80, P710, DOI 10.1161/01.CIR.80.3.710; PETTY GW, 1994, MAYO CLIN PROC, V69, P632, DOI 10.1016/S0025-6196(12)61338-X; RANGANATHAN N, 1973, CIRCULATION, V48, P514, DOI 10.1161/01.CIR.48.3.514; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; ROTHROCK J, 1993, NEUROLOGY, V43, P2473, DOI 10.1212/WNL.43.12.2473; SAHN DJ, 1977, AM J CARDIOL, V39, P422, DOI 10.1016/S0002-9149(77)80100-8; SANDOK BA, 1982, STROKE, V13, P448, DOI 10.1161/01.STR.13.4.448; SCHARF RE, 1982, STROKE, V13, P454, DOI 10.1161/01.STR.13.4.454; THARAKAN J, 1982, ACTA NEUROL SCAND, V66, P295; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WARTH DC, 1985, J AM COLL CARDIOL, V5, P1173, DOI 10.1016/S0735-1097(85)80021-8; WILSON LA, 1977, BRIT MED J, V2, P86, DOI 10.1136/bmj.2.6079.86; WOLF PA, 1983, STROKE, V14, P1010, DOI 10.1161/01.STR.14.6.1010; WOOLEY CF, 1988, MITRAL VALVE PROLAPS, P149	40	96	99	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					8	13		10.1056/NEJM199907013410102	http://dx.doi.org/10.1056/NEJM199907013410102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387936				2022-12-28	WOS:000081195600002
J	Heeb, P; Werner, I; Mateman, AC; Kolliker, M; Brinkhof, MWG; Lessells, CM; Richner, H				Heeb, P; Werner, I; Mateman, AC; Kolliker, M; Brinkhof, MWG; Lessells, CM; Richner, H			Ectoparasite infestation and sex-biased local recruitment of hosts	NATURE			English	Article							GREAT-TITS; NATAL DISPERSAL; PARUS-MAJOR; BIRDS; PHILOPATRY; COMPETITION; ADAPTATION; EVOLUTION; SURVIVAL; SYSTEMS	Dispersal patterns of organisms are a fundamental aspect of their ecology, modifying the genetic and social structure of local populations(1-4). Parasites reduce the reproductive success and survival of hosts and thereby exert selection pressure on host life-history traits(4-6), possibly affecting host dispersal(7-9). Here we test experimentally whether infestation by hen fleas, Ceratophyllus gallinae, affects sex-related recruitment of great tit, Parus major, fledglings. Using sex-specific DNA markers, we show that flea infestation led to a higher proportion of male fledglings recruiting in the local population in one year. In infested broods, the proportion of male recruits increased with brood size over a three year period, whereas the proportion of male recruits from uninfested broods decreased with brood size. Natal dispersal distances of recruits from infested nests were shorter than those from uninfested nests(10). To our knowledge, this study provides the first evidence for parasite-mediated host natal dispersal and local recruitment in relation to sex. Current theory needs to consider parasites as potentially important factors shaping life-history traits associated with host dispersal.	Univ Bern, Dept Zool, Ctr Behav & Evolut, CH-3032 Hinterkappelen, Switzerland; Netherlands Inst Ecol, NL-6666 ZG Heteren, Netherlands	University of Bern; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Heeb, P (corresponding author), Univ Bern, Dept Zool, Ctr Behav & Evolut, CH-3032 Hinterkappelen, Switzerland.	philipp.heeb@esh.unibe.ch	Mateman, Christa/C-9380-2012; Richner, Heinz/B-1659-2008; Lessells, C.M./B-3891-2011	Mateman, Christa/0000-0002-9832-5780; Richner, Heinz/0000-0001-7390-0526; van der Heijden, Marianne/0000-0002-0795-3619; Brinkhof, Martin/0000-0002-9319-665X				Belthoff JR, 1998, ANIM BEHAV, V55, P405, DOI 10.1006/anbe.1997.0625; Brown CR, 1995, P ROY SOC B-BIOL SCI, V262, P313, DOI 10.1098/rspb.1995.0211; BROWN CR, 1992, ECOLOGY, V73, P1718, DOI 10.2307/1940023; Christe P, 1996, BEHAV ECOL, V7, P127, DOI 10.1093/beheco/7.2.127; Clarke AL, 1997, OIKOS, V79, P429, DOI 10.2307/3546885; CLAYTON DH, 1997, HOST PARASITE EVOLUT; Crawley M.J., 1993, GLIM ECOLOGISTS; Danchin E, 1998, ECOLOGY, V79, P2415, DOI 10.2307/176832; DHONDT AA, 1968, BIRD STUDY, V15, P127, DOI 10.1080/00063656809476192; Gandon S, 1996, P ROY SOC B-BIOL SCI, V263, P1003, DOI 10.1098/rspb.1996.0148; GEBHARDTHENRICH SG, 1991, J EVOLUTION BIOL, V4, P341, DOI 10.1046/j.1420-9101.1991.4030341.x; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; HAMILTON WD, 1977, NATURE, V269, P578, DOI 10.1038/269578a0; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Heeb P, 1998, P ROY SOC B-BIOL SCI, V265, P51, DOI 10.1098/rspb.1998.0263; Heeb P, 1996, J ANIM ECOL, V65, P474, DOI 10.2307/5782; HEEB P, IN PRESS ECOLOGY; HERRE EA, 1993, SCIENCE, V259, P1442, DOI 10.1126/science.259.5100.1442; JOHNSON ML, 1990, ANNU REV ECOL SYST, V21, P449, DOI 10.1146/annurev.ecolsys.21.1.449; KACELNIK A, 1995, P ROY SOC B-BIOL SCI, V259, P259, DOI 10.1098/rspb.1995.0038; Kaltz O, 1998, HEREDITY, V81, P361, DOI 10.1046/j.1365-2540.1998.00435.x; Lessells CM, 1998, MOL ECOL, V7, P187, DOI 10.1046/j.1365-294x.1998.00331.x; Poulin R, 1996, AM NAT, V147, P287, DOI 10.1086/285851; RICHNER H, 1993, J ANIM ECOL, V62, P703, DOI 10.2307/5390; Richner H, 1998, ZOOL-ANAL COMPLEX SY, V101, P333; SMITH HG, 1989, J ANIM ECOL, V58, P383, DOI 10.2307/4837; SORCI G, 1994, AM NAT, V144, P153, DOI 10.1086/285666; TINBERGEN JM, 1990, J ANIM ECOL, V59, P1113, DOI 10.2307/5035; Verhulst S, 1997, ECOLOGY, V78, P864, DOI 10.1890/0012-9658(1997)078[0864:NDOGTI]2.0.CO;2; WEATHERHEAD PJ, 1994, BEHAV ECOL, V5, P426, DOI 10.1093/beheco/5.4.426	30	65	65	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1999	400	6739					63	65		10.1038/21881	http://dx.doi.org/10.1038/21881			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403248				2022-12-28	WOS:000081255700050
J	Mankoo, BS; Collins, NS; Ashby, P; Grigorieva, E; Pevny, LH; Candia, A; Wright, CVE; Rigby, PWJ; Pachnis, V				Mankoo, BS; Collins, NS; Ashby, P; Grigorieva, E; Pevny, LH; Candia, A; Wright, CVE; Rigby, PWJ; Pachnis, V			Mox2 is a component of the genetic hierarchy controlling limb muscle development	NATURE			English	Article							SKELETAL MYOGENESIS; PAX-3 EXPRESSION; MET RECEPTOR; MOUSE; CELLS; MIGRATION; MYOD; MUSCULATURE; EMBRYOS; DEFINE	The skeletal muscles of the limbs develop from myogenic progenitors that originate in the paraxial mesoderm and migrate into the limb-bud mesenchyme(1). Among the genes known to be important for muscle development in mammalian embryos are those encoding the basic helix-loop-helix (bHLH) myogenic regulatory factors (MRFs; MyoD, Myf5, myogenin and MRF4)(2-4) and Pax3, a paired-type homeobox gene that is critical for the development of limb musculature(5-7). Mox1 and Mox2 are closely related homeobox genes that are expressed in overlapping patterns in the paraxial mesoderm and its derivatives(8,9), Here we show that mice homozygous for a null mutation of Mox2 have a developmental defect of the limb musculature, characterized by an overall reduction in muscle mass and elimination of specific muscles. Mox2 is not needed for the migration of myogenic precursors into the limb bud, but it is essential for normal appendicular muscle formation and for the normal regulation of myogenic genes, as demonstrated by the downregulation of Pax3 and Myf5 but not MyoD in Mox2-deficient limb buds. Our findings show that the MOX2 homeoprotein is an important regulator of vertebrate limb myogenesis.	Natl Inst Med Res, MRC, Div Dev Neurobiol, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Eukaryot Mol Genet, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Vanderbilt Univ Sch Med, Nashville, TN 37232 USA	MRC National Institute for Medical Research; MRC National Institute for Medical Research; MRC National Institute for Medical Research; Vanderbilt University	Pachnis, V (corresponding author), Natl Inst Med Res, MRC, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.	v-pachni@nimr.mrc.ac.uk		Pachnis, Vassilis/0000-0001-9733-7686				BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Daston G, 1996, DEVELOPMENT, V122, P1017; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; GOULDING M, 1994, DEVELOPMENT, V120, P957; GRIM M, 1991, ANAT EMBRYOL, V183, P67; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Jacob HJ, 1980, TERATOLOGY LIMBS, P89; JAGLA K, 1995, MECH DEVELOP, V53, P345, DOI 10.1016/0925-4773(95)00450-5; Kardon G, 1998, DEVELOPMENT, V125, P4019; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Wachtler F, 1986, Bibl Anat, P24; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yamamoto M, 1998, DEVELOPMENT, V125, P1325; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	26	144	147	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1999	400	6739					69	73		10.1038/21892	http://dx.doi.org/10.1038/21892			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403250				2022-12-28	WOS:000081255700052
J	Tergau, F; Naumann, U; Paulus, W; Steinhoff, BJ				Tergau, F; Naumann, U; Paulus, W; Steinhoff, BJ			Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy	LANCET			English	Article									Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany	University of Gottingen	Tergau, F (corresponding author), Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany.		Paulus, Walter/A-3544-2009	Paulus, Walter/0000-0001-5549-8377				Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; STEINHOFF BJ, 1992, NEUROLOGY, V42, P1429, DOI 10.1212/WNL.42.7.1429-b; WEISS SRB, 1995, NEUROREPORT, V6, P2171, DOI 10.1097/00001756-199511000-00018; Ziemann U, 1998, EPILEPSY RES, V30, P11, DOI 10.1016/S0920-1211(97)00079-X	5	240	270	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2209	2209		10.1016/S0140-6736(99)01301-X	http://dx.doi.org/10.1016/S0140-6736(99)01301-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392988				2022-12-28	WOS:000081091300016
J	Doolittle, WF				Doolittle, WF			Phylogenetic classification and the universal tree	SCIENCE			English	Review							TRANSFER-RNA SYNTHETASE; MOLECULAR EVOLUTION; ARCHAEAL GENOMICS; RIBOSOMAL-RNA; EUKARYOTES; GENE; ROOT; ORIGINS; LIFE; ARCHAEBACTERIA	From comparative analyses of the nucleotide sequences of genes encoding ribosomal RNAs and several proteins, molecular phylogeneticists have constructed a "universal tree of life," taking it as the basis for a "natural" hierarchical classification of all living things. Although confidence in some of the tree's early branches has recently been shaken, new approaches could still resolve many methodological uncertainties. More challenging is evidence that most archaeal and bacterial genomes (and the inferred ancestral eukaryotic nuclear genome) contain genes from multiple sources. If "chimerism" or "lateral gene transfer" cannot be dismissed as trivial in extent: or limited to special categories of genes, then no hierarchical universal classification can be taken as natural. Molecular phylogeneticists will have failed to find the "true tree," not because their methods are inadequate or because they have chosen the wrong genes, but because the history of Life cannot properly be represented as a tree. However, taxonomies based on molecular sequences will remain indispensable, and understanding of the evolutionary process will ultimately be enriched, not impoverished.	Dalhousie Univ, Dept Biochem & Mol Biol, Canadian Inst Adv Res, Halifax, NS B3H 4H7, Canada	Canadian Institute for Advanced Research (CIFAR); Dalhousie University	Doolittle, WF (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Canadian Inst Adv Res, Halifax, NS B3H 4H7, Canada.	ford@is.dal.ca	Rohlf, F J/A-8710-2008; Puigbò, Pere/A-2214-2008	Doolittle, W. Ford/0000-0002-4675-8832				[Anonymous], 1861, ORIGIN SPECIES MEANS; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; BALDAUF SL, UNPUB; Brown JR, 1998, CURR BIOL, V8, pR365, DOI 10.1016/S0960-9822(98)70238-6; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; Doolittle RF, 1998, CURR OPIN GENET DEV, V8, P630, DOI 10.1016/S0959-437X(98)80030-0; DOOLITTLE RF, 1995, P NATL ACAD SCI USA, V92, P2421, DOI 10.1073/pnas.92.7.2421; Doolittle WE, 1998, TRENDS GENET, V14, P307; DOOLITTLE WF, 1994, P NATL ACAD SCI USA, V91, P6721, DOI 10.1073/pnas.91.15.6721; Doolittle WF, 1998, CURR BIOL, V8, pR209, DOI 10.1016/S0960-9822(98)70127-7; Doolittle WF, 1996, EVOLUTION MICROBIAL, P1; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; Ghiselin M. T., 1997, METAPHYSICS ORIGIN S; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GOGARTEN PJ, 1996, EVOLUTION MICROBIAL, P267; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Gupta RS, 1998, MICROBIOL MOL BIOL R, V62, P1435, DOI 10.1128/MMBR.62.4.1435-1491.1998; HILARIO E, 1993, BIOSYSTEMS, V31, P111, DOI 10.1016/0303-2647(93)90038-E; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Ibba M, 1997, P NATL ACAD SCI USA, V94, P14383, DOI 10.1073/pnas.94.26.14383; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Kates M, 1993, BIOCH ARCHAEA ARCHAE; Keeling PJ, 1998, TRENDS MICROBIOL, V6, P19, DOI 10.1016/S0966-842X(97)01185-2; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Lawson FS, 1996, MOL BIOL EVOL, V13, P970, DOI 10.1093/oxfordjournals.molbev.a025665; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; Martin W, 1999, BIOESSAYS, V21, P99, DOI 10.1002/(SICI)1521-1878(199902)21:2<99::AID-BIES3>3.3.CO;2-2; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Mayr E., 1982, GROWTH BIOL THOUGHT; MIYAMOTO MM, 1995, MOL BIOL EVOL, V12, P503; Moreira D, 1999, MOL BIOL EVOL, V16, P234, DOI 10.1093/oxfordjournals.molbev.a026105; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; NOMURA M, 1968, NATURE, V219, P793, DOI 10.1038/219793b0; Nomura M, 1999, P NATL ACAD SCI USA, V96, P1820, DOI 10.1073/pnas.96.5.1820; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; ONEIL DM, 1969, J BACTERIOL, V99, P242, DOI 10.1128/JB.99.1.242-247.1969; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Panchen A. L., 1992, CLASSIFICATION EVOLU; Philippe H, 1998, SYST ASSOC SPEC VOL, V56, P25; Philippe H, 1998, CURR OPIN GENET DEV, V8, P616, DOI 10.1016/S0959-437X(98)80028-2; RAGAN M, 1998, J MICROB COMP GENOMI, V3, P219; Reanney D C, 1978, Int Rev Cytol Suppl, VSuppl 8, P1; Reeve JN, 1997, CELL, V89, P999, DOI 10.1016/S0092-8674(00)80286-X; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; Roger AJ, 1999, MOL BIOL EVOL, V16, P218, DOI 10.1093/oxfordjournals.molbev.a026104; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SONEA S, 1976, REV CAN BIOL EXPTL, V35, P103; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Stiller JW, 1998, P NATL ACAD SCI USA, V95, P11769, DOI 10.1073/pnas.95.20.11769; Ueda K, 1999, J BACTERIOL, V181, P78, DOI 10.1128/JB.181.1.78-82.1999; VOSSBRINCK CR, 1987, NATURE, V326, P411, DOI 10.1038/326411a0; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Xiong J, 1998, P NATL ACAD SCI USA, V95, P14851, DOI 10.1073/pnas.95.25.14851; Yang ZH, 1996, TRENDS ECOL EVOL, V11, P367, DOI 10.1016/0169-5347(96)10041-0; Yang ZH, 1996, J MOL EVOL, V42, P294, DOI 10.1007/BF02198856; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4; ZUCKERKANDL EMILE, 1965, P97	72	1207	1272	5	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2124	2128		10.1126/science.284.5423.2124	http://dx.doi.org/10.1126/science.284.5423.2124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381871				2022-12-28	WOS:000081099300040
J	Garcia, SN; Pillus, L				Garcia, SN; Pillus, L			Net results of nucleolar dynamics	CELL			English	Review							YEAST		Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Garcia, SN (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.							Bachant JB, 1999, NATURE, V398, P757, DOI 10.1038/19641; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.0.CO;2-R; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; San-Segundo PA, 1999, CELL, V97, P313, DOI 10.1016/S0092-8674(00)80741-2; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Singer MS, 1998, GENETICS, V150, P613; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	20	61	63	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					825	828		10.1016/S0092-8674(00)80794-1	http://dx.doi.org/10.1016/S0092-8674(00)80794-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399910	Bronze			2022-12-28	WOS:000081162800003
J	Pierani, A; Brenner-Morton, S; Chiang, C; Jessell, TM				Pierani, A; Brenner-Morton, S; Chiang, C; Jessell, TM			A sonic hedgehog-independent, retinoid-activated pathway of neurogenesis in the ventral spinal cord	CELL			English	Article							FLOOR PLATE DIFFERENTIATION; MOTOR-NEURON INDUCTION; EXPRESSION PATTERN; PARAXIAL MESODERM; HOMEOBOX GENES; CELL FATE; PAX GENES; MOUSE; SPECIFICATION; IDENTITY	Sonic hedgehog (Shh) is thought to control the generation of motor neurons and interneurons in the ventral CNS. We show here that a Shh-independent pathway of interneuron generation also operates in the ventral spinal cord. Evidence for this parallel pathway emerged from an analysis of the induction of ventral progenitors that express the Dbx homeodomain proteins and of Evx1/2 (V0) and En1 (V1) neurons. Shh signaling is sufficient to induce Dbx cells and V0 and V1 neurons but is not required for their generation in vitro or in vivo. Retinoids appear to mediate this parallel pathway. These findings reveal an unanticipated Shh-independent signaling pathway that controls progenitor cell identity and interneuron diversity in the ventral spinal cord.	Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Columbia University; Howard Hughes Medical Institute; Vanderbilt University	Jessell, TM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA.		Pierani, Alessandra/O-6136-2017	Pierani, Alessandra/0000-0002-4872-4791				Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Burrill JD, 1997, DEVELOPMENT, V124, P4493; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GrapinBotton A, 1997, DEVELOPMENT, V124, P849; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; LEBER SM, 1995, J NEUROSCI, V15, P1236; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LU S, 1992, P NATL ACAD SCI USA, V89, P8053, DOI 10.1073/pnas.89.17.8053; LU SW, 1994, MECH DEVELOP, V47, P187, DOI 10.1016/0925-4773(94)90089-2; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Lumsden A, 1995, CURR BIOL, V5, P1347, DOI 10.1016/S0960-9822(95)00266-1; Maden M, 1998, DEVELOPMENT, V125, P4133; Mansouri A, 1998, MECH DEVELOP, V78, P171, DOI 10.1016/S0925-4773(98)00168-3; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1997, J NEUROSCI, V17, P7805; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pituello F, 1999, DEVELOPMENT, V126, P587; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; RANGINI Z, 1991, MECH DEVELOP, V35, P13, DOI 10.1016/0925-4773(91)90037-7; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Shoji H, 1996, MECH DEVELOP, V56, P25, DOI 10.1016/0925-4773(96)00509-6; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAGNER M, 1992, DEVELOPMENT, V116, P55; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	50	275	278	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					903	915		10.1016/S0092-8674(00)80802-8	http://dx.doi.org/10.1016/S0092-8674(00)80802-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399918	hybrid			2022-12-28	WOS:000081162800011
J	Sereno, PC				Sereno, PC			The evolution of dinosaurs	SCIENCE			English	Review							REPUBLIC-OF-CHINA; INNER-MONGOLIA; NORTHEASTERN CHINA; SAUROPOD DINOSAURS; MEDICINE FORMATION; OXYGEN ISOTOPES; AVIAN FLIGHT; COPES RULE; BIRD; THEROPOD	The ascendancy of dinosaurs on Land near the close of the Triassic how appears to have been as accidental and opportunistic as their demise and replacement by therian mammals at the end of the Cretaceous. The dinosaurian radiation, launched by 1-meter-long bipeds, was slower in tempo and more restricted in adaptive scope than that of therian mammals. A notable exception was the evolution of birds from small-bodied predatory dinosaurs, which involved a dramatic decrease in body size. Recurring phylogenetic trends among dinosaurs include, to the contrary, increase in body size. There is no evidence for co-evolution between predators and prey or between herbivores and flowering plants. As the major Land masses drifted apart, dinosaurian biogeography was molded more by regional extinction and intercontinental dispersal than by the breakup sequence of Pangaea.	Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA	University of Chicago	Sereno, PC (corresponding author), Univ Chicago, Dept Organismal Biol & Anat, 1027 E 57th St, Chicago, IL 60637 USA.							Alroy J, 1999, SYST BIOL, V48, P107, DOI 10.1080/106351599260472; Alroy J, 1998, SCIENCE, V280, P731, DOI 10.1126/science.280.5364.731; BARRICK RE, 1994, SCIENCE, V265, P222, DOI 10.1126/science.265.5169.222; Barrick RE, 1996, PALAIOS, V11, P295, DOI 10.2307/3515240; Barsbold R., 1990, P249; Barsbold R., 1990, P408; BARTHOLOMAI A, 1980, MEM QLD MUS, V20, P319; Benton M.J., 1988, Modern Geology, V13, P41; BENTON MJ, 1986, NATURE, V321, P857, DOI 10.1038/321857a0; BENTON MJ, 1990, MAJOR EVOLUTIONARY R, P409; Bonaparte J.F., 1990, NATURAL HIST MUSEUM, V416, P1; Bonaparte Jose F., 1995, Ameghiniana, V32, P341; BONNER J T, 1968, Journal of Paleontology, V42, P1; BRETTSURMAN MK, 1979, NATURE, V277, P560, DOI 10.1038/277560a0; Britt B.B., 1991, Brigham Young University Geology Studies, V37, P1; BROUWERS EM, 1987, SCIENCE, V237, P1608, DOI 10.1126/science.237.4822.1608; Brown B., 1940, Annals of the New York Academy of Sciences, V40, P133; Calder WA., 1984, SIZE FUNCTION LIFE H; Calvo Jorge O., 1994, Gaia, V10, P183; Carpenter K, 1998, NATURE, V393, P782, DOI 10.1038/31684; Carpenter K., 1990, P281, DOI 10.1017/CBO9780511608377.024; Carrano MT, 1999, J ZOOL, V247, P29, DOI 10.1111/j.1469-7998.1999.tb00190.x; Charig A. J., 1984, ZOOL SOC LONDON S, V57, P597; Charig Alan J., 1997, Bulletin of the Natural History Museum Geology Series, V53, P11; Chatterjee Sankar, 1995, Archaeopteryx, V13, P15; Chatterjee Sankar, 1996, Memoirs of the Queensland Museum, V39, P489; Chen PJ, 1998, NATURE, V391, P147, DOI 10.1038/34356; Chiappe LM, 1998, NATURE, V392, P275, DOI 10.1038/32642; CHIAPPE LM, IN PRESS AM MUS NOVI; Chiappe Luis M., 1996, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V30, P203; Chiappe Luis M., 1996, Memoirs of the Queensland Museum, V39, P557; Chinnery BJ, 1998, J VERTEBR PALEONTOL, V18, P569, DOI 10.1080/02724634.1998.10011085; CHINSAMY A, 1990, Palaeontologia Africana, V27, P77; Cifelli RL, 1997, P NATL ACAD SCI USA, V94, P11163, DOI 10.1073/pnas.94.21.11163; Clark James M., 1999, American Museum Novitates, V3265, P1; Clark James M., 1994, American Museum Novitates, V3115, P1; Colbert E. H, 1989, MUSEUM NO ARIZONA B, V57, P1; COLBERT EH, 1981, MUSEUM NO ARIZONA B, V53, P1; COOMBS W P JR, 1978, Palaeontology (Oxford), V21, P143; COOPER M R, 1984, Palaeontologia Africana, V25, P203; CORIA RA, 1995, NATURE, V377, P224, DOI 10.1038/377224a0; Crompton A.W., 1986, P223; CROWLEY TJ, 1989, GEOLOGY, V17, P457, DOI 10.1130/0091-7613(1989)017<0457:SCVOTS>2.3.CO;2; CURIE PJ, 1984, 3 S MES TERR EC, P61; Currie PJ, 1995, J VERTEBR PALEONTOL, V15, P576, DOI 10.1080/02724634.1995.10011250; DODSON P, 1990, P NATL ACAD SCI USA, V87, P7608, DOI 10.1073/pnas.87.19.7608; Dodson P., 1991, Modern Geology, V16, P3; Dong Zhiming, 1997, P68; Dong ZM, 1996, CAN J EARTH SCI, V33, P631, DOI 10.1139/e96-046; Erwin D.H., 1992, Historical Biology, V6, P133; Feduccia A, 1998, NATURE, V391, P754, DOI 10.1038/35777; Feduccia A., 1996, ORIGIN EARLY EVOLUTI; Forster C.A., 1990, Journal of Vertebrate Paleontology, V10, P273; Forster CA, 1998, SCIENCE, V279, P1915, DOI 10.1126/science.279.5358.1915; Galton P.M., 1990, P435; Galton P.M., 1990, P320; Galton P.M., 1984, Geologica et Palaeontologica, V18, P139; GALTON PM, 1973, LETHAIA, V6, P67, DOI 10.1111/j.1502-3931.1973.tb00873.x; Galton PM., 1974, B BRIT MUS NAT HIS A, V25, P1; Gangloff R.A., 1994, 1992 P INT C ARCT MA, P399; Gatesy SM, 1996, EVOLUTION, V50, P331, DOI 10.1111/j.1558-5646.1996.tb04496.x; Gatesy SM, 1999, NATURE, V399, P141, DOI 10.1038/20167; GAUTHIER JA, 1986, MEM CALIF ACAD SCI, V8, P1; Giffin E.B., 1988, Journal of Vertebrate Paleontology, V7, P398; GILMORE CW, 1920, US NATL MUS BULL, V110, P1; GOODWIN MB, 1987, J VERTEBR PALEONTOL, V7, P363; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; HAMMER WR, 1994, SCIENCE, V264, P828, DOI 10.1126/science.264.5160.828; Haubold H., 1990, Revue de Paleobiologie, V9, P149; HE X, 1988, MIDDLE JURASSIC DINO, V3; Head JJ, 1998, J VERTEBR PALEONTOL, V18, P718, DOI 10.1080/02724634.1998.10011101; Holmes Thom, 1997, P125; HOLTZ TR, 1994, J PALEONTOL, V68, P1100, DOI 10.1017/S0022336000026706; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; HOU LH, 1995, NATURE, V377, P616, DOI 10.1038/377616a0; IERLINSKI G, 1997, PRZ GEOL, V45, P419; JACOBS LL, 1993, PALAEONTOLOGY, V36, P523; Jain SL, 1997, J VERTEBR PALEONTOL, V17, P114, DOI 10.1080/02724634.1997.10010958; Janensch W., 1925, Palaeontographica Stuttgart Supplement, V7, P1; Janensch W., 1929, PALAEONTOGRAPHICA S7, V2, P1; Janensch W., 1950, PALAEONTOGRAPHICA, V3, P27; Janis C.M., 1990, P301; Janis Christine M., 1993, Journal of Mammalian Evolution, V1, P103, DOI 10.1007/BF01041590; JENKINS FA, 1988, SCIENCE, V241, P1495, DOI 10.1126/science.241.4872.1495; Ji Q, 1998, NATURE, V393, P753, DOI 10.1038/31635; Kirkland J. I., 1998, NEW MEXICO MUSEUM NA, V14, P271; KIRKLAND JI, 1998, NEW MEXICO MUSEUM NA, V14, P283; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LABARBERA M, 1986, PATTERNS PROCESSES H, P69; Lambe LM., 1917, GEOL SURV, V83, P1, DOI [10.4095/101672, DOI 10.4095/101672]; LARSSON H, UNPUB; Lee YN, 1996, J VERTEBR PALEONTOL, V16, P232, DOI 10.1080/02724634.1996.10011311; Lehman T.M., 1990, P211, DOI 10.1017/CBO9780511608377.019; Lockley MG, 1998, NATURE, V396, P429, DOI 10.1038/24783; Madsen James H. Jr, 1995, Bulletin of Carnegie Museum of Natural History, V31, P1; MADSEN JH, 1976, B UTAH GEOLOGICAL MI, V109, P1; Maryanska T, 1974, Palaeontologia Polonica, VNo. 30, P45; Marzoli A, 1999, SCIENCE, V284, P616, DOI 10.1126/science.284.5414.616; MCINTOSH JS, 1981, MUS N ARIZ B, V53, P345; McKinney M.L., 1990, P28; Mikhailov KE, 1996, J VERTEBR PALEONTOL, V16, P763, DOI 10.1080/02724634.1996.10011364; MOLNAR R E, 1991, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V217, P137; NORELL MA, 1995, NATURE, V378, P774, DOI 10.1038/378774a0; Norell MA, 1998, NATURE, V391, P754, DOI 10.1038/35779; Norell Mark A., 1997, American Museum Novitates, V3215, P1; Norman D.B., 1986, Bulletin de l'Institut Royal des Sciences Naturelles de Belgique Sciences de la Terre, V56, P281; Novacek Michael J., 1993, Journal of Mammalian Evolution, V1, P3, DOI 10.1007/BF01027597; NOVACEK MJ, 1992, SYST BIOL, V41, P58, DOI 10.2307/2992506; Novas FE, 1997, J VERTEBR PALEONTOL, V17, P137, DOI 10.1080/02724634.1997.10010959; Novas FE, 1997, NATURE, V387, P390, DOI 10.1038/387390a0; Novas Fernando E., 1993, Journal of Vertebrate Paleontology, V13, P400; Osmolska H., 1972, PALAEONTOL POL, V27, P96; Ostrom J. H., 1969, Bulletin of the Peabody Museum of Natural History, VNo. 30, P1; OSTROM JH, 1975, ANNU REV EARTH PL SC, V3, P55, DOI 10.1146/annurev.ea.03.050175.000415; OSTROM JH, 1972, PALAEOGEOGR PALAEOCL, V11, P287, DOI 10.1016/0031-0182(72)90049-1; Owen R, 1861, PALAEONTOGRAPHICAL S, V13, P1, DOI [10.1080/02693445.1861.12027929, DOI 10.1080/02693445.1861.12027929]; PARRISH JT, 1982, PALAEOGEOGR PALAEOCL, V40, P67, DOI 10.1016/0031-0182(82)90085-2; Penny D, 1999, SYST BIOL, V48, P76, DOI 10.1080/106351599260454; PEREZMORENO BP, 1994, NATURE, V370, P363, DOI 10.1038/370363a0; Poore SO, 1997, NATURE, V387, P799, DOI 10.1038/42930; Powell J.E., 1992, DINOSAURIOS ENTORNO, P165; ROGERS RR, 1993, SCIENCE, V260, P794, DOI 10.1126/science.260.5109.794; Romer A, 1956, OSTEOLOGY REPTILES; Rowe T., 1989, Journal of Vertebrate Paleontology, V9, P125; RUSSELL DA, 1993, CAN J EARTH SCI, V30, P2107, DOI 10.1139/e93-183; RUSSELL DA, 1993, CAN J EARTH SCI, V30, P2163, DOI 10.1139/e93-187; Salgado Leonardo, 1997, Ameghiniana, V34, P3; Sampson SD, 1995, J VERTEBR PALEONTOL, V15, P743, DOI 10.1080/02724634.1995.10011259; SAMPSON SD, 1998, SCIENCE, V280, P969; Santa Luca A.P., 1980, Annals of the South African Museum, V79, P159; Sanz JL, 1996, NATURE, V382, P442, DOI 10.1038/382442a0; Sereno P.C., 1990, P579; Sereno P.C., 1991, Journal of Vertebrate Paleontology, V11, P168; Sereno Paul C., 1998, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V210, P41; Sereno PC, 1992, J VERTEBR PALEONTOL, V12, P318, DOI 10.1080/02724634.1992.10011463; Sereno Paul C., 1993, Journal of Vertebrate Paleontology, V13, P451; SERENO PC, 1986, NATL GEOGR RES, V2, P234; SERENO PC, 1993, NATURE, V361, P64, DOI 10.1038/361064a0; SERENO PC, 1992, SCIENCE, V255, P845, DOI 10.1126/science.255.5046.845; Sereno PC, 1997, ANNU REV EARTH PL SC, V25, P435, DOI 10.1146/annurev.earth.25.1.435; SERENO PC, 1994, SCIENCE, V266, P267, DOI 10.1126/science.266.5183.267; Sereno PC, 1998, SCIENCE, V282, P1298, DOI 10.1126/science.282.5392.1298; Sereno PC, 1996, SCIENCE, V272, P986, DOI 10.1126/science.272.5264.986; SERENO PC, 1992, SCIENCE, V258, P1137, DOI 10.1126/science.258.5085.1137; SERENO PC, IN PRESS N JAHR GEOL; Sereno PC., 1994, J VERTEBR PALEONTOL, V13, P425, DOI DOI 10.1080/02724634.1994.10011524; SERENO PC, IN PRESS AGE DINOSAU; Smith A.G., 1994, ATLAS MESOZOIC CENOZ; Spray JG, 1998, NATURE, V392, P171, DOI 10.1038/32397; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; SUES H-D, 1987, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V198, P1; THULBORN R A, 1972, Palaeontology (Oxford), V15, P29; THULBORN RA, 1974, ZOOL J LINN SOC-LOND, V55, P151, DOI 10.1111/j.1096-3642.1974.tb01591.x; Thulborn RA., 1990, DINOSAUR TRACKS; Upchurch P, 1998, ZOOL J LINN SOC-LOND, V124, P43, DOI 10.1111/j.1096-3642.1998.tb00569.x; UPCHURCH P, 1995, PHILOS T R SOC B, V349, P365, DOI 10.1098/rstb.1995.0125; VANVALEN L, 1973, EVOLUTION, V27, P27, DOI 10.1111/j.1558-5646.1973.tb05914.x; Varricchio David J., 1993, Journal of Vertebrate Paleontology, V13, P99; Varricchio DJ, 1997, NATURE, V385, P247, DOI 10.1038/385247a0; Vermeij G.J., 1987, EVOLUTION ESCALATION; Vickers-Rich Patricia, 1997, P253; von HUENE FRIEDRICH, 1934, PALAEONT ZEITSCHR, V16, P145; Waddell PJ, 1999, SYST BIOL, V48, P1, DOI 10.1093/sysbio/48.1.1; Weishampel D.B., 1990, P534; Weishampel D.B., 1992, Historical Biology, V6, P159; WEISHAMPEL DB, 1984, ADV ANAT EMBRYOL CEL, V87, P1; WELLES S P, 1984, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V185, P85; Wilson JA, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011115; Wilson JA, 1999, PALEOBIOLOGY, V25, P252, DOI 10.1017/S0094837300026543; Wing Scott L., 1992, P327; Witmer L.M., 1991, P427; Xu X, 1999, NATURE, V399, P350, DOI 10.1038/20670; ZHANG Y, 1988, MIDDLE JURASSIC DINO, V3; ZHAO S, IN PRESS J VERTEBR P; Zhao Zi-Kui, 1994, P184; Zhou S.W, 1984, MIDDLE JURASSIC DINO; ZHOU Z, 1995, COUR FORSCHUNGSINST, V181, P9; Ziegler A.M., 1982, TIDAL FRICTION EARTH, P240, DOI DOI 10.1007/978-3-642-68836-2_17	178	664	703	6	363	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2137	2147		10.1126/science.284.5423.2137	http://dx.doi.org/10.1126/science.284.5423.2137			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381873				2022-12-28	WOS:000081099300042
J	Thompson, JN				Thompson, JN			The evolution of species interactions	SCIENCE			English	Editorial Material							COEVOLUTION; HOSTS; MODEL	Interactions between species are as evolutionarily malleable as the species themselves and have played a central role in the diversification and organization of life. This malleability creates complex geographic mosaics in interspecific interactions that can evolve rapidly over decades, blurring the distinction between evolutionary time and ecological time and making the study of coevolution crucial for human health and welfare.	Washington State Univ, Dept Bot, Pullman, WA 99164 USA; Washington State Univ, Dept Zool, Pullman, WA 99164 USA	Washington State University; Washington State University	Thompson, JN (corresponding author), Washington State Univ, Dept Bot, Pullman, WA 99164 USA.		Thompson, Jessica/GXW-0323-2022					BENKMAN CW, IN PRESS AM NAT; Berenbaum MR, 1998, P NATL ACAD SCI USA, V95, P13743, DOI 10.1073/pnas.95.23.13743; Brown JM, 1997, MOL ECOL, V6, P215, DOI 10.1046/j.1365-294X.1997.t01-1-00171.x; BURDON JJ, IN PRESS AM NAT; DAVIES NB, 1989, J ANIM ECOL, V58, P225, DOI 10.2307/4996; DWYER G, 1990, ECOL MONOGR, V60, P423, DOI 10.2307/1943014; Gandon S, 1996, P ROY SOC B-BIOL SCI, V263, P1003, DOI 10.1098/rspb.1996.0148; Hochberg ME, 1998, AM NAT, V152, P620, DOI 10.1086/286194; JANZEN DH, 1984, CRAWFORD LECT R SWED, V3, P1; Kearns CA, 1998, ANNU REV ECOL SYST, V29, P83, DOI 10.1146/annurev.ecolsys.29.1.83; LIVELY CM, IN PRESS AM NAT; Margulis L., 1991, SYMBIOSISOURCE EVO; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; Nuismer SL, 1999, P ROY SOC B-BIOL SCI, V266, P605, DOI 10.1098/rspb.1999.0679; PARKER MA, IN PRESS AM NAT; Pellmyr O, 1996, AM NAT, V148, P827, DOI 10.1086/285958; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; SOLTIS DE, 1992, SYST BOT, V17, P607, DOI 10.2307/2419730; Szathmary E, 1995, MAJOR TRANSITIONS EV; Thompson J. O. F., UNPUB; Thompson JD., 1994, COEVOLUTIONARY PROCE; Thompson JN, 1998, TRENDS ECOL EVOL, V13, P329, DOI 10.1016/S0169-5347(98)01378-0	22	272	287	2	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2116	2118		10.1126/science.284.5423.2116	http://dx.doi.org/10.1126/science.284.5423.2116			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381869				2022-12-28	WOS:000081099300038
J	Goodwin, AW				Goodwin, AW			Sensorimotor coordination in cerebral palsy	LANCET			English	Editorial Material							CHILDREN		Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3054, Australia	University of Melbourne	Goodwin, AW (corresponding author), Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3054, Australia.							ELIASSON AC, 1991, DEV MED CHILD NEUROL, V33, P661; Gordon A.M., 1997, NEUROPHYSIOLOGY NEUR, P214; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P176, DOI 10.1017/S0012162299000365; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P166, DOI 10.1017/S0012162299000353; Johansson RS, 1996, NATO ADV SCI I D-BEH, V85, P205; NEILSON PD, 1990, DEV MED CHILD NEUROL, V32, P778; WESTLING G, 1984, EXP BRAIN RES, V53, P277; YEKUTIEL M, 1994, DEV MED CHILD NEUROL, V36, P619	8	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2090	2091		10.1016/S0140-6736(99)00136-1	http://dx.doi.org/10.1016/S0140-6736(99)00136-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382689				2022-12-28	WOS:000080969300005
J	Metzger, RJ; Krasnow, MA				Metzger, RJ; Krasnow, MA			Development - Genetic control of branching morphogenesis	SCIENCE			English	Review							TRACHEAL CELL-MIGRATION; FGF RECEPTOR HOMOLOG; EMBRYONIC MOUSE LUNG; MIDLINE GLIAL-CELLS; SONIC HEDGEHOG; EGF RECEPTOR; DROSOPHILA; GROWTH; BREATHLESS; ENCODES		Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Krasnow, MA (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.	krasnow@cmgm.stanford.edu						AFFOLTER M, 1994, DEVELOPMENT, V120, P743; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; ALESCIO T, 1960, Arch Ital Anat Embriol, V65, P323; ALESCIO T, 1962, Z Anat Entwicklungsgesch, V123, P369, DOI 10.1007/BF00531068; ALESCIO T, 1962, J EXP ZOOL, V150, P83, DOI 10.1002/jez.1401500202; Arias A.M., 1993, DEV DROSOPHILA, P609; Aristotle, 1961, PARTS ANIMALS, P251; Bard J. B. L., 1990, MORPHOGENESIS CELLUL; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; CARDOSO W, UNPUB; Cardoso WV, 1997, DEV DYNAM, V208, P398, DOI 10.1002/(SICI)1097-0177(199703)208:3<398::AID-AJA10>3.0.CO;2-X; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; Chen CK, 1998, DEVELOPMENT, V125, P4959; FARKAS RM, UNPUB DATA; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; Guillemin K, 1996, DEVELOPMENT, V122, P1353; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hogan BLM, 1997, COLD SPRING HARB SYM, V62, P249; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Imam F, 1999, GENETICS, V152, P307; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; Jackson D, 1997, J CELL SCI, V110, P1261; JOHNSON EE, UNPUB; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KRAHL VE, 1958, ANAT REC, V130, P327; Krasnow NA, 1997, COLD SPRING HARB SYM, V62, P235; LANDING BH, 1971, AM J CARDIOL, V28, P456, DOI 10.1016/0002-9149(71)90010-5; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Llimargas M, 1997, DEVELOPMENT, V124, P3273; Mandelbrot B, 1983, FRACTAL GEOMETRY NAT; McMinn R.M.H., 1993, COLOR ATLAS HUMAN AN; MEINHARDT H, 1976, DIFFERENTIATION, V6, P117, DOI 10.1111/j.1432-0436.1976.tb01478.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Michelson AM, 1998, DEVELOPMENT, V125, P4379; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rudnick D, 1933, J EXP ZOOL, V66, P125, DOI 10.1002/jez.1400660106; Ruhle H, 1932, Z WISS ZOOL ABT A, V141, P159; Samakovlis C, 1996, DEVELOPMENT, V122, P3531; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; SHANNON JM, 1997, LUNG GROWTH DEV, P81; Shilo BZ, 1997, COLD SPRING HARB SYM, V62, P241; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Thompson D. W., 1917, GROWTH FORM; Vincent S, 1998, MOL CELL, V2, P515, DOI 10.1016/S1097-2765(00)80151-3; Vincent S, 1997, DEVELOPMENT, V124, P2741; Wappner P, 1997, DEVELOPMENT, V124, P4707; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; WEST BJ, 1987, AM SCI, V75, P354; WEST BJ, 1986, J APPL PHYSIOL, V60, P1089, DOI 10.1152/jappl.1986.60.3.1089; Whitsett JA, 1996, CLIN PERINATOL, V23, P753, DOI 10.1016/S0095-5108(18)30207-0; WIGGLESWORTH VB, 1954, Q J MICROSC SCI, V95, P115; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; Zhao JS, 1996, DEV BIOL, V180, P242, DOI 10.1006/dbio.1996.0298	74	369	390	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1999	284	5420					1635	1639		10.1126/science.284.5420.1635	http://dx.doi.org/10.1126/science.284.5420.1635			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383344				2022-12-28	WOS:000080668300034
J	Hawnaur, J				Hawnaur, J			Recent advances - Diagnostic radiology	BRITISH MEDICAL JOURNAL			English	Review							SPIRAL CT; FUTURE-DIRECTIONS; PERSPECTIVE; COMPRESSION; ULTRASOUND; FRACTURES; FILMLESS; IMPACT		Univ Manchester, Dept Diagnost Radiol, Manchester M13 9PT, Lancs, England	University of Manchester	Hawnaur, J (corresponding author), Univ Manchester, Dept Diagnost Radiol, Manchester M13 9PT, Lancs, England.							Bauer DC, 1997, ARCH INTERN MED, V157, P629, DOI 10.1001/archinte.157.6.629; Beauchamp NJ, 1998, AM J ROENTGENOL, V171, P73, DOI 10.2214/ajr.171.1.9648768; Boland GWL, 1998, CLIN RADIOL, V53, P547, DOI 10.1016/S0009-9260(98)80145-1; Britton KE, 1997, CLIN RADIOL, V52, P731, DOI 10.1016/S0009-9260(97)80150-X; Bryan S, 1998, AM J ROENTGENOL, V170, P1153, DOI 10.2214/ajr.170.5.9574575; Buchbinder B R, 1998, Magn Reson Imaging Clin N Am, V6, P67; Castro PF, 1998, AM J MED, V104, P69, DOI 10.1016/S0002-9343(97)00312-4; Chakos M H, 1998, Magn Reson Imaging Clin N Am, V6, P155; Dixon AK, 1998, EUR RADIOL, V8, P488, DOI 10.1007/s003300050423; Duerinckx AJ, 1998, AM J ROENTGENOL, V170, P900, DOI 10.2214/ajr.170.4.9530030; Erickson BJ, 1998, RADIOLOGY, V206, P599, DOI 10.1148/radiology.206.3.9494473; Gray L, 1998, Magn Reson Imaging Clin N Am, V6, P125; HILL MC, 1998, ULTRASOUND Q, V14, P209; Hynes DM, 1997, LANCET, V350, P657, DOI 10.1016/S0140-6736(97)08157-9; Kemmerer SR, 1998, RADIOL CLIN N AM, V36, P247, DOI 10.1016/S0033-8389(05)70020-8; Le Bihan DJ, 1998, RADIOLOGY, V207, P305, DOI 10.1148/radiology.207.2.9577472; MEDLEY CMT, 1997, BR J RADIOL S, V70, P133; Pretorius DH, 1998, ULTRASOUND Q, V14, P218; Rapp-Bernhardt U, 1998, BRIT J RADIOL, V71, P1271, DOI 10.1259/bjr.71.852.10319000; Reddy GP, 1998, RADIOLOGY, V208, P167, DOI 10.1148/radiology.208.1.9646809; REDPATH TW, 1997, BRIT J RADIOL, V70, P70; REES M, 1997, BRIT J RADIOL, V70, P162; Reiner BI, 1998, RADIOLOGY, V207, P481, DOI 10.1148/radiology.207.2.9577498; Remy-Jardin M, 1998, EUR RADIOL, V8, P1376, DOI 10.1007/s003300050557; Richenberg JL, 1998, BRIT J RADIOL, V71, P708, DOI 10.1259/bjr.71.847.9771380; Rosenthal DI, 1998, AM J ROENTGENOL, V170, P23, DOI 10.2214/ajr.170.1.9423591; Shapiro RS, 1998, AM J ROENTGENOL, V171, P1203, DOI 10.2214/ajr.171.5.9798848; Strickland NH, 1996, BRIT J RADIOL, V69, P1089, DOI 10.1259/0007-1285-69-828-1089; Szolar DH, 1997, RADIOLOGY, V202, P211, DOI 10.1148/radiology.202.1.8988213; Wall BF, 1997, BRIT J RADIOL, V70, P437, DOI 10.1259/bjr.70.833.9227222; Weiser JC, 1997, SEMIN ROENTGENOL, V32, P7, DOI 10.1016/S0037-198X(97)80031-4; Williams MB, 1998, RADIOLOGY, V206, P297, DOI 10.1148/radiology.206.2.9457176; Yock PG, 1998, AM J CARDIOL, V81, p27E, DOI 10.1016/S0002-9149(98)00195-7; Zeman RK, 1998, AM J ROENTGENOL, V170, P1427, DOI 10.2214/ajr.170.6.9609149; Zoetelief J, 1998, BRIT J RADIOL, V71, P584, DOI 10.1259/bjr.71.846.9849379	35	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					168	171		10.1136/bmj.319.7203.168	http://dx.doi.org/10.1136/bmj.319.7203.168			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406757	Green Published			2022-12-28	WOS:000081619300027
J	Berger, A; Greenfield, S				Berger, A; Greenfield, S			Scientist, superwoman, and sock drawer sorter	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					78	78						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398625				2022-12-28	WOS:000081438200020
J	Katzman, GL; Dagher, AP; Patronas, NJ				Katzman, GL; Dagher, AP; Patronas, NJ			Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR HEALTH; SINUS ABNORMALITIES; PINEAL CYSTS; MRI	Context Previous reports have discussed incidental disease found on brain magnetic resonance imaging (MRI) scans that had been requested for an unrelated clinical concern or symptom, resulting in a selection bias for disease. However, the prevalence of unexpected abnormalities has not been studied in a healthy population. Objective To evaluate the prevalence of incidental findings on brain MRI scans obtained for a healthy, asymptomatic population without selection bias. Design, Setting, and Participants Retrospective analysis of brain MRI scans obtained between May 17, 1996, and July 25, 1997, from 1000 volunteers who participated as control subjects for various research protocols at the National Institutes of Health. All participants (age range, 3-83 years; 54.6% male) were determined to be healthy and asymptomatic by physician examination and participant history. Main Outcome Measure Prevalence of abnormalities on brain MRI by category of finding (no referral necessary, routine referral, urgent referral [within 1 week of study], and immediate referral [within 1 to several days of study]), Results Eighty-two percent of the MRI results were normal, Of the 18% demonstrating incidental abnormal findings, 15.1% required no referral; 1.8%, routine referral; 1.1%, urgent referral; and 0%, immediate referral. In subjects grouped for urgent referral, 2 confirmed primary brain tumors (and a possible but unconfirmed third) were found, demonstrating a prevalence of at least 0.2%. Conclusion Asymptomatic subjects present with a variety of abnormalities, providing valuable information on disease prevalence in a presumed healthy population, A small percentage of these findings require urgent medical attention and/or additional studies.	NIH, Dept Diagnost Radiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Dagher, AP (corresponding author), NIH, Dept Diagnost Radiol, Bldg 10,Room 1C660, Bethesda, MD 20892 USA.							Baum KA, 1996, NEURORADIOLOGY, V38, P755, DOI 10.1007/s002340050342; BRYAN RN, 1994, AM J NEURORADIOL, V15, P1625; Davis FG, 1996, NEUROEPIDEMIOLOGY, V15, P103, DOI 10.1159/000109895; DICOSTANZO A, 1993, J NEUROL NEUROSUR PS, V56, P207, DOI 10.1136/jnnp.56.2.207; HUME AJ, 1984, GREENFIELDS NEUROPAT, P426; Iwabuchi Y, 1997, ARCH OTOLARYNGOL, V123, P602; MALY PV, 1995, NEURORADIOLOGY, V37, P471, DOI 10.1007/BF00600097; MORRIS P, 1997, PRACTICAL NEUROANGIO, P296; OSBORN AG, 1994, DIAGNOSTIC NEURORADI, P529; Patel K, 1996, J LARYNGOL OTOL, V110, P649, DOI 10.1017/S0022215100134516; PrestonMartin S, 1996, NEUROL CLIN, V14, P273, DOI 10.1016/S0733-8619(05)70256-5; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Robinson R., 1971, PROGR NEUROLOGICAL S, P133, DOI 10.1159/000391818; Salonen O, 1997, NEURORADIOLOGY, V39, P537, DOI 10.1007/s002340050463; SAWAMURA Y, 1995, NEUROSURGERY, V37, P11, DOI 10.1227/00006123-199507000-00002; Yue NC, 1997, RADIOLOGY, V202, P41, DOI 10.1148/radiology.202.1.8988190	16	371	376	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					36	39		10.1001/jama.282.1.36	http://dx.doi.org/10.1001/jama.282.1.36			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404909	Bronze			2022-12-28	WOS:000081195800026
J	Hoft, DF; Tennant, JM				Hoft, DF; Tennant, JM			Persistence and boosting of Bacille Calmette-Guerin-induced delayed-type hypersensitivity	ANNALS OF INTERNAL MEDICINE			English	Article							TUBERCULIN REACTIVITY; YOUNG-ADULTS; VACCINATION; INFECTION; MONTREAL	Background: Bacille Calmette-Guerin (BCC) vaccination may induce persistent and booster purified protein derivative (PPD) responses that complicate tuberculosis screening efforts. Objectives: To investigate the effects of BCC vaccination on serial PPD tests and to study correlations between persistent delayed-type hypersensitivity and other potential surrogate markers of protective immunity. Design: Cohort study. Setting: Midwestern urban university. Participants: 69 healthy adults. Interventions: BCG vaccination, blood samples drawn for immunologic studies, and PPD tests done sequentially over 1 to 3 years. Measurements: Serial PPD induration, lymphoproliferation, and interferon-gamma responses. Results: 10% of participants (95% CI, 4% to 20%) had persistent PPD responses of 15 mm or greater, and 3% (CI, 0% to 10%) demonstrated PPD boosting of 15 mm or greater 1 to 3 yea rs after BCG vaccination. Intradermal BCG vaccination induced a larger number of persistent responses that were 10 mm or greater than did percutaneous BCC vaccination (12 of 46 participants compared with 1 of 23 participants; P = 0.05). Persistent and boosted delayed-type hypersensitivity correlated with mycobacterial-specific lymphoproliferation and interferon-gamma responses. Conclusions: Previous BCG vaccination reduces the predictive value of serial PPD testing. The lowest PPD predictive values will occur in persons without known tuberculosis exposure who were vaccinated recently or many times with intradermal BCG. In addition, BCG-related persistence and boosting of delayed-type hypersensitivity responses correlate with other potential surrogate markers of protective mycobacterial immunity.	St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, St Louis, MO 63110 USA	Saint Louis University	Hoft, DF (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, 3635 Vista Ave,FDT-8N, St Louis, MO 63110 USA.	hoftdf@slu.edu			NIAID NIH HHS [N01-AI-45250] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045250] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; *ADV COMM IMM PRAC, 1996, MMWR-MORBID MORTAL W, V45, P1; BARNES PF, 1992, J IMMUNOL, V148, P1835; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; COMSTOCK GW, 1971, AM REV RESPIR DIS, V103, P572; FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X; HART PD, 1967, BRIT MED J, V1, P587, DOI 10.1136/bmj.1.5540.587; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Kemp EB, 1996, J INFECT DIS, V174, P113, DOI 10.1093/infdis/174.1.113; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; MENZIES R, 1992, AM REV RESPIR DIS, V146, P752, DOI 10.1164/ajrccm/146.3.752; MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003; NARAIN R, 1966, B WORLD HEALTH ORGAN, V34, P623; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Pouchot J, 1997, ANN INTERN MED, V126, P210, DOI 10.7326/0003-4819-126-3-199702010-00005; Ravn P, 1997, J IMMUNOL, V158, P1949; SANCHEZ FO, 1994, INFECT IMMUN, V62, P5673; SEPULVEDA RL, 1990, AM REV RESPIR DIS, V142, P24, DOI 10.1164/ajrccm/142.1.24	18	18	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					32	36		10.7326/0003-4819-131-1-199907060-00007	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391813				2022-12-28	WOS:000081345200006
J	Stephen, KW				Stephen, KW			Use of fluoride	LANCET			English	Letter									Univ Glasgow, Dent Publ Hlth Unit, Glasgow G2 3JZ, Lanark, Scotland	University of Glasgow	Stephen, KW (corresponding author), Univ Glasgow, Dent Publ Hlth Unit, Glasgow G2 3JZ, Lanark, Scotland.							Hawley G M, 1996, Community Dent Health, V13, P189; Horowitz HS, 1999, LANCET, V353, P1462, DOI 10.1016/S0140-6736(99)90026-0; POWELL KR, 1982, J DENT CHILD, V49, P112; *PUBL HLTH ALL, 1992, ON MILL, P58; STEPHEN K, 1999, J DENT RES, V78, P366	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					74	75		10.1016/S0140-6736(05)75343-5	http://dx.doi.org/10.1016/S0140-6736(05)75343-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406392				2022-12-28	WOS:000081243200055
J	Williamson, LM; Lowe, S; Love, EM; Cohen, H; Soldan, K; McClelland, DBL; Skacel, P; Barbara, JAJ				Williamson, LM; Lowe, S; Love, EM; Cohen, H; Soldan, K; McClelland, DBL; Skacel, P; Barbara, JAJ			Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-TRANSFUSION; SYSTEM; RISK	Objective To receive and collate reports of death or major complications of transfusion of blood or components. Design Haematologists were invited confidentially to report deaths and major complications after blood transfusion during October 1996 to September 1998. S etting Hospitals in United Kingdom and Ireland. Subjects Patients who died or experienced serious complications, as defined below; associated with transfusion of red cells, platelets, fresh frozen plasma or cryoprecipitate. Main outcome measures Death, "wrong" blood transfused to patient acute and delayed transfusion reactions, transfusion related acute lung injury, transfusion associated graft versus host disease, post-transfusion purpura, and infection transmitted by transfusion. Circumstances relating to these cases and relative frequency of complications. Results Over 24 months, 366 cases were reported of which 191 (52%) were "wrong blood to patient" episodes. Analysis of these revealed multiple errors of identification, often beginning when blood was collected from the blood bank. There were 22 deaths from all causes, including three from ABO incompatibility. There were 12 infections: four bacterial (one fatal), seven viral, and one fatal case of malaria. During die second 12 months, 164/424 hospitals (39%) submitted a "nil to report" return. Conclusions Transfusion is now extremely safe, but vigilance is needed to ensure correct identification of blood and patient Staff education should include an awareness of ABO incompatibility and bacterial contamination as causes of life threatening reactions to blood.	Univ E Anglia, Natl Blood Serv, Div Transfus Med, Cambridge CB2 2PT, England; Natl Blood Serv Manchester, Manchester M13 9LL, Lancs, England; UCL Hosp, London WC1E 6DB, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Natl Blood Serv, London NW9 5EQ, England; Royal Infirm, Dept Transfus Med, Edinburgh & South East Scotland Blood Transfus Se, Edinburgh EH3 9HB, Midlothian, Scotland; Hammersmith Hosp, Royal Postgrad Med Sch, London W12 0HS, England; Natl Blood Serv, London NW9 5BG, England	University of East Anglia; University College London Hospitals NHS Foundation Trust; University of London; University College London; Public Health England; Royal Infirmary of Edinburgh; Imperial College London	Williamson, LM (corresponding author), Univ E Anglia, Natl Blood Serv, Div Transfus Med, Cambridge CB2 2PT, England.	lorna.williamson@nbs.nhs.uk		Soldan, Kate/0000-0002-0361-3174				AuBuchon JP, 1997, TRANSFUSION, V37, P1211, DOI 10.1046/j.1537-2995.1997.37111298088055.x; BLAJCHMAN MA, 1994, VOX SANG, V67, P25, DOI 10.1111/j.1423-0410.1994.tb04540.x; Calman KC, 1996, BRIT MED J, V313, P799; Chapman JF, 1996, TRANSFUSION MED, V6, P273, DOI 10.1111/j.1365-3148.1996.tb00079.x; *CTR NAT HEM, 1999, HEM ACT DOSS LETT IN; Ingrand P, 1998, TRANSFUSION, V38, P1030, DOI 10.1046/j.1537-2995.1998.38111299056312.x; Kaplan HS, 1998, TRANSFUSION, V38, P1071, DOI 10.1046/j.1537-2995.1998.38111299056319.x; Lumadue JA, 1997, TRANSFUSION, V37, P1169, DOI 10.1046/j.1537-2995.1997.37111298088047.x; MCCLELLAND DBL, 1994, BRIT MED J, V308, P1205, DOI 10.1136/bmj.308.6938.1205; McClelland DBL, 1998, TRANSFUSION, V38, P999, DOI 10.1046/j.1537-2995.1998.38111299056306.x; *NHS EX, 1999, BETT BLOOD TRANSF; SAZAMA K, 1985, TRANSFUSION, V30, P583; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Shiba M, 1997, TRANSFUSION, V37, P457, DOI 10.1046/j.1537-2995.1997.37597293873.x; Williamson LM, 1996, BRIT MED J, V313, P1221, DOI 10.1136/bmj.313.7067.1221; WILLIAMSON LM, 1999, SHOT ANN REPORT 1997; WILLIAMSON LM, 1998, SHOT ANN REPORT 1996	17	233	241	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					16	19		10.1136/bmj.319.7201.16	http://dx.doi.org/10.1136/bmj.319.7201.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390452	Bronze, Green Published			2022-12-28	WOS:000081326500023
J	Burns, T; Creed, F; Fahy, T; Thompson, S; Tyrer, P; White, I				Burns, T; Creed, F; Fahy, T; Thompson, S; Tyrer, P; White, I		UK 700 Grp	Intensive versus standard case management for severe psychotic illness: a randomised trial	LANCET			English	Article							MENTALLY-ILL; COMMUNITY; SERVICES; PEOPLE; CARE; RELIABILITY; DISORDERS; SCALE	Background Case management has increasingly been the recommended approach to care for severely mentally ill patients since the number of psychiatric beds has decreased. Despite equivocal results, in the UK and Europe, this approach is becoming accepted policy. We assessed the effect of smaller case loads. Methods We randomly assigned 708 psychotic patients in four centres standard case management (355 patients, case load 30-35 per case manager) or intensive case management (353 patients, case load 10-15 per case manager). We measured clinical symptoms and social functioning at baseline, 1 year, and 2 years. The impact of treatment on hospital use was assessed at 2 years by subgroup analyses for Afro-Caribbean and for severely socially disabled patients. Analysis was by intention to treat, Findings There was no significant decline in overall hospital use among intensive-case-management patients (mean 73.5 vs 73.1 days in those who received standard care [SD 0.4, 95% CI -17.4 to 18.1]), nor were there any significant gains in clinical or social functioning. There was no evidence of differential effect in Afro-Caribbean patients or the most socially disabled patients. Interpretation In well-coordinated mental-health services, a decline in case load alone does not improve outcome for these patients. Mental-health planners may need to pay more attention to the content of treatment rather than changes in service organisation.	St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England; Maudsley Hosp, Kings Healthcare NHS Trust, London SE5 8AZ, England; Univ London Imperial Coll Sci Technol & Med, London, England; St Marys Hosp, London, England	St Georges University London; University of Manchester; South London & Maudsley NHS Trust; Imperial College London; Imperial College London	Burns, T (corresponding author), St George Hosp, Sch Med, Dept Psychiat, Jenner Wing, London SW17 0RE, England.			White, Ian/0000-0002-6718-7661				ANDREASEN N, 1989, BRIT J PSYCHIAT, V7, P53; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BURNS BJ, 1995, PSYCHIAT SERV, V46, P669; Burns T, 1997, BRIT J PSYCHIAT, V170, P393, DOI 10.1192/bjp.170.5.393; Creed F, 1999, BRIT J PSYCHIAT, V174, P74, DOI 10.1192/bjp.174.1.74; Efron B., 1994, MONOGRAPHS STAT APPL; Ford R, 1997, J MENT HEALTH, V6, P181; GUY W, 1996, ECDEU ASSESSMENT MAN, P534; HOLLOWAY F, 1995, EUR PSYCHIAT, V10, P113, DOI 10.1016/0767-399X(96)80101-5; Holloway F, 1998, BRIT J PSYCHIAT, V172, P19, DOI 10.1192/bjp.172.1.19; HOLLOWAY F, 1995, COMMUNITY PSYCHIAT A; JABLENSKY A, 1980, ACTA PSYCHIAT SCAND, V62, P152, DOI 10.1111/j.1600-0447.1980.tb07687.x; MARKS IM, 1994, BRIT J PSYCHIAT, V165, P179, DOI 10.1192/bjp.165.2.179; MARSHALL M, 1995, LANCET, V345, P409, DOI 10.1016/S0140-6736(95)90399-2; MARSHALL M, 1998, COCHRANE LIBRARY; MARSHALL M, 1995, CASE MANAGEMENT SEVE; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MUIJEN M, 1992, BRIT J PSYCHIAT, V160, P379, DOI 10.1192/bjp.160.3.379; MUIJEN M, 1994, BRIT J PSYCHIAT, V165, P211, DOI 10.1192/bjp.165.2.211; Oliver JPJ, 1997, SOC PSYCH PSYCH EPID, V32, P76, DOI 10.1007/BF00788924; PHELAN M, 1995, BRIT J PSYCHIAT, V167, P589, DOI 10.1192/bjp.167.5.589; SOLOMON P, 1992, COMMUNITY MENT HLT J, V28, P163, DOI 10.1007/BF00756815; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; TYRER PJ, 1979, LANCET, V1, P1014; WHO, 1992, WHO COORD MULT STUD; Wykes T, 1998, BRIT J PSYCHIAT, V173, P385, DOI 10.1192/bjp.173.5.385	27	255	261	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2185	2189		10.1016/S0140-6736(98)12191-8	http://dx.doi.org/10.1016/S0140-6736(98)12191-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	210EC	10392982				2022-12-28	WOS:000081091300010
J	Falloon, J				Falloon, J			Time to genotype for selection of antiretroviral regimens in previously treated patients?	LANCET			English	Editorial Material							RESISTANCE		NIAID, Immunoregulat Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Falloon, J (corresponding author), NIAID, Immunoregulat Lab, 9000 Rockville Pike, Bethesda, MD 20892 USA.							BAXTER JD, 1999, 6 C RETR OPP INF CHI; *BRIT HIV ASS, 1999, BRIT HIV ASS GUID TR; Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection, 1999, GUID US ANT AG HIV I; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Perrin L, 1998, SCIENCE, V280, P1871, DOI 10.1126/science.280.5371.1871	6	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2173	2174		10.1016/S0140-6736(99)00128-2	http://dx.doi.org/10.1016/S0140-6736(99)00128-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392975				2022-12-28	WOS:000081091300003
J	Thomson, H; Ross, S; Wilson, P; McConnachie, A; Watson, R				Thomson, H; Ross, S; Wilson, P; McConnachie, A; Watson, R			Randomised controlled trial of effect of Baby Check on use of health services in first 6 months of life	BRITISH MEDICAL JOURNAL			English	Article							PRESCRIBING STRATEGIES; SORE THROAT; SYMPTOMS; PARENTS; ILLNESS; BABIES; LAY	Objective To evaluate the effect of Baby Check, an illness scoring system for babies of 6 months or less, on parents' use of health services for their baby. Design Randomised controlled trial. Setting 13 general practices in Glasgow. Subjects 997 newly delivered mothers, randomised to receive either Baby Check and Play It Safe, an accident prevention leaflet (n = 497), or Play It Safe alone (control group, n = 500). Main outcome measures Data on consultations and referrals extracted from general practice notes after 6 months. Results At the time of recruitment, maternal characteristics were similar for both groups (mean maternal age 29 years; deprivation categories 6 and 1 in both groups; 424 (45%) mothers were primiparous). At 6 months, general practice notes were available for 467 (94%) of the Baby Check group and 468 (94%) of the control group. The number of general practitioner consultations did not differ between the groups: median number of consultations was 2 (interquartile range 1 to 4) in the Baby Check group, and 2 (1 to 3) in the control group. Use of out of hours services did not differ significantly between the two groups (86 v 85; P = 0.93). Conclusion Distributing Baby Check to an unselected group of mothers does not affect use of health services for infants up to 6 months of age.	Univ Glasgow, Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland; Craigallian Surg, Glasgow G72 8RW, Lanark, Scotland	University of Glasgow	Thomson, H (corresponding author), Univ Edinburgh, Dept Community Hlth Sci, Gen Practice Primary Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland.		Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248				Arblaster L, 1996, J Health Serv Res Policy, V1, P93; CUNNINGHAMBURLEY S, 1987, BMJ-BRIT MED J, V295, P700, DOI 10.1136/bmj.295.6600.700; Field MJ, 1990, CLIN PRACTICE GUIDEL; HOLME CO, 1995, BRIT J GEN PRACT, V45, P65; Hopton J, 1996, BRIT MED J, V313, P991; Kai J, 1996, BRIT MED J, V313, P987; KAI J, 1994, FAM PRACT, V11, P245, DOI 10.1093/fampra/11.3.245; Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; McLoone P., 1994, CARSTAIRS SCORES SCO; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; PERSAUD J, 1997, MEDECONOMICS     JUN, P47; Rogers A, 1998, BRIT MED J, V316, P1816, DOI 10.1136/bmj.316.7147.1816; Russell IT GJ, 1992, HOSP REFERRALS, P179; *SPSS INC, 1993, SPSSX VERS 6 1 3; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106, DOI 10.1136/adc.66.1.106; THURTLE OA, 1985, BRIT MED J, V290, P1434, DOI 10.1136/bmj.290.6479.1434-c	17	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1740	1744		10.1136/bmj.318.7200.1740	http://dx.doi.org/10.1136/bmj.318.7200.1740			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381711	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000081216900034
J	Wheeler, MH				Wheeler, MH			Preoperative parathyroid scanning in secondary hyperparathyroidism	LANCET			English	Editorial Material							LOCALIZATION; GLANDS		Univ Wales Hosp, Dept Endocrine Surg, Cardiff CF4 4XW, S Glam, Wales	Cardiff University	Wheeler, MH (corresponding author), Univ Wales Hosp, Dept Endocrine Surg, Cardiff CF4 4XW, S Glam, Wales.							Doppman JL, 1968, PROG SURG, V18, P1171; KOHRI K, 1992, AM J SURG, V164, P140, DOI 10.1016/S0002-9610(05)80372-1; NEONAKIS E, 1995, ARCH SURG-CHICAGO, V130, P643; OKERLUND MD, 1984, ANN SURG, V200, P381, DOI 10.1097/00000658-198409000-00016; PATROU F, 1998, BRIT J SURG, V85, P1605; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; WEI JP, 1992, SURGERY, V112, P1111; Wheeler MH, 1998, ANN ROY COLL SURG, V80, P305	8	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2174	2175		10.1016/S0140-6736(99)00116-6	http://dx.doi.org/10.1016/S0140-6736(99)00116-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392976				2022-12-28	WOS:000081091300004
J	Chen, DG; Ma, H; Hong, H; Koh, SS; Huang, SM; Schurter, BT; Aswad, DW; Stallcup, MR				Chen, DG; Ma, H; Hong, H; Koh, SS; Huang, SM; Schurter, BT; Aswad, DW; Stallcup, MR			Regulation of transcription by a protein methyltransferase	SCIENCE			English	Article							ARGININE N-METHYLTRANSFERASE; HORMONE RECEPTORS; STEROID-RECEPTORS; COACTIVATOR; BINDING; DOMAINS; ACETYLTRANSFERASE; TRANSACTIVATION; ACETYLATION; SPECIFICITY	The p160 family of coactivators, SRC-1, GRIP1/TIF2, and p/CIP, mediate transcriptional activation by nuclear hormone receptors. Coactivator-associated arginine methyltransferase 1 (CARM1), a previously unidentified protein that binds to the carboxyl-terminal region of p160 coactivators, enhanced transcriptional activation by nuclear receptors, but only when GRIP1 or SRC-1a was coexpressed. Thus, CARM1 functions as a secondary coactivator through its association with p160 coactivators. CARM1 can methylate histone H3 in vitro, and a mutation in the putative S-adenosylmethionine binding domain of CARM 1 substantially reduced both methyltransferase and coactivator activities. Thus, coactivator-mediated methylation of proteins in the transcription machinery may contribute to transcriptional regulation.	Univ So Calif, Dept Pathol HMR 301, Los Angeles, CA 90033 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA USA	University of Southern California; University of California System; University of California Irvine	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol HMR 301, 2011 Zonal Ave, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [DK43093] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ASWAD DW, UNPUB; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHAMBERLIN JP, 1978, ANAL BIOCHEM, V98, P132; Chen D.-Y., UNPUB; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GARY JD, 1996, J BIOL CHEM, V271, P11585; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MA H, IN PRESS MOL CELL BI; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	32	956	995	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2174	2177		10.1126/science.284.5423.2174	http://dx.doi.org/10.1126/science.284.5423.2174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381882				2022-12-28	WOS:000081099300051
J	Ishitani, T; Ninomiya-Tsuji, J; Nagai, S; Nishita, M; Meneghini, M; Barker, N; Waterman, M; Bowerman, B; Clevers, H; Shibuya, H; Matsumoto, K				Ishitani, T; Ninomiya-Tsuji, J; Nagai, S; Nishita, M; Meneghini, M; Barker, N; Waterman, M; Bowerman, B; Clevers, H; Shibuya, H; Matsumoto, K			The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF	NATURE			English	Article							XENOPUS-EMBRYOS; DROSOPHILA; GENE; WINGLESS; TRANSDUCTION; ARMADILLO; LEF-1; AXIS; IDENTIFICATION; ACTIVATION	The Wnt signalling pathway regulates many developmental processes through a complex of beta-catenin and the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of high-mobility-group transcription factors(1-5). Wnt stabilizes cytosolic beta-catenin, which then binds to TCF and activates gene transcription. This signalling cascade is conserved in vertebrates, Drosophila and Caenorhabditis elegans. In C. elegans, the proteins MOM-4 and LIT-I regulate Wnt signalling to polarize responding cells during embryogenesis(6). MOM-4 and LIT-1 are homologous to TAK1 (a kinase activated by transforming growth factor-beta) mitogen-activated protein-kinase-kinase kinase (MAP3K)(7) and MAP kinase (MAPK)-related NEMO-like kinase (NLK)(8,9), respectively, in mammalian cells. These results raise the possibility that TAK1 and NLK are also involved in Wnt signalling in mammalian cells. Here we show that TAK1 activation stimulates NLK activity and downregulates transcriptional activation mediated by beta-catenin and TCF. Injection of NLK suppresses the induction of axis duplication by microinjected beta-catenin in Xenopus embryos. NLK phosphorylates TCF/LEF factors and inhibits the interaction of the beta-catenin-TCF complex with DNA. Thus, the TAK1-NLK-MAPK-like pathway negatively regulates the Wnt signalling pathway.	Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Nagoya University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University of Oregon; Utrecht University; Utrecht University Medical Center; University of California System; University of California Irvine	Matsumoto, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan.		Barker, Nick/AAS-2774-2020; Barker, Nick/A-5535-2011; Ishitani, Tohru/E-9781-2014; Barker, Nick/AAE-9833-2021	Barker, Nick/0000-0003-3566-4475; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blanco DR, 1997, EMERG INFECT DIS, V3, P11, DOI 10.3201/eid0301.970102; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CARDIGAN KM, 1997, GENE DEV, V11, P3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	491	521	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					798	802		10.1038/21674	http://dx.doi.org/10.1038/21674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391247				2022-12-28	WOS:000081101600057
J	Polo, O				Polo, O			Continuous positive airway pressure for treatment of sleep apnoea	LANCET			English	Editorial Material							DAYTIME FUNCTION; APNOEA/HYPOPNOEA SYNDROME; CPAP THERAPY		Univ Turku, Dept Physiol, Sleep Res Unit, FIN-20520 Turku, Finland; Univ Turku, Dept Pulm Dis & Clin Allergol, FIN-20520 Turku, Finland	University of Turku; University of Turku	Polo, O (corresponding author), Univ Turku, Dept Physiol, Sleep Res Unit, FIN-20520 Turku, Finland.							Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Engleman HM, 1998, THORAX, V53, P341, DOI 10.1136/thx.53.5.341; Martin SE, 1997, AM J RESP CRIT CARE, V155, P1596, DOI 10.1164/ajrccm.155.5.9154863; POLO O, 1992, ACTA PHYSL SCAN S606, V145, P1; Wright J, 1997, BRIT MED J, V314, P851	8	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2086	2087		10.1016/S0140-6736(99)99059-1	http://dx.doi.org/10.1016/S0140-6736(99)99059-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382686				2022-12-28	WOS:000080969300002
J	Hirsch, J				Hirsch, J			An association for patient-oriented research	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL RESEARCH		Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Hirsch, J (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	hirsch@rockvax.rockefeller.edu						Cole R, 1928, SCIENCE, V67, P47, DOI 10.1126/science.67.1725.47; Flowers CR, 1997, NAT MED, V3, P136, DOI 10.1038/nm0297-136; Hirsch J, 1997, PERSPECT BIOL MED, V41, P108; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; Mulrow CD, 1997, ANN INTERN MED, V126, P389, DOI 10.7326/0003-4819-126-5-199703010-00008; Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Schechter AN, 1998, JAMA-J AM MED ASSOC, V280, P1440, DOI 10.1001/jama.280.16.1440; Shine KI, 1998, JAMA-J AM MED ASSOC, V280, P1442, DOI 10.1001/jama.280.16.1442; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303	10	10	10	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					1014	1017		10.7326/0003-4819-130-12-199906150-00020	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383351				2022-12-28	WOS:000080894700009
J	Adam, S; Forrest, S				Adam, S; Forrest, S			ABC of intensive care - Other supportive care	BRITISH MEDICAL JOURNAL			English	Article									UCL Hosp, Intens Care Unit, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Adam, S (corresponding author), UCL Hosp, Intens Care Unit, London, England.								0	14	15	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					175	178		10.1136/bmj.319.7203.175	http://dx.doi.org/10.1136/bmj.319.7203.175			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406761	Green Published			2022-12-28	WOS:000081619300030
J	Ponec, RJ; Saunders, MD; Kimmey, MB				Ponec, RJ; Saunders, MD; Kimmey, MB			Neostigmine for the treatment of acute colonic pseudo-obstruction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OGILVIES-SYNDROME; PSEUDOOBSTRUCTION	Background Acute colonic pseudo-obstruction that is, massive dilation of the colon without mechanical obstruction - may develop after surgery or severe illness. Although it may resolve with conservative therapy, colonoscopic decompression is sometimes needed to prevent ischemia and perforation of the bowel, Uncontrolled studies have suggested that neostigmine may be an effective treatment. Methods We studied 21 patients with acute colonic pseudo-obstruction. All had abdominal distention and radiographic evidence of colonic dilation, with a cecal diameter of at least 10 cm, and had had no response to at least 24 hours of conservative treatment. We randomly assigned 11 to receive 2.0 mg of neostigmine intravenously and 10 to receive intravenous saline. A physician who was unaware of the patients' treatment assignments recorded clinical response (defined as prompt evacuation of flatus or stool and a reduction in abdominal distention), abdominal circumference, and measurements of the colon on radiographs. Patients who had no response to the initial injection were eligible to receive open-label neostigmine three hours later. Results Ten of the 11 patients who received neostigmine had prompt colonic decompression, as compared with none of the 10 patients who received placebo (P<0.001). The median time to response was 4 minutes (range, 3 to 30). Seven patients in the placebo group and the one patient in the neostigmine group without an initial response received open-label neostigmine; all had colonic decompression. Two patients who had an initial response to neostigmine required colonoscopic decompression for recurrence of colonic distention; one eventually underwent subtotal colectomy. Side effects of neostigmine included abdominal pain, excess salivation, and vomiting. Symptomatic bradycardia developed in two patients and was treated with atropine. Conclusions In patients with acute colonic pseudoobstruction who have not had a response to conservative therapy, treatment with neostigmine rapidly decompresses the colon. (N Engl J Med 1999;341: 137-41.) (C) 1999, Massachusetts Medical Society.	Univ Washington, Med Ctr, Div Gastroenterol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kimmey, MB (corresponding author), Univ Washington, Med Ctr, Div Gastroenterol, Box 356424,1959 NE Pacific St, Seattle, WA 98195 USA.							CHILD CS, 1984, ANAESTHESIA, V39, P1083, DOI 10.1111/j.1365-2044.1984.tb08927.x; CRONNELLY R, 1979, ANESTHESIOLOGY, V51, P222, DOI 10.1097/00000542-197909000-00008; DORUDI S, 1992, BRIT J SURG, V79, P99, DOI 10.1002/bjs.1800790203; HUTCHINSON R, 1992, ANN ROY COLL SURG, V74, P364; JETMORE AB, 1992, DIS COLON RECTUM, V35, P1135, DOI 10.1007/BF02251964; JOHNSON CD, 1985, AM J ROENTGENOL, V145, P1211, DOI 10.2214/ajr.145.6.1211; NANNI G, 1982, DIS COLON RECTUM, V25, P157; OGILVIE H, 1948, BRIT MED J, V2, P671, DOI 10.1136/bmj.2.4579.671; Rex D K, 1997, Gastrointest Endosc Clin N Am, V7, P499; SLOYER AF, 1988, DIGEST DIS SCI, V33, P1391, DOI 10.1007/BF01536993; SPIRA IA, 1976, AM J GASTROENTEROL, V65, P397; STEPHENSON BM, 1995, DIS COLON RECTUM, V38, P424, DOI 10.1007/BF02054234; SWINSCOW TDV, 1977, STAT SQUARE 1; TureganoFuentes F, 1997, DIS COLON RECTUM, V40, P1353, DOI 10.1007/BF02050822; VANEK VW, 1986, DIS COLON RECTUM, V29, P203, DOI 10.1007/BF02555027; VANTRAPPEN G, 1993, LANCET, V341, P152, DOI 10.1016/0140-6736(93)90010-E; Webb M D, 1995, Anesth Prog, V42, P21	17	315	330	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					137	141		10.1056/NEJM199907153410301	http://dx.doi.org/10.1056/NEJM199907153410301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403850				2022-12-28	WOS:000081413800001
J	Reddel, H; Jenkins, C; Woolcock, A				Reddel, H; Jenkins, C; Woolcock, A			Diurnal variability - time to change asthma guidelines?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEAK EXPIRATORY FLOW; SELF-MANAGEMENT PLANS; BRONCHIAL RESPONSIVENESS; POPULATION-SAMPLE; OBSTRUCTION		Royal Prince Alfred Hosp, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney	Reddel, H (corresponding author), Royal Prince Alfred Hosp, Inst Resp Med, POB M77, Camperdown, NSW 2050, Australia.	hkr@mail.med.usyd.edu.au	Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021	Reddel, Helen/0000-0002-6695-6350; Jenkins, Christine/0000-0003-2717-5647				Brand PLP, 1997, EUR RESPIR J, V10, P1242, DOI 10.1183/09031936.97.10061242; CLARK TJH, 1977, BRIT J DIS CHEST, V71, P87, DOI 10.1016/0007-0971(77)90087-0; CONNOLLY CK, 1994, RESP MED, V88, P453, DOI 10.1016/S0954-6111(05)80049-6; CONNOLLY CK, 1981, BRIT J DIS CHEST, V75, P197, DOI 10.1016/0007-0971(81)90053-X; COTE J, 1993, THORAX, V48, P48, DOI 10.1136/thx.48.1.48; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; DAHL R, 1991, EUR RESPIR J, V4, P1178; DALONZO GE, 1995, AM J RESP CRIT CARE, V152, P1097, DOI 10.1164/ajrccm.152.3.7663789; Fishwick D, 1996, EUR RESPIR J, V9, P861, DOI 10.1183/09031936.96.09050861; Gannon PFG, 1998, THORAX, V53, P790, DOI 10.1136/thx.53.9.790; *GLOB IN ASTHM, 1995, NIH PUBL; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588, DOI 10.1164/ajrccm/145.3.588; Lebowitz MD, 1997, EUR RESPIR J, V10, pS49; Meijer RJ, 1997, EUR RESPIR J, V10, P1163, DOI 10.1183/09031936.97.10051163; *NAT ASHM ED PREV, 1997, NIH PUBL; *NAT ASTHM CAMP AU, 1998, ASTHM MAN HDB; NEUKIRCH F, 1992, AM REV RESPIR DIS, V146, P71, DOI 10.1164/ajrccm/146.1.71; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reddel H, 1999, LANCET, V353, P758; REDDEL HK, 1995, AM J RESP CRIT CARE, V151, P1320, DOI 10.1164/ajrccm.151.5.7735580; Reddel HK, 1998, EUR RESPIR J, V12, P309, DOI 10.1183/09031936.98.12020309; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME C, 1998, AM J RESP CRIT CARE, V157, pA631; SIERSTED HC, 1994, AM J RESP CRIT CARE, V149, P598, DOI 10.1164/ajrccm.149.3.8118624; Toogood JH, 1996, J ALLERGY CLIN IMMUN, V98, P555, DOI 10.1016/S0091-6749(96)70089-1; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	34	34	35	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					45	47		10.1136/bmj.319.7201.45	http://dx.doi.org/10.1136/bmj.319.7201.45			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390464	Green Published			2022-12-28	WOS:000081326500037
J	Aronson, J				Aronson, J			When I use a word ... Oranges and grapefruit	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1758	1758		10.1136/bmj.318.7200.1758	http://dx.doi.org/10.1136/bmj.318.7200.1758			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381718	Green Published			2022-12-28	WOS:000081216900045
J	Horton, R				Horton, R			Croatia and Bosnia: the imprints of war - II. Restoration	LANCET			English	Article									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, 42 Bedford Sq, London WC1B 3SL, England.							ANNAN K, 1999, MED CONFL SURVIV, V15, P115; BAGARIC I, COMMUNICATION; CHOMSKY N, 1999, HARPERS MAGAZINE, P15; Cikes N, 1999, Lijec Vjesn, V121, P1; Eterovic D, 1999, J UROLOGY, V161, P39, DOI 10.1016/S0022-5347(01)62055-X; ETEROVIC D, IN PRESS RESPIRATION; Ivankovic A, 1999, CROAT MED J, V40, P166; Jankovic SM, 1999, CROAT MED J, V40, P67; KOSTOVIC I, 1993, CROAT MED J, V34, P285; Kovacic L, 1998, Croat Med J, V39, P249; Lang S, 1998, Croat Med J, V39, P72; LANG S, 1993, CROAT MED J, V34, P5; LANG S, 1995, CROAT MED J, V36, P3; Leaning J, 1999, LANCET, V353, P921, DOI 10.1016/S0140-6736(99)90043-0; Ljubic B, 1998, Croat Med J, V39, P276; Ljubic B, 1999, CROAT MED J, V40, P160; MARUSIC A, 1998, CBE VIEWS, V21, P12; MARUSIC M, 1996, CROAT MED J, V37, P273; Nietzsche Friedrich, 1998, GOOD EVIL; Primorac D, 1996, J FORENSIC SCI, V41, P891; Puvacic Zlatko, 1997, Croatian Medical Journal, V38, P140; Pyle G F, 1998, Croat Med J, V39, P281; Rajic Zdravko, 1994, Croatian Medical Journal, V35, P203; REINER Z, 1998, EUROHEALTH, V4, P2; SARAC I, 1997, CROAT MED J, V38, P83; Summerfield D, 1999, SOC SCI MED, V48, P1449, DOI 10.1016/S0277-9536(98)00450-X; Wegman ME, 1999, PEDIATRICS, V103, P646, DOI 10.1542/peds.103.3.646; ZIZEK, 1999, NEW LEFT REV, V234, P6	28	27	27	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2223	2228		10.1016/S0140-6736(99)06043-2	http://dx.doi.org/10.1016/S0140-6736(99)06043-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10393000				2022-12-28	WOS:000081091300042
J	Czeisler, CA; Duffy, JF; Shanahan, TL; Brown, EN; Mitchell, JF; Rimmer, DW; Ronda, JM; Silva, EJ; Allan, JS; Emens, JS; Dijk, DJ; Kronauer, RE				Czeisler, CA; Duffy, JF; Shanahan, TL; Brown, EN; Mitchell, JF; Rimmer, DW; Ronda, JM; Silva, EJ; Allan, JS; Emens, JS; Dijk, DJ; Kronauer, RE			Stability, precision, and near-24-hour period of the human circadian pacemaker	SCIENCE			English	Article							FREE-RUNNING PERIOD; DROSOPHILA PERIOD; CLOCK MUTANTS; BRIGHT LIGHT; SUPRACHIASMATIC NUCLEI; MATHEMATICAL-MODEL; BODY-TEMPERATURE; PHASE-SHIFTS; RHYTHMS; SLEEP	Regulation of circadian period in humans was thought to differ from that of other species, with the period of the activity rhythm reported to range from 13 to 65 hours (median 25.2 hours) and the period of the body temperature rhythm reported to average 25 hours in adulthood, and to shorten with age. However, those observations were based on studies of humans exposed to Light Levels sufficient to confound circadian period estimation. Precise estimation of the periods of the endogenous circadian rhythms of melatonin, core body temperature, and cortisol in healthy young and older individuals Living in carefully controlled Lighting conditions has now revealed that the intrinsic period of the human circadian pacemaker averages 24.18 hours in both age groups, with a tight distribution consistent with other species. These findings have important implications for understanding the pathophysiology of disrupted sleep in older people.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med,Div Endocrinol, Circadian Neuroendocrine & Sleep Disorders Sect, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University	Czeisler, CA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med,Div Endocrinol, Circadian Neuroendocrine & Sleep Disorders Sect, 221 Longwood Ave, Boston, MA 02115 USA.		Dijk, Derk-Jan/D-8387-2011; Weydahl, Andi/C-6391-2008; Duffy, Jeanne F./AAJ-4845-2020	Duffy, Jeanne F./0000-0003-4177-4179; Mitchell, Jude/0000-0003-0197-7545; Czeisler, Charles Andrew/0000-0002-7408-1849	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009975] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR02635] Funding Source: Medline; NIA NIH HHS [P01-AG09975] Funding Source: Medline; NIGMS NIH HHS [R01-GM53559] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amir S, 1996, NATURE, V379, P542, DOI 10.1038/379542a0; ASCHOFF J, 1962, NATURWISSENSCHAFTEN, V49, P337; Boivin DB, 1998, NEUROREPORT, V9, P779, DOI 10.1097/00001756-199803300-00002; Boivin DB, 1996, NATURE, V379, P540, DOI 10.1038/379540a0; BROWN EN, 1992, J BIOL RHYTHM, V7, P177, DOI 10.1177/074873049200700301; Buxton OM, 1997, AM J PHYSIOL-ENDOC M, V273, pE536, DOI 10.1152/ajpendo.1997.273.3.E536; CAMPBELL SS, 1993, SLEEP, V16, P638; Carskadon MA, 1999, NEUROSCI LETT, V260, P129, DOI 10.1016/S0304-3940(98)00971-9; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Czeisler C.A., 1990, SLEEP BIOL RHYTHMS B, P87; Czeisler C. A., 1978, THESIS STANFORD U; Czeisler C. A., 1986, SLEEP RES, V15, P266; CZEISLER CA, 1992, LANCET, V340, P933, DOI 10.1016/0140-6736(92)92817-Y; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Davis FC, 1998, AM J PHYSIOL-REG I, V275, pR960; DEMENT WC, 1985, BIOL AGING, P692; Dijk DJ, 1999, J PHYSIOL-LONDON, V516, P611, DOI 10.1111/j.1469-7793.1999.0611v.x; Duffy JF, 1998, AM J PHYSIOL-REG I, V275, pR1478, DOI 10.1152/ajpregu.1998.275.5.R1478; DUFFY JF, 1998, THESIS NE U; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; EASTMAN CI, 1995, PHYSIOL BEHAV, V58, P1287, DOI 10.1016/0031-9384(95)02031-4; EDGAR DM, 1991, J BIOL RHYTHM, V6, P185, DOI 10.1177/074873049100600301; EDGAR DM, 1991, AM J PHYSIOL, V261, pR928, DOI 10.1152/ajpregu.1991.261.4.R928; Emens JS, 1994, SLEEP RES, V23, P256; Eskin A., 1971, P55; GANDER PH, 1984, AM J PHYSIOL, V247, pR427, DOI 10.1152/ajpregu.1984.247.3.R427; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GUNDEL A, 1992, CHRONOBIOL INT, V9, P148, DOI 10.3109/07420529209064526; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hiddinga AE, 1997, J SLEEP RES, V6, P156, DOI 10.1046/j.1365-2869.1997.00047.x; HONMA K, 1985, JPN J PHYSIOL, V35, P643, DOI 10.2170/jjphysiol.35.643; JANIK D, 1993, PHYSIOL BEHAV, V53, P431, DOI 10.1016/0031-9384(93)90135-3; Jewett M.E., 1997, SLEEP RES, V26, P759; Kelly TL, 1999, J BIOL RHYTHM, V14, P190, DOI 10.1177/074873099129000597; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kleitman N., 1939, SLEEP WAKEFULNESS; Klerman EB, 1998, AM J PHYSIOL-REG I, V274, pR991; Klerman EB, 1996, AM J PHYSIOL-REG I, V270, pR271, DOI 10.1152/ajpregu.1996.270.1.R271; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Kronauer R. E., 1993, LIGHT BIOL RHYTHMS M, V63, P217; KRONAUER RE, 1982, AM J PHYSIOL, V242, pR3, DOI 10.1152/ajpregu.1982.242.1.R3; KRONAUER RE, 1986, SLEEP RES, V15, P274; Leproult R, 1997, J BIOL RHYTHM, V12, P245, DOI 10.1177/074873049701200306; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Lockley SW, 1997, J CLIN ENDOCR METAB, V82, P3763, DOI 10.1210/jc.82.11.3763; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOWE CH, 1967, SCIENCE, V156, P531, DOI 10.1126/science.156.3774.531; Middleton B, 1996, J SLEEP RES, V5, P69, DOI 10.1046/j.1365-2869.1996.d01-67.x; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MILLS JN, 1964, J PHYSIOL-LONDON, V174, P217, DOI 10.1113/jphysiol.1964.sp007483; Minors D, 1996, CHRONOBIOL INT, V13, P179, DOI 10.3109/07420529609012651; MORIN LP, 1988, J BIOL RHYTHM, V3, P237, DOI 10.1177/074873048800300302; MORIN LP, 1977, SCIENCE, V196, P305, DOI 10.1126/science.557840; MROSOVSKY N, 1989, EXPERIENTIA, V45, P696, DOI 10.1007/BF01974561; MROSOVSKY N, 1986, NATURE, V319, P536, DOI 10.1038/319536b0; MYERS BL, 1995, NEUROSCI BIOBEHAV R, V19, P553, DOI 10.1016/0149-7634(95)00018-6; ORTH DN, 1979, CLIN ENDOCRINOL, V10, P603, DOI 10.1111/j.1365-2265.1979.tb02120.x; PITTENDRIGH CS, 1974, SCIENCE, V186, P548, DOI 10.1126/science.186.4163.548; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; RIMMER DW, 1997, MED SCI SPORTS EXERC, V30, P5; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SACK RL, 1992, J CLIN ENDOCR METAB, V75, P127, DOI 10.1210/jcem.75.1.1619000; Shanahan T. L., 1995, THESIS HARVARD MED S; SHANAHAN TL, 1991, SLEEP RES A, V20, P557; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SHIROMANI PJ, 1994, BIOL PSYCHIAT, V36, P622, DOI 10.1016/0006-3223(94)90075-2; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VANCAUTER E, 1993, J BIOL RHYTHM, V8, pS99; VANREETH O, 1989, NATURE, V339, P49, DOI 10.1038/339049a0; VANREETH O, 1994, AM J PHYSIOL, V266, pE964, DOI 10.1152/ajpendo.1994.266.6.E964; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Waterhouse J, 1998, NEUROSCI LETT, V245, P97, DOI 10.1016/S0304-3940(98)00174-8; WEITZMAN ED, 1982, NEUROBIOL AGING, V3, P299, DOI 10.1016/0197-4580(82)90018-5; Wever R.A., 1979, CIRCADIAN SYSTEM MAN; WEVER RA, 1984, EXPERIENTIA, V40, P1226, DOI 10.1007/BF01946652; ZULLEY J, 1981, PFLUG ARCH EUR J PHY, V391, P314, DOI 10.1007/BF00581514; ZULLEY J, 1985, HUM NEUROBIOL, V4, P123; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	85	898	923	1	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2177	2181		10.1126/science.284.5423.2177	http://dx.doi.org/10.1126/science.284.5423.2177			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381883				2022-12-28	WOS:000081099300052
J	Lee, JM; Zipfel, GJ; Choi, DW				Lee, JM; Zipfel, GJ; Choi, DW			The changing landscape of ischaemic brain injury mechanisms	NATURE			English	Review							METHYL-D-ASPARTATE; FOCAL CEREBRAL-ISCHEMIA; PROGRAMMED CELL-DEATH; CALCIUM-CHANNEL ANTAGONISTS; CULTURED CORTICAL-NEURONS; CEREBELLAR GRANULE CELLS; NITRIC-OXIDE SYNTHASE; NERVOUS-SYSTEM; MEDIATED NEUROTOXICITY; CAENORHABDITIS-ELEGANS	Thrombolysis has become established as an acute treatment for human stroke. But despite multiple clinical trials, neuroprotective strategies have yet to be proved effective in humans. Here we discuss intrinsic tissue mechanisms of ischaemic brain injury, and present a perspective that broadening of therapeutic targeting beyond excitotoxicity and neuronal calcium overload will be desirable for developing the most effective neuroprotective therapies.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Lee, JM (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA.		Lee, Jin-Moo/K-2024-2015	Lee, Jin-Moo/0000-0002-3979-0906				AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; AUER RN, 1993, DRUG DEV, V2, P307; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Becker KJ, 1998, CURR OPIN NEUROL, V11, P45, DOI 10.1097/00019052-199802000-00008; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; Campagne MV, 1996, NEUROSCI LETT, V213, P111, DOI 10.1016/0304-3940(96)12839-1; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Connor JA, 1999, J NEUROPHYSIOL, V81, P299, DOI 10.1152/jn.1999.81.1.299; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Du C, 1996, BRAIN RES, V718, P233, DOI 10.1016/0006-8993(96)00162-X; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Frerichs KU, 1998, J CEREBR BLOOD F MET, V18, P168, DOI 10.1097/00004647-199802000-00007; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GOLDBERG MP, 1997, STROKE TRIALS DATABA; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Gwag BJ, 1995, NEUROREPORT, V7, P93, DOI 10.1097/00001756-199512000-00022; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Gwag BJ, 1997, NEUROSCIENCE, V77, P393, DOI 10.1016/S0306-4522(96)00473-3; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hyrc K, 1997, J NEUROSCI, V17, P6669; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IRWIN RP, 1994, J NEUROSCI, V14, P1352, DOI 10.1523/JNEUROSCI.14-03-01352.1994; Ivins KJ, 1998, NEUROBIOL DIS, V5, P365, DOI 10.1006/nbdi.1998.0228; JOHANSEN FF, 1993, MOL CHEM NEUROPATHOL, V18, P161, DOI 10.1007/BF03160030; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Kew JNC, 1996, J PHYSIOL-LONDON, V497, P761, DOI 10.1113/jphysiol.1996.sp021807; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LAMPE PA, 1995, J NEUROBIOL, V26, P205, DOI 10.1002/neu.480260205; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; Manev H, 1997, EXP NEUROL, V146, P171, DOI 10.1006/exnr.1997.6510; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; McDonald JW, 1998, J NEUROSCI, V18, P6290; McDonald JW, 1997, BRAIN RES, V759, P228, DOI 10.1016/S0006-8993(97)00248-5; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Nagayama M, 1998, J CEREBR BLOOD F MET, V18, P1107, DOI 10.1097/00004647-199810000-00007; Namura S, 1998, J NEUROSCI, V18, P3659; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; PorteraCailliau C, 1996, J NEUROCHEM, V66, P692, DOI 10.1046/j.1471-4159.1996.66020692.x; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SLOVITER RS, 1985, BRAIN RES, V330, P150, DOI 10.1016/0006-8993(85)90017-4; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Sorensen JC, 1998, BRAIN RES, V812, P265, DOI 10.1016/S0006-8993(98)00943-3; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; WAXMAN SG, 1994, BRAIN RES, V644, P197, DOI 10.1016/0006-8993(94)91680-2; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yin H z, 1994, Neurobiol Dis, V1, P43, DOI 10.1006/nbdi.1994.0006; Ying HS, 1997, J NEUROSCI, V17, P9536; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	100	919	968	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738		S			A7	A14		10.1038/399a007	http://dx.doi.org/10.1038/399a007			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JQ	10392575				2022-12-28	WOS:000081101700003
J	Doetsch, F; Caille, I; Lim, DA; Garcia-Verdugo, JM; Alvarez-Buylla, A				Doetsch, F; Caille, I; Lim, DA; Garcia-Verdugo, JM; Alvarez-Buylla, A			Subventricular zone astrocytes are neural stem cells in the adult mammalian brain	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; MEDIATED GENE-TRANSFER; RAT CEREBRAL-CORTEX; NEURONAL PRECURSORS; VENTRICULAR ZONE; RADIAL GLIA; RECEPTOR IMMUNOREACTIVITY; RECOMBINANT RETROVIRUS; MONOCLONAL-ANTIBODY	Neural stem cells reside in the subventricular zone (SVZ) of the adult mammalian brain. This germinal region, which continually generates new neurons destined for the olfactory bulb, is composed of four cell types: migrating neuroblasts, immature precursors, astrocytes, and ependymal cells. Here we show that SVZ astrocytes, and not ependymal cells, remain labeled with proliferation markers after long survivals in adult mice. After elimination of immature precursors and neuroblasts by an antimitotic treatment, SVZ astrocytes divide to generate immature precursors and neuroblasts. Furthermore, in untreated mice, SVZ astrocytes specifically infected with a retrovirus give rise to new neurons in the olfactory bulb. Finally, we show that SVZ astrocytes give rise to cells that grow into multipotent neurospheres in vitro. We conclude that SVZ astrocytes act as neural stem cells in both the normal and regenerating brain.	Rockefeller Univ, New York, NY 10021 USA; Univ Valencia, E-46100 Burjassot, Spain	Rockefeller University; University of Valencia	Alvarez-Buylla, A (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	alvarez@rockvax.rockefeller.edu	Caillé, Isabelle/AAC-9575-2021; García-Verdugo, José Manuel/L-8421-2017	García-Verdugo, José Manuel/0000-0001-9872-6499; Lim, Daniel/0000-0001-7221-3425; Alvarez-Buylla, Arturo/0000-0003-4426-8925; Caille, Isabelle/0000-0002-9054-2641	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028478, R37NS028478, R29NS028478] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32116] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NINDS NIH HHS [NS28478] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; ALVAREZBUYLLA A, 1990, NEURON, V5, P101, DOI 10.1016/0896-6273(90)90038-H; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Baba H, 1997, DEV NEUROSCI-BASEL, V19, P49, DOI 10.1159/000111185; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Blasco-Ibanez JM, 1998, EUR J NEUROSCI, V10, P1784, DOI 10.1046/j.1460-9568.1998.00190.x; Caille I, 1996, BRAIN RES, V730, P17, DOI 10.1016/0006-8993(96)00424-6; Calaora V, 1996, NEUROSCIENCE, V73, P581, DOI 10.1016/0306-4522(96)00042-5; CAVANAGH JB, 1970, J ANAT, V106, P471; CEPKO CL, 1992, CURRENT PROTOCOLS MO; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DIDIER M, 1986, CELL TISSUE RES, V245, P343; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021, DOI 10.1523/JNEUROSCI.15-03-02021.1995; GRAY GE, 1992, DEVELOPMENT, V114, P271; GRITTI A, 1995, NEUROSCI LETT, V185, P151, DOI 10.1016/0304-3940(95)11247-T; Gritti A, 1999, J NEUROSCI, V19, P3287; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061; Jacobson M., 1991, DEV NEUROBIOLOGY; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KISHI K, 1987, J COMP NEUROL, V258, P112, DOI 10.1002/cne.902580109; KORR H, 1973, J COMP NEUROL, V150, P169, DOI 10.1002/cne.901500205; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MESSIER B, 1958, EXP CELL RES, V14, P224, DOI 10.1016/0014-4827(58)90235-0; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; Okada A, 1999, EXP NEUROL, V156, P394, DOI 10.1006/exnr.1999.7033; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; PATERSON JA, 1973, J COMP NEUROL, V149, P83, DOI 10.1002/cne.901490106; Peters A., 1991, FINE STRUCTURE NERVO; POTTEN CS, 1988, J CELL SCI, P45; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Qian XM, 1998, DEVELOPMENT, V125, P3143; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; Shi JY, 1998, J NEUROSCI, V18, P4627; SMART I, 1961, J COMP NEUROL, V116, P325, DOI 10.1002/cne.901160306; SOTELO JR, 1958, Z ZELLFORSCH MIK ANA, V49, P1, DOI 10.1007/BF00335059; SPRANGRUDE GJ, 1988, SCIENCE, V241, P58; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Weiss S, 1996, J NEUROSCI, V16, P7599; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; WILKIN GP, 1990, TRENDS NEUROSCI, V13, P43, DOI 10.1016/0166-2236(90)90065-I; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403; Yoon SO, 1996, P NATL ACAD SCI USA, V93, P11974, DOI 10.1073/pnas.93.21.11974; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	73	2997	3142	5	172	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					703	716		10.1016/S0092-8674(00)80783-7	http://dx.doi.org/10.1016/S0092-8674(00)80783-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380923	Bronze			2022-12-28	WOS:000080886300009
J	Zimmerberg, J				Zimmerberg, J			Virology - Hole-istic medicine	SCIENCE			English	Editorial Material							PROTEIN SECRETION SYSTEMS; ESCHERICHIA-COLI; MEMBRANE; CHANNELS		NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zimmerberg, J (corresponding author), NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA.	joshz@helix.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001409] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001409] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; MELIKYAN GB, IN PRESS MOL BIOL CE; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Pugsley AP, 1997, GENE, V192, P13, DOI 10.1016/S0378-1119(96)00803-7; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Russel M, 1998, J MOL BIOL, V279, P485, DOI 10.1006/jmbi.1998.1791; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0	13	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1475	+		10.1126/science.284.5419.1475	http://dx.doi.org/10.1126/science.284.5419.1475			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10383325				2022-12-28	WOS:000080548100023
J	Coffman, RL; Reiner, SL				Coffman, RL; Reiner, SL			Immunology - Instruction, selection, or tampering with the odds?	SCIENCE			English	Editorial Material							T-LYMPHOCYTES; EXPRESSION; CELLS; ACTIVATION; MECHANISM; ALLELES; LINEAGE		DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Chicago	Coffman, RL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, 901 Calif Ave, Palo Alto, CA 94304 USA.	Coffman@dnax.org; sreiner@midway.uchicago.edu						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Chess A, 1998, ADV IMMUNOL, V69, P437, DOI 10.1016/S0065-2776(08)60613-6; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Naramura M, 1998, IMMUNITY, V9, P209, DOI 10.1016/S1074-7613(00)80603-2; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; WEINTRAUB H, 1977, COLD SPRING HARB SYM, V42, P401, DOI 10.1101/SQB.1978.042.01.042; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	17	47	48	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1283	+		10.1126/science.284.5418.1283	http://dx.doi.org/10.1126/science.284.5418.1283			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383307				2022-12-28	WOS:000080430600029
J	Batista, AP; Buneo, CA; Snyder, LH; Andersen, RA				Batista, AP; Buneo, CA; Snyder, LH; Andersen, RA			Reach plans in eye-centered coordinates	SCIENCE			English	Article							POSTERIOR PARIETAL CORTEX; PREMOTOR CORTEX; VISUAL SPACE; NEURONAL-ACTIVITY; MACAQUE MONKEY; MOVEMENTS; AREAS; GAZE	The neural events associated with visually guided reaching begin with an image on the retina and end with impulses to the muscles, In between, a reaching plan is formed, This plan could be in the coordinates of the arm, specifying the direction and amplitude of the movement, or it could be in the coordinates of the eye because visual information is initially gathered in this reference frame. In a reach-planning area of the posterior parietal cortex, neural activity was found to be more consistent with an eye-centered than an arm-centered coding of reach targets. Coding of arm movements in an eye-centered reference frame is advantageous because obstacles that affect planning as well as errors in reaching are registered in this reference frame. Also, eye movements are planned in eye coordinates, and the use of similar coordinates for reaching may facilitate hand-eye coordination.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, Mail Code 216-76, Pasadena, CA 91125 USA.		Snyder, Lawrence H/A-4593-2017	Batista, Aaron/0000-0002-1719-0061				BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; Boussaoud D, 1998, J NEUROPHYSIOL, V80, P1132, DOI 10.1152/jn.1998.80.3.1132; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P517, DOI 10.1016/0028-3932(91)90008-V; Colby CL, 1998, NEURON, V20, P15, DOI 10.1016/S0896-6273(00)80429-8; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Galletti C, 1997, EUR J NEUROSCI, V9, P410, DOI 10.1111/j.1460-9568.1997.tb01410.x; GEORGOPOULOS AP, 1983, EXP BRAIN RES, V49, P327; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Hein A, 1958, PERCEPT MOTOR SKILL, V8, P87, DOI [DOI 10.2466/PMS.1958.8.3.87, 10.2466/pms.1958.8.3.87]; Henriques DYP, 1998, J NEUROSCI, V18, P1583; Jeannerod M., 1988, NEURAL BEHAV ORG GOA; JOHNSON PB, 1996, CEREB CORTEX, V6, P1047; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; McIntyre J, 1997, J NEUROPHYSIOL, V78, P1601, DOI 10.1152/jn.1997.78.3.1601; Murata A, 1996, J NEUROPHYSIOL, V75, P2180, DOI 10.1152/jn.1996.75.5.2180; Mushiake H, 1997, J NEUROPHYSIOL, V78, P567, DOI 10.1152/jn.1997.78.1.567; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; Sabes PN, 1997, J NEUROSCI, V17, P7119; SCOTT DW, 1985, ANN STAT, V13, P1024, DOI 10.1214/aos/1176349654; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Soechting J F, 1990, J Cogn Neurosci, V2, P32, DOI 10.1162/jocn.1990.2.1.32; Vetter P, 1999, J NEUROPHYSIOL, V81, P935, DOI 10.1152/jn.1999.81.2.935; WALKER MF, 1995, J NEUROPHYSIOL, V73, P1988, DOI 10.1152/jn.1995.73.5.1988; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	32	524	531	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					257	260		10.1126/science.285.5425.257	http://dx.doi.org/10.1126/science.285.5425.257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398603				2022-12-28	WOS:000081346000043
J	Pitt, B; Waters, D; Brown, WV; van Boven, AJ; Schwartz, L; Title, LM; Eisenberg, D; Shurzinske, L; McCormick, LS				Pitt, B; Waters, D; Brown, WV; van Boven, AJ; Schwartz, L; Title, LM; Eisenberg, D; Shurzinske, L; McCormick, LS		Atorvastatin Versus Revascularization Treatment	Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL THERAPY; REVASCULARIZATION; TRIAL	Background Percutaneous coronary revascularization is widely used in improving symptoms and exercise performance in patients with ischemic heart disease and stable angina pectoris. In this study, we compared percutaneous coronary revascularization with lipid-lowerin Methods We studied 341 patients with stable coronary artery disease, relatively normal left ventricular function, asymptomatic or mild-to-moderate angina, and a serum level of low-density lipoprotein (LDL) cholesterol of at least 115 mg per deciliter (3.0 mmol per liter) who were referred for percutaneous revascularization. We randomly assigned the patients either to receive medical treatment with atorvastatin, at 80 mg per day (164 patients), or to undergo the recommended percutaneous revascularization procedure (angioplasty) followed by usual care, which could include lipid-lowering treatment (177 patients). The follow-up period was 18 months. Results Twenty-two (13 percent) of the patients who received aggressive lipid-lowering treatment with atorvastatin (resulting in a 46 percent reduction in the mean serum LDL cholesterol level, to 77 mg per deciliter [2.0 mmol per liter]) had ischemic events, as compared with 37 (21 percent) of the patients who underwent angioplasty (who had an 18 percent reduction in the mean serum LDL cholesterol level, to 119 mg per deciliter [3.0 mmol per liter]). The incidence of ischemic events was thus 36 percent lower in the atorvastatin group over an 18-month period (P=0.048, which was not statistically significant after adjustment for interim analyses). This reduction in events was due to a smaller number of angioplasty procedures, coronary-artery bypass operations, and hospitalizations for worsening angina. As compared with the patients who were treated with angioplasty and usual care, the patients who received atorvastatin had a significantly longer time to the first ischemic event (P=0.03). Conclusions In low-risk patients with stable coronary artery disease, aggressive lipid-lowering therapy is at least as effective as angioplasty and usual care in reducing the incidence of ischemic events. (N Engl J Med 1999;341:70-6.) (C) 1999, Massachusetts Medical Society.	Univ Michigan, Med Ctr, Sch Med, Dept Med,Div Cardiol, Ann Arbor, MI 48109 USA; Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA USA; Univ Hosp, Thoraxctr, Groningen, Netherlands; Toronto Hosp, Dept Med, Toronto, ON M5T 2S8, Canada; Queen Elizabeth 2 Hlth Sci Ctr, Div Cardiol, Halifax, NS, Canada; Providence St Joseph Med Ctr, Los Angeles, CA USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Ann Arbor, MI USA	University of Michigan System; University of Michigan; Hartford Hospital; Emory University; University of Groningen; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Queen Elizabeth II Health Sciences Centre; Pfizer	Pitt, B (corresponding author), Univ Michigan, Med Ctr, Sch Med, Dept Med,Div Cardiol, 3910 Taubman,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bpitt@umich.edu	Brown, William/GXN-2777-2022					*2 RAND INT TREATM, 1997, LANCET, V350, P461; BRASSEUR LA, 1983, NORMAL VALUES ADULT, P3; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Forrester JS, 1997, CIRCULATION, V96, P1360, DOI 10.1161/01.CIR.96.4.1360; GELLER NL, 1988, BIOPHARMACEUTICAL ST, P489; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; JANICKI JS, 1986, CARDIOPULMONARY EXER, P147; McCormick LS, 1997, AM J CARDIOL, V80, P1130, DOI 10.1016/S0002-9149(97)00627-9; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1993, SF36 HLTH SURVEY MAN; WATERS D, 1994, PROG CARDIOVASC DIS, V37, P107, DOI 10.1016/S0033-0620(05)80038-6	14	684	724	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					70	76		10.1056/NEJM199907083410202	http://dx.doi.org/10.1056/NEJM199907083410202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395630				2022-12-28	WOS:000081316200002
J	Akca, O; Melischek, M; Scheck, T; Hellwagner, K; Arkilic, CF; Kurz, A; Kapral, S; Heinz, T; Lackner, FX; Sessler, DI				Akca, O; Melischek, M; Scheck, T; Hellwagner, K; Arkilic, CF; Kurz, A; Kapral, S; Heinz, T; Lackner, FX; Sessler, DI			Postoperative pain and subcutaneous oxygen tension	LANCET			English	Article							WOUND-INFECTION	Surgical patients randomly assigned to standard pain control had postoperative subcutaneous oxygen partial pressures that were significantly less than patients given better pain treatment. Our data suggest that control of postoperative pain is a major determinant of surgical-wound infection and should be given the same consideration as maintaining adequate vascular volume and normothermia.	Univ Vienna, Dept Anaesthesia & Gen Intens Care, A-1090 Vienna, Austria; Washington Univ, Dept Anaesthesiol, St Louis, MO USA; Univ Vienna, Dept Traumatol, Vienna, Austria; Univ Calif San Francisco, Dept Anaesthesia & Perioperat Care, San Francisco, CA 94143 USA; Ludwig Boltzman Inst Clin Anaesthesia & Intens Ca, Vienna, Austria	University of Vienna; Washington University (WUSTL); University of Vienna; University of California System; University of California San Francisco; Ludwig Boltzmann Institute	Sessler, DI (corresponding author), Univ Vienna, Dept Anaesthesia & Gen Intens Care, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Akca, Ozan/I-8856-2019; Sessler, Daniel/D-3504-2011	Akca, Ozan/0000-0002-7275-1060; Sessler, Daniel/0000-0001-9932-3077; Kurz, Andrea/0000-0001-5887-3099	NIGMS NIH HHS [GM58273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		GOTTRUP F, 1987, CRIT CARE MED, V15, P1030, DOI 10.1097/00003246-198711000-00008; HALTER JB, 1977, J CLIN ENDOCR METAB, V45, P936, DOI 10.1210/jcem-45-5-936; HOHN DC, 1976, SURG FORUM, V27, P18; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901	5	172	180	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					41	42		10.1016/S0140-6736(99)00874-0	http://dx.doi.org/10.1016/S0140-6736(99)00874-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406365				2022-12-28	WOS:000081243200014
J	Chadwick, D				Chadwick, D		Vigabatrin European Monotherapy Study Grp	Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study	LANCET			English	Article							GAMMA-VINYL GABA; DRUG-RESISTANT EPILEPSY; TONIC CLONIC SEIZURES; COMPARATIVE TRIAL; SODIUM VALPROATE; 4-AMINO-HEX-5-ENOIC ACID; ANTIEPILEPTIC DRUGS; MONOTHERAPY; TOLERABILITY; LAMOTRIGINE	Background Vigabatrin is a newly licensed drug for use in patients with epilepsy. We investigated whether this drug was comparable to standard first-line monotherapy in efficacy and incidence of adverse events. Methods We enrolled 459 patients with newly diagnosed, previously untreated partial epileptic seizures from 44 European centres and randomly assigned them carbamazepine 600 mg daily (n=230) or vigabatrin 2 g daily (n=229). After initial maintenance doses were reached, doses were adjusted downwards (in the case of adverse events) or upwards (in the case of seizures) by the clinician. The primary outcome was time to withdrawal because of lack of efficacy or adverse events. Secondary outcomes included efficacy (time to 6-month remission of seizures, time to first seizure after initial dose stabilisation), and adverse events (incidence and severity). Analysis was by intention to treat. Findings Time to withdrawal for lack of efficacy or adverse events did not differ between groups (p=0.318). Vigabatrin was better tolerated than carbamazepine with fewer withdrawals, but was more frequently associated with psychiatric symptoms (58 [25%] vs 34 [15%]) and weight gain (25 [11%] vs 12 [5%]). Carbamazepine was associated with rash (22 [10%] vs seven [3%]). All efficacy outcomes favoured carbamazepine and failed to show equivalence between the two drugs. No significant difference was found for time to achieve 6 months of remission from seizures (p=0.058), but the most powerful outcome, time to first seizure after the first 6 weeks from randomisation, showed carbamazepine to be significantly more effective than vigabatrin (p=0.0001). Interpretation Vigabatrin seems less effective but better tolerated than carbamazepine, which is the first-choice drug for the treatment of partial epilepsies. Vigabatrin cannot therefore be recommended as a first-line drug for monotherapy in this group of patients.	Univ Liverpool, Walton Ctr Neurol & Neurosurg, Dept Neurol Sci, Liverpool L9 1AE, Merseyside, England	University of Liverpool; Walton Centre	Chadwick, D (corresponding author), Univ Liverpool, Walton Ctr Neurol & Neurosurg, Dept Neurol Sci, Liverpool L9 1AE, Merseyside, England.			Tassinari, Carlo Alberto/0000-0002-4183-5165; Beran, Roy/0000-0002-5884-0606; Somerville, Ernest/0000-0001-8789-1122; Duncan, John S/0000-0002-1373-0681; Michelucci, Roberto/0000-0002-9655-7940				Appleton Richard E., 1996, Epilepsia, V37, P125; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; CANNON DJ, 1991, J CHILD NEUROL, V6, pS17; Chadwick D, 1998, EPILEPSIA, V39, P799; Chiron C, 1997, EPILEPSY RES, V26, P389, DOI 10.1016/S0920-1211(96)01006-6; Eke T, 1997, BRIT MED J, V314, P180, DOI 10.1136/bmj.314.7075.180; FERRENDELLI JA, 1995, EPILEPSIA, V36, pS115, DOI 10.1111/j.1528-1157.1995.tb05994.x; Gale K, 1986, Adv Neurol, V44, P343; GRAHAM D, 1989, BRIT J CLIN PHARMACO, V27, pS43, DOI 10.1111/j.1365-2125.1989.tb03460.x; GRAM L, 1985, ANN NEUROL, V17, P262, DOI 10.1002/ana.410170307; GROVE J, 1981, LIFE SCI, V28, P2431, DOI 10.1016/0024-3205(81)90511-7; HAMMOND E J, 1991, Epilepsia, V32, P11; HELLER AJ, 1995, J NEUROL NEUROSUR PS, V58, P44, DOI 10.1136/jnnp.58.1.44; JACKSON GD, 1994, EPILEPSY RES, V18, P127, DOI 10.1016/0920-1211(94)90005-1; Jacoby A, 1998, EPILEPSIA, V39, P776, DOI 10.1111/j.1528-1157.1998.tb01164.x; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; JUNG MJ, 1977, J NEUROCHEM, V29, P797, DOI 10.1111/j.1471-4159.1977.tb10721.x; KALVIAINEN R, 1995, ARCH NEUROL-CHICAGO, V52, P989, DOI 10.1001/archneur.1995.00540340081016; Kalviainen Reetta, 1998, Epilepsia, V39, P72; Krauss GL, 1998, NEUROLOGY, V50, P614, DOI 10.1212/WNL.50.3.614; LOISEAU P, 1986, EPILEPSIA, V27, P115, DOI 10.1111/j.1528-1157.1986.tb03512.x; Marson AG, 1997, EPILEPSIA, V38, P859, DOI 10.1111/j.1528-1157.1997.tb01251.x; Marson AG, 1996, BMJ-BRIT MED J, V313, P1169, DOI 10.1136/bmj.313.7066.1169; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Petroff OAC, 1996, NEUROLOGY, V46, P1459, DOI 10.1212/WNL.46.5.1459; Reunanen M, 1996, EPILEPSY RES, V23, P149, DOI 10.1016/0920-1211(95)00085-2; RICHENS A, 1994, J NEUROL NEUROSUR PS, V57, P682, DOI 10.1136/jnnp.57.6.682; RIMMER EM, 1984, LANCET, V1, P189; SANDER JWAS, 1990, J NEUROL NEUROSUR PS, V53, P1008, DOI 10.1136/jnnp.53.11.1008; Schechter P J, 1979, Adv Exp Med Biol, V123, P43; TANGANELLI P, 1994, EPILIPSIA, V35, pS64; TASSINARI CA, 1987, ARCH NEUROL-CHICAGO, V44, P907, DOI 10.1001/archneur.1987.00520210009010; VERITY CM, 1995, DEV MED CHILD NEUROL, V37, P97; Vigevano F, 1997, EPILEPSIA, V38, P1270; WEISS KL, 1994, NEUROLOGY, V44, P1944, DOI 10.1212/WNL.44.10.1944; WHITE HS, 1997, EPILEPSIES, V2, P1	37	155	157	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					13	19		10.1016/S0140-6736(98)10531-7	http://dx.doi.org/10.1016/S0140-6736(98)10531-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406359				2022-12-28	WOS:000081243200008
J	Perozo, E; Cortes, DM; Cuello, LG				Perozo, E; Cortes, DM; Cuello, LG			Structural rearrangements underlying K+-channel activation gating	SCIENCE			English	Article							PARAMAGNETIC-RESONANCE DATA; STREPTOMYCES-LIVIDANS; SECONDARY STRUCTURE; SPIN-LABELS; CIRCULAR-DICHROISM; POTASSIUM CHANNEL; PROTEIN-STRUCTURE; RECEPTOR CHANNEL; ION-CHANNEL; T4 LYSOZYME	The intramembrane molecular events underlying activation gating in the Streptomyces K+ channel were investigated by site-directed spin-labeling methods and electron paramagnetic resonance spectroscopy. A comparison of the closed and open conformations of the channel revealed periodic changes in spin-label mobility and intersubunit spin-spin interaction consistent with rigid-body movements of the two transmembrane helices TM1 and TM2. These changes involve translations and counterclockwise rotations of both helices relative to the center of symmetry of the channel. The movement of TM2 increases the diameter of the permeation pathway along the point of convergence of the four subunits, thus opening the pore, Although the extracellular residues flanking the selectivity filter remained immobile during gating, small movements were detected at the C-terminal end of the pore helix. with possible implications to the gating mechanism.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Ctr Struct Biol, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Perozo, E (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA.				NIGMS NIH HHS [GM57846, GM54690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057846, R01GM054690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Aidley D.J., 1996, ION CHANNELS MOL ACT; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chapman ML, 1997, BIOPHYS J, V72, P708, DOI 10.1016/S0006-3495(97)78707-1; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; CORTES DM, 1999, 43 ANN M BIOPH SOC B; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; CUELLO LG, 1999, 43 ANN M BIOPH SOC B; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DONNELLY D, 1994, PROTEIN ENG, V7, P645, DOI 10.1093/protein/7.5.645; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EATON GR, 1989, SPIN LABELING THEORY; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B., 1992, ION CHANNELS EXCITAB; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; le Coutre J, 1998, P NATL ACAD SCI USA, V95, P6114, DOI 10.1073/pnas.95.11.6114; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Steinhoff HJ, 1997, BIOPHYS J, V73, P3287, DOI 10.1016/S0006-3495(97)78353-X; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; YELLEN G, IN PRESS Q REV BIOPH; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101	42	489	499	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					73	78		10.1126/science.285.5424.73	http://dx.doi.org/10.1126/science.285.5424.73			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390363				2022-12-28	WOS:000081199800030
J	Swinburn, JMA; Ali, SM; Banerjee, DJ; Khan, ZP				Swinburn, JMA; Ali, SM; Banerjee, DJ; Khan, ZP			To whom is our duty of care?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England		Khan, ZP (corresponding author), City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England.							[Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; *C MED ROYAL COLL, 1995, J R COLL PHYSICIANS, V29, P381; PALLIS C, 1983, BRIT MED J, V286, P123, DOI 10.1136/bmj.286.6359.123; SPRUNG CL, 1995, CRIT CARE MED, V23, P618, DOI 10.1097/00003246-199504000-00004	5	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1753	1754						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381716				2022-12-28	WOS:000081216900038
J	Feneley, MR; Walsh, PC				Feneley, MR; Walsh, PC			Incontinence after radical prostatectomy	LANCET			English	Editorial Material							COLLAGEN INJECTION THERAPY; QUALITY-OF-LIFE; RETROPUBIC PROSTATECTOMY; URINARY-INCONTINENCE; FOLLOW-UP; CONTINENCE; SURGERY; CANCER		Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Feneley, MR (corresponding author), Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA.							APPELL RA, 1994, UROL CLIN N AM, V21, P177; Burnett AL, 1998, J UROLOGY, V160, P1301, DOI 10.1016/S0022-5347(01)62521-7; Eastham JA, 1996, J UROLOGY, V156, P1707, DOI 10.1016/S0022-5347(01)65488-0; Ficazzola MA, 1998, J UROLOGY, V160, P1317, DOI 10.1016/S0022-5347(01)62525-4; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GEARY ES, 1995, UROLOGY, V45, P1000; Haab F, 1997, J UROLOGY, V158, P435, DOI 10.1016/S0022-5347(01)64496-3; MAATHEWSONCHAPM.M, 1997, J CANCER EDUC, V12, P218; SanchezOrtiz RF, 1997, J UROLOGY, V158, P2132, DOI 10.1016/S0022-5347(01)68177-1; STEINER MS, 1991, J UROLOGY, V145, P512, DOI 10.1016/S0022-5347(17)38382-9; Talcott JA, 1997, J NATL CANCER I, V89, P1117, DOI 10.1093/jnci/89.15.1117; Tefilli MV, 1998, UROLOGY, V52, P224, DOI 10.1016/S0090-4295(98)00151-4; Walsh Patrick C., 1999, Journal of Urology, V161, P387; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Walsh PC, 1998, J UROLOGY, V160, P2418, DOI 10.1016/S0022-5347(01)62202-X; WEIN AJ, 1995, UROL CLIN N AM, V22, P557	16	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2091	2092		10.1016/S0140-6736(98)00355-9	http://dx.doi.org/10.1016/S0140-6736(98)00355-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382690	hybrid			2022-12-28	WOS:000080969300006
J	Horton, R				Horton, R			Croatia and Bosnia: the imprints of war - I. Consequences	LANCET			English	Article							MAJOR ARTERIES; INJURIES; RECONSTRUCTION; EXTREMITIES; VESSELS	As Serbia and Kosovo emerge from yet another European war, their people's health and the region's health care, scientific research, and medical education have been seriously damaged and disrupted. There are lessons to be learned from recent Balkan wars, lessons that might help doctors, international relief organisations, and governments to do better than they have done elsewhere during the long reconstruction period that will follow this recent savage conflict. An analysis of the medical legacies of war may also raise issues for doctors worldwide to consider as part of their role in a larger public-health community. For a week in May, 1999, I travelled to Croatia and the Croat-Muslim Federation of Bosnia-Herzegovina to meet doctors working in peace but next to war. In the first part of this essay, I briefly survey some of the medical consequences of the Croatian and Bosnian conflicts. In the second part, to be published in the June 26 issue, I consider plans for and limitations to restoration, and try to identify possible opportunities for prevention of the adverse health effects of war In a newly enlarged Europe.	The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, 42 Bedford Sq, London WC1B 3SL, England.							Arcel Libby Tata, 1998, WAR VIOLENCE TRAUMA, P183; BALEN I, 1995, MIL MED, V160, P588, DOI 10.1093/milmed/160.11.588; *CHILDR RIGHTS COM, 1994, VIOL CONV RIGHTS CHI; DEFINISGOJANOVI.M, 1995, CROAT MED J, V36, P282; Gray C. H., 1997, POSTMODERN WAR NEW P; HALILOVIC E, 1995, CROAT MED J, V36, P65; Janosi Kresimir, 1995, Croatian Medical Journal, V36, P104; Kocijan-Hercigonja D, 1998, NORD J PSYCHIAT, V52, P45, DOI 10.1080/080394898422562; Kozaric-Kovacic D, 1999, NORD J PSYCHIAT, V53, P11; KOZARICKOVACIC D, 1995, AM J ORTHOPSYCHIAT, V65, P428, DOI 10.1037/h0079656; KOZARICKOVACIC D, 1993, CROAT MED J, V34, P86; Lang Slobodan, 1997, Croatian Medical Journal, V38, P265; Ljubic B, 1998, Croat Med J, V39, P276; Lovric Z, 1996, J CARDIOVASC SURG, V37, P223; Lovric Z, 1997, MIL MED, V162, P360, DOI 10.1093/milmed/162.5.360; LOVRIC Z, 1993, J CARDIOVASC SURG, V34, P33; LOVRIC Z, 1994, J TRAUMA, V36, P248, DOI 10.1097/00005373-199402000-00019; LOVRIC Z, 1993, J CARDIOVASC SURG, V34, P267; MIJATOVIC D, 1996, CROAT MED J, V37, P71; Pibernik-Okanovic M., 1991, Diabetologia Croatica, V20, P175; Puntaric D, 1997, MIL MED, V162, P333, DOI 10.1093/milmed/162.5.333; Simunkovic Gorana Tocilj, 1995, Croatian Medical Journal, V36, P253; Soldo S, 1999, MIL MED, V164, P141, DOI 10.1093/milmed/164.2.141; Soldo S, 1998, MIL MED, V163, P420, DOI 10.1093/milmed/163.6.420; Tanner M, 1997, CROATIA NATION FORGE; 1999, LANCET, V353, P1199	26	34	35	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2139	2144		10.1016/S0140-6736(99)05242-3	http://dx.doi.org/10.1016/S0140-6736(99)05242-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382711				2022-12-28	WOS:000080969300039
J	Marshall, MN				Marshall, MN			Improving quality in general practice: qualitative case study of barriers faced by health authorities	BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE INDICATORS	Objectives To identify and assess the barriers that health authorities face as they manage quality improvements in general practice in the context of the NHS reforms. Design Qualitative case study. Setting Three UK health authorities: a rural health authority in the south west, a deprived inner city health authority in the north east, and an affluent suburban health authority in the south east. Participants Senior and junior managers. Main outcome measures Structure of strategic and organisational management, and barriers to the leadership and management of quality improvement in general practice. Results Seven barriers were identified: absence of an explicit strategic plan for general practice, competing priorities for attention of the health authority, sensitivity of health professionals, lack of information due to poor quality of clinical data, lack of authority to implement change, unclear roles and responsibilities of managers within the organisations, and isolation from other authorities or organisations facing similar challenges. Conclusions The health authorities faced significant barriers that would impede their ability to fulfil their responsibilities in the new NHS and that would reduce their capacity to contribute to quality improvements in general practice.	Univ Exeter, Postgrad Sch Med & Hlth Sci, Inst Gen Practice, Exeter EX2 5DW, Devon, England	University of Exeter	Marshall, MN (corresponding author), Univ Exeter, Postgrad Sch Med & Hlth Sci, Inst Gen Practice, Exeter EX2 5DW, Devon, England.							Baker SJ, 1996, BRIT MED J, V312, P58, DOI 10.1136/bmj.312.7022.58b; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BERWICK DM, 1991, CURING HLTH CARE NEW; Clandinin DJ., 1994, HDB QUALITATIVE RES, P413; Davies HTO, 1998, QUAL HEALTH CARE, V7, P159, DOI 10.1136/qshc.7.3.159; FRATER A, 1993, SURVEY PURCHASERS US; GERTEIS M, 1993, PATIENTS EYES UNDERS, P227; Klein Rudolf, 1995, NEW POLITICS NHS; McColl A, 1998, QUAL HEALTH CARE, V7, P90, DOI 10.1136/qshc.7.2.90; Miles M., 2013, QUALITATIVE DATA ANA; Riley J, 1990, GETTING MOST YOUR DA; ROLAND M, 1998, QUALITY ASSESSMENT G; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; WESTON D, 1996, DEV PRIMARY CARE RES	14	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					164	167		10.1136/bmj.319.7203.164	http://dx.doi.org/10.1136/bmj.319.7203.164			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406756	Bronze, Green Published			2022-12-28	WOS:000081619300026
J	Briggs, A				Briggs, A			Economics notes - Handling uncertainty in economic evaluation	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE		Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England	University of Oxford	Briggs, A (corresponding author), Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England.		Briggs, Andrew/ABA-9009-2020	Briggs, Andrew/0000-0002-0777-1997				Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Briggs A., 1995, HANDLING UNCERTAINTY; MANNING WG, 1996, COST EFFECTIVENESS H; OBRIEN BJ, 1994, MED CARE, V32, P150, DOI 10.1097/00005650-199402000-00006; Petrou S, 1993, Pharmacoeconomics, V3, P345, DOI 10.2165/00019053-199303050-00002	6	53	54	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					120	120		10.1136/bmj.319.7202.120	http://dx.doi.org/10.1136/bmj.319.7202.120			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	216JD	10398643	Green Published			2022-12-28	WOS:000081438200042
J	Brisinda, G; Maria, G; Bentivoglio, AR; Cassetta, E; Gui, D; Albanese, A				Brisinda, G; Maria, G; Bentivoglio, AR; Cassetta, E; Gui, D; Albanese, A			A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLYCERYL TRINITRATE OINTMENT; INTERNAL SPHINCTEROTOMY; CONTROLLED TRIAL; NITRIC-OXIDE; THERAPY; RELAXATION; ANO	Background and Methods Lateral internal sphincterotomy, the most common treatment for chronic anal fissure, may cause permanent injury to the anal sphincter, which can lead to fecal incontinence, We compared two nonsurgical treatments that avert the risk of fecal incontinence. We randomly assigned 50 adults with symptomatic chronic posterior anal fissures to receive treatment with either a total of 20 U of botulinum toxin injected into the internal anal sphincter on each side of the anterior midline or 0.2 percent nitroglycerin ointment applied twice daily for six weeks. Results After two months, the fissures were healed in 24 of the 25 patients (96 percent) in the botulinum-toxin group and in 15 of the 25 (60 percent) in the nitroglycerin group (P=0.005). No patient in either group had fecal incontinence. At some time during treatment, five patients in the nitroglycerin group had transient, moderate-to-severe headaches that were related to treatment. None of the patients in the botulinum-toxin group reported adverse effects, Ten patients who did not have a response to the assigned treatment - 1 in the botulinum-toxin group and 9 in the nitroglycerin group - crossed over to the other treatment; the fissures subsequently healed in all 10 patients. There were no relapses during an average of about 15 months of follow-up. Conclusions Although treatment with either topical nitroglycerin or botulinum toxin is effective as an alternative to surgery for patients with chronic anal fissure, botulinum toxin is the more effective nonsurgical treatment. (N Engl J Med 1999;341:65-9.) (C) 1999, Massachusetts Medical Society.	Catholic Univ Rome, Inst Surg, Rome, Italy; Catholic Univ Rome, Inst Neurol, Rome, Italy; San Giovanni Calibita Hosp, Ctr Ricovero & Curo Caraterre Sci, Assoc Fatebenefratelli, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Maria, G (corresponding author), Policlin Univ Agostino Gemelli, Ist Clin Chirurg Gen, Largo Agostino Gemelli 8, I-00168 Rome, Italy.		Brisinda, Giuseppe/G-6436-2010; Bentivoglio, Anna Rita/K-3752-2018; Albanese, Alberto/K-7396-2016	Brisinda, Giuseppe/0000-0001-8820-9471; Albanese, Alberto/0000-0002-5864-0006; Bentivoglio, Anna Rita/0000-0002-9663-095X; Cassetta, Emanuele/0000-0003-1442-1458				ABCARIAN H, 1982, DIS COLON RECTUM, V25, P525, DOI 10.1007/BF02564159; ARMITAGE P, 1996, STAT MED METODI STAT; Bacher H, 1997, DIS COLON RECTUM, V40, P840, DOI 10.1007/BF02055444; Borodic G. E., 1994, THERAPY BOTULINUM TO, P119; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; CORMAN ML, 1998, COLON RECTAL SURG, V206, P23; EISENHAMMER S, 1951, S Afr Med J, V25, P486; FAROUK R, 1994, DIS COLON RECTUM, V37, P424, DOI 10.1007/BF02076185; FLESHMAN JW, 1998, FUNDAMENTALS ANORECT, P209; Garcia-Aguilar J, 1998, DIS COLON RECTUM, V41, P423, DOI 10.1007/BF02235754; GORFINE SR, 1995, NEW ENGL J MED, V333, P1156, DOI 10.1056/NEJM199510263331718; GUI D, 1994, LANCET, V344, P1127, DOI 10.1016/S0140-6736(94)90633-5; HSU TC, 1984, DIS COLON RECTUM, V27, P475, DOI 10.1007/BF02555546; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; JOST WH, 1994, DIS COLON RECTUM, V37, P1321, DOI 10.1007/BF02257805; KHUBCHANDANI IT, 1989, BRIT J SURG, V76, P431, DOI 10.1002/bjs.1800760504; LODER PB, 1994, BRIT J SURG, V81, P1386, DOI 10.1002/bjs.1800810949; Lund JN, 1996, BRIT J SURG, V83, P776, DOI 10.1002/bjs.1800830615; Lund JN, 1996, BRIT J SURG, V83, P1335, DOI 10.1002/bjs.1800831006; Lund JN, 1997, LANCET, V349, P11, DOI 10.1016/S0140-6736(96)06090-4; Lund JN, 1997, LANCET, V349, P656; Madoff RD, 1998, NEW ENGL J MED, V338, P257, DOI 10.1056/NEJM199801223380410; Maria G, 1998, ANN SURG, V228, P664, DOI 10.1097/00000658-199811000-00005; Maria G, 1998, NEW ENGL J MED, V338, P217, DOI 10.1056/NEJM199801223380402; Oettle GJ, 1997, DIS COLON RECTUM, V40, P1318, DOI 10.1007/BF02050816; Parker JD, 1998, NEW ENGL J MED, V338, P520, DOI 10.1056/NEJM199802193380807; RATTAN S, 1992, AM J PHYSIOL, V262, pG107, DOI 10.1152/ajpgi.1992.262.1.G107; ROSEN L, 1992, DIS COLON RECTUM, V35, P206; Simons AJ, 1996, LANCET, V348, P491, DOI 10.1016/S0140-6736(05)64667-3; TOTTRUP A, 1992, GASTROENTEROLOGY, V102, P409, DOI 10.1016/0016-5085(92)90084-C; Watson SJ, 1996, BRIT J SURG, V83, P771, DOI 10.1002/bjs.1800830614	31	263	271	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					65	69		10.1056/NEJM199907083410201	http://dx.doi.org/10.1056/NEJM199907083410201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395629				2022-12-28	WOS:000081316200001
J	Randolph, AG; Haynes, RB; Wyatt, JC; Cook, DJ; Guyatt, GH				Randolph, AG; Haynes, RB; Wyatt, JC; Cook, DJ; Guyatt, GH			Users' guides to the medical literature XVIII. How to use an article evaluating the clinical impact of a computer-based clinical decision support system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; TRIALS; PERFORMANCE; CARE; METAANALYSIS; DIAGNOSIS		McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Dept Anesthesia, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; UCL, Sch Publ Policy, London, England	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; McMaster University; University of London; University College London	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473; Randolph, Adrienne/0000-0002-3084-3071; Haynes, Robert Brian/0000-0002-1453-3196				ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; BERNER ES, 1994, NEW ENGL J MED, V330, P1792, DOI 10.1056/NEJM199406233302506; BRADSHAW KE, 1989, COMPUT BIOMED RES, V22, P575, DOI 10.1016/0010-4809(89)90077-3; CORNFIELD J, 1978, AM J EPIDEMIOL, V108, P100, DOI 10.1093/oxfordjournals.aje.a112592; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Friedman C.P., 1997, EVALUATION METHODS M, P41; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kennedy RL, 1997, COMPUT METH PROG BIO, V52, P93, DOI 10.1016/S0169-2607(96)01782-8; Klar N, 1997, STAT MED, V16, P1753, DOI 10.1002/(SICI)1097-0258(19970815)16:15<1753::AID-SIM597>3.0.CO;2-E; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEPAGE EF, 1992, TRANSFUSION, V32, P253, DOI 10.1046/j.1537-2995.1992.32392213810.x; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Morris A H, 1996, Proc AMIA Annu Fall Symp, P418; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PRYOR TA, 1990, INT J CLIN MONIT COM, V7, P137, DOI 10.1007/BF02915578; ROETHLIGSBURGER FJ, 1939, MANAGEMENT WORKER; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; Salvemini AV, 1998, M D COMPUT, V15, P311; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; Spiegelhalter D J, 1983, Stat Med, V2, P207, DOI 10.1002/sim.4780020215; STRICKLAND JH, 1993, CHEST, V103, P1220, DOI 10.1378/chest.103.4.1220; Tate K E, 1995, Proc Annu Symp Comput Appl Med Care, P164; Thompson SG, 1997, STAT MED, V16, P2063, DOI 10.1002/(SICI)1097-0258(19970930)16:18<2063::AID-SIM642>3.0.CO;2-8; WEINFURT PT, 1990, J CLIN MONITOR, V6, P132, DOI 10.1007/BF02828290; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005	32	86	88	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					67	74		10.1001/jama.282.1.67	http://dx.doi.org/10.1001/jama.282.1.67			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404914				2022-12-28	WOS:000081195800031
J	Andrews, E				Andrews, E			A memorable patient - A spirit of adventure prevails	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					44	44		10.1136/bmj.319.7201.44	http://dx.doi.org/10.1136/bmj.319.7201.44			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390463	Green Published			2022-12-28	WOS:000081326500036
J	Relling, MV; Rubnitz, JE; Rivera, GK; Boyett, JM; Hancock, ML; Felix, CA; Kun, LE; Walter, AW; Evans, WE; Pui, CH				Relling, MV; Rubnitz, JE; Rivera, GK; Boyett, JM; Hancock, ML; Felix, CA; Kun, LE; Walter, AW; Evans, WE; Pui, CH			High incidence of secondary brain tumours after radiotherapy and antimetabolites	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; 2ND MALIGNANT NEOPLASMS; HAMSTER OVARY CELLS; P53 GENE-MUTATIONS; CHEMOTHERAPEUTIC-AGENTS; CHILDHOOD; TUMORS; CANCER; CHILDREN; THERAPY	Background Brain tumours rarely occur in survivors of childhood acute lymphoblastic leukaemia after cranial radiotherapy. An unusually high frequency of brain tumours seen among children enrolled in one of our leukaemia treatment protocols, Total Therapy Study XII, prompted us to identify the potential causes of this complication. Methods We assessed clinical, biological, and pharmacokinetic features in all 52 children who received prophylactic cranial radiotherapy. We compared the cumulative incidence of brain tumours between subgroups, and with that of 421 children who received radiotherapy in previous studies. Findings The incidence of brain tumours among irradiated children (six of 52, 12.8% [SE 5.0]) was high compared with patients in the same study who did not receive radiotherapy (none of 101; p=0.0008) and with other protocols that included cranial radiotherapy (p<0.0001). Of the six children, four had erythrocyte concentrations of thioguanine nucleotide metabolites higher than the 70th percentile for the entire cohort, and three had a genetic defect in thiopurine catabolism, The 8-year cumulative incidence of brain tumour among children with defective versus wild-type thiopurine methyltransferase phenotype was 42.9% (SE 20.6) versus 8.3% (4.7; p=0.0077). This protocol differed from previous protocols, in that mow intensive systemic antimetabolite therapy was given before and during radiotherapy. Interpretation These data support the elimination of prophylactic radiotherapy for acute lymphoblastic leukaemia except in patients at high risk of central-nervous-system relapse. Underlying genetic characteristics and treatment variables may be associated with an increased risk of radiation-associated brain tumours.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Radiat Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat & Epidemiol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA; Univ Tennessee, Coll Pharm, Memphis, TN USA; Univ Penn, Childrens Hosp, Sch Med, Philadelphia, PA 19104 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Relling, MV (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale, Memphis, TN 38105 USA.		Pui, Ching-Hon/N-8076-2018; Rubnitz, Jeffrey E/N-2619-2018; Evans, William E./C-2069-2012; Relling, Mary/N-5032-2018	Pui, Ching-Hon/0000-0003-0303-5658; Rubnitz, Jeffrey E/0000-0001-9885-3527; Evans, William E./0000-0002-9333-5322; 	NATIONAL CANCER INSTITUTE [R29CA051001, R01CA051001, R37CA036401, R01CA036401, R01CA078224] Funding Source: NIH RePORTER; NCI NIH HHS [CA78224, CA36401, CA51001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUILINA G, 1990, CANCER RES, V50, P4248; BEHM FG, 1992, BLOOD, V79, P1011; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; Dalton VMK, 1998, J CLIN ONCOL, V16, P2848, DOI 10.1200/JCO.1998.16.8.2848; ELEXPURUCAMIRUAGA J, 1995, CANCER RES, V55, P4237; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; FELIX CA, 1995, MED PEDIATR ONCOL, V25, P431, DOI 10.1002/mpo.2950250603; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FONTANA M, 1987, CANCER, V60, P1510, DOI 10.1002/1097-0142(19871001)60:7<1510::AID-CNCR2820600718>3.0.CO;2-V; GELBER RD, 1993, CANCER, V72, P261, DOI 10.1002/1097-0142(19930701)72:1<261::AID-CNCR2820720146>3.0.CO;2-O; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; HIESSE C, 1995, TRANSPLANT P, V27, P972; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAMES SJ, 1994, CANCER RES, V54, P5075; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P84; Krynetski EY, 1998, AM J HUM GENET, V63, P11, DOI 10.1086/301941; KUIJTEN RR, 1993, CANCER CAUSE CONTROL, V4, P455, DOI 10.1007/BF00050865; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MODAN B, 1974, LANCET, V1, P277; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEUWELT EA, 1982, P NATL ACAD SCI-BIOL, V79, P4420, DOI 10.1073/pnas.79.14.4420; NYGAARD R, 1991, ACTA PAEDIATR SCAND, V80, P1220, DOI 10.1111/j.1651-2227.1991.tb11812.x; Qin DX, 1997, AM J CLIN ONCOL-CANC, V20, P263, DOI 10.1097/00000421-199706000-00011; ROSSO P, 1994, INT J CANCER, V59, P451, DOI 10.1002/ijc.2910590402; Rubnitz JE, 1997, LEUKEMIA, V11, P1201, DOI 10.1038/sj.leu.2400779; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; Sharif M, 1998, INT J ONCOL, V12, P273; SWENBERG JA, 1977, NATL CANCER I MONOGR, P3; VOLONTE C, 1993, MOL BIOL CELL, V4, P71, DOI 10.1091/mbc.4.1.71; Walter AW, 1998, J CLIN ONCOL, V16, P3761, DOI 10.1200/JCO.1998.16.12.3761; WEISBURGER EK, 1977, CANCER, V40, P1935, DOI 10.1002/1097-0142(197710)40:4+<1935::AID-CNCR2820400827>3.0.CO;2-R	35	284	293	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					34	39		10.1016/S0140-6736(98)11079-6	http://dx.doi.org/10.1016/S0140-6736(98)11079-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406363				2022-12-28	WOS:000081243200012
J	Simon, DB; Lu, Y; Choate, KA; Velazquez, H; Al-Sabban, E; Praga, M; Casari, C; Bettinelli, A; Colussi, C; Rodriguez-Soriano, J; McCredie, D; Milford, D; Sanjad, S; Lifton, RP				Simon, DB; Lu, Y; Choate, KA; Velazquez, H; Al-Sabban, E; Praga, M; Casari, C; Bettinelli, A; Colussi, C; Rodriguez-Soriano, J; McCredie, D; Milford, D; Sanjad, S; Lifton, RP			Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption	SCIENCE			English	Article							THICK ASCENDING LIMB; FAMILIAL HYPOMAGNESEMIA; MAGNESIUM TRANSPORT; COTRANSPORTER; PERMEABILITY; OCCLUDIN; RABBIT; LOOP	Epithelia permit selective and regulated flux from apical to basolateral surfaces by transcellular passage through cells or paracellular flux between cells. Tight junctions constitute the barrier to paracellular conductance; however, Little is known about the specific molecules that mediate paracellular permeabilities. Renal magnesium ion (Mg2+) resorption occurs predominantly through a paracellular conductance in the thick ascending limb of Henle (TAL), Here, positional cloning has identified a human gene, paracellin-1 (PCLN-1), mutations in which cause renal Mg2+ wasting. PCLN-1 is Located in tight junctions of the TAL and is related to the claudin family of tight junction proteins. These findings provide insight into Mg2+ homeostasis, demonstrate the role of a tight junction protein in human disease, and identify an essential component of a selective paracellular conductance.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Hosp 12 Octubre, Serv Nefrol, E-28041 Madrid, Spain; Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Milan, Dept Pediat 2, Milan, Italy; Niguarda Ca Granda Hosp, Div Renal, Milan, Italy; Hosp Cruces, Dept Pediat, E-48903 Baracaldo, Spain; Royal Childrens Hosp, Dept Nephrol, Parkville, Vic 3052, Australia; Childrens Hosp, Dept Nephrol, Birmingham B16 8ET, W Midlands, England; American Univ, Dept Pediat, Beirut, Lebanon	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; King Faisal Specialist Hospital & Research Center; Hospital Universitario 12 de Octubre; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Hospital Universitario Cruces; Royal Children's Hospital Melbourne; American University of Beirut	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		Colussi, Giacomo/AFV-2812-2022; Casari, Giorgio/J-3070-2018	Colussi, Giacomo/0000-0001-6133-1899; Casari, Giorgio/0000-0002-0115-8980	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051696] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK51696] Funding Source: Medline; Telethon [F.1, TGM06S01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Bonnet R, 1895, DEUT MED WOCHENSCHR, V21, P58; BRUNETTE MG, 1974, AM J PHYSIOL, V227, P891, DOI 10.1152/ajplegacy.1974.227.4.891; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; DEROUFFIGNAC C, 1994, PHYSIOL REV, V74, P305, DOI 10.1152/physrev.1994.74.2.305; DISTEFANO A, 1993, RENAL PHYSIOL BIOCH, V16, P157; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Kelepouris E, 1998, SEMIN NEPHROL, V18, P58; KOKKO JP, 1974, FED PROC, V33, P25; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Meij IC, 1999, AM J HUM GENET, V64, P180, DOI 10.1086/302199; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MORITA K, 1999, P NATL ACAD SCI USA, V78, P5759; PRAGA M, 1995, KIDNEY INT, V47, P1419, DOI 10.1038/ki.1995.199; QUAMME GA, 1980, AM J PHYSIOL, V238, P187; SHAREGHI GR, 1982, J CLIN INVEST, V69, P759, DOI 10.1172/JCI110514; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEELE TH, 1968, J LAB CLIN MED, V71, P455; Velazquez H, 1998, KIDNEY INT, V54, P464, DOI 10.1046/j.1523-1755.1998.00036.x; Walder RY, 1997, HUM MOL GENET, V6, P1491, DOI 10.1093/hmg/6.9.1491	24	832	861	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					103	106		10.1126/science.285.5424.103	http://dx.doi.org/10.1126/science.285.5424.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390358				2022-12-28	WOS:000081199800040
J	Socie, G; Stone, JV; Wingard, JR; Weisdorf, D; Henslee-Downey, PJ; Bredeson, C; Cahn, JY; Passweg, JR; Rowlings, PA; Schouten, HC; Kolb, HJ; Klein, JP				Socie, G; Stone, JV; Wingard, JR; Weisdorf, D; Henslee-Downey, PJ; Bredeson, C; Cahn, JY; Passweg, JR; Rowlings, PA; Schouten, HC; Kolb, HJ; Klein, JP		Late Effects Working Comm Int Bone Marr	Long-term survival and late deaths after allogeneic bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOGENOUS LEUKEMIA; SEVERE APLASTIC-ANEMIA; CHILDHOOD-CANCER; MYELOID-LEUKEMIA; UNRELATED DONORS; CHEMOTHERAPY; MORTALITY; BLOOD; CURE	Background and Methods It is uncertain whether mortality rates among patients who have undergone bone marrow transplantation return to the level of the mortality rates of the general population. We analyzed the characteristics of 6691 patients listed in the International Bone Marrow Transplant Registry. All the patients were free of their original disease two years after allogeneic bone marrow transplantation. Mortality rates in this cohort were compared with those of an age-, sex-, and nationality-matched general population. Cox proportional-hazards regression was used to identify risk factors for death more than two years after transplantation (late death). Results Among patients who were free of disease two yea rs after transplantation, the probability of living for five more years was 89 percent (95 percent confidence interval, 88 to 90 percent). Among patients who underwent transplantation for aplastic anemia, the risk of death by the sixth year after transplantation did not differ significantly from that of a normal population. Mortality remained significantly higher than normal throughout the study among patients who underwent transplantation for acute lymphoblastic leukemia or chronic myelogenous leukemia and through the ninth year among those who underwent transplantation for acute myelogenous leukemia. Recurrent leukemia was the chief cause of death among patients who received a transplant for leukemia, whereas chronic graft-versus-host disease was the chief cause among those who received a transplant for aplastic anemia. Advanced, long-standing disease before transplantation and active chronic graft-versus-host disease were important risk factors for late death. Conclusions In patients who receive an allogeneic bone marrow transplant as treatment for acute myelogenous or lymphoblastic leukemia, chronic myelogenous leukemia, or aplastic anemia and who are free of their original disease two years later, the disease is probably cured. However, for many years after transplantation, the mortality among these patients is higher than that in a normal population. (N Engl J Med 1999;341:14-21.) (C)1999, Massachusetts Medical Society.	Hop St Louis, Serv Hematol Greffe Moelle, Paris, France; Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Hlth Policy Inst, Milwaukee, WI 53226 USA; Univ Florida, Coll Med, Gainesville, FL USA; Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; Univ S Carolina, Div Transplantat Med, Columbia, SC 29208 USA; Univ Ottawa, Dept Med, Ottawa, ON, Canada; CHU Besancon, Serv Hematol, F-25030 Besancon, France; Kantonsspital Basel, Dept Med, Basel, Switzerland; Univ Hosp, Dept Internal Med, Maastricht, Netherlands; Univ Munich, Klinikum Grosshadern, Dept Hematol, D-8000 Munich, Germany; Univ Munich, Kinderpoliklin, Dept Hematol Oncol, Munich, Germany; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; Univ Miami, Sch Med, Div Pediat Hematol Oncol, Miami, FL USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical College of Wisconsin; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Ottawa; Universite de Franche-Comte; CHU Besancon; Maastricht University; University of Munich; University of Munich; Medical College of Wisconsin; University of Miami	Socie, G (corresponding author), Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Hlth Policy Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.		passweg, jakob/AAG-3911-2020	Passweg, Jakob R/0000-0001-7092-3351; Wingard, John/0000-0001-7478-5398	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP051028] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U24CA076518, P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-51028, P01-CA-40053, U24-CA-76518] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN PK, 1989, BIOMETRICS, V45, P523, DOI 10.2307/2531494; Appelbaum FR, 1997, CANCER, V80, P2199; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BARRETT AJ, 1994, NEW ENGL J MED, V331, P1253, DOI 10.1056/NEJM199411103311902; Beatty PG, 1997, EXP HEMATOL, V25, P1195; Cella D F, 1995, Oncology (Williston Park), V9, P47; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Deeg HJ, 1998, BLOOD, V91, P3637; deLima M, 1997, BLOOD, V90, P4719, DOI 10.1182/blood.V90.12.4719.4719_4719_4724; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; Freireich EJ, 1997, CANCER, V80, P2215, DOI 10.1002/(SICI)1097-0142(19971201)80:11+<2215::AID-CNCR9>3.0.CO;2-G; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Goldman JM, 1997, NEW ENGL J MED, V337, P270, DOI 10.1056/NEJM199707243370410; Green DM, 1996, MED PEDIATR ONCOL, V26, P72, DOI 10.1002/(SICI)1096-911X(199601)26:1<72::AID-MPO13>3.0.CO;2-D; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; HensleeDowney PJ, 1997, BLOOD, V89, P3864, DOI 10.1182/blood.V89.10.3864.3864_3864_3872; Horowitz M M, 1997, Curr Opin Hematol, V4, P395; Hudson MM, 1997, J CLIN ONCOL, V15, P2205, DOI 10.1200/JCO.1997.15.6.2205; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Klein JP., 2003, SURVIVAL ANAL TECHNI; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; NICHOLSON HS, 1994, CANCER, V73, P3094; Passweg JR, 1997, BLOOD, V90, P858; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; Storek J, 1997, AM J HEMATOL, V54, P131, DOI 10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y; SULLIVAN KM, 1994, BONE MARROW TRANSPL, P339; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	29	526	537	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					14	21		10.1056/NEJM199907013410103	http://dx.doi.org/10.1056/NEJM199907013410103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387937	Bronze			2022-12-28	WOS:000081195600003
J	Tan, LJ; Williams, MA; Khan, MK; Champion, HC; Nielsen, NH				Tan, LJ; Williams, MA; Khan, MK; Champion, HC; Nielsen, NH		American Medical Association	Risk of transmission of bovine spongiform encephalopathy to humans in the United States - Report of the Council on Scientific Affairs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN GENE; AMYLOID PLAQUES; SCRAPIE PRION; VARIANT CJD; PRP GENE; BSE; MICE; EPIDEMIOLOGY; CATTLE	Context The risk of possible transmission of bovine spongiform encephalopathy (BSE) in the United States is a substantial public health concern. Objective To systematically review the current scientific literature and discuss legislation and regulations that have been implemented to prevent the disease. Methods Literature review using the MEDLINE, EMBASE, and Lexis/Nexis databases for 1975 through 1997 on the terms bovine spongiform encephalopathy, prion diseases, prions, and Creutzfeldt-Jakob syndrome. The Internet was used to identify regulatory actions and health surveillance. Data Extraction MEDLINE, EMBASE, and Lexis/Nexis databases were searched from 1975 through 1997 for English-language articles that provided information on assessment of transmission risk. Results Unique circumstances in the United Kingdom caused the emergence and propagation of BSE in cattle, including widespread use of meat and bonemeal cattle feed derived from scrapie-infected sheep and the adoption of a new type of processing that did not reduce the amount of infectious prions prior to feeding. Many of these circumstances do not exist in the United States. In the United Kingdom, new variant Creutzfeldt-Jakob disease probably resulted from the ingestion of BSE-contaminated processed beef. The United Kingdom and the European Union now have strong regulations in place to stop the spread of BSE, While BSE has not been observed in the United States, the US government has surveillance and response plans in effect. Conclusions Current risk of transmission of BSE in the United States is minimal because (1) BSE has not been shown to exist in this country; (2) adequate regulations exist to prevent entry of foreign sources of BSE into the United States; (3) adequate regulations exist to prevent undetected cases of BSE from uncontrolled amplification within the US cattle population; and (4) adequate preventive guidelines exist to prevent high-risk bovine materials from contaminating products intended for human consumption.	Amer Med Assoc, Chicago, IL 60610 USA	American Medical Association	Tan, LJ (corresponding author), Care of Dickinson B, Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014; Tan, Litjen/0000-0001-9054-6696				Almond J, 1997, NATURE, V389, P437, DOI 10.1038/38876; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BECK E, 1964, BRAIN, V87, P153, DOI 10.1093/brain/87.1.153; BERG LJ, 1994, P NATL ACAD SCI USA, V91, P429, DOI 10.1073/pnas.91.2.429; BOLTON DC, 1988, CIBA F SYMP, V135, P164; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Brown P, 1998, BMJ-BRIT MED J, V317, P1688, DOI 10.1136/bmj.317.7174.1688; Brown P, 1997, JAMA-J AM MED ASSOC, V278, P1008, DOI 10.1001/jama.278.12.1008; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARP RI, 1994, ANN NY ACAD SCI, V724, P221, DOI 10.1111/j.1749-6632.1994.tb38912.x; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collee JG, 1997, LANCET, V349, P636, DOI 10.1016/S0140-6736(96)01310-4; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; CUTLIP RC, 1994, J INFECT DIS, V169, P814, DOI 10.1093/infdis/169.4.814; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; Dodelet V, 1996, CAN MED ASSOC J, V155, P549; DUFFY P, 1974, NEW ENGL J MED, V290, P692; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V265, P880, DOI 10.1001/jama.265.7.880; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1993, AM J HUM GENET, V53, P828; Gabizon R, 1997, TRENDS GENET, V13, P264, DOI 10.1016/S0168-9525(97)01116-5; GAJDUSEK DC, 1959, AM J MED, V26, P442, DOI 10.1016/0002-9343(59)90251-7; GAJDUSEK DC, 1985, HUMAN VIRAL INFECTIO, P1519; GIBBS CJ, 1994, J NEUROL NEUROSUR PS, V57, P757, DOI 10.1136/jnnp.57.6.757; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; GUIROY DC, 1993, ACTA NEUROPATHOL, V85, P437, DOI 10.1007/BF00334456; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HELLMAN KB, 1997, NAT MAN HLTH CAR C 2; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Holman RC, 1996, EMERG INFECT DIS, V2, P333, DOI 10.3201/eid0204.960409; HONSTEAD JP, 1997, NAT MAN HLTH CAR C 2; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUESTON WD, 1997, NAT MAN HLTH CAR C 2; Ironside JW, 1996, BRAIN PATHOL, V6, P379, DOI 10.1111/j.1750-3639.1996.tb00869.x; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; MacKnight C, 1996, CAN MED ASSOC J, V155, P529; MARSH RF, 1991, J GEN VIROL, V72, P589, DOI 10.1099/0022-1317-72-3-589; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; *MIN AGR FISH FOOD, 1998, MAFF BSE INF PUBL HL; *MIN AGR FISH FOOD, 1998, MAFF BSE INF SPEC RI; *MIN AGR FISH FOOD, 1998, MAFF BSE INF SEAC M; *MIN AGR FISH FOOD, 1998, MAFF BSE INF INC BSE; *MIN AGR FISH FOOD, 1998, MAFF BSE INF BON BEE; *MIN AGR FISH FOOD, 1998, MAFF BSE INF FEED BA; MURRAY I, 1999, SUNDAY LONDON TIMES; Narang H, 1996, P SOC EXP BIOL MED, V211, P306, DOI 10.3181/00379727-211-43975; Narang H, 1996, P SOC EXP BIOL MED, V212, P208, DOI 10.3181/00379727-212-44009; *NAT CJD SURV UN, 1999, MONTHL CREUTZF FIG; Nathanson N, 1997, AM J EPIDEMIOL, V145, P959, DOI 10.1093/oxfordjournals.aje.a009064; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; *OFF INT EP, 1998, BOV SPONG ENC; *OFF INT EP, 1998, INF REP BOV SPONG EN; Piccardo P, 1998, AM J PATHOL, V152, P1415; PORTER R, 1999, USDA RESTRICTS IMPOR; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Ricketts MN, 1997, EMERG INFECT DIS, V3, P155, DOI 10.3201/eid0302.970208; RIESNER D, 1992, E H S NEURO, P341; ROBAKIS NK, 1986, BIOCHEM BIOPH RES CO, V140, P758, DOI 10.1016/0006-291X(86)90796-5; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; TATEISHI J, 1984, ANN NEUROL, V15, P278, DOI 10.1002/ana.410150313; U. S. Food and Drug Administration, 1997, FED REGISTER, V62, P30936; *US FDA, 1997, FED REGISTER, V62, P52345; *US FDA, 1997, FED REGISTER, V62, P49694; *US FDA, 1999, CHANG GUID ENT REV P; *USDA, 1991, FED REGISTER, V56, P63868; *USDA, 1999, USDA CONT EFF PREV B; *USDA, 1998, BOV SPONG ENC; VONRADOWITZ J, 1998, PA NEWS; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; *WHO, 1999, WHOEMCZOO973; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1993, BRIT MED BULL, V49, P960, DOI 10.1093/oxfordjournals.bmb.a072655; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2; Zhang SG, 1997, P NATL ACAD SCI USA, V94, P23, DOI 10.1073/pnas.94.1.23; 1997, MMWR MORB MORTAL WKL, V46, P1066; 1999, WASHINGTON DRUG 0201, P5	103	26	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2330	2339		10.1001/jama.281.24.2330	http://dx.doi.org/10.1001/jama.281.24.2330			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386559				2022-12-28	WOS:000080925600034
J	Gong, JG; Costanzo, A; Yang, HQ; Melino, G; Kaelin, WG; Levrero, M; Wang, JYJ				Gong, JG; Costanzo, A; Yang, HQ; Melino, G; Kaelin, WG; Levrero, M; Wang, JYJ			The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage	NATURE			English	Article							MISMATCH REPAIR DEFICIENCY; FLOW-CYTOMETRY; CELLS; PROTEIN; P53; RADIATION; STRESS; MICE	Cancer chemotherapeutic agents such as cisplatin exert their cytotoxic effect by inducing DNA damage and activating programmed cell death (apoptosis), The tumour-suppressor protein p53 is an important activator of apoptosis. Although p53-deficient cancer cells are less responsive to chemotherapy, their resistance is not complete, which suggests that other apoptotic pathways may exist. A p53-related gene, p73, which encodes several proteins as a result of alternative splicing(1,2), can also induce apoptosis(3). Here we show that the amount of p73 protein in the cell is increased by cisplatin. This induction of p73 is not seen in cells unable to carry out mismatch repair and in which the nuclear enzyme c-Abl tyrosine kinase is not activated by cisplatin, The half-life of p73 is prolonged by cisplatin and by co-expression with c-Abl tyrosine kinase; the apoptosis-inducing function of p73 is also enhanced by the c-Abl kinase, Mouse embryo fibroblasts deficient in mismatch repair or in c-Abl do not upregulate p73 and are more resistant to killing by cisplatin. Our results indicate that c-Abl and p73 are components ofa mismatch-repair-dependent apoptosis pathway which contributes to cisplatin-induced cytotoxicity.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Roma La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, IRCCS, Ist Dermopatico Immacolata,Biochem Lab, I-00133 Rome, Italy; Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sapienza University Rome; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Costanzo, Antonio/GZG-2433-2022; Costanzo, Antonio/D-3896-2012; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; MELINO, GERRY/0000-0001-9428-5972; Levrero, Massimo/0000-0002-4978-0875	NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BOYER JC, 1995, CANCER RES, V55, P6063; Buermeyer AB, 1999, CANCER RES, V59, P538; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FINK D, 1995, CANCER RES, V57, P1841; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Nehme A, 1997, CANCER RES, V57, P3253; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	22	802	825	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					806	809						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391249				2022-12-28	WOS:000081101600059
J	Agnarsson, U; Thorgeirsson, G; Sigvaldason, H; Sigfusson, N				Agnarsson, U; Thorgeirsson, G; Sigvaldason, H; Sigfusson, N			Effects of leisure-time physical activity and ventilatory function on risk for stroke in men: The Reykjavik study	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; MONICA	Background: Stroke is a major ca use of illness, death, and health expenditures. Leisure-time physical activity may reduce the risk for stroke. Objective: To examine the association of leisure-time physical activity and pulmonary function with risk for stroke. Design: Prospective cohort study. Setting: Reykjavik, Iceland. Participants: 4484 men 45 to 80 yea rs of age followed for a mean (+/- SD) of 10.6 +/- 3.6 years. Measurements: Patients underwent physical examination, blood sampling, and spirometry and completed a questionnaire about health and exercise. Computerized hospital records were used to identify strokes, and the Icelandic National Registry was used to identify deaths. Results: New stroke developed in 249 men (5.6%) (hemorrhagic stroke in 44 [18%] and ischemic stroke in 205 [82%]). In a multivariable hazard analysis that controlled for known risk factors for cerebrovascular disease, leisure-time physical activity maintained after 40 years of age was associated with a reduced risk for stroke (relative risk, 0.69 [Cl, 0.47 to 1.01] for total stroke and 0.62 [Cl, 0.40 to 0.97] for ischemic stroke). Risk for stroke increased with diminished ventilatory function (FVC or FEV1) (relative risk, 1.9 [Cl, 1.06 to 3.25] for the lowest compared with the highest quintile). Conclusion: Middle-aged men who participate in leisure-time physical activity and have good pulmonary function seem to have a lower risk for stroke than men who are not active or have diminished pulmonary function.	Natl Univ Hosp Iceland, IS-101 Reykjavik, Iceland; Iceland Heart Assoc, Reykjavik, Iceland	Landspitali National University Hospital; Icelandic Heart Association	Agnarsson, U (corresponding author), Heart Prevent Clin, Lagmuli 9, IS-108 Reykjavik, Iceland.							ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; Eliasson M, 1996, INT J EPIDEMIOL, V25, P1182, DOI 10.1093/ije/25.6.1182; Eriksson KF, 1996, DIABETOLOGIA, V39, P573, DOI 10.1007/BF00403304; GEBSKI V, 1992, SPIDA USERS MANUAL V; Gillum RF, 1997, STROKE, V28, P1527, DOI 10.1161/01.STR.28.8.1527; KIELY DK, 1994, AM J EPIDEMIOL, V140, P608, DOI 10.1093/oxfordjournals.aje.a117298; KRAMSCH DM, 1981, NEW ENGL J MED, V305, P1483, DOI 10.1056/NEJM198112173052501; Lee IM, 1998, STROKE, V29, P2049, DOI 10.1161/01.STR.29.10.2049; Sacco RL, 1998, STROKE, V29, P380, DOI 10.1161/01.STR.29.2.380; SHINTON R, 1991, J EPIDEMIOL COMMUN H, V45, P138, DOI 10.1136/jech.45.2.138; SIGURDSSON E, 1993, EUR HEART J, V14, P584, DOI 10.1093/eurheartj/14.5.584; SIGURDSSON E, 1995, INT J EPIDEMIOL, V24, P58, DOI 10.1093/ije/24.1.58; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; Thorvaldsen P, 1997, STROKE, V28, P500, DOI 10.1161/01.STR.28.3.500; *US DEP HHS, 1996, PHYS ACT HLTH REP SU, P102; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; Wei M, 1999, ANN INTERN MED, V130, P89, DOI 10.7326/0003-4819-130-2-199901190-00002; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	20	54	54	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					987	990		10.7326/0003-4819-130-12-199906150-00006	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383369				2022-12-28	WOS:000080894700005
J	Owen, DJ; Vallis, Y; Noble, MEM; Hunter, JB; Dafforn, TR; Evans, PR; McMahon, HT				Owen, DJ; Vallis, Y; Noble, MEM; Hunter, JB; Dafforn, TR; Evans, PR; McMahon, HT			A structural explanation for the binding of multiple ligands by the alpha-adaptin appendage domain	CELL			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; COATED VESICLES; PROTEINS; EPS15; MEMBRANE; DYNAMIN; AP-2; AMPHIPHYSIN; COMPLEXES	The alpha subunit of the endocytotic AP2 adaptor complex contains a 30 kDa "appendage" domain, which is joined to the rest of the protein via a flexible linker. The 1.9 Angstrom resolution crystal structure of this domain reveals a single binding site for its ligands, which include amphiphysin, Eps15, and epsin. This domain when overexpressed in COS7 fibroblasts is shown to inhibit transferrin uptake, whereas mutants in which interactions with its binding partners are abolished do not. DPF/W motifs present in appendage domain-binding partners are shown to play a crucial role in their interactions with the domain. A single site for binding multiple ligands would allow for temporal and spatial regulation in the recruitment of components of the endocytic machinery.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Cambridge, CIMR, Dept Haematol, Cambridge CB2 2XY, England	MRC Laboratory Molecular Biology; University of Oxford; University of Cambridge	Evans, PR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pre@mrc-lmb.cam.ac.uk; hmm@mrc-lmb.cam.ac.uk	Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679; Noble, Martin/0000-0002-3595-9807				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CONNOLLY ML, 1985, J APPL CRYSTALLOGR, V18, P499, DOI 10.1107/S0021889885010779; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Goodford P, 1996, J CHEMOMETR, V10, P107; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; Iannolo G, 1997, CANCER RES, V57, P240; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LINDNER R, 1992, J BIOL CHEM, V267, P16567; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; ODRIDGE J, 1998, TRENDS CELL BIOL, V8, P302; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTH TF, 1964, J CELL BIOL, V20, P313, DOI 10.1083/jcb.20.2.313; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	54	241	252	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					805	815		10.1016/S0092-8674(00)80791-6	http://dx.doi.org/10.1016/S0092-8674(00)80791-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380931	Bronze			2022-12-28	WOS:000080886300017
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Dracula's wish	SCIENCE			English	Article									Mednav Com, Byfield, MA 01922 USA		Peters, R (corresponding author), Mednav Com, Byfield, MA 01922 USA.							McLean J, 1916, AM J PHYSIOL, V41, P250, DOI 10.1152/ajplegacy.1916.41.2.250; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Westerduin P, 1994, Bioorg Med Chem, V2, P1267, DOI 10.1016/S0968-0896(00)82078-7	3	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1294	1294		10.1126/science.284.5418.1294	http://dx.doi.org/10.1126/science.284.5418.1294			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383310				2022-12-28	WOS:000080430600035
J	Dickert, N; Grady, C				Dickert, N; Grady, C			What's the price of a research subject? Approaches to payment for research participation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Dickert, N (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							Ackerman Terrence F, 1989, IRB, V11, P1, DOI 10.2307/3564170; ANDERSON E, 1993, VALUE ETHICS EC, P245; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; ARENDT H, 1998, HUMAN CONDITION, P352; Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, P546; BIGORRA J, 1990, EUR J CLIN PHARMACOL, V38, P443, DOI 10.1007/BF02336681; *CENT WATCH, 1999, CENT WATCH CLIN TRIA; COHEN J, 1989, INT J MOD PHYS A, V4, P1, DOI 10.1142/S0217751X89000029; *DEP LAB, 1998, AV HOURL EARN PROD W; EPSTEIN RA, 1997, MORTAL PERIL OUR INA, P503; Faden Ruth, 1986, HIST THEORY INFORMED, P392; *FOOD DRUG ADM, 1998, INF SHEETS GUID I RE; Jonas H., 1970, EXPT HUMAN SUBJECTS, P1; LEVINE RJ, 1986, ETHICS REGULATION CL; Macklin Ruth, 1981, IRB, V3, P1, DOI 10.2307/3564136; McGee G, 1997, JAMA-J AM MED ASSOC, V278, P199, DOI 10.1001/jama.278.3.199; MURRAY TH, 1987, HASTINGS CENT REP, V17, P30, DOI 10.2307/3562041; *NAT COMM PROT HUM, 1979, BELM REP ETH PIRNC G; Newton Lisa H, 1982, IRB, V4, P4, DOI 10.2307/3564325; *NIH GUID GRANT CO, 1994, GUID INCL WOM MIN SU; *NIH GUID GRANTS C, 1998, NIH POL GUID INCL CH; *OFF PROT RES RISK, 1993, OFF IRB GUID; RADIN MJ, 1996, CONTESTED COMMODITIE, P279; Titmuss R. A, 1997, GIFT RELATIONSHIP HU; WARTOFSKY M, 1976, RES INVOLVING PRISON; Wilkinson M, 1997, BIOETHICS, V11, P373, DOI 10.1111/1467-8519.00078	26	275	276	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					198	203		10.1056/NEJM199907153410312	http://dx.doi.org/10.1056/NEJM199907153410312			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403861				2022-12-28	WOS:000081413800012
J	Catlin, EA; Roberts, JD; Erana, R; Preffer, FI; Ferry, JA; Kelliher, AS; Atkins, L; Weinstein, HJ				Catlin, EA; Roberts, JD; Erana, R; Preffer, FI; Ferry, JA; Kelliher, AS; Atkins, L; Weinstein, HJ			Transplacental transmission of natural-killer-cell lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HLA		Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Neonatol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Weinstein, HJ (corresponding author), Massachusetts Gen Hosp, Div Hematol & Oncol, Blake 2,55 Fruit St, Boston, MA 02114 USA.							Antonelli N M, 1996, Obstet Gynecol Surv, V51, P125, DOI 10.1097/00006254-199602000-00022; BENIRSCHKE K, 1995, PATHOLOGY HUMAN PLAC, P489; BENIRSCHKE K, 1995, PATHOLOGY HUMAN PLAC, P449; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; Chan JKC, 1997, BLOOD, V89, P4501, DOI 10.1182/blood.V89.12.4501; CRAMBLETT HG, 1958, NEW ENGL J MED, V259, P727, DOI 10.1056/NEJM195810092591507; DESAI RG, 1963, BLOOD, V21, P665, DOI 10.1182/blood.V21.6.665.665; Dildy G A 3rd, 1989, Obstet Gynecol Surv, V44, P535, DOI 10.1097/00006254-198907000-00008; HARRIS NL, 1994, BLOOD, V84, P1361; Hunt JS, 1997, J IMMUNOL, V158, P4122; HUTCHINSON DL, 1971, AM J OBSTET GYNECOL, V109, P281, DOI 10.1016/0002-9378(71)90876-3; MARZUSCH K, 1993, HUM REPROD, V8, P1203, DOI 10.1093/oxfordjournals.humrep.a138229; Ober C, 1998, AM J HUM GENET, V62, P1, DOI 10.1086/301692; OSADA S, 1990, CANCER, V65, P1146, DOI 10.1002/1097-0142(19900301)65:5<1146::AID-CNCR2820650519>3.0.CO;2-J; Piotrowski P, 1996, BIOL REPROD, V54, P1103, DOI 10.1095/biolreprod54.5.1103; POLLACK MS, 1982, NEW ENGL J MED, V307, P662, DOI 10.1056/NEJM198209093071106; Preffer Frederic I., 1995, P725; ZAROU DM, 1964, AM J OBSTET GYNECOL, V88, P565, DOI 10.1016/0002-9378(64)90881-6	19	60	63	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					85	91		10.1056/NEJM199907083410204	http://dx.doi.org/10.1056/NEJM199907083410204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395632				2022-12-28	WOS:000081316200004
J	Kovacs, A; Schluchter, M; Easley, K; Demmler, G; Shearer, W; La Russa, P; Pitt, J; Cooper, E; Goldfarb, J; Hodes, D; Kattan, M; McIntosh, K				Kovacs, A; Schluchter, M; Easley, K; Demmler, G; Shearer, W; La Russa, P; Pitt, J; Cooper, E; Goldfarb, J; Hodes, D; Kattan, M; McIntosh, K		Pediat Pulmonary Cardiovascular Complications	Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	XIth International Conference on AIDS	JUL 07-13, 1996	VANCOUVER, CANADA				HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; HOMOSEXUAL MEN; MULTIPLE IMPUTATION; AIDS PATIENTS; CMV DISEASE; TYPE-1; DNA; CHILDREN; MONONUCLEOSIS	Background and Methods Cytomegalovirus (CMV) has been implicated as a cofactor in the progression of human immunodeficiency virus type 1 (HIV-1) disease. We assessed 440 infants (75 of whom were HIV-1-infected and 365 of whom were not) whose CMV status was known, who were born to HIV-1-infected women, and who were followed prospectively. HIV-1 disease progression was defined as the presence of class C symptoms (according to the criteria of the Centers for Disease Control and Prevention [CDC]) or CD4 counts of less than 750 cells per cubic millimeter by 1 year of age and less than 500 cells per cubic millimeter by 18 months of age. Results At birth the frequency of CMV infection was similar in the HIV-1-infected and HIV-1-uninfected infants (4.3 percent and 4.5 percent, respectively), but the HIV-1-infected infants had a higher rate of CMV infection at six months of age (39.9 percent vs. 15.3 percent, P=0.001) and continued to have a higher rate of CMV infection through four years of age (P=0.04). By 18 months of age, the infants with both infections had higher rates of HIV-1 disease progression (70.0 percent vs. 30.4 percent, P=0.001), CDC class C symptoms or death (52.5 percent vs. 21.7 percent, P=0.008), and impaired brain growth or progressive motor deficits (35.6 percent vs. 8.7 percent, P=0.005) than infants infected only with HIV-1. In a Cox regression analysis, CMV infection was associated with an increased risk of HIV-1 disease progression (relative risk, 2.59; 95 percent confidence interval, 1.13 to 5.95). Among children infected with HIV-1 alone, but not among those infected with both viruses, children with rapid progression of HIV-1 disease had higher mean levels of HIV-1 RNA than those with slower or no progression of disease. Conclusions HIV-1-infected infants who acquire CMV infection in the first 18 months of life have a significantly higher rate of disease progression and central nervous system disease than those infected with HIV-1 alone. (N Engl J Med 1999;341:77-84.) (C) 1999, Massachusetts Medical Society.	Univ So Calif, Los Angeles Cty Med Ctr, Maternal Child HIV Management & Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Div Pediat Invect Dis, Los Angeles, CA USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Div Pediat & Adolescent Med, Cleveland, OH 44195 USA; Baylor Coll Med, Dept Pediat, Sect Infect Dis, Houston, TX 77030 USA; Baylor Coll Med, Dept Allergy & Immunol, Houston, TX 77030 USA; Columbia Presbyterian Med Ctr, Dept Pediat, New York, NY 10032 USA; Bolston Med Ctr, Dept Pediat, Boston, MA USA; Mt Sinai Sch Med, Pediat Pulm & Crit Care Div, New York, NY USA; Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Pediat, Div Pediat Infect Dis, New York, NY USA	University of Southern California; University of Southern California; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Baylor College of Medicine; Baylor College of Medicine; Columbia University; NewYork-Presbyterian Hospital; Icahn School of Medicine at Mount Sinai; Harvard University; Boston Children's Hospital; Icahn School of Medicine at Mount Sinai	Kovacs, A (corresponding author), Hlth Res Associates Bldg,1640 Marengo St,3rd Fl, Los Angeles, CA 90033 USA.		Easley, Kirk A/K-6910-2015	Easley, Kirk A/0000-0003-4419-2617; Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [M01 RR000188, M01 RR000071, M01 RR000645, M01 RR000533, M01 RR000043, M01 RR002172, K01 RR000188, M01 RR000865] Funding Source: Medline; NHLBI NIH HHS [N01 HR096037, N01-HR-96039, N01 HR096043, N01-HR-96038] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR096037, N01HR096039, N01HR096038, N01HR096043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172, M01RR000043, K01RR000188, M01RR000865, M01RR000533, M01RR000071, M01RR000645, M01RR000188] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; BELMAN AL, 1988, AM J DIS CHILD, V142, P29, DOI 10.1001/archpedi.1988.02150010039017; BELMAN AL, 1988, AM J DIS CHILD, V142, P507; Carcaba V, 1991, An Med Interna, V8, P243; CARNEY WP, 1983, J IMMUNOL, V130, P390; Chandwani S, 1996, PEDIATR INFECT DIS J, V15, P310, DOI 10.1097/00006454-199604000-00006; COLLIER AC, 1987, AM J MED, V82, P593, DOI 10.1016/0002-9343(87)90105-7; COOPER ER, 1992, PEDIATR AIDS HIV INF, V3, P302; CURLESS RG, 1987, CHILD NERV SYST, V3, P255, DOI 10.1007/BF00274063; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; DEMMLER GJ, 1988, J INFECT DIS, V158, P1177, DOI 10.1093/infdis/158.6.1177; DETELS R, 1984, JAMA-J AM MED ASSOC, V251, P1719, DOI 10.1001/jama.251.13.1719; DOREY FJ, 1993, STAT MED, V12, P1589, DOI 10.1002/sim.4780121706; Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010; DREW WL, 1985, ANN INTERN MED, V103, P61, DOI 10.7326/0003-4819-103-1-61; DUDDING L, 1989, J IMMUNOL, V143, P3343; FRENKEL LD, 1990, REV INFECT DIS, V12, pS820; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; Gerard L, 1997, CLIN INFECT DIS, V24, P836, DOI 10.1093/clinids/24.5.836; GERNA G, 1994, J CLIN MICROBIOL, V32, P2709, DOI 10.1128/JCM.32.11.2709-2717.1994; HO DD, 1987, NEW ENGL J MED, V317, P278; JAULT FM, 1994, J VIROL, V68, P959, DOI 10.1128/JVI.68.2.959-973.1994; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P30; Kattan M, 1996, J CLIN EPIDEMIOL, V49, P1285; Kitchen BJ, 1997, PEDIATR INFECT DIS J, V16, P358, DOI 10.1097/00006454-199704000-00005; LANG DJ, 1989, J ACQ IMMUN DEF SYND, V2, P540; LATHEY JL, 1994, VIROLOGY, V199, P98, DOI 10.1006/viro.1994.1101; MCKEATING JA, 1990, NATURE, V343, P659, DOI 10.1038/343659a0; MOSCA JD, 1987, P NATL ACAD SCI USA, V84, P7408, DOI 10.1073/pnas.84.21.7408; Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NGUYEN C, 1991, J INFECT DIS, V164, P219, DOI 10.1093/infdis/164.1.219; Nigro G, 1996, AIDS, V10, P1127, DOI 10.1097/00002030-199609000-00011; PASS RF, 1980, PEDIATRICS, V66, P758; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; RAFFI F, 1990, ANN INTERN MED, V112, P234, DOI 10.7326/0003-4819-112-3-234; Rasmussen L, 1997, J INFECT DIS, V176, P1146, DOI 10.1086/514106; REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101; RINALDO CR, 1980, J INFECT DIS, V141, P488, DOI 10.1093/infdis/141.4.488; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SCHINDLER JM, 1990, KLIN WOCHENSCHR, V68, P237, DOI 10.1007/BF01662723; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shepp DH, 1996, J ACQ IMMUN DEF SYND, V11, P460, DOI 10.1097/00042560-199604150-00006; SKOLNIK PR, 1989, AM J OPHTHALMOL, V107, P361, DOI 10.1016/0002-9394(89)90659-4; SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508; Spector SA, 1998, J CLIN INVEST, V101, P497, DOI 10.1172/JCI1101; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1991, J ACQ IMMUN DEF SYND, V4, pS47; WILEY CA, 1986, J NEUROPATH EXP NEUR, V45, P127, DOI 10.1097/00005072-198603000-00003	53	177	185	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					77	84		10.1056/NEJM199907083410203	http://dx.doi.org/10.1056/NEJM199907083410203			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395631	Green Accepted			2022-12-28	WOS:000081316200003
J	Moynagh, J; Schimmel, H				Moynagh, J; Schimmel, H			Tests for BSE evaluated	NATURE			English	Letter									Commiss European Communities, Consumer Policy & Hlth Protect, B-1049 Brussels, Belgium; Commiss European Communities, Joint Res Ctr, Inst Reference Mat & Measurements, B-2440 Geel, Belgium	European Commission Joint Research Centre; EC JRC Institute for Reference Materials & Measurements (IRMM)	Moynagh, J (corresponding author), Commiss European Communities, Consumer Policy & Hlth Protect, Rue Belliard 232, B-1049 Brussels, Belgium.							Butler D, 1998, NATURE, V395, P205, DOI 10.1038/26051; *EUR COMM, EV TESTS DIAGN TRANS	2	140	149	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					105	105		10.1038/21981	http://dx.doi.org/10.1038/21981			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408430	Bronze			2022-12-28	WOS:000081324900021
J	Mathiesen, ER; Hommel, E; Hansen, HP; Smidt, UH; Parving, HH				Mathiesen, ER; Hommel, E; Hansen, HP; Smidt, UH; Parving, HH			Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria	BRITISH MEDICAL JOURNAL			English	Article							IDDM PATIENTS; PROGRESSION		Steno Diabet Ctr, DK-2860 Copenhagen, Denmark	Steno Diabetes Center	Mathiesen, ER (corresponding author), Univ Copenhagen Hosp, Rigshosp, Med Endocrine Dept, DK-2100 Copenhagen O, Denmark.							LAFFEL LMB, 1995, AM J MED, V99, P497, DOI 10.1016/S0002-9343(99)80226-5; LEVEY AS, 1991, J AM SOC NEPHROL, V1, P1087; Mathiesen ER, 1997, DIABETES CARE, V20, P286, DOI 10.2337/diacare.20.3.286; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P210; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275	5	137	143	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					24	25		10.1136/bmj.319.7201.24	http://dx.doi.org/10.1136/bmj.319.7201.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390455	Bronze, Green Published			2022-12-28	WOS:000081326500026
J	Spurgeon, D				Spurgeon, D			Link between magnetic fields and leukaemia is weak	BRITISH MEDICAL JOURNAL			English	News Item																		Green LM, 1999, CANCER CAUSE CONTROL, V10, P233, DOI 10.1023/A:1008919408855; Green LM, 1999, INT J CANCER, V82, P161, DOI 10.1002/(SICI)1097-0215(19990719)82:2<161::AID-IJC2>3.0.CO;2-X	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					10	10		10.1136/bmj.319.7201.10	http://dx.doi.org/10.1136/bmj.319.7201.10			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390442	Green Published			2022-12-28	WOS:000081326500013
J	Hamiche, A; Sandaltzopoulos, R; Gdula, DA; Wu, C				Hamiche, A; Sandaltzopoulos, R; Gdula, DA; Wu, C			ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF	CELL			English	Article							NUCLEOSOME CORE PARTICLE; YEAST SWI/SNF COMPLEX; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; MULTISUBUNIT COMPLEX; GENE-PRODUCTS; DNA; BINDING; ISWI; MOBILITY	Drosophila NURF is an ATP-dependent chromatin remodeling complex that contains ISWI, a member of the SW12/SNF2 family of ATPases. We demonstrate that NURF catalyzes the bidirectional redistribution of mononucleosomes reconstituted on hsp70 promoter DNA. In the presence of NURF, nucleosomes adopt one predominant position from an ensemble of possible locations within minutes. Movements occur in cis, with no transfer to competing DNA. Migrating intermediates trapped by fro III digestion reveal progressive nucleosome motion in increments of several base pairs. All four core histones are retained quantitatively during this process, indicating that the general integrity of the histone octamer is maintained. We suggest that NURF remodels nucleosomes by transiently decreasing the activation energy for short-range sliding of the histone octamer.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, C (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.							Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; GLOTOV BO, 1982, BIOCHIM BIOPHYS ACTA, V696, P275, DOI 10.1016/0167-4781(82)90058-6; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; ITO T, 1999, IN PRESS GENES DEV; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Sandaltzopoulos R, 1999, METHOD ENZYMOL, V304, P757; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIMPSON RT, 1979, J BIOL CHEM, V254, P123; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Travers A, 1997, BIOPOLYMERS, V44, P423, DOI 10.1002/(SICI)1097-0282(1997)44:4<423::AID-BIP6>3.0.CO;2-M; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; van Holde KE., 1989, SPRINGER SERIES MOL; VANHOLDE KE, 1985, STRUCTURE FUNCTION G; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEISCHET WO, 1978, NUCLEIC ACIDS RES, V5, P139, DOI 10.1093/nar/5.1.139; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu C, 1998, COLD SPRING HARB SYM, V63, P525, DOI 10.1101/sqb.1998.63.525; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	75	277	281	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					833	842		10.1016/S0092-8674(00)80796-5	http://dx.doi.org/10.1016/S0092-8674(00)80796-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399912	Bronze			2022-12-28	WOS:000081162800005
J	DiSanti, MA; Mumma, MJ; Dello Russo, N; Magee-Sauer, K; Novak, R; Rettig, TW				DiSanti, MA; Mumma, MJ; Dello Russo, N; Magee-Sauer, K; Novak, R; Rettig, TW			Identification of two sources of carbon monoxide in comet Hale-Bopp	NATURE			English	Article							PLANETARY-ATMOSPHERES; HALLEY; P/HALLEY; MODEL; GAS; CO; EVOLUTION; TIME; DUST	The composition of ices in comets may reflect that of the molecular cloud in which the Sun formed, or it may show evidence of chemical processing in the pre-planetary accretion disk around the proto-Sun. As carbon monoxide (CO) is ubiquitous in molecular clouds(1,2), its abundance with respect to water could help to determine the degree to which pre-cometary material was processed, although variations in CO abundance may also be influenced by the distance from the Sun at which comets formed(3-5). Observations have not hitherto provided an unambiguous measure of CO in the cometary ice (native CO). Evidence for an extended source of CO associated with comet Halley was provided by the Giotto spacecraft(6-9), but alternative interpretations exist(10). Here we report observations of comet Hale-Bopp which show that about half of the CO in the comet comes directly from ice stored in the nucleus. The abundance of this CO with respect to water (12 per cent) is smaller than in quiescent regions of molecular clouds, but is consistent with that measured in proto-stellar envelopes(11), suggesting that the ices underwent some processing before their inclusion into Hale-Bopp. The remaining CO arises in the coma, probably through thermal destruction of more complex molecules.	Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA; NASA, Goddard Space Flight Ctr, Extraterr Phys Lab, Greenbelt, MD 20771 USA; Rowan Univ, Dept Chem & Phys, Glassboro, NJ 08028 USA; Iona Coll, Dept Phys, New Rochelle, NY 10801 USA; Univ Notre Dame, Dept Phys & Astron, Notre Dame, IN 46556 USA	Catholic University of America; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Rowan University; Iona College; University of Notre Dame	DiSanti, MA (corresponding author), Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA.		mumma, michael j/I-2764-2013; Russo, Neil Dello/G-2727-2015; Magee-Sauer, Karen/K-6061-2015	mumma, michael j/0000-0003-4627-750X; Russo, Neil Dello/0000-0002-8379-7304; Magee-Sauer, Karen/0000-0002-4979-9875				Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BIVER N, IN PRESS EARTH MOON; BOICE DC, 1990, GEOPHYS RES LETT, V17, P1813, DOI 10.1029/GL017i011p01813; Chiar JE, 1998, ASTROPHYS J, V498, P716, DOI 10.1086/305569; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; CRIFO JF, 1995, ASTROPHYS J, V445, P470, DOI 10.1086/175712; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; Dello Russo N, 1998, ICARUS, V135, P377, DOI 10.1006/icar.1998.5990; DELLORUSSO N, 1995, UNPUB ICARUS; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; Green S.F., 1986, ESA SP250, VII, P81; Greenberg JM, 1998, ASTRON ASTROPHYS, V332, P374; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P311; Herzberg G, 2008, MOL SPECTRA MOL STRU, VI; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; HUEBNER WF, 1987, ASTROPHYS J, V320, pL149, DOI 10.1086/184992; HUNTRESS WT, 1991, NATURE, V352, P316, DOI 10.1038/352316a0; Jewitt D, 1999, ASTRON J, V117, P1056, DOI 10.1086/300743; KUNDE VG, 1974, J QUANT SPECTROSC RA, V14, P803, DOI 10.1016/0022-4073(74)90124-1; LAMMERZAHL P, 1987, ASTRON ASTROPHYS, V187, P169; MEIER R, 1993, ASTRON ASTROPHYS, V277, P677; Mumma M. J., 1997, Astronomical Society of the Pacific Conference Series, V122, P369; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; RANK DM, 1971, SCIENCE, V174, P1083, DOI 10.1126/science.174.4014.1083; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SANDFORD SA, 1988, ICARUS, V76, P201, DOI 10.1016/0019-1035(88)90069-3; TURNER BE, 1989, SPACE SCI REV, V51, P235, DOI 10.1007/BF00172023; WEAVER HA, IN PRESS EARTH MOON; Womack M, 1997, ASTRON J, V114, P2789, DOI 10.1086/118687; Xie XF, 1996, ASTROPHYS J, V464, P457, DOI 10.1086/177336; XIE XF, 1992, ASTROPHYS J, V386, P720, DOI 10.1086/171053	32	83	83	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					662	665		10.1038/21378	http://dx.doi.org/10.1038/21378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385117				2022-12-28	WOS:000080932800051
J	Fisher, B; Dignam, J; Wolmark, N; Wickerham, DL; Fisher, ER; Mamounas, E; Smith, R; Begovic, M; Dimitrov, NV; Margolese, RG; Kardinal, CG; Kavanah, MT; Fehrenbacher, L; Oishi, RH				Fisher, B; Dignam, J; Wolmark, N; Wickerham, DL; Fisher, ER; Mamounas, E; Smith, R; Begovic, M; Dimitrov, NV; Margolese, RG; Kardinal, CG; Kavanah, MT; Fehrenbacher, L; Oishi, RH			Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial	LANCET			English	Article							CARCINOMA IN-SITU; RADIATION-THERAPY; RECEPTORS; ESTROGEN; LUMPECTOMY; INSITU; PROGESTERONE; FAILURE; DMBA; P53	Background: We have shown previously that lumpectomy with radiation therapy was more effective than lumpectomy alone for the treatment of ductal carcinoma in situ (DCIS). We did a double-blind randomised controlled trial to find out whether lumpectomy, radiation therapy, and tamoxifen was of more benefit than lumpectomy and radiation therapy alone for DCIS. Methods: 1804 women with DCIS, including those whose resected sample margins were involved with tumour, were randomly assigned lumpectomy, radiation therapy (50 Gy), and placebo (n = 902), or lumpectomy, radiation therapy, and tamoxifen (20 mg daily for 5 years, n = 902). Median follow-up was 74 months (range 57-93), We compared annual event rates and cumulative probability of invasive or non-invasive ipsilateral and contralateral tumours over 5 years. Findings: Women in the tamoxifen group had fewer breast-cancer events at 5 years than did those on placebo (8.2 vs 13.4%, p = 0 0009). The cumulative incidence of all invasive breast-cancer events in the tamoxifen group was 4.1% at 5 years: 2.1% in the ipsilateral breast, 1.8% in the contralateral breast, and 0.2% at regional or distant sites. The risk of ipsilateral-breast cancer was lower in the tamoxifen group even when sample margins contained tumour and when DCIS was associated with comedonecrosis. Interpretation: The combination of lumpectomy, radiation therapy, and tamoxifen was effective in the prevention of invasive cancer.	Allegheny Univ Hlth Sci, Natl Surg Adjuvant Breast & Bowel Project, Allegheny Ctr 4, Pittsburgh, PA 15212 USA; Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, NSABP Biostat Ctr, Pittsburgh, PA 15260 USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; Shadyside Hosp, Inst Pathol, Pittsburgh, PA 15232 USA; Mt Sinai Ctr Breast Hlth, Cleveland, OH USA; Michigan State Univ, E Lansing, MI 48824 USA; McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA; Boston Med Ctr, Boston, MA USA; Kaiser Permanente, No Calif Reg, Oakland, CA USA; Univ Hawaii, Honolulu, HI USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Allegheny General Hospital; Michigan State University; McGill University; Ochsner Health System; Boston Medical Center; Kaiser Permanente; University of Hawaii System	Fisher, B (corresponding author), Allegheny Univ Hlth Sci, Natl Surg Adjuvant Breast & Bowel Project, Allegheny Ctr 4, Suite 602, Pittsburgh, PA 15212 USA.			Kavanah, Maureen/0000-0001-8447-6441	NATIONAL CANCER INSTITUTE [U10CA037377, U10CA012027, U10CA069651] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA-37377, U10-CA-12027, U10-CA-69651] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1997, DUCTAL CARCINOMA IN, P37; BARNES R, 1990, AM J CLIN PATHOL, V94, P533, DOI 10.1093/ajcp/94.5.533; Berardo MD, 1996, LAB INVEST, V74, P68; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; FISHER B, 1991, J NATL CANCER I, V83, P1278, DOI 10.1093/jnci/83.18.1278; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 1985, WORLD J SURG, V9, P692, DOI 10.1007/BF01655182; Fisher ER, 1997, CA-CANCER J CLIN, V47, P52, DOI 10.3322/canjclin.47.1.52; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; FISHER ER, 1999, IN PRESS CANCER; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; GIRI DD, 1989, HISTOPATHOLOGY, V15, P575, DOI 10.1111/j.1365-2559.1989.tb01623.x; JORDAN VC, 1980, EUR J CANCER, V16, P239, DOI 10.1016/0014-2964(80)90156-5; JORDAN VC, 1976, EUR J CANCER, V12, P419, DOI 10.1016/0014-2964(76)90030-X; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LEAL CB, 1995, CANCER, V75, P2123, DOI 10.1002/1097-0142(19950415)75:8<2123::AID-CNCR2820750815>3.0.CO;2-V; PALLIS L, 1992, ANTICANCER RES, V12, P2113; PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374; Recht A., 1998, European Journal of Cancer, V34, P1664, DOI 10.1016/S0959-8049(98)00220-2; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; ZAFRANI B, 1994, SEMIN DIAGN PATHOL, V11, P208	26	734	773	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					1993	2000		10.1016/S0140-6736(99)05036-9	http://dx.doi.org/10.1016/S0140-6736(99)05036-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376613				2022-12-28	WOS:000080812200008
J	Pollak, P; Destee, A; Lille, CHU; Tison, F; Pere, JJ; Malmaison, R; Bordeix, I; Agid, Y; Allain, H; Borg, M; Broussolle, E; Durif, F; Geny, C; Prunier-Levilon, C; Bretonneau, CHU; Rascol, O; Sangla, S; Verin, M; Viallet, F; Tranchant, C				Pollak, P; Destee, A; Lille, CHU; Tison, F; Pere, JJ; Malmaison, R; Bordeix, I; Agid, Y; Allain, H; Borg, M; Broussolle, E; Durif, F; Geny, C; Prunier-Levilon, C; Bretonneau, CHU; Rascol, O; Sangla, S; Verin, M; Viallet, F; Tranchant, C		French Clozapine Parkinson Study Grp	Clozapine in drug-induced psychosis in Parkinson's disease	LANCET			English	Article									Hop Nord, Grenoble, France; CHU Lille, F-59037 Lille, France; Hop Sud Haut Eveque, Pessac, France; Novartis Pharma, Rueil Malmaison, France; Hop La Pitie Salpetriere, Paris, France; Hop Louis Pasteur, F-06002 Nice, France; Hop Neurol, Lyon, France; Hop Gabriel Montpied, Clermont Ferrand, France; Ctr Hosp Gen, Pau, France; CHU Bretonneau, F-37044 Tours, France; Hop Purpan, Toulouse, France; Hop Delafontaine, Paris, France; CHU, Rennes, France; Hop Gen Aix en Provence, Aix En Provence, France; Hop Civil, Strasbourg, France	CHU Grenoble Alpes; Universite de Lille - ISITE; CHU Lille; Novartis; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Nice; CHU Lyon; CHU Clermont Ferrand; CHU Tours; CHU de Toulouse; CHU Rennes; CHU Strasbourg	Pollak, P (corresponding author), CHU Grenoble, Serv Neurol, BP 217 X, F-38043 Grenoble 9, France.		Broussolle, Emmanuel/H-1592-2017; Verin, Marc/ABC-6924-2020	Broussolle, Emmanuel/0000-0002-0410-9519; tranchant, christine/0000-0002-2895-1292				BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; Friedman J, 1999, NEW ENGL J MED, V340, P757; KAY S R, 1989, British Journal of Psychiatry, V155, P59; SCHOLZ E, 1985, EUR ARCH PSY CLIN N, V235, P60, DOI 10.1007/BF00380972	5	182	196	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2041	2042						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376627				2022-12-28	WOS:000080812200022
J	Duff, SE; Wong, CKM; May, RE				Duff, SE; Wong, CKM; May, RE			Surgeons' and occupational health departments' awareness of guidelines on post-exposure prophylaxis for staff exposed to HIV: telephone survey	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CARE WORKERS; BLOOD; RISK		Frenchay Hosp, Dept Surg, Bristol BS16 1LE, Avon, England		Duff, SE (corresponding author), Royal Hampshire Cty Hosp, Winchester & Eastleigh Healthcare, Dept Surg, Winchester SO22 5DG, Hants, England.		Duff, Sarah E/AAW-3795-2021					Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *DEP HLTH, 1997, GUID POST EXP PROPH; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001	5	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					162	163		10.1136/bmj.319.7203.162	http://dx.doi.org/10.1136/bmj.319.7203.162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406752	Green Published, Bronze			2022-12-28	WOS:000081619300023
J	Morgan, K; Prothero, D; Frankel, S				Morgan, K; Prothero, D; Frankel, S			The rise in emergency admissions - crisis or artefact? Temporal analysis of health services data	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Avon Hlth Author, Bristol BS2 8EE, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.							Blatchford O, 1997, BRIT MED J, V315, P1322, DOI 10.1136/bmj.315.7119.1322; Capewell S, 1996, BRIT MED J, V312, P991; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; Kendrick S, 1996, Health Bull (Edinb), V54, P169	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					158	159		10.1136/bmj.319.7203.158	http://dx.doi.org/10.1136/bmj.319.7203.158			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406749	Green Published, Bronze			2022-12-28	WOS:000081619300020
J	Pollock, AM; Dunnigan, MG; Gaffney, D; Price, D; Shaoul, J				Pollock, AM; Dunnigan, MG; Gaffney, D; Price, D; Shaoul, J			The private finance initiative - Planning the "new" NHS: downsizing for the 21st century	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England; Univ Glasgow, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland; Northumbria Univ, Social Welfare Res Unit, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England; Univ Manchester, Dept Accounting, Manchester M13 9PL, Lancs, England	University of London; University College London; University of Glasgow; Northumbria University; University of Manchester	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				Aitken RJ, 1997, BRIT MED J, V315, P426, DOI 10.1136/bmj.315.7105.426a; BEECH R, 1997, ANAL ACUTE INPATIENT; BUTLER P, 1998, HLTH SERVICE J, V109, P10; *CALD HEALTHC NHS, FULL BUS CAS; *CHKS LTD, 1998, AC CAR 19978 HEALTHC; *DARTF GRAV NHS TR, FULL BUS CAS; *DEP HLTH, 1998, STAT B NHS HOSP ACT; *DEP HLTH, 1996, BED AV ENGL FIN YEAR; *DEP HLTH, 1998, BED AV OCC ENGL FIN; *DEP HLTH, 1996, ORD DAY CAS ADM ENGL; *DEP HLTH, 1998, ORD DAY CAS ADM ENGL; *DEP HLTH, 1999, NURS MAK DIFF RECR C; *DEP HLTH, 1997, BED AV OCC ENGL FIN; DUNNIGAN MG, 1998, BRIT MED J, V318, P668; Gaffney D, 1999, PUBLIC MONEY MANAGE, V19, P55, DOI 10.1111/1467-9302.00153; Gaffney D, 1999, BMJ-BRIT MED J, V319, P48, DOI 10.1136/bmj.319.7201.48; Gaffney D, 1999, BRIT MED J, V319, P116, DOI 10.1136/bmj.319.7202.116; GAFFNEY D, 1999, DOWNSIZING 21 CENTUR; GAFFNEY D, 1997, CAN NHS AFF PRIV FIN; GALBRAITH S, 1999, HERALD          0219, P19; HAYMAN B, 1999, HANSARD         0202, P202; *HLTH COMM, 1999, MIN EV          0520; *HM, 1992, GREEN BOOK APPR EV C; *JOINT WORK PART B, 1998, PROV GEN HOSP SERV; *N DURH NHS TRUST, FULL BUS CAS; National Health Service (NHS), 1994, CAP INV MAN; *NEWCH CO, 1998, PFI FUT CAP INV WHIT; *NHS, 1998, SUMM ACC 1996 97; *NHS, 1998, LOTH HLTH BMA INF IS; *NHS, 1995, CAP INV MAN BUS CAS; *PARL HLTH SEL COM, 1999, 3 PARL HLTH SEL COMM, V1; Pollock AM, 1997, BRIT MED J, V314, P1266, DOI 10.1136/bmj.314.7089.1266; Pollock AM, 1998, BRIT MED J, V317, P157, DOI 10.1136/bmj.317.7152.157; RHIND G, 1999, HERALD          0223, P19; *ROYAL COLL SURG E, 1997, PROV EM SURG SERV OR; Scottish Office, 1998, AC SERV REV REP; Shaoul J., 1998, MANAGEMENT ACCOUNTIN, V9, P95; *U YORK, 1997, 8 CRD U YORK HLTH EC; WOODCOCK B, 1998, E DAILY PRESS   0714, P14; WOODCOCK B, 1998, E DAILY PRESS   0714, P16; *WOYAL COLL PHYS, 1996, FUT PATT CAR GEN SPE	41	50	50	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	1999	319	7203					179	184		10.1136/bmj.319.7203.179	http://dx.doi.org/10.1136/bmj.319.7203.179			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406762	Green Published			2022-12-28	WOS:000081619300031
J	Thurnheer, R; Laube, I; Speich, R				Thurnheer, R; Laube, I; Speich, R			Possible interaction between clindamycin and cyclosporin	BRITISH MEDICAL JOURNAL			English	Letter							CLARITHROMYCIN		Univ Zurich Hosp, Dept Internal Med, Div Pulm Dis, Zurich, Switzerland	University of Zurich; University Zurich Hospital	Thurnheer, R (corresponding author), Univ Zurich Hosp, Dept Internal Med, Div Pulm Dis, Zurich, Switzerland.							FERRARI SL, 1994, TRANSPLANTATION, V58, P725; Lown KS, 1997, CLIN PHARMACOL THER, V62, P248, DOI 10.1016/S0009-9236(97)90027-8; Spicer ST, 1997, BRIT J CLIN PHARMACO, V43, P194, DOI 10.1046/j.1365-2125.1997.54310.x	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					163	163		10.1136/bmj.319.7203.163	http://dx.doi.org/10.1136/bmj.319.7203.163			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406753	Green Published, Bronze			2022-12-28	WOS:000081619300024
J	Berger, A				Berger, A			What are leukotrienes and how do they work in asthma?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					90	90		10.1136/bmj.319.7202.90	http://dx.doi.org/10.1136/bmj.319.7202.90			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398630	Green Published			2022-12-28	WOS:000081438200026
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					80	80		10.1016/S0140-6736(05)75353-8	http://dx.doi.org/10.1016/S0140-6736(05)75353-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406402				2022-12-28	WOS:000081243200064
J	Schnabel, C; Pierazzo, E; Xue, S; Herzog, GF; Masarik, J; Cresswell, RG; di Tada, ML; Liu, K; Fifield, LK				Schnabel, C; Pierazzo, E; Xue, S; Herzog, GF; Masarik, J; Cresswell, RG; di Tada, ML; Liu, K; Fifield, LK			Shock melting of the Canyon Diablo Impactor: Constraints from nickel-59 contents and numerical modeling	SCIENCE			English	Article							METEOR-CRATER; METALLIC SPHEROIDS; ARIZONA; BE-10; CL-36; AL-26; AGE	Two main types of material survive from the Canyon Diablo impactor, which produced Meteor Crater in Arizona: iron meteorites, which did not melt during the impact; and spheroids, which did. Ultrasensitive measurements using accelerator mass spectrometry show that the meteorites contain about seven times as much nickel-59 as the spheroids. Lower average nickel-59 contents in the spheroids indicate that they typically came from 0.5 to 1 meter deeper in the impactor than did the meteorites. Numerical modeling for an impact velocity of 20 kilometers per second shows that a shell 1.5 to 2 meters thick, corresponding to 16 percent of the projectile volume, remained solid on the rear surface; that most of the projectile melted; and that little, if any, vaporized.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Australian Natl Univ, Res Sch Phys Sci & Engn, Dept Nucl Phys, Canberra, ACT 0200, Australia	University of Arizona; Rutgers State University New Brunswick; University of Rhode Island; University of California System; University of California Berkeley; Australian National University	Pierazzo, E (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.		Cresswell, Richard/AAA-2411-2020; Masarik, Jozef/A-8008-2018	Cresswell, Richard/0000-0002-1629-9479; Masarik, Jozef/0000-0002-0963-0055; Fifield, Leslie/0000-0003-2866-4944				Bass J.D, 1987, HIGH PRESSURE RES MI, P393, DOI DOI 10.1029/GM039; BASS JD, 1990, J GEOPHYS RES-SOLID, V95, P21767, DOI 10.1029/JB095iB13p21767; BLAU PJ, 1973, J GEOPHYS RES, V78, P363, DOI 10.1029/JB078i002p00363; Briesmeister J. F., 1993, LA12625M; Bryan J.B, 1978, P 9 LUN PLAN SCI C, P3931; CHYBA CF, 1991, ICARUS, V92, P217, DOI 10.1016/0019-1035(91)90047-W; *CROSS SECT EV WOR, 1995, BNLNCS44945 CROSS SE; HEYMANN D, 1966, J GEOPHYS RES, V71, P619, DOI 10.1029/JZ071i002p00619; Honda M., 1967, HDB PHYS, V46, P613; KAYE JH, 1962, NUCL CHEM RES CARNEG, P43; KELLY WR, 1974, GEOCHIM COSMOCHIM AC, V38, P533, DOI 10.1016/0016-7037(74)90039-8; KIEFFER SW, 1980, REV GEOPHYS, V18, P143, DOI 10.1029/RG018i001p00143; KLEIN J, 1995, LUNAR PLANET SCI, V26, P763; MASARIK J, 1994, GEOCHIM COSMOCHIM AC, V58, P5307, DOI 10.1016/0016-7037(94)90314-X; Masarik J, 1999, J GEOPHYS RES-ATMOS, V104, P12099, DOI 10.1029/1998JD200091; MASON B, 1973, MINERAL MAG, V39, P204, DOI 10.1180/minmag.1973.039.302.08; MEAD CW, 1965, AM MINERAL, V50, P667; Melosh H.L, 1989, IMPACT CRATERING GEO; MICHLOVICH ES, 1994, J GEOPHYS RES-PLANET, V99, P23187, DOI 10.1029/94JE02267; Moore C.B., 1969, METEORITE RES, P738; NININGER HH, 1956, ARIZONAS METEORITE C, P81; NISHIZUMI K, 1991, GEOCHIM COSMOCHIM AC, V55, P2699, DOI 10.1016/0016-7037(91)90388-L; OWEN TC, 1994, HAZARDS DUE COMETS A, P9; PAUL M, 1993, NUCL INSTRUM METH B, V83, P275, DOI 10.1016/0168-583X(93)95938-2; PHILLIPS FM, 1991, GEOCHIM COSMOCHIM AC, V55, P2695, DOI 10.1016/0016-7037(91)90387-K; Pierazzo E, 1999, EARTH PLANET SC LETT, V165, P163, DOI 10.1016/S0012-821X(98)00263-5; Pierazzo E, 1997, ICARUS, V127, P408, DOI 10.1006/icar.1997.5713; Pierazzo E, 1998, J GEOPHYS RES-PLANET, V103, P28607, DOI 10.1029/98JE02496; PRAEL RE, 1989, LAUR8930141; RODDY DJ, 1980, P 11 LUN PLAN SCI C, P2275; RODDY DJ, 1978, LUNAR PLANET SCI C P, V9, P3891; Schmidt R. M., 1980, P LUN PLAN SCI C 11, P2099; SHOEMAKER EM, 1990, STRUCTURE EARTS CRUS, P418; SHOEMAKER EM, 1963, SOLAR SYSTEM, V4, P301; SUTTON SR, 1985, J GEOPHYS RES-SOLID, V90, P3690, DOI 10.1029/JB090iB05p03690; Thompson S. L., 1972, SCRR710714; Thompson S. L., 1979, SAND771339 SAND NAT; XUE S, 1995, METEORITICS, V30, P303, DOI 10.1111/j.1945-5100.1995.tb01128.x; [No title captured]	39	17	17	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					85	88		10.1126/science.285.5424.85	http://dx.doi.org/10.1126/science.285.5424.85			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390367				2022-12-28	WOS:000081199800034
J	Ayus, JC; Arieff, AI				Ayus, JC; Arieff, AI			Chronic hyponatremic encephalopathy in postmenopausal women - Association of therapies with morbidity and mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	31st Congress of the American-Society-of-Nephrology	OCT 25-28, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Soc Nephrol			BRAIN-DAMAGE; SYMPTOMATIC HYPONATREMIA; POSTOPERATIVE HYPONATREMIA; MANAGEMENT; SALINE; COMPLICATIONS; SEIZURES; HYPOXIA	Context Chronic hyponatremia in postmenopausal women is a common clinical problem often viewed as benign. Fluid restriction is usually the recommended therapy, largely because the extent of morbidity is unknown and because it has been postulated that intravenous (IV) sodium chloride may cause brain damage. Objective To compare IV sodium chloride with fluid restriction in the treatment of postmenopausal women with chronic symptomatic hyponatremia. Design Nonrandomized prospective study. Setting Two university medical centers and affiliated community hospitals. Patients A total of 53 postmenopausal women with chronic symptomatic hyponatremia (chronic plasma sodium <130 mmol/L in the presence of central nervous system manifestations) treated consecutively from 1988-1997 and followed up for 1 year. The mean (SD) age of the patients was 62 (11) years. Interventions The therapeutic interventions were IV sodium chloride before respiratory insufficiency (n = 17), IV sodium chloride after respiratory insufficiency (n = 22), and fluid restriction only (n = 14). Main Outcome Measures Morbidity and neurological outcome at 4 months or longer as assessed by cerebral performance category (CPC) in relation to the therapy, initial plasma sodium level, and rate of correction. Results Chronic symptomatic hyponatremia(mean [SD] sodium level 111 [12] mmol/L) was present for 5.2 [4.5] days. Death or major morbidity occurred in 44 (83%) of 53 patients, including 10 with orthopedic injury. Twelve patients had hypoxemia (PO2 = 63 [25] mm Hg) and cerebral edema. Among patients who received IV sodium chloride before respiratory insufficiency, plasma sodium levels were increased by 22 (10) mmol/L in 35 hours and patients had a CPC of 1.0 (normal or slight disability). Among patients who received IV sodium chloride after respiratory insufficiency, plasma sodium levels were increased by 30 (6) mmol/L in 41 hours and patients had a CPC of 3.0 (1.2) (severe disability). Among patients who had fluid restriction only, plasma sodium levels were increased by 3 (2) mmol/L in 41 hours and patients had a CPC of 4.6 (0.7) (4 = persistent vegetative st-ate; 5 = death). The outcomes did not correlate with either the initial plasma sodium level (r = 0.05, P>.12) or the rate of correction (r = 0.31, P>.10). Conclusions Chronic symptomatic hyponatremia in postmenopausal women can be associated with major morbidity and mortality. Therapy with IV sodium chloride was associated with significantly better outcomes than fluid restriction.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA	Baylor College of Medicine; University of California System; University of California San Francisco	Arieff, AI (corresponding author), 299 South St, Sausalito, CA 94965 USA.				NATIONAL INSTITUTE ON AGING [R01AG008575] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG 08575-01A2] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; ARIEFF AL, 1994, MAGNETIC RESONANCE N, P319; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; Ayus JC, 1996, NEUROLOGY, V46, P323, DOI 10.1212/WNL.46.2.323; AYUS JC, 1995, CHEST, V107, P517, DOI 10.1378/chest.107.2.517; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; AYUS JC, 1989, AM J PHYSIOL, V257, P18; Behringer W, 1998, ANN INTERN MED, V129, P450, DOI 10.7326/0003-4819-129-6-199809150-00004; CHENG JC, 1990, AM J MED, V88, P561, DOI 10.1016/0002-9343(90)90518-I; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; Ellis SJ, 1995, QJM-MON J ASSOC PHYS, V88, P905; Fraser CL, 1997, AM J MED, V102, P67, DOI 10.1016/S0002-9343(96)00274-4; HARRIS CP, 1993, J NEUROL NEUROSUR PS, V56, P626, DOI 10.1136/jnnp.56.6.626; Hirshberg B, 1997, AM J MED, V103, P270, DOI 10.1016/S0002-9343(97)00250-7; HOCHMAN I, 1989, ISRAEL J MED SCI, V25, P73; JENNETT B, 1972, LANCET, V1, P734; Kokko J. P., 1996, CECIL TXB MED, P532; Lauriat SM, 1997, J AM SOC NEPHROL, V8, P1599; Luchins DJ, 1997, BIOL PSYCHIAT, V42, P767, DOI 10.1016/S0006-3223(96)00491-X; Miller M, 1996, J AM GERIATR SOC, V44, P404, DOI 10.1111/j.1532-5415.1996.tb06410.x; REMEC PT, 1983, CLIN ORTHOP RELAT R, P118; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; SMITH JD, 1995, FLUID ELECTROLYTE AC, P387; SONNENBLICK M, 1993, CHEST, V103, P601, DOI 10.1378/chest.103.2.601; Soupart A, 1997, J LAB CLIN MED, V130, P226, DOI 10.1016/S0022-2143(97)90100-1; Steele A, 1997, ANN INTERN MED, V126, P20, DOI 10.7326/0003-4819-126-1-199701010-00003; STEMS RH, 1987, ANN INTERN MED, V107, P656; Verbalis J, 1997, DIS KIDNEY, P2393; Verbalis J G, 1993, Curr Opin Nephrol Hypertens, V2, P636, DOI 10.1097/00041552-199307000-00015; VEXLER ZS, 1994, J CLIN INVEST, V93, P256, DOI 10.1172/JCI116953; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168	32	158	162	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2299	2304		10.1001/jama.281.24.2299	http://dx.doi.org/10.1001/jama.281.24.2299			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386554	Bronze			2022-12-28	WOS:000080925600029
J	Dormann, P; Balbo, I; Benning, C				Dormann, P; Balbo, I; Benning, C			Arabidopsis galactolipid biosynthesis and lipid trafficking mediated by DGD1	SCIENCE			English	Article							CHLOROPLAST ENVELOPES; MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE; MUTANT DEFICIENT; OUTER-MEMBRANE; THALIANA; DIGALACTOSYLDIACYLGLYCEROL; PLANTS; GALACTOSYLTRANSFERASE; DIACYLGLYCEROL; CLONING	The photosynthetic apparatus in plant cells is associated with membranes of the thylakoids within the chloroplast and is embedded into a highly specialized Lipid matrix. Diacylglycerol galactolipids are common in thylakoid membranes but are excluded from all others. Isolation of the gene DGD1, encoding a galactosyltransferase-like protein, now provides insights into assembly of the thylakoid Lipid matrix and subcellular Lipid trafficking in Arabidopsis thaliana.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany	Michigan State University; Max Planck Society	Benning, C (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	benning@pilot.msu.edu	Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667				ANDERSSON L, 1995, J LIPID RES, V36, P1392; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BROWSE J, 1994, ARABIDOPSIS, P881; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chen LJ, 1998, PLANT J, V16, P33, DOI 10.1046/j.1365-313x.1998.00270.x; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Hartel H, 1998, PLANT PHYSIOL BIOCH, V36, P407, DOI 10.1016/S0981-9428(98)80204-0; Hartel H, 1997, PLANT PHYSIOL, V115, P1175, DOI 10.1104/pp.115.3.1175; HEEMSKERK JWM, 1990, PLANT PHYSIOL, V93, P1286, DOI 10.1104/pp.93.4.1286; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; Joyard J, 1998, PLANT PHYSIOL, V118, P715, DOI 10.1104/pp.118.3.715; KUNST L, 1988, P NATL ACAD SCI USA, V85, P4143, DOI 10.1073/pnas.85.12.4143; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; MEYER K, 1996, GENOME MAPPING PLANT, P137; Mongrand S, 1998, PHYTOCHEMISTRY, V49, P1049, DOI 10.1016/S0031-9422(98)00243-X; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; Ohlsson L, 1998, J NUTR, V128, P239, DOI 10.1093/jn/128.2.239; Reifarth F, 1997, BIOCHEMISTRY-US, V36, P11769, DOI 10.1021/bi9709654; Shimojima M, 1997, P NATL ACAD SCI USA, V94, P333, DOI 10.1073/pnas.94.1.333; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; Uwer U, 1998, PLANT CELL, V10, P1277, DOI 10.1105/tpc.10.8.1277; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; VONSCHAEVEN A, 1989, THESIS FREIE U BERLI	32	163	169	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2181	2184		10.1126/science.284.5423.2181	http://dx.doi.org/10.1126/science.284.5423.2181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381884				2022-12-28	WOS:000081099300053
J	Langst, G; Bonte, EJ; Corona, DFV; Becker, PB				Langst, G; Bonte, EJ; Corona, DFV; Becker, PB			Nucleosome movement by CHRAC and ISWI without disruption or trans-displacement of the histone octamer	CELL			English	Article							REMODELING FACTOR; RNA-POLYMERASE; IN-VITRO; CHROMATIN ACCESSIBILITY; DNA; TRANSCRIPTION; COMPLEX; PROTEIN; YEAST; MOBILITY	The chromatin accessibility complex (CHRAC) belongs to the class of nucleosome remodeling factors that increase the accessibility of nucleosomal DNA in an ATP-dependent manner. We found that CHRAC induces movements of intact histone octamers to neighboring DNA segments without facilitating their displacement to competing DNA or histone chaperones in trans. CHRAC-induced energy-dependent nucleosome sliding may, in principle, explain nucleosome remodeling, nucleosome positioning, and nucleosome spacing reactions known to be catalyzed by CHRAC. The catalytic core of CHRAC, the ATPase ISWI, also mobilized nucleosomes at the expense of energy. However, the directionality of the CHRAC- and ISWI-induced nucleosome movements differed drastically, indicating that the geometry of the native complex modulates the activity of its catalytic core.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Becker, PB (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	becker@embl-heidelberg.de	Corona, Davide F.V./H-8467-2012; Längst, Gernot/G-5287-2015	Längst, Gernot/0000-0002-8232-1179; Becker, Peter/0000-0001-7186-0372				Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Grigoriev M, 1998, MOL CELL, V2, P373, DOI 10.1016/S1097-2765(00)80281-6; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Langst G, 1997, NUCLEIC ACIDS RES, V25, P511, DOI 10.1093/nar/25.3.511; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marilley M, 1996, NUCLEIC ACIDS RES, V24, P2204, DOI 10.1093/nar/24.12.2204; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; RAMSPERGER U, 1995, EMBO J, V14, P3215, DOI 10.1002/j.1460-2075.1995.tb07324.x; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VANHOLDE KE, 1985, STRUCTURE FUNCTION G; Varga-Weisz PD, 1999, METHOD ENZYMOL, V304, P742; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Widom J, 1999, METH MOL B, V119, P61; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0	52	288	295	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					843	852		10.1016/S0092-8674(00)80797-7	http://dx.doi.org/10.1016/S0092-8674(00)80797-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399913	hybrid			2022-12-28	WOS:000081162800006
J	Clarkson, MJ; Wells, JRE; Gibson, F; Saint, R; Tremethick, DJ				Clarkson, MJ; Wells, JRE; Gibson, F; Saint, R; Tremethick, DJ			Regions of variant histone His2AvD required for Drosophila development	NATURE			English	Article							NUCLEOSOME	One way in which a distinct chromosomal domain could be established to carry out a specialized function is by the localized incorporation of specific histone variants into nucleosomes. H2AZ, one such variant of the histone protein H2A, is required for the survival of Drosophila melanogaster(1), Tetrahymena thermophila(2) and mice (R. Faast et al., in preparation). To search for the unique features of Drosophila H2AZ (His2AvD, also referred to as H2AvD) that are required for its essential function, we have performed amino-acid swap experiments in which residues unique to Drosophila His2AvD were replaced with equivalently positioned Drosophila H2A.1 residues. Mutated His2AvD genes encoding modified versions of this histone were transformed into Drosophila and tested for their ability to rescue null-mutant lethality. We show that the unique feature of His2AvD does not reside in its histone fold but in its carboxy-terminal domain. This C-terminal region maps to a short alpha-helix in H2A that is buried deep inside the nuceleosome core.	Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia	Australian National University; John Curtin School of Medical Research; University of Adelaide; University of Adelaide	Tremethick, DJ (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, POB 334, Canberra, ACT 2601, Australia.		Saint, Robert/A-4190-2008	Saint, Robert/0000-0002-7989-6043; Tremethick, David/0000-0001-5274-8078				HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ng KW, 1997, EMBO J, V16, P2072, DOI 10.1093/emboj/16.8.2072; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593	8	158	163	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					694	697		10.1038/21436	http://dx.doi.org/10.1038/21436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385122				2022-12-28	WOS:000080932800062
J	Das, A; Gilbert, CD				Das, A; Gilbert, CD			Topography of contextual modulations mediated by short-range interactions in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONALLY CHARACTERIZED SITES; CROSS-CORRELATION ANALYSIS; HORIZONTAL CONNECTIONS; ORIENTATION SELECTIVITY; DIRECTION SELECTIVITY; INTRINSIC CONNECTIONS; CORTICAL DYNAMICS; CAT; SENSITIVITY	Neurons in primary visual cortex (V1) respond differently to a simple visual element presented in isolation from when it is embedded within a complex image. This difference, a specific modulation by surrounding elements in the image, is mediated by short- and long-range connections within V1 and by feedback from other areas. Here we study the role of short-range connections in this process, and relate it to the layout of local inhomogeneities in the cortical maps of orientation and space. By measuring correlation between neuron pairs located in optically imaged maps of V1 orientation columns we show that the strength of local connections between cells is a graded function of lateral separation across cortex, largely radially symmetrical and relatively independent of orientation preferences. We then show the contextual influence of flanking visual elements on neuronal responses varies systematically with a neuron's position within the cortical orientation map. The strength of this contextual influence on a neuron can be predicted from a model of local connections based on simple overlap with particular features of the orientation map. This Indicates that local Intracortical circuitry could endow neurons with a graded specialization for processing angular visual features such as corners and T functions, and this specialization could have its own functional cortical map, linked with the orientation map.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Gilbert, CD (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	gilbert@rockvax.rockefeller.edu						AERTSEN AMHJ, 1985, BRAIN RES, V340, P341, DOI 10.1016/0006-8993(85)90931-X; Bauer U, 1999, VISION RES, V39, P613, DOI 10.1016/S0042-6989(98)00172-2; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bosking WH, 1997, J NEUROSCI, V17, P2112; CRIST RE, 1997, ABSTR SOC NEUROSCI, V23, P1543; Crook JM, 1997, VISUAL NEUROSCI, V14, P141, DOI 10.1017/S095252380000883X; Crook JM, 1998, EUR J NEUROSCI, V10, P2056, DOI 10.1046/j.1460-9568.1998.00218.x; DAS A, 1995, J NEUROPHYSIOL, V74, P779, DOI 10.1152/jn.1995.74.2.779; Das A, 1997, NATURE, V387, P594, DOI 10.1038/42461; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Gawne TJ, 1996, CEREB CORTEX, V6, P482, DOI 10.1093/cercor/6.3.482; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HATA Y, 1991, J PHYSIOL-LONDON, V441, P593, DOI 10.1113/jphysiol.1991.sp018769; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; HUBENER M, 1992, J COMP NEUROL, V324, P67, DOI 10.1002/cne.903240106; Ito M, 1999, NEURON, V22, P593, DOI 10.1016/S0896-6273(00)80713-8; Ito M, 1998, NEURON, V20, P1191, DOI 10.1016/S0896-6273(00)80499-7; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KATZ LC, 1989, J NEUROSCI, V9, P1389; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALACH R, 1994, TRENDS NEUROSCI, V17, P101, DOI 10.1016/0166-2236(94)90113-9; MALACH R, 1992, J COMP NEUROL, V315, P303, DOI 10.1002/cne.903150306; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MELSSEN WJ, 1987, BIOL CYBERN, V57, P403, DOI 10.1007/BF00354985; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; Polat U, 1998, NATURE, V391, P580, DOI 10.1038/35372; Shevelev IA, 1998, NEUROSCIENCE, V84, P713, DOI 10.1016/S0306-4522(97)00393-X; SHEVELEV IA, 1995, NEUROSCIENCE, V69, P51, DOI 10.1016/0306-4522(95)00188-O; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; TSO DY, 1989, J NEUROSCI, V9, P2432; ULLMAN S, 1990, COLD SH Q B, V55, P889; Wertheimer M., 1938, SOURCE BOOK GESTALT, P71, DOI 10.1037/11496-005	45	238	241	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					655	661		10.1038/21371	http://dx.doi.org/10.1038/21371			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385116				2022-12-28	WOS:000080932800050
J	Dickerson, JEC; Hingorani, AD; Ashby, MJ; Palmer, CR; Brown, MJ				Dickerson, JEC; Hingorani, AD; Ashby, MJ; Palmer, CR; Brown, MJ			Optimisation of antihypertensive treatment by crossover rotation of four major classes	LANCET			English	Article							ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; RENIN; AWARENESS; LISINOPRIL; NIFEDIPINE; MANAGEMENT; POPULATION; RESPONSES; EFFICACY	Background. Most comparisons of antihypertensive drugs are undertaken in parallel groups. We undertook a crossover rotation of the four main classes of antihypertensive drugs, in untreated young hypertensive patients, to assess the response rate with monotherapy achieved by a systematic rotation. Methods. 56 patients, mean blood pressure 161/98 mm Hg, entered the relation, of whom 36 received all four monthly cycles of treatment with an angiotensin-converting-enzyme (ACE) inhibitor (A), beta-blocker (B), calcium-channel blocker (C), and diuretic (D). Each patient's best drug was then repeated to assess repeatability. Two measures of individual variability in response were used. First, the value of rotation was measured by the increased proportion of patients reaching target blood pressure on their best drug versus their first drug. Second, we assessed whether the responses to each drug were correlated with each other. Findings. Significant variability in response was found. 20 of the 41 patients reaching target blood pressure (less than or equal to 140/90 mm Hg) failed to achieve this target on their first drug, Relation increased from 22/56 (39%) to 41/56 (73%) the success of monotherapy (p = 0.0001); in half the patients, blood-pressure on the best treatment was 135/85 mm Hg or less. There were significant correlations between the blood pressure responses to A and B (r = 0.5, p < 0.01), and C and D (r = 0.6, p < 0.001), but not between the other four pairings of treatments. The responses to the AB pair were, on average, at least 50% higher than those to the CD pair; this difference was highly significant by multivariate repeated-measures ANOVA. Interpretation. There is a marked variability in hypertensive patients' response to different antihypertensive drugs. The basis may be underlying variability in types of essential hypertension. Optimisation of treatment requires systematic rotation through several therapies; however, an "AB/CD" rule is proposed in which one of each of the two pairs of treatments is initially selected to abbreviate the rotation in routine practice.	Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England; Univ Cambridge, Inst Publ Hlth, Dept Community Med, Ctr Appl Med Stat, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Brown, MJ (corresponding author), Addenbrookes Hosp, Addenbrookes Ctr Clin Invest, Clin Pharmacol Unit, Hills Rd,Level 6,Box 110, Cambridge CB2 2QQ, England.			Hingorani, Aroon/0000-0001-8365-0081				ATTWOOD S, 1994, J HYPERTENS, V12, P1053; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BIDIVILLE J, 1988, HYPERTENSION, V11, P166, DOI 10.1161/01.HYP.11.2.166; Black HR, 1997, ARCH INTERN MED, V157, P2413; BROGDEN RN, 1995, DRUGS, V50, P495, DOI 10.2165/00003495-199550030-00007; Brown MJ, 1996, BRIT J CLIN PHARMACO, V42, P21, DOI 10.1046/j.1365-2125.1996.03785.x; BRUNNER HR, 1990, J HYPERTENS, V8, P3, DOI 10.1097/00004872-199001000-00002; BUHLER FR, 1975, AM J CARDIOL, V36, P653, DOI 10.1016/0002-9149(75)90168-X; CAPPUCCIO FP, 1993, J HYPERTENS, V11, P839, DOI 10.1097/00004872-199308000-00011; CHALMERS J, 1990, J HYPERTENS, V8, pS27; deLeeuw PW, 1997, J HYPERTENS, V15, P87, DOI 10.1097/00004872-199715010-00009; DICKERSON JEC, 1995, BRIT MED J, V310, P574, DOI 10.1136/bmj.310.6979.574; EDMONDS D, 1990, J HYPERTENS, V8, pS49; GADALLAH MF, 1995, AM J KIDNEY DIS, V25, P829, DOI 10.1016/0272-6386(95)90564-2; GIESE J, 1970, SCAND J CLIN LAB INV, V26, P355, DOI 10.3109/00365517009046246; GILL JS, 1985, LANCET, V1, P567; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; Hingorani AD, 1995, J HYPERTENS, V13, P1602; JENNER DA, 1981, J CHROMATOGR, V224, P507, DOI 10.1016/S0378-4347(00)80229-7; JIA H, IN PRESS HYPERTENSIO; JOFFRES MR, 1992, CAN MED ASSOC J, V146, P1997; LARAGH JH, 1988, HYPERTENSION, V12, P223, DOI 10.1161/01.HYP.12.3.223; LARAGH JH, 1979, JAMA-J AM MED ASSOC, V241, P151, DOI 10.1001/jama.241.2.151; Mancia Giuseppe, 1998, Journal of Cardiovascular Pharmacology, V31, pS41, DOI 10.1097/00005344-199800002-00007; MATERSON BJ, 1995, AM J HYPERTENS, V8, P189, DOI 10.1016/0895-7061(94)00196-I; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; NIETO FJ, 1995, ARCH INTERN MED, V155, P677, DOI 10.1001/archinte.155.7.677; NIUTTA E, 1990, J HYPERTENS, V8, pS53; SEEDAT YK, 1989, J HYPERTENS, V7, P515, DOI 10.1097/00004872-198907000-00001; SENN S, 1993, CROSSOVER TRIALS CLI; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; STOCKWELL DH, 1994, AM J PUBLIC HEALTH, V84, P1768, DOI 10.2105/AJPH.84.11.1768; WAEBER B, 1990, J HYPERTENS, V8, pS37; ZANCHETTI A, 1993, J HYPERTENS, V11, P905	34	254	257	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2008	2013		10.1016/S0140-6736(98)07614-4	http://dx.doi.org/10.1016/S0140-6736(98)07614-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376615				2022-12-28	WOS:000080812200010
J	Fambrough, D; McClure, K; Kazlauskas, A; Lander, ES				Fambrough, D; McClure, K; Kazlauskas, A; Lander, ES			Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR-BETA-RECEPTOR; PHOSPHORYLATION SITES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; AUTOPHOSPHORYLATION SITES; SERINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; INTERFERON-GAMMA	We sought to explore the relationship between receptor tyrosine kinase (RTK) activated signaling pathways and the transcriptional induction of immediate early genes (IEGs). Using global expression monitoring, we identified 66 fibroblast IEGs induced by platelet-derived growth factor beta receptor (PDGFR beta) signaling. Mutant receptors lacking binding sites for activation of the PLC gamma, PI3K, SHP2, and RasGAP pathways still retain partial ability to induce 64 of these IEGs. Removal of the Grb2-binding site further broadly reduces induction. These results suggest that the diverse pathways exert broadly overlapping effects on IEG induction. Interestingly, a mutant receptor that restores the RasGAP-binding site promotes induction of an independent group of genes, normally induced by interferons. Finally, we compare the PDGFR beta and fibroblast growth factor receptor 1; each induces essentially identical IEGs in fibroblasts.	Schepens Eye Res Inst, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Schepens Eye Research Institute; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.	lander@wi.mit.edu						ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM L, 1995, MOL CELL BIOL, V15, P4553; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; STJOHNSTON D, 1992, CELL, V68, P201; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; TAMAYO P, 1999, IN PRESS P NATL ACAD; TAVERSE S, 1994, CURR BIOL, V4, P694; UENO H, 1993, J BIOL CHEM, V268, P22814; Vaillancourt RR, 1996, ONCOGENE, V13, P151; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	59	381	395	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					727	741		10.1016/S0092-8674(00)80785-0	http://dx.doi.org/10.1016/S0092-8674(00)80785-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380925	Bronze			2022-12-28	WOS:000080886300011
J	Wu, Q; Maniatis, T				Wu, Q; Maniatis, T			A striking organization of a large family of human neural cadherin-like cell adhesion genes	CELL			English	Article							CLASSIC CADHERINS; STRUCTURAL BASIS; NERVOUS-SYSTEM; N-CADHERIN; EXPRESSION; SUPERFAMILY; MOLECULES; PROTEIN; PROTOCADHERINS; COMPLEX	We have identified 52 novel human cadherin-like genes organized into three closely linked clusters. Comparison of the genomic DNA sequences with those of representative cDNAs reveals a striking genomic organization similar to that of immunoglobulin and T cell receptor gene clusters. The N-terminal extracellular and transmembrane domains of each cadherin protein are encoded by a distinct and unusually large exon. These exons are organized in a tandem array. By contrast, the C-terminal cytoplasmic domain of each protein is identical and is encoded by three small exons located downstream from the cluster of N-terminal exons. This unusual organization has interesting implications regarding the molecular code required to establish complex networks of neuronal connections in the brain and the mechanisms of cell-specific cadherin-like gene expression.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Maniatis, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.		Wu, Qiang/A-6751-2009	Wu, Qiang/0000-0003-3841-3591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arndt K, 1998, MOL CELL NEUROSCI, V10, P211, DOI 10.1006/mcne.1998.0665; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Bradley RS, 1998, CURR BIOL, V8, P325, DOI 10.1016/S0960-9822(98)70132-0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Chun J, 1999, NEURON, V22, P7, DOI 10.1016/S0896-6273(00)80671-6; Colman DR, 1997, MOL CELL NEUROSCI, V10, P1, DOI 10.1006/mcne.1997.0648; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hagler DJ, 1998, NEURON, V20, P1059, DOI 10.1016/S0896-6273(00)80486-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hirano S, 1999, J NEUROSCI, V19, P995; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Matsunami H, 1995, DEV BIOL, V172, P466, DOI 10.1006/dbio.1995.8029; MISHKEVICH F, 1998, MOL CELL NEUROSCI, V12, P240; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OBATA S, 1995, J CELL SCI, V108, P3765; Obata S, 1998, CELL ADHES COMMUN, V6, P323, DOI 10.3109/15419069809010791; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; SAGO H, 1995, GENOMICS, V29, P631, DOI 10.1006/geno.1995.9956; Sanes JR, 1999, CURR OPIN NEUROBIOL, V9, P79, DOI 10.1016/S0959-4388(99)80010-5; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Serafini T, 1997, TRENDS NEUROSCI, V20, P322; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097-4644(19960616)61:4<531::AID-JCB6>3.0.CO;2-P; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	55	545	620	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					779	790		10.1016/S0092-8674(00)80789-8	http://dx.doi.org/10.1016/S0092-8674(00)80789-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380929	Bronze			2022-12-28	WOS:000080886300015
J	Kandela, P				Kandela, P			Royalty	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							1830, LANCET          0522, P296; 1830, LANCET          0505, P296; 1952, LANCET          0216, P349; 1902, LANCET          0712, P84; 1902, LANCET          0705, P28; 1952, LANCET          0531, P1097	6	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1983	1983		10.1016/S0140-6736(05)77206-8	http://dx.doi.org/10.1016/S0140-6736(05)77206-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10400519				2022-12-28	WOS:000080668500075
J	Bagust, A; Place, M; Posnett, JW				Bagust, A; Place, M; Posnett, JW			Dynamics of bed use in accommodating emergency admissions: stochastic simulation model	BRITISH MEDICAL JOURNAL			English	Article								Objective To examine the daily bed requirements arising from the now of emergency admissions to an acute hospital, to identify the implications of fluctuating and unpredictable demands for emergency admission for the management of hospital bed capacity, and to quantify the daily risk of insufficient capacity for patients requiring immediate admission. Design Modelling of the dynamics of the hospital system, using a discrete-event stochastic simulation model, which reflects the relation between demand and available bed capacity. Setting Hypothetical acute hospital in England. Subjects Simulated emergency admissions of all types except mental disorder. Main outcome measures The risk of having no bed available for any patient requiring immediate admission; the daily risk that there is no bed available for at least one patient requiring immediate admission; the mean bed occupancy rate. Results Risks are discernible when average bed occupancy rates exceed about 85%, and an acute hospital can expect regular bed shortages and periodic bed crises if average bed occupancy rises to 90% or more. Conclusions There are limits to the occupancy rates that can be achieved safely without considerable risk to patients and to the efficient delivery of emergency care. Spare bed capacity is therefore essential for the effective management of emergency admissions, and its cost should be borne by purchasers as an essential element of an acute hospital service.	Univ York, York Hlth Econ Consortium, York YO10 5DD, N Yorkshire, England	University of York - UK	Bagust, A (corresponding author), Univ York, York Hlth Econ Consortium, York YO10 5DD, N Yorkshire, England.							Blatchford O, 1997, BRIT MED J, V315, P1322, DOI 10.1136/bmj.315.7119.1322; Capewell S, 1996, BRIT MED J, V312, P991; CROSSENWHITE H, RISE EMERGENCY ADMIS; EPPLER E, 1994, ANN EMERG MED, V24, P202, DOI 10.1016/S0196-0644(94)70131-8; *GOV STAT SERV, 1997, DEP HLTH STAT B; Kendrick S, 1997, Health Bull (Edinb), V55, P167; Kendrick S, 1996, Health Bull (Edinb), V54, P169; LANE DG, 1998, LSE WORKING PAPER SE; MACLAREN RE, 1993, BRIT J SURG, V80, P215, DOI 10.1002/bjs.1800800230; PIDD M, 1998, COMPUTER SIMULATION; SHAUGHNESSY PW, 1985, INQUIRY-J HEALTH CAR, V22, P303	11	266	267	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					155	158		10.1136/bmj.319.7203.155	http://dx.doi.org/10.1136/bmj.319.7203.155			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406748	Green Published, Bronze			2022-12-28	WOS:000081619300019
J	McNiece, R; Majeed, A				McNiece, R; Majeed, A			Socioeconomic differences in general practice consultation rates in patients aged 65 and over: prospective cohort	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PEOPLE; CARE; PRACTITIONERS; HEALTH; INEQUALITIES	Objective To examine socioeconomic differences in general practice consultation rates among patients aged 65 years and over. Design Secondary anal,sis of data from the fourth national survey of morbidity in general practice. Setting 60 general practices in England and Wales. Subjects 71 984 people aged 65 years and over. Main outcome measures Annual contract rates and home visiting rates with general practitioners and practice nurses. Results Social class differences in contact rates were greatest in 65-74 year olds, with rates 23% higher in patients from social class V than in class I (4.82 v 3.93 per person). In 75-84 year olds there was no clear association between social class and contact rates, and in people aged greater than or equal to 85 years contact rates were highest in patients from class I. Home visiting rates were twice as high in patients from class V as in patients from class I (1.38 v 0.66 per person). Contact rates were 17% higher in people living in communal establishments and 8% higher in those living alone than in those living with others but not in a communal establishment. 16% of contacts with patients in communal establishments and 26% of those with patients living alone were in patients' homes compared with 18% with those living in standard accommodation. These differences persisted after adjustment in a generalised linear model. Conclusions Elderly people show socioeconomic differences in consultation rates. The extra workload generated by elderly people living alone and in communal establishments suggests additional payments to general practitioners are needed.	Off Natl Stat, London SW1V 2QQ, England; Kingston Univ, Sch Math, Kingston upon Thames KT2 6SB, Surrey, England	Kingston University	Majeed, A (corresponding author), Off Natl Stat, London SW1V 2QQ, England.			Majeed, Azeem/0000-0002-2357-9858				Avorn J, 1997, BRIT MED J, V315, P1033, DOI 10.1136/bmj.315.7115.1033; Aylin P, 1996, BRIT MED J, V313, P207, DOI 10.1136/bmj.313.7051.207; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; Dahl E, 1997, SOC SCI MED, V44, P871, DOI 10.1016/S0277-9536(96)00189-X; Greengross S, 1997, BRIT MED J, V315, P1029, DOI 10.1136/bmj.315.7115.1029; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; IMPALLOMENI M, 1995, J PUBLIC HEALTH MED, V17, P171, DOI 10.1093/oxfordjournals.pubmed.a043089; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; Jefferys M, 1996, AM J PUBLIC HEALTH, V86, P474, DOI 10.2105/AJPH.86.4.474; Kavanagh S, 1998, BRIT MED J, V317, P322, DOI 10.1136/bmj.317.7154.322; MCCORMICK A, 1995, MORBIDITY STAT GEN P; Richards T, 1998, BRIT MED J, V317, P896; Saxena S, 1999, BRIT MED J, V318, P642, DOI 10.1136/bmj.318.7184.642; Thorslund M, 1994, J Aging Health, V6, P51, DOI 10.1177/089826439400600104; Turrell AR, 1998, BRIT MED J, V317, P942	15	26	26	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					26	28		10.1136/bmj.319.7201.26	http://dx.doi.org/10.1136/bmj.319.7201.26			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214KE	10390456	Green Published, Bronze			2022-12-28	WOS:000081326500030
J	Rockey, DC				Rockey, DC			Occult gastrointestinal bleeding	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IRON-DEFICIENCY ANEMIA; FECAL BLOOD-LOSS; COLORECTAL-CANCER; PUSH ENTEROSCOPY; BARIUM ENEMA; NEGATIVE COLONOSCOPY; DIAGNOSTIC YIELD; UPPER ENDOSCOPY; POSITIVE STOOL; CHEMICAL-TESTS		Duke Univ, Med Ctr, Ctr Liver, Div Gastroenterol, Durham, NC 27710 USA	Duke University	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Ctr Liver, Div Gastroenterol, Sands Bldg,Rm 336,Res Dr,Box 3083, Durham, NC 27710 USA.							AHLQUIST DA, 1992, CANCER, V70, P1259, DOI 10.1002/1097-0142(19920901)70:3+<1259::AID-CNCR2820701511>3.0.CO;2-D; AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; AHLQUIST DA, 1989, CANCER, V63, P1826; AHLQUIST DA, 1995, TXB GASTROENTEROLOGY, V1, P699; Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; BARKIN JS, 1992, GASTROINTEST ENDOSC, V38, P55, DOI 10.1016/S0016-5107(92)70333-2; BERNER JS, 1994, AM J GASTROENTEROL, V89, P2139; Bini ET, 1998, AM J MED, V105, P281, DOI 10.1016/S0002-9343(98)00260-5; Blackshear JL, 1996, ARCH INTERN MED, V156, P658, DOI 10.1001/archinte.156.6.658; Chak A, 1998, GASTROINTEST ENDOSC, V47, P18, DOI 10.1016/S0016-5107(98)70293-7; Chak A, 1998, GASTROINTEST ENDOSC, V47, P144, DOI 10.1016/S0016-5107(98)70347-5; CHEN YK, 1993, AM J GASTROENTEROL, V88, P2026; COOK IJ, 1986, BRIT MED J, V292, P1380, DOI 10.1136/bmj.292.6532.1380; Dickey W, 1997, SCAND J GASTROENTERO, V32, P469, DOI 10.3109/00365529709025083; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P245, DOI 10.1080/00365521.1984.12005716; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P235, DOI 10.1080/00365521.1984.12005715; DYBDAHL JH, 1981, SCAND J GASTROENTERO, V16, P245, DOI 10.3109/00365528109181963; EISNER MS, 1991, ARCH INTERN MED, V151, P2180, DOI 10.1001/archinte.151.11.2180; Ferguson A, 1996, GUT, V38, P120, DOI 10.1136/gut.38.1.120; Ferrucci JT, 1997, GASTROENTEROLOGY, V112, P294, DOI 10.1016/S0016-5085(97)70248-8; Fine KD, 1996, NEW ENGL J MED, V334, P1163, DOI 10.1056/NEJM199605023341804; FOUTCH PG, 1993, AM J GASTROENTEROL, V88, P807; Gordon S, 1996, AM J GASTROENTEROL, V91, P885; GOSTOUT CJ, 1993, GASTROINTEST ENDOSC, V39, P76, DOI 10.1016/S0016-5107(93)70018-8; Greenberg PD, 1996, AM J MED, V100, P598, DOI 10.1016/S0002-9343(96)00009-5; HALLBERG L, 1995, EUR J CLIN NUTR, V49, P200; Hara AK, 1996, GASTROENTEROLOGY, V110, P284, DOI 10.1053/gast.1996.v110.pm8536869; Haseman JH, 1997, GASTROINTEST ENDOSC, V45, P451, DOI 10.1016/S0016-5107(97)70172-X; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; HSIA PC, 1992, AM J GASTROENTEROL, V87, P1571; JAFFIN BW, 1987, AM J MED, V83, P269, DOI 10.1016/0002-9343(87)90697-8; KEPCZYK MT, 1995, DIGEST DIS SCI, V40, P1283, DOI 10.1007/BF02065539; KEWENTER J, 1995, ENDOSCOPY, V27, P159, DOI 10.1055/s-2007-1005655; LAINE L, 1998, SLEISENGER FORDTRANS, P198; LAINE LA, 1988, DIGEST DIS SCI, V33, P172, DOI 10.1007/BF01535729; Landi B, 1998, GUT, V42, P421, DOI 10.1136/gut.42.3.421; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LAU WY, 1992, SURG GYNECOL OBSTET, V174, P119; Lee JG, 1998, AM J GASTROENTEROL, V93, P772; Levin B, 1997, ARCH INTERN MED, V157, P970, DOI 10.1001/archinte.157.9.970; LEWIS BS, 1991, GUT, V32, P763, DOI 10.1136/gut.32.7.763; LEWIS BS, 1992, J CLIN GASTROENTEROL, V15, P99, DOI 10.1097/00004836-199209000-00004; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; MASSEY AC, 1992, MED CLIN N AM, V76, P549, DOI 10.1016/S0025-7125(16)30339-X; MCINTYRE AS, 1993, GUT, V34, P1102, DOI 10.1136/gut.34.8.1102; Morris AJ, 1996, GASTROINTEST ENDOSC, V44, P394, DOI 10.1016/S0016-5107(96)70087-1; Mujica V R, 1996, Gastrointest Endosc Clin N Am, V6, P833; OMahony S, 1996, QJM-MON J ASSOC PHYS, V89, P685; OTT DJ, 1989, SOUTHERN MED J, V82, P197, DOI 10.1097/00007611-198902000-00013; Ott DJ, 1997, BRIT J RADIOL, V70, pS171, DOI 10.1259/bjr.1997.0021; Ransohoff DF, 1997, ANN INTERN MED, V126, P811, DOI 10.7326/0003-4819-126-10-199705150-00014; RESS AM, 1992, AM J SURG, V163, P94, DOI 10.1016/0002-9610(92)90259-T; REX DK, 1989, GASTROENTEROLOGY, V97, P58, DOI 10.1016/0016-5085(89)91415-7; Rex DK, 1997, GASTROENTEROLOGY, V112, P17, DOI 10.1016/S0016-5085(97)70213-0; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Rockey DC, 1998, NEW ENGL J MED, V339, P153, DOI 10.1056/NEJM199807163390303; Rockey DC, 1999, AM J GASTROENTEROL, V94, P344, DOI 10.1111/j.1572-0241.1999.855_r.x; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; ROLLINS ES, 1991, AM J ROENTGENOL, V156, P385, DOI 10.2214/ajr.156.2.1898820; Saito H, 1996, JPN J CANCER RES, V87, P1011, DOI 10.1111/j.1349-7006.1996.tb03103.x; Schiff L, 1942, AM J MED SCI, V203, P409, DOI 10.1097/00000441-194203000-00016; STJOHN DJB, 1978, AUST NZ J MED, V8, P121; STROEHLEIN JR, 1976, AM J DIG DIS, V21, P841, DOI 10.1007/BF01072074; VANCUTSEM E, 1990, LANCET, V335, P953, DOI 10.1016/0140-6736(90)91010-8; VANDAM J, 1995, ARCH INTERN MED, V155, P2389, DOI 10.1001/archinte.155.22.2389; VOELLER GR, 1991, SURGERY, V110, P799; Waye JD, 1997, GASTROENTEROLOGY, V112, P292, DOI 10.1016/S0016-5085(97)70247-6; Waye JD, 1997, GASTROINTEST ENDOSC, V46, P247, DOI 10.1016/S0016-5107(97)70095-6; Wilcox CM, 1997, AM J MED, V103, P405, DOI 10.1016/S0002-9343(97)00168-X; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; Yip R, 1997, JAMA-J AM MED ASSOC, V277, P1135, DOI 10.1001/jama.277.14.1135; Zaman A, 1998, GASTROINTEST ENDOSC, V47, P372, DOI 10.1016/S0016-5107(98)70221-4; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62	75	160	168	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					38	46		10.1056/NEJM199907013410107	http://dx.doi.org/10.1056/NEJM199907013410107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387941				2022-12-28	WOS:000081195600007
J	Uhlmann, F; Lottspeich, F; Nasmyth, K				Uhlmann, F; Lottspeich, F; Nasmyth, K			Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; FISSION YEAST; BUDDING YEAST; CELL-CYCLE; STRUCTURAL MAINTENANCE; CUT2 PROTEOLYSIS; CHROMOSOMES; PROTEINS	Cohesion between sister chromatids is established during DNA replication and depends on a multiprotein complex called cohesin. Attachment of sister kinetochores to the mitotic spindle during mitosis generates forces that would immediately split sister chromatids were it not opposed by cohesion. Cohesion is essential for the alignment of chromosomes in metaphase but must be abolished for sister separation to start during anaphase. In the budding yeast Saccharomyces cerevisiae, loss of sister-chromatid cohesion depends on a separating protein (separin) called Esp 1 and is accompanied by dissociation from the chromosomes of the cohesion subunit Scc1. Here we show that Esp1 causes the dissooiation of Scc1 from chromosomes by stimulating its cleavage by proteolysis. A mutant Scc1 is described that is resistant to Esp1-dependent cleavage and which blocks both sister-chromatid separation and the dissociation of Scc1 from chromosomes. The evolutionary conservation of separins indicates that the proteolytic cleavage of cohesion proteins might be a general mechanism for triggering anaphase.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Uhlmann, Frank/0000-0002-3527-6619; Nasmyth, Kim/0000-0001-7030-4403				Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; ECKERSKORN C, 1993, ELECTROPHORESIS, V14, P831, DOI 10.1002/elps.11501401133; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; LIN Y, 1992, GENETICS, V132, P75; LOSADA A, 1998, GENE DEV, V12, P1003; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Rose M, 1990, LAB COURSE MANUAL ME; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99	37	743	757	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					37	42		10.1038/21831	http://dx.doi.org/10.1038/21831			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403247				2022-12-28	WOS:000081255700042
J	Neuberger, J				Neuberger, J			Let's do away with "patients"	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund Inst, London W1M 0AN, England		Neuberger, J (corresponding author), Kings Fund Inst, London W1M 0AN, England.								0	42	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1756	1757		10.1136/bmj.318.7200.1756	http://dx.doi.org/10.1136/bmj.318.7200.1756			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381717	Green Published			2022-12-28	WOS:000081216900042
J	Taylor, DW; Barnett, HJM; Haynes, RB; Ferguson, GG; Sackett, DL; Thorpe, KE; Simard, D; Silver, FL; Hachinski, V; Clagett, GP; Barnes, R; Spence, JD				Taylor, DW; Barnett, HJM; Haynes, RB; Ferguson, GG; Sackett, DL; Thorpe, KE; Simard, D; Silver, FL; Hachinski, V; Clagett, GP; Barnes, R; Spence, JD		ASA Carotid Endarterectomy ACE Tri	Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial	LANCET			English	Article							SECONDARY PREVENTION; CEREBRAL-ISCHEMIA; ASPIRIN; STENOSIS; STROKE	carotid stenosis, but benefits are lessened by perioperative surgical risk. Acetylsalicylic acid lowers the risk of stroke in patients who have experienced transient ischaemic attack and stroke. We investigated appropriate doses and the role of acetylsalicylic acid in patients undergoing carotid endarterectomy. Methods In a randomised, double-blind, controlled trial, 2849 patients scheduled for endarterectomy were randomly assigned 81 mg (n=709), 325 mg (n=708), 650 mg (n=715), or 1300 mg (n=717) acetylsalicylic acid daily, started before surgery and continued for 3 months. We recorded occurrences of stroke, myocardial infarction, and death. We compared patients on the two higher doses of acetylsalicylic acid with patients on the two lower doses. Findings Surgery was cancelled in 45 patients, none were lost to follow-up by 30 days, and two were lost by 3 months. The combined rate of stroke, myocardial infarction, and death was lower in the low-dose groups than in the high-dose groups at 30 days (5.4 vs 7.0%, p=0.07) and at 3 months (6.2 vs 8.4%, p=0.03). In an efficacy analysis, which excluded patients taking 650 mg or more acetylsalicylic acid before randomisation, and patients randomised within 1 day of surgery, combined rates were 3.7% and 8.2%, respectively, at 30 days (p=0.002) and 4.2% and 10.0% at 3 months (p=0.0002). Interpretation The risk of stroke, myocardial infarction, and death within 30 days and 3 months of endarterectomy is lower for patients laking 81 mg or 325 mg acetylsalicylic acid daily than for those taking 650 mg or 1300 mg.	McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; Univ Oxford, Nuffield Dept Clin Med, Oxford, England; Hop Enfants Jesus, Dept Neurol Sci, Quebec City, PQ G1J 1Z4, Canada; Toronto Hosp, Western Div, Toronto, ON M5T 2S8, Canada; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Arkansas, Dept Neurol, Serv Neurol, John L McClellan Mem Vet Hosp, Little Rock, AR 72204 USA	McMaster University; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Oxford; Laval University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Taylor, DW (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.		Spence, J. David/K-6396-2013	Spence, J. David/0000-0001-7478-1098; Hershey, Linda/0000-0001-5090-6634; Thorpe, Kevin/0000-0002-7586-3893; Haynes, Robert Brian/0000-0002-1453-3196	NINDS NIH HHS [R01-NS-32832-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032832] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1988, NEW ENGL J MED, V318, P262; [Anonymous], 1991, Lancet, V338, P1345; *ANT TRIAL COLL, 1994, BMJ-BRIT MED J, V308, P83; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; DEHAAN R, 1995, STROKE, V26, P2027, DOI 10.1161/01.STR.26.11.2027; DYKEN ML, 1993, 18 INT JOINT C STROK; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; GUIRAUDCHAUMEIL B, 1982, REV NEUROL, V138, P367; HARRISON MJ, 1971, LANCET, V2, P743; KOZAK LJ, 1998, VITAL HLTH STAT, V135, P1; KUSTER LJ, 1986, PROSTAGLANDINS, V32, P415, DOI 10.1016/0090-6980(86)90009-2; OBRIEN JR, 1990, THROMB HAEMOSTASIS, V64, P486; Rothwell PM, 1996, STROKE, V27, P266, DOI 10.1161/01.STR.27.2.266; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOHGI H, 1992, STROKE, V23, P1400, DOI 10.1161/01.STR.23.10.1400; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WEISS HJ, 1967, LANCET, V2, P495	22	385	404	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2179	2184		10.1016/S0140-6736(99)05388-X	http://dx.doi.org/10.1016/S0140-6736(99)05388-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392981				2022-12-28	WOS:000081091300009
J	Fruman, DA; Rameh, LE; Cantley, LC				Fruman, DA; Rameh, LE; Cantley, LC			Phosphoinositide binding domains: Embracing 3-phosphate	CELL			English	Review							3-KINASE; PATHWAY		Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Cantley, LC (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; KUTATELADZE TG, 1999, IN PRESS MOL CELL; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; PASTERIS NG, 1994, CELL, V79, P669; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	19	105	111	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					817	820		10.1016/S0092-8674(00)80792-8	http://dx.doi.org/10.1016/S0092-8674(00)80792-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399908	Bronze			2022-12-28	WOS:000081162800001
J	Wilf, P; Labandeira, CC				Wilf, P; Labandeira, CC			Response of plant-insect associations to Paleocene-Eocene warming	SCIENCE			English	Article							PHYTOPHAGOUS ARTHROPOD FAUNA; ELEVATED ATMOSPHERIC CO2; TROPICAL FORESTS; DECIDUOUS TREES; UPPER FRANKONIA; ALDERS ALNUS; HERBIVORY; GROWTH; PALATABILITY; COMMUNITIES	The diversity of modern herbivorous insects and their pressure on plant hosts generally increase with decreasing Latitude. These observations imply that the diversity and intensity of herbivory should increase with rising temperatures at constant Latitude. Insect damage on fossil Leaves found in southwestern Wyoming, from the Late Paleocene-early Eocene global warming interval, demonstrates this prediction. Early Eocene plants had more types of insect damage per host species and higher attack frequencies than Late Paleocene plants. Herbivory was most elevated on the most abundant group, the birch family (Betulaceae). Change in the composition of the herbivore fauna during the Paleocene-Eocene interval is also indicated.	Smithsonian Inst, Natl Museum Amer Hist, Dept Paleobiol, Washington, DC 20560 USA; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA	Smithsonian Institution; Smithsonian National Museum of Natural History; University System of Maryland; University of Maryland College Park	Wilf, P (corresponding author), Smithsonian Inst, Natl Museum Amer Hist, Dept Paleobiol, Washington, DC 20560 USA.			Wilf, Peter/0000-0001-6813-1937				ARNONE JA, 1995, OECOLOGIA, V104, P72, DOI 10.1007/BF00365564; AUBRY MP, 1998, LATE PALEOCENE EARLY; Awmack CS, 1997, GLOBAL CHANGE BIOL, V3, P545, DOI 10.1046/j.1365-2486.1997.t01-1-00087.x; BASSET Y, 1994, ACTA OECOL, V15, P181; Beck AL, 1998, PALAEOGEOGR PALAEOCL, V142, P139, DOI 10.1016/S0031-0182(98)00060-1; Behrensmeyer Anna K., 1992, P15; Bond G., 1976, International Biological Programme, P443; BURNHAM RJ, 1992, PALEOBIOLOGY, V18, P30, DOI 10.1017/S0094837300012203; COBOSSUAREZ JM, 1988, B ANID VEG, V14, P1; Coley P.D., 1991, PLANT ANIMAL INTERAC, P25; COLEY PD, 1985, SCIENCE, V230, P895, DOI 10.1126/science.230.4728.895; COLEY PD, 1988, OECOLOGIA, V74, P531, DOI 10.1007/BF00380050; Coley PD, 1998, CLIMATIC CHANGE, V39, P455, DOI 10.1023/A:1005307620024; Coley PD, 1996, ANNU REV ECOL SYST, V27, P305, DOI 10.1146/annurev.ecolsys.27.1.305; Coulson RN, 1984, FOREST ENTOMOLOGY EC; Dury SJ, 1998, GLOBAL CHANGE BIOL, V4, P55, DOI 10.1046/j.1365-2486.1998.00102.x; ERWIN T L, 1982, Coleopterists Bulletin, V36, P74; FAJER ED, 1989, SCIENCE, V243, P1198, DOI 10.1126/science.243.4895.1198; Feeny P., 1976, BIOCH INTERACTION PL, P1, DOI [DOI 10.1007/978-1-4684-2646-5_1, 10.1007/978-1-4684-2646-5_1]; Fleming R. A., 1996, Silva Fennica, V30, P281; Furlow J. J., 1997, FLORA N AM N MEXICO, V3, P507; Gharadjedaghi B, 1997, FORSTWISS CENTRALBL, V116, P158, DOI 10.1007/BF02766892; Gharadjedaghi B, 1997, ANZ SCHADLINGSKD PFL, V70, P145, DOI 10.1007/BF01907351; HENDRICKSON OQ, 1991, CAN J BOT, V69, P1919, DOI 10.1139/b91-241; JANZEN DH, 1968, AM NAT, V102, P592, DOI 10.1086/282574; LABANDEIRA CC, 1994, P NATL ACAD SCI USA, V91, P12278, DOI 10.1073/pnas.91.25.12278; Labandeira CC, 1998, ANNU REV EARTH PL SC, V26, P329, DOI 10.1146/annurev.earth.26.1.329; LINDROTH RL, 1993, ECOLOGY, V74, P763, DOI 10.2307/1940804; Manchester SR, 1996, INT J PLANT SCI, V157, P644, DOI 10.1086/297386; MATTSON WJ, 1980, ANNU REV ECOL SYST, V11, P119, DOI 10.1146/annurev.es.11.110180.001003; Oleksyn J, 1998, NEW PHYTOL, V140, P239, DOI 10.1046/j.1469-8137.1998.00270.x; ONUF CP, 1977, ECOLOGY, V58, P514, DOI 10.2307/1939001; OPLER PA, 1974, AM SCI, V62, P67; REA DK, 1990, PALAEOGEOGR PALAEOCL, V79, P117, DOI 10.1016/0031-0182(90)90108-J; REICHHOLF J, 1974, Waldhygiene, V10, P247; RICKLEFS RE, 1982, CAN J BOT, V60, P2037, DOI 10.1139/b82-251; SCHOONHOVEN LM, 1997, INSECT PLANT BIOL; SOLTIS DE, 1995, P NATL ACAD SCI USA, V92, P2647, DOI 10.1073/pnas.92.7.2647; STORK NE, 1988, BIOL J LINN SOC, V35, P321, DOI 10.1111/j.1095-8312.1988.tb00474.x; Thomas E, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P214; WEBB LJ, 1959, J ECOL, V47, P551, DOI 10.2307/2257290; Whittaker JB, 1998, J ANIM ECOL, V67, P987, DOI 10.1046/j.1365-2656.1998.6760987.x; Wilf P, 1997, PALEOBIOLOGY, V23, P373, DOI 10.1017/S0094837300019746; Wilf P, 1998, GEOLOGY, V26, P203, DOI 10.1130/0091-7613(1998)026<0203:UFLAPI>2.3.CO;2; Wilf P, 1998, PALAIOS, V13, P514, DOI 10.2307/3515344; WILF P, IN PRESS SOC AM B; Wing Scott L., 1999, WARM CLIMATES EARTH, P197; Wright MG, 1998, OECOLOGIA, V115, P427, DOI 10.1007/s004420050537; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266	49	186	196	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2153	2156		10.1126/science.284.5423.2153	http://dx.doi.org/10.1126/science.284.5423.2153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381875	Green Submitted			2022-12-28	WOS:000081099300044
J	McNamara, JO				McNamara, JO			Emerging insights into the genesis of epilepsy	NATURE			English	Review							FRONTAL-LOBE EPILEPSY; POTASSIUM CHANNEL GENE; FAMILIAL NEONATAL CONVULSIONS; GRANULE CELL NEUROGENESIS; GLUTAMATE-RECEPTOR GLUR3; KAINATE-TREATED RATS; HUMAN TEMPORAL-LOBE; DENTATE GYRUS; RASMUSSENS ENCEPHALITIS; LIMBIC SEIZURES	Epilepsies are a diverse collection of brain disorders that affect 1-2% of the population. Current therapies are unsatisfactory as they provide only symptomatic relief, are effective fin only a subset of affected individuals, and are often accompanied by persistent toxic effects. It is hoped that Insight into the cellular and molecular mechanisms of epileptogenesis will lead to new therapies, prevention, or even a cure. Emerging Insights point to alterations of synaptic function and intrinsic properties of neurons as common mechanisms underlying the hyperexcitability In diverse forms of epilepsy.	Vet Affairs Med Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University; Duke University	McNamara, JO (corresponding author), Vet Affairs Med Ctr, 401 Bryan Res Bldg,Res Dr,Box 3676, Durham, NC 27710 USA.							Adams B, 1998, BRAIN RES, V804, P331, DOI 10.1016/S0006-8993(98)00605-2; Adams B, 1997, BRAIN RES, V775, P193, DOI 10.1016/S0006-8993(97)01061-5; ADAMS RD, 1997, PRINCIPLES NEUROLOGY, P1; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Andrews PI, 1996, NEUROLOGY, V46, P242, DOI 10.1212/WNL.46.1.242; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Antozzi C, 1998, NEUROLOGY, V51, P302, DOI 10.1212/WNL.51.1.302; AYALA GF, 1973, BRAIN RES, V52, P1, DOI 10.1016/0006-8993(73)90647-1; Bausch S. B., 1998, Society for Neuroscience Abstracts, V24, P1936; Behr J, 1996, NEUROSCI LETT, V216, P41; BENDOTTI C, 1993, EUR J NEUROSCI, V5, P1312, DOI 10.1111/j.1460-9568.1993.tb00917.x; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; BERKOVIC SF, 1997, EPILEPSY COMPREHENSI, P217; Bertrand S, 1998, BRIT J PHARMACOL, V125, P751, DOI 10.1038/sj.bjp.0702154; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Bruton C., 1988, NEUROPATHOLOGY TEMPO; Cajal S.Ry., 1928, DEGENERATION REGENER, P656; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; COLLINS RC, 1983, BRAIN RES, V280, P25, DOI 10.1016/0006-8993(83)91170-8; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DOYLE WK, 1997, EPILEPSY COMPREHENSI, V2, P1807; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; He XP, 1998, NEURON, V20, P153, DOI 10.1016/S0896-6273(00)80443-2; HOUSER CR, 1990, J NEUROSCI, V10, P267; Kopeloff LM, 1942, AM J PSYCHIAT, V98, P881, DOI 10.1176/ajp.98.6.881; Kuryatov A, 1997, J NEUROSCI, V17, P9035; LABINER DM, 1993, J NEUROSCI, V13, P744; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; LAXER KD, 1991, CHRONIC ENCEPHALITIS, P135; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; Li Y, 1997, J IMMUNOL, V158, P1428; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MCLEAN MJ, 1983, J PHARMACOL EXP THER, V227, P779; McNamara J, 1996, GOODMAN GILMANS PHAR, P461; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V29, P82, DOI 10.1001/archneur.1973.00490260026003; MELLO LEAM, 1992, EPILEPSY RES, P51; Merritt HH, 1938, ARCH NEURO PSYCHIATR, V39, P1003, DOI 10.1001/archneurpsyc.1938.02270050129007; Merritt HH, 1938, J AMER MED ASSOC, V111, P1068, DOI 10.1001/jama.1938.02790380010004; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Parent J. M., 1998, Society for Neuroscience Abstracts, V24, P1934; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; PHILLIPS HA, 1995, NAT GENET, V10, P117, DOI 10.1038/ng0595-117; Phillips HA, 1998, AM J HUM GENET, V63, P1108, DOI 10.1086/302047; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; PURANAM RS, IN PRESS CURR OPIN N; RASMUSSEN T, 1958, NEUROLOGY, V8, P435, DOI 10.1212/WNL.8.6.435; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; Ribak C E, 1991, Hippocampus, V1, P355, DOI 10.1002/hipo.450010403; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Salin P, 1995, J NEUROSCI, V15, P8234; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; SERESS L, 1992, EPILEPSY RES, P3; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Singh R, 1999, ANN NEUROL, V45, P75, DOI 10.1002/1531-8249(199901)45:1<75::AID-ART13>3.0.CO;2-W; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula T, 1998, J COMP NEUROL, V390, P578, DOI 10.1002/(SICI)1096-9861(19980126)390:4<578::AID-CNE9>3.0.CO;2-Y; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x; Watanabe Y, 1996, J NEUROSCI, V16, P3827; Weiland S, 1996, FEBS LETT, V398, P91, DOI 10.1016/S0014-5793(96)01215-X; Wenzel H. J., 1995, Society for Neuroscience Abstracts, V21, P1472; WHITNEY KD, IN PRESS NEUROLOGY; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Wuarin JP, 1996, J NEUROSCI, V16, P4438	86	294	308	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738		S			A15	A22		10.1038/399a015	http://dx.doi.org/10.1038/399a015			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JQ	10392576				2022-12-28	WOS:000081101700004
J	Vidal, R; Frangione, B; Rostagno, A; Mead, S; Revesz, T; Plant, G; Ghiso, J				Vidal, R; Frangione, B; Rostagno, A; Mead, S; Revesz, T; Plant, G; Ghiso, J			A stop-codon mutation in the BRI gene associated with familial British dementia	NATURE			English	Article							CEREBRAL AMYLOID ANGIOPATHY; CREUTZFELDT-JAKOB DISEASE; ALZHEIMERS-DISEASE; PLAQUE-FORMATION; PROTEIN; VARIANT	Familial British dementia (FBD), previously designated familial cerebral amyloid angiopathy-British type(1), is an autosomal dominant disorder of undetermined origin characterized by progressive dementia, spasticity, and cerebellar ataxia, with onset at around the fifth decade of life. Cerebral amyloid angiopathy, non-neuritic and perivascular plaques and neurofibrillary tangles are the predominant pathological lesions(1-4). Here we report the identification of a unique 4K protein subunit named ABri from isolated amyloid fibrils. This highly insoluble peptide is a fragment of a putative type-II single-spanning transmembrane precursor that is encoded by a novel gene, BRI; located on chromosome 13. A single base substitution at the scop codon of this gene generates a longer open reading frame, resulting in a larger, 277-residue precursor. Release of the 34 carboxy-terminal amino acids from the mutated precursor generates the ABri amyloid subunit. The mutation creates a cutting site for the restriction enzyme XbaI, which is useful for detecting asymptomatic carriers. Antibodies against the amyloid or homologous synthetic peptides recognize both parenchymal and vascular lesions in FED patients. A point mutation at the stop codon of BRI therefore results in the generation of the ABri peptide, which is deposited as amyloid fibrils causing neuronal disfunction and dementia.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Inst Neurol, Dept Neuropathol, London WC1N 3BG, England	New York University; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Ghiso, J (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	ghisoj01@popmail.med.nyu.edu	Rostagno, Agueda/A-5801-2008; Mead, Simon/E-9414-2011; Revesz, Tamas/A-8732-2010	Mead, Simon/0000-0002-4326-1468; Revesz, Tamas/0000-0003-2501-0259; Rostagno, Agueda/0000-0002-6817-2074				AIKAWA H, 1985, ANN NEUROL, V17, P297, DOI 10.1002/ana.410170313; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baumann MH, 1996, BIOCHEM BIOPH RES CO, V219, P238, DOI 10.1006/bbrc.1996.0211; CORSELLIS JAN, 1954, BRAIN, V77, P571, DOI 10.1093/brain/77.4.571; COURTENMYERS G, 1987, NEUROLOGY, V37, P269; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GHISO J, 1995, J NEUROL SCI, V129, P74, DOI 10.1016/0022-510X(94)00274-R; GHISO J, 1994, MOL NEUROBIOL, V8, P49, DOI 10.1007/BF02778007; KEOHANE C, 1985, J NEUROL NEUROSUR PS, V48, P1175, DOI 10.1136/jnnp.48.11.1175; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; PEARLMAN RL, 1988, NEUROLOGY, V38, P1249, DOI 10.1212/WNL.38.8.1249; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; Revesz T, 1999, ACTA NEUROPATHOL, V97, P170, DOI 10.1007/s004010050970; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Vidal R, 1996, AM J PATHOL, V148, P361; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; Worster-Drought C, 1940, BRAIN, V63, P237, DOI 10.1093/brain/63.3.237; Worster-Drought C, 1933, J NEUROL PSYCHOPATHO, V14, P27; Worster-Drougt C, 1944, BRAIN, V67, P38, DOI 10.1093/brain/67.1.38	23	379	405	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					776	781						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391242				2022-12-28	WOS:000081101600052
J	Turner, BJ; Newschaffer, CJ; Zhang, DZ; Fanning, T; Hauck, WW				Turner, BJ; Newschaffer, CJ; Zhang, DZ; Fanning, T; Hauck, WW			Translating clinical trial results into practice: The effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Conference on Women and HIV	MAY 04-07, 1997	LOS ANGELES, CA				HUMAN-IMMUNODEFICIENCY-VIRUS; PRENATAL-CARE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ZIDOVUDINE USE; HEART-DISEASE; TRANSMISSION; COHORT; EXPERIENCE; TYPE-1	Background: The success of Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 in preventing vertical HIV transmission prompted intensive efforts to inform laypersons and professionals about the trial's results. Objective: To explore community responsiveness to these efforts by assessing temporal, maternal, and health care factors associated with prescribed antiretroviral therapy before and after PACTG Protocol 076, Design: Retrospective cohort study. Setting: New York State Medicaid program. Patients: 2607 HIV-infected women who delivered a living child between January 1993 and September 1996. Measurements: Adjusted odds of being prescribed antiretroviral treatment in the second or third trimester for women who delivered in period 1 (during the trial [January 1993 to February 1994]), period 2 (after the trial's end and announcement of the results to publication of the results [March 1994 to November 1994]), and period 3 (after publication of the trial results [December 1994 to September 1996]). Results: The adjusted odds of being prescribed antiretroviral therapy increased 21% per month in period 2 and decreased to 3% per month in period 3. In all time periods, the adjusted odds of being prescribed antiretroviral therapy were at least 60% greater (P < 0.05) for women who were treated at an institution that performed HIV clinical trials, received HIV-focused ambulatory care, or had adequate prenatal care visits. After the trial, women receiving methadone treatment had at least twofold (95% CI, 1.5- to 4.3-fold) greater adjusted odds of being prescribed antiretroviral therapy than women who did not take any illicit drugs. Latin-American women, older women, and women born in the United States had greater adjusted odds (P < 0.05) of being prescribed treatment in period 3. Conclusion: Community practice responded rapidly to efforts to disseminate the results of PACTG Protocol 076; however, the absolute increase in prescribed therapy was greatest for women who had adequate prenatal visits or were receiving HIV-focused care, care at a site that performed clinical trials, or methadone therapy.	Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; New York State Dept Hlth, Albany, NY 12237 USA	Jefferson University; State University of New York (SUNY) System	Turner, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, 1025 Walnut St,Room 132, Philadelphia, PA 19107 USA.	barbara.turner@mail.tju.edu			NIDA NIH HHS [R01 DA07904] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007904] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		*AM PUBL HLTH ASS, 1998, AM PUBL HLTH ASS M; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; Avanzini F, 1997, EUR HEART J, V18, P1447; Bobat R, 1996, PEDIATR INFECT DIS J, V15, P604, DOI 10.1097/00006454-199607000-00009; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P807, DOI 10.1001/jama.271.11.807; Fanning TR, 1995, AIDS PUBLIC POLICY J, V10, P39; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gwinn M, 1997, JAMA-J AM MED ASSOC, V277, P299, DOI 10.1001/jama.277.4.299a; Healton C, 1996, AM J PREV MED, V12, P47, DOI 10.1016/S0749-3797(18)30258-7; ISCOE NA, 1994, CAN MED ASSOC J, V150, P1109; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; Laine C, 1998, AIDS, V12, P417, DOI 10.1097/00002030-199804000-00011; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; McDermott J, 1997, PAEDIATR PERINAT EP, V11, P105, DOI 10.1046/j.1365-3016.1997.d01-4.x; *NY DEP HLTH MEM, 1993, HLTH FAC SER, V23; Phillips KA, 1997, J ACQ IMMUN DEF SYND, V14, P174, DOI 10.1097/00042560-199702010-00012; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; Silverman NS, 1997, AM J PERINAT, V14, P341, DOI 10.1055/s-2007-994157; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Smith Sidney C. Jr., 1998, American Journal of Medicine, V104, p23S, DOI 10.1016/S0002-9343(98)00043-6; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; Turner BJ, 1998, J GEN INTERN MED, V13, P16, DOI 10.1046/j.1525-1497.1998.00003.x; Turner BJ, 1997, J ACQ IMMUN DEF SYND, V14, P327, DOI 10.1097/00042560-199704010-00004; TURNER BJ, 1995, J ACQ IMMUN DEF SYND, V9, P371; Turner BJ, 1996, J ACQ IMMUN DEF SYND, V12, P259, DOI 10.1097/00042560-199607000-00005; Wiznia AA, 1996, JAMA-J AM MED ASSOC, V275, P1504, DOI 10.1001/jama.275.19.1504; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; 1989, N Y STATE J MED, V89, P542; 1998, MMWR MORB MORTAL WKL, V47, P688	37	31	31	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					979	986		10.7326/0003-4819-130-12-199906150-00005	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	206TE	10383368				2022-12-28	WOS:000080894700004
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1958: George Wells Beadle (1903-89), Edward Lawrie Tatum (1909-75) and Joshua Lederberg (b 1925)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.							MORGAN T, 1999, LANCET          0109, P157	1	3	3	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2082	2082		10.1016/S0140-6736(05)77919-8	http://dx.doi.org/10.1016/S0140-6736(05)77919-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376666				2022-12-28	WOS:000080812200077
J	Lofdahl, CG; Reiss, TF; Leff, JA; Israel, E; Noonan, MJ; Finn, AF; Seidenberg, BC; Capizzi, T; Kundu, S; Godard, P				Lofdahl, CG; Reiss, TF; Leff, JA; Israel, E; Noonan, MJ; Finn, AF; Seidenberg, BC; Capizzi, T; Kundu, S; Godard, P			Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; MK-0476	Objective To determine the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients, Design Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inhaled corticosteroids dose decreases occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks. Setting 23 academic asthma centres in United States, Canada, and Europe. Participants 226 clinically stable patients with chronic asthma receiving high doses of inhaled corticosteroids (113 randomised to montelukast and 113 to placebo). Interventions Every 2 weeks, the inhaled corticosteroids dose was tapered, maintained, or increased (rescue) based on a standardised clinical score. Main outcome measures Last tolerated dose of inhaled corticosteroids, Results Compared with placebo, montelukast allowed significant (P = 0.046) reduction in the inhaled corticosteroid dose (montelukast 47% v placebo 30%; least square mean difference 17.6%, 95% confidence interval 0.3 to 34.8). Fewer patients on montelukast (18 (16%) v 34 (30%) placebo, P = 0.01) required discontinuation because of failed rescue. Conclusions Montelukast reduces the need for inhaled corticosteroids among patients requiring moderate to high doses of corticosteroid to maintain asthma control.	Merck Res Labs, Dept Pulm & Immunol, Rahway, NJ 07065 USA; Univ Lund Hosp, S-22185 Lund, Sweden; Merck Res Labs, Dept Biostat & Res Data Syst, Rahway, NJ 07065 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Allergy Associate PC Res Ctr, Portland, OR USA; Allergy & Asthma Ctr Charleston, Charleston, NC USA; Arnaud Vilenueve Hosp, Montpellier, France	Merck & Company; Lund University; Skane University Hospital; Merck & Company; Harvard University; Brigham & Women's Hospital	Reiss, TF (corresponding author), Merck Res Labs, Dept Pulm & Immunol, Rahway, NJ 07065 USA.	Theodore_Reiss@Merck.com						[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KUNDU S, 1997, AM J RESP CRIT CARE, V155, pA352; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Noonan MJ, 1998, EUR RESPIR J, V11, P1232, DOI 10.1183/09031936.98.11061232; NORR B, 1998, JAMA-J AM MED ASSOC, V279, P1181; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; PIZZICHINI E, IN PRESS EUR RESP J; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Reiss TF, 1996, J ALLERGY CLIN IMMUN, V98, P528, DOI 10.1016/S0091-6749(96)70086-6; RIDIDICK CA, 1997, EUR J BIOCHEM, V246, P112; Santanello NC, 1997, EUR RESPIR J, V10, P646; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; *US DEP HHS, 1995, NIH PUBL, pCH7	21	180	186	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					87	90		10.1136/bmj.319.7202.87	http://dx.doi.org/10.1136/bmj.319.7202.87			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398629	Bronze, Green Published			2022-12-28	WOS:000081438200025
J	Salmon, DA; Haber, M; Gangarosa, EJ; Phillips, L; Smith, NJ; Chen, RT				Salmon, DA; Haber, M; Gangarosa, EJ; Phillips, L; Smith, NJ; Chen, RT			Health consequences of religious and philosophical exemptions from immunization laws - Individual and societal risk of measles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATION; OUTBREAK	Context All US states require proof of immunization for school entry. Exemptions are generally offered for medical, religious, or philosophical reasons, but the health consequences of claiming such exemptions are poorly documented. Objectives To quantify the risk of contracting measles among individuals claiming religious and/or philosophical exemptions from immunization (exemptors) compared with vaccinated persons, and to examine the risk that exemptors pose to the nonexempt population. Design, Setting, and Participants Population-based, retrospective cohort study of data from 1985 through 1992, collected by the Measles Surveillance System of the Centers for Disease Control and Prevention, as well as from annual state immunization program reports on prevalence of exemptors and vaccination coverage. The study group was restricted to individuals aged 5 to 19 years. To empirically determine and quantify community risk, a mathematical model was developed that examines the spread of measles through communities with varying proportions of exemptors and vaccinated children. Main Outcome Measures Relative risk of contracting measles for exemptors vs vaccinated individuals based on cohort study data. Community risk of contracting measles derived from a mathematical model. Results On average, exemptors were 35 times more likely to contract measles than were vaccinated persons (95% confidence interval, 34-37), Relative risk varied by age and year. Comparing the incidence among exemptors with that among vaccinated children and adolescents during the years 1985-1992 indicated that the 1989-1991 measles resurgence may have occurred 1 year earlier among exemptors. Mapping of exemptors by county in California indicated that exempt populations tended to be clustered in certain geographic regions. Depending on assumptions of the model about the degree of mixing between exemptors and nonexemptors, an increase or decrease in the number of exemptors would affect the incidence of measles in nonexempt populations. If the number of exemptors doubled, the incidence of measles infection in nonexempt individuals would increase by 5.5%, 18.6%, and 30.8%, respectively, for intergroup mixing ratios of 20%, 40%, and 60%. Conclusions These data suggest the need for systematic review of vaccine-preventable incidents to examine the effect of exemptors, increased surveillance of the number of exemptors and cases among them, and research to determine the reasons why individuals claim exemptions.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Calif Dept Human Serv, Immunizat Branch, Berkeley, CA USA	Centers for Disease Control & Prevention - USA; Emory University; Rollins School Public Health	Salmon, DA (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Room 580,624 N Broadway, Baltimore, MD 21205 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367; salmon, daniel/0000-0002-1035-4422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032042] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI32042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINSON W, 1995, EPIDEMIOLOGY PREVENT; CDC, 1991, MMWR 40, P369; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P414; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, pR3; *CDCP, 1996, STAT IMM REQ 1994 95; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P766; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; ETKIND P, 1992, AM J DIS CHILD, V146, P173, DOI 10.1001/archpedi.1992.02160140039017; FINE PEM, 1986, AM J EPIDEMIOL, V124, P1012, DOI 10.1093/oxfordjournals.aje.a114471; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; HABER M, 1991, INT J EPIDEMIOL, V20, P300, DOI 10.1093/ije/20.1.300; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HERSHEY JC, 1994, ORGAN BEHAV HUM DEC, V59, P177, DOI 10.1006/obhd.1994.1055; JACKSON CL, 1969, PUBLIC HEALTH REP, V84, P787, DOI 10.2307/4593678; MELLINGER AK, 1995, PEDIATR INFECT DIS J, V14, P573, DOI 10.1097/00006454-199507000-00004; *NAT HEART LUNG BL, 1998, NIH PUBL, P1; *NAT VAC ADV COMM, 1991, MEASL EP PROBL BARR; NOVOTNY T, 1988, PUBLIC HEALTH REP, V103, P49; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; Plotkin Stanley A., 1994, VACCINES; ROBBINS KB, 1981, AM J PUBLIC HEALTH, V71, P270, DOI 10.2105/AJPH.71.3.270; SUTTER RW, 1991, J INFECT DIS, V163, P12, DOI 10.1093/infdis/163.1.12; WHITE FM, 1979, MMWR-MORBID MORTAL W, V28, P345	24	196	198	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					47	53		10.1001/jama.282.1.47	http://dx.doi.org/10.1001/jama.282.1.47			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	212BE	10404911				2022-12-28	WOS:000081195800028
J	Maulitz, RC				Maulitz, RC			That was the century that was: Historical perspectives on medical life at the Fin de Siecle	ANNALS OF INTERNAL MEDICINE			English	Article							CARE		MCP Hahnemann Sch Med, Telemed Project, Philadelphia, PA 19144 USA; Drexel Univ, Philadelphia, PA 19144 USA	Drexel University; Drexel University	Maulitz, RC (corresponding author), MCP Hahnemann Sch Med, Telemed Project, Cambridge Bldg 109,Alden Pk ,W Sch House Lane 296, Philadelphia, PA 19144 USA.							Berg M, 1997, RATIONALIZING MED WO; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; DAVIDOFF F, 1998, NEW DIS OLD STORY, V129, P327; Donohoe MT, 1998, ARCH INTERN MED, V158, P1596, DOI 10.1001/archinte.158.15.1596; Fye B., 1996, AM CARDIOLOGY HIST S; Ginzberg E, 1998, JAMA-J AM MED ASSOC, V280, P1539, DOI 10.1001/jama.280.17.1539; Howell JD, 1995, TECHNOLOGY HOSP TRAN; IGLEHART JK, 1981, NEW ENGL J MED, V305, P1027, DOI 10.1056/NEJM198110223051733; KASSIRER JP, 1993, NEW ENGL J MED, V328, P1268, DOI 10.1056/NEJM199304293281710; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Kevles B., 1997, NAKED BONE MED IMAGI; Krause Elliott, 1996, DEATH GUILDS PROFESS; LESY M, 1997, DREAMLAND AM DAWN 20; Marks H., 1997, PROGR EXPT SCI THERA; Schechter AN, 1998, JAMA-J AM MED ASSOC, V280, P1440, DOI 10.1001/jama.280.16.1440; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; STEVENS R, 1988, GRAND ROUNDS 100 YEA; STEVENS R, 1998, AM MED PUBLIC INTERE, pR9; STEVENS R, 1989, SICKNESS WEALTH; Stevens Rosemary, 1971, AM MED PUBLIC INTERE; TEMKIN O, 1991, HIPPOCRATES WORLD PA, P254; Wailoo Keith., 1997, DRAWING BLOOD TECHNO, P46; 1997, ECONOMIST, V129, P756	24	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					75	78		10.7326/0003-4819-131-1-199907060-00033	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00033			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391831				2022-12-28	WOS:000081345200031
J	Tembon, A				Tembon, A			A memorable patient - From cerebral malaria to preventive medicine	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					36	36		10.1136/bmj.319.7201.36	http://dx.doi.org/10.1136/bmj.319.7201.36			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390459	Green Published			2022-12-28	WOS:000081326500033
J	Vaira, D; Malfertheiner, P; Megraud, F; Axon, ATR; Deltenre, M; Hirschl, AM; Gasbarrini, G; O'Morain, C; Garcia, JMP; Quina, N; Tytgat, GNJ				Vaira, D; Malfertheiner, P; Megraud, F; Axon, ATR; Deltenre, M; Hirschl, AM; Gasbarrini, G; O'Morain, C; Garcia, JMP; Quina, N; Tytgat, GNJ		HpSA European Study Grp	Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay	LANCET			English	Article							DYSPEPTIC PATIENTS	Background Helicobacter pylori is a common human pathogen implicated in certain gastrointestinal diseases. in the search for new non-invasive techniques to diagnose H pylori infection, we evaluated an EIA for H pylori antigen in stool (HpSA). Methods In a prospective multicentre study, stool specimens from 501 patients (276 men, 225 women; age range 17-88 years, mean 52) undergoing gastroscopy in 11 centres throughout Europe were tested with HpSA and the carbon-13-urea breath test. At endoscopy, four biopsy samples were taken for histology (haematoxylin and eosin) and H pylori detection (giemsa in both antrum and corpus, culture and rapid urease test). Patients were defined as positive for H pylori if histology (antrum, corpus, or both) and urease test were positive, or if culture was positive. Patients classified as having H pylori infection received an eradication regimen; 107 were reassessed 4 weeks after therapy. Findings Of 272 patients with H pylori infection by the predefined criteria, 256 were positive by HpSA (sensitivity 94.1% [95% CI 90.6-96.6]). Of 219 patients without infection, 201 were negative by HpSA (specificity 91.8% [87.3-95.1]). Interpretation The stool assay was a reliable and easy-to-use tool for diagnosis:of H pylori infection. The test was accurate even shortly after treatment.	Otto Von Guericke Univ, Dept Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany; Hop Pellegrin, Bacteriol Lab, F-33076 Bordeaux, France; Gen Infirm, Gastroenterol Unit, Leeds LS1 3EX, W Yorkshire, England; Ctr Hosp Univ Brugmann, Gastroenterol Unit, Brussels, Belgium; Allgemeines Krankenhaus Wien Inst, Abt Klin Mikrobiol Hyg, Vienna, Austria; Policlin Gemelli, Rome, Italy; AMNCH, Gastroenterol Off, Dublin, Ireland; Hosp Princessa, Madrid, Spain; Hosp Pulido Valente, Lisbon, Portugal; Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands; Univ Bologna, Med Clin 1, Bologna, Italy	Otto von Guericke University; CHU Bordeaux; Leeds General Infirmary; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Trinity College Dublin; Hospital de La Princesa; University of Amsterdam; University of Bologna	Vaira, D (corresponding author), Univ Bologna, Policlin S Orsola, Med Clin 1, Nuouv Patol, I-40138 Bologna, Italy.	vairadin@med.unibo.it						BLEAU BL, 1998, GUT, V43, P50; Briggs AH, 1996, BRIT MED J, V312, P1321, DOI 10.1136/bmj.312.7042.1321; BUSCAGLIA S, 1998, GUT, V43, P50; Cutler AF, 1996, AM J GASTROENTEROL, V91, P85; Forne M, 1998, GUT, V43, pA50; Galen RS, 1975, NORMALITY PREDICTIVE; GAMBINO SR, 1983, CLIN CHEM, V29, P1319; Gardner M. J., 1989, STAT CONFIDENCE; Gasbarrini A, 1997, EUR J GASTROEN HEPAT, V9, P231, DOI 10.1097/00042737-199703000-00001; International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, V61, P177; Logan RPH, 1996, HELICOBACTER PYLORI, P74; Makristathis A, 1998, J CLIN MICROBIOL, V36, P2772, DOI 10.1128/JCM.36.9.2772-2774.1998; Malfertheiner P, 1997, GUT, V41, P8; Megraud F, 1997, GASTROENTEROLOGY, V113, pS93, DOI 10.1016/S0016-5085(97)80020-0; Palli D, 1997, ALIMENT PHARM THERAP, V11, P719, DOI 10.1046/j.1365-2036.1997.00215.x; PATEL P, 1995, LANCET, V346, P1315, DOI 10.1016/S0140-6736(95)92340-3; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; Trevisani L, 1998, GUT, V43, pA47; Vaira D, 1996, LANCET, V347, P269; VAIRA D, 1994, GUT, V35, P309, DOI 10.1136/gut.35.3.309; van't Hoff BWM, 1998, GUT, V43, pA49; *WORK PART EUR HEL, 1997, GUT, V41, pS10	22	320	342	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					30	33		10.1016/S0140-6736(98)08103-3	http://dx.doi.org/10.1016/S0140-6736(98)08103-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406362				2022-12-28	WOS:000081243200011
J	Moss, ME; Lanphear, BP; Auinger, P				Moss, ME; Lanphear, BP; Auinger, P			Association of dental caries and blood lead levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; NATIONAL-HEALTH; NHANES-III; CHILDREN; POPULATION; DENTITION	Context Experiments show that dental caries rates are higher among lead-exposed animals, but this association has not been established in humans. Objective To examine the relationship between blood lead levels and dental caries. Design Cross-sectional survey conducted from 1988 to 1994 that included a dental examination and venipuncture blood lead assay. Setting and Participants A total of 24 901 persons aged 2 years and older who participated in the Third National Health and Nutrition Examination Survey, which assessed the health and nutritional status of children and adults in the United States. Main Outcome Measures For children aged 2 to 11 years, the sum of decayed and filled deciduous or primary surfaces; for persons aged 6 years and older, the sum of decayed and filled permanent surfaces; for those 12 years and older, the sum of decayed, missing, and filled surfaces. Results The log of blood lead level was significantly associated with the number of affected surfaces for both deciduous and permanent teeth in all age groups, even after adjusting for sociodemographic characteristics, diet, and dental care. Among children aged 5 to 17 years, a 0.24-mu mol/L (5-mu g/dL) change in blood lead level was associated with an elevated risk of dental caries (odds ratio, 1.8; 95% confidence interval, 1.3-2.5). Differences in blood lead level explained some of the differences in caries prevalence in different income levels and regions of the United States. We estimated the population attributable risk of lead exposure to be 13.5% and 9.6% of dental caries occurring in 5- to 17-year-olds exposed to the high and moderate levels, respectively. Conclusions Environmental lead exposure is associated with an increased prevalence of dental caries in the US population, Findings may help explain the distribution of caries by income and region of the United States.	Univ Rochester, Sch Med & Dent, Eastman Dept Dent, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Childrens Hosp, Med Ctr, Dept Pediat, Rochester, NY USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA	University of Rochester; University of Rochester; University System of Ohio; University of Cincinnati	Moss, ME (corresponding author), Univ Rochester, Med Ctr, Dept Community & Prevent Med, Box 644,601 Elmwood Ave, Rochester, NY 14642 USA.	moss@prevmed.rochester.edu	Moss, Mark E/Q-3014-2019; Moss, Mark E/AAF-1697-2020	Moss, Mark E/0000-0003-0105-0416	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D15PE010027] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES-08338] Funding Source: Medline; BHP HRSA HHS [1T-32 PE-10027] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); BHP HRSA HHS		BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BRUDEVOLD F, 1977, J DENT RES, V56, P1165, DOI 10.1177/00220345770560100701; Brunelle J A, 1990, J Dent Res, V69 Spec No, P723; BRUNELLE JA, 1982, J DENT RES, V61, P1346; *CDC, 1992, MMWR-MORBID MORTAL W, V41, P381; *CDC, 1992, MMWR-MORBID MORTAL W, V41, P372; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P141; Curzon M.E.J., 1983, TRACE ELEMENTS DENT; DAVIES BE, 1987, EXPERIENTIA, V43, P87, DOI 10.1007/BF01940359; Drury TF, 1996, J DENT RES, V75, P620, DOI 10.1177/002203459607502S02; EDELSTEIN BL, 1995, PUBLIC HEALTH REP, V110, P522; Gil F, 1996, SCI TOTAL ENVIRON, V192, P183, DOI 10.1016/S0048-9697(96)05313-2; GIL F, 1994, SCI TOTAL ENVIRON, V156, P145, DOI 10.1016/0048-9697(94)90351-4; HAYES EB, 1994, PEDIATRICS, V93, P195; Kaste LM, 1996, J DENT RES, V75, P631, DOI 10.1177/002203459607502S03; McClure Frank J., 1970, WATER FLUORIDATION S; RAO GS, 1984, ANNU REV NUTR, V4, P115, DOI 10.1146/annurev.nu.04.070184.000555; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; Stack MV, 1983, TRACE ELEMENTS DENTA, P357; Stamm J. W., 1991, RISK MARKERS ORAL DI, V1, P132; Vargas CM, 1998, J AM DENT ASSOC, V129, P1229, DOI 10.14219/jada.archive.1998.0420; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; Watson GE, 1997, NAT MED, V3, P1024, DOI 10.1038/nm0997-1024; Winn DM, 1996, J DENT RES, V75, P642, DOI 10.1177/002203459607502S04; [No title captured]	26	81	85	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2294	2298		10.1001/jama.281.24.2294	http://dx.doi.org/10.1001/jama.281.24.2294			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386553				2022-12-28	WOS:000080925600028
J	Bashaw, GJ; Goodman, CS				Bashaw, GJ; Goodman, CS			Chimeric axon guidance receptors: The cytoplasmic domains of slit and netrin receptors specify attraction versus repulsion	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; GENETIC-ANALYSIS; CNS MIDLINE; COLORECTAL-CANCER; SEMAPHORIN-III; MOTOR AXONS; DROSOPHILA; PROTEIN; COMPLEMENTARY	Frazzled (Fra) is the DCC-like Netrin receptor in Drosophila that mediates attraction; Roundabout (Robo) is a Slit receptor that mediates repulsion. Both ligands are expressed at the midline; both receptors have related structures and are often expressed by the same neurons. To determine if attraction versus repulsion is a modular function encoded in the cytoplasmic domain of these receptors, we created chimeras carrying the ectodomain of one receptor and the cytoplasmic domain of the other and tested their function in transgenic Drosophila. Fra-Robo (Fra's ectodomain and Robe's cytoplasmic domain) functions as a repulsive Netrin receptor; neurons expressing Fra-Robo avoid the Netrin-expressing midline and muscles. Robo-Fra (Robo's ectodomain and Fra's cytoplasmic domain) is an attractive Slit receptor; neurons and muscle precursors expressing Robo-Fra are attracted to the Slit-expressing midline.	Univ Calif Berkeley, Dept Cell & Mol Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, CS (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagnard D, 1998, DEVELOPMENT, V125, P5043; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wong JTW, 1997, DEVELOPMENT, V124, P3597	37	161	171	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					917	926		10.1016/S0092-8674(00)80803-X	http://dx.doi.org/10.1016/S0092-8674(00)80803-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399919	Bronze			2022-12-28	WOS:000081162800012
J	Kumar, KK; Rajagopalan, B; Cane, MA				Kumar, KK; Rajagopalan, B; Cane, MA			On the weakening relationship between the Indian monsoon and ENSO	SCIENCE			English	Article							ASIAN SUMMER MONSOON; EURASIAN SNOW COVER; NINO SOUTHERN OSCILLATION; SEA-SURFACE TEMPERATURES; AIR-TEMPERATURE; RAINFALL SERIES; VARIABILITY; CLIMATE; MODEL; SIMULATIONS	Analysis of the 140-year historical record suggests that the inverse relationship between the El Nino-Southern Oscillation (ENSO) and the Indian summer monsoon (weak monsoon arising from warm ENSO event) has broken down in recent decades. Two possible reasons emerge from the analyses. A southeastward shift in the Walker circulation anomalies associated with ENSO events may Lead to a reduced subsidence over the Indian region, thus favoring normal monsoon conditions. Additionally, increased surface temperatures over Eurasia in winter and spring, which area parr. of the midlatitude continental warming trend, may favor the enhanced land-ocean thermal gradient conducive to a strong monsoon. These observations raise the possibility that the Eurasian warming in recent decades helps to sustain the monsoon rainfall at a normal Level despite strong ENSO events.	Columbia Univ, Lamont Doherty Earth Observ, Int Res Inst Climate Predict, Palisades, NY 10964 USA; Indian Inst Trop Meteorol, Pune 411008, Maharashtra, India	Columbia University; Ministry of Earth Sciences (MoES) - India; Indian Institute of Tropical Meteorology (IITM)	Kumar, KK (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Int Res Inst Climate Predict, POB 1000,Route 9W, Palisades, NY 10964 USA.		Rajagopalan, Balaji/CAJ-3111-2022; Cane, Mark/I-8086-2012; BALAJI, RAJAGOPALAN/A-5383-2013	Rajagopalan, Balaji/0000-0002-6883-7240; Cane, Mark/0000-0001-5408-2388; BALAJI, RAJAGOPALAN/0000-0003-1433-7520				AMZAI A, 1998, 53 COLA; BARNETT TP, 1989, J ATMOS SCI, V46, P661, DOI 10.1175/1520-0469(1989)046<0661:TEOESC>2.0.CO;2; BHASKARAN B, 1995, INT J CLIMATOL, V15, P873, DOI 10.1002/joc.3370150804; Blanford HF., 1884, P R SOC LOND, V37, P3, DOI DOI 10.1098/RSPL.1884.0003; HAHN DG, 1976, J ATMOS SCI, V33, P2461, DOI 10.1175/1520-0469(1976)033<2461:AARBES>2.0.CO;2; Hastenrath S, 1991, CLIMATE DYNAMICS TRO, DOI DOI 10.1007/978-94-011-3156-8; JONES PD, 1994, J CLIMATE, V7, P1794, DOI 10.1175/1520-0442(1994)007<1794:HSATVA>2.0.CO;2; JU JH, 1995, Q J ROY METEOR SOC, V121, P1133, DOI 10.1002/qj.49712152509; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; KRISHNAMURTHY V, 1998, 62 COLA; KUMAR A, 1994, SCIENCE, V266, P632, DOI 10.1126/science.266.5185.632; Kumar K. K., 1995, Weather, V50, P449, DOI 10.1002/j.1477-8696.1995.tb06071.x; Kumar KK, 1999, GEOPHYS RES LETT, V26, P75, DOI 10.1029/1998GL900226; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; MEEHL GA, 1994, SCIENCE, V266, P263, DOI 10.1126/science.266.5183.263; Meehl GA, 1998, J CLIMATE, V11, P1356, DOI 10.1175/1520-0442(1998)011<1356:TAAMAE>2.0.CO;2; NICHOLLS N, 1996, CLIMATE CHANGE 1995, P133; PANT GB, 1981, ARCH METEOR GEOPHY B, V29, P245, DOI 10.1007/BF02263246; Parker DE, 1995, CLIMATIC CHANGE, V31, P559, DOI 10.1007/BF01095162; PARTHASARATHY B, 1991, J CLIMATE, V4, P927, DOI 10.1175/1520-0442(1991)004<0927:EOSVII>2.0.CO;2; PARTHASARATHY B, 1994, THEOR APPL CLIMATOL, V49, P217, DOI 10.1007/BF00867461; RASMUSSON EM, 1983, MON WEATHER REV, V111, P517, DOI 10.1175/1520-0493(1983)111<0517:TRBEEP>2.0.CO;2; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Sankar Rao M., 1996, INT J CLIMATOL, V16, P605; Shen XH, 1998, J METEOROL SOC JPN, V76, P217, DOI 10.2151/jmsj1965.76.2_217; SHUKLA J, 1983, MON WEATHER REV, V111, P1830, DOI 10.1175/1520-0493(1983)111<1830:TSOALR>2.0.CO;2; Shukla J., 1987, MONSOONS, P399; SONTAKKE NA, 1993, J CLIMATE, V6, P1807, DOI 10.1175/1520-0442(1993)006<1807:COAISM>2.0.CO;2; Sperber KR, 1996, J CLIMATE, V9, P2727, DOI 10.1175/1520-0442(1996)009<2727:ITRVIG>2.0.CO;2; VERMA RK, 1985, P INDIAN AS-EARTH, V94, P187; VERNEKAR AD, 1995, J CLIMATE, V8, P248, DOI 10.1175/1520-0442(1995)008<0248:TEOESC>2.0.CO;2; WALKER GT, 1918, Q J R METEOROL SOC, V22, P223; Webster PJ, 1998, J GEOPHYS RES-OCEANS, V103, P14451, DOI 10.1029/97JC02719; WEBSTER PJ, 1987, MONSOONS, P275; Yang S, 1996, INT J CLIMATOL, V16, P125, DOI 10.1002/(SICI)1097-0088(199602)16:2<125::AID-JOC999>3.0.CO;2-V; YASUNARI T, 1991, J METEOROL SOC JPN, V69, P473, DOI 10.2151/jmsj1965.69.4_473	36	1113	1167	4	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2156	2159		10.1126/science.284.5423.2156	http://dx.doi.org/10.1126/science.284.5423.2156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381876				2022-12-28	WOS:000081099300045
J	Lichtenstein, AH; Ausman, LM; Jalbert, SM; Schafer, EJ				Lichtenstein, AH; Ausman, LM; Jalbert, SM; Schafer, EJ			Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; COMMERCIAL IMMUNOTURBIDIMETRIC ASSAY; REFERENCE INTERVALS; PLASMA-LIPOPROTEIN; HEALTHY-SUBJECTS; STEARIC-ACID; HIGH-DENSITY; LIPIDS; HUMANS; RISK	Background Metabolic studies suggest that fatty acids containing at least one double bond in the trans configuration, which are found in hydrogenated fat, have a detrimental effect on serum lipoprotein cholesterol levels as compared with unsaturated fatty acids containing double bonds only in the cis configuration. We compared the effects of diets with a broad range of trans fatty acids on serum lipoprotein cholesterol levels. Methods Eighteen women and 18 men consumed each of six diets in random order for 35-day periods. The foods were identical in each diet, and each diet provided 30 percent of calories as fat, with two thirds of the fat contributed as soybean oil (<0.5 g of trans fatty acid per 100 g of fat), semiliquid margarine (<0.5 g per 100 g), soft margarine (7.4 g per 100 g), shortening (9.9 g per 100 g), or stick margarine (20.1 g per 100 g). The effects of those diets on serum lipoprotein cholesterol, triglyceride, and apolipoprotein levels were compared with those of a diet enriched with butter, which has a high content of saturated fat. Results The mean (+/-SD) serum low-density lipoprotein (LDL) cholesterol level was 177+/-32 mg per deciliter (4.58+/-0.85 mmol per liter) and the mean high-density lipoprotein (HDL) cholesterol level was 45+/-10 mg per deciliter (1.2+/-0.26 mmol per liter) after subjects consumed the butter-enriched diet. The LDL cholesterol level was reduced on average by 12 percent, 11 percent, 9 percent, 7 percent, and 5 percent, respectively, after subjects consumed the diets enriched with soybean oil, semiliquid margarine, soft margarine, shortening, and stick margarine; the HDL cholesterol level was reduced by 3 percent, 4 percent, 4 percent, 4 percent, and 6 percent, respectively. Ratios of total cholesterol to HDL cholesterol were lowest after the consumption of the soybean-oil diet and semiliquid-margarine diet and highest after the stick-margarine diet. Conclusions Our findings indicate that the consumption of products that are low in trans fatty acids and saturated fat has beneficial effects on serum lipoprotein cholesterol levels. (N Engl J Med 1999;340: 1933-40.) (C) 1999, Massachusetts Medical Society.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Sch Nutr Sci & Policy, Medford, MA USA	Tufts University; United States Department of Agriculture (USDA); Tufts University	Lichtenstein, AH (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054727] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDINGEN K, 1995, J LIPID RES, V36, P1370; Aro A, 1997, AM J CLIN NUTR, V65, P1419, DOI 10.1093/ajcn/65.5.1419; BROWN SA, 1993, ARTERIOSCLER THROMB, V13, P1558, DOI 10.1161/01.ATV.13.11.1558; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Clevidence BA, 1997, ARTERIOSCL THROM VAS, V17, P1657, DOI 10.1161/01.ATV.17.9.1657; Contois JH, 1996, CLIN CHEM, V42, P515; Contois JH, 1996, CLIN CHEM, V42, P507; DENKE MA, 1995, AM J CLIN NUTR, V62, pS693; EMKEN EA, 1995, AM J CLIN NUTR, V62, pS659; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1993, AM J CLIN NUTR, V58, P245; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; JUDD JT, 1994, AM J CLIN NUTR, V59, P861, DOI 10.1093/ajcn/59.4.861; Kennedy E, 1996, J AM DIET ASSOC, V96, P234, DOI 10.1016/S0002-8223(96)00072-7; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KROMHOUT D, 1995, PREV MED, V24, P308, DOI 10.1006/pmed.1995.1049; Lichtenstein AH, 1997, CIRCULATION, V95, P2588, DOI 10.1161/01.CIR.95.11.2588; LICHTENSTEIN AH, 1993, ARTERIOSCLER THROMB, V13, P154, DOI 10.1161/01.ATV.13.2.154; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Wild SH, 1997, ARTERIOSCL THROM VAS, V17, P239, DOI 10.1161/01.ATV.17.2.239; Wild SH, 1997, ARTERIOSCL THROM VAS, V17, P1010, DOI 10.1161/01.ATV.17.5.1010; ZOCK PL, 1992, J LIPID RES, V33, P399; Zock PL, 1996, CURR OPIN LIPIDOL, V7, P34, DOI 10.1097/00041433-199602000-00008	29	238	255	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1933	1940		10.1056/NEJM199906243402501	http://dx.doi.org/10.1056/NEJM199906243402501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379016				2022-12-28	WOS:000081088500001
J	Jenkinson, C; Davies, RJO; Mullins, R; Stradling, JR				Jenkinson, C; Davies, RJO; Mullins, R; Stradling, JR			Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial	LANCET			English	Article							DAYTIME SLEEPINESS; MEDICAL OUTCOMES; HEALTH-STATUS; APNEA; SF-36; SCALE	Background Nasal continuous positive airway pressure (NCPAP) is widely used as a treatment for obstructive sleep apnoea. However, to date there are no randomised controlled trials of this therapy against a well-matched control. We undertook a randomised prospective parallel trial of therapeutic NCPAP for obstructive sleep apnoea compared with a control group on subtherapeutic NCPAP. Methods Men with obstructive sleep apnoea, defined as an Epworth sleepiness score of 10 or more and ten or more dips per h of more than 4% SaO(2) caused by obstructive sleep apnoea on overnight sleep study, were randomly assigned therapeutic NCPAP or subtherapeutic NCPAP (about 1 cm H2O) for 1 month. Primary outcomes were subjective sleepiness (Epworth sleepiness score), objective sleepiness (maintenance of wakefulness test), and SF-36 questionnaire measurements of self-reported functioning and well-being. Findings 107 men entered the study: 53 received subtherapeutic NCPAP and 54 therapeutic NCPAP. Use of NCPAP by the two treatment groups was similar: 54 h (therapeutic) and 4.6 h (subtherapeutic) per night. Subtherapeutic NCPAP did not alter the overnight number of SaO(2) dips per h compared with baseline, and thus acted as a control. Therapeutic NCPAP was superior to subtherapeutic NCPAP in all primary outcome measures. The Epworth score was decreased from a median of 15.5 to 7.0 on therapeutic NCPAP, and from 15.0 to 13.0 on subtherapeutic NCPAP (between treatments, p<0.0001). Mean maintenance-of-wakefulness time increased from 22.5 to 32.9 min on therapeutic NCPAP and, not significantly, from 20.0 to 23.5 min on subtherapeutic NCPAP (between treatments p<0.005). Effect sizes for SF-36 measures of energy and vitality were 1.68 (therapeutic) and 0.97 (subtherapeutic) NCPAP (between treatments p<0.0001). For mental summary score, the corresponding values were 1.02 and 0.4 (between treatments p=0.002). Interpretation Therapeutic NCPAP reduces excessive daytime sleepiness and improves self-reported health status compared with a subtherapeutic control. Compared with controls, the effects of therapeutic NCPAP are large and confirm previous uncontrolled clinical observations and the results of controlled trials that used an oral placebo.	Oxford Radcliffe Trust, Osler Chest Unit, Oxford OX3 7LJ, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Care, Hlth Serv Res Unit, Oxford, England	University of Oxford	Stradling, JR (corresponding author), Oxford Radcliffe Trust, Osler Chest Unit, Churchill Campus, Oxford OX3 7LJ, England.							AUBERTTULKENS G, 1980, CLIN RES PROC, V16, P587; *AUSTR HLTH TECHN, 1996, EFF COST EFF NAS CON; Bennett LS, 1998, AM J RESP CRIT CARE, V158, P778, DOI 10.1164/ajrccm.158.3.9711033; Bennett LS, 1997, J SLEEP RES, V6, P142, DOI 10.1046/j.1365-2869.1997.00039.x; CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; COHEN J, 1977, STAT POWER BEHAV SCI; Doghramji K, 1997, ELECTROEN CLIN NEURO, V103, P554, DOI 10.1016/S0013-4694(97)00010-2; Douglas NJ, 1998, THORAX, V53, P414, DOI 10.1136/thx.53.5.414; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; FRASER AK, 1997, OBSTRUCTIVE SLEEP AP; GUILLEMINAULT C, 1976, ANNU REV MED, V27, P465, DOI 10.1146/annurev.me.27.020176.002341; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; ISSA FG, 1986, ELECTROEN CLIN NEURO, V63, P10, DOI 10.1016/0013-4694(86)90056-8; JENKINSON C, 1995, AGE AGEING, V24, P505, DOI 10.1093/ageing/24.6.505; Jenkinson C, 1997, J SLEEP RES, V6, P199, DOI 10.1046/j.1365-2869.1997.00043.x; Jenkinson C, 1997, AGE AGEING, V26, P7, DOI 10.1093/ageing/26.1.7; Johns M, 1997, SLEEP, V20, P844, DOI 10.1093/sleep/20.10.844; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KRIEGER J, 1983, LANCET, V2, P1429; Mitler MM, 1998, ANN NEUROL, V43, P88; Stradling JR, 1999, AM J RESP CRIT CARE, V159, P130, DOI 10.1164/ajrccm.159.1.9805074; Stradling JR, 1997, THORAX, V52, P72, DOI 10.1136/thx.52.1.72; STRADLING JR, 1998, AM J RESP CRIT CARE, V157, pA344; SULLIVAN CE, 1981, LANCET, V1, P862; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; *WESS I HLTH RES D, 1994, CONT POS AIRW PRESS; Wright J, 1997, BRIT MED J, V314, P851; WRIGHT L, 1992, HLTH LIFESTYLES OXFO	30	567	571	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2100	2105		10.1016/S0140-6736(98)10532-9	http://dx.doi.org/10.1016/S0140-6736(98)10532-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382693				2022-12-28	WOS:000080969300009
J	Kleinert, S				Kleinert, S			Modern medicine: the state we're in	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Kleinert, S (corresponding author), The Lancet, London WC1B 3SL, England.							Davies RJ, 1998, CLIN EXP ALLERGY, V28, P8; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; GEHRMANN W, 1999, ZEIT            0602, P25; Horton R, 1998, LANCET, V351, P1525, DOI 10.1016/S0140-6736(05)61115-4; Le Fanu J., 1999, RISE FALL MODERN MED	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2092	2092		10.1016/S0140-6736(99)99110-9	http://dx.doi.org/10.1016/S0140-6736(99)99110-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382691				2022-12-28	WOS:000080969300007
J	Bacon, BR; Olynyk, JK; Brunt, EM; Britton, RS; Wolff, RK				Bacon, BR; Olynyk, JK; Brunt, EM; Britton, RS; Wolff, RK			HFE genotype in patients with hemochromatosis and other liver diseases	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVAL; HEPATIC IRON INDEX; HEREDITARY HEMOCHROMATOSIS; NONALCOHOLIC STEATOHEPATITIS; GENETIC HEMOCHROMATOSIS; MUTATION ANALYSIS; HLA-H; FIBROSIS; HETEROZYGOTES; OVERLOAD	Background: Hereditary hemochromatosis is a common inherited disorder of iron metabolism. The gene HFE, which contains two missense mutations (C282Y and H63D), was recently identified. Objective: To determine how HFE genotyping for the C282Y and H63D mutations contributes to the diagnosis of hemochromatosis and to determine the prevalence of HFE mutations in a group of patients with liver disease. Design: Cross-sectional study. Setting: Academic medical center. Patients: 66 patients with hereditary hemochromatosis and 132 referred patients with other liver diseases. Measurements: At initial diagnosis, fasting transferrin saturation, ferritin level, routine chemistry panel, and complete blood count were determined. Percutaneous liver biopsy was done on all patients for histologic analysis and measurement of hepatic iron concentration and hepatic iron index. HFE genotyping for the C282Y and H63D mutations was done on all patients by using genomic DNA samples. Results: Of the 66 patients with hemochromatosis diagnosed on the basis of serum iron studies and liver biopsy findings, 60 (91%) were C282Y homozygotes, 2 (3%) were compound heterozygotes, 1 (1.5%)was a C282Y heterozygote, 2 (3%) were H63D heterozygotes, and 1 (1.5%) was negative for both mutations, Of the 132 patients with liver disease, 6 (5%) were C282Y homozygotes, 8 (6%) were compound heterozygotes, 6 (5%) were C282Y heterozygotes, 5 (4%) were H63D homozygotes, 20 (15%) were H63D heterozygotes, and 87 (66%) were negative for both mutations, All 66 C282Y homozygotes had an elevated hepatic iron concentration, and 65 of the 66 patients (98%) had a transferrin saturation of at least 45%, Ten of the 66 patients (15% [95% Cl, 7.5% to 26%]) had a hepatic iron index less than 1.9 mmol/kg per year; hemochromatosis was not suspected in 6 of the 10 patients before genotyping. Cirrhosis or substantial hepatic fibrosis was not seen in any (0% [Cl, 0% to 18%]) of the 19 patients younger than 40 years of age who were homozygous for the C282Y mutation. Conclusions: All 66 patients homozygous for the C282Y mutation of HFE had an elevated hepatic iron concentration, but approximately 15% of these patients did not meet a previous diagnostic criterion for hemochromatosis (hepatic iron index > 1.9 mmol/kg per year). Determination of HFE genotype is clinically useful in patients with liver disease and suspected iron overload and may lead to identification of otherwise unsuspected C282Y homozygotes.	Univ Dept Med, Dept Gastroenterol, Fremantle Hosp, Fremantle 6160, Australia; St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Sch Med,Dept Pathol, St Louis, MO 63110 USA; Progenitor Inc, Menlo Pk, CA 94025 USA	University of Western Australia; Saint Louis University	Bacon, BR (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Sch Med,Dept Pathol, 3635 Vista Ave, St Louis, MO 63110 USA.	baconbr@slu.edu		Olynyk, John/0000-0003-0417-3411	NIDDK NIH HHS [DK-41816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Bacon BR, 1997, AM J GASTROENTEROL, V92, P784; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BONKOVSKY HL, 1990, GASTROENTEROLOGY, V99, P1079, DOI 10.1016/0016-5085(90)90629-F; Bothwell, 1980, METHODS HEMATOLOGY, V1, P90; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Carella M, 1997, AM J HUM GENET, V60, P828; CHAPMAN RW, 1982, DIGEST DIS SCI, V27, P909, DOI 10.1007/BF01316575; DEUGNIER YM, 1993, HEPATOLOGY, V17, P30, DOI 10.1002/hep.1840170107; DIBISCEGLIE AM, 1992, GASTROENTEROLOGY, V102, P2108, DOI 10.1016/0016-5085(92)90339-Z; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; FARGION S, 1994, HEPATOLOGY, V20, P1426, DOI 10.1002/hep.1840200608; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Grove J, 1998, GUT, V43, P262, DOI 10.1136/gut.43.2.262; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Jawaid O, 1998, GASTROENTEROLOGY, V114, pA1264; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kazemi-Shirazi L, 1999, GASTROENTEROLOGY, V116, P127, DOI 10.1016/S0016-5085(99)70236-2; Kowdley KV, 1997, GASTROENTEROLOGY, V113, P1270, DOI 10.1053/gast.1997.v113.pm9322522; Ludwig J, 1997, GASTROENTEROLOGY, V112, P882, DOI 10.1053/gast.1997.v112.pm9041250; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OLYNYK J, 1990, HEPATOLOGY, V12, P26, DOI 10.1002/hep.1840120106; Piperno A, 1998, HEPATOLOGY, V28, P1105, DOI 10.1002/hep.510280427; SEARLE JW, 1994, PATHOLOGY LIVER, P223; Smith BC, 1998, HEPATOLOGY, V27, P1695, DOI 10.1002/hep.510270631	32	153	158	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					953	962		10.7326/0003-4819-130-12-199906150-00002	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383365				2022-12-28	WOS:000080894700001
J	Nowak, TV				Nowak, TV			The ritual	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Nowak, TV (corresponding author), 1472 Stormy Ridge Court, Carmel, IN 46032 USA.								0	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					1025	1026		10.7326/0003-4819-130-12-199906150-00024	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00024			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383355				2022-12-28	WOS:000080894700013
J	Adams, JFA; Scholvinck, EH; Gie, RP; Potter, PC; Beyers, N; Beyers, AD				Adams, JFA; Scholvinck, EH; Gie, RP; Potter, PC; Beyers, N; Beyers, AD			Decline in total serum IgE after treatment for tuberculosis	LANCET			English	Article							CELLULAR IMMUNE-RESPONSES; T-CELL; RECEPTOR DEFICIENCY; SKIN-TEST; INFECTION; MYCOBACTERIAL; HELMINTH; MICE; MODULATION	Background. Infection with Mycobacterium tuberculosis induces a type-1 immune response, whereas intestinal parasites elicit a type-2 response. Given that type-1 and type-2 responses inhibit each other, we investigated. if M tuberculosis downregulates serum IgE, a marker of a type-2 response. Methods. A prospective study was done in the Western Cape Province of South Africa, where tuberculosis and intestinal-parasite infection are common. Total serum IgE was determined for 37 controls and for 33 adolescent patients at presentation with tuberculosis and after successful completion of treatment. IgE specific for ascaris and allergens were measured in a subset of these individuals. Mantoux skin tests were done on 35 controls and on 31 patients at diagnosis. Findings. Total IgE concentrations were high in controls (mean 313 kU/L) and in patients before treatment (mean 457 kU/L, p = 0.085) and declined in all patients following successful treatment (mean 175 kU/L, p < 0.0001). Posttreatment IgE concentrations did not differ from concentrations in controls. Ascaris-specific IgE was lower in controls (mean 1.73 kU/L) than in patients before treatment (4.62 kU/L, p = 0.023) and was 2.39 kU/L in patients after treatment (p = 0.0625). Tuberculin induration correlated inversely with IgE in patients but not in controls. Interpretation. Infection with M tuberculosis as such is not incompatible with a prominent IgE response. IgE concentrations decreased after successful treatment of tuberculosis, showing that IgE concentrations in human beings can be downregulated under these circumstances, presumably due to enhancement of a type-1 response.	Univ Stellenbosch, Sch Med, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Sch Med, Dept Biochem Med, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Sch Med, Dept Paediat & Child Hlth, ZA-7505 Tygerberg, South Africa; Univ Cape Town, Sch Med, Dept Immunol, ZA-7700 Rondebosch, South Africa	Stellenbosch University; Stellenbosch University; Stellenbosch University; University of Cape Town	Beyers, AD (corresponding author), Univ Stellenbosch, Sch Med, Ctr Cellular & Mol Biol, POB 19063, ZA-7505 Tygerberg, South Africa.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Arnadottir T, 1996, TUBERCLE LUNG DIS, V77, P1, DOI 10.1016/S0962-8479(96)90127-6; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; Beyers N, 1996, S AFR MED J, V86, P40; BUNDY DAP, 1991, PARASITE IMMUNOL, V13, P629, DOI 10.1111/j.1365-3024.1991.tb00558.x; Calleja C, 1998, NAT MED, V4, P92, DOI 10.1038/nm0198-092; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; de Jong R, 1998, SCIENCE, V280, P1435; *DEP HLTH, 1996, EPIDEMIOLOGICAL COMM, V23, P22; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; FERREIRA AP, 1995, CELL IMMUNOL, V162, P202, DOI 10.1006/cimm.1995.1070; GREENE BM, 1985, REV INFECT DIS, V7, P789; Gunders AE, 1993, S AFR J EPIDEMIOL IN, V8, P48; Israel HL., 1941, JAMA-J AM MED ASSOC, V117, P461; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; KAHN EA, 1995, EMERG INFECT DIS, V1, P115; MAHER J, 1992, RESP MED, V86, P481, DOI 10.1016/S0954-6111(96)80006-0; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; NEEDHAM CS, 1992, PARASITOLOGY, V105, P273, DOI 10.1017/S0031182000074205; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PEARLMAN E, 1993, J IMMUNOL, V151, P4857; Ramirez F, 1996, J IMMUNOL, V156, P2406; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; SARTONO E, 1995, J INFECT DIS, V171, P1683, DOI 10.1093/infdis/171.6.1683; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; Wang CC, 1998, IMMUNOLOGY, V93, P307; Wilkinson RJ, 1998, J INFECT DIS, V178, P760, DOI 10.1086/515336; YONG AJ, 1989, TUBERCLE, V70, P273, DOI 10.1016/0041-3879(89)90021-4	35	52	56	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2030	2033		10.1016/S0140-6736(98)08510-9	http://dx.doi.org/10.1016/S0140-6736(98)08510-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376618				2022-12-28	WOS:000080812200013
J	Oliveira, L; Moraes, MF; Oliveira, P; Abecasis, P				Oliveira, L; Moraes, MF; Oliveira, P; Abecasis, P			A train driver with painful legs	LANCET			English	Article							ERDHEIM-CHESTER-DISEASE		Hosp Egas Moniz, Serv Med 2, P-1300 Lisbon, Portugal; Inst Portugues Oncol, Dept Pathol, Lisbon, Portugal	Egas Moniz Hospital; Portuguese Institute of Oncology	Moraes, MF (corresponding author), Hosp Egas Moniz, Serv Med 2, Rua Junqueira 126, P-1300 Lisbon, Portugal.			Moraes-Fontes, Maria Francisca/0000-0002-8917-6592				Chester W, 1930, VIRCHOWS ARCH A, V279, P561, DOI 10.1007/BF01942684; FREYSCHMIDT J, 1986, SKELETAL RADIOL, V15, P316, DOI 10.1007/BF00349822; Lieberman PH, 1996, AM J SURG PATHOL, V20, P519, DOI 10.1097/00000478-199605000-00001; VALDEZ IH, 1990, ORAL SURG ORAL MED O, V70, P294, DOI 10.1016/0030-4220(90)90143-G; VeyssierBelot C, 1996, MEDICINE, V75, P157, DOI 10.1097/00005792-199605000-00005	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2034	2034		10.1016/S0140-6736(99)03099-8	http://dx.doi.org/10.1016/S0140-6736(99)03099-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376619				2022-12-28	WOS:000080812200014
J	Johnson, RE; Kondratick, CM; Prakash, S; Prakash, L				Johnson, RE; Kondratick, CM; Prakash, S; Prakash, L			hRAD30 mutations in the variant form of xeroderma pigmentosum	SCIENCE			English	Article							ESCHERICHIA-COLI DINB; POSTREPLICATION REPAIR; EXCISION-REPAIR; DNA-SYNTHESIS; REPLICATION; SENSITIVITY; HOMOLOG; BYPASS; DIMER; CELLS	Xeroderma pigmentosum (XP) is an autosomal recessive disease characterized by a high incidence of skin cancers. Yeast RAD30 encodes a DNA polymerase involved in the error-free bypass of ultraviolet (UV) damage. Here it is shown that XP variant (XP-V) cell lines harbor nonsense or frameshift mutations in hRAD30, the human counterpart of yeast RAD30. Of the eight mutations identified, seven would result in a severely truncated hRad30 protein. These results indicate that defects in hRAD30 cause XP-V, and they suggest that error-free replication of UV lesions by hRad30 plays an important role in minimizing the incidence of sunlight-induced skin cancers.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER JC, 1990, CANCER RES, V50, P2593; CLEAVER JE, 1980, CARCINOGENESIS, V1, P647, DOI 10.1093/carcin/1.8.647; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; CLEAVER JE, 1981, CYTOGENET CELL GENET, V31, P188, DOI 10.1159/000131646; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KONDRATICK CM, UNPUB; KRAEMER KH, 1994, J INVEST DERMATOL, V103, pS96, DOI 10.1111/1523-1747.ep12399329; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Roush AA, 1998, MOL GEN GENET, V257, P686; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Svoboda DL, 1998, CANCER RES, V58, P2445; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276	17	657	669	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					263	265		10.1126/science.285.5425.263	http://dx.doi.org/10.1126/science.285.5425.263			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398605				2022-12-28	WOS:000081346000045
J	Benedetti, JK; Zeh, J; Corey, L				Benedetti, JK; Zeh, J; Corey, L			Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time	ANNALS OF INTERNAL MEDICINE			English	Article						herpes genitalis; virus activation; recurrence; time factors; antiviral agents	PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ORAL ACYCLOVIR; SUPPRESSION; ANTIBODIES; THERAPY; TYPE-2; WOMEN; POPULATIONS; RECURRENCES	Background: Visits to physicians for genital herpes simplex virus (HSV) infection continue to increase. Most patients with symptomatic infections have recurrences, but no studies of the long-term clinical course of genital herpes are available. Objective: To determine whether the frequency of HSV recurrences decreases over time. Design: Observational cohort study. Setting: University-based research clinic. Patients: 664 persons with genital herpes followed for at least 14 months. Measurements: Patients were classified as having initial or recurrent HSV-1 or HSV-2 infection. Patient-reported recurrences and observed recurrences were recorded in a database; more than 12 000 recurrences were analyzed. Results: Median recurrence rates in the first year of follow-up were one and five per year in patients with newly acquired HSV-1 and HSV-2 infection, respectively; second-year rates were significantly lower in both groups. Patients presenting with recurrent HSV-2 infection had higher rates of recurrence in the first and second years and no significant decrease; significant decreases were detected with longer follow-up. One third of all patients experienced a decrease of two or more recurrences per year between years 1 and 2. Patients infected with HSV-2 who were followed for more than 4 years had a median decrease of two recurrences between years 1 and 5. However, 25% of these patients had an increase of at least one recurrence in year 5, illustrating the variability among HSV-infected persons. Decreases overtime among patients who never received suppressive therapy were similar to decreases during untreated periods in patients who received suppressive therapy. Conclusions: Herpes simplex virus type 2 infection continues to be a chronic remitting illness. Over time, however, clinically significant reductions occur in a majority of patients. Physicians may wish to periodically assess the need for continued treatment with daily suppressive antiviral chemotherapy.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Stat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), 1100 Fairview Ave N D3-100,Box 19024, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030619, P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30619, AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1998, LAB DIAGNOSIS VIRAL, P489; BASSETT I, 1994, MED J AUSTRALIA, V160, P697, DOI 10.5694/j.1326-5377.1994.tb125907.x; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; BENEDETTI JK, 1995, AM J MED, V98, P237, DOI 10.1016/S0002-9343(99)80369-6; CATOTTI DN, 1993, SEX TRANSM DIS, V20, P77, DOI 10.1097/00007435-199303000-00004; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P20; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; Corey L, 1999, SEX TRANSM DIS, V3rd, P285; Cowan FM, 1996, J INFECT DIS, V174, P470, DOI 10.1093/infdis/174.3.470; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; FIFE KH, 1994, J INFECT DIS, V169, P1338, DOI 10.1093/infdis/169.6.1338; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1994, INT J STD AIDS, V5, P113, DOI 10.1177/095646249400500207; GARLAND SM, 1995, J VIROL METHODS, V55, P285, DOI 10.1016/0166-0934(95)00061-9; HARGER JH, 1986, OBSTET GYNECOL, V67, P637, DOI 10.1097/00006250-198605000-00007; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; KNOX SR, 1982, SEX TRANSM DIS, V9, P15, DOI 10.1097/00007435-198201000-00003; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; MATTISON HR, 1988, AM J MED, V85, P20; Mertz GJ, 1997, ARCH INTERN MED, V157, P343, DOI 10.1001/archinte.157.3.343; MINDEL A, 1988, LANCET, V1, P926; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; NILSEN AE, 1982, LANCET, V2, P571; Oliver L, 1995, Arch Fam Med, V4, P228, DOI 10.1001/archfami.4.3.228; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; Velleman P. F., 1981, APPL BASICS COMPUTIN; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; Weinberg Adriana, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P285	33	126	131	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					14	+		10.7326/0003-4819-131-1-199907060-00004	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391810				2022-12-28	WOS:000081345200003
J	Torp-Pedersen, C; Kober, L				Torp-Pedersen, C; Kober, L		TRACE Study Grp	Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction	LANCET			English	Article							CONVERTING ENZYME-INHIBITION; CARDIAC EVALUATION; HEART-FAILURE; PROGNOSIS; MORTALITY; TRACE	Background The survival benefit from the use of inhibitors of angiotensin-converting enzyme (ACE) in patients with acute myocardial infarction is usually presented in terms of risk ratios and lives saved per 1000 people treated. A more relevant way to present the extent of benefit would be in terms of an increase in life expectancy, but this approach has not previously been possible because of limited data on long-term outcome. We aimed to calculate the effect of trandolapril on life expectancy with follow-up data from the Trandolapril Cardiac Evaluation (TRACE) Study. Methods The TRACE study previously showed a significant survival benefit with trandolapril in patients with reduced left-ventricular function after an acute myocardial infarction who were treated for at least 2 years. We ascertained the survival status of all patients in the TRACE study in June, 1998, at which time they had been followed up for a minimum of 6 years. We estimated life expectancy as median lifetime, which was the time for 50% of the patients to have died. Change in life expectancy is expressed as change in median lifetime. Analysis was by intention to treat. Findings The life expectancy of patients was 4.6 years far those given placebo versus 6 2 years for those on trandolapril. Thus, for patients on trandolapril, median lifetime was increased by 15.3 months or 27% (95% CI 7 to 51). Analysis of follow-up after the end of the study indicated no decrease of this benefit during the course of double-blind treatment; continued use of trandolapril was recommended at study closure. Interpretation In patients with severely reduced left-ventricular function, long-term treatment with an ACE inhibitor during the critical period after myocardial infarction is associated with a substantial increase in life expectancy.	Gentofte Univ Hosp, Dept Cardiol, DK-2900 Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital	Torp-Pedersen, C (corresponding author), Gentofte Univ Hosp, Dept Cardiol, DK-2900 Copenhagen, Denmark.		Torp-Pedersen, Christian/E-5931-2013	Kober, Lars/0000-0002-6635-1466				BALL SG, 1993, LANCET, V342, P821; BERNING J, 1992, CARDIOLOGY, V80, P257, DOI 10.1159/000175011; EMANUELSSON H, 1994, EUR HEART J, V15, P761, DOI 10.1093/oxfordjournals.eurheartj.a060583; Gustafsson F, 1997, J HYPERTENS, V15, P793, DOI 10.1097/00004872-199715070-00012; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOBER L, 1995, AM J CARDIOL, V76, P1, DOI 10.1016/S0002-9149(99)80791-7; KOBER L, 1994, EUR HEART J, V15, P1616; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEIFFER MA, 1992, NEW ENGL J MED, V327, P69; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; TorpPedersen C, 1996, AM HEART J, V132, P235, DOI 10.1016/S0002-8703(96)90559-1; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	14	138	145	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					9	12		10.1016/S0140-6736(98)09374-X	http://dx.doi.org/10.1016/S0140-6736(98)09374-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406358				2022-12-28	WOS:000081243200007
J	Freed, LA; Levy, D; Levine, RA; Larson, MG; Evans, JC; Fuller, DL; Lehman, B; Benjamin, EJ				Freed, LA; Levy, D; Levine, RA; Larson, MG; Evans, JC; Fuller, DL; Lehman, B; Benjamin, EJ			Prevalence and clinical outcome of mitral-valve prolapse	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENERAL-POPULATION; FOLLOW-UP; REGURGITATION; FEATURES; IDENTIFICATION; ASSOCIATION; DIAGNOSIS; WOMEN; RISK; MEN	Background Mitral-valve prolapse has been described as a common disease with frequent complications. To determine the prevalence of mitral-valve prolapse in the general population, as diagnosed with the use of current two-dimensional echocardiographic criteria, we examined the echocardiograms of 1845 women and 1646 men (mean [+/-SD] age, 54.7+/-10.0 years) who participated in the fifth examination of the offspring cohort of the Framingham Heart Study. Methods Classic mitral-valve prolapse was defined as superior displacement of the mitral leaf lets of more than 2 mm during systole and as a maximal leaflet thickness of at least 5 mm during diastasis, and nonclassic prolapse was defined as displacement of more than 2 mm, with a maximal thickness of less than 5 mm. Results A total of 84 subjects (2.4 percent) had mitral-valve prolapse: 47 (1.3 percent) had classic prolapse, and 37 (1.1 percent) had nonclassic prolapse. Their age and sex distributions were similar to those of the subjects without prolapse. None of the subjects with prolapse had a history of heart failure, one (1.2 percent) had atrial fibrillation, one (1.2 percent) had cerebrovascular disease, and three (3.6 percent) had syncope, as compared with unadjusted prevalences of these findings in the subjects without prolapse of 0.7, 1.7, 1.5, and 3.0 percent, respectively. The frequencies of chest pain, dyspnea, and electrocardiographic abnormalities were similar among subjects with prolapse and those without prolapse. The subjects with prolapse were leaner (P<0.001) and had a greater degree of mitral regurgitation than those without prolapse, but on average the regurgitation was classified as trace or mild. Conclusions In a community-based sample of the population, the prevalence of mitral-valve prolapse was lower than previously reported. The prevalence of adverse sequelae commonly associated with mitral-valve prolapse in studies of patients referred for that diagnosis was also low. (N Engl J Med 1999;341:1-7.) (C)1999, Massachusetts Medical Society.	NHLBI, Framingham Heart Study, Framingham, MA USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Clin Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Epidemiol & Prevent Med, Boston, MA 02118 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University; Boston University	Benjamin, EJ (corresponding author), Boston Univ, Sch Med, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.		Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Larson, Martin/0000-0002-9631-1254	NHLBI NIH HHS [2-R01-HL-38176-06, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [5-R01-NS-17950-16] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRYHN M, 1984, ACTA MED SCAND, V215, P157; CHANDRARATNA PAN, 1984, AM J CARDIOL, V54, P1283; COHEN JL, 1987, AM HEART J, V113, P341, DOI 10.1016/0002-8703(87)90275-4; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX R B, 1986, Journal of the American College of Cardiology, V8, P763; DEVEREUX RB, 1989, ANN INTERN MED, V111, P305, DOI 10.7326/0003-4819-111-4-305; DEVEREUX RB, 1994, AM J CARDIOL, V74, P1024, DOI 10.1016/0002-9149(94)90853-2; DEVEREUX RB, 1986, AM J MED, V81, P751, DOI 10.1016/0002-9343(86)90339-6; DEVEREUX RB, 1982, LANCET, V2, P792; DUREN DR, 1988, J AM COLL CARDIOL, V11, P42; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1988, NIH PUBLICATION; KANNEL WB, 1974, DHEW PUBLICATION; LEATHAM A, 1980, AM HEART J, V99, P659, DOI 10.1016/0002-8703(80)90740-1; LEVINE RA, 1989, CIRCULATION, V80, P589, DOI 10.1161/01.CIR.80.3.589; LEVINE RA, 1988, J AM COLL CARDIOL, V11, P1010, DOI 10.1016/S0735-1097(98)90059-6; LEVINE RA, 1987, CIRCULATION, V75, P756, DOI 10.1161/01.CIR.75.4.756; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1987, AM HEART J, V113, P1281, DOI 10.1016/0002-8703(87)90956-2; Louie EK, 1996, J AM COLL CARDIOL, V28, P465, DOI 10.1016/0735-1097(96)00160-X; MARKIEWICZ W, 1978, AM HEART J, V96, P555, DOI 10.1016/0002-8703(78)90172-2; MARKIEWICZ W, 1976, CIRCULATION, V53, P464, DOI 10.1161/01.CIR.53.3.464; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; NIDORF SM, 1993, J AM SOC ECHOCARDIOG, V6, pS8; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P305; PERLOFF JK, 1989, CIRCULATION, V80, P710, DOI 10.1161/01.CIR.80.3.710; PROCACCI PM, 1976, NEW ENGL J MED, V294, P1086, DOI 10.1056/NEJM197605132942004; SAHN DJ, 1977, AM J CARDIOL, V39, P422, DOI 10.1016/S0002-9149(77)80100-8; SAVAGE DD, 1983, AM HEART J, V106, P571, DOI 10.1016/0002-8703(83)90704-4; SAVAGE DD, 1983, AM HEART J, V106, P577, DOI 10.1016/0002-8703(83)90705-6; Shah P M, 1994, J Am Soc Echocardiogr, V7, P286; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; VIVALDI MT, 1994, CIRCULATION, V90, P222; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WARTH DC, 1985, J AM COLL CARDIOL, V5, P1173, DOI 10.1016/S0735-1097(85)80021-8; WEISSMAN NJ, 1994, AM J CARDIOL, V73, P1080, DOI 10.1016/0002-9149(94)90287-9; WILCKEN DEL, 1988, CIRCULATION, V78, P10, DOI 10.1161/01.CIR.78.1.10; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8	40	666	687	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					1	7		10.1056/NEJM199907013410101	http://dx.doi.org/10.1056/NEJM199907013410101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387935				2022-12-28	WOS:000081195600001
J	Freemantle, N; Cleland, J; Young, P; Mason, J; Harrison, J				Freemantle, N; Cleland, J; Young, P; Mason, J; Harrison, J			beta Blockade after myocardial infarction: systematic review and meta regression analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIAL; MULTICENTER TRIAL; CLINICAL-TRIALS; HEART-FAILURE; CARDIAC DEATH; PROPRANOLOL; MORTALITY; METAANALYSIS; METOPROLOL; PREVENTION	Objectives To assess the effectiveness of beta blockers in short term treatment for acute myocardial infarction and in longer term secondary prevention; to examine predictive factors that may influence outcome and therefore choice of drug; and to examine the clinical importance of the results in the light of current treatment. Design Systematic review of randomised controlled trials. Setting Randomised controlled trials. Subjects Patients with acute or past myocardial infarction. Intervention beta Blockers compared with control. Main outcome measures All cause mortality and non-fatal reinfarction. Results Overall, 5477 of 54 234 patients (10.1%) randomised to beta blockers or control died. We identified a 23% reduction in the odds of death in long term trials (95% confidence interval 15%, to 31%), but only a 4% reduction in the odds of death in short term trials (-8% to 15%). Meta regression in long term trials did not identify a significant reduction in effectiveness in drugs with cardioselectivity but did identify a near significant trend towards decreased benefit in drugs with intrinsic sympathomimetic activity. Most evidence is available for propranolol timolol, and metoprolol. In long term trials, the number needed to treat for 2 years to avoid a death is 42, which compares favourably with other treatments for patients with acute or past myocardial infarction. Conclusions beta Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity.	Univ York, Ctr Hlth Econ, Med Evaluat Grp, York YO10 5DD, N Yorkshire, England; Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull U16 5JQ, Yorks, England; Univ York, Dept Hlth Sci & Clin Evaluat, York YO1 5DD, N Yorkshire, England	University of York - UK; University of Hull; University of York - UK	Freemantle, N (corresponding author), Univ York, Ctr Hlth Econ, Med Evaluat Grp, York YO10 5DD, N Yorkshire, England.	meg@york.ac.uk	Young, Philip/ABI-1480-2020; Cleland, John G./AAZ-4185-2020; Mason, James M/D-9904-2011	Young, Philip/0000-0003-0201-9277; Cleland, John G./0000-0002-1471-7016; Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				AHLMARK G, 1974, LANCET, V2, P1563; ANDERSEN MP, 1979, LANCET, V2, P865; [Anonymous], 1987, Eur Heart J, V8, P1056; [Anonymous], 1966, LANCET, V2, P1435; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1986, Lancet, V2, P57; Aronow WS, 1997, AM J CARDIOL, V80, P207, DOI 10.1016/S0002-9149(97)00320-2; *AUSTR SWED PIND S, 1983, EUR HEART J, V4; AZANCOT I, 1982, CIRCULATION, V66, P986, DOI 10.1161/01.CIR.66.5.986; BABER NS, 1980, BRIT HEART J, V44, P96; BALCON R, 1996, LANCET, V348, P917; Barber J M, 1967, Ulster Med J, V36, P127; BARBER JM, 1976, ACTA MED SCAND, P213; Basu S, 1997, CIRCULATION, V96, P183; BOISSEL JP, 1990, AM J CARDIOL, V66, pC24, DOI 10.1016/0002-9149(90)90759-T; CAMPBELL RC, 1985, PROG CARDIOVASC DIS, V27, P255; CARLIN JB, 1992, STAT MED, V11, P141, DOI 10.1002/sim.4780110202; CATS VM, 1983, CIRCULATION, V68, P181; CLAUSEN J, 1966, LANCET, V2, P920; CURTIS JL, 1991, AM HEART J, V121, P1655, DOI 10.1016/0002-8703(91)90009-7; DARASZ KH, 1995, INT J CARDIOL, V51, P137, DOI 10.1016/0167-5273(95)02422-S; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOTREMONT G, 1968, Acta Clinica Belgica, V23, P163; EVEMY KL, 1978, EUR J CARDIOL, V7, P391; FEDERMAN J, 1985, PROG CARDIOVASC DIS, V27, P225; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FUCCELLA LM, 1968, PROG CARDIOVASC DIS, V10, P561; GUPTA RC, 1982, 9TH WORLD C CARD MOS, V2, P616; GUPTA RC, 1984, J ASSOC PHYSICIAN I, V32, P67; HANSTEEN V, 1982, BRIT MED J, V284, P155, DOI 10.1136/bmj.284.6310.155; HEBER ME, 1987, EUR HEART J, V8, P11, DOI 10.1093/oxfordjournals.eurheartj.a062152; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HJALMARSON A, 1981, LANCET, V2, P823; HJALMARSON A, 1985, EUR HEART J, V6, P199; HUTTON I, 1979, EXCERPTA MED I C SER, V2, P824; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; JOHANSSON BW, 1980, ACTA MED SCAND, V207, P47; JULIAN DG, 1982, LANCET, V1, P1142; KAHLER RL, 1968, CARDIOVASCULAR BETA, P213; KAUL UA, 1988, INT J CARDIOL, V21, P301, DOI 10.1016/0167-5273(88)90107-6; LEDWICH JR, 1968, CAN MED ASSOC J, V98, P988; LLOYD EA, 1988, S AFR MED J, V74, P5; LOMBARDO M, 1979, P FLOR INT M MYOC IN, V2, P803; LOPEZ FN, 1993, AM J CARDIOL, V72, P1234; MACLEOD A, 1980, 8 EUR C CARD PAR; MAZUR NA, 1984, COR VASA, V26, P241; MCMURRAY J, 1991, INT J CARDIOL, V31, P295, DOI 10.1016/0167-5273(91)90380-8; MUELLER HS, 1980, J CLIN INVEST, V65, P338, DOI 10.1172/JCI109677; *MULT INT STUD, 1975, BMJ-BRIT MED J, V3, P735; NIGAM PD, 1983, 9 WORLD C CARD MOSC, V2, P616; NORRIS RM, 1968, BRIT MED J, V2, P398, DOI 10.1136/bmj.2.5602.398; NORRIS RM, 1984, LANCET, V2, P883; NORRIS RM, 1978, LANCET, V2, P907; OWENSBY DA, 1984, CIRCULATION, V70, P156; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PETER T, 1978, CIRCULATION, V57, P1091, DOI 10.1161/01.CIR.57.6.1091; PITT B, 1976, CIRCULATION S2, V29, P53; RANGANATHAN N, 1988, AM HEART J, V115, P340, DOI 10.1016/0002-8703(88)90480-2; REHNQVIST N, 1983, CIRCULATION, V68, P369; REHNQVIST N, 1980, P EUR C CARD, P16; REYNOLDS JL, 1972, BRIT HEART J, V34, P252; ROBERTS R, 1984, NEW ENGL J MED, V311, P218, DOI 10.1056/NEJM198407263110403; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; ROQUE F, 1987, CIRCULATION, V76, P610, DOI 10.1161/01.CIR.76.3.610; SALATHIA KS, 1985, EUR HEART J, V6, P190, DOI 10.1093/oxfordjournals.eurheartj.a061844; SCHRODER R, 1984, EUR HEART J, V5, P189; SCHWARTZ PJ, 1992, J CARDIOVASC ELECTR, V3, P2, DOI 10.1111/j.1540-8167.1992.tb01090.x; SEDERHOLM M, 1984, NEW ENGL J MED, V310, P9; SINGH S, 1985, CLINICIAN, V49, P384; SLOMAN G, 1967, BRIT MED J, V4, P508, DOI 10.1136/bmj.4.5578.508; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; TAYLOR SH, 1981, EUR HEART J, V2, P389; TAYLOR SH, 1982, NEW ENGL J MED, V307, P1293, DOI 10.1056/NEJM198211183072101; THOMPSON PL, 1979, AUST NZ J MED, V9, P757; TONKIN AM, 1981, MED J AUSTRALIA, V2, P145, DOI 10.5694/j.1326-5377.1981.tb100839.x; Van de Werf F, 1993, J AM COLL CARDIOL, V22, P407, DOI 10.1016/0735-1097(93)90044-2; Viskin S, 1996, AM J CARDIOL, V78, P821, DOI 10.1016/S0002-9149(96)00428-6; VONESSEN R, 1982, DEUT MED WOCHENSCHR, V107, P1267; WAAGSTEIN F, 1975, ACTA MED SCAND     S, V587, P201; WILCOX RG, 1980, BRIT MED J, V280, P885, DOI 10.1136/bmj.280.6218.885; WILCOX RG, 1980, LANCET, V2, P765; WILHELMSSON C, 1974, LANCET, V2, P1157; YANG XS, 1987, ACTA CARDIOL, V42, P273; YUSUF S, 1980, LANCET, V2, P273; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1979, LANCET, V2, P868	87	997	1048	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1730	1737		10.1136/bmj.318.7200.1730	http://dx.doi.org/10.1136/bmj.318.7200.1730			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381708	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000081216900030
J	Hart, CL; Smith, GD; Hole, DJ; Hawthorne, VM				Hart, CL; Smith, GD; Hole, DJ; Hawthorne, VM			Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: Results from a prospective cohort study of Scottish men with 21 years of follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; ALL-CAUSE MORTALITY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; SOCIOECONOMIC POSITION; BLOOD-PRESSURE; BRITISH MEN; BEER; POPULATION; WOMEN	Objectives To relate alcohol consumption to mortality. Design Prospective cohort study. Setting 27 workplaces in the west of Scotland. Participants 5766 men aged 35-64 when screened in 1970-3 who answered questions on their usual weekly alcohol consumption. Main outcome measures Mortality from all causes, coronary heart disease, stroke, and alcohol related causes over 21 years of follow up related to units of alcohol consumed per week. Results Risk for all cause mortality was similar for non-drinkers and men drinking up to 14 units a week. Mortality risk then showed a graded association with alcohol consumption (relative rate compared with non-drinkers 1.34 (95% confidence interval 1.14 to 1.58) for 15-21 units a week, 1.49 (1.27 to 1.75) for 22-34 units, 1.74 (1.47 to 2.06) for 35 or more units). Adjustment for risk factors attenuated the increased relative risks, but they remained significantly above 1 for men drinking 22 or more units a week. There was no strong relation between alcohol consumption and mortality from coronary heart disease after adjustment A strong positive relation was seen between alcohol consumption and risk of mortality from stroke,with men drinking 35 or more units having double the risk of non-drinkers, even after adjustment. Conclusions The overall association between alcohol consumption and mortality is unfavourable for men drinking over 22 units a week, and there is no clear evidence of any protective effect for men drinking less than this.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of Bristol; University of Glasgow; University of Glasgow; University of Michigan System; University of Michigan	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				[Anonymous], 1965, LANCET, V1, P775; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; Brenner H, 1997, INT J EPIDEMIOL, V26, P85, DOI 10.1093/ije/26.1.85; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHOUDHURY SR, 1994, INT J EPIDEMIOL, V23, P940, DOI 10.1093/ije/23.5.940; COX DR, 1972, J R STAT SOC B, V34, P187; DAVEYSMITH G, 1992, JAMA-J AM MED ASSOC, V267, P70; DIGHT S, 1976, SCOTTISH DRINKING HA; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; General Register Office, 1966, CLASS OCC 1966; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Hart CL, 1997, INT J EPIDEMIOL, V26, P508, DOI 10.1093/ije/26.3.508; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; HOLE D, 1993, J EPIDEMIOL COMMUNIT, V47, P402; ISO H, 1995, STROKE, V26, P767, DOI 10.1161/01.STR.26.5.767; Kauhanen J, 1997, EPIDEMIOLOGY, V8, P310, DOI 10.1097/00001648-199705000-00014; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; MARMOT MG, 1994, BRIT MED J, V308, P1263, DOI 10.1136/bmj.308.6939.1263; McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802; *OFF NAT STAT, 1997, HLTH AD BRIT 1841 19; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; Prineas R.J, 1982, MINNESOTA MANUAL ELE; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Rose G, 1982, CARDIOVASCULAR SURVE; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; *SAS I, 1991, P217 SAS I; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, J HUM HYPERTENS, V2, P71; SHINTON R, 1993, J NEUROL NEUROSUR PS, V56, P458, DOI 10.1136/jnnp.56.5.458; SMIT JWA, 1995, AM J CARDIOL, V76, pA89; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P153; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WESTIN S, 1995, BRIT MED J, V311, P1167, DOI 10.1136/bmj.311.7013.1167a; White IR, 1996, BRIT MED J, V312, P1179; *WHO, 1977, CLASS DIS 9 REV; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354; Yuan JM, 1997, BRIT MED J, V314, P18, DOI 10.1136/bmj.314.7073.18	47	197	204	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1725	1729		10.1136/bmj.318.7200.1725	http://dx.doi.org/10.1136/bmj.318.7200.1725			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381706	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000081216900028
J	Jorde, R; Nordoy, A				Jorde, R; Nordoy, A			Improvement in clinical work through feedback: intervention study	BRITISH MEDICAL JOURNAL			English	Article									Univ Tromso Hosp, Dept Internal Med, N-9038 Tromso, Norway	UiT The Arctic University of Tromso; University Hospital of North Norway	Jorde, R (corresponding author), Royal Newcastle Hosp, Ctr Clin Epidemiol & Biostat, David Maddison Clin Sci Bldg, Newcastle, NSW 2300, Australia.							GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; Robertson N, 1996, QUAL HEALTH CARE, V5, P51, DOI 10.1136/qshc.5.1.51; Stocking B, 1992, Qual Health Care, V1, P56, DOI 10.1136/qshc.1.1.56	4	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1738	1739		10.1136/bmj.318.7200.1738	http://dx.doi.org/10.1136/bmj.318.7200.1738			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381710	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000081216900032
J	Stirrat, GM				Stirrat, GM			Choice of treatment for menorrhagia	LANCET			English	Editorial Material							INTRAUTERINE SYSTEM; HYSTERECTOMY		St Michaels Hosp, Dept Obstet & Gynaecol, Bristol BS2 8EG, Avon, England		Stirrat, GM (corresponding author), St Michaels Hosp, Dept Obstet & Gynaecol, Bristol BS2 8EG, Avon, England.							Crossman DC, 1997, QJM-MON J ASSOC PHYS, V90, P157, DOI 10.1093/qjmed/90.3.157; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Garry R, 1997, BRIT J OBSTET GYNAEC, V104, P1329, DOI 10.1111/j.1471-0528.1997.tb10998.x; Grant A, 1999, BRIT J OBSTET GYNAEC, V106, P360; Higham JM, 1999, EUR J OBSTET GYN R B, V82, P73, DOI 10.1016/S0301-2115(98)00224-3; Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x; KILLETSEN N, 1998, GYNECOL ENDOSC, V7, P61; LAHTEENMAKI, 1998, BMJ, V316, P1122; Lilford RJ, 1997, BRIT MED J, V314, P160, DOI 10.1136/bmj.314.7075.160; *ROYAL COLL OBST G, 1998, IN MAN MEN EV BAS CL; *U LEEDS, 1995, EFF HLTH CAR, V9, P1	11	25	33	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2175	2176		10.1016/S0140-6736(99)00132-4	http://dx.doi.org/10.1016/S0140-6736(99)00132-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392977				2022-12-28	WOS:000081091300005
J	Anderson, GJ; Powell, LW				Anderson, GJ; Powell, LW			Haemochromatosis and control of intestinal iron absorption	LANCET			English	Editorial Material							HEREDITARY HEMOCHROMATOSIS; GENETIC HEMOCHROMATOSIS; TRANSPORTER		Queensland Inst Med Res, Joint Clin Sci Program, Brisbane, Qld 4029, Australia; Univ Queensland, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; University of Queensland	Anderson, GJ (corresponding author), Queensland Inst Med Res, Joint Clin Sci Program, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Anderson, Gregory/G-4148-2013	Anderson, Gregory/0000-0002-8814-5866				Anderson GJ, 1996, J GASTROEN HEPATOL, V11, P1030, DOI 10.1111/j.1440-1746.1996.tb00029.x; Cairo G, 1997, BLOOD, V89, P2546, DOI 10.1182/blood.V89.7.2546; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; MCLAREN GD, 1991, J LAB CLIN MED, V117, P390; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; POWELL LW, 1970, GUT, V11, P727, DOI 10.1136/gut.11.9.727; Powell W.L., 1994, IRON METABOLISM HLTH; SHELDON JH, 1935, HEMOCHROMATOSIS; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579	15	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2089	2090		10.1016/S0140-6736(99)00113-0	http://dx.doi.org/10.1016/S0140-6736(99)00113-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382688				2022-12-28	WOS:000080969300004
J	Dudley, R				Dudley, R			Biomechanics - Unsteady aerodynamics	SCIENCE			English	Editorial Material							POWER REQUIREMENTS; INSECT FLIGHT; LIFT; AIRFOIL		Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Dudley, R (corresponding author), Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA.							Dickinson MH, 1999, SCIENCE, V284, P1954, DOI 10.1126/science.284.5422.1954; DUDLEY R, 1990, J EXP BIOL, V148, P53; Ellington CP, 1996, NATURE, V384, P626, DOI 10.1038/384626a0; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P145, DOI 10.1098/rstb.1984.0054; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; OHMI K, 1991, J FLUID MECH, V225, P607, DOI 10.1017/S0022112091002197; PANDA J, 1994, J FLUID MECH, V265, P65, DOI 10.1017/S0022112094000765; RUPPELL G, 1989, J EXP BIOL, V144, P13; Siemann E, 1996, NATURE, V380, P704, DOI 10.1038/380704a0; Sorensson M, 1997, SYST ENTOMOL, V22, P257, DOI 10.1046/j.1365-3113.1997.d01-40.x; WOOTTON RJ, 1992, ANNU REV ENTOMOL, V37, P113, DOI 10.1146/annurev.en.37.010192.000553	11	10	18	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1937	+		10.1126/science.284.5422.1937	http://dx.doi.org/10.1126/science.284.5422.1937			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10400535				2022-12-28	WOS:000080932700026
J	Masutani, C; Kusumoto, R; Yamada, A; Dohmae, N; Yokoi, M; Yuasa, M; Araki, M; Iwai, S; Takio, K; Hanaoka, F				Masutani, C; Kusumoto, R; Yamada, A; Dohmae, N; Yokoi, M; Yuasa, M; Araki, M; Iwai, S; Takio, K; Hanaoka, F			The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta	NATURE			English	Article							ESCHERICHIA-COLI DINB; SACCHAROMYCES-CEREVISIAE; THYMINE DIMER; EXCISION-REPAIR; HUMAN HOMOLOG; REPLICATION; MUTAGENESIS; BYPASS; CELLS; ZETA	Xeroderma pigmentosum variant (XP-V) is an inherited disorder which is associated with increased incidence of sunlight-induced skin cancers, Unlike other xeroderma pigmentosum cells (belonging to groups XP-A to XP-G), XP-V cells carry out normal nucleotide-excision repair processes but are defective in their replication of ultraviolet-damaged DNA(1,2). It has been suspected for some time that the XPV gene encodes a protein that is involved in trans-lesion DNA synthesis; but the gene product has never been isolated Using an improved cell-free assay for trans-lesion DNA synthesis, we have recently isolated a DNA polymerase from HeLa cells that continues replication on damaged DNA by bypassing ultraviolet-induced thymine dimers in XP-V cell extracts(3). Here we show that this polymerase is a human homologue of the yeast Rad30 protein, recently identified as DNA polymerase eta (ref. 4). This polymerase and yeast Rad30 are members of a family of damage-bypass replication proteins(5-10) which comprises the Escherichia coli proteins UmuC and DinB and the yeast Rev1 protein. We found that all XP-V cells examined carry mutations in their DNA polymerase eta gene. Recombinant human DNA polymerase eta corrects the inability of XP-V cell extracts to carry out DNA replication by bypassing thymine dimers on damaged DNA. Together these results indicate that DNA polymerase eta could be the XPV gene product.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Nara 63001, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Osaka 5650871, Japan; Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan	Osaka University; Nara Institute of Science & Technology; Osaka University; RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.		Dohmae, Naoshi/C-2040-2011; Araki, Marito/T-4283-2019; Masutani, Chikahide/I-6160-2014	Dohmae, Naoshi/0000-0002-5242-9410; Araki, Marito/0000-0002-3502-5000; Masutani, Chikahide/0000-0002-8600-8227; Yamada, Ayumi/0000-0002-6085-8928				Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; JASPERS NGJ, 1981, EXP CELL RES, V136, P81, DOI 10.1016/0014-4827(81)90039-2; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MASUTANI C, IN PRESS EMBO J; McDonald JP, 1997, GENETICS, V147, P1557; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Roush AA, 1998, MOL GEN GENET, V257, P686; Smith BT, 1998, GENETICS, V148, P1599; Svoboda DL, 1998, CANCER RES, V58, P2445; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945	24	1103	1130	0	238	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					700	704		10.1038/21447	http://dx.doi.org/10.1038/21447			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385124				2022-12-28	WOS:000080932800064
J	Jasmer, RM; Hahn, JA; Small, PM; Daley, CL; Behr, MA; Moss, AR; Creasman, JM; Schecter, GF; Paz, EA; Hopewell, PC				Jasmer, RM; Hahn, JA; Small, PM; Daley, CL; Behr, MA; Moss, AR; Creasman, JM; Schecter, GF; Paz, EA; Hopewell, PC			A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK-CITY; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; OUTBREAK; POPULATION; HOMELESS; PTBN12	Background: To decrease tuberculosis case rates and cases due to recent infection (clustered cases) in San Francisco, California, tuberculosis control measures were intensified beginning in 1991 by focusing on prevention of Mycobacterium tuberculosis transmission and on the use of preventive therapy. Objective: To describe trends in rates of tuberculosis cases and clustered cases in San Francisco from 1991 through 1997. Design: Population-based study. Setting: San Francisco, California. Patients: Persons with tuberculosis diagnosed between 1 January 1991 and 31 December 1997. Measurements: DNA fingerprinting was performed. During sequential 1-year intervals, changes in annual case rates per 100 000 persons for all cases, clustered cases (cases with M. tuberculosis isolates having identical fingerprint patterns), and cases in specific subgroups with high rates of clustering (persons born in the United States and HIV-infected persons) were examined. Results: Annual tuberculosis case rates peaked at 51.2 cases per 100 000 persons in 1992 and decreased significantly thereafter to 29.8 cases per 100 000 persons in 1997 (P < 0.001). The rate of clustered cases decreased significantly over time in the entire study sample (from 10.4 cases per 100 000 persons in 1991 to 3.8 cases per 100 000 persons in 1997 [P < 0.001]), in persons born in the United States (P < 0.001), and in HIV-infected persons (P = 0.003). Conclusions: The rates of tuberculosis cases and clustered tuberculosis cases decreased both overall and among persons in high-risk groups. This occurred in a period during which tuberculosis control measures were intensified.	Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Gen Hosp, Ctr Med, San Francisco, CA 94110 USA; Francis J Curry Natl TB Ctr, San Francisco, CA 94110 USA; Dept Publ Hlth, San Francisco, CA USA; Stanford Univ, Dept Med, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Stanford University	Jasmer, RM (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Gen Hosp, Ctr Med, Room K1,1001 Potrero Ave, San Francisco, CA 94110 USA.		Daley, Charles L./AAC-3231-2021; Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264	NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [AI 35969, AI 34238] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238, U01AI035969] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *CA DEP HLTH SERV, 1998, REP TUB CAL 1997; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Glynn JR, 1999, AM J EPIDEMIOL, V149, P366, DOI 10.1093/oxfordjournals.aje.a009822; HOPEWELL PC, 1996, TUBERCULOSIS, P113; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; MCGOWAN JE, 1995, J HOSP INFECT, V30, P282, DOI 10.1016/0195-6701(95)90031-4; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; POULET S, 1995, ARCH MICROBIOL, V163, P87, DOI 10.1007/s002030050176; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P604; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; *SF DEP PUBL HLTH, 1997, 1997 HIV CONS REP HI; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; *US BUR CENS, 1992, 1990 CENS POP HOUS; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Woelffer GB, 1996, AM J MED SCI, V311, P17, DOI 10.1097/00000441-199601000-00004; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; Yeh RW, 1998, J INFECT DIS, V177, P1107, DOI 10.1086/517406; 1998, MMWR MORB MORTAL WKL, V47, P253	33	153	156	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					971	978		10.7326/0003-4819-130-12-199906150-00004	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383367				2022-12-28	WOS:000080894700003
J	Barres, BA				Barres, BA			A new role for glia: Generation of neurons!	CELL			English	Review							CEREBRAL WALL; RADIAL GLIA; CELLS; DIFFERENTIATION; BRAIN; PROGENITORS; ASTROCYTES; MIGRATION; CNS		Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Barres, BA (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.							ALVAREZBUYLLA A, 1990, NEURON, V5, P101, DOI 10.1016/0896-6273(90)90038-H; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Chernoff EAG, 1996, INT J DEV BIOL, V40, P823; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GOULD SJ, 1990, DEV BRAIN RES, V55, P255, DOI 10.1016/0165-3806(90)90207-F; GRAY GE, 1992, DEVELOPMENT, V114, P271; HALLIDAY AL, 1992, NEURON, V9, P15, DOI 10.1016/0896-6273(92)90216-Z; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MISSON JP, 1988, DEV BRAIN RES, V38, P183, DOI 10.1016/0165-3806(88)90043-0; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Zhao SL, 1997, INT REV CYTOL, V171, P225	20	86	93	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					667	670		10.1016/S0092-8674(00)80777-1	http://dx.doi.org/10.1016/S0092-8674(00)80777-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380916	Bronze			2022-12-28	WOS:000080886300001
J	von Kries, R; Koletzko, B; Sauerwald, T; von Mutius, E; Barnert, D; Grunert, V; von Voss, H				von Kries, R; Koletzko, B; Sauerwald, T; von Mutius, E; Barnert, D; Grunert, V; von Voss, H			Breast feeding and obesity: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ENDOCRINE RESPONSES; GROWTH; CHILDHOOD; ADIPOSITY; PROTEIN; INFANTS; NUTRITION; CHILDREN; WEIGHT; ADULTS	Objective To assess the impact of breast feeding on the risk of obesity and risk of being overweight in children at the time of entry to school. Design Cross sectional survey. Setting Bavaria, southern Germany. Methods Routine data were collected on the height and weight of 134 577 children participating in the obligatory health examination at the time of school entry in Bavaria. In a subsample of 13 345 children, early feeding, diet, and lifestyle factors were assessed using responses to a questionnaire completed by parents. Subjects 9357 children aged 5 and 6 who had German nationality. Main outcome measures Being overweight was defined as having a body mass index above the 90th centile and obesity was defined as body mass index above the 97th centile of all enrolled German children. Exclusive breast feeding was defined as the child being fed no food other than breast milk. Results The prevalence of obesity in children who had never been breast fed was 4.5% as compared with 2.8% in breastfed children. A clear dose-response effect was identified for the duration of breast feeding on the prevalence of obesity: the prevalence was 3.8% for 2 months of exclusive breast feeding, 2.3% for 3-5 months, 1.7% for 6-12 months, and 0.8% for more than 12 months. Similar relations were found with the prevalence of being overweight. The protective effect of breast feeding was not attributable to differences in social class or lifestyle. After adjusting for potential confounding factors, breast feeding remained a significant protective factor against the development of obesity (odds ratio 0.75, 95% CI 0.57 to 0.98) and being overweight (0.79, 0.68 to 0.93). Conclusions In industrialised countries promoting prolonged breast feeding may help decrease the prevalence of obesity in childhood. Since obese children have a high risk of becoming obese adults, such preventive measures may eventually result in a reduction in the prevalence of cardiovascular diseases and other diseases related to obesity.	Univ Munich, Inst Social Paediat & Adolescent Med, D-81377 Munich, Germany; Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany	University of Munich; University of Munich	von Kries, R (corresponding author), Univ Munich, Inst Social Paediat & Adolescent Med, Heiglhofstr 63, D-81377 Munich, Germany.			von Mutius, Erika/0000-0002-8893-4515				ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; BARANOWSKI T, 1990, J DEV BEHAV PEDIATR, V11, P234; Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703; CHARNEY E, 1976, NEW ENGL J MED, V295, P6, DOI 10.1056/NEJM197607012950102; Deheeger M, 1996, PHYSIOL BEHAV, V59, P403, DOI 10.1016/0031-9384(95)02011-X; Desai M, 1997, BIOL REV, V72, P329, DOI 10.1017/S0006323196005026; Desai M, 1997, AM J PHYSIOL-GASTR L, V272, pG1083, DOI 10.1152/ajpgi.1997.272.5.G1083; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Freedman DS, 1997, PEDIATRICS, V99, P420, DOI 10.1542/peds.99.3.420; GOLDBLOOM R, 1994, CAN MED ASSOC J, V150, P871; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HEINIG MJ, 1993, AM J CLIN NUTR, V58, P152, DOI 10.1093/ajcn/58.2.152; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; LUCAS A, 1980, LANCET, V1, P1267; LUCAS A, 1981, ACTA PAEDIATR SCAND, V70, P195, DOI 10.1111/j.1651-2227.1981.tb05541.x; PETRUSCHKE T, 1994, INT J OBESITY, V18, P532; POSKITT EME, 1978, BRIT MED J, V1, P603, DOI 10.1136/bmj.1.6113.603; Power C, 1997, INT J OBESITY, V21, P507, DOI 10.1038/sj.ijo.0800454; ROLLANDCACHERA MF, 1995, INT J OBESITY, V19, P573; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; RollandCachera MF, 1996, AM J CLIN NUTR, V64, P663, DOI 10.1093/ajcn/64.4.663; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; VONEHRENSTEIN O, 1999, IN PRESS CLIN EXP AL; WHITEHEAD RG, 1995, PEDIATR RES, V37, P239, DOI 10.1203/00006450-199502000-00019; WILKINSON PW, 1977, LANCET, V1, P350	25	541	564	0	47	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					147	150		10.1136/bmj.319.7203.147	http://dx.doi.org/10.1136/bmj.319.7203.147			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406746	Green Published, Bronze			2022-12-28	WOS:000081619300017
J	Reid, FDA; Cook, DG; Majeed, A				Reid, FDA; Cook, DG; Majeed, A			Explaining variation in hospital admission rates between general practices: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY ADMISSIONS; REFERRAL RATES; EAST LONDON; PRACTITIONERS; DEPRIVATION; PATIENT; ASTHMA	Objectives To quantify the extent of the variation in hospital admission rates between general practices, and to investigate whether this variation can be explained by factors relating to the patient, the hospital, and the general practice. Design Cross sectional analysis of routine data. Setting Merton, Sutton, and Wandsworth Health Authority, which includes areas of inner and outer London. Subjects 209 136 hospital admissions in 1995-6 in patients registered with 120 general practices in the study area. Main outcome measures Hospital admission rate for general practices for overall, emergency, and elective admissions. Results Crude admission rates for general practices displayed a twofold difference between the 10th and the 90th centile for all, emergency, and elective admissions. This difference was only minimally reduced by standardising for age and sex. Sociodemographic patient factors derived from census data accounted for 42% of the variation in overall admission rates; 45% in emergency admission rates; and 25% in elective admission rates. There was a strong positive correlation between factors related to deprivation and emergency, but not elective, admission rates, raising questions about equity of provision of health care. The percentage of each practice's admissions to different local hospitals added significantly to the explanation of variation, while the general practice characteristics considered added very little. Conclusions Hospital admission rates varied greatly between general practices; this was largely explained by differences in patient populations. The lack of significant factors related to general practice is of little help for the direct management of admission rates, although the effect of sociological rather than organisational practice variables should routinely be standardised for differences in patient populations and hospitals used.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England	St Georges University London; St Georges University London	Reid, FDA (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.			Majeed, Azeem/0000-0002-2357-9858; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1993, SPSS WINDOWS BASE SY; ARMITAGE P, 1987, STATISTICAL METHODS, P403; Capewell S, 1996, BRIT MED J, V312, P991; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; Crombie D L, 1988, Health Trends, V20, P53; DEMARCO P, 1993, BRIT MED J, V307, P1465, DOI 10.1136/bmj.307.6917.1465; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HippisleyCox J, 1997, BRIT MED J, V314, P1458, DOI 10.1136/bmj.314.7092.1458; MAJEED A, 1996, HLTH TRENDS, V28, P52; Majeed A, 1998, CLIN MANAGE, V7, P160; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; NEWTON J, 1991, FAM PRACT, V8, P308, DOI 10.1093/fampra/8.4.308; NOONE A, 1989, J ROY COLL GEN PRACT, V39, P404; Pollock AM, 1998, BMJ-BRIT MED J, V317, P245, DOI 10.1136/bmj.317.7153.245; THAKKER Y, 1994, ARCH DIS CHILD, V70, P488, DOI 10.1136/adc.70.6.488; Whynes DK, 1996, FAM PRACT, V13, P174, DOI 10.1093/fampra/13.2.174; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; WILKIN D, 1987, FAM PRACT, V4, P160, DOI 10.1093/fampra/4.3.160	24	82	82	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					98	103		10.1136/bmj.319.7202.98	http://dx.doi.org/10.1136/bmj.319.7202.98			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398636	Green Published, Bronze			2022-12-28	WOS:000081438200035
J	Burman, ML; Taplin, SH; Herta, DF; Elmore, JG				Burman, ML; Taplin, SH; Herta, DF; Elmore, JG			Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization	ANNALS OF INTERNAL MEDICINE			English	Article						mammography; false-positive reactions; patient compliance; age factors; mass screening	WOMEN; PROGRAM; RISK	Background: Despite the mortality benefits of breast cancer screening, not all women receive regular mammography. Such factors as age, socioeconomic status, and physician recommendation have been associated with greater use of screening. However, we do not know whether having an abnormal mammogram affects future screening. Objective: To examine the effect of a false-positive mammogram on adherence to the next recommended screening mammogram. Design: Prospective cohort study. Setting: The breast cancer screening program at Group Health Cooperative, a health maintenance organization in Washington state. Patients: 5059 women 40 years of age or older with no history of breast cancer or breast surgery who had false-positive (n = 813) or true-negative (n = 4246) index screening mammograms between 1 August 1990 and 31 July 1992. Measurements: Screening rates and odds ratios for recommended interval screening up to 42 months after the index mammogram. Results: After adjustment for differences in age; previous use of mammography; family history of breast cancer; exogenous hormone use; and age at menarche, first childbirth, and menopause, women with false-positive index mammograms were more likely than those with true-negative index mammograms to obtain their next recommended screening mammogram (odds ratio, 1.21 [95% CI, 1.01 to 1.45]). The relation between a false-positive mammogram and the likelihood of adherence to screening in the next recommended interval was strongest among women who had not previously undergone mammography (odds ratio, 1.66 [CI, 1.26 to 2.17]). Conclusions: Having a false-positive mammogram did not adversely affect screening behavior in the next recommended interval. Women with false-positive mammograms, especially those without previous mammography, were more likely to return for the next scheduled screening.	Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA; Grp Hlth Cooperat Puget Sound, Dept Prevent Care, Seattle, WA 98101 USA; Univ Washington, Sch Med, Div Gen Internal Med, Dept Med, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Group Health Cooperative; University of Washington; University of Washington Seattle	Burman, ML (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way,Mailstop 152, Seattle, WA 98108 USA.	mburman@u.washington.edu			NCI NIH HHS [CA6371] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIKEN LS, 1994, HEALTH PSYCHOL, V13, P526, DOI 10.1037/0278-6133.13.6.526; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; CARTER AP, 1987, PREV MED, V16, P19, DOI 10.1016/0091-7435(87)90003-X; ELLMAN R, 1989, BRIT J CANCER, V60, P781, DOI 10.1038/bjc.1989.359; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; FEIG SA, 1998, ACR B, V54, P8; FINK R, 1968, PUBLIC HEALTH REP, V83, P479, DOI 10.2307/4593330; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; GRAM IT, 1992, AM J PUBLIC HEALTH, V82, P249, DOI 10.2105/AJPH.82.2.249; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; JEFFERSON VA, 1993, BREAST IMAGING REPOR; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KING ES, 1990, AM J PUBLIC HEALTH, V80, P1386, DOI 10.2105/AJPH.80.11.1386; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; Mickey RM, 1997, MED CARE, V35, P1204, DOI 10.1097/00005650-199712000-00004; Taplin S H, 1993, J Am Board Fam Pract, V6, P13; TAPLIN SH, 1990, CANCER, V66, P812, DOI 10.1002/1097-0142(19900815)66:4<812::AID-CNCR2820660436>3.0.CO;2-1; Taplin SH, 1997, CANCER EPIDEM BIOMAR, V6, P625; TAPLIN SH, 1994, AM J PUBLIC HEALTH, V84, P571, DOI 10.2105/AJPH.84.4.571; THOMPSON RS, 1988, HMO PRACT, V2, P177; VERNON SW, 1990, SOC SCI MED, V30, P1107, DOI 10.1016/0277-9536(90)90297-6; ZAPKA JG, 1991, MED CARE, V29, P697, DOI 10.1097/00005650-199108000-00003; 1997, MMWR MORB MORTAL WKL, V46, P937	26	75	75	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					1	+		10.7326/0003-4819-131-1-199907060-00002	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214UD	10391809				2022-12-28	WOS:000081345200001
J	Ledergerber, B; Telenti, A; Egger, M				Ledergerber, B; Telenti, A; Egger, M		Swiss HIV Cohort Study	Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Hlth Serv Res Collaborat, MRC, Bristol BS8 2PR, Avon, England; Univ Zurich Hosp, Dept Med, Div Infect Dis, CH-8091 Zurich, Switzerland; Univ Lausanne, Dept Med, Div Infect Dis, CH-1011 Lausanne, Switzerland	University of Bristol; University of Zurich; University Zurich Hospital; University of Lausanne	Egger, M (corresponding author), Univ Bristol, Dept Social Med, Hlth Serv Res Collaborat, MRC, Bristol BS8 2PR, Avon, England.		Ledergerber, Bruno/B-5656-2009	Ledergerber, Bruno/0000-0002-6881-4401; Egger, Matthias/0000-0001-7462-5132				CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2	5	191	194	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					23	24		10.1136/bmj.319.7201.23	http://dx.doi.org/10.1136/bmj.319.7201.23			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390454	Green Published, Bronze			2022-12-28	WOS:000081326500025
J	Lowry, PW; Sandborn, WJ; Lipsky, JJ				Lowry, PW; Sandborn, WJ; Lipsky, JJ			Mycophenolate mofetil for Crohn's disease?	LANCET			English	Editorial Material							RENAL-ALLOGRAFT RECIPIENTS; ACUTE REJECTION; CYCLOSPORINE; PREVENTION		Mayo Clin & Mayo Fdn, Dept Internal Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Clin Pharmacol Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Lowry, PW (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.		Sandborn, William/ABE-8342-2020					Fickert P, 1998, AM J GASTROENTEROL, V93, P2529, DOI 10.1016/S0002-9270(98)00487-0; Florin THJ, 1998, AUST NZ J MED, V28, P344, DOI 10.1111/j.1445-5994.1998.tb01960.x; Lipsky JJ, 1996, LANCET, V348, P1357, DOI 10.1016/S0140-6736(96)10310-X; Mathew TH, 1998, TRANSPLANTATION, V65, P1450, DOI 10.1097/00007890-199806150-00007; Neurath MF, 1999, GUT, V44, P625, DOI 10.1136/gut.44.5.625; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; Sandborn WJ, 1996, AM J GASTROENTEROL, V91, P423; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; Wiesel M, 1998, J UROLOGY, V159, P28, DOI 10.1016/S0022-5347(01)64000-X; Zeeh JM, 1999, GASTROENTEROLOGY, V116, pA948	10	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					3	4		10.1016/S0140-6736(99)00152-X	http://dx.doi.org/10.1016/S0140-6736(99)00152-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406354				2022-12-28	WOS:000081243200003
J	Spodick, DH; Pezzella, AT				Spodick, DH; Pezzella, AT			A grade 6 systolic murmur	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Vincent Hosp, Worcester, MA 01604 USA		Spodick, DH (corresponding author), St Vincent Hosp, Worcester, MA 01604 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					27	27		10.1056/NEJM199907013410105	http://dx.doi.org/10.1056/NEJM199907013410105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387939				2022-12-28	WOS:000081195600005
J	Bateson, MC				Bateson, MC			Fortnightly review - Gallbladder disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GALL-STONES; LAPAROSCOPIC CHOLECYSTECTOMY; NECROPSY; DISSOLUTION; PREVALENCE; GALLSTONES; RECURRENCE; SCOTLAND; TOWN		Gen Hosp, Bishop Auckland DL14 6AD, Durham, England		Bateson, MC (corresponding author), Gen Hosp, Bishop Auckland DL14 6AD, Durham, England.							ACALOVSCHI M, 1987, DIGEST DIS SCI, V32, P354, DOI 10.1007/BF01296287; [Anonymous], 1982, LANCET, V2, P957; BALZER K, 1986, DIGESTION, V33, P189, DOI 10.1159/000199294; BARBARA L, 1995, AM J EPIDEMIOL, V141, P158, DOI 10.1093/oxfordjournals.aje.a117403; BARKER DJP, 1979, BRIT MED J, V2, P1389, DOI 10.1136/bmj.2.6202.1389; BATES T, 1984, GUT, V25, pA579; BATES T, 1992, GUT, V33, P103, DOI 10.1136/gut.33.1.103; BATESON MC, 1975, BMJ-BRIT MED J, V4, P427; BATESON MC, 1984, LANCET, V2, P621; BATESON MC, 1991, RECENT ADV EPIDEMIOL; FULLARTON GM, 1994, GUT, V35, P1121, DOI 10.1136/gut.35.8.1121; GLEESON D, 1985, J HEPATOL, V1, P597, DOI 10.1016/S0168-8278(85)80003-9; GRODSTEIN F, 1994, OBSTET GYNECOL, V84, P207; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; Hellstern A, 1998, DIGEST DIS SCI, V43, P911, DOI 10.1023/A:1018811409538; HOOD KA, 1993, GUT, V34, P1277, DOI 10.1136/gut.34.9.1277; Lam CM, 1996, GUT, V38, P282, DOI 10.1136/gut.38.2.282; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MCFARLANE MJ, 1990, J GEN INTERN MED, V5, P495, DOI 10.1007/BF02600878; NELIGAN P, 1983, DIGESTION, V28, P225, DOI 10.1159/000198992; PASTIDES H, 1990, ARCH INTERN MED, V150, P1409, DOI 10.1001/archinte.150.7.1409; PIXLEY F, 1985, BRIT MED J, V291, P11, DOI 10.1136/bmj.291.6487.11; RIMM AA, 1975, PUBLIC HEALTH REP, V90, P44; ROS E, 1987, GUT, V28, P1500, DOI 10.1136/gut.28.11.1500; Russello D, 1997, Minerva Chir, V52, P1435; Tham TCK, 1999, BMJ-BRIT MED J, V318, P617, DOI 10.1136/bmj.318.7184.617	27	16	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1745	1748		10.1136/bmj.318.7200.1745	http://dx.doi.org/10.1136/bmj.318.7200.1745			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381713	Green Published			2022-12-28	WOS:000081216900036
J	Hughes, PM; Turton, P; Evans, CDH				Hughes, PM; Turton, P; Evans, CDH			Stillbirth as risk factor for depression and anxiety in the subsequent pregnancy: cohort study	BRITISH MEDICAL JOURNAL			English	Article							POSTNATAL DEPRESSION; PERINATAL DEATH	Objective To assess women's symptoms of depression and anxiety during pregnancy and the postpartum year in the pregnancy after stillbirth; to assess relevance of time since loss. Design Cohort study with four assessments: in third trimester and 6 weeks, 6 months, and 12 months after birth. Setting Outpatient departments of three district general hospitals; subjects' homes. Subjects 60 women whose previous pregnancy ended in stillbirth after 18 weeks' gestation; 60 matched controls. Main outcome measures Depression and anxiety measured by Edinburgh postnatal depression scale, Beck depression inventory, and Spielberger state-trait anxiety scale. Results In the third trimester women whose previous pregnancy had ended in stillbirth were significantly more depressed than control women (10.8 v 8.2; P = 0.004) and had greater state anxiety (39.8 v 32.8, P = 0.003) The difference was accounted for by those women who conceived less than 12 months after the stillbirth, who were also more depressed at 1 year. Results in those who conceived 12 months or more after stillbirth were similar to those in their controls at all points and showed lower trait anxiety 1 year post partum. One year after the birth 8% of control women and 19% of subjects scored high for depression (P = 0.39), with most of the depression among the more recently bereaved (28% v 11%; P = 0.18). In the women who had experienced stillbirth, depression in the third trimester was highly predictive of depression 1 year after subsequent birth (P less than or equal to 0.0005). Conclusion Vulnerability to depression and anxiety in the next pregnancy and puerperium is related to time since stillbirth, with more recently bereaved women at significantly greater risk than controls. As there are problems for mother and infant associated with high anxiety and depression during and after pregnancy, there may be advantage in waiting 12 months before the next conception.	St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England; Tavistock & Portman NHS Trust, Tavistock Clin, London NW3 5BA, England	St Georges University London	Hughes, PM (corresponding author), St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England.		Evans, Chris/E-7526-2011	Evans, Chris/0000-0002-4197-4202				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOURNE S, 1984, BRIT MED J, V289, P147, DOI 10.1136/bmj.289.6438.147; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DAVIS DL, 1989, J AM ACAD CHILD PSY, V28, P481, DOI 10.1097/00004583-198907000-00002; FORREST CG, 1982, BRIT MED J, V285, P1475; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; Hunfeld JAM, 1997, PRENATAL DIAG, V17, P843, DOI 10.1002/(SICI)1097-0223(199709)17:9<843::AID-PD147>3.0.CO;2-Q; LEWIS E, 1979, BRIT MED J, V2, P27, DOI 10.1136/bmj.2.6181.27; LOU HC, 1994, DEV MED CHILD NEUROL, V36, P826; Murray D, 1990, J REPROD INFANT PSYC, V8, P99, DOI DOI 10.1080/02646839008403615; MURRAY L, 1992, J CHILD PSYCHOL PSYC, V33, P543, DOI 10.1111/j.1469-7610.1992.tb00890.x; *OFF NAT STAT, 1998, SER FMI, V15, P1; PHIPPS S, 1985, INT J PSYCHIAT MED, V15, P243, DOI 10.2190/GDC5-KA60-JPNH-PND2; ROWE J, 1978, PEDIATRICS, V62, P166; SPIELBERGER CD, 1970, TEST STATE TRAIT ANX; SROUFE LA, 1983, MINN SYM CHILD PSYCH, V16, P41; TEIXEIRA JMA, IN PRESS BMJ; THEUT SK, 1988, J AM ACAD CHILD PSY, V27, P289, DOI 10.1097/00004583-198805000-00004; WADWA PD, 1993, AM J OBSTET GYNECOL, V169, P858; ZUCKERMAN B, 1989, AM J OBSTET GYNECOL, V160, P1107, DOI 10.1016/0002-9378(89)90170-1	21	159	161	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1721	1724		10.1136/bmj.318.7200.1721	http://dx.doi.org/10.1136/bmj.318.7200.1721			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381705	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000081216900022
J	Kmietowicz, Z				Kmietowicz, Z			Model predicts who benefits from carotid endarterectomy	BRITISH MEDICAL JOURNAL			English	News Item																		Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1719	1719		10.1136/bmj.318.7200.1719	http://dx.doi.org/10.1136/bmj.318.7200.1719			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381699	Green Published			2022-12-28	WOS:000081216900016
J	Nunnerly, H; Husband, JE				Nunnerly, H; Husband, JE			John William Laws - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		LAWS JW, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1767	1767		10.1136/bmj.318.7200.1767	http://dx.doi.org/10.1136/bmj.318.7200.1767			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381736	Green Published			2022-12-28	WOS:000081216900075
J	de Rosa, R; Grenier, JK; Andreeva, T; Cook, CE; Adoutte, A; Akam, M; Carroll, SB; Balavoine, G				de Rosa, R; Grenier, JK; Andreeva, T; Cook, CE; Adoutte, A; Akam, M; Carroll, SB; Balavoine, G			Hox genes in brachiopods and priapulids and protostome evolution	NATURE			English	Article							HOMEOBOX GENES; CLUSTER; IDENTIFICATION; ARTHROPODS; ANNELIDA; ANIMALS; ELEGANS; ORIGIN; CLADE	Understanding the early evolution of animal body plans requires knowledge both of metazoan phylogeny and of the genetic and developmental changes involved in the emergence of particular forms. Recent 18S ribosomal RNA phylogenies suggest a three-branched tree for the Bilateria comprising the deuterostomes and two great protostome clades, the lophotrochozoans(1) and ecdysozoans(2). Here, we show that the complement of Nor genes in critical protostome phyla reflects these phylogenetic relationships and reveals the early evolution of developmental regulatory potential in bilaterians. We have identified Hox genes that are shared by subsets of protostome phyla. These include a diverged pair of posterior (Abdominal-B-like) genes in both a brachiopod and a polychaete annelid, which supports the lophotrochozoan assemblage, and a distinct posterior Hox gene shared by a priapulid, a nematode and the arthropods, which supports the ecdysozoan dade. The ancestors of each of these two major protostome lineages had a minimum of eight to ten Hox genes. The major period of Hox gene expansion and diversification thus occurred before the radiation of each of the three great bilaterian clades.	Univ Paris Sud, CNRS, UPRESA Q8080, Lab Biol Cellulaire 4, F-91405 Orsay, France; Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; St Petersburg State Univ, Inst Biol, Dept Embryol, St Petersburg 199034, Russia; Univ Cambridge, Museum Zool, Dept Zool, Lab Dev & Evolut, Cambridge CB2 3EJ, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Saint Petersburg State University; University of Cambridge	Balavoine, G (corresponding author), CNRS, Ctr Genet Mol, UPR 9061, Ave Terrasse,Batiment 26, F-91198 Gif Sur Yvette, France.	Guillaume.Balavoine@cgm.cnrs-gif.fr		de Rosa, Renaud/0000-0002-3239-6324; Cook, Charles E/0000-0002-4145-8048	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adoutte A, 1999, TRENDS GENET, V15, P104, DOI 10.1016/S0168-9525(98)01671-0; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; Balavoine G, 1996, NUCLEIC ACIDS RES, V24, P1547, DOI 10.1093/nar/24.8.1547; Balavoine G, 1998, AM ZOOL, V38, P843; BOARDMANN RS, 1987, FOSSIL INVERTEBRATES; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Degnan Bernard M., 1993, Molecular Marine Biology and Biotechnology, V2, P1; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Grenier JK, 1997, CURR BIOL, V7, P547, DOI 10.1016/S0960-9822(06)00253-3; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Kmita-Cunisse M, 1998, P NATL ACAD SCI USA, V95, P3030, DOI 10.1073/pnas.95.6.3030; Lorenzen S., 1985, ORIGINS RELATIONSHIP, P210; Mackey LY, 1996, J MOL EVOL, V42, P552, DOI 10.1007/BF02352285; Martinez P, 1999, P NATL ACAD SCI USA, V96, P1469, DOI 10.1073/pnas.96.4.1469; Nielsen C., 1995, ANIMAL EVOLUTION; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SHANKLAND M, 1991, DEVELOPMENT, P29; SNOW P, 1994, MOL PHYLOGENET EVOL, V3, P360, DOI 10.1006/mpev.1994.1042; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WONG VY, 1995, J NEUROSCI, V15, P5551; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	30	389	393	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					772	776						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391241				2022-12-28	WOS:000081101600051
J	Fred, HL; Accad, M				Fred, HL; Accad, M			Images in clinical medicine - Lipemia retinalis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Fred, HL (corresponding author), Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1969	1969		10.1056/NEJM199906243402506	http://dx.doi.org/10.1056/NEJM199906243402506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379021	Bronze			2022-12-28	WOS:000081088500006
J	Joo, H; Lin, ZL; Arnold, FH				Joo, H; Lin, ZL; Arnold, FH			Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation	NATURE			English	Article							DIRECTED EVOLUTION; HYDROGEN-PEROXIDE; GENE; CRYSTALLOGRAPHY; SUPERFAMILY; OXIDATION; ESTERASE; OXYGEN; H2O2	Enzyme-based chemical transformations typically proceed with high selectivity under mild conditions, and are;becoming increasingly important in the pharmaceutical and chemical industries. Cytochrome P450 monooxygenases (P450s) constitute a large family(1) of enzymes of particular interest in this regard. Their biological functions, such as detoxification of xenobiotics and steroidogenesis(2-5), are based on the ability to catalyse the insertion of oxygen into:a wide variety of compounds(6). Such a catalytic transformation might find technological applications in areas ranging from gene therapy and environmental remediation to the selective synthesis of pharmaceuticals and chemicals(7-10). But relatively low turnover rates (particularly towards non-natural substrates), low stability and the need for electron-donating cofactors prohibit the practical use of P450s as isolated enzymes. Here we report the directed evolution(11) of the P450 from Pseudomonas putida to create mutants that hydroxylate naphthalene in the absence of cofactors through the 'peroxide shunt' pathway(12,13) with more than 20-fold higher activity than the native enzyme. We are able to screen efficiently for improved mutants by coexpressing them with horseradish peroxidase, which converts the products of the P450 reaction into fluorescent compounds amenable to digital imaging screening. This system should allow us to select and develop mono- and di-oxygenases into practically useful biocatalysts for the hydroxylation of a wide range of aromatic compounds.	CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA.		Lin, Zhanglin/A-7232-2011	Arnold, Frances H./0000-0002-4027-364X				Cerniglia Carl E., 1992, Biodegradation, V3, P351, DOI 10.1007/BF00129093; Cook DL, 1997, BIOCHEMISTRY-US, V36, P10801, DOI 10.1021/bi971284b; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Duport C, 1998, NAT BIOTECHNOL, V16, P186, DOI 10.1038/nbt0298-186; England PA, 1998, FEBS LETT, V424, P271, DOI 10.1016/S0014-5793(98)00189-6; FABER K, 1997, BIOTRANSFORMATIONS O, P208; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HRYCAY EG, 1975, BIOCHEM BIOPH RES CO, V66, P209, DOI 10.1016/S0006-291X(75)80315-9; HUMMEL W, 1989, EUR J BIOCHEM, V184, P1, DOI 10.1111/j.1432-1033.1989.tb14983.x; Jounaidi Y, 1998, CANCER RES, V58, P4391; Lin ZL, 1999, BIOTECHNOL PROGR, V15, P467, DOI 10.1021/bp990037r; MCKAY CP, 1991, ORIGINS LIFE EVOL B, V21, P157, DOI 10.1007/BF01809444; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; Samuilov VD, 1997, BIOCHEMISTRY-MOSCOW+, V62, P451; Seelbach K, 1996, TETRAHEDRON LETT, V37, P1377, DOI 10.1016/0040-4039(96)00010-X; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; UNGER BP, 1986, J BIOL CHEM, V261, P1158; vanDeurzen MPJ, 1997, TETRAHEDRON, V53, P13183, DOI 10.1016/S0040-4020(97)00477-8; WACKETT LP, 1994, NATURE, V368, P627, DOI 10.1038/368627a0; Waxman David J., 1995, P391; Zhao H., 1999, MANUAL IND MICROBIOL, P597; Zhao HM, 1999, PROTEIN ENG, V12, P47, DOI 10.1093/protein/12.1.47; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	32	338	402	3	120	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					670	673		10.1038/21395	http://dx.doi.org/10.1038/21395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385118				2022-12-28	WOS:000080932800054
J	Ferrer, M; Bauer, TT; Torres, A; Hernandez, C; Piera, C				Ferrer, M; Bauer, TT; Torres, A; Hernandez, C; Piera, C			Effect of nasogastric tube size on gastroesophageal reflux and microaspiration in intubated patients	ANNALS OF INTERNAL MEDICINE			English	Article							RECEIVING MECHANICAL VENTILATION; INTENSIVE-CARE UNIT; GASTRIC COLONIZATION; NOSOCOMIAL PNEUMONIA; PULMONARY ASPIRATION; RESPIRATORY-TRACT; ENTERAL NUTRITION; STOMACH; POSITION; TRIAL	Background: Little evidence exists to support the theory that small-bore nasogastric tubes prevent gastroesophageal reflux and microaspiration in intubated patients. Objective: To determine whether gastroesophageal reflux and microaspiration in intubated patients can be reduced by the use of a small-bore nasogastric tube. Design: Randomized, two-period crossover trial. Setting: Respiratory intensive care unit of a university hospital. Patients: 17 patients intubated for more than 72 hours. Interventions: Radioactive technetium colloid was instilled in each patient's stomach. Patients were studied with two nasogastric tubes (one tube with a 6.0-mm external bore and one tube with a 2.85-mm external bore) in randomized order; measurements of radioactive counts with the alternate size of nasogastric tube were repeated 72 hours after original measurements were taken. Sequential samples of serum, gastric juice, and pharyngeal and tracheal secretions were obtained. Measurements: Comparison of the time course of radioactive counting in all samples (obtained during the use of each nasogastric tube size in each patient). Results: The mean radioactive count of pharyngeal aspirates (P = 0.004) was greater than the baseline count at all time points, as was the cumulative radioactive count of pharyngeal aspirates 17 hours after the first dose of technetium colloid was administered (P = 0.001); however, the count of tracheal aspirates was never greater than the count at baseline. No differences were found between tube types when the time course and cumulative counts of pharyngeal and tracheal samples were compared. Conclusion: Small-bore nasogastric tubes in intubated patients do not reduce gastroesophageal reflux or microaspiration.	Univ Barcelona, Barcelona, Spain	University of Barcelona	Torres, A (corresponding author), Hosp Clin Barcelona, Serv Pneumol, Villarroel 170, E-08036 Barcelona, Spain.	atorres@medicina.ub.es	Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167; Hernandez, Carme/0000-0002-1123-1889; Ferrer, Miguel/0000-0001-8171-6673				Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; APTE NM, 1992, CRIT CARE MED, V20, P590, DOI 10.1097/00003246-199205000-00008; BONTEN MJM, 1994, CHEST, V105, P878, DOI 10.1378/chest.105.3.878; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; DOTSON RG, 1994, AM J RESP CRIT CARE, V149, P1659, DOI 10.1164/ajrccm.149.6.8004326; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; HARDY JF, 1988, CAN J ANAESTH, V35, P162, DOI 10.1007/BF03010658; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; IBANEZ J, 1992, JPEN-PARENTER ENTER, V16, P419, DOI 10.1177/0148607192016005419; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; MILLER KS, 1985, CHEST, V88, P230, DOI 10.1378/chest.88.2.230; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; SCHULZEDELRIEU K, 1982, DISEASES ESOPHAGUS, P35; SIMMS HH, 1991, J TRAUMA, V31, P531, DOI 10.1097/00005373-199104000-00013; Torres A, 1996, EUR RESPIR J, V9, P1729, DOI 10.1183/09031936.96.09081729; TORRES A, 1993, AM REV RESPIR DIS, V148, P352, DOI 10.1164/ajrccm/148.2.352; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540	19	58	66	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					991	994		10.7326/0003-4819-130-12-199906150-00007	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383370				2022-12-28	WOS:000080894700006
J	Kuroda, MI; Kelley, RL				Kuroda, MI; Kelley, RL			Developmental biology - Sex and repression	SCIENCE			English	Editorial Material							CHROMOSOME DOSAGE COMPENSATION; X-CHROMOSOME; C-ELEGANS; NEMATODE; PROTEIN; HOMOLOG; GENE		Baylor Univ, Howard Hughes Med Inst, Dept Cell Biol, Houston, TX 77030 USA; Baylor Univ, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor University; Howard Hughes Medical Institute; Baylor University	Kuroda, MI (corresponding author), Baylor Univ, Howard Hughes Med Inst, Dept Cell Biol, Houston, TX 77030 USA.							Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Davis TL, 1997, DEVELOPMENT, V124, P1019; Dawes HE, 1999, SCIENCE, V284, P1800, DOI 10.1126/science.284.5421.1800; DELONG L, 1993, GENETICS, V133, P875; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUSBAUM C, 1989, GENETICS, V122, P579	13	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1787	1788		10.1126/science.284.5421.1787	http://dx.doi.org/10.1126/science.284.5421.1787			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10391797				2022-12-28	WOS:000080809000037
J	Pawson, T; Saxton, TM				Pawson, T; Saxton, TM			Signaling networks - Do all roads lead to the same genes?	CELL			English	Review							TERNARY COMPLEX FACTORS; EPIDERMAL GROWTH-FACTOR; ACTIVATION; RECEPTOR; PHOSPHORYLATION; KINASE		Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Pawson, Tony J/E-4578-2013					Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Partanen J, 1998, GENE DEV, V12, P2332, DOI 10.1101/gad.12.15.2332; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RONNSTRAND L, 1999, IN PRESS ONCOGENE; SOLER C, 1994, ONCOGENE, V9, P2207; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Weatherbee SD, 1999, CELL, V97, P283, DOI 10.1016/S0092-8674(00)80737-0	22	126	128	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					675	678		10.1016/S0092-8674(00)80779-5	http://dx.doi.org/10.1016/S0092-8674(00)80779-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380918	Bronze			2022-12-28	WOS:000080886300003
J	Pilon, M; Schekman, R				Pilon, M; Schekman, R			Protein translocation: How Hsp70 pulls it off	CELL			English	Review							PREPROTEIN TRANSLOCATION; ER MEMBRANE; MITOCHONDRIA; COMPLEX; IMPORT; TRANSPORT; BINDING; BIP		Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Colorado State University; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Pilon, M (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.							Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Simon S.M., 1992, P NATL ACAD SCI USA, V89, P3370; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	19	84	85	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					679	682		10.1016/S0092-8674(00)80780-1	http://dx.doi.org/10.1016/S0092-8674(00)80780-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380919	Bronze			2022-12-28	WOS:000080886300004
J	Gaidos, EJ; Nealson, KH; Kirschvink, JL				Gaidos, EJ; Nealson, KH; Kirschvink, JL			Biogeochemistry - Life in ice-covered oceans	SCIENCE			English	Editorial Material							EARLY EARTH; HYDROTHERMAL SYSTEMS; SNC METEORITES; LIQUID WATER; EUROPA; MARS; SURFACE; SATELLITES; REDUCTION; JUPITER		CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Wisconsin, Ctr Great Lakes Studies, Milwaukee, WI 53204 USA	California Institute of Technology; University of Wisconsin System; University of Wisconsin Milwaukee	Gaidos, EJ (corresponding author), CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA.	gaidos@gps.caltech.edu		Gaidos, Eric/0000-0002-5258-6846				Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; BALLHAUS C, 1990, NATURE, V348, P437, DOI 10.1038/348437a0; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CHANG S, 1993, NATO ADV SCI INST SE, V416, P259; CRAWFORD GD, 1988, ICARUS, V73, P66, DOI 10.1016/0019-1035(88)90085-1; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; DICHRISTINA TJ, 1988, WATER SCI TECHNOL, V20, P69, DOI 10.2166/wst.1988.0268; DSON FJ, 1997, ATL MON, V280, P71; Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; GREELEY R, 1991, SCIENCE, V254, P996, DOI 10.1126/science.254.5034.996; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HOBBS PV, 1974, ICE PHYSICS; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Jean-Baptiste P, 1998, EARTH PLANET SC LETT, V158, P81, DOI 10.1016/S0012-821X(98)00045-4; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; KNAUER GA, 1993, BIOGEOCHEMICAL CYCLE, P211; LOVLEY DR, 1986, APPL ENVIRON MICROB, V51, P683, DOI 10.1128/AEM.51.4.683-689.1986; MAHER KA, 1988, NATURE, V331, P612, DOI 10.1038/331612a0; McCollom TM, 1997, GEOCHIM COSMOCHIM AC, V61, P4375, DOI 10.1016/S0016-7037(97)00241-X; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MOOD S, 1983, ASTRONOMY, V11, P16; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; MURRELL JC, 1992, FEMS MICROBIOL LETT, V88, P233, DOI 10.1016/0378-1097(92)90805-X; MYERS CR, 1990, J BACTERIOL, V172, P6232, DOI 10.1128/jb.172.11.6232-6238.1990; Navarro-Gonzalez R, 1998, GEOPHYS RES LETT, V25, P3123, DOI 10.1029/98GL02423; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Orton GS, 1996, SCIENCE, V274, P389, DOI 10.1126/science.274.5286.389; OVERMANN J, 1992, LIMNOL OCEANOGR, V37, P150, DOI 10.4319/lo.1992.37.1.0150; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; Powell CS, 1997, SCI AM, V276, P28, DOI 10.1038/scientificamerican0497-28; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; Rathbun JA, 1998, GEOPHYS RES LETT, V25, P4157, DOI 10.1029/1998GL900135; Reynolds R T, 1987, Adv Space Res, V7, P125, DOI 10.1016/0273-1177(87)90364-4; REYNOLDS RT, 1983, ICARUS, V56, P246, DOI 10.1016/0019-1035(83)90037-4; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; Shock EL, 1997, J GEOPHYS RES-PLANET, V102, P23687, DOI 10.1029/97JE01087; Shock EL, 1996, CIBA F SYMP, V202, P40; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; Spaun NA, 1998, GEOPHYS RES LETT, V25, P4277, DOI 10.1029/1998GL900176; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; Stumm W., 1981, AQUATIC CHEM; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; YUNG YL, 1996, AM ASTR SOC DIV PLAN; Zahnle K, 1998, ICARUS, V136, P202, DOI 10.1006/icar.1998.6015	55	132	138	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1631	1633		10.1126/science.284.5420.1631	http://dx.doi.org/10.1126/science.284.5420.1631			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383341				2022-12-28	WOS:000080668300031
J	Burke, K				Burke, K			Doctors fear that inequalities are slipping down agenda	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					144	144		10.1136/bmj.319.7203.144	http://dx.doi.org/10.1136/bmj.319.7203.144			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406741	Green Published			2022-12-28	WOS:000081619300012
J	Faderl, S; Talpaz, M; Estrov, Z; O'Brien, S; Kurzrock, R; Kantarjian, HM				Faderl, S; Talpaz, M; Estrov, Z; O'Brien, S; Kurzrock, R; Kantarjian, HM			Mechanisms of disease - The biology of chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC MYELOGENOUS LEUKEMIA; IN-SITU HYBRIDIZATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; LONG-TERM REMISSION; CHRONIC MYELOCYTIC-LEUKEMIA; BCR-ABL ONCOGENE; PHILADELPHIA-CHROMOSOME; INTERFERON-ALPHA; SIGNAL-TRANSDUCTION		Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kantarjian, HM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Box 61, Houston, TX 77030 USA.		Kurzrock, Razelle/AAU-9782-2020	Talpaz, Moshe/0000-0003-3361-3981				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; Bhatia R, 1996, BLOOD, V87, P3883, DOI 10.1182/blood.V87.9.3883.bloodjournal8793883; BIERNAUX C, 1995, BLOOD, V86, P3118; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; BROWN RD, 1986, BLOOD, V68, P37; Buno I, 1998, BLOOD, V92, P2315, DOI 10.1182/blood.V92.7.2315.2315_2315_2321; Chung SW, 1996, CRIT REV ONCOGENESIS, V7, P33, DOI 10.1615/CritRevOncog.v7.i1-2.30; CLARKSON B, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309047871; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Cornelissen JJ, 1998, J CLIN INVEST, V102, P976, DOI 10.1172/JCI2366; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DERDERIAN PM, 1993, AM J MED, V94, P69, DOI 10.1016/0002-9343(93)90122-6; Dewald GW, 1998, BLOOD, V91, P3357, DOI 10.1182/blood.V91.9.3357.3357_3357_3365; ESTROV Z, 1991, BLOOD, V78, P1476; Estrov Z., 1993, INTERFERONS BASIC PR; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FINKE J, 1993, J CLIN ONCOL, V11, P1668, DOI 10.1200/JCO.1993.11.9.1668; GALE RP, 1993, LEUKEMIA, V7, P653; Gordon MY, 1998, J CLIN INVEST, V102, P710, DOI 10.1172/JCI3094; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GRIFFIN JD, 1983, BLOOD, V61, P85; GUINN BA, 1997, LEUKEMIA LYMPHOMA, V26, P221; GUO JQ, 1991, CANCER RES, V51, P3048; Hochhaus A, 1998, RECENT RESULTS CANC, V144, P36; HOCHHAUS A, 1995, BRIT J HAEMATOL, V91, P126, DOI 10.1111/j.1365-2141.1995.tb05257.x; KANTARJIAN HM, 1988, CANCER, V61, P1441, DOI 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Kurzrock R, 1998, J CLIN ONCOL, V16, P1526, DOI 10.1200/JCO.1998.16.4.1526; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Litz CE, 1996, BLOOD, V88, P2241, DOI 10.1182/blood.V88.6.2241.bloodjournal8862241; MALINEN T, 1991, BLOOD, V77, P2435; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MELO JV, 1994, LEUKEMIA, V8, P208; Melo JV, 1996, LEUKEMIA, V10, P751; MITELMAN F, 1993, LEUKEMIA LYMPHOMA, V11, P11, DOI 10.3109/10428199309047856; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Muhlmann J, 1998, GENE CHROMOSOME CANC, V21, P90, DOI 10.1002/(SICI)1098-2264(199802)21:2<90::AID-GCC3>3.0.CO;2-2; NOWELL PC, 1960, SCIENCE, V132, P1497; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PANE F, 1997, BLOOD, V89, P4244; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pfeffer LM, 1998, CANCER RES, V58, P2489; PULL L, 1994, EMBO J, V13, P764; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SACCHI S, 1995, J CLIN ONCOL, V13, P2401, DOI 10.1200/JCO.1995.13.9.2401; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEONG DC, 1995, BLOOD, V86, P2343, DOI 10.1182/blood.V86.6.2343.bloodjournal8662343; SHEPHERD P, 1995, BRIT J HAEMATOL, V89, P546, DOI 10.1111/j.1365-2141.1995.tb08362.x; SIRARD C, 1994, BLOOD, V83, P1575; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; SPECCHIA G, 1995, LEUKEMIA LYMPHOMA, V18, P37, DOI 10.3109/10428199509075301; STILL H, 1995, BLOOD, V85, P2013; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; TALPAZ M, 1994, J CLIN INVEST, V94, P1383, DOI 10.1172/JCI117473; TALPAZ M, 1987, BLOOD, V69, P1280; TOBAL K, 1995, BRIT J HAEMATOL, V91, P104, DOI 10.1111/j.1365-2141.1995.tb05253.x; TOBAL K, 1995, BRIT J HAEMATOL, V90, P615, DOI 10.1111/j.1365-2141.1995.tb05592.x; Verfaillie CM, 1997, J LAB CLIN MED, V129, P584, DOI 10.1016/S0022-2143(97)90192-X; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7	73	919	985	1	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					164	172		10.1056/NEJM199907153410306	http://dx.doi.org/10.1056/NEJM199907153410306			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403855				2022-12-28	WOS:000081413800006
J	Evans, JMM; Newton, RW; Ruta, DA; MacDonald, TM; Stevenson, RJ; Morris, AD				Evans, JMM; Newton, RW; Ruta, DA; MacDonald, TM; Stevenson, RJ; Morris, AD			Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC CONTROL; POPULATION; MELLITUS; IMPACT	Objectives To investigate patterns of self monitoring of blood glucose concentration in diabetic patients who use insulin and to determine whether frequency of self monitoring is related to glycaemic control. Setting Diabetes database, Tayside, Scotland. Subjects Patients resident in Tayside in 1993-5 who were using insulin and were registered on the database and diagnosed with insulin dependent (type 1) or non-insulin dependent (type 2) diabetes before 1993. Main outcome measures Number of glucose monitoring reagent strips dispensed (reagent strip uptake) derived from records of prescriptions. First recorded haemoglobin A(1c), concentration in the study period, and reagent strips dispensed in the previous 6 months. Results Among 807 patients with type 1 diabetes, 128 (16%) did not redeem any prescriptions for glucose monitoring reagent strips in the 3 year study period. Only 161 (20%) redeemed prescriptions for enough reagent strips to test glucose daily. The corresponding figures for the 790 patients with type 2 diabetes who used insulin were 162 (21%; no strips) and 131 (17%; daily tests). Reagent strip uptake was influenced both by age and by deprivation category. There was a direct relation between uptake and glycaemic control for 258 patients (with recorded haemoglobin A(1c) concentrations) with type 1 diabetes. In a linear regression model the decrease in haemoglobin A(1c) concentration for every extra 180 reagent strips dispensed was 0.7%. For the 290 patients with type 2 diabetes who used insulin there was no such relation. Conclusions Self monitoring of blood glucose concentration is associated with improved glycaemic control in patients with type 1 diabetes. Regular self monitoring in patients with type 1 and type 2 diabetes is uncommon.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Evans, JMM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Med Monitoring Unit, Dundee DD1 9SY, Scotland.	josie@memo.dundee.ac.uk	Morris, Andrew D/C-2837-2009; Ruta, Danny A/E-4472-2013	Ruta, Danny/0000-0002-2024-3267; MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1987, DIABETES CARE, V10, P95; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BELMONTE MM, 1988, DIABETES CARE, V11, P484, DOI 10.2337/diacare.11.6.484; *BRIT MED ASS, 1998, BRIT NAT FORM, V35; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; DANEMAN D, 1985, DIABETES CARE, V8, P1, DOI 10.2337/diacare.8.1.1; DCCT Research Group, 1989, NEW ENGL J MED, V329, P977; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Gallichan M, 1997, BRIT MED J, V314, P964, DOI 10.1136/bmj.314.7085.964; GILL GV, 1989, PRACTICAL DIABETES, V6, P77; GORDON D, 1991, DIABETIC MED, V8, P679, DOI 10.1111/j.1464-5491.1991.tb01677.x; HARRIS MI, 1993, DIABETES CARE, V16, P1116, DOI 10.2337/diacare.16.8.1116; *INF STAT DIV, 1996, SCOTT HLTH STAT 1996; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; MOLITCH ME, 1994, DIABETES CARE, V17, P81; Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; Morris AD, 1997, DIABETES CARE, V20, P1363, DOI 10.2337/diacare.20.9.1363; Morris AD, 1998, DIABETES CARE, V21, P738, DOI 10.2337/diacare.21.5.738; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; PATRICK AW, 1994, DIABETIC MED, V11, P62, DOI 10.1111/j.1464-5491.1994.tb00231.x; Ray NF, 1998, DIABETES CARE, V21, P296; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WORTH R, 1982, BRIT MED J, V285, P1233, DOI 10.1136/bmj.285.6350.1233	24	179	182	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					83	86		10.1136/bmj.319.7202.83	http://dx.doi.org/10.1136/bmj.319.7202.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398627	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000081438200023
J	Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD				Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD			Are we really dying for a tan?	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; VITAMIN-D; EXPOSURE; SUNLIGHT; POPULATION; MORTALITY; MELANOMA		Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England	University of Bristol	Ness, AR (corresponding author), Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England.		Ness, Andy R/M-7612-2013; Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Ness, Andy R/0000-0003-3548-9523; Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ARTHEY S, 1995, SOC SCI MED, V40, P265, DOI 10.1016/0277-9536(94)E0063-X; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; Bridgwood A, 1996, HLTH ENGLAND 1995 WH; CARTER S, 1997, TOURISM HLTH; CHEW KSY, 1995, SOC SCI MED, V40, P223, DOI 10.1016/0277-9536(94)E0070-9; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; Finkel E, 1998, LANCET, V351, P1866, DOI 10.1016/S0140-6736(05)78819-X; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Freedman DM, 1997, BRIT MED J, V314, P1451, DOI 10.1136/bmj.314.7092.1451; Grimes DS, 1996, QJM-INT J MED, V89, P579; Haines A, 1997, BRIT MED J, V315, P870, DOI 10.1136/bmj.315.7112.870; HUTTON D, 1998, VOGUE            MAY, P114; KHAW KT, 1995, LANCET, V345, P337, DOI 10.1016/S0140-6736(95)90336-4; LUND B, 1978, HORM METAB RES, V10, P553, DOI 10.1055/s-0028-1093390; MARKS R, 1995, ARCH DERMATOL, V131, P415, DOI 10.1001/archderm.131.4.415; McMichael AJ, 1997, EPIDEMIOLOGY, V8, P642, DOI 10.1097/00001648-199710000-00005; MELIA J, 1995, HLTH HYG, V16, P153; *OFF NAT STAT, 1997, MORT STAT CAUS ENGL; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; *SECR STAT HLTH, 1992, HLTH NAT; Utiger RD, 1998, NEW ENGL J MED, V338, P828, DOI 10.1056/NEJM199803193381209; VIK T, 1979, BMJ-BRIT MED J, V2, P176, DOI 10.1136/bmj.2.6183.176; WEHR TA, 1989, AM J PSYCHIAT, V146, P829; West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714	25	42	42	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					114	116		10.1136/bmj.319.7202.114	http://dx.doi.org/10.1136/bmj.319.7202.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398641	Green Published			2022-12-28	WOS:000081438200040
J	Maser, P; Sutterlin, C; Kralli, A; Kaminsky, R				Maser, P; Sutterlin, C; Kralli, A; Kaminsky, R			A nucleoside transporter from Trypanosoma brucei involved in drug resistance	SCIENCE			English	Article							UNUSUAL ADENOSINE TRANSPORTER; MOLECULAR-CLONING	Drug resistance of pathogens is an increasing problem whose underlying mechanisms are not fully understood, Cellular uptake of the major drugs against Trypanosoma brucei spp,, the causative agents of sleeping sickness, is thought to occur through an unusual, so far unidentified adenosine transporter, Saccharomyces cerevisiae was used in a functional screen to clone a gene (TbAT1) from Trypanosoma brucei brucei that encodes a nucleoside transporter. When expressed in yeast, TbAT1 enabled adenosine uptake and conferred susceptibility to melaminophenyl arsenicals. Drug-resistant trypanosomes harbor a defective TbAT1 variant. The molecular identification of the entry route of trypanocides opens the way to approaches for diagnosis and treatment of drug-resistant sleeping sickness.	Swiss Trop Inst, CH-4002 Basel, Switzerland; Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Kaminsky, R (corresponding author), Novartis CRA, CH-1566 St Aubin, Switzerland.			Maser, Pascal/0000-0003-3122-1941				Barrett MP, 1999, PARASITOL TODAY, V15, P136, DOI 10.1016/S0169-4758(99)01414-3; BARRETT MP, 1995, MOL BIOCHEM PARASIT, V73, P223, DOI 10.1016/0166-6851(95)00120-P; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; FROMMEL TO, 1987, MOL BIOCHEM PARASIT, V26, P183, DOI 10.1016/0166-6851(87)90142-3; FULTON JD, 1955, ANN TROP MED PARASIT, V49, P377; GIBSON WC, 1983, T ROY SOC TROP MED H, V77, P114, DOI 10.1016/0035-9203(83)90033-0; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Hernandez A, 1998, BIOINFORMATICS, V14, P227, DOI 10.1093/bioinformatics/14.2.227; Maser P, 1997, RRD ANTIMICROB AG CH, V2, P113; MASER P, UNPUB; MazhariTabrizi R, 1996, BIOCHEM J, V316, P853, DOI 10.1042/bj3160853; POSPICHAL H, 1994, ACTA TROP, V58, P187, DOI 10.1016/0001-706X(94)90013-2; Tye CK, 1998, BIOORG MED CHEM LETT, V8, P811, DOI 10.1016/S0960-894X(98)00095-X; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; YORKE WARRINGTON, 1931, Annals of Tropical Medicine and Parasitology, V25, P351	20	221	228	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					242	244		10.1126/science.285.5425.242	http://dx.doi.org/10.1126/science.285.5425.242			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398598				2022-12-28	WOS:000081346000038
J	Froggatt, P				Froggatt, P			Sir Ian Fraser - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		FRASER IU, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					60	60		10.1136/bmj.319.7201.60	http://dx.doi.org/10.1136/bmj.319.7201.60			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390485	Green Published			2022-12-28	WOS:000081326500069
J	Horton, R				Horton, R			Scientific misconduct: exaggerated fear but still real and requiring a proportionate response	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							Ault A, 1999, LANCET, V353, P2138, DOI 10.1016/S0140-6736(05)75585-9; Budd JM, 1998, JAMA-J AM MED ASSOC, V280, P296, DOI 10.1001/jama.280.3.296; *DAN COMM SCI DISH, 1998, GUID GOOD SCI PRACT; FARTHING M, 1998, COPE REPORT 1998, P1; HORTON R, 1995, LANCET, V346, P1610, DOI 10.1016/S0140-6736(95)91935-X; Kaiser J, 1999, SCIENCE, V284, P901, DOI 10.1126/science.284.5416.901; Kevles Daniel J., 1998, BALTIMORE CASE TRIAL; LOCK S, 1996, FRAUD MISCONDUCT MED; Marshall E, 1999, SCIENCE, V284, P1749; NYLENNA M, 1998, DISHONESTY HUMAN RES, P22; Parrish DM, 1999, ACAD MED, V74, P221, DOI 10.1097/00001888-199903000-00009; Peto R, 1997, CONTROL CLIN TRIALS, V18, P1, DOI 10.1016/S0197-2456(96)00225-5; Rose J, 1999, SCIENCE, V283, P1829; 1999, ORI NEWSLETTER  MAR, P1; 1996, LANCET, V347, P843	15	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					7	8		10.1016/S0140-6736(99)00227-5	http://dx.doi.org/10.1016/S0140-6736(99)00227-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406357				2022-12-28	WOS:000081243200006
J	Trieman, N; Leff, J; Glover, G				Trieman, N; Leff, J; Glover, G			Outcome of long stay psychiatric patients resettled in the community: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TAPS PROJECT; FOLLOW-UP; POPULATIONS; HOSPITALS; DIFFICULT; CLOSURE	Objective To examine the outcome of a population of long stay psychiatric patients resettled in the community. Design Prospective study with 5 year follow up. Setting Over 140 residential settings in north London. Subjects 670 long stay patients from two London hospitals (Friern and Claybury) discharged to the community from 1985 to 1993. Main outcome measures Continuity and quality of residential care, readmission to hospital, mortality, crime, and vagrancy. Results Of the 523 patients who survived the 5 year follow up period, 469 (89.6%) were living in the community by the end of follow up, 310 (59.2%) in their original community placement A third (210) of all patients were readmitted at least once. Crime and homelessness presented few problems. Standardised mortality ratios for the group were comparable with those reported for similar populations. Conclusions When carefully planned and adequately resourced, community care for long star psychiatric patients is beneficial to most individuals and has minimal detrimental effects on society.	UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; Inst Psychiat, Sect Community Psychiat, London SE5 8AF, England	University of London; University College London; UCL Medical School; University of London; King's College London	Trieman, N (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England.	n.trieman@fleet69.demon.co.uk						CLIFFORD P, 1991, BRIT J PSYCHIAT, V158, P190, DOI 10.1192/bjp.158.2.190; Gooch C, 1996, PSYCHOL MED, V26, P511, DOI 10.1017/S0033291700035595; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; HAUGLAND G, 1983, AM J PSYCHIAT, V140, P848; HAZEL M, 1998, BRIT J PSYCHIAT, V172, P35; JONES D, 1993, BRIT J PSYCHIAT, V162, P36, DOI 10.1192/S0007125000292234; *KINGS FUND, 1997, LOND MENT HLTH; LAMB HR, 1993, BRIT J PSYCHIAT, V162, P587, DOI 10.1192/bjp.162.5.587; Leff J, 1996, AM J PSYCHIAT, V153, P1318; LEFF J, 1994, BRIT J PSYCHIAT, V165, P13, DOI 10.1192/S000712500029315X; MODESTIN J, 1995, BRIT J PSYCHIAT, V166, P667, DOI 10.1192/bjp.166.5.667; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P30, DOI 10.1192/S0007125000292222; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P18, DOI 10.1192/S0007125000292209; Timms P W, 1989, Health Trends, V21, P70; Trieman N, 1998, ACTA PSYCHIAT SCAND, V98, P354, DOI 10.1111/j.1600-0447.1998.tb10098.x; Trieman N, 1996, BRIT J PSYCHIAT, V169, P289, DOI 10.1192/bjp.169.3.289; Trieman N, 1996, PSYCHOL MED, V26, P765, DOI 10.1017/S0033291700037788; WELLER MPI, 1989, NATURE, V339, P249, DOI 10.1038/339249a0	18	39	45	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					13	16		10.1136/bmj.319.7201.13	http://dx.doi.org/10.1136/bmj.319.7201.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214KE	10390451	Bronze, Green Published			2022-12-28	WOS:000081326500022
J	Kenis, PJA; Ismagilov, RF; Whitesides, GM				Kenis, PJA; Ismagilov, RF; Whitesides, GM			Microfabrication inside capillaries using multiphase laminar flow patterning	SCIENCE			English	Article							CALCIUM-PHOSPHATE; MICROEMULSIONS	The reaction of species in solutions flowing laminarly (without turbulent mixing) inside capillaries was used as the basis for a broadly applicable method of microfabrication. In this method, patterning occurs as a result of transport of reactive species to interfaces within the capillary by laminar flow. A wide range of chemistries can be used to generate structures with feature sizes of less than 5 micrometers and with spatial localization to within 5 micrometers. The method is applicable to the patterning of metals, organic polymers, inorganic crystals, and ceramics on the inner walls of preformed capillaries, using both additive and subtractive processes.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Kenis, Paul J A/S-7229-2016	Kenis, Paul J A/0000-0001-7348-0381				Aizenberg J, 1998, NATURE, V394, P868, DOI 10.1038/29730; Aizenberg J, 1999, NATURE, V398, P495, DOI 10.1038/19047; ATKINS PW, 1994, PHYSICAL CHEM; Brody JP, 1996, BIOPHYS J, V71, P3430, DOI 10.1016/S0006-3495(96)79538-3; Cormier M.J., 1973, CHEMILUMINESCENCE BI; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; Lowenstam HA, 1989, BIOMINERALIZATION; Madou M., 1997, FUNDAMENTALS MICROFA; Mann S., 1989, BIOMINERALIZATION CH; Reynolds O., 1895, PHIL T ROY SOC LOND, V186, P123; Walsh D, 1996, CHEM MATER, V8, P1944, DOI 10.1021/cm9601345; WALSH D, 1994, SCIENCE, V264, P1576, DOI 10.1126/science.264.5165.1576; Weigl BH, 1999, SCIENCE, V283, P346, DOI 10.1126/science.283.5400.346	13	592	777	6	205	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					83	85		10.1126/science.285.5424.83	http://dx.doi.org/10.1126/science.285.5424.83			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390366	Green Accepted			2022-12-28	WOS:000081199800033
J	Sartori, C; Allemann, Y; Trueb, L; Delabays, A; Nicod, P; Scherrer, U				Sartori, C; Allemann, Y; Trueb, L; Delabays, A; Nicod, P; Scherrer, U			Augmented vasoreactivity in adult life associated with perinatal vascular insult	LANCET			English	Article							PERSISTENT PULMONARY-HYPERTENSION; NITRIC-OXIDE; HYPOXIA; VASOCONSTRICTION; RESISTANCE; NEWBORN	Background Adverse environmental events occurring early in life have received little attention as predictors of disease in the later stages of life. At birth, the transition from gas exchange by the placenta to gas exchange by the lungs requires dramatic changes in the pulmonary circulation, which during this period is particularly vulnerable to noxious stimuli. We measured pulmonary-artery pressure responses to high-altitude exposure, a stimulus that causes pronounced pulmonary vasoconstriction, in young adults who had had transient perinatal hypoxic pulmonary hypertension and in controls of similar age and sex distribution. Methods Review of neonatal-care records at the Lausanne University Hospital for Children identified 15 individuals who met the eligibility criteria (birth at greater than or equal to 34 weeks of gestation, persistence of hypoxaemia during ventilation with oxygen during the first week of life, and persistence of fetal circulation), Ten of these individuals agreed to take part; the control group was ten volunteers without any history of perinatal complications. Systolic pulmonary-artery pressure (by echocardiography) and arterial oxygen saturation were measured at baseline and at high altitude (4559 m). Findings The mean increase in pulmonary-artery pressure at high altitude was significantly greater (p=0.01) in the participants who had had perinatal pulmonary hypertension (from 26.2 mm Hg [SD 2.1] to 62.3 mm Hg [7.3]) than in the controls (from 25.8 mm Hg [2.3] to 49.7 mm Hg [11.3]). The fall in arterial oxygen saturation was similar in the two groups. Interpretation These findings suggest that a transient perinatal insult to the pulmonary circulation leaves a persistent and potentially fatal imprint, which when activated in adult life predisposes to a pathological response. Survivors of perinatal pulmonary hypertension may be at risk of developing this disorder in later life.	CHU Vaudois, Dept Internal Med, CH-1011 Lausanne, Switzerland; CHU Vaudois, Div Cardiol, CH-1011 Lausanne, Switzerland; Univ Hosp, Dept Cariol, Bern, Switzerland; Univ Lausanne, Inst Physiol, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bern; University Hospital of Bern; University of Lausanne	Scherrer, U (corresponding author), CHU Vaudois, Dept Internal Med, BH 10-642, CH-1011 Lausanne, Switzerland.	Urs.Scherrer@chuv.hospvd.ch		Sartori, Claudio/0000-0002-8172-3002				Barker D. J. P., 1994, MOTHERS BABIES DIS L; Blitzer ML, 1996, J AM COLL CARDIOL, V28, P591, DOI 10.1016/0735-1097(96)00218-5; CASLIN A, 1991, J PATHOL, V163, P133, DOI 10.1002/path.1711630209; DOLLBERG S, 1995, PEDIATR RES, V37, P31, DOI 10.1203/00006450-199501000-00007; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; HAKIM TS, 1990, CAN J PHYSIOL PHARM, V68, P419, DOI 10.1139/y90-059; HAMPL V, 1990, AM REV RESPIR DIS, V142, P619, DOI 10.1164/ajrccm/142.3.619; HAWORTH SG, 1988, CHEST, V3, pS133; MORIN FC, 1995, AM J RESP CRIT CARE, V151, P2010, DOI 10.1164/ajrccm.151.6.7767553; PERRELLA MA, 1992, AM J PHYSIOL, V263, pR45, DOI 10.1152/ajpregu.1992.263.1.R45; RABINOVITCH M, 1981, AM J PHYSIOL, V240, pH62, DOI 10.1152/ajpheart.1981.240.1.H62; Sartori C, 1997, Cardiologia, V42, P559; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Smith A. P. L., 1997, European Respiratory Journal Supplement, V10, p433S; STENMARK KR, 1988, CHEST, V3, pS127; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; VENDER RL, 1996, CHEST, V106, P206	17	127	130	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2205	2207		10.1016/S0140-6736(98)08352-4	http://dx.doi.org/10.1016/S0140-6736(98)08352-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392986				2022-12-28	WOS:000081091300014
J	Bell, E; Wingate, RJT; Lumsden, A				Bell, E; Wingate, RJT; Lumsden, A			Homeotic transformation of rhombomere identity after localized Hoxb1 misexpression	SCIENCE			English	Article							TARGETED DISRUPTION; CHICK HINDBRAIN; CRANIAL NERVES; MOTOR-NEURONS; NEURAL CREST; MUTANT MICE; HOXA-1; EXPRESSION; MIGRATION; ALTERS	Segmentation of the hindbrain and branchial region is a conserved feature of head development, involving the nested expression of Hox genes. Although it is presumed that vertebrate Hox genes function as segment identifiers, responsible for mediating registration between elements of diverse embryonic origin, this assumption has remained untested. To assess this, retroviral misexpression was combined with orthotopic grafting in chick embryos to generate a mismatch in Hox coding between a specific rhombomere and its corresponding branchial arch. Rhombomere-restricted misexpression of a single gene, Hoxb1, resulted in the homeotic transformation of the rhombomere, revealed by reorganization of motor axon projections.	Kings Coll London, Guys Hosp, Dept Dev Neurobiol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Lumsden, A (corresponding author), Kings Coll London, Guys Hosp, Dept Dev Neurobiol, London SE1 9RT, England.	andrew.lumsden@kcl.ac.uk	Lumsden, Andrew/C-5146-2009; Bell, Esther/C-5329-2009; Wingate, Richard JT/C-5341-2009	Wingate, Richard JT/0000-0002-1662-6097	NICHD NIH HHS [N01-HD-7-3263] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073263] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexandre D, 1996, DEVELOPMENT, V122, P735; Bateson W., 1894, MAT STUDY VARIATION; BELL E, IN PRESS MECH DEV; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; Gavalas A, 1997, DEVELOPMENT, V124, P3693; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Goddard JM, 1996, DEVELOPMENT, V122, P3217; Goulding M, 1998, NEURON, V21, P943, DOI 10.1016/S0896-6273(00)80612-1; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORGAN BA, 1996, METHOD CELL BIOL, V51, P186; PATA I, UNPUB; POURQUIE O, 1990, DEVELOPMENT, V109, P743; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Tiret L, 1998, DEVELOPMENT, V125, P279; Wingate RJT, 1996, DEVELOPMENT, V122, P2143; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	28	121	121	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2168	2171		10.1126/science.284.5423.2168	http://dx.doi.org/10.1126/science.284.5423.2168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381880				2022-12-28	WOS:000081099300049
J	Hoogerwaard, EM; Bakker, E; Ippel, PF; Oosterwijk, JC; Majoor-Krakauer, DF; Leschot, NJ; Van Essen, AJ; Brunner, HG; van der Wouw, PA; Wilde, AAM; de Visser, M				Hoogerwaard, EM; Bakker, E; Ippel, PF; Oosterwijk, JC; Majoor-Krakauer, DF; Leschot, NJ; Van Essen, AJ; Brunner, HG; van der Wouw, PA; Wilde, AAM; de Visser, M			Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in the Netherlands: a cohort study	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MANIFESTING CARRIERS; FEMALE CARRIERS; CARDIOMYOPATHY; INACTIVATION; DIAGNOSIS; GIRLS	Background Carriers of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) may show muscle weakness or dilated cardiomyopathy. Studies focusing on skeletal-muscle involvement were done before DNA analysis was possible. We undertook a cross-sectional study in a population of definite carriers to estimate the proportion and to assess the clinical profile of carriers with symptoms. We also assessed a possible correlation between genotype and phenotype. Methods Carriers of DMD and BMD, aged 18-60 years, were traced through the files of the central register kept at the Department of Human Genetics in Leiden, Netherlands. For each carrier who agreed to participate a medical history was taken, and muscle-strength assessment by hand-held dynamometry and manual muscle testing and cardiological assessment were done. Findings 129 carriers of muscular dystrophy (85 DMD, 44 BMD) participated in the study. In 90 women from 52 (70%) families, 37 different mutations were found. 28 (22%) women had symptoms. 22 (17%) had muscle weakness, varying from mild to moderately severe, Muscle weakness was found in carriers of DMD and BMD, but dilated cardiomyopathy was found only in seven (8%) carriers of DMD, of whom one had concomitant muscle weakness. There was an unexpectedly high proportion of left-ventricle dilation (18%). No genotype-phenotype correlation was found. Interpretation Clinical manifestation of muscle weakness, dilated cardiomyopathy, or both can be found in about a fifth of carriers of DMD and BMD. If left-ventricle dilation is taken into account, the proportion of carriers with symptoms is even higher, amounting to 40%.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Univ Utrecht, Dept Human Genet, Utrecht, Netherlands; Univ Rotterdam, Dept Human Genet, Rotterdam, Netherlands; Univ Groningen, Dept Human Genet, Groningen, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Utrecht University; Erasmus University Rotterdam; University of Groningen; Radboud University Nijmegen	Hoogerwaard, EM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Brunner, Han/C-9928-2013; Majoor-Krakauer, Danielle/AAC-3939-2020; Bakker, Egbert/D-3525-2009; Oosterwijk, Jan C./G-5770-2011	Bakker, Egbert/0000-0002-2843-7357; 				ABBADI N, 1994, AM J MED GENET, V52, P198, DOI 10.1002/ajmg.1320520215; AZOFEIFA J, 1995, HUM GENET, V96, P167, DOI 10.1007/BF00207374; BAKKER E, 1986, J MED GENET, V23, P573, DOI 10.1136/jmg.23.6.573; BEGGS AH, 1990, HUM GENET, V86, P45; BOYD Y, 1986, J MED GENET, V23, P484, DOI 10.1136/jmg.23.6.484; BUSHBY KMD, 1993, NEUROMUSCULAR DISORD, V3, P57, DOI 10.1016/0960-8966(93)90042-I; CARLQUIST JF, 1991, CIRCULATION, V83, P515, DOI 10.1161/01.CIR.83.2.515; CHAMBERLAIN JS, 1992, JAMA-J AM MED ASSOC, V267, P2609; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COMI LI, 1992, INT J CARDIOL, V34, P297, DOI 10.1016/0167-5273(92)90028-2; EMERY AEH, 1969, BMJ-BRIT MED J, V2, P418, DOI 10.1136/bmj.2.5654.418; FEIGENBAUM H, 1994, ECHOCARDIOGR-J CARD, P658; FROUHAR ZR, 1975, AM J HUM GENET, V27, P37; GLASS IA, 1992, J MED GENET, V29, P578, DOI 10.1136/jmg.29.8.578; HAGINOYA K, 1991, J NEUROL, V238, P375, DOI 10.1007/BF00319855; HORDER M, 1991, EUR J CLIN CHEM CLIN, V29, P435; IONASESCU VV, 1989, ACTA NEUROL SCAND, V79, P500, DOI 10.1111/j.1600-0404.1989.tb03821.x; MATTHEWS PM, 1995, NEUROMUSCULAR DISORD, V5, P209, DOI 10.1016/0960-8966(94)00057-G; MIRABELLA M, 1993, NEUROLOGY, V43, P2342, DOI 10.1212/WNL.43.11.2342; MOSER H, 1974, CLIN GENET, V5, P271; MOSER H, 1971, HUMANGENETIK, V11, P328, DOI 10.1007/BF00278661; *MRC, 1986, AIDS INV PER NERV SY; NORMAN A, 1989, CLIN GENET, V36, P31; PENN AS, 1970, NEUROLOGY, V20, P147, DOI 10.1212/WNL.20.2.147; PERLOFF JK, 1967, AM J MED, V42, P179, DOI 10.1016/0002-9343(67)90017-4; Politano L, 1996, JAMA-J AM MED ASSOC, V275, P1335, DOI 10.1001/jama.275.17.1335; REDDY BK, 1984, HUM GENET, V67, P460, DOI 10.1007/BF00291412; RICHARDS CS, 1990, AM J HUM GENET, V46, P672; SCHMIDTACHERT M, 1992, LANCET, V340, P1235, DOI 10.1016/0140-6736(92)92942-9; SEWRY CA, 1993, NEUROMUSCULAR DISORD, V3, P141, DOI 10.1016/0960-8966(93)90006-6; VANDERPLOEG RJO, 1991, J NEUROL NEUROSUR PS, V54, P244, DOI 10.1136/jnnp.54.3.244; vanEssen AJ, 1997, J MED GENET, V34, P805, DOI 10.1136/jmg.34.10.805; YOSHIOKA M, 1981, CLIN GENET, V20, P6	33	156	165	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2116	2119		10.1016/S0140-6736(98)10028-4	http://dx.doi.org/10.1016/S0140-6736(98)10028-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382696				2022-12-28	WOS:000080969300012
J	Goodman, SN				Goodman, SN			Toward evidence-based medical statistics. 1: The P value fallacy	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; CONFIDENCE-INTERVALS; MULTIPLE COMPARISONS; JOURNALS; TESTS; HYPOTHESES; INFERENCE; TRENDS; FUTURE; DEBATE		Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Goodman, SN (corresponding author), Johns Hopkins Univ, Sch Med, 550 N Broadway,Suite 409, Baltimore, MD 21205 USA.	sgoodman@jhu.edu		Goodman, Steven/0000-0002-3872-5723				ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P129, DOI 10.1001/jama.272.2.129; ALTMAN DG, 1991, J R STAT SOC A STAT, V154, P223, DOI 10.2307/2983040; ANSCOMBE FJ, 1963, J AM STAT ASSOC, V58, P365, DOI 10.2307/2283272; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Barnett ML, 1997, J DENT RES, V76, P534, DOI 10.1177/00220345970760010201; BARNETT V, 1982, COMP STAT INFERENCE; BEGG CB, 1990, BIOMETRIKA, V77, P467; Berger J.O., 1985, P BERKELEY C HONOR J, P15; Berkson J, 1942, J AM STAT ASSOC, V37, P325, DOI 10.2307/2279000; BERRY G, 1986, MED J AUSTRALIA, V144, P618, DOI 10.5694/j.1326-5377.1986.tb112339.x; BORAK J, 1982, SOC SCI MED, V16, P1939, DOI 10.1016/0277-9536(82)90393-8; BRAITMAN LE, 1988, ANN INTERN MED, V108, P296, DOI 10.7326/0003-4819-108-2-296; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; Carnap R., 1950, LOGICAL FDN PROBABIL; Carroll L, 1996, AM J CARDIOL, V78, P608, DOI 10.1016/S0002-9149(96)90531-7; Chia KS, 1997, SCAND J WORK ENV HEA, V23, P152, DOI 10.5271/sjweh.193; Clarke M, 1998, JAMA-J AM MED ASSOC, V280, P280, DOI 10.1001/jama.280.3.280; Colton T, 1974, STAT MED; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CORNFIELD J, 1966, AM STAT, V20, P18, DOI 10.2307/2682711; CORNFIELD J, 1969, BIOMETRICS, V25, P617, DOI 10.2307/2528565; COX DR, 1982, BRIT J CLIN PHARMACO, V14, P325, DOI 10.1111/j.1365-2125.1982.tb01987.x; Cox DR, 1974, THEORETICAL STAT; DAR R, 1994, J CONSULT CLIN PSYCH, V62, P75, DOI 10.1037/0022-006X.62.1.75; DIAMOND GA, 1983, ANN INTERN MED, V98, P385, DOI 10.7326/0003-4819-98-3-385; DUPONT WD, 1983, CONTROL CLIN TRIALS, V4, P3, DOI 10.1016/S0197-2456(83)80003-8; EDWARDS AWF, 1972, LIKELIHOOD; ETZIONI RD, 1995, ANNU REV PUBL HEALTH, V16, P23; EVANS SJW, 1988, BRIT HEART J, V60, P177; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Feinstein AR, 1998, J CLIN EPIDEMIOL, V51, P355, DOI 10.1016/S0895-4356(97)00295-3; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; Fisher LD, 1999, CONTROL CLIN TRIALS, V20, P1, DOI 10.1016/S0197-2456(98)00052-X; Fisher LD, 1999, CONTROL CLIN TRIALS, V20, P16, DOI 10.1016/S0197-2456(98)00054-3; Fisher R.A., 1958, STAT METHODS RES WOR; Fisher Ronald A., 1973, STAT METHODS SCI INF; Freedman L, 1996, BMJ-BRIT MED J, V313, P569; FREEMAN PR, 1993, STAT MED, V12, P1443, DOI 10.1002/sim.4780121510; Gigerenzer G., 1989, EMPIRE CHANCE; Goodman SN, 1998, AM J EPIDEMIOL, V147, P807, DOI 10.1093/oxfordjournals.aje.a009531; GOODMAN SN, 1988, AM J PUBLIC HEALTH, V78, P1568, DOI 10.2105/AJPH.78.12.1568; GOODMAN SN, 1993, AM J EPIDEMIOL, V137, P485, DOI 10.1093/oxfordjournals.aje.a116700; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; GREENLAND S, 1991, EPIDEMIOLOGY, V2, P387, DOI 10.1097/00001648-199109000-00015; Hacking Ian, 1975, EMERGENCE PROBABILIT; HAYDEN GF, 1983, PEDIATRICS, V72, P84; KADANE JB, 1995, CONTROL CLIN TRIALS, V16, P313, DOI 10.1016/0197-2456(95)00072-0; Lang JM, 1998, EPIDEMIOLOGY, V9, P7, DOI 10.1097/00001648-199805000-00019; LEHMANN EL, 1993, J AM STAT ASSOC, V88, P1242; Lilford RJ, 1996, BRIT MED J, V313, P603; LUDBROOK J, 1994, AUST NZ J SURG, V64, P630, DOI 10.1111/j.1445-2197.1994.tb02308.x; MAINLAND D, 1963, CLIN PHARMACOL THER, V4, P580; MAINLAND D, 1984, BMJ-BRIT MED J, V288, P841, DOI 10.1136/bmj.288.6420.841; MAINLAND D, 1984, BMJ-BRIT MED J, V288, P920, DOI 10.1136/bmj.288.6421.920; Marks H., 1997, PROGR EXPT SCI THERA; Matthews JR., 1995, QUANTIFICATION QUEST, DOI 10.1515/9781400821808; McKenzie R, 1998, JAMA-J AM MED ASSOC, V280, P1061, DOI 10.1001/jama.280.12.1061; Morrison D.E., 1970, SIGNIFICANCE TEST CO; Moye LA, 1999, CONTROL CLIN TRIALS, V20, P40, DOI 10.1016/S0197-2456(98)00051-8; Neyman J, 1933, PHILOS T R SOC LOND, V231, P289, DOI 10.1098/rsta.1933.0009; Oakes M. W., 1986, STAT INFERENCE COMME; PEARSON ES, 1962, ANN MATH STAT, V33, P394, DOI 10.1214/aoms/1177704566; PEARSON ES, 1938, BIOMETRIKA, V30, P210, DOI DOI 10.2307/2332648; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; POOLE C, 1987, AM J PUBLIC HEALTH, V77, P195, DOI 10.2105/AJPH.77.2.195; Porter Theodore, 1996, TRUST NUMBERS PURSUI, DOI DOI 10.1515/9781400821617; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; Royall R, 1997, MONOGRAPHS STAT APPL, V71; ROZEBOOM WW, 1960, PSYCHOL BULL, V57, P416, DOI 10.1037/h0042040; Salmon WC., 1966, FDN SCI INFERENCE; SALSBURG DS, 1985, AM STAT, V39, P220, DOI 10.2307/2683942; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; SAVITZ DA, 1993, REPROD TOXICOL, V7, P95, DOI 10.1016/0890-6238(93)90242-Y; Seidenfeld T., 1979, PHILOS PROBLEMS STAT; SIMON R, 1994, BRIT J CANCER, V69, P979, DOI 10.1038/bjc.1994.192; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SKELLAM JG, 1969, BIOMETRICS, V25, P457, DOI 10.2307/2528899; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; Stigler, 1986, HIST STAT MEASUREMEN; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; THOMAS DC, 1985, AM J EPIDEMIOL, V122, P1080, DOI 10.1093/oxfordjournals.aje.a114189; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011; Urbach P., 1993, SCI REASONING BAYESI, V2; WULFF HR, 1987, STAT MED, V6, P3, DOI 10.1002/sim.4780060103; [No title captured]; [No title captured]; [No title captured]; [No title captured]	89	1033	1051	0	86	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					995	1004		10.7326/0003-4819-130-12-199906150-00008	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	206TE	10383371				2022-12-28	WOS:000080894700007
J	Oransky, I				Oransky, I			Disarming life's invisible enemies: Mikhail Bulgakov's A Country Doctor's Notebook	LANCET			English	Editorial Material									Yale New Haven Hosp, New Haven, CT 06511 USA	Yale University	Oransky, I (corresponding author), Yale New Haven Hosp, 877 Orange St, New Haven, CT 06511 USA.		Oransky, Ivan/J-9412-2019	Oransky, Ivan/0000-0002-0746-9288				BULGAKOV M, 1995, COUNTRY DOCTORS NOTE; CURTIS JAE, 1984, BULGAKOV LIFE WORK, P3; CURTIS JAE, 1991, MANUSCRIPTS BURN M B, P7; GLENNY M, 1995, COUNTRY DOCTORS NOTE, P9; Milne Lesley, 1990, M BULGAKOV CRITICAL, p[128, 228]; Proffer Ellendea, 1984, BULGAKOV LIFE WORK, P92; SAHNI KA, 1984, MIND FERMENT M BULGA, P45	7	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2059	2061		10.1016/S0140-6736(98)08180-X	http://dx.doi.org/10.1016/S0140-6736(98)08180-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376633				2022-12-28	WOS:000080812200041
J	Gustafsson, JA				Gustafsson, JA			Biochemistry - Seeking ligands for lonely orphan receptors	SCIENCE			English	Editorial Material							BILE-ACID SYNTHESIS; NUCLEAR RECEPTOR; IDENTIFICATION; PATHWAYS		Karolinska Inst, NOVUM Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden; Karolinska Inst, NOVUM Huddinge Hosp, Dept Biosci, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Gustafsson, JA (corresponding author), Karolinska Inst, NOVUM Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden.	jan-ake.gustafsson@mednut.ki.se						Bergstrom S, 1963, Biochem Soc Symp, V24, P63; Clarke ND, 1998, SCIENCE, V282, P2018, DOI 10.1126/science.282.5396.2018; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GUSTAFSSON BE, 1981, LIPIDS, V16, P228, DOI 10.1007/BF02535021; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; WANG H, IN PRESS MOL CELL	14	35	38	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1285	1286		10.1126/science.284.5418.1285	http://dx.doi.org/10.1126/science.284.5418.1285			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383308				2022-12-28	WOS:000080430600030
J	O'Conor, R				O'Conor, R			Organisational and cultural aspects are also important - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Pinderfields Hosp, Clin Audit Dept, Wakefield WF1 4DG, England	Pinderfields Hospital	O'Conor, R (corresponding author), Pinderfields Hosp, Clin Audit Dept, Wakefield WF1 4DG, England.							Anderson R, 1996, SECURITY CLIN INFORM; *DEP HLTH, 1998, INF HLTH; Department of Health, 1997, REP REV PAT ID INF C	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1331	1331						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10383209				2022-12-28	WOS:000080418400032
J	Graham, A; Fahey, T				Graham, A; Fahey, T			Evidence based case report - Sore throat: diagnostic and therapeutic dilemmas	BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCAL PHARYNGITIS; PRESCRIBING STRATEGIES; RANDOMIZED TRIAL; ANTIBIOTICS; MANAGEMENT; PENICILLIN		Univ Bristol, Div Primary Hlth Care, Bristol BS8 2PR, Avon, England	University of Bristol	Graham, A (corresponding author), Univ Bristol, Div Primary Hlth Care, Canynge Hall, Bristol BS8 2PR, Avon, England.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783				Bisno AL, 1997, CLIN INFECT DIS, V25, P574, DOI 10.1086/513768; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; DELMAR C, 1992, MED J AUSTRALIA, V156, P572, DOI 10.5694/j.1326-5377.1992.tb121422.x; DELMAR G, 1998, COCHRANE COLLABORATI; Kai J, 1996, BRIT MED J, V313, P987; KORNAROFF A, 1991, DIAGNOSTIC STRATEGIE, P186; Little P, 1996, FAM PRACT, V13, P317, DOI 10.1093/fampra/13.3.317; Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; PICHICHERO ME, 1987, PEDIATR INFECT DIS J, V6, P635, DOI 10.1097/00006454-198707000-00004; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES; VALKENBURG HA, 1971, J INFECT DIS, V124, P348, DOI 10.1093/infdis/124.4.348; 1995, DRUGS THER B, V33, P9	13	15	16	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					173	174		10.1136/bmj.319.7203.173	http://dx.doi.org/10.1136/bmj.319.7203.173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406759	Green Published			2022-12-28	WOS:000081619300029
J	Grant, IS; Andrews, PJD				Grant, IS; Andrews, PJD			ABC of intensive care - Neurological support	BRITISH MEDICAL JOURNAL			English	Article									Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Grant, IS (corresponding author), Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.								0	6	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					110	113		10.1136/bmj.319.7202.110	http://dx.doi.org/10.1136/bmj.319.7202.110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398640	Green Published			2022-12-28	WOS:000081438200039
J	Day, R; Forbes, A				Day, R; Forbes, A			Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease	LANCET			English	Article							FIBROBLAST GROWTH-FACTOR; GASTRODUODENAL ULCERS; ULCERATIVE-COLITIS; FACTOR BFGF; INHIBITION; ANTICOAGULANT; LOCALIZATION; DEGRADATION; RECEPTOR; BIOLOGY	Tissue repair involves a close interplay between growth factors and cell adhesion molecules. The normal healing process may be disrupted by pathophysiological states such as inflammation, due to loss of growth factors, cell adhesion molecules, or both, which results in a reduced rate of healing. Such events may occur in inflammatory bowel disease during mucosal restitution. We postulate that the beneficial response to heparin observed in Inflammatory bowel disease may result from mechanisms in addition to anticoagulation. These include the restoration of high-affinity receptor binding by antiulcerogenic growth factors, such as basic fibroblast growth factor, that normally rely on the presence of heparan sulphate proteoglycans, such as syndecan-2, as coreceptors. Loss of syndecan-1 has been observed In the ulcerated mucosa of patients with inflammatory bowel disease. This loss may lead to impaired binding of basic fibroblast growth factor and a reduced rate of ulcer healing. We suggest that heparin restores high-affinity receptor binding of basic fibroblast growth, and so increases the rate of mucosal recovery.	St Marks Hosp, Inflammatory Bowel Dis Res Grp, Harrow HA1 3UJ, Middx, England	Imperial College London	Day, R (corresponding author), St Marks Hosp, Inflammatory Bowel Dis Res Grp, Harrow HA1 3UJ, Middx, England.		Day, Richard M/C-5725-2009	Day, Richard/0000-0002-3124-2294; Forbes, Alastair/0000-0001-7416-9843				BEMFIELD M, 1992, ANN REV CELL BIOL, V8, P365; BOBIK A, 1993, PHARMACOL REV, V45, P1; Bousvaros A, 1997, DIGEST DIS SCI, V42, P378, DOI 10.1023/A:1018882322566; BRAZIER F, 1996, GASTROENTEROLOGY, V110, pA872; DAY R, 1997, GUT, V41, P113; DWARAKANATH A, 1995, GUT, V35, P585; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Engelberg H, 1995, CLIN APPL THROMB-HEM, V1, P283, DOI 10.1177/107602969500100407; ERNST H, 1994, EUR J GASTROEN HEPAT, V6, P559, DOI 10.1097/00042737-199406000-00019; EVANS R, 1997, ALIMEN PHARM THER, V1, P1037; FLOWACZNY C, 1997, AM J GASTROENTEROL, V92, P911; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; GAFFNEY PR, 1991, LANCET, V337, P238, DOI 10.1016/0140-6736(91)92201-C; GAFFNEY PR, 1995, AM J GASTROENTEROL, V90, P220; GORRSKI A, J IMMUNOL 2, V150, pPA239; Kainulainen V, 1996, J BIOL CHEM, V271, P18759, DOI 10.1074/jbc.271.31.18759; KAM A, 1975, GASTROENTEROLOGY, V68, P245; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRATZ G, 1997, SCAND J PLAST RECONS, V31, P19; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MARTZ E, 1973, CLIN IMMUNOL IMMUNOP, V1, P533, DOI 10.1016/0090-1229(73)90009-3; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MURCH S, 1993, LANCET, V341, P74; NELSON RM, 1993, BLOOD, V82, P3253; OHTANI H, 1993, LAB INVEST, V68, P520; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; Syngal S, 1996, GASTROENTEROLOGY, V110, pA267; SZABO S, 1995, SCAND J GASTROENTERO, V30, P15, DOI 10.3109/00365529509090262; TEFFERI A, 1989, BLOOD, V74, P252; WOLFE MM, 1994, GASTROENTEROLOGY, V106, pA212; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZAVGORODNY LG, 1982, KLIN MED MOSCOW+, V60, P74	36	86	88	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					62	65		10.1016/S0140-6736(98)09267-8	http://dx.doi.org/10.1016/S0140-6736(98)09267-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406379				2022-12-28	WOS:000081243200041
J	Nobbenhuis, MAE; Walboomers, JMM; Helmerhorst, TJM; Rozendaal, L; Remmink, AJ; Risse, EKJ; van der Linden, HC; Voorhorst, FJ; Kenemans, P; Meijer, CJLM				Nobbenhuis, MAE; Walboomers, JMM; Helmerhorst, TJM; Rozendaal, L; Remmink, AJ; Risse, EKJ; van der Linden, HC; Voorhorst, FJ; Kenemans, P; Meijer, CJLM			Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; HIGH-RISK; INFECTION; GENOTYPES; WOMEN; CIN	Background A relation has been established between infection with high-risk types of human papillomavirus and development of cervical cancer. We investigated a role for testing for human papillomavirus as part of cervical-cancer screening. Methods We monitored by cytology, colposcopy, and testing for high-risk human papillomavirus 353 women referred to gynaecologists with mild to moderate and severe dyskaryosis. The median follow-up time was 33 months. At the last visit we took biopsy samples. Our primary endpoint was clinical progression, defined as cervical intraepithelial neoplasia (CIN) 3, covering three or more cervical quadrants on colposcopy, or a cervical-smear result of suspected cervical cancer. Findings 33 women reached clinical progression. All had persistent infection with high-risk human papillomavirus. The cumulative 6-year incidence of clinical progression among these women was 40% (95% CI 21-59). in women with end histology CIN 3, 98 (95%) of 103 had persistent infection with high-risk human papillomavirus from baseline. Among women with mild to moderate dyskaryosis at baseline, a second test for human papillomavirus at 6 months predicted end histology CIN 3 better than a second cervical smear. Interpretation Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of CIN 3. All women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dyskaryosis should be referred only after a second positive test for high-risk human papillomavirus at 6 months.	Univ Hosp Vrije Univ, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Obstet & Gynaecol, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands; Univ Rotterdam Hosp, Dept Obstet & Gynecol, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC	Meijer, CJLM (corresponding author), Univ Hosp Vrije Univ, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.							Anderson MC, 1995, HAINES TAYLOR OBSTET, P292; BAUER HM, 1993, SEX TRANSM DIS, V20, P274, DOI 10.1097/00007435-199309000-00007; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; HELMERHORST TJM, 1987, EUR J OBSTET GYN R B, V24, P221, DOI 10.1016/0028-2243(87)90021-9; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hopman E H, 1998, Obstet Gynecol Surv, V53, P97, DOI 10.1097/00006254-199802000-00021; HOPMAN EH, 1995, GYNECOL ONCOL, V58, P206, DOI 10.1006/gyno.1995.1212; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; KATAJA V, 1992, SEX TRANSM DIS, V19, P154, DOI 10.1097/00007435-199205000-00009; Kjaer SK, 1996, INT J CANCER, V65, P601, DOI 10.1002/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Meijer CJLM, 1998, HISTOPATHOLOGY, V33, P83, DOI 10.1046/j.1365-2559.1998.00436.x; Meijer CJLM, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P338; NGEANGEL C, 1998, J NATL CANCER I, V90, P43; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; Syrjanen KJ, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P93; VANDERGRAAF Y, 1988, J CLIN EPIDEMIOL, V41, P21, DOI 10.1016/0895-4356(88)90005-4; Vooijs G P, 1987, Ned Tijdschr Geneeskd, V131, P1662; WALBOOMERS JMM, 1999, IN PRESS J PATHOL; WALBOOMERS JMM, 1997, HUMAN PAPILLOMAVIRUS, P341; Wright TC, 1995, BLAUSTEINS PATHOLOGY, P248	30	510	543	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					20	25		10.1016/S0140-6736(98)12490-X	http://dx.doi.org/10.1016/S0140-6736(98)12490-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406360				2022-12-28	WOS:000081243200009
J	Urban, BC; Ferguson, DJP; Pain, A; Willcox, N; Plebanski, M; Austyn, JM; Roberts, DJ				Urban, BC; Ferguson, DJP; Pain, A; Willcox, N; Plebanski, M; Austyn, JM; Roberts, DJ			Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells	NATURE			English	Article							MALARIA-PARASITIZED ERYTHROCYTES; ANTIGENIC VARIATION; RECEPTOR; CYTOADHERENCE; SEQUESTRATION; ASSOCIATION; PHENOTYPES; IMMUNITY; ADHESION; INVITRO	The malaria parasite Plasmodium falciparum is one of the most successful human pathogens. Specific virulence factors remain poorly defined, although the adhesion of infected erythrocytes to the venular endothelium has been associated with some of the syndromes of severe disease(1). Immune responses cannot prevent the development of symptomatic infections throughout life, and clinical immunity to the disease develops only slowly during childhood. An understanding of the obstacles to the development of protective immunity is crucial for developing rational approaches to prevent the disease. Here we show that intact malaria-infected erythrocytes adhere to dendritic cells, inhibit the maturation of dendritic cells and subsequently reduce their capacity to stimulate T cells. These data demonstrate both a novel mechanism by which malaria parasites induce immune dysregulation and a functional role beyond endothelial adhesion for the adhesive phenotypes expressed at the surface of infected erythrocytes.	John Radcliffe Hosp, Oxford Ctr, Inst Mol Med, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Nuffield Dept Pathol, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Mol Immunol Grp, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Nuffield Dept Surg, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Natl Blood Serv, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford	Roberts, DJ (corresponding author), John Radcliffe Hosp, Oxford Ctr, Inst Mol Med, Oxford OX3 9DU, England.		Plebanski, Magdalena/AAU-3144-2021; Pain, Arnab/L-5766-2015; Urban, Britta/W-6087-2018	Pain, Arnab/0000-0002-1755-2819; Urban, Britta/0000-0002-4197-8393; Ferguson, David/0000-0001-5045-819X; , Magdalena/0000-0001-6889-3667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Austyn J M, 1998, Curr Opin Hematol, V5, P3, DOI 10.1097/00062752-199801000-00002; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; Brown K.N., 1993, Parassitologia (Rome), V35, P13; Coppel R L, 1998, Curr Opin Hematol, V5, P132; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P340, DOI 10.1016/0035-9203(80)90095-4; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOWARD RJ, 1984, CONTEMP TOP IMMUNOBI, V12, P127; HOWARD RJ, 1983, P NATL ACAD SCI-BIOL, V80, P4129, DOI 10.1073/pnas.80.13.4129; LANGRETH SG, 1985, INFECT IMMUN, V47, P760, DOI 10.1128/IAI.47.3.760-766.1985; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; Nagvekar N, 1998, J CLIN INVEST, V101, P2268, DOI 10.1172/JCI2068; Newbold C, 1997, AM J TROP MED HYG, V57, P389, DOI 10.4269/ajtmh.1997.57.389; PLEBANSKI M, 1992, IMMUNOLOGY, V75, P86; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHWARZER E, 1994, BRIT J HAEMATOL, V88, P740, DOI 10.1111/j.1365-2141.1994.tb05112.x; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0; WALSH DS, 1995, CLIN IMMUNOL IMMUNOP, V77, P89, DOI 10.1016/0090-1229(95)90141-8; WILLIAMSON WA, 1978, LANCET, V1, P1328; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	30	470	488	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					73	77		10.1038/21900	http://dx.doi.org/10.1038/21900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403251				2022-12-28	WOS:000081255700053
J	Simon, JA; Hudes, ES				Simon, JA; Hudes, ES			Relationship of ascorbic acid to blood lead levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-C	Context Some animal studies suggest that orally administered ascorbic acid may chelate lead and decrease the risk of the toxic effects of lead. However, results from. several small studies in humans have yielded inconclusive evidence of a beneficial effect of ascorbic acid on lead toxicity. Objective To examine the relationship between serum ascorbic acid levels and prevalence of elevated blood lead levels. Design, Setting, and Participants Cross-sectional analysis of a probability sample of the US population enrolled in the Third National Health and Nutrition Examination Survey, 1988-1994 (4213 youths aged 6-16 years and 15 365 adults aged greater than or equal to 17 years) without a history of lead poisoning. Main Outcome Measures Elevated and log blood lead levels by serum ascorbic acid level. Results A total of 22 youths (0.5%) and 57 adults (0.4%) had elevated blood lead levels (defined as greater than or equal to 0.72 mu mol/L [15 mu g/dL]) and greater than or equal to 0.97 mu mol/L [20 mu g/dL], respectively). After controlling for the effects of age, race, sex, income level, and dietary energy, fat, calcium, iron, and zinc intake, youths in the highest serum ascorbic acid tertile had an 89% decreased prevalence of elevated blood lead levels compared with youths in the lowest serum ascorbic acid tertile (odds ratio, 0.11; 95% confidence interval, 0.04-0.35; P for trend =.002), Adults in the highest 2 serum ascorbic acid tertiles had a 65% to 68% decreased prevalence of elevated blood lead levels compared with adults in the lowest serum ascorbic acid tertile (P for trend =.03). As a continuous predictor, serum ascorbic acid level was independently associated with decreased log blood lead levels among adults (P<.001), but not among youths (P=.14). Conclusions Our data suggest that high serum levels of ascorbic acid are independently associated with a decreased prevalence of elevated blood lead levels. If these associations are related causally, ascorbic acid intake may have public health implications for control of lead toxicity.	San Francisco VA Med Ctr, Med Serv, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Simon, JA (corresponding author), San Francisco VA Med Ctr, Med Serv, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	jasimon@itsa.ucsf.edu			NHLBI NIH HHS [HL53479] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, VITAL HLTH STAT, V1, P1; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; CALABRESE EJ, 1987, ANN NY ACAD SCI, V498, P347, DOI 10.1111/j.1749-6632.1987.tb23773.x; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DAWSON EB, 1997, J AM COLL NUTR, V16, P480; FLANAGAN PR, 1982, AM J CLIN NUTR, V36, P823, DOI 10.1093/ajcn/36.5.823; GEY KF, 1994, BIBL NUTR DIET, P84; GOYER RA, 1979, LIFE SCI, V24, P433, DOI 10.1016/0024-3205(79)90215-7; Gunter EW, 1996, LAB PROCEDURES USED; Holmes HN, 1939, J LAB CLIN MED, V24, P1119; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACOB RA, 1992, J NUTR, V122, P1111, DOI 10.1093/jn/122.5.1111; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; LAUWERYS R, 1983, J OCCUP ENVIRON MED, V25, P668, DOI 10.1097/00043764-198309000-00015; MARCHMONTROBINS.SW, 1940, J LAB CLIN MED, V26, P1478; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; SASIENI P, 1995, STATA TECHNICAL B, V24; SASIENI P, 1998, STATA TECHNICAL B, V41; SIMON JA, 1992, J AM COLL NUTR, V11, P107; SOHLER A, 1977, J ORTHOMOL MED, V6, P272; *STATA STAT SOFTW, 1996, REL 5 0; SUZUKI T, 1979, J NUTR, V109, P1974, DOI 10.1093/jn/109.11.1974; SUZUKI T, 1979, J NUTR, V109, P982, DOI 10.1093/jn/109.6.982; Tukey J. W., 1977, EXPLORATORY DATA ANA; U.S. Department of Health and Human Services Public Health Service Agency for Toxic Substances and Disease Registry, 1988, NAT EXT LEAD POIS CH; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV	26	83	91	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2289	2293		10.1001/jama.281.24.2289	http://dx.doi.org/10.1001/jama.281.24.2289			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386552				2022-12-28	WOS:000080925600027
J	Gulbis, JM; Mann, S; MacKinnon, R				Gulbis, JM; Mann, S; MacKinnon, R			Structure of a voltage-dependent K+ channel beta subunit	CELL			English	Article							KETO REDUCTASE SUPERFAMILY; HUMAN ALDOSE REDUCTASE; 3-ALPHA-HYDROXYSTEROID DIHYDRODIOL DEHYDROGENASE; SHAKER POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; SEQUENCE ALIGNMENTS; ALDEHYDE REDUCTASE; BOVINE BRAIN; INACTIVATION; EXPRESSION	The integral membrane subunits of many voltage-dependent potassium channels are associated with an additional protein known as the beta subunit. One function of beta subunits is to modify K+ channel gating. We have determined the structure of the conserved core of mammalian beta subunits by X-ray crystallography at 2.8 Angstrom resolution. Like the integral membrane component of K+ channels, beta subunits form a fourfold symmetric structure. Each subunit is an oxidoreductase enzyme complete with a nicotinamide cofactor in its active site. Several structural features of the enzyme active site, including its location with respect to the four-fold axis, imply that it may interact directly or indirectly with the K+ channel's voltage sensor. This structure suggests a mechanism for coupling membrane electrical excitability directly to chemistry of the cell.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BENNER SA, 1982, EXPERIENTIA, V38, P633, DOI 10.1007/BF02327092; Bennett MJ, 1997, STRUCTURE, V5, P799, DOI 10.1016/S0969-2126(97)00234-7; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; Branden C., 1999, INTRO PROTEIN STRUCT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELKABBANI O, 1995, NAT STRUCT BIOL, V2, P687, DOI 10.1038/nsb0895-687; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Hille B., 1992, IONIC CHANNELS EXCIT; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN WD, 1969, GENETICS, V61, P399; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Tang HX, 1996, PLANT CELL, V8, P1545, DOI 10.1105/tpc.8.9.1545; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728	45	239	245	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					943	952		10.1016/S0092-8674(00)80805-3	http://dx.doi.org/10.1016/S0092-8674(00)80805-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399921	Bronze			2022-12-28	WOS:000081162800014
J	Tyson, JE; Wright, LL; Oh, WOM; Kennedy, KA; Mele, L; Ehrenkranz, RA; Stoll, BJ; Lemons, JA; Stevenson, DK; Bauer, CR; Korones, SB; Fanaroff, AA				Tyson, JE; Wright, LL; Oh, WOM; Kennedy, KA; Mele, L; Ehrenkranz, RA; Stoll, BJ; Lemons, JA; Stevenson, DK; Bauer, CR; Korones, SB; Fanaroff, AA		Natl Inst Child Hlth Human Dev Neonatal Res Net	Vitamin A supplementation for extremely-low-birth-weight infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING PROTEIN RESPONSE; BRONCHOPULMONARY DYSPLASIA; A SUPPLEMENTATION; PREMATURE-INFANTS; SERUM RETINOL; TRIAL; CAROTENOIDS; LIVER; PREVENTION; MORTALITY	Background Vitamin A supplementation may reduce the risk of chronic lung disease and sepsis in extremely-low-birth-weight infants. The results of our pilot study suggested that a dose of 5000 IU administered intramuscularly three times per week for four weeks was more effective than the lower doses given in past trials. Methods We performed a multicenter, blinded, randomized trial to assess the effectiveness and safety of this regimen as compared with sham treatment in 807 infants in need of respiratory support 24 hours after birth. The mean birth weight was 770 g in the vitamin A group and 769 g in the control group, and the respective gestational ages were 26.8 and 26.7 weeks. Results By 36 weeks' postmenstrual age, 59 of the 405 infants (15 percent) in the vitamin A group and 55 of the 402 infants (14 percent) in the control group had died. The primary outcome - death or chronic lung disease at 36 weeks' postmenstrual age - occurred in significantly fewer infants in the vitamin A group than in the control group (55 percent vs. 62 percent; relative risk, 0.89; 95 percent confidence interval, 0.80 to 0.99). Overall, 1 additional infant survived without chronic lung disease for every 14 to 15 infants who received vitamin A supplements. The proportions of infants in the vitamin A group and the control group who had signs of potential vitamin A toxicity were similar. The proportion of infants with serum retinol values below 20 mu g per deciliter (0.70 mu mol per liter) was lower in the vitamin A group than in the control group (25 percent vs. 54 percent, P<0.001). Conclusions Intramuscular administration of 5000 IU of vitamin A three times per week for four weeks reduced biochemical evidence of vitamin A deficiency and slightly decreased the risk of chronic lung disease in extremely-low-birth-weight infants. (N Engl J Med 1999;340:1962-8.) (C) 1999, Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Houston, TX 77030 USA; NICHHD, Bethesda, MD 20892 USA; Brown Univ, Women & Infants Hosp, Providence, RI USA; George Washington Univ, Ctr Biostat, Rockville, MD USA; Yale Univ, New Haven, CT USA; Emory Univ, Atlanta, GA 30322 USA; Indiana Univ, Indianapolis, IN 46204 USA; Stanford Univ, Stanford, CA 94305 USA; Univ Miami, Miami, FL 33152 USA; Univ Tennessee, Memphis, TN USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Brown University; Women & Infants Hospital Rhode Island; George Washington University; Yale University; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; Stanford University; University of Miami; University of Tennessee System; University of Tennessee Health Science Center; Case Western Reserve University	Tyson, JE (corresponding author), Univ Texas, SW Med Ctr, 6431 Fannin,Suite 3-228, Houston, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027904, U10HD021373] Funding Source: NIH RePORTER; NICHD NIH HHS [U10 HD19897, U10 HD21373, U10 HD27904] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGOESTINA T, 1994, B WORLD HEALTH ORGAN, V72, P859; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BAUERNFEIND JC, 1986, VITAMIN A DEFICIENCY, P115; BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358; Bental RY., 1994, S AFRICAN J FOOD SCI, V6, P141; CHALMERS I, 1989, EFFECTIVE CARE PREGN, V2, P1295; DARLOW B, 1998, NEONATAL MODULE COCH; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; FLORES H, 1984, AM J CLIN NUTR, V40, P1281, DOI 10.1093/ajcn/40.6.1281; GEORGIEFF MK, 1989, J PEDIATR-US, V114, P301, DOI 10.1016/S0022-3476(89)80801-7; GEORGIEFF MK, 1991, J PEDIATR GASTR NUTR, V13, P376, DOI 10.1097/00005176-199111000-00007; GREENE HL, 1987, PEDIATRICS, V79, P894; Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1; Kennedy KA, 1997, EARLY HUM DEV, V49, P19, DOI 10.1016/S0378-3782(97)01869-0; KENNEDY KA, 1993, SEMIN PERINATOL, V17, P247; KORNER WF, 1975, INT J VITAM NUTR RES, V45, P363; Massaro GD, 1996, AM J PHYSIOL-LUNG C, V270, pL305, DOI 10.1152/ajplung.1996.270.2.L305; MUPANEMUNDA RH, 1994, EARLY HUM DEV, V38, P45, DOI 10.1016/0378-3782(94)90049-3; OLSON JA, 1984, J NATL CANCER I, V73, P1439; OLSON JA, 1996, VITAMIN A DEFICIENCY, P226; Palta M, 1998, J PEDIATR-US, V132, P57, DOI 10.1016/S0022-3476(98)70485-8; PAPAGAROUFALIS C, 1991, J PERINAT MED, V19, P382; PAPAGAROUFALIS C, 1988, Pediatric Research, V23, p518A; PEARSON E, 1992, J PEDIATR-US, V121, P420, DOI 10.1016/S0022-3476(05)81800-1; RUSH MG, 1994, J PEDIATR-US, V125, P458, DOI 10.1016/S0022-3476(05)83295-0; Sackett DL, 1996, EVIDENCE BASED MED, V1, P37; SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613; SHENAI JP, 1985, PEDIATR RES, V19, P892, DOI 10.1203/00006450-198509000-00003; SHENAI JP, 1995, BIOCHEM MOL MED, V54, P67, DOI 10.1006/bmme.1995.1010; SHENAI JP, 1990, J PEDIATR-US, V116, P607, DOI 10.1016/S0022-3476(05)81614-2; SHENAI JP, 1985, PEDIATR RES, V19, P185, DOI 10.1203/00006450-198502000-00007; SHENAI JP, 1987, J PEDIATR-US, V111, P269, DOI 10.1016/S0022-3476(87)80086-0; SHENNAN AT, 1988, PEDIATRICS, V82, P527; STACEWICZSAPUNTZAKIS M, 1987, J MICRONUTR ANAL, V3, P27; TSANG RG, 1988, NUTR INFANCY, P258; WEST KP, 1992, B WORLD HEALTH ORGAN, V70, P733; Zachman RD, 1996, AM J CLIN NUTR, V63, P123, DOI 10.1093/ajcn/63.1.123	37	331	354	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1962	1968		10.1056/NEJM199906243402505	http://dx.doi.org/10.1056/NEJM199906243402505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379020				2022-12-28	WOS:000081088500005
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1959: Severo Ochao (1905-1993) and Arthur Kornberg (born 1918)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.							Raju TNK, 1999, LANCET, V353, P1108, DOI 10.1016/S0140-6736(05)76476-X; 1998, LANCET, V352, P496	2	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2166	2166		10.1016/S0140-6736(05)75613-0	http://dx.doi.org/10.1016/S0140-6736(05)75613-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382736				2022-12-28	WOS:000080969300069
J	Xu, L; Furukawa, S; Middlebrooks, JC				Xu, L; Furukawa, S; Middlebrooks, JC			Auditory cortical responses in the cat to sounds that produce spatial illusions	NATURE			English	Article							HUMAN LISTENERS; SPECTRAL CUES; MEDIAN PLANE; LOCALIZATION; CORTEX	Humans and cats can localize a sound source accurately if its spectrum is fairly broad and flat(1-3), as is typical of most natural sounds. However, if sounds are filtered to reduce the width of the spectrum, they result:in illusions of sources that are very different from the actual locations, particularly in the up/down and front/back dimensions(4-6). Such illusions reveal that the auditory system relies on specific characteristics of sound spectra to obtain cues for localization(7). In the-auditory cortex of cats, temporal firing patterns of neurons can signal the locations of broad-band sounds(8-9). Here we show that such spike patterns systematically mislocalize sounds that have been passed through a narrow-band filter. Both correct and incorrect locations signalled by neurons can be predicted quantitatively by a model of spectral processing that also predicts correct and incorrect localization judgements by human listeners(6). Similar cortical mechanisms, if present in humans, could underlie human auditory spatial perception.	Univ Michigan, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Middlebrooks, JC (corresponding author), Univ Michigan, Kresge Hearing Res Inst, 1301 E Ann St, Ann Arbor, MI 48109 USA.		Xu, Li/C-5908-2008	Xu, Li/0000-0002-0988-7934; Furukawa, Shigeto/0000-0002-5833-7891				BLAUERT J, 1969, ACUSTICA, V22, P205; HEBRANK J, 1974, J ACOUST SOC AM, V56, P1829, DOI 10.1121/1.1903520; Huang AY, 1996, J ACOUST SOC AM, V100, P1070, DOI 10.1121/1.416293; MAKOUS JC, 1990, J ACOUST SOC AM, V87, P2188, DOI 10.1121/1.399186; MIDDLEBROOKS JC, 1990, J ACOUST SOC AM, V87, P2149, DOI 10.1121/1.399183; MIDDLEBROOKS JC, 1992, J ACOUST SOC AM, V92, P2607, DOI 10.1121/1.404400; Middlebrooks JC, 1998, J NEUROPHYSIOL, V80, P863, DOI 10.1152/jn.1998.80.2.863; MIDDLEBROOKS JC, 1991, ANNU REV PSYCHOL, V42, P135, DOI 10.1146/annurev.ps.42.020191.001031; MIDDLEBROOKS JC, IN PRESS J ACOUST SO; NAJAFI K, 1985, IEEE T ELECTRON DEV, V32, P1206, DOI 10.1109/T-ED.1985.22102; Populin LC, 1998, J NEUROSCI, V18, P2147; Xu L, 1998, J NEUROPHYSIOL, V80, P882, DOI 10.1152/jn.1998.80.2.882	12	22	23	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					688	691		10.1038/21424	http://dx.doi.org/10.1038/21424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385120	Green Published			2022-12-28	WOS:000080932800060
J	Trommsdorff, M; Gotthardt, M; Hiesberger, T; Shelton, J; Stockinger, W; Nimpf, J; Hammer, RE; Richardson, JA; Herz, J				Trommsdorff, M; Gotthardt, M; Hiesberger, T; Shelton, J; Stockinger, W; Nimpf, J; Hammer, RE; Richardson, JA; Herz, J			Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-E RECEPTOR-2; REELER-LIKE PHENOTYPE; LAMINAR ORGANIZATION; TARGETED DISRUPTION; ADAPTER PROTEINS; CEREBRAL-CORTEX; MOUSE; GENE; SCRAMBLER	Layering of neurons in the cerebral cortex and cerebellum requires Reelin, an extracellular matrix protein, and mammalian Disabled (mDab1), a cytosolic protein that activates tyrosine kinases. Here, we report the requirement for two other proteins, cell surface receptors termed very low density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 (ApoER2). Both receptors can bind mDab1 on their cytoplasmic tails and are expressed in cortical and cerebellar layers adjacent to layers that express Reelin. mDab1 expression is upregulated in knockout mice that lack both VLDLR and ApoER2. Inversion of cortical layers and absence of cerebellar foliation in these animals precisely mimic the phenotype of mice lacking Reelin or mDab1. These findings suggest that VLDLR and ApoER2 participate in transmitting the extracellular Reelin signal to intracellular signaling processes initiated by mDab1.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	herz@utsw.swmed.edu	Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Nimpf, Johannes/0000-0002-9273-3492; Hammer, Robert E./0000-0001-5487-7551	NHLBI NIH HHS [R37 HL063762, HL20948] Funding Source: Medline; NIA NIH HHS [AG12300] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Gallagher E, 1998, J COMP NEUROL, V402, P238; Goldowitz D, 1997, J NEUROSCI, V17, P8767; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; HOWELL BW, 1999, IN PRESS MOL CELL BI; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Janz R, 1998, J NEUROSCI, V18, P9269; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Komuro H, 1998, J NEUROSCI, V18, P1478; KORNACK DR, 1995, NEURON, V15, P311, DOI 10.1016/0896-6273(95)90036-5; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Miyata T, 1997, J NEUROSCI, V17, P3599; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; NOVAK S, 1996, J BIOL CHEM, V271; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OROURKE NA, 1995, DEVELOPMENT, V121, P2165; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; Rice DS, 1998, DEVELOPMENT, V125, P3719; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305	45	1027	1058	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					689	701		10.1016/S0092-8674(00)80782-5	http://dx.doi.org/10.1016/S0092-8674(00)80782-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380922	Bronze			2022-12-28	WOS:000080886300008
J	Blumstein, DT				Blumstein, DT			Behavior - Selfish sentinels	SCIENCE			English	Editorial Material							VIGILANCE; EVOLUTION		Macquarie Univ, Dept Biol, N Ryde, NSW 2109, Australia; Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia	Macquarie University; Macquarie University	Blumstein, DT (corresponding author), Macquarie Univ, Dept Biol, N Ryde, NSW 2109, Australia.		Blumstein, Daniel T./B-6199-2012	Blumstein, Daniel T./0000-0001-5793-9244				Bednekoff PA, 1998, TRENDS ECOL EVOL, V13, P284, DOI 10.1016/S0169-5347(98)01327-5; Bednekoff PA, 1997, AM NAT, V150, P373, DOI 10.1086/286070; Blumstein DT, 1997, ANIM BEHAV, V53, P173, DOI 10.1006/anbe.1996.0286; Clutton-Brock TH, 1999, SCIENCE, V284, P1640, DOI 10.1126/science.284.5420.1640; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HART BL, 1992, ANIM BEHAV, V44, P1073, DOI 10.1016/S0003-3472(05)80319-7; MCGOWAN KJ, 1989, ANIM BEHAV, V37, P1000, DOI 10.1016/0003-3472(89)90144-9; RASA OAE, 1987, S AFR J SCI, V83, P587; SHERMAN PW, 1977, SCIENCE, V197, P1246, DOI 10.1126/science.197.4310.1246; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; ZAHAVI A, 1990, COOPERATIVE BREEDING	11	8	8	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1633	1634		10.1126/science.284.5420.1633	http://dx.doi.org/10.1126/science.284.5420.1633			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383342				2022-12-28	WOS:000080668300032
J	Roberts, C; Torgerson, DJ				Roberts, C; Torgerson, DJ			Understanding controlled trials - Baseline imbalance in randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS		Univ Manchester, Natl Primary Care Res Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roberts, C (corresponding author), Univ Manchester, Natl Primary Care Res Dev Ctr, Manchester M13 9PL, Lancs, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				ALMAN DG, 1990, LANCET, V335, P149; Altman DG, 1996, BRIT MED J, V313, P570; ALTMAN DG, 1985, STATISTICIAN, V34, P125; Kennedy A, 1997, CONTROL CLIN TRIA S3, V18, pS77; SENN S, 1994, STAT MED, V13, P1715, DOI 10.1002/sim.4780131703; SENN SJ, 1989, STAT MED, V8, P467, DOI 10.1002/sim.4780080410	6	166	169	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					185	185		10.1136/bmj.319.7203.185	http://dx.doi.org/10.1136/bmj.319.7203.185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406763	Green Published			2022-12-28	WOS:000081619300032
J	Tang, JL; Zhan, SY; Ernst, E				Tang, JL; Zhan, SY; Ernst, E			Review of randomised controlled trials of traditional Chinese medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Chinese Univ Hong Kong, Dept Community & Family Med, Shatin, New Territories, Peoples R China; Beijing Med Univ, Sch Publ Hlth, Beijing 100083, Peoples R China; Univ Exeter, Postgrad Med Sch, Dept Complementary Med, Exeter EX2 4NT, Devon, England	Chinese University of Hong Kong; Peking University; University of Exeter	Tang, JL (corresponding author), Chinese Univ Hong Kong, Dept Community & Family Med, Shatin, New Territories, Peoples R China.	jltang@cuhk.edu.hk	Tang, JL/G-1759-2013; Tang, Jin-Ling/AAJ-4090-2021					CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; Collins R, 1996, OXFORD TXB MED, V1, P21; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; XIE ZF, 1995, CHINESE J INTEGRATED, V1, P3016; YU GP, 1994, CHINESE J INTEGRATED, V14, P50	5	167	197	1	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	1999	319	7203					160	161		10.1136/bmj.319.7203.160	http://dx.doi.org/10.1136/bmj.319.7203.160			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406751	Bronze, Green Published			2022-12-28	WOS:000081619300022
J	Megee, PC; Koshland, D				Megee, PC; Koshland, D			A functional assay for centromere-associated sister chromatid cohesion	SCIENCE			English	Article							BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; GENETIC-ANALYSIS; MINICHROMOSOMES; PLASMID	Cohesion of sister chromatids occurs along the entire Length of chromosomes, including the centromere where it plays essential roles in chromosome segregation. Here, minichromosomes in the budding yeast Saccharomyces cerevisiae are exploited to generate a functional assay for DNA sequences involved in cohesion. The centromeric DNA element CDEIII was found to be necessary but not sufficient for cohesion. This element was shown previously to be required for assembly of the kinetochore, the centromere-associated protein complex that attaches chromosomes to the spindle. These observations establish a link between centromere-proximal cohesion and kinetochore assembly.	Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Koshland, D (corresponding author), Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.			Megee, Paul/0000-0002-9397-2161	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41718] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, J MOL BIOL, V225, P25, DOI 10.1016/0022-2836(92)91023-I; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; MEGEE PC, UNPUB; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Sorger PK, 1995, P NATL ACAD SCI USA, V92, P12026, DOI 10.1073/pnas.92.26.12026; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519	19	63	64	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					254	257		10.1126/science.285.5425.254	http://dx.doi.org/10.1126/science.285.5425.254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398602				2022-12-28	WOS:000081346000042
J	Olivieri, NF				Olivieri, NF			The beta-thalassemias	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IRON-CHELATION-THERAPY; GLOBIN GENE-EXPRESSION; BONE-MARROW TRANSPLANTATION; SICKLE-CELL DISEASE; FETAL HEMOGLOBIN; HEPATIC IRON; ALPHA-GLOBIN; HEREDITARY HEMOCHROMATOSIS; PULMONARY-HYPERTENSION; MULTIPLE TRANSFUSIONS		Univ Toronto, Toronto, ON, Canada	University of Toronto	Olivieri, NF (corresponding author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	noliv@sickkids.on.ca	Olivieri, Nancy/AAI-2250-2020					AESSOPOS A, 1995, CHEST, V107, P50, DOI 10.1378/chest.107.1.50; Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736; ANAPLIOTOU MLG, 1995, CLIN ENDOCRINOL, V42, P279, DOI 10.1111/j.1365-2265.1995.tb01876.x; Angelucci E, 1997, BLOOD, V90, P4736, DOI 10.1182/blood.V90.12.4736.4736_4736_4742; ANGELUCCI E, 1997, BLOOD S, V90, pA265; Arruda VR, 1997, NEW ENGL J MED, V336, P964, DOI 10.1056/NEJM199703273361318; Atweh GF, 1999, BLOOD, V93, P1790; BACALO A, 1992, CHEST, V101, P362, DOI 10.1378/chest.101.2.362; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BorgnaPignatti C, 1997, J PEDIATR-US, V130, P86, DOI 10.1016/S0022-3476(97)70314-7; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; BUJA LM, 1971, AM J MED, V51, P209, DOI 10.1016/0002-9343(71)90240-3; CAMASCHELLA C, 1995, HAEMATOLOGICA, V80, P58; Cao A, 1998, BAILLIERE CLIN HAEM, V11, P215, DOI 10.1016/S0950-3536(98)80076-0; CAO A, 1988, THALASSEMIA PATHOP B, V23, P219; Cappellini M. D., 1996, Blood, V88, p311A; CARTHEW P, 1994, BIOMETALS, V7, P267; CARTWRIGHT GE, 1979, NEW ENGL J MED, V301, P175, DOI 10.1056/NEJM197907263010402; CAVALLOPERIN P, 1995, METABOLISM, V44, P281, DOI 10.1016/0026-0495(95)90155-8; Cazzola M, 1997, TRANSFUSION, V37, P135, DOI 10.1046/j.1537-2995.1997.37297203514.x; CHANG YC, 1995, BLOOD, V85, P1111, DOI 10.1182/blood.V85.4.1111.bloodjournal8541111; Chui DHK, 1998, BLOOD, V91, P2213, DOI 10.1182/blood.V91.7.2213.2213_2213_2222; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; CONSTANTOULAKIS P, 1991, BLOOD, V77, P1326; CONTU L, 1994, BONE MARROW TRANSPL, V13, P329; Cooley T. B., 1925, T AM PEDIATRIC SOCIE, V37, P29; DESANCTIS V, 1995, CLIN ENDOCRINOL, V42, P581; DOVER GJ, 1992, BLOOD, V80, P816; Du ZD, 1997, AM HEART J, V134, P532, DOI 10.1016/S0002-8703(97)70091-7; FACTOR M, 1994, AM J RESP CRIT CARE, V149, P1570; Filosa A, 1997, ACTA PAEDIATR, V86, P342, DOI 10.1111/j.1651-2227.1997.tb09019.x; FLINT J, 1993, BAILLIERE CLIN HAEM, V6, P215, DOI 10.1016/S0950-3536(05)80071-X; FOSBURG MT, 1990, BLOOD, V76, P435; Gabutti V, 1996, ACTA HAEMATOL-BASEL, V95, P26, DOI 10.1159/000203853; Giardini C, 1997, Curr Opin Hematol, V4, P79; GRATWICK GM, 1978, ANN INTERN MED, V88, P494, DOI 10.7326/0003-4819-88-4-494; Greppi E, 1928, MINN MED, V8, P1; GRINBERG LN, 1995, C INSERM, P519; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; GULLO L, 1993, PANCREAS, V8, P176, DOI 10.1097/00006676-199303000-00007; Hershko C, 1998, BRIT J HAEMATOL, V101, P399, DOI 10.1046/j.1365-2141.1998.00726.x; HERSHKO C, 1988, CRC CR REV CL LAB SC, V26, P303, DOI 10.3109/10408368809105894; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; Higgs DR, 1998, SEMIN HEMATOL, V35, P93; Ho PJ, 1998, BRIT J HAEMATOL, V100, P70; Hoffbrand AV, 1998, BLOOD, V91, P295, DOI 10.1182/blood.V91.1.295.295_295_300; Hoffbrand AV, 1996, SEMIN HEMATOL, V33, P1; HUISMAN THJ, 1997, SYLLABUS THALASSEMIA, P309; IANCU TC, 1977, CIBA F S IRON METABO, V51, P293; ISSARAGRISIL S, 1995, NEW ENGL J MED, V332, P367, DOI 10.1056/NEJM199502093320605; JEAN G, 1984, ARCH DIS CHILD, V59, P67, DOI 10.1136/adc.59.1.67; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KREMASTINOS DT, 1995, CIRCULATION, V91, P66, DOI 10.1161/01.CIR.91.1.66; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; Lucarelli G, 1997, Cancer Treat Res, V77, P305; MAGRO S, 1990, ACTA HAEMATOL-BASEL, V84, P72; MAHARAJ B, 1986, LANCET, V1, P523; MCDONAGH KT, 1992, EXP HEMATOL, V20, P1156; MICHELI P, 1935, ATTI SOC ITAL EMA S1, V16, P10; NATHAN DG, 1995, NEW ENGL J MED, V332, P1315; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Olivieri, 1997, BLOOD, V89, P2621; Olivieri N, 1998, BAILLIERE CLIN HAEM, V11, P147, DOI 10.1016/S0950-3536(98)80073-5; Olivieri N. F., 1996, Blood, V88, p310A; Olivieri NF, 1997, BLOOD, V89, P739, DOI 10.1182/blood.V89.3.739; Olivieri NF, 1997, LANCET, V350, P491, DOI 10.1016/S0140-6736(05)63080-2; Olivieri NF, 1996, SEMIN HEMATOL, V33, P24; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056/NEJM199808133390701; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; OLYNYK JK, 1994, GASTROENTEROLOGY, V106, P674, DOI 10.1016/0016-5085(94)90701-3; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; ORVIETO R, 1992, CALCIFIED TISSUE INT, V50, P397, DOI 10.1007/BF00296768; PACE B, 1994, BLOOD, V84, P4344, DOI 10.1182/blood.V84.12.4344.bloodjournal84124344; PARKES JG, 1995, BBA-GEN SUBJECTS, V1243, P373, DOI 10.1016/0304-4165(94)00162-Q; PARKES JG, 1993, J LAB CLIN MED, V122, P36; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PIPPARD MJ, 1979, LANCET, V2, P819; POOTRAKUL P, 1988, BLOOD, V71, P1124; Porter JB, 1997, BLOOD, V90, P1163; Porter JB, 1997, DRUG SAFETY, V17, P407, DOI 10.2165/00002018-199717060-00006; Rigano P, 1997, HEMOGLOBIN, V21, P219, DOI 10.3109/03630269708997382; RIOJA L, 1990, BONE MINER, V8, P69, DOI 10.1016/0169-6009(91)90142-M; RISDON RA, 1973, GUT, V14, P421; RODGERS GP, 1995, BRIT J HAEMATOL, V91, P263, DOI 10.1111/j.1365-2141.1995.tb05288.x; Rund D, 1997, AM J HEMATOL, V54, P16, DOI 10.1002/(SICI)1096-8652(199701)54:1<16::AID-AJH3>3.3.CO;2-9; Saxon BR, 1998, BRIT J HAEMATOL, V101, P416, DOI 10.1046/j.1365-2141.1998.00719.x; Schrier S L, 1997, Curr Opin Hematol, V4, P75; SHALEV O, 1995, BLOOD, V86, P2008, DOI 10.1182/blood.V86.5.2008.bloodjournal8652008; SHER GD, 1995, NEW ENGL J MED, V332, P1606, DOI 10.1056/NEJM199506153322404; SHESELY EG, 1991, P NATL ACAD SCI USA, V88, P4294, DOI 10.1073/pnas.88.10.4294; SHINAR E, 1993, BAILLIERE CLIN HAEM, V6, P357, DOI 10.1016/S0950-3536(05)80150-7; SKLAR CA, 1987, AM J DIS CHILD, V141, P327, DOI 10.1001/archpedi.1987.04460030105036; SORENSEN S, 1990, BLOOD, V75, P1333; STAMATOYANNOPOULOS JA, 1992, ANNU REV MED, V43, P497; Tai DYH, 1996, EUR RESPIR J, V9, P1389, DOI 10.1183/09031936.96.09071389; Thakerngpol K, 1996, BIOMETALS, V9, P177, DOI 10.1007/BF00144623; THEIN SL, 1993, BAILLIERE CLIN HAEM, V6, P151, DOI 10.1016/S0950-3536(05)80069-1; THEIN SL, 1990, P NATL ACAD SCI USA, V87, P3924, DOI 10.1073/pnas.87.10.3924; THEIN SL, 1994, AM J HUM GENET, V54, P214; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Weatherall DJ, 1996, NAT MED, V2, P847, DOI 10.1038/nm0896-847; WEATHERALL DJ, 1987, ANN TROP MED PARASIT, V81, P539, DOI 10.1080/00034983.1987.11812155; Weatherall DJ, 1998, J PEDIATR-US, V132, P765, DOI 10.1016/S0022-3476(98)70301-4; WEATHERALL DJ, IN PRESS THALASSAEMI; Weatherall DJ, 1994, MOL BASIS BLOOD DIS, P157; Westgren M, 1996, TRANSPLANTATION, V61, P1176, DOI 10.1097/00007890-199604270-00010; Whipple GH, 1936, J PEDIATR-US, V9, P279, DOI 10.1016/S0022-3476(36)80021-3; Wickramasinghe S N, 1976, CONGENITAL DISORDERS, P221; WITZLEBEN C, 1961, J PATHOL BACTERIOL, V82, P1, DOI 10.1002/path.1700820102; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; Wong A, 1997, BIOMETALS, V10, P247, DOI 10.1023/A:1018312113969; WOOD WG, 1983, BIOCHEM J, V215, P1; WOOD WG, 1993, BAILLIERE CLIN HAEM, V6, P177, DOI 10.1016/S0950-3536(05)80070-8; YUAN J, 1993, BLOOD, V82, P374, DOI 10.1182/blood.V82.2.374.bloodjournal822374; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	120	548	564	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					99	109		10.1056/NEJM199907083410207	http://dx.doi.org/10.1056/NEJM199907083410207			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395635				2022-12-28	WOS:000081316200007
J	Brown, SL; Hansen, SL; Langone, JJ				Brown, SL; Hansen, SL; Langone, JJ			Role of serology in the diagnosis of Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROFICIENCY TESTING PROGRAM; BORRELIA-BURGDORFERI; OVERDIAGNOSIS; LABORATORIES; VACCINATION; ANTIBODY	Numerous concerns regarding the potential for misdiagnosis of Lyme disease using commercial assays have been voiced by the US Food and Drug Administration (FDA). We attempted to clarify the clinical value of serologic testing for Lyme disease using the results of commonly marketed assays for detecting antibody to Borrelia burgdorferi, the organism that causes Lyme disease, We reviewed published studies on B burgdorferi test performance published through 1998, package insert labeling from FDA-cleared test kits for B burgdorferi, and Lyme Disease Survey Set LY-A from the College of American Pathologists. We assessed the sensitivity and specificity of commercial serologic tests (enzyme-linked immunosorbent assay [ELISA], immunofluorescence antibody [IFA], and immunodot) for diagnosis of Lyme disease. To reduce this risk of misdiagnosis, it is important that clinicians understand the performance characteristics and limitations of these tests. These tests, in common use in clinical or commercial laboratories, should be used only to support a clinical diagnosis of Lyme disease, not as the primary basis for making diagnostic or treatment decisions. Serologic testing is not useful early in the course of Lyme disease because of the low sensitivity of tests in early disease. Serologic testing may be more useful in later disease, at which time sensitivity and specificity of the test are improved. Positive or equivocal results on an ELISA, IFA, or immunodot assay requires supplemental testing with a Western blot assay. A negative result on the Western blot or ELISA indicates that there is no serologic evidence of infection by B burgdorferi at the time the sample was drawn.	US FDA, Off Surveillance & Biometr, Div Postmarket Surveillance, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Off Device Evaluat, Div Clin Lab Devices, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Off Sci & Technol, Div Life Sci, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Brown, SL (corresponding author), 1350 Piccard Dr,HFZ-541, Rockville, MD 20850 USA.							AgueroRosenfeld ME, 1996, J CLIN MICROBIOL, V34, P1; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; Bakken LL, 1997, J CLIN MICROBIOL, V35, P537, DOI 10.1128/JCM.35.3.537-543.1997; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1998, INFECT DIS; DURAY PH, 1997, PATHOLOGY INFECT DIS, V1; *FDA PUBL HLTH ADV, 1999, ASS ANT BORR BURGD L; Fix AD, 1998, JAMA-J AM MED ASSOC, V279, P206, DOI 10.1001/jama.279.3.206; Hofmann H, 1996, INFECTION, V24, P470, DOI 10.1007/BF01713052; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; Reid MC, 1998, ANN INTERN MED, V128, P354, DOI 10.7326/0003-4819-128-5-199803010-00003; SCHMITZ JL, 1993, EUR J CLIN MICROBIOL, V12, P419, DOI 10.1007/BF01967435; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; Sigal LH, 1997, ANNU REV IMMUNOL, V15, P63, DOI 10.1146/annurev.immunol.15.1.63; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1995, ADV INTERNAL MED, V40, P69; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; Strickland GT, 1997, J INFECT DIS, V176, P819, DOI 10.1086/517311; Tierno PM, 1996, LAB MED, V27, P542, DOI 10.1093/labmed/27.8.542; Tugwell P, 1997, ANN INTERN MED, V127, P1106, DOI 10.7326/0003-4819-127-12-199712150-00011; Tugwell P, 1997, ANN INTERN MED, V127, P1109, DOI 10.7326/0003-4819-127-12-199712150-00011; *US FDA, 1996, FDA ADV PAN M 1996 M, V2; Zhang YQ, 1997, J CLIN MICROBIOL, V35, P233, DOI 10.1128/JCM.35.1.233-238.1997; 1997, MMWR MORB MORTAL WKL, V46, P531	30	82	89	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					62	66		10.1001/jama.282.1.62	http://dx.doi.org/10.1001/jama.282.1.62			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404913				2022-12-28	WOS:000081195800030
J	Emery, J; Walton, R; Coulson, A; Glasspool, D; Ziebland, S; Fox, J				Emery, J; Walton, R; Coulson, A; Glasspool, D; Ziebland, S; Fox, J			Computer support for recording and interpreting family histories of breast and ovarian cancer in primary care (RAGs): qualitative evaluation with simulated patients	BRITISH MEDICAL JOURNAL			English	Article							EXPERT-SYSTEMS; TECHNOLOGY; KNOWLEDGE; PROFORMA; GENETICS; SERVICES	Objectives To explore general practitioners' attitudes ton ards and use of a computer program for assessing genetic risk of cancer in primary care. Design Qualitative analysis of semistructured interviews and video recordings of simulated consultations. Participants Purposive sample of 15 general practitioners covering a range of computer literacy; interest in genetics, age, and sex. Interventions Each doctor used the program in two consultations in which an actor played a woman concerned about her family history of cancer. Consultations were videotaped and followed by interviews with the video as a prompt to questioning, Main outcome measures Use of computer program in the consultation. Results The program was viewed as an appropriate application of information technology because of the complexity of cancer genetics and a sense of "guideline chaos" in primary care. Doctors found the program easy to use, but it often affected their control of the consultation. They needed to balance their desire to share the computer screen with the patient, driven by their concerns about the effect of the computer on doctor-patient communication against the risk of premature disclosure of bad news. Conclusions This computer program could provide the necessary. support to assist assessment of genetic risk of cancer in primary care. The potential impact of computer software on the consultation should not be underestimated. This study highlights the need for careful evaluation when developing medical information systems.	Inst Hlth Sci, Div Publ Hlth & Primary Care, Gen Practice Res Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England; Imperial Canc Res Fund, Adv Computat Lab, London WC2A 3PX, England	University of Oxford; Cancer Research UK	Emery, J (corresponding author), Inst Hlth Sci, Div Publ Hlth & Primary Care, Gen Practice Res Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England.			Ziebland, Sue/0000-0002-6496-4859				ARBORELIUS E, 1991, Scandinavian Journal of Primary Health Care, V9, P71, DOI 10.3109/02813439109026587; *CANC RES CAMP, 1998, 1 CRC; EMERY J, IN PRESS BR J GEN PR; ERIKSON F, 1982, SOCIOL METHOD RES, V11, P213; Fischer C, 1996, HUM GENET, V97, P129, DOI 10.1007/BF02265253; Fox J, 1998, ARTIF INTELL MED, V14, P157, DOI 10.1016/S0933-3657(98)00021-9; Fox J, 1997, COMPUT METH PROG BIO, V54, P59, DOI 10.1016/S0169-2607(97)00034-5; Friedman C.P., 1997, EVALUATION METHODS M, P41; FRY A, IN PRESS FAM PRACT; GREATBATCH D, 1995, FAM PRACT, V12, P32, DOI 10.1093/fampra/12.1.32; Harris R, 1996, J MED GENET, V33, P346, DOI 10.1136/jmg.33.4.346; HARRIS R, 1995, BRIT MED J, V311, P275; Heathfield H, 1998, BRIT MED J, V316, P1959, DOI 10.1136/bmj.316.7149.1959; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; Mays N, 1996, QUALITATIVE RES HLTH; OHAGAN JJ, 1986, NEW ZEAL MED J, V99, P948; Patton M. Q., 1990, QUALITATIVE EVALUATI; Ridsdale L, 1997, SCAND J PRIM HEALTH, V15, P180, DOI 10.3109/02813439709035024; *ROYAL COLL GEN PR, 1998, 77 ROYAL COLL GEN PR; Silverman D., 2015, INTERPRETING QUALITA; Strauss A., 1990, BASICS QUALITATIVE R; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; Timpka T, 1994, Artif Intell Med, V6, P501, DOI 10.1016/0933-3657(94)90027-2; Walton RT, 1997, BRIT MED J, V315, P791; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; 1997, QSR NUD IST PROGRAM	27	61	62	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					32	36		10.1136/bmj.319.7201.32	http://dx.doi.org/10.1136/bmj.319.7201.32			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390458	Green Published, Bronze			2022-12-28	WOS:000081326500032
J	Lohmann, V; Korner, F; Koch, JO; Herian, U; Theilmann, L; Bartenschlager, R				Lohmann, V; Korner, F; Koch, JO; Herian, U; Theilmann, L; Bartenschlager, R			Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line	SCIENCE			English	Article							CDNA CLONE; GENOME; IDENTIFICATION; 3'-TERMINUS; POLYMERASE; TRANSLATION; TRANSCRIPTS; CHIMPANZEE; GROWTH; REGION	An estimated 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease. Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems. A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons. Upon transfection into a human hepatoma cell line, these RNAs were found to replicate to high levels, permitting metabolic radiolabeling of viral RNA and proteins. This work defines the structure of HCV replicons functional in cell culture and provides the basis fora long-sought cellular system that should allow detailed molecular studies of HCV and the development of antiviral drugs.	Johannes Gutenberg Univ Mainz, Inst Virol, D-55131 Mainz, Germany; Stadt Klinikum Pforzheim, Med Klin 2, D-75116 Pforzheim, Germany	Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	Bartenschlager, R (corresponding author), Johannes Gutenberg Univ Mainz, Inst Virol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	bartnsch@mail.uni-mainz.de	Lohmann, Volker/H-4211-2019; Bartenschlager, Ralf/L-2582-2015	Lohmann, Volker/0000-0001-8719-7608; Bartenschlager, Ralf/0000-0001-5601-9307				Bartenschlager R, 1997, INTERVIROLOGY, V40, P378, DOI 10.1159/000150570; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Behrens SE, 1998, J VIROL, V72, P2364, DOI 10.1128/JVI.72.3.2364-2372.1998; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Fournier C, 1998, J GEN VIROL, V79, P2367, DOI 10.1099/0022-1317-79-10-2367; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gong YH, 1996, J GEN VIROL, V77, P2729, DOI 10.1099/0022-1317-77-11-2729; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; KEDZIERSKI W, 1991, BIOTECHNIQUES, V10, P210; Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; LOHMANN V, UNPUB; Mizutani T, 1996, J VIROL, V70, P7219, DOI 10.1128/JVI.70.10.7219-7223.1996; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; Yamada N, 1996, VIROLOGY, V223, P255, DOI 10.1006/viro.1996.0476; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291; YOO BJ, 1995, J VIROL, V69, P32, DOI 10.1128/JVI.69.1.32-38.1995	32	2327	2700	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1999	285	5424					110	113		10.1126/science.285.5424.110	http://dx.doi.org/10.1126/science.285.5424.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390360				2022-12-28	WOS:000081199800042
J	York, JD; Odom, AR; Murphy, R; Ives, EB; Wente, SR				York, JD; Odom, AR; Murphy, R; Ives, EB; Wente, SR			A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR EXPORT; SCHIZOSACCHAROMYCES-POMBE; PORE; HEXAKISPHOSPHATE; TRISPHOSPHATE; NUCLEOPORIN; METABOLISM; PHOSPHATES; TRANSPORT	In order to identify additional factors required for nuclear export of messenger RNA, a genetic screen was conducted with a yeast mutant deficient in a factor Gle1p, which associates with the nuclear pore complex (NPC). The three genes identified encode phospholipase C and two potential inositol polyphosphate kinases. Together, these constitute a signaling pathway from phosphatidylinositol 4,5-bisphosphate to inositol hexakisphosphate (IP6). The common downstream effects of mutations in each component were deficiencies in IP6 synthesis and messenger RNA export, indicating a role for IP6 in GLE7 function and messenger RNA export.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Duke University; Duke University; Washington University (WUSTL)	York, JD (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.		John, Audrey Odom/AAF-1300-2019	John, Audrey Odom/0000-0001-8395-8537				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; ESTEVEZ F, 1994, BIOCHEM J, V302, P709, DOI 10.1042/bj3020709; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; Lee MS, 1997, CURR OPIN GENET DEV, V7, P212, DOI 10.1016/S0959-437X(97)80131-1; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; PHILLIPPY B, 1994, J BIOL CHEM, V269, P28693; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STEPHENS L, 1990, NATURE, V326, P580; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275	29	429	447	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					96	100		10.1126/science.285.5424.96	http://dx.doi.org/10.1126/science.285.5424.96			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390371				2022-12-28	WOS:000081199800038
J	Lin, YX; Fletcher, CM; Zhou, JX; Allis, CD; Wagner, G				Lin, YX; Fletcher, CM; Zhou, JX; Allis, CD; Wagner, G			Solution structure of the catalytic domain of GCN5 histone acetyltransferase bound to coenzyme A	NATURE			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; YEAST GCN5P; IN-VIVO; PROTEIN; ACTIVATION; ACETYLATION; SUPERFAMILY; COMPLEX; CBP	Gene transcription requires the release of inactive DNA from its packaging of histone proteins. Following the discovery of the first transcription-associated histone acetyltransferase, tetrahymena GCN5(1), it was shown that yeast GCN5 is recruited to the promoter and causes hyper-acetylation of histones and transcriptional activation of target genes(2,3), establishing a direct connection between histone acetylation and transcriptional activation. Many other important transcription regulators have been found to have histone acetyltransferase activity, including TAFII230/250, p300/CBP and its associated factor PCAF(4-9). Here we present the solution structure of the catalytic domain of tGCN5 (residues 47-210) in complex with coenzyme A. The structure contains two domains; the amino-terminal domain is similar to those of other GCN5-related N-acetyltransferases(10,11) but the carboxy-terminal domain is not. Coenzyme A binds in a deep hydrophobic pocket between the two domains. Chemical shift changes upon titration with histone H3 peptides indicate a binding site at the domain boundary opposite to the coenzyme A site. The structural data indicate a single-step acetyl-transfer reaction mechanism catalysed by a hydrogen bond to the backbone amide group of leucine 126 and the side-chain carboxyl group of a conserved acidic residue.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; MIT, Harvard Ctr Magnet Resonance, Cambridge, MA 02139 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; University of Virginia	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.			/0000-0002-7002-1275				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LIN Y, UNPUB J AM CHEM SOC; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	21	78	81	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					86	89		10.1038/21922	http://dx.doi.org/10.1038/21922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403255				2022-12-28	WOS:000081255700057
J	Ferriman, A				Ferriman, A			NHS ombudsman will name doctors who do not accept ruling	BRITISH MEDICAL JOURNAL			English	News Item																		*HLTH SERV COMM EN, 1989, HLTH SERVICE COMMISS; *HLTH SERV OMB, 1999, HLTH SERV OMB INV CO	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1718	1718		10.1136/bmj.318.7200.1718	http://dx.doi.org/10.1136/bmj.318.7200.1718			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381696	Green Published			2022-12-28	WOS:000081216900013
J	Hofmann, MA; Drury, S; Fu, CF; Qu, W; Taguchi, A; Lu, Y; Avila, C; Kambham, N; Bierhaus, A; Nawroth, P; Neurath, MF; Slattery, T; Beach, D; McClary, J; Nagashima, M; Morser, J; Stern, D; Schmidt, AM				Hofmann, MA; Drury, S; Fu, CF; Qu, W; Taguchi, A; Lu, Y; Avila, C; Kambham, N; Bierhaus, A; Nawroth, P; Neurath, MF; Slattery, T; Beach, D; McClary, J; Nagashima, M; Morser, J; Stern, D; Schmidt, AM			RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides	CELL			English	Article							GLYCATION END-PRODUCTS; CALCIUM-BINDING PROTEINS; ADHESION MOLECULE-1; ALZHEIMERS-DISEASE; CALGRANULIN-C; DIABETIC COMPLICATIONS; NEURITE OUTGROWTH; SOLUBLE RECEPTOR; OXIDANT STRESS; S100 FAMILY	S100/calgranulin polypeptides are present at sites of inflammation, likely released by inflammatory cells targeted to such loci by a range of environmental cues. We report here that receptor for AGE (RAGE) is a central cell surface receptor for EN-RAGE (extracellular newly identified RAGE-binding protein) and related members of the S100/calgranulin superfamily. Interaction of EN-RAGEs with cellular RAGE on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Blockade of EN-RAGE/RAGE quenches delayed-type hypersensitivity and inflammatory colitis in murine models by arresting activation of central signaling pathways and expression of inflammatory gene mediators. These data highlight a novel paradigm in inflammation and identify roles for EN-RAGEs and RAGE in chronic cellular activation and tissue injury.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Berlex Biosci, Richmond, CA 94804 USA; Univ Tubingen, D-72076 Tubingen, Germany; Univ Mainz, D-55101 Mainz, Germany	Columbia University; Eberhard Karls University of Tubingen; Johannes Gutenberg University of Mainz	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.			Kambham, Neeraja/0000-0003-1136-3686	NHLBI NIH HHS [HL60901, HL56881] Funding Source: Medline; NIDDK NIH HHS [DK52495] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060901, R01HL056881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DUNN CJ, 1993, J PHARMACOL EXP THER, V266, P1691; Geczy C, 1996, BBA-MOL CELL RES, V1313, P246, DOI 10.1016/0167-4889(96)00096-1; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOTTSCH JD, 1997, T AM OPTHALMOL SOC, V14, P111; Hitomi J, 1996, J CELL SCI, V109, P805; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Ilg EC, 1996, BIOCHEM BIOPH RES CO, V225, P146, DOI 10.1006/bbrc.1996.1144; King GL, 1996, ENDOCRIN METAB CLIN, V25, P255, DOI 10.1016/S0889-8529(05)70324-8; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kuehn Ralf, 1993, Cell, V75, P263; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; LI J, 1997, J BIOL CHEM, V271, P16498; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; MARSHAK DR, 1992, NEUROBIOL AGING, V13, P1, DOI 10.1016/0197-4580(92)90002-F; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Rammes A, 1997, J BIOL CHEM, V272, P9496; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1998, HORM SIGNAL, V1, P41; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1; Yamamura T, 1996, BIOCHEM BIOPH RES CO, V221, P356, DOI 10.1006/bbrc.1996.0600; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	42	1527	1602	3	75	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					889	901		10.1016/S0092-8674(00)80801-6	http://dx.doi.org/10.1016/S0092-8674(00)80801-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399917	hybrid			2022-12-28	WOS:000081162800010
J	Bown, N; Cotterill, S; Lastowska, M; O'Neill, S; Pearson, ADJ; Plantaz, D; Meddeb, M; Danglot, G; Brinkschmidt, C; Christiansen, H; Laureys, G; Speleman, F				Bown, N; Cotterill, S; Lastowska, M; O'Neill, S; Pearson, ADJ; Plantaz, D; Meddeb, M; Danglot, G; Brinkschmidt, C; Christiansen, H; Laureys, G; Speleman, F			Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; INSITU HYBRIDIZATION; ALLELIC LOSS; CELL-LINES; 1P; TUMORS; TRANSLOCATIONS; ASSOCIATION; ONCOGENE; PLOIDY	Background Gain of genetic material from chromosome arm 17q (gain of segment 17q21-qter) is the most frequent cytogenetic abnormality of neuroblastoma cells. This gain has been associated with advanced disease, patients who are greater than or equal to 1 year old, deletion of chromosome arm 1p, and amplification of the N-myc oncogene, all of which predict an adverse outcome. We investigated these associations and evaluated the prognostic importance of the status of chromosome 17. Methods We compiled molecular cytogenetic analyses of chromosome 17 in primary neuroblastomas in 313 patients at six European centers. Clinical and survival information were collected, along with data on 1p, N-myc, and ploidy. Results Unbalanced gain of segment 17q21-qter was found in 53.7 percent of the tumors, whereas the chromosome was normal in 46.3 percent. The gain of 17q was characteristic of advanced tumors and of tumors in children greater than or equal to 1 year of age and was strongly associated with the deletion of 1p and amplification of N-myc. No tumor showed amplification of N-myc in the absence of either deletion of 1p or gain of 17q. Gain of 17q was a significant predictive factor for adverse outcome in univariate analysis. Among the patients with this abnormality, overall survival at five years was 30.6 percent (95 percent confidence interval, 21 to 40 percent), as compared with 86.0 percent (95 percent confidence interval, 78 to 91 percent) among those with normal 17q status. In multivariate analysis, gain of 17q was the most powerful prognostic factor, followed by the presence of stage 4 disease and deletion of 1p (hazard ratios, 3.4, 2.3, and 1.9, respectively). Conclusions Gain of chromosome segment 17q21-qter is an important prognostic factor in children with neuroblastoma. (N Engl J Med 1999;340:1954-61.) (C) 1999, Massachusetts Medical Society.	Newcastle Univ, Dept Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Newcastle Univ, Inst Child Hlth, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ Hosp Ctr, Dept Pediat, Grenoble, France; Inst Gustave Roussy, Villejuif, France; Univ Munster, Gerhard Domagk Inst Pathol, D-4400 Munster, Germany; Univ Marburg, Kinderklin, Dept Pediat Hematol & Oncol, Marburg, Germany; Ghent Univ Hosp, Dept Pediat Oncol, B-9000 Ghent, Belgium; Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium	Newcastle University - UK; Newcastle University - UK; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UNICANCER; Gustave Roussy; University of Munster; Philipps University Marburg; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Bown, N (corresponding author), Newcastle Univ, Dept Human Genet, 19-20 Claremont Pl, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	nicholas.bown@ncl.ac.uk	laureys, genevieve/AAG-2390-2021; speleman, frank/AAR-5184-2020	speleman, frank/0000-0002-6628-8559; Lastowska, Maria/0000-0003-0632-6995				Ambros IM, 1996, NEW ENGL J MED, V334, P1505, DOI 10.1056/NEJM199606063342304; BERNSTEIN, 1992, J CLIN ONCOL, V10, P1202, DOI 10.1200/JCO.1992.10.7.1202; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; BIEDLER JL, 1980, ADV NEUROBLASTOMA RE, P81; Brinkschmidt C, 1997, J PATHOL, V181, P394; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; GILBERT F, 1984, CANCER RES, V44, P5444; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Katzenstein HM, 1998, J CLIN ONCOL, V16, P2007, DOI 10.1200/JCO.1998.16.6.2007; Lastowska M, 1997, GENE CHROMOSOME CANC, V19, P143; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; Lastowska M, 1997, EUR J CANCER, V33, P1627, DOI 10.1016/S0959-8049(97)00282-7; Lastowska M, 1998, GENE CHROMOSOME CANC, V23, P116; Matthay KK, 1998, J CLIN ONCOL, V16, P2003, DOI 10.1200/JCO.1998.16.6.2003; Meddeb M, 1996, GENE CHROMOSOME CANC, V17, P156, DOI 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; PETER M, 1992, INT J CANCER, V52, P544, DOI 10.1002/ijc.2910520408; Plantaz D, 1997, AM J PATHOL, V150, P81; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; STREHL S, 1993, CYTOGENET CELL GENET, V63, P24, DOI 10.1159/000133494; Van Gele M, 1997, EUR J CANCER, V33, P1979, DOI 10.1016/S0959-8049(97)00289-X; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205	29	372	379	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1954	1961		10.1056/NEJM199906243402504	http://dx.doi.org/10.1056/NEJM199906243402504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379019				2022-12-28	WOS:000081088500004
J	Goodman, SN				Goodman, SN			Toward evidence-based medical statistics. 2: The Bayes factor	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; MULTIPLE COMPARISONS; RANDOMIZED TRIALS; METAANALYSIS	Bayesian inference is usually presented as a method for determining how scientific belief should be modified by data. Although Bayesian methodology has been one of the most active areas of statistical development in the past 20 years, medical researchers have been reluctant to embrace what they perceive as a subjective approach to data analysis. It is little understood that Bayesian methods have a data-based core, which can be used as a calculus of evidence. This core is the Bayes factor, which in its simplest form is also called a likelihood ratio. The minimum Bayes factor is objective and can be used in lieu of the P value as a measure of the evidential strength. Unlike P values, Bayes factors have a sound theoretical foundation and an interpretation that allows their use in both inference and decision making. Bayes factors show that P values greatly overstate the evidence against the null hypothesis. Most important, Bayes factors require the addition of background knowledge to be transformed into inferences-probabilities that a given conclusion is right or wrong. They make the distinction clear between experimental evidence and inferential conclusions while providing a framework in which to combine prior with current evidence.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Goodman, SN (corresponding author), Johns Hopkins Univ, Sch Med, 550 N Broadway,Suite 409, Baltimore, MD 21205 USA.	sgoodman@jhu.edu		Goodman, Steven/0000-0002-3872-5723				BACON F, 1962, PRACTICAL COGITATOR; BAYARRI M, 1998, P 6 VAL INT M BAYES, P1; BELANGER D, 1991, J CLIN ONCOL, V9, P7, DOI 10.1200/JCO.1991.9.1.7; Berger J.O., 1995, STAT DECISION THEORY, V2nd ed; BERGER JO, 1988, AM SCI, V76, P159; BERGER JO, 1987, J AM STAT ASSOC, V82, P112, DOI 10.2307/2289131; Berry D A, 1995, Cancer Treat Res, V75, P125; Berry DA, 1998, JNCI-J NATL CANCER I, V90, P1431, DOI 10.1093/jnci/90.19.1431; BERRY DA, 1985, STAT MED, V4, P521, DOI 10.1002/sim.4780040412; BERRY DA, 1993, STAT MED, V12, P1377, DOI 10.1002/sim.4780121504; Berry DA, 1996, BAYESIAN BIOSTATISTI; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; Carlin C, 1996, BAYES EMPIRICAL BAYE; CASELLA G, 1987, J AM STAT ASSOC, V82, P106, DOI 10.2307/2289130; CHALONER K, 1993, STATISTICIAN, V42, P341, DOI 10.2307/2348469; Chaloner K., 1996, BAYESIAN BIOSTATISTI; CORNFIELD J, 1966, AM STAT, V20, P18, DOI 10.2307/2682711; CORNFIELD J, 1969, BIOMETRICS, V25, P617, DOI 10.2307/2528565; CORNFIELD J, 1966, J AM STAT ASSOC, V61, P577, DOI 10.2307/2282772; DIAMOND GA, 1983, ANN INTERN MED, V98, P385, DOI 10.7326/0003-4819-98-3-385; EDWARDS AWF, 1974, INT STAT REV, V42, P9, DOI 10.2307/1402681; EDWARDS AWF, 1972, LIKELIHOOD; EDWARDS W, 1963, PSYCHOL REV, V70, P193, DOI 10.1037/h0044139; Efron B, 1996, J AM STAT ASSOC, V91, P538, DOI 10.2307/2291646; ETZIONI RD, 1995, ANNU REV PUBL HEALTH, V16, P23; Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.0.CO;2-U; Fisher LD, 1996, CONTROL CLIN TRIALS, V17, P423, DOI 10.1016/S0197-2456(96)00043-8; Fisher Ronald A., 1973, STAT METHODS SCI INF; Freedman L, 1996, BMJ-BRIT MED J, V313, P569; Good I. J., 1950, PROBABILITY WEIGHING; GOODMAN S, 1995, JAMA-J AM MED ASSOC, V274, P873, DOI 10.1001/jama.1995.03530110035029; GOODMAN SN, 1989, CONTROL CLIN TRIALS, V10, P188, DOI 10.1016/0197-2456(89)90030-5; Goodman SN, 1998, AM J EPIDEMIOL, V147, P807, DOI 10.1093/oxfordjournals.aje.a009531; GOODMAN SN, 1988, AM J PUBLIC HEALTH, V78, P1568, DOI 10.2105/AJPH.78.12.1568; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; GREENLAND S, 1991, EPIDEMIOLOGY, V2, P387, DOI 10.1097/00001648-199109000-00015; Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A; Howard JV, 1998, STAT SCI, V13, P351; HUGHES MD, 1993, STAT MED, V12, P1651, DOI 10.1002/sim.4780121802; Jeffreys H., 1961, THEORY PROBABILITY; Kass R.E., 1989, STAT SCI, V4, P310, DOI DOI 10.1214/SS/1177012386; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Lilford RJ, 1996, BRIT MED J, V313, P603; Omoigui NA, 1998, J AM COLL CARDIOL, V31, P265, DOI 10.1016/S0735-1097(97)00498-1; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Royall R, 1997, MONOGRAPHS STAT APPL, V71; RUBIN DB, 1984, ANN STAT, V12, P1151, DOI 10.1214/aos/1176346785; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; Shafer G., 1986, STAT SCI, V1, P463, DOI DOI 10.1214/SS/1177013518; SPIEGELHALTER D, 1998, BUGS BAYESIAN INFERE; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; THOMAS DC, 1985, AM J EPIDEMIOL, V122, P1080, DOI 10.1093/oxfordjournals.aje.a114189; TVERSKY A, 1982, JUDGMENT UNCERTAINTY, P1; Walley P., 1991, STAT REASONING IMPRE	57	206	238	0	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					1005	1013		10.7326/0003-4819-130-12-199906150-00019	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00019			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383350				2022-12-28	WOS:000080894700008
J	Silove, D				Silove, D			Health and human rights of the East Timorese	LANCET			English	Editorial Material									Univ New S Wales, Liverpool Hosp, Psychiat Res & Teaching Unit, Liverpool, NSW 2170, Australia	Liverpool Hospital; University of New South Wales Sydney	Silove, D (corresponding author), Univ New S Wales, Liverpool Hosp, Psychiat Res & Teaching Unit, Hlth Serv Bldg, Liverpool, NSW 2170, Australia.								0	13	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2067	2067		10.1016/S0140-6736(99)00105-1	http://dx.doi.org/10.1016/S0140-6736(99)00105-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376636				2022-12-28	WOS:000080812200044
J	Teter, SA; Houry, WA; Ang, D; Tradler, T; Rockabrand, D; Fischer, G; Blum, P; Georgopoulos, C; Hartl, FU				Teter, SA; Houry, WA; Ang, D; Tradler, T; Rockabrand, D; Fischer, G; Blum, P; Georgopoulos, C; Hartl, FU			Polypeptide flux through bacterial Hsp70: DnaK cooperates with trigger factor in chaperoning nascent chains	CELL			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; IN-VIVO; PRESECRETORY PROTEINS; CELLULAR DEFECTS; GENE; RECOGNITION; SYSTEM; TEMPERATURES	A role for DnaK, the major E. coli Hsp70, in chaperoning de novo protein folding has remained elusive. Here we show that under nonstress conditions DnaK transiently associates with a wide variety of nascent and newly synthesized polypeptides, with a preference for chains larger than 30 kDa. Deletion of the nonessential gene encoding trigger factor, a ribosome-associated chaperone, results in a doubling of the fraction of nascent polypeptides interacting with DnaK. Combined deletion of the trigger factor and DnaK genes is lethal under normal growth conditions. These findings indicate important, partially overlapping functions of DnaK and trigger factor in de novo protein folding and explain why the loss of either chaperone can be tolerated by E. coli.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva, Switzerland; Max Planck Gesell Forschungsstelle Enzymol Protei, D-06120 Halle, Germany; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	Max Planck Society; University of Geneva; Max Planck Society; University of Nebraska System; University of Nebraska Lincoln	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hartl, F. Ulrich/Y-8206-2019					ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Ayling A, 1996, PROTEIN SCI, V5, P478; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chattopadhyay S, 1999, BBA-PROTEIN STRUCT M, V1429, P293, DOI 10.1016/S0167-4838(98)00179-4; Checa SK, 1997, EUR J BIOCHEM, V248, P848, DOI 10.1111/j.1432-1033.1997.00848.x; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gothel SF, 1998, BIOCHEMISTRY-US, V37, P13392, DOI 10.1021/bi981253w; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kandror O, 1997, P NATL ACAD SCI USA, V94, P4978, DOI 10.1073/pnas.94.10.4978; Kandror O, 1997, J BIOL CHEM, V272, P1730, DOI 10.1074/jbc.272.3.1730; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KRSKA J, 1993, J BACTERIOL, V175, P6433, DOI 10.1128/jb.175.20.6433-6440.1993; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LLOYD RG, 1985, J BACTERIOL, V164, P836, DOI 10.1128/JB.164.2.836-844.1985; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rockabrand D, 1998, J BACTERIOL, V180, P846, DOI 10.1128/JB.180.4.846-854.1998; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Yoshimune K, 1998, BIOCHEM BIOPH RES CO, V250, P115, DOI 10.1006/bbrc.1998.9255	49	335	340	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					755	765		10.1016/S0092-8674(00)80787-4	http://dx.doi.org/10.1016/S0092-8674(00)80787-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380927	Bronze			2022-12-28	WOS:000080886300013
J	Chen, P; Wu, X; Lin, J; Tan, KL				Chen, P; Wu, X; Lin, J; Tan, KL			High H-2 uptake by alkali-doped carbon nanotubes under ambient pressure and moderate temperatures	SCIENCE			English	Article							HYDROGEN STORAGE; GRAPHITE	Lithium- or potassium-doped carbon nanotubes can absorb similar to 20 or similar to 14 weight percent of hydrogen at moderate (200 degrees to 400 degrees C) or room temperatures, respectively, under ambient pressure. These values are greater than those of metal hydride and cryoadsorption systems. The hydrogen stored in the lithium- or potassium-doped carbon nanotubes can be released at higher temperatures, and the sorption-desorption cycle can be repeated with Little decrease in the sorption capacity. The high hydrogen-uptake capacity of these systems may be derived from the special open-edged, layered structure of the carbon nanotubes made from methane, as well as the catalytic effect of alkali metals.	Natl Univ Singapore, Dept Phys, Singapore 119260, Singapore	National University of Singapore	Lin, J (corresponding author), Natl Univ Singapore, Dept Phys, 10 Kent Ridge, Singapore 119260, Singapore.		Chen, Ping/D-1456-2011	Chen, Ping/0000-0002-0625-0639; Yang, Shuman/0000-0002-9638-0890				BUCHNER H, 1995, HYDROGEN OTHER ALTER, pCH7; CARTER GC, 1981, METAL HYDROGEN SYSTE, pCH7; Chambers A, 1998, J PHYS CHEM B, V102, P4253, DOI 10.1021/jp980114l; Chen P, 1997, CARBON, V35, P1495, DOI 10.1016/S0008-6223(97)00100-0; Chen P, 1999, PHYS REV LETT, V82, P2548, DOI 10.1103/PhysRevLett.82.2548; Dillon AC, 1997, NATURE, V386, P377, DOI 10.1038/386377a0; HOLZWARTH NAW, 1978, PHYS REV B, V18, P5190, DOI 10.1103/PhysRevB.18.5190; Hynek S, 1997, INT J HYDROGEN ENERG, V22, P601, DOI 10.1016/S0360-3199(96)00185-1; MASEL RI, 1996, PRINCIPLES ADSORPTIO, P443; NITSCH J, 1988, HYDROGEN ENERGY CA B; Schlogl R, 1994, PROGR INTERCALATION, P83; Silverstein RM, 1991, SPECTROMETRIC IDENTI, P103; WU X, IN PRESS INT J HYDRO; Ye Y, 1999, APPL PHYS LETT, V74, P2307, DOI 10.1063/1.123833	14	1074	1163	9	225	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1999	285	5424					91	93		10.1126/science.285.5424.91	http://dx.doi.org/10.1126/science.285.5424.91			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390369				2022-12-28	WOS:000081199800036
J	Carr, DB; Goudas, LC				Carr, DB; Goudas, LC			Acute pain	LANCET			English	Article							METAANALYSES; TRIALS; MANAGEMENT; RECOVERY; INFANTS	Postanaesthesia care units used to echo with cries of patients in pain after general anaesthesia. Each as-needed dose of analgesia was given only after permission of the surgeon or anaesthesiologist. Once conscious, patients were required to request each subsequent analgesic dose until hospital discharge. Not surprisingly, nearly half the patients who have an operation experience moderate to severe pain after surgery. Acute pain control has advanced dramatically and is now a field with dedicated texts, journals, and research. Despite improved surgical techniques that have transformed many operations into same-day procedures, inadequately controlled pain may still extend the length of hospital stay and predispose to expensive, time-consuming complications such as pneumonia. Recognition of economic and humanitarian benefits of pain control has prompted worldwide attention from professional groups, insurers, and governments. This paper describes the process of acute pain and measures to control it with drugs or non-pharmacological interventions. Even brief intervals of acute pain can induce long-term neuronal remodelling and sensitisation ("plasticity"), chronic pain, and lasting psychologial distress. Hence, acute pain and other types of pain (cancer-related or chronic) that are classified as distinct actually have many similarities.	Tufts Univ, New England Med Ctr, Sch Med, Dept Anesthesia & Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Carr, DB (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Dept Anesthesia & Med, Box 298, Boston, MA 02111 USA.	dcarr02@emerald.tufts.edu		Goudas, Leonidas C./0000-0002-3614-3455				Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Basbaum AI, 1999, REGION ANESTH PAIN M, V24, P59, DOI 10.1016/S1098-7339(99)90167-0; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Besson JM, 1999, LANCET, V353, P1610, DOI 10.1016/S0140-6736(99)01313-6; BLACHER RS, 1987, PSYCHOL EXPERIENCE S; Carlton SM, 1998, PAIN FORUM, V7, P71; Carr DB, 1998, J CLIN ANESTH, V10, P77, DOI 10.1016/S0952-8180(97)00227-4; Carr DB, 1998, JAMA-J AM MED ASSOC, V279, P1114, DOI 10.1001/jama.279.14.1114; CARR DB, 1992, PUBLICATION DEP HLTH; CARR DB, 1998, NEURAL BLOCKADE CLIN; CEPEDA MS, 1996, REGIONAL ANESTHESIA; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CHAPMAN CR, 1999, IN PRESS LANCET; Crile GW, 1910, BOSTON MED SURG J, V163, P893, DOI 10.1056/NEJM191012151632401; DEARDORFF WW, 1997, PREPARING SURG MIND; DENTON JE, 1949, JAMA-J AM MED ASSOC, V141, P1051, DOI 10.1001/jama.1949.62910150002007; EGBERT LD, 1964, NEW ENGL J MED, V270, P825, DOI 10.1056/NEJM196404162701606; Federation of State Medical Boards of the United States, 1998, MOD GUID US CONTR SU; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; Gibson HB, 1994, PSYCHOL PAIN ANAESTH; GOUDAS LC, 1995, CURR OPIN ANAESTH, V8, P455; HORTON CW, 1983, LONG TIME PREDICTION; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; JONES JG, 1996, 11 WORLD C AN LOND; KEATS AS, 1959, J APPL PHYSIOL, V3, P35; Kehlet H, 1997, BRIT J ANAESTH, V78, P606, DOI 10.1093/bja/78.5.606; Kiecolt-Glaser JK, 1998, AM PSYCHOL, V53, P1209, DOI 10.1037/0003-066X.53.11.1209; Lambert DG, 1998, BRIT J ANAESTH, V81, P1; LASAGNA L, 1962, LANCET, V2, P572; LASAGNA L, 1954, AM J MED, V16, P770, DOI 10.1016/0002-9343(54)90441-6; LIPKOWSKI AW, 1995, PEPTIDES SYNTHESIS S; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCORMACK K, 1994, PAIN, V59, P9, DOI 10.1016/0304-3959(94)90045-0; MCGRATH PA, 1996, PAIN 1996 UPDATED RE; MCQUAY H, 1999, IN PRESS LANCET; McQuay HJ, 1998, EVIDENCE BASED RESOU; Merskey H., 1994, CLASSIFICATION CHRON, V2nd ed; *NAT HLTH MED RES, INP RESS CLIN PRACT; NIV D, 1998, EVALUATION TREATMENT; PRICE DD, 1994, PROGR PAIN RES MANAG, V3; RAWAL N, 1994, PAIN, V57, P117, DOI 10.1016/0304-3959(94)90115-5; READY LB, 1995, ANESTHESIOLOGY, V82, P1071; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; Ready LB, 1992, MANAGEMENT ACUTE PAI; Royal College of Surgeons of England and The College of Anaesthetists, 1990, REP WORK PART PAIN S; SCHEINERMAN ER, 1996, INIVITATION DYNAMICA; SILBERT BS, 1998, ANESTHESIA BIOL FDN; SINATRA RS, 1998, NEURAL BLOCKADE CLIN; STRUNIN L, 1995, BRIT J ANAESTH, V75, P123; TADDIO A, 1995, J PAIN SYMPTOM MANAG, V10, P456, DOI 10.1016/0885-3924(95)00058-7; ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402; WALTERS ET, 1992, HYPERALGESIA ALLODYN; WILLIAMSON PB, 1988, PATTONS PRINCIPLES L; Woolf CJ, 1998, PAIN, V77, P227, DOI 10.1016/S0304-3959(98)00099-2; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; WULF H, 1997, CURR OPIN ANAESTH, V10, P380	58	475	503	2	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	1999	353	9169					2051	2058		10.1016/S0140-6736(99)03313-9	http://dx.doi.org/10.1016/S0140-6736(99)03313-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376632				2022-12-28	WOS:000080812200040
J	Giuffrida, A; Gravelle, H; Roland, M				Giuffrida, A; Gravelle, H; Roland, M			Measuring quality of care with routine data: avoiding confusion between performance indicators and health outcomes	BRITISH MEDICAL JOURNAL			English	Article							PREVENTABLE HOSPITALIZATIONS; ACCESS; RATES; POPULATION; ADMISSIONS; CHILDREN	Objective To investigate the impact of factors outside the control of primary care on performance indicators proposed as measures of the quality of primary care. Design Multiple regression analysis relating admission rates standardised for age and sex for asthma, diabetes, and epilepsy to socioeconomic population characteristics and to the supply of secondary care resources. Setting 90 family health services authorities in England, 1989-90 to 1994-5. Results At health authority level socioeconomic characteristics, health status, and secondary care supply factors explained 45% of the variation in admission rates for asthma, 33% for diabetes, and 55% for epilepsy. When health authorities were ranked, only four of the 10 with the highest age-sex standardised admission rates for asthma in 1994-5 remained in the top 10 when allowance was made for socioeconomic characteristics, health status, and secondary care supply factors. There was also substantial year to year variation in the rates. Conclusion Health outcomes should relate to crude rates of adverse events in the population. These give the best indication of the size of a health problem. Performance indicators, however, should relate to those aspects of care which can be altered by the staff whose performance is being measured.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO10 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.			Gravelle, Hugh/0000-0002-7753-4233				ARNOLD J, 1989, USING HLTH OUTCOMES; Aveyard P, 1997, J Eval Clin Pract, V3, P275, DOI 10.1046/j.1365-2753.1997.t01-1-00004.x; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BEGLEY CE, 1994, J COMMUN HEALTH, V19, P377, DOI 10.1007/BF02260406; Billings J, 1996, HEALTH AFFAIR, V15, P239, DOI 10.1377/hlthaff.15.3.239; Billings J, 1989, USE SMALL AREA ANAL; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; CASANOVA C, 1995, INT J HEALTH SERV, V25, P283, DOI 10.2190/PCF7-ALX9-6CN3-7X9G; DUROJAIYE LIA, 1989, PUBLIC HEALTH, V103, P181, DOI 10.1016/S0033-3506(89)80073-3; FARMER A, 1990, BRIT J GEN PRACT, V40, P56; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Lambrew JM, 1996, MED CARE, V34, P138, DOI 10.1097/00005650-199602000-00006; *MA DIV HLTH CAR F, 1995, IMPR PRIM CAR US PRE; MACKINNON JG, 1983, J ECONOMETRICS, V21, P53, DOI 10.1016/0304-4076(83)90119-7; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; *NHS EX, 1998, NEW NHS NAT FRAM ASS; *NHS EX, 1994, HLTH SERV IND HDB 19; *SECR STAT HLTH, 1997, CM3807; Smith P., 1994, FORMULA DISTRIBUTING; WATTS JP, 1996, EUR RESPIR J, V9, P2087; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITE H, 1978, ECONOMETRICA, V46, P817	24	118	121	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					94	98		10.1136/bmj.319.7202.94	http://dx.doi.org/10.1136/bmj.319.7202.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	216JD	10398635	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000081438200034
J	Lakhani, M				Lakhani, M			A memorable patient - "Thank you for ending 40 years of misery"	BRITISH MEDICAL JOURNAL			English	Article																		AYULO JA, 1972, AM J GASTROENTEROL, V57, P207; Balint M., 1986, DOCTOR HIS PATIENT I; DUNCOMBE VM, 1977, GUT, V18, P531, DOI 10.1136/gut.18.7.531	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					86	86		10.1136/bmj.319.7202.86	http://dx.doi.org/10.1136/bmj.319.7202.86			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398628	Green Published			2022-12-28	WOS:000081438200024
J	Ho, PKH; Thomas, DS; Friend, RH; Tessler, N				Ho, PKH; Thomas, DS; Friend, RH; Tessler, N			All-polymer optoelectronic devices	SCIENCE			English	Article							LIGHT-EMITTING-DIODES; CONJUGATED POLYMERS; MICROCAVITIES; EMISSION; ENHANCEMENT; VINYLENE); LASERS; LAYER	Composites of nanoparticles and conjugated polymers that exhibit composition-tunable optical constants have been developed for use in semiconducting photonic structures. For example, the 550-nanometer wavelength in-plane refractive index of poly(p-phenylenevinylene)-silica composites can be tailored over the range of 1.6 to 2.7, allowing efficient distributed Bragg reflectors and waveguides to be fabricated. Low levels of chemical doping improve electrical conductivity through these structures without detriment to their photonic properties, Exemplifying these concepts, all-polymer microcavities and microcavity light-emitting diodes were demonstrated. Appropriate confinement of photons and electron-hole pairs in these organic semiconductor-based structures can be achieved.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England	University of Cambridge	Tessler, N (corresponding author), Univ Cambridge, Cavendish Lab, Madingley Rd, Cambridge CB3 0HE, England.		Tessler, Nir/A-9849-2008	Tessler, Nir/0000-0002-5354-3231; Thomas, Steve/0000-0002-7802-4825; Friend, Richard Henry/0000-0001-6565-6308				ARIAS AC, IN PRESS PHYS REV B; Blom PWM, 1998, APPL PHYS LETT, V73, P3914, DOI 10.1063/1.122934; Brittain S, 1998, PHYS WORLD, V11, P31; Carter JC, 1997, APPL PHYS LETT, V71, P34, DOI 10.1063/1.119483; Carter SA, 1997, APPL PHYS LETT, V71, P1145, DOI 10.1063/1.119848; Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736; Friend RH, 1999, NATURE, V397, P121, DOI 10.1038/16393; Granlund T, 1998, CHEM PHYS LETT, V288, P879, DOI 10.1016/S0009-2614(98)00320-0; Gruner J, 1996, J APPL PHYS, V80, P207, DOI 10.1063/1.362806; HAN CC, 1989, SYNTHETIC MET, V30, P123, DOI 10.1016/0379-6779(89)90648-6; HARRISON MG, 1993, SYNTHETIC MET, V55, P218, DOI 10.1016/0379-6779(93)90936-Q; Heeger AJ, 1998, SOLID STATE COMMUN, V107, P673, DOI 10.1016/S0038-1098(98)00215-4; Jordan RH, 1996, APPL PHYS LETT, V69, P1997, DOI 10.1063/1.116858; Krevelen D.W.V., 1990, PROPERTIES POLYM; Lidzey DG, 1998, NATURE, V395, P53, DOI 10.1038/25692; NAKAYAMA T, 1993, APPL PHYS LETT, V63, P594, DOI 10.1063/1.109959; PILENI MP, 1993, J PHYS CHEM-US, V97, P6961, DOI 10.1021/j100129a008; Sakamoto A, 1997, J PHYS CHEM B, V101, P1726, DOI 10.1021/jp9619649; Schubert EF, 1996, J LIGHTWAVE TECHNOL, V14, P1721, DOI 10.1109/50.507950; SCHUBERT EF, 1994, SCIENCE, V265, P943, DOI 10.1126/science.265.5174.943; Schwartz BJ, 1997, PHILOS T R SOC A, V355, P775, DOI 10.1098/rsta.1997.0043; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; TAI K, 1990, APPL PHYS LETT, V56, P2496, DOI 10.1063/1.102869; Tessler N, 1997, APPL PHYS LETT, V70, P556, DOI 10.1063/1.118207; Tessler N, 1998, ADV MATER, V10, P64, DOI 10.1002/(SICI)1521-4095(199801)10:1<64::AID-ADMA64>3.0.CO;2-G; Yamamori A, 1998, APPL PHYS LETT, V72, P2147, DOI 10.1063/1.121304; YOKOYAMA H, 1992, SCIENCE, V256, P66, DOI 10.1126/science.256.5053.66	27	281	295	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					233	236		10.1126/science.285.5425.233	http://dx.doi.org/10.1126/science.285.5425.233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398595				2022-12-28	WOS:000081346000035
J	Muretto, P; Angelucci, E				Muretto, P; Angelucci, E			Successful treatment of severe thalassemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Azienda Osped Pesaro, I-61100 Pesaro, Italy		Muretto, P (corresponding author), Azienda Osped Pesaro, I-61100 Pesaro, Italy.		Angelucci, Emanuele/AAC-1855-2021	Angelucci, Emanuele/0000-0002-6512-6080					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					92	92		10.1056/NEJM199907083410205	http://dx.doi.org/10.1056/NEJM199907083410205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395633				2022-12-28	WOS:000081316200005
J	Philips, DP; Christenfeld, N; Ryan, NM				Philips, DP; Christenfeld, N; Ryan, NM			An increase in the number of deaths in the United States in the first week of the month - An association with substance abuse and other causes of death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; ALCOHOL-CONSUMPTION; EMERGENCY ROOM; DISABILITY; MORTALITY; WORKING; INCOME	Background and Methods There are regular changes in mortality rates, such as increased rates of death from influenza in the winter and from motor vehicle accidents on long holiday weekends. Previous research has shown that among persons with schizophrenia, the rates of cocaine use and hospital admissions increase at the beginning of the month, after the receipt of disability payments, Using computerized data from all death certificates in the United States between 1973 and 1988, we compared the number of deaths in the fi rst week of the month with the number of deaths in the last week of the preceding month. Results The average number of deaths was about 5500 per day, or about 165,000 in a 30-day month. There were 100.9 deaths (95 percent confidence interval, 100.8 to 101.0) in the first week of the month for every 100 deaths in the last week of the preceding month, This was equivalent to about 4320 more deaths in the first week of each month than in the last week of the preceding month in an average year. Between 1983 and 1988, for deaths involving substance abuse and an external cause (such as suicides, accidents, and homicides), there were 114.2 deaths (95 percent confidence interval, 110.5 to 117.9) in the first week of the month for every 100 in the last week of the preceding month. There were significant increases in the number of deaths in the first week of the month for many causes of death, including substance abuse, natural causes, homicides, suicides, and motor vehicle accidents. Conclusions In the United States, the number of deaths is higher in the first week of the month than in the last week of the preceding month. The increase at the beginning of the month is associated with substance abuse and other causes of death. (N Engl J Med 1999;341:93-8.) (C) 1999, Massachusetts Medical Society.	Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Philips, DP (corresponding author), Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA.							Borges G, 1996, J STUD ALCOHOL, V57, P543, DOI 10.15288/jsa.1996.57.543; CHERPITEL CJ, 1994, ALCOHOL ALCOHOLISM, V29, P211; Chou SP, 1996, ALCOHOL CLIN EXP RES, V20, P1423, DOI 10.1111/j.1530-0277.1996.tb01144.x; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; Cornelius JR, 1996, ALCOHOL CLIN EXP RES, V20, P1451, DOI 10.1111/j.1530-0277.1996.tb01148.x; *DEP COMM, 1998, STAT ABSTR US 1998; *DEP COMM, 1998, STAT ABSTR US 1988; DUFFY JC, 1995, INT J EPIDEMIOL, V24, P100, DOI 10.1093/ije/24.1.100; Durkheim E, 1897, SUICIDE; Gardner M. J., 1989, STAT CONFIDENCE; Gresenz CR, 1998, COMMUNITY MENT HLT J, V34, P337, DOI 10.1023/A:1018779805833; *NAT CTR HLTH STAT, 1977, VIT STAT US 1973 1 A, V2; *NAT CTR HLTH STAT, 1985, MULT CAUS DEATH 1983; *NAT CTR HLTH STAT, 1991, VIT STAT US 1973 1 A, V2; *NAT CTR HLTH STAT, 1984, MORT DET FIL 1973 19; *NAT CTR HLTH STAT, 1984, VIT STAT US 1979 1 A, V2; PHILLIPS DP, 1988, LANCET, V2, P728; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; PHILLIPS DP, 1992, PSYCHOSOM MED, V54, P532, DOI 10.1097/00006842-199209000-00001; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; POIKOLAINEN K, 1995, J CIN EPIDEMIOL, V48, P1; Rosenheck R, 1997, PSYCHIATR SERV, V48, P789; SATEL SL, 1995, NEW ENGL J MED, V333, P794, DOI 10.1056/NEJM199509213331210; SHANER A, 1995, NEW ENGL J MED, V333, P777, DOI 10.1056/NEJM199509213331207; Spielberg C, 1996, AM HEART J, V132, P579, DOI 10.1016/S0002-8703(96)90241-0; VANDERPALEN J, 1995, NEW ZEAL MED J, V108, P332; WILLICH SN, 1994, CIRCULATION, V90, P87, DOI 10.1161/01.CIR.90.1.87	27	97	98	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					93	98		10.1056/NEJM199907083410206	http://dx.doi.org/10.1056/NEJM199907083410206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214ET	10395634	Bronze			2022-12-28	WOS:000081316200006
J	Gaffney, D; Pollock, AM; Price, D; Shaoul, J				Gaffney, D; Pollock, AM; Price, D; Shaoul, J			The private finance initiative - NHS capital expenditure and the private finance initiative - expansion or contraction?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England; Northumbria Univ, Social Welf Res Unit, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England; Univ Manchester, Dept Accounting, Manchester M13 9PL, Lancs, England	University of London; University College London; Northumbria University; University of Manchester	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				Gaffney D, 1999, PUBLIC MONEY MANAGE, V19, P55, DOI 10.1111/1467-9302.00153; Gaffney D., 1997, CAN NHS AFFORD PRIVA; *HC, 1998, NHS ENGL SUMM ACC 19; MEARA R, 1991, 11 KINGS FUND I, P6; Pollock AM, 1998, BRIT MED J, V317, P157, DOI 10.1136/bmj.317.7152.157; POLLOCK AM, 1998, HLTH REV         WIN, P20; Shaoul J., 1998, MANAGEMENT ACCOUNTIN, V9, P95; WEBSTER C, 1998, NATL HLTH SERVICE PO, P1; WEBSTER C, 1990, HLTH SERVICES WAR, V2, P261	9	61	61	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					48	51		10.1136/bmj.319.7201.48	http://dx.doi.org/10.1136/bmj.319.7201.48			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390465	Green Published			2022-12-28	WOS:000081326500038
J	Guyatt, G; Delbanco				Guyatt, G; Delbanco			A 75-year-old man with congestive heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; BETA-BLOCKER THERAPY; MEDICAL LITERATURE; USERS GUIDES; DILATED CARDIOMYOPATHY; MULTIDISCIPLINARY INTERVENTION; INDIVIDUAL PATIENTS; DIURETIC THERAPY; ELDERLY PATIENTS; CARDIAC-FAILURE		McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University; McMaster University	Guyatt, G (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							Adams KF, 1998, AM HEART J, V135, pS204, DOI 10.1016/S0002-8703(98)70251-0; Auerbach D, 1997, CHEST, V112, P1514; Avezum A, 1998, CAN J CARDIOL, V14, P1045; BIGGER JT, 1987, CIRCULATION, V75, P28; Brater DC, 1998, NEW ENGL J MED, V339, P387, DOI 10.1056/NEJM199808063390607; Cleland JGF, 1996, J INTERN MED, V239, P317, DOI 10.1046/j.1365-2796.1996.462801000.x; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Connolly SJ, 1997, LANCET, V350, P1417; Cowie MR, 1997, EUR HEART J, V18, P208; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; Dormans TPJ, 1998, DRUGS, V55, P165, DOI 10.2165/00003495-199855020-00001; Doughty RN, 1997, EUR HEART J, V18, P560; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Elkayam U, 1998, CARDIOLOGY, V89, P38, DOI 10.1159/000047278; Ferguson JJ, 1997, CIRCULATION, V95, P761; FLENLEY DC, 1981, LANCET, V1, P681; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gheorghiade M, 1998, AM HEART J, V135, pS231, DOI 10.1016/S0002-8703(98)70253-4; GOLD MR, 1991, CHEST, V100, P1215, DOI 10.1378/chest.100.5.1215; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Guyatt GH., 1991, ACP J CLUB, V114, pA; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; HARLAN WR, 1977, ANN INTERN MED, V86, P133, DOI 10.7326/0003-4819-86-2-133; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HO KKL, 1993, J AM COLL CARDIOL  S, V22, P6; JAESCHKE R, 1995, CAN MED ASSOC J, V152, P351; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; KALON KL, 1993, CIRCULATION, V88, P107; KANNEL WB, 1994, BRIT HEART J, V72, P3; KANNEL WB, 1988, AM HEART J, V115, P869, DOI 10.1016/0002-8703(88)90891-5; Koniaris LS, 1998, J AM COLL CARDIOL, V31, P745, DOI 10.1016/S0735-1097(98)00003-5; Konstam MA, 1998, PROG CARDIOVASC DIS, V41, P65, DOI 10.1016/S0033-0620(98)80033-9; KVALE PA, 1980, ANN INTERN MED, V93, P391; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; Mahon J, 1996, BRIT MED J, V312, P1069; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PATEL A, 1991, AM REV RESPIR DIS, V14, P962; Perry G, 1997, NEW ENGL J MED, V336, P525; Piepoli MF, 1998, EUR HEART J, V19, P830; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; REMES J, 1992, EUR HEART J, V13, P588, DOI 10.1093/oxfordjournals.eurheartj.a060220; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rich MW, 1996, AM J MED, V101, P270, DOI 10.1016/S0002-9343(96)00172-6; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; Schulman KA, 1996, INT J TECHNOL ASSESS, V12, P698, DOI 10.1017/S0266462300010989; Senni M, 1999, ARCH INTERN MED, V159, P29, DOI 10.1001/archinte.159.1.29; Stevenson LW, 1998, AM HEART J, V135, pS293, DOI 10.1016/S0002-8703(98)70257-1; TEERLINK JR, 1991, AM HEART J, V121, P1852, DOI 10.1016/0002-8703(91)90072-P; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; Tresch DD, 1997, J AM GERIATR SOC, V45, P1128, DOI 10.1111/j.1532-5415.1997.tb05979.x; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; Visser FC, 1996, CARDIOLOGY, V87, P23, DOI 10.1159/000177164; WHEELDON NM, 1993, Q J MED, V86, P17; Zarembski DG, 1996, AM J CARDIOL, V77, P1247, DOI 10.1016/S0002-9149(96)00175-0	68	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2321	2328		10.1001/jama.281.24.2321	http://dx.doi.org/10.1001/jama.281.24.2321			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386557				2022-12-28	WOS:000080925600032
J	Shapiro, MF; Morton, SC; McCaffrey, DF; Senterfitt, JW; Fleishman, JA; Perlman, JF; Athey, LA; Keesey, JW; Goldman, DP; Berry, SH; Bozzette, SA				Shapiro, MF; Morton, SC; McCaffrey, DF; Senterfitt, JW; Fleishman, JA; Perlman, JF; Athey, LA; Keesey, JW; Goldman, DP; Berry, SH; Bozzette, SA		HCSUS Consortium	Variations in the care of HIV-infected adults in the United States - Results from the HIV Cost and Services Utilization Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIRETROVIRAL THERAPY; MANAGED CARE; DRUG-USE; DISEASE; GROWTH; RECOMMENDATIONS; LESSONS; PANEL; RACE	Context Studies of selected populations suggest that not all persons infected with human immunodeficiency virus (HIV) receive adequate care. Objective To examine variations in the care received by a national sample representative of the adult US population infected with HIV. Design Cohort study that consisted of 3 interviews from January 1996 to January 1998 conducted by the HIV Cost and Services Utilization Consortium. Patients and Setting Multistage probability sample of 2864 respondents (68% of those targeted for sampling), who represent the 231 400 persons at least 18 years old, with known HIV infection receiving medical care in the 48 contiguous United States in early 1996 in facilities other than emergency departments, the military, or prisons. The first follow-up consisted of 2466 respondents and the second had 2267 (65% of all surviving sampled subjects). Main Outcome Measures Service utilization (<2 ambulatory visits, at least 1 emergency department visit that did not lead to hospitalization, at least 1 hospitalization) and medication utilization (receipt of antiretroviral therapy and prophylaxis against Pneumocystis carinii pneumonia), Results Inadequate HIV care was commonly reported at the time of interviews conducted from early 1996 to early 1997 but declined to varying degrees by late 1997, Twenty-three percent of patients initially and 15% of patients subsequently had emergency department visits that did not lead to hospitalization, 30% initially and 26% subsequently of those who had CD4 cell counts below 0.20 x 10(9)/L did not receive P carinii pneumonia prophylaxis, and 41% initially and 15% subsequently of those who had CD4 cell counts below 0.50 x 10(9)/L did not receive antiretroviral therapy (protease inhibitor or nonnucleoside reverse transcriptase inhibitor). Inferior patterns of care were seen far many of these measures in blacks and Latinos compared with whites, the uninsured and Medicaid-insured compared with the privately insured, women compared with men, and other risk and/or exposure groups compared with men who had sex with men even after CD4 cell count adjustment. With multivariate adjustment, many differences remained statistically significant. Even by early 1998, fewer blacks, women, and uninsured and Medicaid-insured persons had started taking antiretroviral medication (CD4 cell count adjusted P Values <.001 to <.005). Conclusions Access to care improved from 1996 to 1998 but remained suboptimal. Blacks, Latinos, women, the uninsured, and Medicaid-insured all had less desirable patterns of care. Strategies to ensure optimal care for patients with HIV requires identifying the causes of deficiency and addressing these important shortcomings in care.	Rand Corp, HCSUS Off, Hlth Program, Santa Monica, CA 90407 USA; Rand Corp, Survey Res Grp, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA; Cty Los Angeles, AIDS Off, Los Angeles, CA USA; Agcy Hlth Care Policy & Res, Ctr Cost & Financing Studies, Rockville, MD 20852 USA; Univ Chicago, Natl Opin Res Ctr, Survey Operat Ctr, Chicago, IL 60637 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, Hlth Serv Res & Dev Unit, San Diego, CA USA	RAND Corporation; RAND Corporation; University of California System; University of California Los Angeles; Agency for Healthcare Research & Quality; University of Chicago; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Shapiro, MF (corresponding author), Rand Corp, HCSUS Off, Hlth Program, 1700 Main St, Santa Monica, CA 90407 USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				BERRY SH, 1988, MR1090AHCPR RAND; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Brick J M, 1996, Stat Methods Med Res, V5, P215, DOI 10.1177/096228029600500302; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Cunningham WE, 1997, J CLIN EPIDEMIOL, V50, P829, DOI 10.1016/S0895-4356(97)00061-9; DUAN N, 1998, MR1060AHCPR RAND; FLEISHMAN JA, 1994, HEALTH SERV RES, V29, P527; FRANKEL MR, IN PRESS HLTH SERV R; Gold M, 1996, HEALTH AFFAIR, V15, P153, DOI 10.1377/hlthaff.15.3.153; GRAVES EJ, 1997, VITAL HLTH STAT 13, V128, P1; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; Kish L, 1965, SURVEY SAMPLING; Lam NSN, 1996, PROF GEOGR, V48, P321, DOI 10.1111/j.0033-0124.1996.00321.x; MILLER RH, 1994, ANNU REV PUBL HEALTH, V15, P437; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Niemcryk SJ, 1998, J COMMUN HEALTH, V23, P137, DOI 10.1023/A:1018713524788; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SHALALA D, 1998, BRIEFING PRESS ELIMI; SHAPIRO MF, IN PRESS HLTH SERV R; SIRKEN MG, 1970, J AM STAT ASSOC, V65, P257, DOI 10.2307/2283590; Stone VE, 1997, J GEN INTERN MED, V12, P150, DOI 10.1046/j.1525-1497.1997.012003150.x; Welch WP, 1996, HEALTH AFFAIR, V15, P201, DOI 10.1377/hlthaff.15.3.201	24	594	599	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2305	2315		10.1001/jama.281.24.2305	http://dx.doi.org/10.1001/jama.281.24.2305			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207FN	10386555	Bronze			2022-12-28	WOS:000080925600030
J	Ascherio, A; Katan, MB; Zock, PL; Stampfer, MJ; Willett, WC				Ascherio, A; Katan, MB; Zock, PL; Stampfer, MJ; Willett, WC			Trans fatty acids and coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION; PLASMA-LIPOPROTEIN; HEALTHY-SUBJECTS; UNITED-STATES; STEARIC-ACID; DIETARY-FAT; RISK; HUMANS; LIPIDS; SERUM		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands	Harvard University; Harvard T.H. Chan School of Public Health; Wageningen University & Research	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793; Zock, Peter/0000-0002-0322-0565				ALMENDINGEN K, 1995, J LIPID RES, V36, P370; ANDERSON JT, 1961, J NUTR, V75, P388, DOI 10.1093/jn/75.4.388; ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; Aro A, 1997, AM J CLIN NUTR, V65, P1419, DOI 10.1093/ajcn/65.5.1419; Aro A, 1998, NUTR METAB CARDIOVAS, V8, P402; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; BoltonSmith C, 1996, EUR HEART J, V17, P837; Clevidence BA, 1997, ARTERIOSCL THROM VAS, V17, P1657, DOI 10.1161/01.ATV.17.9.1657; *EXP PAN T FATT AC, 1995, AM J CLIN NUTR, V62, pS655; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNTER JE, 1991, AM J CLIN NUTR, V54, P363, DOI 10.1093/ajcn/54.2.363; Judd J, 1998, FASEB J, V12, pA229; JUDD JT, 1994, AM J CLIN NUTR, V59, P861, DOI 10.1093/ajcn/59.4.861; KATAN MB, 1995, LANCET, V346, P1245, DOI 10.1016/S0140-6736(95)91858-2; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI [10.1146/annurev.nu.15.070195.002353, 10.1146/annurev.nutr.15.1.473]; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KROMHOUT D, 1995, PREV MED, V24, P308, DOI 10.1006/pmed.1995.1049; Lichtenstein AH, 1999, NEW ENGL J MED, V340, P1933, DOI 10.1056/NEJM199906243402501; LICHTENSTEIN AH, 1993, ARTERIOSCLER THROMB, V13, P154, DOI 10.1161/01.ATV.13.2.154; LITIN L, 1993, NEW ENGL J MED, V329, P1969, DOI 10.1056/NEJM199312233292620; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Sundram K, 1997, J NUTR, V127, pS514, DOI 10.1093/jn/127.3.514S; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; Zock PL, 1997, ATHEROSCLEROSIS, V131, P7, DOI 10.1016/S0021-9150(96)06063-7; ZOCK PL, 1992, J LIPID RES, V33, P399	31	351	379	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1994	1998		10.1056/NEJM199906243402511	http://dx.doi.org/10.1056/NEJM199906243402511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379026				2022-12-28	WOS:000081088500011
J	Salib, RJ; Prior, AJ; Howard, DJ				Salib, RJ; Prior, AJ; Howard, DJ			Prevention before cure	LANCET			English	Article									Royal Natl Throat Nose & Ear Hosp, Inst Laryngol & Otol, Professorial Unit, London WC1X 8EE, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Salib, RJ (corresponding author), 10 Roxborough Ave, Harrow HA1 3BU, Middx, England.							Beaty MM, 1998, HEAD NECK-J SCI SPEC, V20, P399, DOI 10.1002/(SICI)1097-0347(199808)20:5<399::AID-HED7>3.0.CO;2-T; Dohar JE, 1996, OTOLARYNG HEAD NECK, V115, P94, DOI 10.1016/S0194-5998(96)70143-2; GAFFNEY R, 1993, CLIN OTOLARYNGOL, V18, P268, DOI 10.1111/j.1365-2273.1993.tb00845.x; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2124	2124		10.1016/S0140-6736(99)03529-1	http://dx.doi.org/10.1016/S0140-6736(99)03529-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382698				2022-12-28	WOS:000080969300014
J	Wilson, AM; Dempsey, OJ; Coutie, WJR; Sims, EJ; Lipworth, BJ				Wilson, AM; Dempsey, OJ; Coutie, WJR; Sims, EJ; Lipworth, BJ			Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids	LANCET			English	Article							FLUTICASONE PROPIONATE		Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.							Agertoft L, 1997, J ALLERGY CLIN IMMUN, V99, P773, DOI 10.1016/S0091-6749(97)80011-5; BERG E, 1995, J AEROSOL MED S3, V8, P3; Johnson M, 1998, J ALLERGY CLIN IMMUN, V101, pS434, DOI 10.1016/S0091-6749(98)70155-1; Lipworth BJ, 1998, SEMIN RESP CRIT CARE, V19, P625, DOI 10.1055/s-2007-1009437; OLSSON B, 1995, J AEROSOL MED, V8, pS13	5	31	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2128	2128		10.1016/S0140-6736(99)01443-9	http://dx.doi.org/10.1016/S0140-6736(99)01443-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382703				2022-12-28	WOS:000080969300019
J	Zoller, H; Pietrangelo, A; Vogel, W; Weiss, G				Zoller, H; Pietrangelo, A; Vogel, W; Weiss, G			Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis	LANCET			English	Article							TRANSFERRIN RECEPTOR; NUCLEOTIDE-SEQUENCE; IRON-METABOLISM; HEMOCHROMATOSIS; GENE; MICE; HFE	Background Although the gene for hereditary haemochromatosis has been cloned, the mechanism by which iron uptake is inappropriately increased in this disorder is unclear. Iron absorption is regulated by the duodenal metal transporter, DMT-1, also called NRAMP-2. We investigated the expression of NRAMP-2 in patients with hereditary haemochromatosis. Methods Duodenal biopsy samples were taken from 20 patients with haemochromatosis homozygous for the C282Y mutation and from ten controls. NRAMP-2 expression was assessed by northern blotting and competitive PCR, NRAMP-2 mRNA was sequenced in seven patients and two controls. Findings Duodenal NRAMP-2 mRNA concentrations were increased in patients as estimated by Northern blotting. Accordingly, competitive PCR showed significantly higher NRAMP-2 cDNA concentrations in patients than in controls (mean 3.43 [SD 0.61] vs 1.11 [0.74] log ng competitorx10(4); p<0.001). No mutations were found within the NRAMP-2 mRNA. Duodenal NRAMP-2 mRNA expression was correlated with serum ferritin in controls (r=-0.94, p=0.001) but not in patients (r=-0.18, p=0.8). Interpretation Increased NRAMP-2 mRNA expression in duodenal mucosa of patients with hereditary haemochromatosis may promote duodenal iron uptake and lead to iron overload.	Univ Innsbruck Hosp, Dept Internal Med, A-6020 Innsbruck, Austria; Univ Modena, Dept Med, I-41100 Modena, Italy	Medical University of Innsbruck; Universita di Modena e Reggio Emilia	Weiss, G (corresponding author), Univ Innsbruck Hosp, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	guenter.weiss@uibk.ac.at	Pietrangelo, Antonello/K-1517-2016; Zoller, Heinz/AAD-7225-2019	Pietrangelo, Antonello/0000-0002-7411-935X; Weiss, Guenter/0000-0003-0709-2158	Telethon [E.0609] Funding Source: Medline	Telethon(Fondazione Telethon)		Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kishi F, 1997, MOL IMMUNOL, V34, P839, DOI 10.1016/S0161-5890(97)00110-7; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; POWELL LW, 1994, IRON METABOLISM HLTH, P228; Rothenberg BE, 1996, P NATL ACAD SCI USA, V93, P1529, DOI 10.1073/pnas.93.4.1529; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	21	145	148	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2120	2123		10.1016/S0140-6736(98)11179-0	http://dx.doi.org/10.1016/S0140-6736(98)11179-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382697				2022-12-28	WOS:000080969300013
J	Quill, TE				Quill, TE			Same old seventeen-dollar lamps	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Genesee Hosp, Rochester, NY 14607 USA		Quill, TE (corresponding author), Genesee Hosp, 224 Alexander St, Rochester, NY 14607 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					1022	1024		10.7326/0003-4819-130-12-199906150-00023	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00023			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383354				2022-12-28	WOS:000080894700012
J	Palmer, C				Palmer, C			Physicians for Human Rights raise concerns for ethnic Albanians in refugee camps and those left inside Kosovo	LANCET			English	Editorial Material									Phys Human Rights, Bosnia Project, Boston, MA 02116 USA		Palmer, C (corresponding author), Phys Human Rights, Bosnia Project, 100 Baylston St,Suite 702, Boston, MA 02116 USA.							Leaning J, 1999, LANCET, V353, P921, DOI 10.1016/S0140-6736(99)90043-0	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2065	2066		10.1016/S0140-6736(99)05294-0	http://dx.doi.org/10.1016/S0140-6736(99)05294-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376635				2022-12-28	WOS:000080812200043
J	Torrance, CJ; Das, R; Allison, MC				Torrance, CJ; Das, R; Allison, MC			Use of chaperones in clinics for genitourinary medicine: survey of consultants	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS		Royal Gwent Hosp, Dept Genitourinary Med, Newport NP9 2UB, Gwent, Wales; Royal Gwent Hosp, Dept Adult Med, Newport NP9 2UB, Gwent, Wales	Royal Gwent Hospital; Royal Gwent Hospital	Allison, MC (corresponding author), Royal Gwent Hosp, Dept Genitourinary Med, Newport NP9 2UB, Gwent, Wales.							JONES RH, 1983, J ROY COLL GEN PRACT, V33, P25; PENN MA, 1992, J FAM PRACTICE, V35, P639; *ROYAL COLL OBST G, 1997, INT EX REP WORK PART; SPEELMAN A, 1993, BRIT MED J, V307, P986, DOI 10.1136/bmj.307.6910.986	4	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					159	160		10.1136/bmj.319.7203.159	http://dx.doi.org/10.1136/bmj.319.7203.159			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406750	Bronze, Green Published			2022-12-28	WOS:000081619300021
J	Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG				Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG			Lesson of the week - Managing patients with deliberate self harm who refuse treatment in the accident and emergency department	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England		Hassan, TB (corresponding author), Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England.							*BRIT ASS ACC EM M, 1996, DIR 1996; *BRIT MED ASS, 1993, RIGHTS RESP DOCT; British Medical Association, 1995, ASS MENT CAP GUID DO; HAWTON K, 1996, ATTEMPTED SUICIDE OX; *MED DEF UN, 1996, CONS TREATM; *MEN PROT SOC, 1998, CONS	6	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					107	109		10.1136/bmj.319.7202.107	http://dx.doi.org/10.1136/bmj.319.7202.107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398639	Green Published			2022-12-28	WOS:000081438200038
J	Wang, HC; Bloom, O; Zhang, MH; Vishnubhakat, JM; Ombrellino, M; Che, JT; Frazier, A; Yang, H; Ivanova, S; Borovikova, L; Manogue, KR; Faist, E; Abraham, E; Andersson, J; Andersson, U; Molina, PE; Abumrad, NN; Sama, A; Tracey, KJ				Wang, HC; Bloom, O; Zhang, MH; Vishnubhakat, JM; Ombrellino, M; Che, JT; Frazier, A; Yang, H; Ivanova, S; Borovikova, L; Manogue, KR; Faist, E; Abraham, E; Andersson, J; Andersson, U; Molina, PE; Abumrad, NN; Sama, A; Tracey, KJ			HMG-1 as a late mediator of endotoxin lethality in mice	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; GROUP-1 PROTEIN HMG1; SEPTIC SHOCK; CHROMOSOMAL-PROTEINS; RECEPTOR ANTAGONIST; DEFICIENT MICE; FACTOR-ALPHA; GENE; AMPHOTERIN; CACHECTIN	Endotoxin, a constituent of Gram-negative bacteria, stimulates macrophages to release Large quantities of tumor necrosis factor (TNF) and interleukin-1 (IL-1), which can precipitate tissue injury and lethal shock (endotoxemia). Antagonists of TNF and IL-1 have shown Limited efficacy in clinical trials, possibly because these cytokines are early mediators in pathogenesis, Here a potential Late mediator of Lethality is identified and characterized in a mouse model. High mobility group-1 (HMG-1) protein was found to be released by cultured macrophages more than 8 hours after stimulation with endotoxin, TNF, or IL-1. Mice showed increased serum Levels of HMG-1 from 8 to 32 hours after endotoxin exposure. Delayed administration of antibodies to HMG-1 attenuated endotoxin lethality in mice, and administration of HMG-1 itself was lethal. Septic patients who succumbed to infection had increased serum HMG-1 levels, suggesting that this protein warrants investigation as a therapeutic target.	NYU, Sch Med, N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA; NYU, Sch Med, N Shore Univ Hosp, Dept Surg, Manhasset, NY 11030 USA; Picower Inst Med Res, Manhasset, NY 11030 USA; Univ Munich, Klinikum Grosshadern, Dept Surg, D-8000 Munich, Germany; Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Huddinge Univ Hosp, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden; Karolinska Inst, Astrid Lindgrens Childrens Hosp, Dept Rheumatol, Stockholm, Sweden	New York University; Northwell Health; North Shore University Hospital; New York University; Northwell Health; North Shore University Hospital; Northwell Health; University of Munich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Karolinska Institutet; Karolinska Institutet	Wang, HC (corresponding author), NYU, Sch Med, N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA.		Molina, Patricia E./AAK-9814-2021; Wang, Haichao/K-6310-2012; Andersson, Ulf/ABD-5162-2021; Wang, Haichao/AAU-2237-2021	Molina, Patricia E./0000-0002-3598-384X; Wang, Haichao/0000-0002-0211-9000; Andersson, Ulf/0000-0003-0316-3860; Wang, Haichao/0000-0002-0211-9000; BLOOM, ONA/0000-0002-8340-2392; Tracey, Kevin J/0000-0003-1884-6314				ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; Bao J, UNPUB; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; Bianchi M, 1996, J EXP MED, V183, P927, DOI 10.1084/jem.183.3.927; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BUSTIN M, 1979, CELL, V16, P181, DOI 10.1016/0092-8674(79)90199-5; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; Ferrari S, 1996, GENOMICS, V35, P367, DOI 10.1006/geno.1996.0369; FERRARI S, 1994, J BIOL CHEM, V269, P28803; FINK MP, 1995, CRIT CARE MED, V23, P989, DOI 10.1097/00003246-199506000-00001; FINK MP, 1990, J SURG RES, V49, P186, DOI 10.1016/0022-4804(90)90260-9; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; KILLION JW, 1986, INFECT IMMUN, V54, P1; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LEE KLD, 1987, NUCLEIC ACIDS RES, V15, P5051, DOI 10.1093/nar/15.13.5051; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MOLDAWER LL, 1994, CRIT CARE MED, V22, pS3; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REMICK DG, 1990, AM J PATHOL, V136, P49; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; Tracey KJ, 1999, SHOCK, V11, P224, DOI 10.1097/00024382-199903000-00012; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WALKER JM, 1980, FEBS LETT, V122, P264, DOI 10.1016/0014-5793(80)80453-4; Walker RE, 1996, J INFECT DIS, V174, P63, DOI 10.1093/infdis/174.1.63	37	2714	3146	2	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					248	251		10.1126/science.285.5425.248	http://dx.doi.org/10.1126/science.285.5425.248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398600				2022-12-28	WOS:000081346000040
J	Proctor, R; Burns, A; Powell, HS; Tarrier, N; Faragher, B; Richardson, G; Davies, L				Proctor, R; Burns, A; Powell, HS; Tarrier, N; Faragher, B; Richardson, G; Davies, L			Behavioural management in nursing and residential homes: a randomised controlled trial	LANCET			English	Article							PSYCHIATRIC-ILLNESS; ELDERLY PEOPLE; AGECAT; CARE	Background As more and more elderly people are being cared for in residential and nursing homes, how best can their psychiatric needs be met? We report on evaluation of a behavioural intervention by an old-age psychiatry hospital outreach team. Methods This randomised controlled trial of a training and education intervention over 6 months was done in south Manchester, UK. 12 matched nursing and residential homes were randomised to the control or intervention group and within each, the staff selected 10 residents whose behavioural problems made them difficult to care for. Care staff in the intervention homes attended seminars from the hospital outreach team and received measures were cognitive impairment and depression, behavioural disturbance, and functional ability, assessed developing care planning skills. The main outcome measures were cognitive impairment and depression, by the geriatric mental state schedule, Crichton Royal behaviour rating scale, and Barthel index, respectively. Findings Residents in the intervention group had significantly improved scores for depression (before-and-after change difference -0.5 [95% CI -0.8 to -0.1]) and for cognitive impairment (-0.7 [-1.1 to -0.2]) but not for behaviour rating or Barthel index. Interpretation Elderly residents can benefit from improved quality of care achieved training from a hospital outreach team.	Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Burns, A (corresponding author), Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England.			Davies, Linda/0000-0001-8801-3559; Burns, Alistair/0000-0002-9837-0645				American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; AMES D, 1988, AGE AGEING, V17, P249, DOI 10.1093/ageing/17.4.249; BARROWCLOUGH C, 1986, BEHAV PSYCHOTHER, V14, P192, DOI 10.1017/S0141347300014737; BARROWCLOUGH C, 1986, GOAL PLANNING ELDERL; BOND J, 1987, INT J GERIATR PSYCH, V2, P39, DOI 10.1002/gps.930020107; CLOUGH R, 1987, INDEPENDENT REV RESI; COPELAND JRM, 1990, INT J GERIATR PSYCH, V5, P47, DOI 10.1002/gps.930050108; COPELAND JRM, 1986, PSYCHOL MED, V16, P89, DOI 10.1017/S0033291700057779; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DEAN R, 1993, INT J GERIATR PSYCH, V8, P807, DOI 10.1002/gps.930081003; MAHONEY F I, 1965, Md State Med J, V14, P61; STERN MC, 1993, BRIT MED J, V306, P827, DOI 10.1136/bmj.306.6881.827; Wade D T, 1988, Int Disabil Stud, V10, P64; Wilkin D, 1982, Health Trends, V14, P98; WILKIN D, 1978, BRIT MED J, V2, P1274, DOI 10.1136/bmj.2.6147.1274; Willcocks D., 1987, PRIVATE LIVES PUBLIC	16	83	83	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					26	29		10.1016/S0140-6736(98)08237-3	http://dx.doi.org/10.1016/S0140-6736(98)08237-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	212XP	10406361				2022-12-28	WOS:000081243200010
J	McNaughton, NJ; Rasmussen, B; Fletcher, IR				McNaughton, NJ; Rasmussen, B; Fletcher, IR			SHRIMP uranium-lead dating of diagenetic xenotime in siliciclastic sedimentary rocks	SCIENCE			English	Article							U-PB	Diagenetic xenotime is common in silicic lactic sedimentary rocks, where it starts to form on detrital zircon shortly after sediment deposition. It is possible to estimate the age of sedimentary rocks by in situ uranium-lead analysis of that xenotime. Two Proterozoic sandstone units from northwestern Australia, previously constrained to the age interval of 1790 to 750 million years ago, have diagenetic xenotime ages of 1704 +/- 7 and 1704 +/- 14 million years ago. This method has potential for dating sedimentary sequences of all ages but should be especially valuable for refining the Precambrian time scale.	Univ Western Australia, Dept Geol & Geophys, Ctr Strateg Mineral Deposits, Nedlands, WA 6907, Australia	University of Western Australia	McNaughton, NJ (corresponding author), Univ Western Australia, Dept Geol & Geophys, Ctr Strateg Mineral Deposits, Nedlands, WA 6907, Australia.		McNaughton, Neal/AAV-9941-2020; McNaughton, Neal/E-3884-2014; McNaughton, Neal/AAD-7067-2022	Rasmussen, Birger/0000-0002-2745-0904				BROWN SJA, INPRESS GEOLOGY; COATS RP, 1980, PRECAMBRIAN RES, V13, P181, DOI 10.1016/0301-9268(80)90004-2; Evans J, 1996, EARTH PLANET SC LETT, V144, P421, DOI 10.1016/S0012-821X(96)00177-X; Griffin T J, 1990, W AUSTR GEOLOGICAL S, V3, P293; Obradovich JD, 1988, PALEOCEANOGRAPHY, V3, P757, DOI 10.1029/PA003i006p00757; PAGE RW, 1994, GEOL SOC AUSTR ABSTR, V37, P332; Rasmussen B, 1996, AM J SCI, V296, P601, DOI 10.2475/ajs.296.6.601; Rasmussen B, 1998, EARTH PLANET SC LETT, V164, P135, DOI 10.1016/S0012-821X(98)00199-X; Smith JB, 1998, PRECAMBRIAN RES, V88, P143, DOI 10.1016/S0301-9268(97)00067-3; Smith PE, 1998, SCIENCE, V279, P1517, DOI 10.1126/science.279.5356.1517	10	88	92	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					78	80		10.1126/science.285.5424.78	http://dx.doi.org/10.1126/science.285.5424.78			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390364				2022-12-28	WOS:000081199800031
J	Mellitzer, G; Xu, QL; Wilkinson, DG				Mellitzer, G; Xu, QL; Wilkinson, DG			Eph receptors and ephrins restrict cell intermingling and communication	NATURE			English	Article							NEURAL CREST MIGRATION; TRANSMEMBRANE LIGANDS; TYROSINE PHOSPHORYLATION; MOLECULAR-BASIS; GAP-JUNCTIONS; CHICK-EMBRYO; ADHESION; PERMEABILITY; RHOMBOMERES; ATTACHMENT	Eph proteins are receptors with tyrosine-kinase activity which, with their ephrin ligands, mediate contact-dependent cell interactions' that are implicated in the repulsion mechanisms that guide migrating cells and neuronal growth cones to specific destinations(2,3). Ephrin-B proteins have conserved cytoplasmic tyrosine residues that are phosphorylated upon interaction with an EphB receptor(4,5), and may transduce signals that regulate a cellular response(6). Because Eph receptors and ephrins have complementary expression in many tissues during embryogenesis(7), bidirectional activation of Eph receptors and ephrin-B proteins could occur at interfaces of their expression domains, for example at segment boundaries in the vertebrate hindbrain, Previous work(8,9) has implicated Eph receptors and ephrin-B proteins in the restriction of cell intermingling between hindbrain segments(10). We therefore analysed whether complementary expression of Eph receptors and ephrins restricts cell intermingling, and whether this requires bidirectional or unidirectional signalling. Here we report that bidirectional but not unidirectional signalling restricts the intermingling of adjacent cell populations, whereas unidirectional activation is sufficient to restrict cell communication through gap junctions. These results reveal that Eph receptors and ephrins regulate two aspects of cell behaviour that can stabilize a distinct identity of adjacent cell populations.	Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	MRC National Institute for Medical Research	Wilkinson, DG (corresponding author), Natl Inst Med Res, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.		Georg, Mellitzer/R-4180-2016	Georg, Mellitzer/0000-0003-4467-0789; Wilkinson, David/0000-0001-6757-7080				BAGNALL KM, 1992, ANAT EMBRYOL, V186, P195; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lo CW, 1996, J BIOENERG BIOMEMBR, V28, P379, DOI 10.1007/BF02110114; MARTINEZ S, 1992, DEVELOPMENT, V116, P1069; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WARNER AE, 1982, CELL, V28, P243, DOI 10.1016/0092-8674(82)90342-7; Wizenmann A, 1997, MOL CELL NEUROSCI, V9, P448, DOI 10.1006/mcne.1997.0642; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Xu QL, 1995, DEVELOPMENT, V121, P4005; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U	28	398	411	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					77	81		10.1038/21907	http://dx.doi.org/10.1038/21907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403252				2022-12-28	WOS:000081255700054
J	Almond, S				Almond, S			A lesson learnt - A painful lesson	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1744	1744		10.1136/bmj.318.7200.1744	http://dx.doi.org/10.1136/bmj.318.7200.1744			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381712	Green Published			2022-12-28	WOS:000081216900035
J	Anderson, P				Anderson, P			England publishes first tables of hospital performance	BRITISH MEDICAL JOURNAL			English	News Item																			0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1715	1715		10.1136/bmj.318.7200.1715	http://dx.doi.org/10.1136/bmj.318.7200.1715			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381688	Green Published			2022-12-28	WOS:000081216900006
J	Dobson, R				Dobson, R			Closed circuit television does not reduce violence	BRITISH MEDICAL JOURNAL			English	News Item																		Sivarajasingam V, 1999, J ACCID EMERG MED, V16, P255	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1717	1717		10.1136/bmj.318.7200.1717	http://dx.doi.org/10.1136/bmj.318.7200.1717			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381694	Green Published			2022-12-28	WOS:000081216900011
J	Swinburn, JMA; Banerjee, DJ; Khan, ZP				Swinburn, JMA; Banerjee, DJ; Khan, ZP			Ethical dilemma - Discontinuation of ventilation after brain stem death	BRITISH MEDICAL JOURNAL			English	Editorial Material									City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England		Swinburn, JMA (corresponding author), City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England.								0	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1753	1753						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381716				2022-12-28	WOS:000081216900039
J	Hing, H; Xiao, J; Harden, N; Lim, L; Zipursky, SL				Hing, H; Xiao, J; Harden, N; Lim, L; Zipursky, SL			Pak functions downstream of dock to regulate photoreceptor axon guidance in Drosophila	CELL			English	Article							SH2/SH3 ADAPTER PROTEIN; GROWTH CONE GUIDANCE; KINASE PAK; ALPHA-PAK; ACTIN; GTPASES; FAMILY; CDC42; RAC; NCK	The SH2/SH3 adaptor protein Dock has been proposed to transduce signals from guidance receptors to the actin cytoskeleton in Drosophila photoreceptor (R cell) growth cones. Here, we demonstrate that Drosophila p21-activated kinase (Pak) is required in a Dock pathway regulating R cell axon guidance and targeting. Dock and Pak colocalize to R cell axons and growth cones, physically interact, and their loss-of-function phenotypes are indistinguishable. Normal patterns of R cell connectivity require Pak's kinase activity and binding sites for both Dock and Cdc42/Rac. A membrane-tethered form of Pak (Pak(myr)) acts as a dominant gain-of-function protein. Retinal expression of Pak(myr) rescues the R cell connectivity phenotype in dock mutants. These data establish Pak as a critical regulator of axon guidance and a downstream effector of Dock in vivo.	Calif State Univ Los Angeles, Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Inst Neurol, London WC1N 1PJ, England	California State University System; California State University Los Angeles; Howard Hughes Medical Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London	Zipursky, SL (corresponding author), Calif State Univ Los Angeles, Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	zipursky@hhmi.ucla.edu		Zipursky, Stephen/0000-0001-5630-7181				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; DELATORRE JR, 1997, CELL, V19, P1211; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Garrity PA, 1999, NEURON, V22, P707, DOI 10.1016/S0896-6273(00)80730-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harden N, 1996, MOL CELL BIOL, V16, P1896; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; Salecker I, 1998, CELL, V95, P587, DOI 10.1016/S0092-8674(00)81627-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Suter DM, 1998, CURR OPIN NEUROBIOL, V8, P106, DOI 10.1016/S0959-4388(98)80014-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	36	244	249	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					853	863		10.1016/S0092-8674(00)80798-9	http://dx.doi.org/10.1016/S0092-8674(00)80798-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399914	Bronze			2022-12-28	WOS:000081162800007
J	Marks, DL; Stack, RA; Brady, DJ; Munson, DC; Brady, RB				Marks, DL; Stack, RA; Brady, DJ; Munson, DC; Brady, RB			Visible cone-beam tomography with a lensless interferometric camera	SCIENCE			English	Article							RECONSTRUCTION	Digital processing of optical coherence functions can reconstruct three-dimensional objects illuminated by incoherent light. It is shown that Fourier analysis of the mutual intensity of the field produces projections that are mathematically identical to the projections of x-ray cone-beam tomography. A lensless interferometric camera that captures planes of mutual intensity data is described and used to reconstruct an incoherently illuminated visible object in three dimensions.	Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ Illinois, Natl Ctr Supercomp Applicat, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Brady, DJ (corresponding author), Univ Illinois, Dept Elect & Comp Engn, 405 N Matthews Ave, Urbana, IL 61801 USA.		Brady, David/A-6455-2008	Brady, David Jones/0000-0001-5655-2478				ARMITAGE JD, 1965, OPT ACTA, V12, P185; CARTER WH, 1981, OPT ACTA, V28, P227, DOI 10.1080/713820525; DEVANEY AJ, 1979, J MATH PHYS, V20, P1687, DOI 10.1063/1.524277; FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612; ITOH K, 1986, J OPT SOC AM A, V3, P94, DOI 10.1364/JOSAA.3.000094; ITOH K, 1990, JPN J APPL PHYS 2, V29, pL1561, DOI 10.1143/JJAP.29.L1561; LAHAIE IJ, 1985, J OPT SOC AM A, V2, P35, DOI 10.1364/JOSAA.2.000035; Mandel L, 1995, OPTICAL COHERENCE QU; Marks DL, 1999, APPL OPTICS, V38, P1332, DOI 10.1364/AO.38.001332; RODDIER F, 1979, P INT ASTR UN C SYDN; Rosen J, 1996, OPT LETT, V21, P1803, DOI 10.1364/OL.21.001803; SCHOONEVELD CV, 1978, IMAGE FORMATION COHE, V76; SWENSON GW, 1986, J OPT SOC AM A, V3, P1311, DOI 10.1364/JOSAA.3.001311; TUY HK, 1983, SIAM J APPL MATH, V43, P546, DOI 10.1137/0143035; Yoshimori K, 1997, J OPT SOC AM A, V14, P3379, DOI 10.1364/JOSAA.14.003379; ZARUBIN AM, 1993, OPT COMMUN, V100, P491, DOI 10.1016/0030-4018(93)90251-Y	16	56	60	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2164	2166		10.1126/science.284.5423.2164	http://dx.doi.org/10.1126/science.284.5423.2164			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381878				2022-12-28	WOS:000081099300047
J	Martin, JB				Martin, JB			Molecular basis of the neurodegenerative disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOMINANT CEREBELLAR-ATAXIA; AMYOTROPHIC-LATERAL-SCLEROSIS; FAMILIAL ALZHEIMERS-DISEASE; SPINAL MUSCULAR-ATROPHY; CAG REPEAT EXPANSION; SPORADIC HUNTINGTONS-DISEASE; MOTOR NEURON DISEASE; SPINOCEREBELLAR ATAXIA; PARKINSONS-DISEASE; FRIEDREICHS-ATAXIA		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Martin, JB (corresponding author), Harvard Univ, Sch Med, 25 Shattuck St,Rm A111, Boston, MA 02115 USA.	joseph_martin@hms.harvard.cdu						Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Benson KF, 1998, HUM MOL GENET, V7, P1779, DOI 10.1093/hmg/7.11.1779; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Brahe C, 1996, HUM MOL GENET, V5, P1971, DOI 10.1093/hmg/5.12.1971; Brown RH, 1998, MOL NEUROLOGY, P223; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; Burke RE, 1998, NEUROSCIENTIST, V4, P301, DOI 10.1177/107385849800400418; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; Clark C. M., 1998, BLUE BOOK PRACT NEUR, V19; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; CRUTS M, 1998, BLUE BOOK PRACT NEUR, V19, P155; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Del-Favero J, 1998, HUM MOL GENET, V7, P177, DOI 10.1093/hmg/7.2.177; DURR A, 1995, J NEUROL SCI, V129, P51, DOI 10.1016/0022-510X(94)00250-R; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; EDWARDS RH, 1998, MOL NEUROLOGY, P155; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; FRASER P, 1998, PRESENILINS ALZHEIME, P1; Friedlander RM, 1998, NATURE, V392, P560; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Gomez CM, 1997, ANN NEUROL, V42, P933, DOI 10.1002/ana.410420616; GOMEZISLA T, 1998, BLUE BOOK PRACT NEUR, V19, P171; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; GURNEY ME, 1995, SCIENCE, V269, P149, DOI 10.1126/science.269.5221.149-a; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Gusella JF, 1997, MOL MED, V3, P238, DOI 10.1007/BF03401677; GUSELLA JF, 1998, MOL NEUROLOGY, P1; Haass C, 1998, J NEURAL TRANSM-SUPP, P159; Hahnen E, 1997, HUM MOL GENET, V6, P821, DOI 10.1093/hmg/6.5.821; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Heintz N, 1997, NAT GENET, V16, P325, DOI 10.1038/ng0897-325; Heinzlef O, 1998, J MED GENET, V35, P89, DOI 10.1136/jmg.35.2.89; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; HYMAN BT, 1990, NEUROLOGY, V40, P1721, DOI 10.1212/WNL.40.11.1721; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Ikeuchi T, 1997, ANN NEUROL, V42, P879, DOI 10.1002/ana.410420609; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; KOWALL NW, 1987, TRENDS NEUROSCI, V10, P24, DOI 10.1016/0166-2236(87)90120-2; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEIGH PN, 1988, NEUROSCI LETT, V93, P197, DOI 10.1016/0304-3940(88)90081-X; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACDONALD ME, 1993, J MED GENET, V30, P982, DOI 10.1136/jmg.30.12.982; Martin JB, 1996, NEUROREPORT, V8, pR1, DOI 10.1097/00001756-199612200-00076; MARTIN JB, 1998, MOL NEUROLOGY; Marx J, 1998, SCIENCE, V281, P507, DOI 10.1126/science.281.5376.507; McConnell LM, 1998, NAT MED, V4, P757, DOI 10.1038/nm0798-757; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Nielsen JE, 1997, HUM MOL GENET, V6, P1811, DOI 10.1093/hmg/6.11.1811; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Poorkaj, 1998, ANN NEUROL, V44, P428; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Robitaille Y, 1997, BRAIN PATHOL, V7, P901, DOI 10.1111/j.1750-3639.1997.tb00893.x; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schols L, 1997, ANN NEUROL, V42, P924, DOI 10.1002/ana.410420615; Selkoe D.J., 1998, BLUE BOOK PRACT NEUR, P257; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; TERRY RD, IN PRESS ALZHEIMER D; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; YOUNG AB, 1998, MOL NEUROLOGY, P35; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	98	299	332	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1970	1980		10.1056/NEJM199906243402507	http://dx.doi.org/10.1056/NEJM199906243402507			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379022				2022-12-28	WOS:000081088500007
J	Meneghini, MD; Ishitani, T; Carter, JC; Hisamoto, N; Ninomiya-Tsuji, J; Thorpe, CJ; Hamill, DR; Matsumoto, K; Bowerman, B				Meneghini, MD; Ishitani, T; Carter, JC; Hisamoto, N; Ninomiya-Tsuji, J; Thorpe, CJ; Hamill, DR; Matsumoto, K; Bowerman, B			MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans	NATURE			English	Article							BETA SIGNAL-TRANSDUCTION; C-ELEGANS; GENE; SPECIFICATION; DROSOPHILA; WINGLESS; EMBRYOS; ACTIVATOR; MESODERM; ENDODERM	The signalling protein Wnt regulates transcription factors containing high-mobility-group (HMG) domains to direct decisions on cell fate during animal development(1). In Caenorhabditis elegans, the HMG-domain-containing repressor POP-1 distinguishes the fates of anterior daughter cells from their posterior sisters throughout development(2,3), and Wnt signalling downregulates POP-1 activity in one posterior daughter cell called E (refs 2, 4, 5). Here we show that the genes mom-4 and lit-1 are also required to downregulate POP-1, not only in E but also in other posterior daughter cells. Consistent with action in a common pathway, mom-4 and lit-1 exhibit similar mutant phenotypes and encode components of the mitogen-activated protein kinase (MAPK) pathway that are homologous to vertebrate transforming-growth-factor-beta-activated kinase (TAK1) and NEMO-like kinase (NLK), respectively. Furthermore, MOM-4 and TAK1 bind related proteins that promote their kinase activities. We conclude that: a MAPK-related pathway cooperates with Wnt signal transduction to downregulate POP-1 activity. These functions are likely to be conserved in vertebrates, as TAK1 and NLK can downregulate HMG-domain-containing proteins related to POP-1 (ref. 6).	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chkusa Ku, Nagoya, Aichi 4648602, Japan	University of Oregon; Nagoya University; Japan Science & Technology Agency (JST)	Bowerman, B (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	bbowerman@molbio.uoregon.edu	, Tohru/AAH-8979-2020; Ishitani, Tohru/E-9781-2014	, Tohru/0000-0002-6200-7043; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	PHS HHS [R01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BRENNER S, 1974, GENETICS, V77, P71; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; EPSTEIN HF, 1995, MODERN BIOL ANAL ORG; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1221; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PRIESS JR, 1987, CELL, V34, P85; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	231	243	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					793	797						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391246				2022-12-28	WOS:000081101600056
J	Altschuler, EL; Wisdom, SB; Stone, L; Foster, C; Galasko, D; Llewellyn, DME; Ramachandran, VS				Altschuler, EL; Wisdom, SB; Stone, L; Foster, C; Galasko, D; Llewellyn, DME; Ramachandran, VS			Rehabilitation of hemiparesis after stroke with a mirror	LANCET			English	Article									Univ Calif San Diego, Brain & Percept Lab, La Jolla, CA 92093 USA; USN, Med Ctr, Dept Neurosci, San Diego, CA 92134 USA	University of California System; University of California San Diego; United States Department of Defense; United States Navy	Altschuler, EL (corresponding author), Univ Calif San Diego, Brain & Percept Lab, 9500 Gilman Dr,0190, La Jolla, CA 92093 USA.							Altschuler E. L., 1998, Society for Neuroscience Abstracts, V24, P1408; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; RAMACHANDRAN VS, 1995, NATURE, V377, P489, DOI 10.1038/377489a0; Seitz RJ, 1998, ARCH NEUROL-CHICAGO, V55, P1081, DOI 10.1001/archneur.55.8.1081; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152	5	355	407	4	69	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2035	2036		10.1016/S0140-6736(99)00920-4	http://dx.doi.org/10.1016/S0140-6736(99)00920-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376620				2022-12-28	WOS:000080812200015
J	Wang, J; Smolyar, A; Tan, KM; Liu, J; Kim, MY; Sun, ZJ; Wagner, G; Reinherz, EL				Wang, J; Smolyar, A; Tan, KM; Liu, J; Kim, MY; Sun, ZJ; Wagner, G; Reinherz, EL			Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors	CELL			English	Article							T-CELL ACTIVATION; FUNCTION-ASSOCIATED ANTIGEN-3; PROTEIN-PROTEIN INTERFACES; CRYSTAL-STRUCTURE; MOLECULE CD2; IMMUNOGLOBULIN SUPERFAMILY; RECEPTOR CD2; MOUSE CHROMOSOME-1; GLYCOPROTEIN CD2; LIGAND-BINDING	Interaction between CD2 and its counterreceptor, CD58 (LFA-3), on opposing cells optimizes immune recognition, facilitating contacts between helper T lymphocytes and antigen-presenting cells as well as between cytolytic effecters and target cells. Here, we report the crystal structure of the heterophilic adhesion complex between the amino-terminal domains of human CD2 and CD58. A strikingly asymmetric, orthogonal, face-to-face interaction involving the major beta sheets of the respective immunoglobulin-like domains with poor shape complementarity is revealed. In the virtual absence of hydrophobic forces, interdigitating charged amino acid side chains form hydrogen bonds and salt links at the interface (similar to 1200 Angstrom(2)), imparting a high degree of specificity albeit with low affinity (K-D of similar to mu M). These features explain CD2-CD58 dynamic binding, offering insights into interactions of related immunoglobulin superfamily receptors.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wang, J (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	jwang@red.dfci.harvard.edu; ellis_reinherz@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226, R01AI037581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21226, AI37581] Funding Source: Medline; NIGMS NIH HHS [GM56008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; DENGLER TJ, 1992, EUR J IMMUNOL, V22, P2809, DOI 10.1002/eji.1830221109; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Freedman SJ, 1996, BIOCHEMISTRY-US, V35, P13733, DOI 10.1021/bi9610257; Garbe TR, 1996, MOL MED, V2, P134, DOI 10.1007/BF03402209; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GOLLOB JA, 1995, J EXP MED, V182, P721, DOI 10.1084/jem.182.3.721; Gollob JA, 1996, J IMMUNOL, V157, P1886; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENSKY AM, 1983, J IMMUNOL, V131, P611; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lehninger A.L., 1975, BIOCH MOL BASIS CELL, Vsecond; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MOSELEY WS, 1989, GENOMICS, V5, P899, DOI 10.1016/0888-7543(89)90132-8; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; OSBORN L, 1995, J EXP MED, V181, P429, DOI 10.1084/jem.181.1.429; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PARISH CR, 1988, J IMMUNOL, V141, P3498; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RECNY MA, 1992, J BIOL CHEM, V267, P22428; REINHOLD BB, 1992, TECHNIQUES PROTEIN C, V3, P287; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SEWELL WA, 1988, IMMUNOGENETICS, V28, P278, DOI 10.1007/BF00345506; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; SHER PK, 1987, PEDIATR NEUROL, V3, P197; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUN ZYJ, 1999, IN PRESS EMBO J; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412	86	196	201	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					791	803		10.1016/S0092-8674(00)80790-4	http://dx.doi.org/10.1016/S0092-8674(00)80790-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380930	Bronze			2022-12-28	WOS:000080886300016
J	Galitski, T; Saldanha, AJ; Styles, CA; Lander, ES; Fink, GR				Galitski, T; Saldanha, AJ; Styles, CA; Lander, ES; Fink, GR			Ploidy regulation of gene expression	SCIENCE			English	Article							CELL-SURFACE FLOCCULIN; SACCHAROMYCES-CEREVISIAE; YEAST; CHROMOSOMES; GROWTH; FLO11	Microarray-based gene expression analysis identified genes showing ploidy-dependent expression in isogenic Saccharomyces cerevisiae strains that varied in ploidy from haploid to tetraploid. These genes were induced or repressed in proportion to the number of chromosome sets, regardless of the mating type. Ploidy-dependent repression of some G(1) cyclins can explain the greater cell size associated with higher ploidies, and suggests ploidy-dependent modifications of cell cycle progression. Moreover, ploidy regulation of the FLO11 gene had direct consequences for yeast development.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Fink, GR (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	fink@wi.mit.edu			NIGMS NIH HHS [GM35010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGNER SH, 1984, PROG EXP TUMOR RES, V27, P67; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Futcher B, 1996, YEAST, V12, P1635; Guo M, 1996, GENETICS, V142, P1349; Henikoff S, 1998, CELL, V93, P329, DOI 10.1016/S0092-8674(00)81161-7; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MORTIMER RK, 1958, RADIAT RES, V9, P312, DOI 10.2307/3570795; NAGL W, 1978, ENDOPOLYPLOIDY POLYL; Nelson MA, 1996, TRENDS GENET, V12, P69, DOI 10.1016/0168-9525(96)81403-X; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Royzman I, 1998, GENES CELLS, V3, P767, DOI 10.1046/j.1365-2443.1998.00232.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	26	509	545	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					251	254		10.1126/science.285.5425.251	http://dx.doi.org/10.1126/science.285.5425.251			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398601				2022-12-28	WOS:000081346000041
J	Nylenna, M; Andersen, D; Dahlquist, G; Sarvas, M; Aakvaag, A				Nylenna, M; Andersen, D; Dahlquist, G; Sarvas, M; Aakvaag, A		Natl Comm Sci Dishonesty Nordic Countries	Handling of scientific dishonesty in the Nordic countries	LANCET			English	Review							MISCONDUCT; AUTHORSHIP; SCIENCE	Despite a widely recognised need, most countries still have no coherent system to deal with scientific misconduct. Committees have been established by the national medical research councils in Denmark (1992), Norway (1994), and Sweden (1997), and by the Ministry of Education in Finland (1994), to deal with scientific misconduct-ie, to initiate preventive measures, to investigate alleged cases, or both. Each committee includes both scientifically and legally qualified members. The employing institutions are responsible for possible sanctions or punishments. So far, 47 cases have been accepted for investigation, the majority (25) being Danish. Disputed authorship was the most frequent reason for investigation. Junior researchers made complaints in only three of the investigated cases. Investigations have been completed in 37 cases; in nine cases, dishonesty was revealed-two of them were related to the same researchers. Cooperation between the four Nordic committees has shown close agreement on specific issues and cases, despite minor differences in definitions, organisation, and procedures.	Res Council Norway, Oslo, Norway; Danish Res Agcy, Copenhagen, Denmark; Swedish Med Res Council, Stockholm, Sweden; Natl Res Eth Council Finland, Helsinki, Finland	Research Council of Norway	Nylenna, M (corresponding author), Journal Norwegian Med Assoc, POB 1152 Sentrum, N-0107 Oslo, Norway.							ANERSEN D, 1992, SCI DISHONESTY GOOD; Bekkelund S I, 1995, Tidsskr Nor Laegeforen, V115, P3148; BUZZELLI DE, 1993, SCIENCE, V259, P584, DOI 10.1126/science.8430300; *COMM PUBL ETH, 1998, ANN REP 1998; *COMM RES INT, 1995, INT MISC RES; *DAN COMM SCI DISH, 1998, GUID GOOD SCI PRACT; *DAN COMM SCI DISH, 1994, ANN REP 1993 96; EVERED D, 1995, LANCET, V345, P1161, DOI 10.1016/S0140-6736(95)90984-2; Farthing MJG, 1998, BRIT MED J, V316, P1729; *INT COMM MED J ED, 1997, ANN INTERN MED, V126, P34; LAFOLLETTE M, 1992, STEALING PRINT; LOCK S, 1996, FRAUD MISCONDUCT MED; MAUS KW, 1997, NORWEGIAN RES SYSTEM; *NAT ACAD SCI, 1992, RESP SCI ENS INT RES, V1; POON P, 1995, J LAW MED ETHICS, V23, P88, DOI 10.1111/j.1748-720X.1995.tb01336.x; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; Research Triangle Institute, 1995, CONS WHISTL WHISTL M; SCHACHMAN HK, 1993, SCIENCE, V261, P148, DOI 10.1126/science.8305005; Smith R, 1996, BRIT MED J, V312, P789; Smith R, 1997, BRIT MED J, V315, P201, DOI 10.1136/bmj.315.7102.201; Wilcox LJ, 1998, JAMA-J AM MED ASSOC, V280, P216, DOI 10.1001/jama.280.3.216; Woolf Patricia K, 1988, Jurimetrics, V29, P67; 1996, LANCET, V347, P843	23	46	50	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					57	61		10.1016/S0140-6736(98)07133-5	http://dx.doi.org/10.1016/S0140-6736(98)07133-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406378				2022-12-28	WOS:000081243200040
J	Pelosi, AJ				Pelosi, AJ			Mix of perspectives needed in purchasing of care - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Hairmyres Hosp, Dept Psychiat, E Kilbride G75 8RG, Lanark, Scotland	University Hospital Hairmyres	Pelosi, AJ (corresponding author), Hairmyres Hosp, Dept Psychiat, E Kilbride G75 8RG, Lanark, Scotland.			Pelosi, Anthony/0000-0002-5501-2661				DOLAN B, 1998, RETHINKING CLIN AUDI	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1412	1412						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10391709				2022-12-28	WOS:000080524700037
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1952: Selman Abraham Waksman (1888-1973)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1536	1536		10.1016/S0140-6736(05)67238-8	http://dx.doi.org/10.1016/S0140-6736(05)67238-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232360				2022-12-28	WOS:000080278200072
